ARO_id,DNA Sequence,Gene Family,Resistance Mechanism,Drug Class,Mega id,type,MEGARes_header,Source_header,label
,atgaatccctatctacagttagttagcaaagaatttccgttagaaaaaaaccaagaaccccctcatttagtccttgctgccttcagcgaagacgaggtttacttgcagccagaagcagccaaacaatgggaacggctcgtcaaagccttaaagcttgaaaacgagatctgcttgttagatggctaccgaaccgaaaagcagcaacggtatttatgggaatattccttgaaagaaaatgggctagcctatacgaaacaatttgtggcattgcccggttgcagtgaacatcagttaggcttagcgatcgatgttggtttaaagggcagccaggatgatttgatctgcccactatttcgtgacagcgcagccgctgatttatttacccaggaaatgatgaactatgggtttattttacgctatcccgcagacaaacaggagattacagggattggctatgaaccatggcatttccggtatgtcgggctgcctcatagtcaaatcatcgccagtcaacagtggaccttggaagaataccatcaataccttgaacaaactgcgaggcagttcgcatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7575,Drugs,MEG_7575|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,1028100653|WP_063856788.1|NG_048504|1|1|vanXY-C|vanXY-C|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C NG_048504:1-573,5
,atgaaaaagacactctctcgctggcggcgcggcgcgctcgcgctgcgcctcctcggtgcgctggcctcgcccgtggtcttcgcaatgcccggacacgccgccgaacccgcgcattcttccgcggtgcgcatcgccgagcgggccgactggggcaagtactttgccgacgaaggcgtcaagggcacggtcatcgtgctggacggccggacccagacctatcaggcttacgatgccgcacgcgccgagcgccgcatgtcgcccgcatcgacctacaagatattcaacagcctgctcgcgctggagtccggcgcgctcgacaacgagcgcgaggtcatcccgtgggacggcaagccgcgtcgcgtcaaggcgtggaacgccgcgctcgacctgcgcaacgcgtttcgcgtgtcgtgcctgccttgctatcaggtcgtctcgcacaagatcccgcgccagtacgcgcaggccaagctcaacgaggcgggctacggcaatcgcacaatcggccgcgccgcgcacgcctactggatcgacgacagcctgcagatttcggcgcgcgagcaagtcgacttcctgcagcgtctggccacgggtgcgctgccgttctcggcgcgctcgcaggacatcgtgcgcaacatatcgatcgtcgaagcgaacgtcgactacgtgctgcacggcaagacgggctggtttaccgaaaagaaacccgacatcgggtggtgggtcggctggctcgagcgtgacggcaacctcaccatgatcgcgttgaacatcgacattcaaaccgatgccgacgcgccaaagcgcgcgcgcatcgttcgcaacgtgctcaaggatctgaagctgatctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4410,Drugs,MEG_4410|Drugs|betalactams|Class_D_betalactamases|OXA,1028106120|WP_063861087.1|NG_049458|1|1|blaOXA-159|blaOXA-62_like|OXA-62_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-159 NG_049458:101-952,0
,atgcgattccaaaaagtttcttgcttacttttatcccctctttttatttttagcacctcaatttatgcaggcaatacaccaaaagaacaagaaatcaaaaaactggtagatcaaaactttaagcctttattagaaaaatataatgtgcccggtatggcagttggcatcatccagaataataaaaagtatgaaacctattatggtctacaatccgttcaagataaaaaagctgtaaatagcagcaccatttttgagctaggttcagtcagtaaattatttactgcgacagcgggtggatatgccaaaacaaaaggaaccctctcttttgaagacacgcccggaaaatattggaaagaactaaaaaacacaccgattgatcaagttaacttacttcaacttgcgacatataccagcggcaaccttgctttgcaatttccagatgaagtaaaaacagatcagcaagttttaacttttttcaaagactggaaacctaaaaattcaatcggtgaatacagacaatattcaaacccaagtattggtttatttggaaaagttgtggctttgtctatgaatcaatctttcgaccaagtcttagaaaaaacaatttttccagatcttggcttaaaacatagttatgtcaatgtgcctaaacttcaaatgcaaaactatgcatttggctataaccaacaaaatcagcccattcgagttaaccccggcccactcgatgcaccagcatacggcgtcaaatcgacattaccagacatgctgagttttattaatgccaacctcaacccgcagaaatatccagcagatattcaacgtgcaattaatgaaacacatcaaggtttctatcaagtcggcacaatgtatcaagcacttggctgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagaacaaatcgtgatgaagcctaataaagtgactgctatttcaaaagaacctaccgttaagatgttccataaaactggttcaacaaatggctttggaacatatgttgtgttcattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgtattaaggcagcgtatgcagttttaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_520,Drugs,MEG_520|Drugs|betalactams|Class_C_betalactamases|ADC,507075251|WP_016146025.1|NG_064694|1|1|blaADC-138|blaADC|class_C_beta-lactamase_ADC-138 NG_064694:101-1252,0
,ATGGCAATCCGAATCTTCGCAATACTTTTCTCCACTTTTGTTTTTGGCACGTTCGCGCATGCACAAGAAGGCATGCGCGAACGTTCTGACTGGCGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAACAGATCGTGTCATATTGGTTTTTGATCAGGTGCGGTCAGAGAAACGCTACTCGCCGGCCTCGACATTCAAGATTCCACATACACTTTTTGCACTTGACGCAGGCGCTGCACGTGATGAGTTTCAAGTTTTCCGATGGGACGGCATCAAAAGAAGCTTTGCAGCTCACAACCAAGACCAAGACTTGCGATCAGCAATGCGGAATTCTACTGTCTGGATTTATGAGCTATTTGCAAAAGAGATCGGTGAAGACAAGGCTCGACGCTATTTGAAGCAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGATGGCAATCTTGCTATCGCGGCACAGGAACAGATTGCATTTCTCAGGAAGCTCTATCATAACGAGTTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGACCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGCGCAAAGACGGGCTGGGAAGGCCGCATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCCCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGGATGGATGACCTTTTCAAAAGGGAGGCAATAGTGCGGGCAATCCTTCGCTCTATCGAAGCGTTGCCGCCCAACCCGGCAGTCAACTCGGACGCAGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5243,Drugs,MEG_5243|Drugs|betalactams|Class_D_betalactamases|OXA,gi|685424881|gb|KM009138.1|1200-2027 gi|635661971|gb|KJ569108.1|721-1548 gi|116248472|gb|DQ993182.1|1190-2017,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaaatggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgctgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6678,Drugs,MEG_6678|Drugs|betalactams|Class_A_betalactamases|TEM,691334079|WP_032072208.1|NG_050243|1|1|blaTEM-210|blaTEM|class_A_beta-lactamase_TEM-210 NG_050243:101-961,0
,TTGTCAAACGCGCGGGAGTCGCGGATAGTCCGGGCAGTTCATCACTATCAAGGAGTCAGAGATGTTGAAAAGTTCGTGGCGTAAAAGCGCCCTGATGGCCGCCGCCGTTCCGCTACTGCTGGCGAGCGGTTCATTATGGGCCAGTGCCGATACTCTCCAGCAGAAGCTGGCTGATTTAGAAAAACGTTCCGGCGGTCGGCTGGGCGTGGCGCTGATTAACACGGCAGATGATTCGCAGACCCTCTATCGCGGCGACGAACGTTTTGCCATGTGCAGCACCGGTAAAGTGATGGCCGCCGCCGCGGTGTTAAAACAGAGCGAAAGCCATCCCGATGTGGTGAATAAAAGGCTGGAGATTAAAAAATCGGATTTAGTGGTCTGGAGCCCGATTACCGAAAAACATCTGCAAAGCGGAATGACCCTGGCGGAACTCAGCGCTGCGGCGCTGCAGTATAGCGACAATACCGCGATGAATAAGATTATCGGTTACCTTGGCGGGCCGGAAAAAGTCACCGCATTCGCCCAGAGCATCGGTGACGTTACTTTTCGTCTCGATCGGATGGAGCCGGCGCTGAACAGCGCGATTCCCGGTGATAAGCGCGATACCACCACCCCATTGGCGATGGCCGAAAGTCTGCGTAAGCTGACGCTGGGCAATGCGCTGGGCGAACAGCAGCGCGCCCAGTTAGTGACATGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGTGCAGGCCTGCCCGCAAGCTGGGCGGTCGGGGATAAAACCGGCGGCGGAGATTACGGCACCACCAACGATATCGCGGTGATCTGGCCGGAAAATCATGCTCCGCTGGTGCTAGTGACCTATTTTACCCAACCGCAGCAGGATGCGAAAAGCCGCAAAGAGGTGCTAGCCGCGGCGGCGAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5312,Drugs,MEG_5312|Drugs|betalactams|Class_A_betalactamases|OXY,gi|23264039|gb|AY077481.1|125-1058,0
,atggctaaattactaataatgagcgtagtaagcttttgttttatatttctattgttagtattttttaggtatatattaaaacgctattttaattatagtttaaattataaagtttggtatctaactgtgcttgctggattaattccttttatcccaattaaattctcttttataaaatttaataatgtgaataatcaatcgcccacagttgaaagtaggtcacacgacttgaaccataacataaataccaccaaacctgttcaagagttcacaacagatatccataagtttaattgggattcaattgataatatctgcacagttatttggatagttttggttattattttaagttttaaatttttgaaatccttattatatcttaaatatttaaagagacagtcactttatctaaacgaaaatgaaaaaaataaaatagatacgatacttttcaaccatcaatataaaaaaaatattgtgattcgaaaagcagagactattcaatctccaataactttttggtatgggaaatatattattttgattcctagttcatattttaaaagtgtaattgacaaaagactaaaatatataatattgcatgaatatgctcatgctaaaaatagagatactttacatttaattatctttaatatcttctctattgttatgagttacaatccattaatacatattgtaaaaagaaagataattcatgacaatgaagtagaagccgatagatttgttcttaataatattaacaaaaatgaatttaaaacttatgcggaatctattatggactccgtattaaatattccattttttaataaaaatatattaagccattcatttaatggtaaaaagtcattactcaaaagaagattaattaatataaaagaagccaatttgaaaaaacagtccaaattaattccaatttttatttgtatttttacttttttgctcatggtaattcaaagccagtttttgatggggcaatccataactgattataattataaaaagcccttacagaacgatcaccaaattttagatgaaagtaaaaattttggttcaaatagtggatctttcgtcatgtacagcatgaagaaagacaaatactatatttataatgaaaaagaaagtagaaagagatattctcctgattcaacttataaaatttatttagcgatgtttggacttgaccatcatatcataagtgataaaaattcacgtatgtcatggaatcataaacattatcctttcgagtcttggaataaggaacaagatttaaatacagcaatgcaaaattcagttaattggtacttcgaacgtattagtaatcaaataccaaagaactatactgcggctcaactcaagcaattaaattatggtaatgaaaacttgggaagttataaaagctattggatggaagatagtttgaaaatatctaatcttgaacaagtaatagtttttaaaaatatgatggaacaaaataaccattttagtaaaaaagcaaagaatcaattatcttcttcattattgattaagaaaaatgaaaagtatgaactgtatgggaaaacaggtacaggtatagtaaacgggaagtataataatgggtggtttgtaggttacgtaattacaaatcatgataagtattattttgctacacatttatcagatggaaagccgtctgggaaaaatgctgaattaatcagtgaaaaaatattaaaagaaatgggtgttttaaatggccaataa,beta-lactamase,antibiotic target alteration,betalactams,MEG_1300,Drugs,MEG_1300|Drugs|betalactams|Penicillin_binding_protein_regulator|BLAR,447019130|WP_001096386.1|NG_047537|1|1|blaR1-2|blaR1-2|beta-lactam_sensor/signal_transducer_BlaR1 NG_047537:101-1858,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgacgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggacctggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaaacgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5438,Drugs,MEG_5438|Drugs|betalactams|Class_C_betalactamases|PDC,1028110191|WP_063864561.1|NG_049869|1|1|blaPDC-102|blaPDC|class_C_beta-lactamase_PDC-102 NG_049869:1-1194,0
,atgttaattacagaatttgaacgcgataatcgtattttaaaagatcaactggcggatcttttagctaagacttggccaaatgactatgggcagaccgcaaaaaatgaagttgaaaaattactagcaccagagcgaattgcagtggcggctttagtggatgatgatttagtcggctttgtaggagccattcctcaatatggtcaaacaggttgggagatgcacccgttagttgttgtagcagattttagacgtcaaaaaattggcgctcgtttagtttcttttttagaatctgaaattgcatctcgtggcggaattactatttatttgggcacggatgatgaaaatgatgaaacgactttaagccaagtgaatttatataatgagccgttgcaagcaatcgctaatattaaaaatcttaaagcccatccttacagtttttacgagaaattagggtatcaaattaccggtgtgattcccgatgccaatggttggtttaaaccagatattattatgtccaaacgaatcggcgattttgaagaattaactgaagatgaatag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_211,Drugs,MEG_211|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,510798120|WP_016172918.1|NG_052169|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052169:101-658,2
,atgaatattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttaattatccaacaagaccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggcatacctagctctgttcgaaaagagattacttataaaagcttagaactattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4529,Drugs,MEG_4529|Drugs|betalactams|Class_D_betalactamases|OXA,691051692|WP_031998610.1|NG_062344|1|1|blaOXA-716|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-716 NG_062344:13-837,0
,atgaccaaggcaacctgcgaactccgcggaaccgacgtcctcctccgcccggtgcaggacaccgacatcgcaaccctcgaccgcatcgtccgggaaccggcggtcgccgcctggtggtcgccaccggacgactacgccgacatgctcgccatcacccactccggcaaggtcattggcgccatccaattctccgaagagaccgaccccgacttccgccacgccggcatcgacatcttcctcaccacgtcccaccacggcaaaggcctcggcaccgacgccgtccgcaccctcgcccactggctgatccacgaacgcggccaccaccgcctcaccatcgaccccgccgccgccaacaccgcagcgatcgccagctaccgcaaggtcggtttcaagccagtcggcatcatgcgagcgtacgggcgcgactaccgcacgggaggttgggcggacggcctcctcatggacctactcgctgacgagctgacgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_124,Drugs,MEG_124|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,822206438|WP_046928126.1|NG_054688|1|1|aacA-STR-15|aacA-STR-15|aminoglycoside_6'-N-acetyltransferase NG_054688:101-589,2
,atgcgttatgttcgcctgtgtgttatctccctgttagccaccctgccactggcggtagacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgtcgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgccgggctcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgtcgacgggatgacgatcggcgaactctgcgccgccgccatcaccctgagcgataacagcgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcctttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggcactgaatgaggcgcttcccggcgacgcgcgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcgcccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccgccgggctggtttatcgccgacaaaaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgctctatctgcgggataccccggcgagtatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3542,Drugs,MEG_3542|Drugs|betalactams|Class_A_betalactamases|LEN,502733296|WP_012968280.1|NG_050777|1|1|blaLEN-13|blaLEN|class_A_beta-lactamase_LEN-13 NG_050777:101-961,0
,ATGAGCGATATGGCAGAGCGCCTTGCGCTACATGAATTTACGGAAAACGCCTACTTAAACTACTCCATGTACGTGATCATGGACCGTGCGTTGCCGTTTATTGGTGATGGTCTGAAACCTGTTCAGCGCCGCATTGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCCAAATTTAAAAAATCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGCGATAGCGCCTGTTATGAAGCGATGGTCCTGATGGCGCAGCCGTTCTCTTACCGTTATCCGCTGGTTGATGGTCAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCGTTCGCGGCAATGCGTTACACCGAATCCCGGTTGTCGAAATATTCCGAGCTGCTATTGAGCGAGCTGGGGCAGGGGACGGCTGACTGGGTGCCAAACTTCGACGGCACTTTGCAGGAGCCGAAAATGCTACCTGCCCGTCTGCCAAACATTTTGCTTAACGGCACCACCGGTATTGCCGTCGGCATGGCGACCGATATTCCACCGCATAACCTGCGTGAAGTAGCTCAGGCGGCAATCGCATTAATCGACCAGCCGAAAACTACGCTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATTATCCGACTGAAGCGGAAATTATCACTTCGCGCGCCGAGATTCGTAAAATCTACGAGAACGGACGTGGTTCAGTGCGTATGCGCGCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTTATCAGCGCATTACCGCATCAGGTTTCAGGTGCGCGCGTACTGGAGCAAATTGCTGCGCAAATGCGCAACAAAAAGCTGCCGATGGTTGACGATCTGCGCGATGAATCTGACCACGAGAACCCGACCCGTCTGGTGATTGTGCCGCGTTCCAACCGCGTGGATATGGATCAGGTGATGAACCACCTCTTCGCTACCACCGATCTGGAAAAGAGCTATCGCATTAACCTCAATATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAACCTGCTGGAAATCCTCTCCGAATGGCTGGTGTTCCGTCGCGATACCGTGCGCCGCCGACTGAACTATCGTCTGGAGAAAGTCCTCAAGCGCCTGCATATCCTGGAAGGTTTGCTGGTGGCGTTTCTCAACATCGACGAAGTGATTGAGATCATTCGTAACGAAGATGAACCGAAACCGGCGCTGATGTCGCGGTTTGGCCTTACGGAAACCCAGGCGGAAGCGATCCTCGAACTGAAACTGCGTCATCTTGCCAAACTGGAAGAGATGAAGATTCGCGGTGAGCAGAGTGAGCTGGAAAAAGAGCGCGACCAGTTGCAGGGCATTTTGGCTTCCGAGCGTAAAATGAATAACCTGCTGAAGAAAGAACTGCAGGCAGACGCGCAAGCCTACGGTGACGATCGTCGTTCGCCGTTGCAGGAACGCGAAGAAGCGAAAGCGATGAGCGAGCACGACATGCTGCCGTCTGAACCTGTCACCATTGTGCTGTCGCAGATGGGCTGGGTACGCAGCGCTAAAGGCCATGATATCGACGCGCCGGGCCTGAATTATAAAGCGGGTGATAGCTTCAAAGCGGCGGTGAAAGGTAAGAGTAACCAACCGGTAGTGTTTGTTGATTCCACCGGTCGTAGCTATGCCATCGACCCGATTACGCTGCCGTCGGCGCGTGGTCAGGGCGAACCACTCACCGGCAAATTAACGTTGCCGCCTGGGGCGACCGTTGACCATATGCTGATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGATGCGGGTTACGGTTTCGTCTGCACCTTTAACGATCTGGTAGCGCGTAACCGTGCGGGTAAGGCTTTGATCACCTTACCGGAAAATGCCCATGTTATGCCGCCGGTGGTGATTGAAGATGCTTCCGATATGCTGCTGGCAATCACTCAGGCAGGCCGTATGTTGATGTTCCCGGTAAGCGATCTGCCGCAGCTGTCGAAGGGCAAAGGCAACAAGATTATCAACATTCCATCGGCAGAAGCCGCGCGTGGCGAGGATGGTCTGGCGCAACTGTACGTTCTGCCGCCGCAAAGCACGCTGACCATTCATGTTGGGAAACGCAAAATTAAACTGCGTCCGGAAGAGCTACAGAAAGTCACTGGCGAACGTGGACGCCGCGGTACGTTGATGCGCGGTTTGCAGCGTATCGATCGTGTTGAGATCGACTCTCCTCGCCGTGCCAGCAGCGGTGATAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5332,Drugs,MEG_5332|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gb|NC_004337.2|-|3159154-3161413|ARO:3003941|Shigella flexneri parC conferring resistance to fluoroquinolones [Shigella flexneri 2a str. 301] ,3
,ATGCGGCCCACCATGCGACAGATACGTTCCACTGCGCCCATAAGCGGCCCTGGCGACTCCATGGAGCAGGACATGGCCTCGATCTGGCGGTTGGGCGGCGGGCGGACCCTGGACTGCTCCGGGGACCGCGTCATTGGCATCGTCAACGCCACGCCCGACTCCTTCTACGACGGCGGCCGCCACGGCGACGTGGCGGCCGCCGTATCCCATGGCCTGCGTCTGGCCGGGGAAGGGGCCGACATGCTCGACATCGGCGGCGAGTCCACCCGCCCCGGGGCCGCGCCTGTCACCGACGCCGAAGAAATCGACCGGGTCGTGCCGGTCATCGCCGAGCTTGCCCGCCGACTGCCGGACATGCCCATTGCCGTGGACACCTACCGGGCCGGCTGCGCCACCGCCGCCCTGGCCGCCGGAGCCTGCGCGGTCAACGACGTGTCGGGGCTGGCTTTCGATCCGGCGCTGCTTGAGGTCGTTGCGCAGCGCCAGCCCGGCTACGTGCTCATGCATACCAAAGGCCGGCCTGACGTCATGCAGCGCGACCCCCGTTACGACGATGTAATCGGCGAAATCCTGGCCTATTTCGAACAGGGGCTCACGCGCCTGACTCGGGCCGGGCTGCCTGAGGACCATGTGGTCCTTGATCCCGGCATCGGTTTCGGCAAGCTCTCGGAGCACAATCTGGAAATTTTGCGCAATCTTGAACGGTTTACGGTCTTTGGCCGGCCGGTCTATCTCGGGCTGTCCAACAAGTCGTTTTTCGGCGCGCTCCTTGGGCTGCCCGTGGGCGAGCGCACCGTGGCCACGGCCGTGGCCTCGGCCCTGTGCGCCGGGCGCGGGGCGCGCCTGCACCGCGTCCACGACGTCGCCGCCGTCAAACAAGCCCTGGGCCTGGCCGCCGCCCTGGCCGGCTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2941,Drugs,MEG_2941|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|239794502|dbj|AP010904.1|2875004-2874093 gi|295429362|gb|CP002008.1|2735747-2735717 gi|365809978|gb|CP003229.1|837792-837820 gi|337762320|emb|FQ859184.1|975363-975335,8
,atgaaactatccaccttagctttagcccctattactgcagcactacttacttttaatgcaagtgctaaaggccatgaccacgacaatcaacgcgcgatttttttccctggtgaaactgttcaagacactgtgaaagtcgaagttgagccttctgcgactcagtctctgaaactgggacaaaaaattaataatctgtatgagcgccagtttgataacagccaagccaccgttcaaaaattgggcaagaatacctactggataggggtcaattattacaacgctaccgttgtggttaacgaagactctgtcttgctgattgacccactaggcgatggtcgtattgatgcgctttttaaaggggtgcaatccatcacgaataaaccgatcactacgattatgtattctcactaccacttagatcatttaggtggtggcaaccaactggttgacttaattaagaaaaattatccaaaagtagataaaatccgcgttattgctagccaaaccgttgcggacaagatcaaccaacacgccgaagtaggcgaaaacggtgtgaaaaccccgaaagttccagcgccgaatgacatatacgacctgacgaagcctcaaacggttcaatttggctcaatgaaaatcaagatgatggcaccaaaaggctctggccatacacctgataacaccatgattctgatcccaagcgatcgcgtgttgcatttcgcggacatgattaatcccgatcaactaccgttttacaatttcgcgggagcagaacatttccacggttacgaagaagatctacaaagccttctgagcaaaccgctgagcaaacagtgggactttattaacggtggccatggcaatataggttcgaaacaggatgtaaaagatctgcttgagtatattgcggacatcagaactgaagtgggcaagcagctagaagtcgccccctacactccagtgttgagtgacggtaaccactttgtttggttcaaacgctggcaagatgagatcactaacaatgtacataccgcactggcaaacaagtatggccacatgtacggtttcgattcaggcgtggttgaaacacacgcggcaatgattctcgcagatatgattgatcactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7618,Drugs,MEG_7618|Drugs|betalactams|Class_B_betalactamases|VARG,446700834|WP_000778180.1|NG_057468|1|1|varG|varG|VarG_family_subclass_B1-like_metallo-beta-lactamase NG_057468:101-1225,0
,atgaaaaaaattatactcctatttatcttgacaagccagttggtgcttgctcaacatacttcaatattaaatgatataaatgctgttaccaaagacaagaaagccacagtagctgtttctgttttggggatagaaaatgattttcagtttagtaacgccaatggtaatttgaaaatgccgatgctgagtgtttttaaatttcatattgcattggcggttctaaatcaggtagacaaaggtaaccttaccttggatcagaaaatactgattaaaaaatcggatctattagaaaatacatggtcaccacttcgtgagaagtatccggatggaaatgtagaacttcctttaagcgaaattattacttatactgtagcccaaagtgacaacaacggatgcgacatactattaaggctaattggcgggactaaaactgttcagaaattaatggatgtgaatggtgtaaaaaactttcagataaaatataatgaggaagaaatgcataaaaatgatgtaaaaactctttatgcaaattacacaactacagcatctatggtaaaaactctgaaagcgttctataaaggaatgtttttatcaaaaagatccacaatttttctaatggatattatgactaaaaccaataccggaatgtcaaagcttccgggcttgctgccaaaagttagaatggccagaaaaacaggttcttcgggtaaaatgaaaaacggattaacgattgctgagaacgattcaggaattgtaactttagcaaatggtaaacattatgcaattgcagtatttgtaaaggactctatggaaggtgaggaagtcaattgtggaatcattgcccaggtctcgaaaattgtctgggatgctttaaataaaaaaaataaaccctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1735,Drugs,MEG_1735|Drugs|betalactams|Class_A_betalactamases|CME,1028104150|WP_063859570.1|NG_048765|1|1|blaCME-2|blaCME|class_A_extended-spectrum_beta-lactamase_CME-2 NG_048765:1-894,0
,ATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_361,Drugs,MEG_361|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|954629879|gb|CP013215.1|130784-131302 gi|944545016|gb|KR868995.1|371-889 gi|944545013|gb|KR868994.1|370-888 gi|806639053|gb|KM972600.1|1257-1775 gi|806639006|gb|KM972594.1|1230-1748 gi|806638978|gb|KM972589.1|1230-1748 gi|925170830|gb|KR337993.1|2043-2561 gi|925170817|gb|KR337990.1|1079-1597 gi|918039404|gb|KR259332.1|1738-2256 gi|914244709|gb|KR184824.1|573-1091,2
,CGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTATGCCGCACCCACCCCTATGGAGTCTTGATGTTAAAAGTTATTAGTAGTTTATTGGTCTACATGACCGCGTCTGTCATGGCTGTCGCAAGTCCGTTAGCCCATTCCGGGGAGCCGAGTGGTGAGTATCCGACAGTCAACGAAATTCCGGTCGGAGAGGTCCGACTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCGGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAAAAGCAAATTGGACTTCCCGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGCAGAGGGGAACGAGATTCCCACGCATTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAGCTCTTCTATCCTGGTGCTGCGCATTCGACCGACAATCTGGTTGTATACGTCCCGTCAGCGAACGTGCTATACGGTGGTTGTGCCGTTCATGAGTTGTCACGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCGTTGAGCGGATTCAAAAACACTACCCGGAAGCAGAGGTCGTCATTCCCGGGCACGGTCTACCGGGCGGTCTAGACTTGCTCCAGCACACAGCGAACGTTGTCAAAGCACACAAAAATCGCTCAGTCGCCGAGTAGCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_7766,Drugs,MEG_7766|Drugs|betalactams|Class_B_betalactamases|VIM,gi|825088250|gb|KP975074.1|107551-106682 gi|825088250|gb|KP975074.1|106601-105768 gi|636528809|gb|KJ551510.1|1120-1989 gi|402694763|gb|JX275775.1|1316-2185 gi|695225810|ref|NG_041423.1|17-886 gi|346720643|gb|JF915437.1|18-887 gi|346720643|gb|JF915437.1|900-1057 gi|283580179|gb|GU250441.1|71-940 gi|283580179|gb|GU250441.1|953-1110 gi|283580176|gb|GU250440.1|50-919 gi|283580176|gb|GU250440.1|932-1089 gi|242322372|emb|FN397623.1|197-1066 gi|194032844|emb|FM179467.1|206-1075 gi|194032844|emb|FM179467.1|1088-1245 gi|695212620|ref|NG_036464.1|6565-7434,0
,atgaataaatattttacttgctatgtgtttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaaccccgagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatctgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggactggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttctgcagtcccagtctatcaggaacttgcgcgacgtatcggtcttgatctcatgcaaaaagaagtaaaacgtattggtttcggtaatgctgaaattggacagcaggttgataatttctggttggtagggccattaaaggttacgcctattcaagaggtagagtttgtttctcaattggcgcatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgctacttctagaagagagtaatggctacaaaatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcactaaatatggaaatgcggtcaggaatgcctgcatctatacgtaatgaattattgatgaaatcattaaaacagctgaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4526,Drugs,MEG_4526|Drugs|betalactams|Class_D_betalactamases|OXA,1625655425|WP_136512102.1|NG_064769|1|1|blaOXA-811|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-811 NG_064769:1-822,0
,atgaaaaaattatttgttttatgtgtctttgtcttttgtagtattactgtcgcagctgagactttgcctaatttgagagttgaaaagcttgaagaaggtgtttatgttcatacatcgtatgaagaagttaaaggttggggtgttgttactaaacacggtttggtggttctcataggcgctgacgcctatctgattgatactccatttactgctaaagatactgaaaagttagtcaattggtttgtggagcgcggctataaaataaaaggcactgtttcctcacatttccatagcgacagtacggggggaatagagtggcttaactctcagtctatccccacgtatgcgtctgaattaacgaatgaacttctgaaaaaagacggtaaggttcaagccaaaaactcatttgacggggttagttattggctggcgaaagataaaatagaagtgttttatcctggccctggccacactcaagacaacgtagtagtttggctgcctgaaaaggaaatattatttggcggttgctttgttaagcctcacggccttggtaatttgggtgacgcaaatttagaggcttggccagagtccgccaaaatattgatggaaaaatatggtaaagcaaagctggttgtttcaggtcatagcgaaaccggagacgcgacacacttgaagcgtacctgggagcaggctgttaaaggacttaaagaaagtaaaaagacattgcagccaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3323,Drugs,MEG_3323|Drugs|betalactams|Class_B_betalactamases|IMP,1102724730|WP_071593226.1|NG_054710|1|1|blaIMP-64|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-64 NG_054710:101-841,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcgggtatctccgagccagccatgatcgacgttgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgctcacgttgtcccgcatttggtacaccgaagtaaccggcaaaatcgtgccgaaggatgtcgctgccgactgggcaatggagcgcctacctgcccagcatcagcccgtcttacttgaagctagacaggcttatcttggacaaaaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcacttcgtgaaaggcgagatcactaaggtagtcggcaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_806,Drugs,MEG_806|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502120|WP_071846272.1|NG_052313|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052313:101-892,2
,atgagcaactctatacacaccggaatctcaagacagctttcacaggcacgcgatgtaattaaacgccatttggcatcaacgctgaaggccatacacttgtatggttctgcaattgatggtggcctcaaaccatatagcgacattgatctgctggttaccgtggatgcacgcttggatgaagctaccagacgctccctgatgctcgatttcttgaatatctcggcaccaccatgcgaaagctcaatactccggccgctagaggtaactgttgttgcatgcaacgaagtagtgccttggcgttatccggcacgacgagaactgcagttcggggagtggctgcgggaggatattcttgaaggtgtcttcgagccagccgccttggacgccgaccttgcaattctaataacgaaagctaggcaacacagcatcgctttagtaggtccagtggctcaaaaagtcttcatgccggtgccagagcatgactttctccaggtgctttccggtacccttaagctgtggaatactcatgaggattgggaaaatgaggagcggaacatcgtactcacgttagctcggatctggtatagcactgaaactggaggaatcgtccccaaggatgtggccgccgaatgggttttagagcgcttgccagctgagcataagccaatactggttgaggcgcggcaagcctatcttgggctttgcaaggatagtcttgctttgcgtgcagatgagacttcggcgttcattggctatgcaaagtctgcggtcgctgatttgctcgaaaagcgaaaatctcaaacttcgcatatttgcgatggcgccaagaacgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_765,Drugs,MEG_765|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081075|WP_063840458.1|NG_047369|1|1|aadA9|aadA9|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA9 NG_047369:101-937,2
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagcaagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaattccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggataggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggagcgacttggcatcgcggtgattggttag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5913,Drugs,MEG_5913|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1189819218|WP_085843691.1|NG_059332|1|1|qnrB95|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB95 NG_059332:101-745,3
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCCCTTTATCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCTGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGATGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1918,Drugs,MEG_1918|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JX440353|+|1026-2172|ARO:3002090|CMY-77 [Citrobacter sp. W1065] ,0
,gtgagctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttattggcatcactcggcatggacatgtacttgccagcagttccgtttatgccaaacgcgcttggtacgacagcgagcacaattcagcttacgctgacaacgtacttggtcatgattggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgctcttacgtcatcggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacatttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaatgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggcctgaaacccgggtgcaacgagttgcgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaatgatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgttcgccacagtggcaattgccatggtgtttacggctcgttttatggggcgtgtgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggctttgcagtccgtgttaggctttattgctccaatgtggctagtgggtattggtgtcgccacagcggtatctgtggcgcccaatggcgctcttcgaggattcgaccatgttgctggaacggtcacggcagtctacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagtgaagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacatcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1754,Drugs,MEG_1754|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,446017870|WP_000095725.1|NG_047648|1|1|cmlA1|cmlA1|chloramphenicol_efflux_MFS_transporter_CmlA1 NG_047648:101-1360,6
,atgaatcattccccgttgcgccgttcgctgctcatcgcagccgtttccgcaccgctcgtcggcgcatgtgcgccgctgcgggacaacgccagaaacgtcgccgccgagcagcaattgcgcgaactcgagtcgaccttcgacggccgcctcggcttcgtcgcgctcgataccgcgacaggcgcgcgcatcgcgcatcgcgccgacgagcgcttcccgttctgcagtacgttcaagacgatgctgtcggccgcggttctcgcgcgcagcgccggcgacgccgcgctgttgcagcgacggattccgtatgcgaagcgcgacctcgtccgctactcgccgatcaccgagaagcacgtcggcgccggcatgacggttgccgagctgtgcgcggcgacgctccagtacagcgacaacaccgcggcgaatctgctgatcgcgttgctcggcggcccgcaggccgtcaccgcgtatgcgcgctcgatcggcgacgcgacattccgcctcgatcgccgcgagaccgaactgaacacggcgattcccggcgacgagcgcgatacgacgacgcctgccgcgatggccgcgagcgtgcgccggctgctcgtcggcgacgcgctcggcaccgcgcagcgcgctcagctcaatgcgtggatgctcggcaacaagacgggcgacgcgcgaatccgcgcgggcgtgccggccggctggcgcgttgccgacaagacgggcacgggcgactacggcacggggaacgacatcggcgtcgcgtatccgcccgatcgcgcgccgatcgtgttcgtcgtctatacgacgatgcgcagtcggaacgcgcaggcgcgcgacgacgtgatcgcgtcggcggcgcggatcgccgcgcgcgctttcgtctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5756,Drugs,MEG_5756|Drugs|betalactams|Class_A_betalactamases|PENI,644829382|WP_025370306.1|NG_048033|1|1|penI_Bp|penI_Bp|PenI_family_class_A_extended-spectrum_beta-lactamase NG_048033:101-985,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgcgacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5583,Drugs,MEG_5583|Drugs|betalactams|Class_C_betalactamases|PDC,730627004|WP_034056534.1|NG_049948|1|1|blaPDC-72|blaPDC|class_C_beta-lactamase_PDC-72 NG_049948:1-1194,0
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctcagcgcaatccccactgttaaaagagcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctgggctccgataatgaaagcgtatcagggagacgagtttagtgttccagtgcagcaactgctgctatactcggtctcgcacagcgataacgtggcctgtgatttgttatttgaactggttggtggaccagctgctttgcatgactatatccagtctatgggtataaaggagaccgctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaaaggtgctgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccaccacaggaccagagcggttaaaaggtttgttaccagctggtactgtggtcgcacataaaactggtacttcgggtatcaaagccggaaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggttgctcagactgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5759,Drugs,MEG_5759|Drugs|betalactams|Class_A_betalactamases|PER,1028110227|WP_063864597.1|NG_049968|1|1|blaPER-9|blaPER|class_A_extended-spectrum_beta-lactamase_PER-9 NG_049968:1-927,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttagcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_883,Drugs,MEG_883|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1102724707|WP_071593203.1|NG_052028|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052028:101-892,2
,TGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCGGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGGGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3510,Drugs,MEG_3510|Drugs|betalactams|Class_A_betalactamases|KPC,gi|909893998|gb|CP012168.1|175556-174676 gi|902717325|gb|KR091915.1|29965-30845 gi|429201046|gb|JX193301.1|54275-55155 gi|392356698|gb|JQ837276.1|28045-28925 gi|218685693|gb|FJ473382.1|365-1245 gi|168830102|gb|EU447304.1|16-896 gi|51557251|gb|AY700571.1|1-881,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgctatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcatggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3476,Drugs,MEG_3476|Drugs|betalactams|Class_A_betalactamases|KPC,1121570438|WP_073800284.1|NG_055495|1|1|blaKPC-32|blaKPC|inhibitor-resistant_carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-32 NG_055495:101-982,0
,ATGCAGTTAATATCTTTACCAAAGCAGATTTTACAGTGTGGACAGCTTCAATTAGATTTATCTCAGCCCCATGTTATGGGTATCTTAAATGTCACTCCTGATTCTTTCAGTGATGGTGGTAAACATAACCAATTAGACCAAGCGGTTGATCATGCACTTAGTATGATTGAGCAAGGCGCGACTATTATTGATATTGGGGGGGAATCTACCCGACCTGGTGCTTCAGAAGTTGTAGTAGAAGAAGAAGTGCGTCGTGTGGTACCTGTGGTCGAGGCTTTATCTTACCATAACGTTATTTTGTCGATCGACACAAGTCAGCCAGAAGTTATTCGCGCAGCAAAAGCAGCAGGGGCACATATCTGGAATGATGTCCGTGCCTTAACACGTCCCAATGCTTTAAAAACTGCCGTAGAATTAGATATACCTGTAGTAATTATGCATATGCGCGGTGAACCAACGACAATGAATCAGTTGGATCAGTACACTGATGTAACACTCGATGTGATGCAAGAGTTGCAACAGCGTATTGATGAGGCTTTGGCTGCTGGGGTAAAAAAGCACAATATTATTGTTGATCCTGGATTTGGCTTTGCGAAAAATGCCCAGCAAAATTTAAAACTATTAAAAGAATTTTGGAAACTTAATGAACTTGGTTATCCAATTTTATCCGGGCTTTCTCGTAAACGTTTCATAGGTGAAGCTTTACAAGGTGTTCCTGCAGATCAACGTGCTGTGGGAAGTGTAACTGGGCATTTGCTTAGTATTCAGCAGGGAGCATCCATTGTAAGAGCGCATGATGTAAAGGAAATGCATGAAGCAATTTTAGTTTGGAAAGCTATGCAGCAAGCCTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2961,Drugs,MEG_2961|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|939559781|gb|CP012952.1|947948-948799 gi|751410783|gb|CP010781.1|3063963-3063112 gi|213985689|gb|CP001172.1|855500-856351 gi|213054530|gb|CP001182.1|3203718-3202867 gi|169147133|emb|CU459141.1|853404-854255,8
,atggaaaaatacaacaattggaaacgaaaattttatgcaatatgggcagggcaagcagtatcattaatcactagtgccatcctgcaaatggcgattattttttaccttacagaaaaaacaggatctgcgatggtcttgtctatggcttcattagtaggttttttaccctatgcgattttgggacctgccattggtgtgctagtggatcgtcatgataggaagaagataatgattggtgccgatttaattatcgcagcagctggtgcagtgcttgctattgttgcattctgtatggagctacctgtctggatgattatgatagtattgtttatccgtagcattggaacagcttttcataccccagcactcaatgcggttacaccacttttagtaccagaagaacagctaacgaaatgcgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcagttgcagcactcttatactccgtttgggatttaaatgctattattgccatcgacgtattgggtgctgtgattgcatctattacggtagcaattgtacgtatacctaagctgggtaatcaagtgcaaagtttagaaccaaatttcataagggagatgaaagaaggagttgcggttctgagacaaaacaaaggattgtttgccttattactcttaggaacactatatacttttgtttatatgccaatcaatgcactatttcctttaataagcatggaacactttaatggaacgcctgtgcatatttctattacggaaatttcctttgcatttgggatgctagcaggaggcttattattaggaagattagggggcttcgaaaagcatgtattactaataacaagttcattttttataatggggaccagtttagccgtttcgggaatacttcctccaaatggatttgtaatattcgtagtttgctgtgcaataatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttgatcggaagtatcatgtcacttgctatgccaattgggttaattctttctggattctttgctgataaaatcggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgccaaatgataactgaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3805,Drugs,MEG_3805|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,1028096951|WP_063853648.1|NG_047969|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047969:1-1218,7
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCAATGAGTGTAATCGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCTTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTCAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGCGATAGCGCCGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGGTAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTGTTAATTAACGGTGCTGCTGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACCGGTCCTGATTTCCCTACAAGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATTCGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAAGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGTCATATCTTGGAAGGCTTGACAGTTGCCTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCAATTTATCGTCTGTCTCCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTCAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGCGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTAATTCCAGAAGAGCAAGTGGTATTAACTGTTTCACAAACAGGTTATGCAAAAACTCAACCACTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCAACCTCAATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCAAACCATGCGACCGTACTTTGCTTTACCAATGTGGGTAAAGTGTACCGTCTGAAAGTATTTGAAGTTCCTCAAGCATCACGTGGGGCAAAAGGTCGTCCAATCGTGAACTTGTTACCTCTAGATGCAACAGAAACCGTAACCGCAATCTTGCCGTTAACCGAGTTCCTGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAACAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACCTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAAGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGTGGTATGCGTGTAAGCTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAGCAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTGCCTGAGACAGGTGAAGTACTGTGTGCGAGTGCCAACGGCTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTTGTTGGCGTAGTTTCAATTGAAACTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3193,Drugs,MEG_3193|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|169150821|emb|CU468230.2|799373-802087,3
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccaatgatatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggtatggtaccttccaacggaatgattgttatcaacaaccatcaggcagcgttgctggacacaccgatcaatgacgcacaaacggaaacgctggtcaactgggtagcggactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccaatcatatgcaaaccagatgacgatagacctcgccaaggaaaaagggttgcccgtaccggaacatggattcaccgattcactgaccgtcagcttggacggcatgcctctccaatgttattatttaggaggcggacatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccaggcgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggcgactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacctcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1658,Drugs,MEG_1658|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444886|WP_085562388.1|NG_054673|1|1|cfiA18|cfiA|subclass_B1_metallo-beta-lactamase_CfiA18 NG_054673:1-750,0
,atggaactgcgtggggacagggtcgtgctgcggccggtggcagagggcgatcccgaagtcctcgaccggatcgtcagggaaccggaagtcgcggcgtggtggtcgcccccggacgactacgccggcatgctggccgtcgtcctcgggggtgacgtcatcggagccgtccagttcgacgaggagaccgaccccgagttccgccgggcgggcatcgacatcttcctgacggcgcggcgccacgggcaggggctcggcaccgacacggtccgcacgctggcccggtggctggtacgggaacgcggccaccaccggctgaccatcgatcccgccgcagccaacacagcggcgatccgcagctaccgcaaggtcggattcaaacccgtggggatcatgcgcaagtactggcgcggccaccggacgggcacctggcaggacgggctgctgatggacctgctcgcggacgagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_193,Drugs,MEG_193|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,702800658|WP_033268654.1|NG_052341|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052341:101-574,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaataccccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggtccactcgatgccccagaatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaacctcaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaccggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_608,Drugs,MEG_608|Drugs|betalactams|Class_C_betalactamases|ADC,1440786780|WP_114699268.1|NG_061390|1|1|blaADC-174|blaADC|class_C_beta-lactamase_ADC-174 NG_061390:1-1152,0
,TGAACATAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTACACATGCAAGTCGGACGGCAGCACAGAGAAGCTTGCTTCTCGGGTGGCGAGTGGCGAACGGGTGAGTAACATATCGGAACGTACCGAGTAGTGGGGGATAACTGATCGAAAGATCAGCTAATACCGCATACGTCTTGAGAGAGAAAGCAGGGGACCTTCGGGCCTTGCGCTATTCGAGCGGCCGATATCTGATTAGCTAGTTGGTGGGGTAAAGGCCTACCAAGGCGACGATCAGTAGCGGGTCTGAGAGGATGATCCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGGACAATGGGCGCAAGCCTGATCCAGCCATGCCGCGTGTCTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCAGGGAAGAAAAGGCTGTTGCTAATATCAGCGGCTGATGACGGTACCTGAAGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTAATCGGAATTACTGGGCGTAAAGCGGGCGCAGACGGTTACTTAAGCAGGATGTGAAATCCCCGGGCTCAACCCGGGAACTGCGTTCTGAACTGGGTGACTCGAGTGTGTCAGAGGGAGGTAGAATTCCACGTGTAGCAGTGAAATGCGTAGAGATGTGGAGGAATACCGATGGCGAAGGCAGCCTCCTGGGACAACACTGACGTTCATGCCCGAAAGCGTGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCCTAAACGATGTCAATTAGCTGTTGGGCAACCTGATTGCTTGGTAGCGTAGCTAACGCGTGAAATTGACCGCCTGGGGAGTACGGTCGCAAGATTAAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATGTACGGAATCCTCCGGAGACGGAGGAGTGCCTTCGGGAGCCGTAACACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCATTAGTTGCCATCATTCAGTTGGGCACTCTAATGAGACTGCCGGTGACAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTATGACCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTAGCCAAGCCGCGAGGCGGAGCCAATCTCACAAAACCGATCGTAGTCCGGATTGCACTCTGCAACTCGAGTGCATGAAGTCGGAATCGCTAGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTGGGGGATACCAGAAGTAGGTAGGATAACCACAAGGAGTCCGCTTACCACGGTATGCTTCATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTAGGGGAACCTGCGGCTGGATCACCTCCTTTCT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_7,Drugs,MEG_7|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NC_003112|+|60970-62514|ARO:3003497|Neisseria meningitidis 16S rRNA mutation conferring resistance to spectinomycin [Neisseria meningitidis MC58] ,2
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagttaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7224,Drugs,MEG_7224|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,705394234|WP_033493020.1|NG_048299|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048299:101-2020,4
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAACGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1905,Drugs,MEG_1905|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733571|+|1027-2173|ARO:3002062|CMY-51 [Citrobacter freundii] ,0
,AAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGTTTCATTCTGGCGACGTCCGTATTTGCCTTTCGGAAGCATAAAATCGGACGCGTTGTGGCTCGCTTCAGGTAAAATATTGACTATTCATGTTGTTGTTATTTCGTCTCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAATGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGTGCTGTCGCCCACCTGCGCTTGCGCATACCAGGCCATAAGCTCCGTGGTTCCTGGTTCTCCTTCCGCTGGAGCCCAGTGCGCATAGTCATCGGCAGCCACGGGTTGATAGCCACCGTGTTTTACTTCAAAAATTATGCCACCGGTATCCAGCGACAGCACGGCATGCCAGGTTCCTGCGGCCATCTCCAGCACCGTACAGGTTTCCCCCAATATCGCTCGATGGGTGACGGTACCCCGATCGTCAAAATTCAGCACCACGAAACGACCCCTTAATGGCAACAGTAGCTCGAAGGTGTGAGGGTGTCGGTGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2421,Drugs,MEG_2421|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695212498|ref|NG_036425.1|1-1486 gi|529205529|gb|KC788405.1|41495-41384,0
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGATAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGGCTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTATAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCCATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTTATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1697,Drugs,MEG_1697|Drugs|betalactams|Class_A_betalactamases|CFX,gi|21327012|gb|AF504914.1|1-966,0
,ATGAGCAAGTTATCTGTATTCTTTATATTTTTGTTTTGTAGCATTGCTACCGCAGCAGAGCCTTTGCCAGATTTAAAAATTGAAAAACTTGATGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGGTGGGGCGTTTTTCCTAAACATGGTTTGGTTGTTCTTGTAGATGCTGAAGCTTATCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACTTGGTTTGTGGAACGTGGCTATAAAATAAAAGGCAGTATTTCCTCTCATTTTCATAGTGACAGCACGGGCGGAATAGAGTGGCTTAATTCTCAATCCATCCCCACGTATGCGTCTGAATTAACTAATGAGCTGCTTAAAAAAGACGGTAAGGTTCAAGCTAAAAATTCATTTGGCGGGGTTAACTATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCAGGACACACTCCAGATAACCTAGTAGTTTGGCTGCCTGAAAGGAAAATATTATTCGGTGGTTGTTTTATTAAACCGTACGGTCTAGGTAATTTGGGTGACGCAAATTTAGAAGCTTGGCCAAAGTCCGCTAAATTATTAATATCCAAATATGGTAAGGCAAAACTGGTTGTTCCAAGTCACAGTGAAGCTGGAGACGCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAACCATCAAAACTAAGCAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3341,Drugs,MEG_3341|Drugs|betalactams|Class_B_betalactamases|IMP,(Bla)IMP-4:DQ307573:3-743:741,0
,atgagtaacgcagtacccgccgagatttcggtacagctatcactggctctcaacgccatcgagcgtcatctggaatcaacgttgctggccgtgcatttgtacggctctgcactggacggtggcctgaagccatacagtgatattgatttgctggttactgtggctgcacggctcgatgagactgtccgacaagccctggtcgtagatctcttggaaatttctgcctcccctggccaaagtgaagctctccgcgccttggaagttaccatcgtcgtgcatggtgatgttgtcccttggcgttatccggccagacgggaactgcaattcggggagtggcagcgtaaggacattcttgcgggcatcttcgagcccgccacaaccgatgttgatctggctattctgctaactaaagtaaggcagcatagccttgcattggcaggttcggccgcagaggatttctttaacccagttccggagggcgatctattcaaggcattgagcgacactctgaaactatggaattcgcagccggattggggaggcgatgagcggaatgtagtgcttaccttttctcggatttggtacagcgcagcaacccgcaagatcgcaccaaaggatatcgttgccaactgggcaatggagcgtctgccagatcaacataagcccgtactgcttgaagcccggcaggcttatcttggacaaggagaagattgcttggcctcacgcgcggatcagttggcggcgttcgttcacttcgtgaaacatgaagccactaaattgcttagtgccatgccagtgatgtctaacaatttatatatggactctccccacaagcagtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_898,Drugs,MEG_898|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502042|WP_071846194.1|NG_052151|1|1|aadA6|aadA6|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA6 NG_052151:101-940,2
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttatccacgtttgccgccgccaaaacagaaccacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggctgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcaccaataaccacccagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctacacggcaggcggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgtttttatcaaaactggcagccgcaatgggccccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaaggctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggtcaacatggacgccagccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcaatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggatccactggaggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccttgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1812,Drugs,MEG_1812|Drugs|betalactams|Class_C_betalactamases|CMY,1028104597|WP_063859917.1|NG_048893|1|1|blaCMY-96|blaCMY|class_C_beta-lactamase_CMY-96 NG_048893:1-1146,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttagaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtagttcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_536,Drugs,MEG_536|Drugs|betalactams|Class_C_betalactamases|ADC,1028102028|WP_063857805.1|NG_048662|1|1|blaADC-51|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-51 NG_048662:1-1152,0
,ATGAAAAAAATTGCCGTTTTATTTGGAGGGAATTCTCCAGAATACTCAGTGTCACTAACCTCAGCAGCAAGTGTGATCCAAGCTATTGACCCGCTGAAATATGAAGTAATGACCATTGGCATCGCACCAACAATGGATTGGTATTGGTATCAAGGAAACCTCGCGAATGTTCGCAATGATACTTGGCTAGAAGATCACAAAAACTGTCACCAGCTGACTTTTTCTAGCCAAGGATTTATATTAGGAGAAAAACGAATCGTCCCTGATGTCCTCTTTCCAGTCTTGCATGGGAAGTATGGCGAGGATGGCTGTATCCAAGGACTGCTTGAACTAATGAACCTGCCTTATGTTGGTTGCCATGTCGCTGCCTCCGCATTATGTATGAACAAATGGCTCTTGCATCAACTTGCTGATACCATGGGAATCGCTAGTGCTCCCACTTTGCTTTTATCCCGCTATGAAAACGATCCTGCCACAATCGATCGTTTTATTCAAGACCATGGATTCCCGATCTTTATCAAGCCGAATGAAGCCGGTTCTTCAAAAGGGATCACAAAAGTAACTGACAAAACAGCGCTCCAATCTGCATTAACGACTGCTTTTGCTTACGGTTCTACTGTGTTGATCCAAAAGGCGATAGCGGGTATTGAAATTGGCTGCGGCATCTTAGGAAATGAGCAATTGACGATTGGTGCTTGTGATGCGATTTCTCTTGTCGACGGTTTTTTTGATTTTGAAGAGAAATACCAATTAATCAGCGCCACGATCACTGTCCCAGCACCATTGCCTCTCGCGCTTGAATCACAGATCAAGGAGCAGGCACAGCTGCTTTATCGAAACTTGGGATTGACGGGTCTGGCTCGAATCGATTTTTTCGTCACCAATCAAGGAGCGATTTATTTAAACGAAATCAACACCATGCCGGGATTTACTGGGCACTCCCGCTACCCAGCTATGATGGCGGAAGTCGGGTTATCCTACGAAATATTAGTAGAGCAATTGATTGCACTGGCAGAGGAGGACAAACGATGAACACATTACAATTGATCAATAAAAACCATCCATTGAAAAAAAATCAAGAGCCCCCGCACTTAGTGCTAGCTCCTTTTAGCGATCACGATGTTTACCTGCAGCCAGAAGTGGCAAAACAATGGGAACGACTCGTACGAGCAACCGGACTAGAAAAGGACATTCGTCTGGTAGATGGGTATCGTACGGAAAAAGAACAGCGACGCTTGTGGGAGTATTCTCTAAAAGAAAACGGGTTAGCTTATACCAAACAATTCGTTGCTTTGCCAGGTTGCAGTGAACATCAAATCGGTCTGGCCATTGATGTAGGACTAAAGAAACAAGAAGATGATGATCTTATCTGCCCTCATTTTCGAGATAGTGCTGCTGCTGATTTATTTATGCAGCAGATGATGAATTATGGCTTTATTCTACGCTATCCGGAAGATAAACAAGAGATCACCGGTATCAGTTATGAACCTTGGCATTTTCGTTATGTCGGGCTTCCCCATAGCCAAGTCATCACTGCCCAAAAATGGACTCTGGAAGAATACCATGATTACTTGGCTCAGACAGTGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7373,Drugs,MEG_7373|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC1XY_1_AF162694,5
,TATCGCGTGTCTTTCGAGTACGGCATTAGCTGGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTCTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAACGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAGCAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTTCAACAAATCACCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCCTATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAAGACCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCATCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATATCTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGTGAGGGCATCATTGGTGGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5268,Drugs,MEG_5268|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-16_1_AF043100 ,0
,atgaaaaacacaatacatatcaacttcgctatttttttaataattgcaaatattatctacagcagcgccagagcatcaacagatatctctactgttgcatctcaattatttgaaggaactgaaggttgttttttactttacgatgcatccacaaacgctgaaattgctcaattcaataaagcaaagtgttcagcgcaaatggcaccagattcaactttcaaaatcgcattatcacttatggcatttgatgcagaaataatagatcagaaaaccatattcaaatgggataaaatcccaaaaggaatggaaatttggaacagcaatcatacaccaaagacgtggatgcaattttctgttgtttgggtttcgcaagaaataacccaaaaaattggattaaataaaattaagaattatctcaaagattttgattatggaaatcaagacttctcgggagataaagaaagaaacaatggattaacagaagcatggctcgaaagtagcttaaaaatttcaccggaagaacaaattcaattcctgcgtaaaattattaatcacaatcttccagttagaaattcagccatagaaaacaccatagataacatgtatctacaagatctggagaatagtacaaaactgtatgggaaaactggtgcaggattcacagcaaatagaaccctacaaaacggatggtttgaagggtttatcataagcaaatcaggacgtaaatatgtttttgtgtccgcacttacaggaaacttggggtcgaatttaacatcaagcataaaagccaagaaaaatgcaattaccattctaaacacactaaatttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4669,Drugs,MEG_4669|Drugs|betalactams|Class_D_betalactamases|OXA,1509794548|WP_122630857.1|NG_062270|1|1|blaOXA-675|blaOXA-1_like|OXA-1_family_class_D_beta-lactamase_OXA-675 NG_062270:1-831,0
,CAATTTTATAAGTCTTATGAACATTAAAGCCCTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTCTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGACAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGACGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTAAAGGAAATATTGTAGCATTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTTACCATTTTGATCTGGGCCATTGCCTATTTTCAAAACTGATAATCTAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5228,Drugs,MEG_5228|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389145|gb|KF986255.1|1-916,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_230,Drugs,MEG_230|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080897|WP_063840280.1|NG_056043|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_056043:5-559,2
,GTGCGTTTCGACAATGCATCTATTGTAGTATATTATTGCTTAATCCAAATGAATATTATAAATTTAGGAATTCTTGCTCACATTGATGCAGGAAAAACTTCCGTAACCGAGAATCTGCTGTTTGCCAGTGGAGCAACGGAAAAGTGCGGCCGTGTGGATAATGGTGACACCATAACAGACTCTATGGATATAGAGAAACGTAGAGGAATTACTGTTCGGGCTTCTACGACATCTATTATCTGGAATGGAGTGAAATGCAATATCATTGACACTCCGGGACACATGGATTTTATTGCGGAAGTGGAGCGGACATTCAAAATGCTTGATGGAGCAGTCCTCATCTTATCCGCAAAGGAAGGCATACAAGCGCAAACAAAGTTGCTGTTCAATACTTTACAAAAACTGCAAATCCCGACAATTATATTTATCAATAAAATTGACCGTGACGGTGTGAATTTAGAGCGTTTGTATCTGGATATAAAAACAAATCTGTCTCAAGATGTCCTGTTTATGCAAACTGTTGTCGATGGATTGGTTTATCCGATTTGCTCCCAAACATATATAAAGGAAGAATACAAAGAATTTGTATGCAACCATGACGACAATATATTAGAACGATATTTGGCGGATAGCGAAATTTCACCGGCTGATTATTGGAATACGATAATCGATCTTGTGGCAAAAGCCAAAGTCTATCCGGTACTACATGGATCAGCAATGTTCAATATCGGTATCAATGAGTTGTTGGACGCCATCTCTTCTTTTATACTTCCTCCAGAATCAGTCTCAAACAGACTTTCAGCTTATCTCTATAAGATAGAGCATGACCCCAAAGGACATAAAAGAAGTTTTCTAAAAATAATTGACGGAAGTCTGAGACTTCGAGACATTGTAAGAATCAACGATTCGGAAAAATTCATCAAGATTAAAAATCTAAAGACTATTTATCAGGGCAGAAAGATAAATGTTGATGAAGTGGGGGCCAATGATATCGCGATTGTAGAAGATATGGAAGATTTTCGAATCGGAGATTATTTAGGTACTAAACCTTGTTTGATTCAAGGGTTATCTCATCAGCATCCCGCTCTCAAATCCTCCGTCCGGCCAGACAGGTCCGAAGAGAGAAGCAAGGTGATATCCGCTCTGAATACATTGTGGATTGAAGACCCGTCTTTGTCCTTTTCCATAAACTCATATAGTGATGAATTGGAAATCTCGTTATATGGTTTGACACAAAAGGAAATCATACAGACATTGCTGGAAGAACGATTTTCCGTAAAGGTCCATTTTGATGAGATCAAGACTATCTACAAAGAACGACCTGTAAAAAAGGTCAATAAGATTATTCAGATCGAAGTGCCACCCAACCCTTACTGGGCCACAATAGGGCTGACGCTTGAACCCTTGCCGTTAGGGACAGGGTTGCAAATCGAAAGTGACATCTCCTATGGTTATCTGAACCATTCTTTTCAAAATGCCGTTTTTGAAGGGATTCGTATGTCTTGCCAATCTGGTTTACATGGATGGGAAGTGACTGATCTGAAAGTAACTTTTACTCAAGCCGAGTATTATAGCCCGGTAAGTACACCTGCTGATTTCAGACAGCTGACCCCTTATGTCTTCAGGCTGGCCTTGCAACAGTCAGGTGTGGACATTCTCGAACCGATGCTCTATTTTGAGTTGCAGATACCCCAAGCGGCAAGTTCCAAAGCTATTACAGATTTGCAAAAAATGATGTCTGAGATTGAAGACATCAGTTGCAATAATGAGTGGTGTCATATTAAAGGGAAAGTTCCATACAATACAAGTAAAGACTACGCCTCAGAAGTAAGTTCATACACTAAGGGCTTAGGCGTTTTTATGGTCAAGCCATGCGGGTATCAAATAACAAAAGGCGATTATTCTGATAATATCCGCATGAACGAAAAAGATAAAATTTTATTCATGTTCCAAAAATCCAATGTCATCAAAATAATGGAGCGGTCAGGAAATTTCTATAAGGCAATACAGTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7182,Drugs,MEG_7182|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETQ,gi|1916015|gb|U73497.1|PIU73497|308-2320,4
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagatacttcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2166,Drugs,MEG_2166|Drugs|betalactams|Class_A_betalactamases|CTX,1035157526|WP_064511491.1|NG_050813|1|1|blaCTX-M-184|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-184 NG_050813:1-876,0
,atgaactatacaaaatttgatgtaaaaaattgggttcgccgtgagcattttgagttttatcggcatcgtttaccatgtggttttagcttaacaagcaaaattgatatcacgacgttaaaaaagtcattggatgattcagcgtataagttttatccggtaatgatctatctgattgctcaggccgtgaatcaatttgatgagttgagaatggcgataaaagatgatgaattgatcgtatgggattcagtcgacccacaattcaccgtattccatcaagaaacagagacattttcagcactgagttgcccatactcatccgatattgatcaatttatggtgaattatttatcggtaatggaacgttataaaagtgataccaagttatttcctcaaggggtaacaccagaaaatcatttaaatatttcagcattaccttgggttaattttgatagctttaatttaaatgttgctaattttaccgattattttgcacccattataacaatggcaaaatatcagcaagaaggggatagactgttattgccgctctcagtacaggttcatcatgcagtttgtgatggcttccatgttgcacgctttattagtcggctacaagagttgtgtaacagtaaattaaaataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1562,Drugs,MEG_1562|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,492379426|WP_005826111.1|NG_052661|1|1|catA3|catA3|type_A-3_chloramphenicol_O-acetyltransferase_CatIII NG_052661:1-642,6
,atgaaaagcaaagtcagtgcgctgttaatgatgatagttctcgcgggccatgcgcaggccgcgcccgttgcgccaccggatgcggtcgttaagccgttgatggcgcgttaccagatcccgggcatggcggtggcggtgtcggtcaatggcgaaacgcatttctggcactacggcgtggcgtcaaaagcgacgcgcaagccggtggatgaaaaaacgcttttcgaaatcggctcgctcagtaaaacctttaccgcgacgctcgcaagcggggcgcagcatgaggggaaactggatttcagcgcgcccgccagccagtatcttcctgcactgaaaggcagcgcgttcgaccacgtgacgctgctgaacctcgccacgcacaccgcgggaacgccgctctttgtgccggatgcggtgaaaaacaccgcgcagctgatggcatggtatcgcgcctggcagcctgaaaagccggtcggcaccgagcgcgtatactcgaatctcgggatcgggctgctcgggatgattaccgcgaaggcgctcgataaaccgttcagcgaggcgatggagcaggggctgcttaagggtttcggcatgacgcacacctttatcaacgtgccggatgccgcgatggacgactacgcccagggctataacaaagacgacaaaccggtgcgggtgacgcccggcccgctggatgctgaatcctatgggctgaagtccggcagcgccgacctgctgcgttatctgcaaattcagcttggcgagcaggaggtggcgccaggctggcgtcaggcgattaacgccacgcataacggctactaccgcagcggtgagttcacacagggaatgatgtgggaatattatccgtggccatcgccgctctcgcgccttgttgaaggcaacagcagccagcgcatcatgaaagggctcgcggccaccgctattgtgccgccgcagcccgcaccagaggccgcgtggtataacaaaaccggttcgaccaacgggttttccacttacgcggtgtttatccctgaaaagcgtatcgcgctgattatgctcgccaacaagtggttcccgaatgacgaccgcgtgaaggcggcgtatgcgattattcagcagcttgataagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1734,Drugs,MEG_1734|Drugs|betalactams|Class_C_betalactamases|CMA,696402111|WP_032974004.1|NG_062222|1|1|blaCMA-1|blaCMA|class_C_beta-lactamase_CMA-1 NG_062222:101-1228,0
,ATGTCAAAATCACTTATAACCGCACTCATTGTTGTCGCGCTTGATGCGATTGGTTTGGGATTAATCATGCCGGTGGTTCCGGCTTTATTAAATGAATTTGTACCGGCAGAGCAAACAGCATTTCACTATGGTGTTTTTTTATCGCTTTATGCGTTTATGCAGGTCTTTTGCGCGCCCGTTTTAGGGCGGTTATCTGACCGCTATGGACGGCGGATTATTTTGCTGGTTTCATTTTTAGGTGCCACGATTGATTATAGCATAATGGCGGCAGCGCCTGTTTTATGGGTGCTTTATATCGGCCGGATCATCTCAGGTGTTACCGGAGCAACTGGTGCAATCGCGGCATCAATTATCGCTGATACAACTAAACAGGAAGAACGTGCGCGTTGGTTTGGTTTTATGGGGGCGTGTTTTGGTGCAGGTATGATTGCAGGGCCTGCTATTGGCGGTGTTCTTGGTGATATATCTGTGCATGCGCCCTTTGTGGCAGGGGCTCTTCTCAATGCAATTGCTTTTTGTTTGGTGGCTTTCTTGTTGCCCAAAGCGTCGTCACAACCGCCCGAAGGGCAGCCAGCCAAAATCAATTTGTTTGAAGGTTTTCGTTTCAATTTTGCAGTTCAGGGACTTACCAGCTTTTTTGCGTTGTTTTTTCTTATGCAGCTGATCGGGCAGGCGCCCGCCGCTCTGTGGGTGATTTATGGCGAACAGCGCTTGAATTGGGATATTGGCACAGCAGGTGTGTCGCTGGCCATTTTTGGTGCAGCACATACATTCGTACAAGCTGTTTTAACCGGCACTCTTTCAAAGCGACTGGGCGACCGCGGTGTGTTGCTGCTTGGTATGGGCGCTGATATTTGCGGGTTTCTATTGCTGGCTTTTATCACGCAAAGCTGGATGGTTCTGCCGGCAATTTTCATGCTGGCTACAGGCGGCATTGGTATGCCTGCTTTGCAGGCTATTATTTCCGGTCTTGTTCGTGATGAAAAGCAAGGTGCTTTACAAGGAACTTTAACAGGCTTGACGAATATAACTTCGATCATCGGGCCGGTCGGATTTACGACGCTTTATGGCTTAACCGCGGGGCGGTGGGATGGTTGGGTTTGGCTCGTCGCAGCAAGTCTTTATTTTATAGCTATACCATTATTGCGCCAGTCAGCCAGTTTGTTACGATCTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7246,Drugs,MEG_7246|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETY,gi|29467414|dbj|AB089604.1|1-1176 gi|239829526|gb|FJ950717.1|1-134 gi|239829524|gb|FJ950715.1|115-1,4
,atgcgcctttgcctgacgacccttgccctgactgccacacttgcctttgatgtgactgccgccgacgcaccgctgccgcagctgcaggcctacaccgtggacgcctcgtggctgcagccgatggcaccgctgcagattgccgaccgcacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgacggtgcggtactgctcgacggcggcatgccgcagatggccggtcacctgctggacaacatgaaggcacgcggggtggcagcacaggatctacggctgatcctgctcagccacgcacacgccgaccatgccgggccagtggcggagctgaagcgccgtaccggcgccagcgtagcggccaacgccgaatcggccgtgctgctggcgcgcggtggcagcaacgacctgcactttggcgacagcatcacctttccgccggccagcgccgaccgcatcatcatggatggcgaagaggtcaccgtaggcggcatcgcgttcaccgcgcacttcatgccggggcacaccccaggcagcaccgcctggacctggaccgatacccgcgatggccagccggtgcgcatcgcctacgccgacagcctgagtgcgccgggctaccagctgcagggcaacgcccgttatccccgcctggtcgaggactaccggcgcagcttcgctacggtgcgcggcctgccctgcgacctgctgctgacgccgcatccgggcgccagcaactggaactatgccgccggtgcagaggccggagccaacgccctgacctgcaaggcctacgcggatgcggccgagaagaagttcgacgcacagctggccaaggaaacagccacggcacgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3521,Drugs,MEG_3521|Drugs|betalactams|Class_B_betalactamases|L1,815697313|WP_046430859.1|NG_047507|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047507:1-870,0
,atgacattcctgatccgacccgtagaacaaagtgacgctgaatcttgggagcgcttacgcaaccttttgtgggagggcgacgaccacaaaagcgagatcacacaattcttcaacggcgaagtagaagaacccaatgaagtgttgcttgccgtaaccgaagaaaatgatgcaatagcgcacatcgagctatcgttgaggtatgacattgatggcttgacgggcatcaagaccggttacatcgaaggcctttttgtagaggagcggcaccgtgccgcaggtgtagtcctcaagctattgcgagccgcagagttctgggcaagagatcaaggatgtctggcgtttgcctcagacagggatgatcgtgtcatcatctatgctcgctacacgggagcgccacctaacaattcattcaagccgacgccccttcggggcgcggcttaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_123,Drugs,MEG_123|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,917038817|WP_051645529.1|NG_051559|1|1|aac(6')-30|aac(6')-30|aminoglycoside_6'-N-acetyltransferase_AAC(6')-30 NG_051559:101-541,2
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTAAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCAGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTACTAGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGACTCGGCGGTTTATGACACGATCGTCCGTATGGCGCAGCCATTCTCGCTGCGTTACATGCTGGTAGACGGTCAGGGTAACTTCGGTTCCATCGACGGCGACTCTGCGGCGGCAATGCGTTATACGGAAATCCGTCTGGCGAAAATTGCCCATGAACTGATGGCCGATCTCGAAAAAGAGACGGTCGATTTCGTTGATAACTATGACGGCACGGAAAAAATTCCCGACGTCATGCCAACCAAAATTCCTAACCTGCTGGTGAACGGTTCTTCCGGTATCGCCGTAGGTATGGCAACCAACATCCCGCCGCACAACCTGACGGAAGTCATCAACGGTTGTCTGGCGTATATCGATGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGGCCGGACTTCCCGACGGCGGCAATCATTAACGGTCGTCGCGGTATTGAAGAAGCTTACCGTACCGGTCGCGGCAAGGTATATATCCGCGCCCGTGCTGAAGTGGAAGTTGACGCCAAAACCGGACGTGAAACCATTATCGTCCACGAAATTCCGTATCAGGTAAACAAAGCGCGCCTGATCGAGAAGATTGCGGAACTGGTAAAAGAAAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAGTCTGACAAAGACGGTATGCGCATCGTGATTGAAGTGAAACGCGATGCGGTCGGTGAAGTTGTGCTCAACAACCTCTACTCCCAGACCCAGTTGCAGGTTTCTTTCGGTATCAACATGGTGGCATTGCACCATGGTCAGCCGAAGATCATGAACCTGAAAGACATCATCGCGGCGTTTGTTCGTCACCGCCGTGAAGTGGTGACCCGTCGTACTATTTTCGAACTGCGTAAAGCTCGCGATCGTGCTCATATCCTTGAAGCATTAGCCGTGGCGCTGGCGAACATTGACCCGATCATCGAACTGATCCGTCATGCGCCGACGCCTGCAGAAGCGAAAACTGCGCTGGTTGCTAATCCGTGGCAGCTGGGCAACGTTGCCGCCATGTTGGAACGTGCTGGCGACGATGCTGCGCGTCCGGAATGGCTGGAGCCAGAGTTCGGCGTGCGTGATGGTCTGTACTACCTGACCGAACAGCAAGCTCAGGCGATTCTGGATCTGCGTTTGCAGAAACTGACCGGCCTTGAGCACGAAAAACTGCTCGACGAATACAAAGAGCTGCTGGATCAGATCGCGGAACTGTTGCGTATTCTTGGTAGCGCCGATCGTCTGATGGAAGTGATCCGCGAAGAGCTGGAGCTGGTTCGTGAACAGTTCGGTGACAAACGTCGTACTGAAATCACCGCCAACAGCGCAGACATCAACCTGGAAGATCTGATCACCCAGGAAGATGTGGTCGTGACGCTCTCTCACCAGGGCTACGTTAAATATCAGCCGCTTTCTGAATACGAAGCGCAGCGTCGTGGCGGGAAAGGTAAATCTGCCGCACGTATTAAAGAAGAAGACTTTATCGACCGACTGCTGGTGGCGAACACGCACGACCATATTCTGTGCTTCTCCAGCCGTGGTCGCGTCTATTCGATGAAAGTTTACCAGTTGCCGGAAGCCACTCGTGGCGCGCGCGGTCGTCCGATCGTCAACCTGCTACCGCTGGAACAGGACGAACGTATCACCGCGATCCTGCCGGTGACCGAGTTTGAAGAAGGCGTGAAAGTCTTCATGGCGACCGCTAACGGTACTGTGAAGAAAACCGTCCTCACCGAATTCAACCGTCTGCGTACCGCCGGTAAAGTGGCGATCAAACTGGTTGACGGCGATGAGCTGATCGGCGTTGATCTGACCAGTGGCGAAGATGAAGTAATGCTGTTCTCCGCCGAAGGTAAAGTGGTGCGCTTTAAAGAGTCTTCTGTCCGTGCGATGGGCTGCAATACCACTGGTGTGCGCGGTATTCGCTTAGGTGAAGGCGATAAAGTCGTCTCTCTGATCGTGCCTCGTGGCGATGGCGCAATCCTCACCGCAACGCAAAACGGTTACGGTAAACGTACTGCAGTGGCGGAATACCCAACCAAGTCGCGTGCGACGAAAGGGGTTATCTCCATCAAGGTTACCGAACGTAACGGTTTAGTGGTTGGCGCGGTGCAGGTAGATGACTGCGACCAGATCATGATGATCACCGATGCCGGTACGCTGGTACGTACTCGCGTTTCAGAAATCAGCATCGTGGGCCGTAACACCCAGGGCGTGATCCTCATCCGTACTGCGGAAGATGAAAACGTAGTGGGTCTGCAGCGTGTTGCTGAACCGGTTGACGAGGAAGATCTGGATACCATCGACGGCAGTGCCGCGGAAGGGGATGATGAAATTGCTCCGGAAGTGGACGTTGACGACGAGCCAGAAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3178,Drugs,MEG_3178|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|AE005674.2|-|2352231-2354859|ARO:3003940|Shigella flexneri gyrA conferring resistance to fluoroquinolones [Shigella flexneri 2a str. 301] ,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattccgagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaccaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4464,Drugs,MEG_4464|Drugs|betalactams|Class_D_betalactamases|OXA,1559613000|WP_128268265.1|NG_063870|1|1|blaOXA-766|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-766 NG_063870:41-865,0
,ATGAATAACATCGGCATTACTGTTTATGGATGTGAGCAGGATGAGGCAGATGCATTCCATGCTCTTTCGCCTCGCTTTGGCGTTATGGCAACGATAATTAACGCCAACGTGTCGGAATCCAACGCCAAATCCGCGCCTTTCAATCAATGTATCAGTGTGGGACATAAATCAGAGATTTCCGCCTCTATTCTTCTTGCGCTGAAGAGAGCCGGTGTGAAATATATTTCTACCCGAAGCATCGGCTGCAATCATATAGATACAACTGCTGCTAAGAGAATGGGCATCACTGTCGACAATGTGGCGTACTCGCCGGATAGCGTTGCCGATTATACTATGATGCTAATTCTTATGGCAGTACGCAACGTAAAATCGATTGTGCGCTCTGTGGAAAAACATGATTTCAGGTTGGACAGCGACCGTGGCAAGGTACTCAGCGACATGACAGTTGGTGTGGTGGGAACGGGCCAGATAGGCAAAGCGGTTATTGAGCGGCTGCGAGGATTTGGATGTAAAGTGTTGGCTTATAGTCGCAGCCGAAGTATAGAGGTAAACTATGTACCGTTTGATGAGTTGCTGCAAAATAGCGATATCGTTACGCTTCATGTGCCGCTCAATACGGATACGCACTATATTATCAGCCACGAACAAATACAGAGAATGAAGCAAGGAGCATTTCTTATCAATACTGGGCGCGGTCCACTTGTAGATACCTATGAGTTGGTTAAAGCATTAGAAAACGGGAAACTGGGCGGTGCCGCATTGGATGTATTGGAAGGAGAGGAAGAGTTTTTCTACTCTGATTGCACCCAAAAACCAATTGATAATCAATTTTTACTTAAACTTCAAAGAATGCCTAACGTGATAATCACACCGCATACGGCCTATTATACCGAGCAAGCGTTGCGTGATACCGTTGAAAAAACCATTAAAAACTGTTTGGATTTTGAAAGGAGACAGGAGCATGAATAGAATAAAAGTTGCAATACTGTTTGGGGGTTGCTCAGAGGAGCATGACGTATCGTTAAAATCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGTGTATGGAAAATGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACAATTGCTATTCAGCTGTACTCTCGCCGGATAAAAAAATGCACGGATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCATGGCAAGTCAGGTGAAGATGGATCCATACAAGGTCTGTTTGAATTGTCCGGTATCCCTTTTGTAGGCTGCGATATTCAAAGCTCAGCAATTTGTATGGACAAATCGTTGACATACATCGTTGCGAAAAATGCTGGGATAGCTACTCCCGCCTTTTGGGTTATTAATAAAGATGATAGGCCGGTGGCAGCTACGTTTACCTATCCTGTTTTTGTTAAGCCGGCGCGTTCAGGCTCATCCTTCGGTGTGAAAAAAGTCAATAGCGCGGACGAATTGGACTACGCAATTGAATCGGCAAGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTCGGGCTGTGAGGTCGGTTGTGCGGTATTGGGAAACAGTGCCGCGTTAGTTGTTGGCGAGGTGGACCAAATCAGGCTGCAGTACGGAATCTTTCGTATTCATCAGGAAGTCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCGTTCCCGCAGACCTTTCAGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAAAGCGCTCGGCTGTAGAGGTCTAGCCCGTGTGGATATGTTTTTACAAGATAACGGCCGCATTGTACTGAACGAAGTCAATACTCTGCCCGGTTTCACGTCATACAGTCGTTATCCCCGTATGATGGCCGCTGCAGGTATTGCACTTCCCGAACTGATTGACCGCTTGATCGTATTAGCGTTAAAGGGGTGATAAGCATGGAAATAGGATTTACTTTTTTAGATGAAATAGTACACGGTGTTCGTTGGGACGCTAAATATGCCACTTGGGATAATTTCACCGGAAAACCGGTTGACGGTTATGAAGTAAATCGCATTGTAGGGACATACGAGTTGGCTGAATCGCTTTTGAAGGCAAAAGAACTGGCTGCTACCCAAGGGTACGGATTGCTTCTATGGGACGGTTACCGTCCTAAGCGTGCTGTAAACTGTTTTATGCAATGGGCTGCACAGCCGGAAAATAACCTGACAAAGGAAAGTTATTATCCCAATATTGACCGAACTGAGATGATTTCAAAAGGATACGTGGCTTCAAAATCAAGCCATAGCCGCGGCAGTGCCATTGATCTTACGCTTTATCGATTAGACACGGGTGAGCTTGTACCAATGGGGAGCCGATTTGATTTTATGGATGAACGCTCTCATCATGCGGCAAATGGAATATCATGCAATGAAGCGCAAAATCGCAGACGTTTGCGCTCCATCATGGAAAACAGTGGGTTTGAAGCATATAGCCTCGAATGGTGGCACTATGTATTAAGAGACGAACCATACCCCAATAGCTATTTTGATTTCCCCGTTAAATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7411,Drugs,MEG_7411|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,VanHAX_1_FJ866609,5
,GCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCGGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGCTCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3579,Drugs,MEG_3579|Drugs|betalactams|Class_A_betalactamases|LEN,blaLEN10_1_AJ635419 ,0
,ATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6936,Drugs,MEG_6936|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695199351|ref|NG_035209.1|1-1008,0
,atgttcacgcttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggggcgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7719,Drugs,MEG_7719|Drugs|betalactams|Class_B_betalactamases|VIM,1343491230|WP_104009846.1|NG_056405|1|1|blaVIM-56|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-56 NG_056405:1-801,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaaattgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1820,Drugs,MEG_1820|Drugs|betalactams|Class_C_betalactamases|CMY,1407696519|WP_111273851.1|NG_060523|1|1|blaCMY-162|blaCMY|class_C_beta-lactamase_CMY-162 NG_060523:1-1146,0
,atgaaacagaccagatccctgccactgctggccctcggcaccctgctgcttgccccgctttccctggcggcccccgtcgatccgctgaacgctgtggtggatgacgccatccgccccatgctcaagcagcacaggatcccgggcatggcggtcgccgtgctgaagggggggcaggcccactacttcaactacgggctggccgatatggcggccgggaagaaggtcagcgagcagaccctgttcgagattggctcggtcagcaaaacctataccgccacccttggtgcctacgccgtggtcaagggggggattgggctggatgacaaggtgagccggcacgcgccctggctcaagggctccgccttcgatggcgtcaccatggcggagctcgccacctacagcgccggcgggctgccgctgcaattccccgacgaggtggaatcggtcgaacaaatgcagtcttactatcgccagtggacgccggcctatcagccgggcagccatcgccagtactccaatcccagtatcggtctgttcggccatctggcggcgagcagcctgcagcagccatttgcccagttgatggagcagaccctgctgcccgggctcggcttgcatcacacttatctcgatgtgccggaagcagccatggcgagttatgcctatggctattcgaaggaggacaagcctatcagggtcaatcccggcatgctggccgacgaggcctacggcatcaagaccagctcggcggatctgctcgccttcgtgaaggccaatatcagcggggttgatgacaaggcgttgcagcaggccatctccctgacccaccaagggcgctactcggtcggcgagatgacccaggggctgggctgggagagttacacctatcccgtcagcgagcagacgctgctggcgggcaactcctcggcggtgatttacaatgccaacccggtcaaacctgttgccgcgtcccaagagacggggggggcgcgactctacaacaagaccggctcgaccaacggctttggtgcctatgtggccttcgtgccggccaaagggatcggcatcgtcatgctggccaaccgcaactaccccaacgaagccagaatcagcgcggcccatgccattttgagccagctggccccctga,antibiotic molecule,antibiotic inactivation,betalactams,MEG_1653,Drugs,MEG_1653|Drugs|betalactams|Class_C_betalactamases|CEPH,1028084266|WP_063843234.1|NG_047628|1|1|cepH|cepH|cephalosporin-hydrolyzing_class_C_beta-lactamase_CepH NG_047628:101-1249,0
,atgcgttttaccctgctcgccttcgccctggccgtcgcgcttccggccgcccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatggcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacatgaaactgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcattcaccgcgcacttcatgccggggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatgggaagccggtgcgcatcgcctacgccgacagcctgagtgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtacgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactatgccgccggcagcaaggccagcgccgaggcactgacctgcaatgcctacgcggatgcggccgagaagaagttcgacgcgcagttggccagggaaacggccggggcccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3527,Drugs,MEG_3527|Drugs|betalactams|Class_B_betalactamases|L1,1028083720|WP_063842688.1|NG_047505|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047505:1-873,0
,ATGGTCCATGCCGCCGTCAGCAGGGTCGGCCGCCTGCTCGATGGCCCCGACACCATCATCGCCGCCCTGCGCGATACCGTCGGCCCGGGCGGTACCGTTCTCGCCTATGCCGATTGGGAGGCACGATACGAGGACCTGGTCGACGACGCGGGCCGCGTGCCTCCGGAATGGCGCGAACATGTCCCACCCTTCGACCCGCAGCGCTCGCGTGCGATCCGCGACAATGGTGTGCTGCCGGAATTCCTGCGGACCACGCCCGGCACGCTCCGCAGCGGCAACCCCGGCGCCTCGCTCGTCGCGCTCGGGGCGAAGGCGGAGTGGTTCACTGCCGACCACCCGCTCGACTACGGCTATGGCGAGGGCTCGCCGCTGGCCAAGCTGGTCGAGGCCGGCGGCAAGGTGCTGATGCTTGGGGCGCCGCTCGACACGCTGACCCTGCTGCACCATGCCGAGCATCTGGCTGATATCCCCGGCAAGCGGATCAAGCGGATCGAGGTGCCGTTCGCGACACCTACAGGCACGCAATGGCGCATGATCGAGGAGTTCGACACCGGCGATCCGATCGTCGCAGGGCTGGCCGAGGACTATTTCGCGGGAATCGTGACCGAATTCCTCGCCAGCGGCCAGGGTCGGCAAGGGTTGATCGGCGCCGCTCCCTCGGTGCTGGTCGATGCCGCGGCGATCACCGCCTTCGGCGTCACCTGGCTCGAAAAACGGTTCGGTACGCCCTCGCCCTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_66,Drugs,MEG_66|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,aac(3)-IIIb_1_L06160 ,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaagaccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagcccgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4447,Drugs,MEG_4447|Drugs|betalactams|Class_D_betalactamases|OXA,1559612987|WP_128268252.1|NG_063857|1|1|blaOXA-753|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-753 NG_063857:40-864,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagaggcggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3096,Drugs,MEG_3096|Drugs|betalactams|Class_A_betalactamases|GES,1028105365|WP_063860514.1|NG_049132|1|1|blaGES-29|blaGES|class_A_beta-lactamase_GES-29 NG_049132:1-864,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccatagggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4444,Drugs,MEG_4444|Drugs|betalactams|Class_D_betalactamases|OXA,1559613012|WP_128268277.1|NG_063883|1|1|blaOXA-782|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-782 NG_063883:1-825,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaaataaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4446,Drugs,MEG_4446|Drugs|betalactams|Class_D_betalactamases|OXA,1559612986|WP_128268251.1|NG_063856|1|1|blaOXA-752|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-752 NG_063856:14-838,0
,atgtcaaccacactaaccagcttcaaatggggtgaacgcacctacatcatgggcatcctcaacgtcactccagacagcttttctggagatggcgttatggttgaagaagatgtcatcgccaaagcggtagcccaggccaaacaatttgtagccgacggcgcagacatcatcgacattggcggcgagagtacccgccctggcagctcacctataagcgcagaggaagaactggcgcgggtgctgccggtggtgcaggccgtacgccaggctgtggacgtcgttatttccatcgacagctaccgcgcttccgtggccgaagcggccctggcggcaggcgccagctggctcaacgacgtctgggggctgcgcatggacccggacatggccggcctggcagcacaagccggctgccccatcgtccttatgcacaaccgcagcaaaccaaagaacatagcgcaagaaaaaaagctgggcgggcgcttcatcggggtaaaatacgacgacctcatcaccgacgttaaacgtgaattacaagaaagcatcgacatcgccttaaaagccggcgtaaaagagtcccaaattatcctggatcccggcatcggcttcggtaaaaccgtcgagcaaagtttgcaactgctcgaccagattaatcagttcaaaacaatgggatttcccatcttaataggtccgtcgcgcaaatcatttattggctatacgctcgatttgccgccagaccagcgcatagaaggaacggcggccaccgtcgccattggcattgaccgaggagccgacgttgtgcgcgtccatgacgtcaaagcaatcgttcgggtcgcccgtatgacagatgcaatcgtgagacgttaa,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6585,Drugs,MEG_6585|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,1331531447|WP_102607457.1|NG_056174|1|1|sul4|sul4|sulfonamide-resistant_dihydropteroate_synthase_Sul4 NG_056174:101-964,8
,TTATACATTTAACAATTGCTGAAACGTAAAGTCGGGTTTAAACATTTCAATTTCGTTTTGAGTTGATTCTTCTTGTGCTTCTTTGCCATAGATAAACATTTGCTGTTCATAATTTTCAATAGCCTCTTCAATGCTGTTAAATTTCCCATTGGTCAGATTATCCGACAATATCAAGGCATCCATCAACCCGCTGTTTACGCCTTGTCCTGCAAAAGGAGGCATCAAATGAGCAGCATCTCCAATCATCGTTATGGGTAATGGACGCTTACTTTTCCAAGACTTACCTAAGGGAAATATTCGTGTCGCTAACCCTACAAAAGATGATGTCACACGAATCAGTTCTTTGTAGCGTTCGTCCCAATCGGAAAATTCTTTCAGAAGAAAATCAACGACACTATTTCTGTTTTGAAAATCTACCTGCGTTTGGTTTTTCCATTCATCAGGTGTTTTAAAACTTATTCCAAAATGCAATGCACCATTATTATTAGGATTCGCAAATAATAAATTACCTTGATGAGCAGCCATTAGCCGGTTTCCATTGCATAGCTGAAAAAATCCAGGACAGTTCACCTCTGGATGATGAATATCGGCTTGTATATTGAAAGTACCTGTTTCTTCAACTTCCGTGTCGGTAACAAATTTTCTTACTTTAGACATTCCACCATTGGCAATAATAACCAGATCTGCTGTTTCACTCGGTTTATTCTCAAAAGTTAGTGTCCACTTCTTCTTACCAGGTTCAAGCATAACAAGTTTTCTATCCCAAATAACCGTGTCGTTTTCTAAACTATTCAACAAGATAGCCCTTAAGTCATTTCTGTTTATTTCAGGATTGTCAAATCGATTTTCGGGCTTTACATTTTTTGTGGATAAAATATTGCCTTTTTCATCAGCAATATTTACACCCATTGGTAAGGCTAAGTCATAATAAGTTTGTAACAATCCCGCTTTTTTCATTGCTTCCTGACCTGAACCTTTGTGTAGGTCAAGGGTTCCACCAAAAATTCTTGCCTCTCGGTCGTTGTCTCTTTCGTAAACTGAAACGTCTATGCCGTTTTGCTGTAATAATTTTGCCATAGTCAGTCCAACGGGTCCACCACCAATTATTGCAACGTTCTTATCACTAAGTAAATTCATTTGTTTTTCTTTATTGCTCAT,tetracycline inactivation enzyme,antibiotic inactivation,Tetracyclines,MEG_7242,Drugs,MEG_7242|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TETX,gb|MK134376.1|+|324-1482|ARO:3004720|Tet(X4) [Escherichia coli] ,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttggccaaaaagtccaacatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4696,Drugs,MEG_4696|Drugs|betalactams|Class_D_betalactamases|OXA,1509794599|WP_122630908.1|NG_062328|1|1|blaOXA-706|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-706 NG_062328:18-842,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagttccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgagctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1828,Drugs,MEG_1828|Drugs|betalactams|Class_C_betalactamases|CMY,1028104512|WP_063859833.1|NG_048824|1|1|blaCMY-29|blaCMY|class_C_beta-lactamase_CMY-29 NG_048824:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggcgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccattgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5665,Drugs,MEG_5665|Drugs|betalactams|Class_C_betalactamases|PDC,1343491219|WP_104009835.1|NG_056392|1|1|blaPDC-237|blaPDC|class_C_beta-lactamase_PDC-237 NG_056392:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGTATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6242,Drugs,MEG_6242|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-11:HM751098:1-861:861,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgccagcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgtgatatcgccgcttggaatcgtgaccatgacttaattaccgcgatgaagtactcagttgtgcctgtttatcaagaatttgcccgccaaattggtgaggcacgtatgagtaaaatgctgcacgccttcgattatggcaatgaggatatctcgggcaatgtagacagtttttggctcgatggtggtattcgcatttcggctacccagcaaatcgcttttttacgcaagctgtatcacaacaagctgcacgtttctgagcgtagtcagcgcatcgtgaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaacgggatactcgactagtatcgaacctaagattggctggtgggttggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcacacaggagaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4608,Drugs,MEG_4608|Drugs|betalactams|Class_D_betalactamases|OXA,1693892947|WP_140423324.1|NG_065443|1|1|blaOXA-833|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-833 NG_065443:27-824,0
,atgaaaagaatatttccggcttacattctgcttacagctttcctactggcctgctccagcaacgccacgactcaaaatgctaatcaatcaaacaagcccgccgctgctcaggaagcaaaggcggatgataagcagaaccgcgagctgcaaaaacagatagagcagatagcttcagcggcacgcgggcgcgtgggcgttcatgcggtcgtgctggaaacgggtgaatccgtctccctggatgagcagggccgatttcctatgcagagcgtttataagttcccgattggcatggctgtactcgcgcaagtagatgccggaaagctaaagcttgacgagcgcgtgcgcgttgaaaagagcgaatacgttagagagggcatgcacagccccttgcgagacaaaaatccgaacgaagctgaggtgagcgtgcgcgagttgctgcgattagctgtctctgaatcggacggtacggcgagcgatgtgctgttcagactggcgggcggcagcgaagcaatcaccagatacctcagcgaccttaaggtcacagagattatcgtagccgacacggagaaagagatagggcaggactgggacactcagtatcgcaactgggcttcgcccaagggagcagttatgcttctacgcgcattccatgaggggcgcgggctctccgcagagagcagggcgctcttgctgaaattgatgactgacacccctaccggaccgaaaaggctgaaaggacttttgcctaagggcacagtcgtcgcgcacaagaccggaacatctggagcaaacgctagcggcatcagcgccgcgaccaacgatataggaatagtgacgctgccgaacggtcgccatctggccatagccgttttcgtttccgattctccggccgatctaaccacgcgcgagggcgtgattgccaaagtcgctaaggctgcgtgggaccagtggggaaagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1244,Drugs,MEG_1244|Drugs|betalactams|Class_A_betalactamases|BLAA,"1028083116|WP_063842272.1|NG_047486|1|1|bla-A2|bla-A2|class_A_beta-lactamase,_subclass_A2 NG_047486:101-1060",0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGCGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6421,Drugs,MEG_6421|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948448|emb|AM176552.2|1-891,0
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatgctatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_878,Drugs,MEG_878|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502236|WP_071846386.1|NG_052521|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052521:101-892,2
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgccaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3471,Drugs,MEG_3471|Drugs|betalactams|Class_A_betalactamases|KPC,1511261581|WP_123002101.1|NG_062357|1|1|blaKPC-38|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-38 NG_062357:1-882,0
,ATGGAGAAGATCTCGGCGAAGGCGGCGGCCAAGCCCGCGAAGGGCGGCCTGCCCAACCTGCTGTACCTGTGGGCCACCGCCGAGCGGCTCCCCCCGTTGTCGGGGGTGGGCGAGCTGCACGTCCTCATGCCGTGGGGCAGCCTGCTGCGCGGGGTCCTCGGCTCCTCGCCGGAGATGCTGCGCGGGATGGCGGCGGTGTGCCGGCCGGGCGCGTCCTTCCTGGTCGCGCTGAACCTGCACGCCTGGCGGCCCTCGGTGCCGGAGGTGGGCGAGCACCCCGAGCCCACCCCGGACTCCGCCGACGAGTGGCTGGCGCCCCGCTACGCCGAGGCCGGGTGGAAGCTCGCCGACTGCCGCTACCTGGAGCCGGAGGAGGTGGCGGGTCTGGAGACCTCCTGGACCCGCCGTCTGCACTCCTCCCGCGACCGGTTCGACGTGCTCGCGCTCACCGGCACGATCAGTCCGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3444,Drugs,MEG_3444|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|KAMB,kamB_1_AJ629123 ,2
,GGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAGCTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTTCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTCTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAACATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAACTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAATACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCGCCTAGGGTCATGTTCTTTTCCCATTCTGGGAATAGCCTTTTTTGCCCGTCCCACTTAAATACTTCTGTAGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAATTTGGCCTTGTTGAATAACTAAAACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCACTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGCTTGAATGTTCATAAGACTTATAAGATTGAATTTGAAGTTTAGCTAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5232,Drugs,MEG_5232|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389153|gb|KF986259.1|1-879,0
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttagttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_740,Drugs,MEG_740|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502065|WP_071846217.1|NG_052226|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052226:101-634,2
,atgaaaactttacaatttggactcatcgccctcattacaaccttcggttctgcatgtaccacaataagcccctcagtagaaacagctaaaaatcaccagcaacaaagcgcgcagcagcagatccaacaggccttcgatcaactccaaaccactggggtgattgtcattaaggataagcatggcttacgcagctacggcaatgacttgagccgtgctcagacagcctatgtacccgcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcactgaggtgtttaaatgggatggtcaaaagcgtagtttccctgcctgggaaaaagacatgactttagggcaagccatgcaagcatctgctgttcccgtttatcaggagcttgcacggcgcattggtctagacctgatgcaaaaagaagtacagcgcattggatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacgcctgtgcaagaagtcctttttgtagagaagctggccaatacgcaactcgcttttaagccagatgtgcaacataccgtacaagacatgctgctgattgaacaaaaaccgaattataaactctacgccaaatctggttggggcatggacctagaaccgcaagtgggctggtggacaggctgggtcgaaacagcaacaggtgaaaaagtgtattttgctttgaatatgcatatgaaaacaggaatttcagccagcgtgcgtgagcaactggtcaaacaaagtctgacagcactgggaataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4677,Drugs,MEG_4677|Drugs|betalactams|Class_D_betalactamases|OXA,971009535|WP_058870660.1|NG_059326|1|1|blaOXA-651|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-651 NG_059326:101-925,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacactctacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4432,Drugs,MEG_4432|Drugs|betalactams|Class_D_betalactamases|OXA,1559612976|WP_128268241.1|NG_063846|1|1|blaOXA-742|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-742 NG_063846:34-858,0
,atgcgccatgcaacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggcggcgccggcggagcgcctgaaggctctggtagacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcaccctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacagcgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactactaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggttcgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggttgggaagcctacgattggccgatcgacctgaagcgcctgcaggcgggcaactcggcgccgatggcgctacaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5428,Drugs,MEG_5428|Drugs|betalactams|Class_C_betalactamases|PDC,1035157545|WP_064511510.1|NG_050833|1|1|blaPDC-160|blaPDC_var|class_C_beta-lactamase_PDC-160 NG_050833:1-1194,0
,atgttcgctagaaccggagccggcctcgcacttgcggccgcgtgcctcgccggctgcgcaccgccgatccagtcccgtcccgacctgcccgcgcccgagcaggttacgccgcagcaatgggctgccggttgcgagccgtgggacgattgggacaagcccgccccgccctaccgcatccacggctcgacctattatgtcggcacttgcggcatcacggcgatcctcgtcgcggggccggccggacacctgctgatcgacagcgggaccgaggcgggcgccaaagtggtgctcgacaacatcggcaaggtcggtttccgccccgacgagatcgccagcctgctgcacagccacgaacatttcgaccacaccggcggccatgcgcgcgtcaagcaagccagcggcgcgcatatcgtcgcttcgcccgctgccgcgcctgcgctacgcagcggcctgagcattgccgaagatccgcaatacggactgcacgaaccgatggcgccggtggctgtcgacgtgctggtccgcggcggcgagacggtgcgcagcgaaaccgccacgctcaccgcgatcgccacgccggggcacacgccgggcgcgctgagctggacatggcgctcgtgcgacgcggcgggtgactgcctcgacgtggtctatgccgactcgctctccgcgatcagccgcgaaggataccgctttgccgaccatcccgcctatgtcgccgcgttccgcgccggattgcagcggctgcgcgaaaccgcctgcgacctgctgctgaccccgcacccctccgcgagcgagatggtcgcgcgcgcggcgagcggaacgctggccggcgggatgagctgcgccgcctatgccgatgccgccgaggcccggctcgatgcgcggttggcggaggaagcggatggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1285,Drugs,MEG_1285|Drugs|betalactams|Class_B_betalactamases|BLAECM,1509794515|WP_122630824.1|NG_062207|1|1|blaECM-1|blaECM|subclass_B3_metallo-beta-lactamase_ECM-1 NG_062207:19-930,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcagcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_226,Drugs,MEG_226|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080936|WP_063840319.1|NG_047289|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_047289:52-606,2
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggaatattccttacaatttaagcacacaaattattaaaaaagtggtttttgaaagccgtgcgtctgacatctatctgactgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatataagtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcgtcaagcaatgaaacacgccaaagtaaacaatttaagtaccattacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2790,Drugs,MEG_2790|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,752296432|WP_041152457.1|NG_047803|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047803:101-838,7
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgagaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagataccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1510,Drugs,MEG_1510|Drugs|betalactams|Class_A_betalactamases|CARB,525983615|WP_020835015.1|NG_054946|1|1|blaCARB-20|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-20 NG_054946:101-952,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGAACAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1346,Drugs,MEG_1346|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_60_NZ_JVML01000111,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATATAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1417,Drugs,MEG_1417|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_84_FHDH01000010,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgagtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctgttggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggctggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4134,Drugs,MEG_4134|Drugs|betalactams|Class_B_betalactamases|NDM,1270501712|WP_099156050.1|NG_055664|1|1|blaNDM-21|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-21 NG_055664:1-813,0
,ATGAAAAATATCGGCATTACCATTTATGGATGTGAGAGGGACGAGGCTGAAGTGTTCAATGAACTTTCGCCACGCTTTGGTGTCATACCTGCCATTACAAGCTCTGCCGTATCGGAAACCAACGCAATGTTAGCTCCCGGCAATCAATGTATCAGCGTGGGGCACAAATCTGAGATTTCCGAATCCATTCTTCTTGCTCTGAAGGAATCCGGCGTCAAATATATCTCTACCCGAAGTATTGGCTGCAATCACATAGACGTGAAGGCCGCGGAAAGTATGGGTATCGCTGTTGGAAACGTGGCATATTCACCGGATAGCGTTGCCGATTATACATTGATGCTGATGCTGATGGCGATACGAAACGCAAAATCCATTGTGAGCCGTGCGGAAAAATATGATTTCAGATTGGATACTGTCCCTGGAAAAGAATTGCGTGAGATGACGGTTGGCGTGCTGGGAACCGGTCAAATAGGCAAGGCGGTTATTGAGCGACTGCGGGGATTTGGATGTCATGTGCTGGCGTATGGTCACAGCAAAGAGGCGGCGGCCAATTATGTATCCCTCAATGAATTGCTGCAGAAAAGCGACATTCTCACCATTCATGTGCCGCTCGGCACGGACACATATCATATGATTGGTCACGAACAGATTGAAGCAGTGAAACAGGGCGCGTTTCTTATCAATACAGCGCGCGGCGGGCTTGTGGATACCGGCGCGCTGATCAAAGCGTTGGAAAATGGAAGGTTAGGCGGCGCGGCGTTGGATGTGTTGGAAGGAGAAGAAGGGCTTTTCTATTTTGATTGCACACAGAAACCGATTGACAACCAACTATTGCTTAAGCTCCACAAGATGCCAAATGTGATCATCACGCCGCATACGGCGTACTATACCGGACGGGCACTGTATGATACCGTTGAAAAGACAATATTGAACTGTCTGGAATTTGAGAGGAGAGAGACACTTGAATAGATTAAAAATAGCCATCCTGTTTGGGGGCTGTTCAGAGGAACACGATGTGTCGGTAAAATCGGCGAAAGAGATTGCCAATAACATTGACACGGAAAAATATGAGCCGATATACATCGGAATCACCCGATCCGGCGTCTGGAAAATGTGCGAAAAGCCATGCATGGATTGGGACAACGAAAACTGCCGTTCGGCAGTGCTTTCTCCGGACAAAAAAATGCACGGGCTGCTTGTTATGCGGAATAAAGGATATCAAATCCAACGTATAGACGCGGTATTTTCGGTTTTGCACGGCAAATCGGGTGAAGACGGCGCCATACAAGGTTTATTTGAATTGTCCAGCATCCCCTATGTAGGCTGTGATGTTCAAAGTTCGGCGGTGTGTATGGACAAATCCCTGACATACATTGTGGCCCAAAATGCTGGTTTTGGCACTCCTGAATTTTTGATTTTGAATCATGGCGATATACCGGATTCAAATACCTTAACATATCCTGTTTTTGTTAAACCGGCGCGTTCCGGCTCATCTTTCGGCGTGAATAAAGTCAATAACGAGGACGAATTAGACGCCGCCATTGAAACAGCAAGGCAGTATGACAGTAAAGTCCTGATTGAACAAGCTGTTCCAGGCCTTGAAGTTGGCTGTGCCGTGTTGGGAAACGGTACCGACTTAATCGTTGGCGAAGTGGACCAAATTTCACTTTCGCATGGTATCTTTCGTATTCATCAAGAAGATCAACCAGAAAAAGGCTCCGAAAACGCAGTTGTTTTGGTTCCCGCAAACCTGTCGGCAGAGAAACGCATAAAGATACAAGAGACGGCGAAAGCAATTTATAAGGCGCTCGGCTGTAAAGGTCTTTCTCGTGTTGATATGTTTTTGCAGGAAAACGGACGTATTATACTGAATGAAGTCAATACGTTGCCGGGATTCACGGCATACAGCCGTTATCCCCGTATGATGGCTGCCGCGGGGATGACACTGTCCGGGTTAATTGATCATTGCATCACACTGGCACTCAAAGGATGATACCCATGGAAAAAGATTTTGTTTTTTTAGATGAAATATTGCATGGAGTTCGTTGGGACTCCAAATATGCCACATGGGACAATTTCACTGGAAAACCGGTAGACGGATATGAAGTCAATCGCATAGCGGGGACATATGCTTTGGCTGTTGCGCTGCTGGAGGTAAAGAAGCAGGCGGCTGCTCTAGGGTACGGCTTGCTCCTGTGGGATGGCTATCGTCCTCAACGTGCGGTAAACTGTTTCTTGCATTGGTCTGCGCAGCCGGAAGACGGCCGCACAAAAGAAAGATATTATCCCAATATTGATCGGATCGAGATGGTTACAAAGGGATATGTGGCTTCAAAATCAAGCCACAGTCGCGGAAGCGCGATTGACCTTACGCTTTATCGATTGGACACGGGTGCGCTTGTCCCTATGGGGAGCGGCTTCGATTTTATGGATGAACGTTCACATCATACCTCAAAAGGAATTTCAAGTAACGAAGCGCAAAATCGCCAGTTATTATGTTCTATTATGGAATACAGCGGATTTGAATCATATGTATATGAATGGTGGCACTACGTATTAAGAAACGAACCATACCCCAGCAGCTATTTTGATTTTCCCATTGGCGGGAACCATCTAGACCCATTTTCCAACTTTTGTGGGACAGTGCCACTTGATGCGTTGTCGCCCTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7429,Drugs,MEG_7429|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHFX_1_AF155139,5
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATTGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1891,Drugs,MEG_1891|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ185697|+|1267-2413|ARO:3002072|CMY-58 [Escherichia coli] ,0
,TTGATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGTTAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCAATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGCTAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACCTTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTACAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGAAAAAGCGACTTCACATCTATTAGGTTATGTTGGTCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAAAAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACGATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAACTATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATCCACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATGGCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGATTACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGACGATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACAAGGAGAAACAGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCTATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATGATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3784,Drugs,MEG_3784|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|961586173|gb|CP013621.1|39642-41651 gi|908234448|gb|CP010309.1|43020-45029 gi|817181192|gb|KP777553.1|8027-6018 gi|403411202|emb|HE980450.1|5886-3877 gi|340545416|dbj|AB505630.1|5948-7957,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcgatgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2175,Drugs,MEG_2175|Drugs|betalactams|Class_A_betalactamases|CTX,1028104886|WP_063860072.1|NG_049025|1|1|blaCTX-M-73|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-73 NG_049025:101-976,0
,ATGACGGATTCAATCCATTCCTCTATTACCCCAGTCAATATTGAAGAAGAACTAAAATCTTCTTACCTTGACTACGCCATGTCGGTGATTGTTGGGCGTGCTTTGCCTGATGTGCGTGACGGTTTAAAACCGGTGCATCGACGTGTGCTTTTCTCCATGGATCAATCTGGCATCACTGCCGGCAAAAAATACGTAAAATCTGCCCGTGTGGTAGGTGATGTAATCGGTAAATATCACCCGCACGGTGATTCTGCAGTGTACGACACCATTGTGCGTATGGCACAGCCGTTCTCATTGCGCTACATGTTGGTAGATGGGCAAGGTAACTTCGGTTCAATCGACGGTGATGCGCCAGCGGCAATGCGTTATACCGAAGTCCGTATGCAAAAAATCACCCAAGCGTTATTAACTGACTTGGATAAAGAAACCGTAAATTTCTCGCCAAACTATGATGGCGAATTAATGATTCCGGATGTATTACCAACTCGTATTCCTGCACTTTTAGCAAACGGTTCTTCCGGTATTGCGGTGGGGATGGCAACCAACATTCCACCACACAACTTAAATGAAGTTTTAGATGGATGCTTGGCTTATATTGATAACGAAAACATCACCATTGATGAGTTAATGCAATATATCCCGGGCCCAGACTTCCCAACAGCGGCATTAATTAATGGCCGTAAAGGGATTGAAGAAGCTTATCGCACTGGTCGCGGCAAAGTGTATGTTCGCGCTCGCGCTAGCGTAGAAACCACAGATAAAGGCAAAGAGCAAATTATTGTGACCGAATTGCCTTATCAAGTGAACAAAGCCAAATTAGTGGAAAAAATTGCTGAGCTTATCAAAGATAAAAAAATCGAAGGCATCAGCAATATTATCGACCTTTCGAACAAAGAAGGGATTCGCATTGAAATTGACATCAAACGTGATGCCGTAGGCGAAGTAGTATTAAATCACCTCTATGCGCTTACCCAAATGCAGGTAACCTTCGGGATTAACATGGTGGCCTTGGATCACGGTCAACCACGTTTATTCAACTTAAAACAAATCATTGAAGCCTTTGTGATGCACCGTCGCGAAGTGGTGATTCGCCGTTCTTTATTTGAATTGCGTAAAGCCCGCGAGCGTACCCATATTTTAGAAGGTTTAGCGGTTGCAACATCAAATATCGATGAAATCATCGATATCATCCGTCAATCGAAAGAGCGTAAAGAAGCGGCAGAAAAATTAATCTCTCGCCCTTGGAAATTGAATAACGAAATTTTAGGTTTACTTGATGCAGCGGCACGTCCAGCTGAGTTAGCGGCTGAATTTGGTATTAAAGGTTCGGATTACTATCTTTCTCCAGAACAAGTTGATGCAATCTTAGAACTTCGCTTGCATCGTTTAACCGGTCTTGCTACCGAAGAAGTAATCAATGAATACAAAGAGTTATTGGTTAAAATTGCAGAACTTCTCCACATCATCAACAGCCCTGAGCGTTTGATGGAAGTGATTCGTGAAGAGCTTGAACAAGTACGCGCACAATTCGCGGATGAACGTCGTACCGAAATTACTGCGGCTTCTGGTGATATTGATTTAGAAGATTTAATTGCTCAAGAAGATGTGGTAGTGACCCTTTCTCACGAAGGTTATGTGAAATATCAACCGCTTACCGACTACGAAGCACAACGTCGTGGTGGTAAAGGTAAATCCGCAACGAAGATGAAAGATGAAGACTTCATTGAAAAACTCTTAGTAGCGAATACTCACGATACGATTCTCTGTTTCTCTAGCCGCGGTCGCTTATATTGGTTGAAAGTCTATCAATTACCACAAGCAAGCCGTGGTGCGCGTGGTCGTCCGATTGTGAATATTCTACCGTTGCAAGAAAACGAGCGTATCACCGCAATCTTGCCAATCTCTGCTTATGAAGAAGATAAATTCGTCATCATGGCAACGGCTGGTGGTATTGTGAAGAAAATTGCGCTAACCGAATTCAGCCGTCCACGTTCAAGCGGTATCATCGCCTTGAACTTACGTGATGAAGATGAATTAATCGGCGTGGATATCACCGATGGTTCTAACGAAATCATGTTGTTCTCTTCGCAAGGTCGCGTAGTACGTTTCGCTGAAAGTGCAGTGCGTGCAATGGGTCGTTTAGCAACAGGTGTACGCGGTATTAAACTCGCCCTAACCAACGACATCGCTGACGATGAAAGTGCGGTCGAAATTGAAGAGGTTTCCGATGATAATGCAGAAGAAACCCTCGATCTCAATATCGATAAAGTGGTTTCCTTAGTTGTGCCGAAAAATGACGGCGCAATCCTTACGGCGACGCAAAACGGTTACGGTAAACGCACACAATTAAGCGAATACCCAACCAAATCCCGTAATACCAAAGGGGTGATTTCGATTAAAGTGAGCGAACGTAACGGTAAAGTCGTTGCGGCGACACAAGTGGAAGAAACCGACCAAATTATGCTTATCACTGATGCGGGTACCTTAGTGCGTACTCGTGTAAGTGAAGTGAGCATCGTTGGCCGTAACACCCAAGGGGTTCGTTTAATTCGTACCGCAGAAGATGAGCACGTAGTCAGTCTTGAACGTGTTTGTGATGTGGATGATGAAGACGAAGGCACTGAAGATGTGACTTCTGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3184,Drugs,MEG_3184|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gb|FQ312002.1|+|1996520-1999166|ARO:3003924|Haemophilus parainfluenzae gyrA conferring resistance to fluoroquinolones [Haemophilus parainfluenzae T3T1] ,3
,TATCGCGTGTCTTTCGAGTACGGCATTAGCTGGTTCAATTACAGAAAATACGTCTTGGAACAAAGAGTTCTCTGCCGAAGCCGTCAATGGTGTCTTCGTGCTTTGTAAAAGTAGCAGTAAATCCTGCGCTACCAATGACTTAGCTCGTGCATCAAAGGAATATCTTCCAGCATCAACATTTAAGATCCCCAACGCAATTATCGGCCTAGAAACTGGTGTCATAAAGAATGAGCATCAGGTTTTCAAATGGGACGGAAAGCCAAGAGCCATGAAGCAATGGGAAAGAGACTTGACCTTAAGAGGGGCAATACAAGTTTCAGCTGTTCCCGTATTTCAACAAATCACCAGAGAAGTTGGCGAAGTAAGAATGCAGAAATACCTTAAAAAATTTTCCTATGGCAACCAGAATATCAGTGGTGGCATTGACAAATTCTGGTTGGAAGACCAGCTTAGAATTTCCGCAGTTAATCAAGTGGAGTTTCTAGAGTCTCTATATTTAAATAAATTGTCAGCATCTAAAGAAAACCAGCTAATAGTAAAAGAGGCTTTGGTAACGGAGGCGGCACCTGAATATCTAGTGCATTCAAAAACTGGTTTTTCTGGTGTGGGAACTGAGTCAAATCCTGGTGTCGCATGGTGGGTTGGGTGGGTTGAGAAGGAGACAGAGGTTTACTTTTTCGCCTTTAACATGGATATAGACAACGAAAGTAAGTTGCCGCTAAGAAAATCCATTCCCACCAAAATCATGGAAAGTGAGGGCATCATTGGTGGCTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4763,Drugs,MEG_4763|Drugs|betalactams|Class_D_betalactamases|OXA,gb|AF043100|+|0-774|ARO:3001411|OXA-16 [Pseudomonas aeruginosa] ,0
,CATCGCCGCGGTCGGGTGCGTGCTGAGCTGGATCGCCGCGGCGACGACGATCGAGGTGGCGCCCGTGCTGGAAGGCGAGCCGGCCACCACGGCGATCAGCTACTCGTCGCCGCTGTTGGTATTGGCGCTGGCCCTGGCGGGTCTGGCCGGCGTGCTGGCGGTGTTGGGTATTGCCCGGTTGCGTCGCTGATCCGTGACCGAGTGGCTGCCCGTCACACGCGGTGAATCCGGTGCCGGGGTCTTCAGGAACTCCGACGGTTCGAGCTACGCGAAGGTGGTCGACGCCGCGGCGGTGGCAGACCTGGCCGCGGAGCGTGACCGGGTGTCCTGGGCCCACAGGCACGGTGTCCCCGGGCCCGCGGTCATCGACTGGCGTGTCACCGAAGACGGCGGCGCGTGCTTGATCACGAGCACTGTGCGCGGTGTCGCTGCCGATCGGCTTTCCGAATCGGCGCTGCGGGCGGCCTGGCCGGCGATTGTGGAGGCGGTCCGGACACTGCACGCCCTTCCGGCCGACGGTTGTCCCTACCGGCGCGATCTCGACGACATGCTGGCCCGGGCCCGCGCGGTCGTCGGCGCCGGTGCCGTGAACCCGGAGTTCCTGTCCGACGAGGACCGCGAGGTACCGGCGGAGGCGCTGCTGGACCGAGTCGAACGGGAAGCCGATCTACGTCGTCGGGAGGAGGCCGCCGACTGGGTGGTGTGCCACGGCGATCTGTGCCTGCCGAACATTTTGGTCGACCCCGACCGTCACACCGTCGAGGGATTCATCGATCTGGGCAGGCTGGGGCTGGCCGACCGGCACGCCGACCTGGC,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1056,Drugs,MEG_1056|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|84993815|gb|DQ336355.1|410-1225,2
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtttcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1823,Drugs,MEG_1823|Drugs|betalactams|Class_C_betalactamases|CMY,1391852880|WP_109545065.1|NG_057479|1|1|blaCMY-161|blaCMY|class_C_beta-lactamase_CMY-161 NG_057479:1-1146,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacgataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2181,Drugs,MEG_2181|Drugs|betalactams|Class_A_betalactamases|CTX,1331531441|WP_102607451.1|NG_056165|1|1|blaCTX-M-191|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-191 NG_056165:1-876,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1934,Drugs,MEG_1934|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KJ207205|+|1039-2185|ARO:3002117|CMY-105 [Citrobacter freundii] ,0
,ACCAATAAATTTATTAGTACTGGTCAGCTGAATGCATTGCTGCACTTACACCTCCAGCCTATCAACCTCATAGTCTATAAGGAATTTTAAAGGGAATACTAATCTTTGAGGGGGCTTCCCGCTTAGATGCTTTCAGCGGTTATCCCTGCCGCACTTGGCTACCCAGCTATGCTTCTGGCGAAACAACTGGCACACCATCGGTGCGTCCACTCCGGTCCTCTCGTACTAAGAGTAGCTCTCATCAATATTCCAACGCCCACATCAGATAGGAACCAAACTGTCTCACGACGTTTTGAACCCAGCTCGCGTACCGCTTTAATGGGCGAACAGCCCAACCCTTGGAACCGACTCCAGCTCCAGGATGCGATGAGCCGACATCGAGGTGCCAAACCTTCCCGTCGATGTGATCTCTTGGGAAAGATAAGCCTGTTATCCCCGGGGTAGCTTTTATCCGTTGAGCGACGGCCTTTCCACGAAGAACCGCCGGATCACTAAGTCCTGCTTTCGCACCTGCTCGACTTGTAGGTCTCACAGTCAATCACACTTCTACCTTTATGCTCTTAGATACGGTTTCTGACCGTATTGAGTGTAACTTTGAACGCCTCCGTTACCCTTTAGGAGGCGACCGCCCCAGTCAAACTACCCACCACACACTGTCCTCTTCCCGGATAACGGGAACAAGTTAGAAGTTCAATGTAACAAGGGTGGTATTTCAACGGCGACTACTCTTAAACTAGCGTTCAAGCATCAACGTCTCCCACCTATCCTACACATGTTAAATCAAACTCCAATATGAAGTTATAGTAAAGCTCCACGGGGTCTTTTCGTCTAGATGCGGGTCTCCGGCGTCTTCGCCGGAACCATAATTTCACCGAGTCTATTGTCGAGACAGTTAAGAGATAATTACTCCTTTCGTGCAGGTCAGTATTTAGCCGACAAGGAATTTCGCTACCTTAGGACCGTTATAGTTACGGCCGCCGTTCACCCGGGCTTCACATTAATGCTTCGCTAATGCTAACACCTCTGCTTAACCTTCGGGCACTGGGCAGGAGTCACCCCATATACATCATCTTACGACTTAGCATAGAGCTGTGTTTTTGATAAACAGTTCCCCCTTACTATTCACTGCGGCCCACATTTTATTGTGGGCATCCCTTCTTGCGAACTTACGGGATGAATTTGCAGAGTTCCTTGACAATAGTTTTCTCGCTCGCCTTAGAATACTCATCTTGGGGACGTGTGTCCGTTCTCGGTACGGGTTTCCTAACACTTAATGTTAGAAGCTTTTTTAAGAGGCATGAAATCATCTAATTCGCTACTCAGTTGCCCTTTTGCTATGCGTCGTAACTCCCAGTTAAGTTATGCGGATTTGCCTACATAACCCAGTTGTTACTTACCCCACAATCCAATTAGTGGTAAAATTATCCTTCCCCGTCACTCCATCACATGTTAAGAAAGTACAGGAATATTAACCTGTTGTCCATCGGCTACGCCTTTCGGCCTCGTCTTAGGACCCGACTAACCCTGGGTGGACGAACCTTGCCCAGGAAACCTTCCCCAATAGGCGTCAGAGATTCTCACTCTGAATCGTTACTCATACCGGCATTCTCACTTGTAAGCGCTCCACCAGTCCTCACGGTCTGGCTTCTAAGCCCTTACAACGCTCTCCTAACGCATTTCTGCCCGTAGCTTCGGTATTGTGTTTTAGTCCCGTTGAATTATCGGCACAAAGTCTCTCGACTAGTGAGCTATTACGCACTCTTTAAACGGTGGCTGCTTCTAAGCCAACATCCTAGCTGTTTAAGAAACTTCACAACCTTTCTCACTTAACACAATTTTGGGACCTTAGCTGACGATCTGGGTTGTTCCCCTCGCGTGCATCGACGTTATCACCGATGTACCGACTGCATAGTAATACATGATAGTATTCGGAGTTTGATTATAGTCAGTACGGCTAGGCGCCGCCATTCCATATTCAGTGCTCTACCCCCATCATTTAACACTACACGCTAGCCCTAAAGCTATTTCGGAGAGAACCAGCTATCTCCAAGTTCGATTGGAATTTCACCCCTACCCACAAGTCATCCGGGCACTTTTTAGCGTACTGCGGTTCGGTCCTCCACTTAGTGTTACCTAAGTTTCAACCTGCTCATGGGTAGATCACCTGGTTTCGGGTCTATATCAACATACTAAATCGCCCTATTCAGACTCGATTTCTCTACGGCTTCGCTTTATTCTACTTAACCTCGCATGTTGACATAACTCGCCGGTCCATTCTGCAAGATGTACGCCATCACCCATTAACGGGCTCTGACTAACTGTAAGTAATTGGTTTCAGAATCTATTTCACTCCCCTCCCGGGGTTCTTTTCACCTTTCCCTCACGGTACTAGTTCACTATCGGTGTCTGGTTAGTATTTAGCCTTACCGGGTGGTCCCGGCAAATTCAGACAGGGTTTCACGTGCCCCGCCCTACTCAGGATACTGCTAGGAGATTTATACATTTCGCTTACGGGAATTTCACCCTCTATGTTTAAGCGTTCCAACTTATTCTGCTATGTACAAATTCATTAATCCATGTCGCAGTCCTACAACCCCAACAACATGTGTTGGTTTGGGCTCTTCCCCGTTCGCTCGCCACTACTTAGGGAATCATTCTTTATTTTCTCTTCCTGCTGCTACTGAGATGTTTCAATTCACAGCGTGTCTCTTCATTCGACTATGAATTCATCGATATGATAATTGAGGATTAGCTCAATTAGGTTTCCCCATTCGGAAATCCCCGGATAACAGCTTATTTCCAGCTAACCGAGGCTTATCGCAGGTAATCACGTCCTTCATCGACTTCCAGACCCAAGGCATCCACCAAAAACTCTTGCTTGTTT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3979,Drugs,MEG_3979|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|CP011538.1|-|333282-336166|ARO:3004176|Mycoplasma hominis 23S rRNA with mutation conferring resistance to macrolide antibiotic [Mycoplasma hominis] ,7
,atgcgttcgttcgccatatcgactgtgttggtgatgtcctcactgttagcgtcgtcaaccatagctgccccaacttttgcctcaacagcggcgaagacagagtggcaagaaacccgcagttgggatgccatttttactcagcaccaagttgaaccgcaacaagctaagcaacaacaagctaaaccgcaaaaaactaagtcccaacaagcctctggagtggtggtgctgtggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttaccggcatcgacctttaaaatccccaatagcttgattgcgctcgagttgggtgtggtgaaggatgagcaccaagtgtttaaatgggatggtaaaagtcgtgatatcgccacttggaatcgtgatcataacttgattactgggatgaagtattcggttgtgcccgtctatcaagagtttgcccgccaaattggtgaggcgaggatgtcgaagatgatcgcctccttcgattatggcaatgaggatatctcgggtaacttagatagcttttggctcgatggcggtattcggatttcggccactgagcaaattgatttcctgcgtcggctttatcacaacaagatccacgcttcagaacgcagtcaacgaattgttaagcaggctatgctcaccgaggcgaattctgactatattatccgcgcaaaaaccggctatgcggtcagagctgagccaagtattggctggtgggtgggttgggtagaactcgataataatgtgtggttttttgcaatgaatatggatatacccgacgccgcaggtttgccattgcgtcaagccatcactaaagaagttttaaaactggaacacgttattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4622,Drugs,MEG_4622|Drugs|betalactams|Class_D_betalactamases|OXA,1201190422|WP_087587942.1|NG_054956|1|1|blaOXA-551|blaOXA-548_like|OXA-548_family_class_D_beta-lactamase_OXA-551 NG_054956:1-888,0
,atgaataaatattttacttgctatgtggttgcttctctttttctttctggttgtacggttcagcataatttaataaatgaaacccagagtcagattgttcaaggacataatcaggtgattcatcaatactttgatgaaaaaaacacctcaggtgtgctggttattcaaacagataaaaaaattaatttgtatggtaatgctctaagccgcgcaaatacagaatatgtgccagcctctacatttaaaatgttgaatgccctgatcggattggagaaccagaaaacggatattaatgaaatatttaaatggaagggcgagaaaaggtcatttaccgcttgggaaaaagacatgacactaggagaagccatgaagctttctgcagtcccagtctatcaggaacttgcaagacgtatcggtcttgatctcatgcaaaaagaagtagaacgtattgatttcggtaatgctgaaattggacagcaggttgacaatttctggttgataggcccattaaaggtcacgcctattcaagaggtagagtttgtttctcaattggcacatacacagcttccatttagtgaaaaagtgcaggctaatgtaaaaaatatgctacttctagaagagaataatggctacaagatttttggaaagactggttgggcaatggatataaaaccacaagtgggctggttgaccggctgggttgagcagccagatggaaaaattgtcgcttttgcattaaatatggaaatgcggtcagaaatgccggcatctatacgtaatgaattattgatgaaatcattaaaacagctaaatattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4521,Drugs,MEG_4521|Drugs|betalactams|Class_D_betalactamases|OXA,1407752030|WP_111280830.1|NG_064773|1|1|blaOXA-815|blaOXA-23_like|OXA-23_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-815 NG_064773:1-822,0
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4507,Drugs,MEG_4507|Drugs|betalactams|Class_D_betalactamases|OXA,1058244051|WP_068981639.1|NG_051474|1|1|blaOXA-524|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-524 NG_051474:1-825,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacaccgctggcggcctgccgctacagttccccgatgcggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccgccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccgcccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgattggccgatcgacctgaggcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggtytggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5613,Drugs,MEG_5613|Drugs|betalactams|Class_C_betalactamases|PDC,927320859|WP_053813381.1|NG_050589|1|1|blaPDC-125|blaPDC_var|class_C_beta-lactamase_PDC-125 NG_050589:1-1194,0
,atgccccgtatgctgttgtccggtctgcttgctgctggcctcttctgtgcactgcctgccagcgccgcttctggctgcatgctgtttgcggatggaaccggcaaacccgtcagcacccagggggactgtgccgcccagttgaccccggcctccaccttcaagatcccgctggcactgatgggctatgacagcggcttcctggtggatgaacaactgccggccctgccgttcaaggccggtgatcctgatttcctgccggagtggaaacagaccaccaccccgagcagctggatgaagaactccgtcatctggtattcccagcgcctcaccgagtggctgggagaggctcgcttccagcactacgtggacagcttcgactacggcaaccgggatctcgaaggcaacccgggcaagcacgacggtctgacccaggcctggctcagcgccagcctcgccatcagcccccaggagcaagcccgcttccttggcaagatggtgagcggcaagctgccggtctccgcccagaccctgcgccataccgccaacctgatgcgtcagcccgacatcgacggttggcagatccacggcaagaccggcatgggttaccccaagctgctggatggcagcctggacagggagcagcagatcggctggttcgtcggctgggccagcaaacagggcaagacgctcatcttcgtccacaccgtcatccagaagccgggcaagcagttcgcttccctcagggccagggaggaggtgttcgccgccctgccggcccggttgaagacactctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4601,Drugs,MEG_4601|Drugs|betalactams|Class_D_betalactamases|OXA,902765661|WP_049637206.1|NG_063881|1|1|blaOXA-780|blaOXA-PR|class_D_beta-lactamase_OXA-780 NG_063881:101-895,0
,GGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCGAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2335,Drugs,MEG_2335|Drugs|betalactams|Class_A_betalactamases|CTX,gb|JF274248.1|-|0-865|ARO:3001969|CTX-M-109 [Shigella sp. SH361] ,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtactaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggccttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcagtttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacgggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgttccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaagaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_853,Drugs,MEG_853|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502085|WP_071846237.1|NG_052249|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052249:101-892,2
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCACGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2310,Drugs,MEG_2310|Drugs|betalactams|Class_A_betalactamases|CTX,gb|FJ873739|+|0-875|ARO:3001948|CTX-M-88 [Salmonella enterica subsp. enterica serovar Infantis] ,0
,ATGAGTGTGTCTTCCCGTTTTCCGCCTGAGGTCACTGCGTGGATGGAGCGCTGGCGCCTGCTGCGCGACGGCGAGCTGCTCACCACCCACTCGAGCTGGATACTTCCCGTCCGCCAGGGGGACATGCCGGCGATGCTGAAGGTCGCGCGCATTCCCGATGAAGAGGCCGGTTACCGCCTGTTGACCTGGTGGGACGGGCAGGGCGCCGCCCGAGTCTTCGCCTCGGCGGCGGGCGCTCTGCTCATGGAGCGCGCGTCCGGGGCCGGGGACCTTGCACAGATAGCGTGGTCCGGCCAGGACGACGAGGCTTGCAGGATCCTCTGCGACACCGCCGCTCGTCTGCACGCGCCGCGGTCCGGACCGCCGCCCGATCTCCATCCGCTACAGGAATGGTTCCAGCCGCTTTTCCGGTTGGCCGCTGAGCACGCGGCACTTGCGCCCGCCGCCAGCGTAGCGCGCCAACTTCTGGCGGCGCCGCGCGAGGTGTGCCCGCTCCACGGCGACCTGCACCACGAGAACGTGCTCGACTTCGGCGACCGCGGCTGGCTGGCCATCGACCCGCACGGACTGCTCGGCGAGCGCACCTTCGACTATGCCAACATCTTCACGAATCCCGATCTCAGCGACCCCGGTCGCCCGCTTGCGATCCTGCCGGGCAGGCTGGAGGCTCGACTCAGCATTGTGGTCGCGACGACCGGGTTTGAGCCCGAACGGCTTCTTCGCTGGATCATTGCATGGACGGGCTTGTCGGCAGCCTGGTTCATCGGCGACGGCGACGGCGAGGGCGAGGGCGCTGCGATTGATCTGGCCGTAAACGCCATGGCACGCCGGTTGCTTGACTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1090,Drugs,MEG_1090|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,(AGly)Sph:AY037297:3548-2706:801,2
,GGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAACTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTCTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGGCCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCCTTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCGTCGCCTAGGGTCATGTCCTTTTCCCATTCTGGGAATAGCCTTTTTTGCCCGTCCCACTTAAATACTTCTGTGGCGGTTGCCTTATGGTGCTCAAGGCTGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGGCCTTGTTGGATAACTAAGACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCGCTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGGGCTTTAATGTTCATAAGACTTATAAGATTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5226,Drugs,MEG_5226|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389141|gb|KF986253.1|1-856,0
,atgaggctgcacgggaatcaagtggtgctgcgtgcggtgaccgggagcgacatcgggaccctcgacaggatcgtgcgggaaccggaggtcgcggcgtggtggtcgccccccgaggactacgggggcatgctggccgtcgtcttcgagggtgaggtcgtcggcgcggtccagttccacgaggagaccgatcccgagttccgccacgccggcatcgacatcttcctgacggcacggcagcacgggaagggactcggcaccgacacggtgcgcacgctggcccgttggctggtggaggaacgcggccaccaccggctgaccatcgaccccgccgcggccaacaccgcggcgatccgctgctacgccggggtcggcttcaaacccgtgggaatcatgcgggcctacgcccgcgaccaccgcacgggcacctggcaggacggtctgctgatggacctgctcgcggccgagctgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_135,Drugs,MEG_135|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,663407871|WP_030403494.1|NG_052205|1|1|aacA-STR-7|aacA-STR-7|aminoglycoside_6'-N-acetyltransferase NG_052205:101-574,2
,atgagaaacacagtgcccgccgagatttcggtacagttatcacaggcactcaacgtcatcgagcatcatctgggatcgacgttgctggccatgcatttgtatggctctgcactcgacggtggcctgaagccatacagtgacattgatttgctggttactgtgaccgcacggctcgatgagagtgtgcggaaagctctgttcgtcgatctcttgggggtttccgttttccctggtcaaagcagagttctccgcgccttggaagttaccattgtcgtgcacagtgacatcgttccttggcgctatccggccagacgggaactgcaattcggggagtggcagcgcaaagacattcttgcgggcatcttcgagcctgcgacaaccgatgttgatctagccattctgctaacaaaagcaaggcaacatagccttgccttggccggttcggctgcggaagatttcttcaacccagtcccggaaagcgatctgttcaaggcactggccgacaccctgaaactatggaactcacagccggattggataggtgacgagcggaatgtagtgcttactttgtctcgtatttggtacagcgcagcaaccggcaagatcgcgccgaaggatgttgccgccaactgggtaatggagcgtttgccagttcaacatcagcccgtgctgcttgaagcccggcaggcttatctaggacaaggagaagattgcttggcttcgctcacggatcagttagaggcgtttgttcacttcgtgaagcatgaagccactaaactgcttggtgccacgccaatgatgtctaattcaggcgttatgcgctcacgtccttaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_758,Drugs,MEG_758|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502114|WP_071846266.1|NG_052307|1|1|aadA10|aadA10|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA10 NG_052307:101-934,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatggtcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaaacgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4467,Drugs,MEG_4467|Drugs|betalactams|Class_D_betalactamases|OXA,1188444911|WP_085562413.1|NG_054703|1|1|blaOXA-559|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-559 NG_054703:1-825,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctctttatcatggaagtgcaaaaagtaatatagggattgataaccttatagaagttattactaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaagaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggttgcgaacaaggattatatggttggaatgtgacggattgtaaaatctgttttaagtacggtttatactatagccctgttagtactccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7126,Drugs,MEG_7126|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,446614390|WP_000691736.1|NG_048223|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048223:13-1932,4
,atgcgtatccgccccacccgtcgtcttctcctcggcgcggtcgcgccgctcgccctcgttccgctggtggcctgcggtcaggcgtcgggctccgagagcgcgggcagcagcccggcctcagcggtgcggacgagcgcacacggctcggcggacgcccacgagaaggaattccgggcgctggagaagaagttcgacgccaccctgggcgtctacgccatcgacaccgccgacggccaggagatcacccaccgggccgacgagcgcttcgcctacggctcgaccttcaaggccctccaggcgggcgcgatcctgcgcaagttctccgagacgggcgcgaagtccggcgcgggcgccgaggccgacggcatggacaaggtggtccactacgggcaggacgcgatcctgcccaactcgccggtgaccgagaagcacgtcgcggacggcatgtccctgcgcgagctgtgcgacgccgtcgtccgctacagcgacaacaccgcggccaacctgctcttcgaccagctcggcggcccgaaggggctcaacgcggtcctcaagcagctcggcgaccacaccacgagcatggaccgctacgagcaggagctgggctcggccgtccccggcgacccccgggacaccagcacgccgcgcgcgttcgccgaggacctgcgcgccttcgccgtcgaggacggcaagaaggccgccctcgcgcccaacgaccgcgagcagctgaacgactggatgagcgggaacgccaccggcgacgcgctgatccgggccggtgtgccgaaggactggaaggtggcggacaagagcggccaggtcaagtacggcacccggaacgacatcgccgtcgtccgcccgcccggccgtgcgccgatcgtcgtctcggtgatgagccacggcgacacggaggacgccgagccgcacgacgagctggtggccgaggccgcctccgtcgtcgccgacggtctgaagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1291,Drugs,MEG_1291|Drugs|betalactams|Class_A_betalactamases|BLAL,664365047|WP_030892446.1|NG_050597|1|1|blaL|blaL|BlaL_family_class_A_beta-lactamase NG_050597:101-1078,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatttcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_846,Drugs,MEG_846|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,749295996|WP_040120354.1|NG_052030|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052030:101-892,2
,atgcgattcaaaaaaatttcttacttaattctaccttctctttttatttttaatacctcaatttatgcaggtaacacatcaaaagaacaagatatcaagaaagttgttgatcagaactttaaaccattattagaaaaatatgacgttcctggtatggcggttggtgtcatccaaaacaataaaaagtacgaaatgtattatggcctacaatcagttcaagataaaaaatccgtaaatggcaatacgatttttgaactaggctcagtcagtaaattatttactgcgacggcaggtggatatgccaaaactaaagaaaaaatctcttttgacgacaccccaggaaaatactggaaagagctaaaaaatacaccgattgaccgagtaaacctacttcaacttgcgacgtatacgagtggcaaccttggcttacaattcccagatgaagttcaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaaccaaattggtgaatatagacaatattcaaaccctagtattggcctatttggaaaagttgtaggcttatcgatgaaccagccttttagtcaggttttagaaaagacaatttttccgtctcttcacttaaaacatagctatgtaaatgtgcctaaaactcagatgcaaaactatgcatttggctataaccaagaaaatcagccgattcgtgtgaccccaggcccactagatgcgcctgcctacggggttaaatctacattaccagacatgcttagctttattgatgccaatctaaatccacaaaaatatccggcagatattcgacgcgcaattgatgagactcataaaggtttttatcaagtcggtacgatgtatcaggcgcttggttgggaagagttttcttatccagctcctttacaaactttattagacagtaattctgaacaaatcgtgatgaaacctaataaagtgactgctatttccaaagaaccttcaatcaagatgttccataaaactggttcaactaacggatttggaacttatgtcgtgtttattcccaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaagcagcttatgctgtactaaatgcgattaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_519,Drugs,MEG_519|Drugs|betalactams|Class_C_betalactamases|ADC,490781350|WP_004643536.1|NG_064684|1|1|blaADC-128|blaADC|class_C_beta-lactamase_ADC-128 NG_064684:101-1252,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATGGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGGTTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGCCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2222,Drugs,MEG_2222|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-43:HQ734713:1-876:876,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacagtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2196,Drugs,MEG_2196|Drugs|betalactams|Class_A_betalactamases|CTX,1393270464|WP_109791209.1|NG_057608|1|1|blaCTX-M-216|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-216 NG_057608:1-876,0
,atgatgaacacgcgattatcctgcacgctggcgctctccgcgctgctgctctcctcgggcgcccaggcgtctacgccgccgtcggcagagatgcgggtcgccgaggcggtgaaacagacgatccctgcgctgatgcagcagcagcagatccccggcatggccgtggccgtaatctatcagggaaccccttactacttcagctatggcgtcgccgataaggccacccggcgggcagtgacgccacaaacgctgtttgagctggggtccgtgagcaagacctttaccggcgtgctgggtggctatgcgctgcagcgtggcgatattcgcctgcaggacacggtcgcgtcccaatggccggcgttaaatggcccgcagtggcgggcgataaccctacagcagctggcgacctacaccgcgggcggcctgccgctgcaggtgcccgacgccgttaccgatacggcacagctgctcgacttttatcaacgctggcagccgcgctgggctccgggaacgatgcgcagctactccaacgccagtattggcctttttggcatgctggcggtacggcccagcggcatggattttagccaggcgatgacacgctgggtgctgcagccgctgggattgaagcatacctatttccgcgtaccgcctgccgcggagggagaatatgcctggggataccgcgagggtaaggccctgcgcgtgagcccgggtatgctggagcaggaggcctatggaattaaatccagcgcgcaggatatggccacctggctacaggctaatctggatcccgccgcggtgacacaggcgacgctgcgtcaggccttgctgcgggcgcagacgcgctactaccaatccggtgagatgtatcaagggctcggctgggagatgctcagctggcctctgcaggcgcagaccttgatagacggtagcgataatcgggtcgctctgcagccgcagccagtccatctcatcgagccgccgacgccgccgcaaccggcttcctgggtacataagaccggttcaaccaatggatttggcgcctatattgcctttattcccggatctcggctggggatcgtgatgttggccaataaaaactacccgaacccggcgcgggttcaggccgcctataccatcctgcagcagctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1271,Drugs,MEG_1271|Drugs|betalactams|Class_C_betalactamases|BLAC,754045620|WP_041692555.1|NG_047492|1|1|bla-C|bla-C|class_C_beta-lactamase NG_047492:101-1261,0
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGACGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6418,Drugs,MEG_6418|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948438|emb|AM176549.2|1-891,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttatcggcatgttcttttaatacggtagaacagcatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcgttgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctactattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagagataaaacgcattagtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggaaaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4556,Drugs,MEG_4556|Drugs|betalactams|Class_D_betalactamases|OXA,691143886|WP_032057042.1|NG_064778|1|1|blaOXA-820|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-820 NG_064778:1-822,0
,ATGCGTTATATTCGCCTGTGTATTATCTACCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGTGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6250,Drugs,MEG_6250|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-56:AY352599:1-861:861,0
,atggcactggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagattttcgcggcgcaagttttatgaatatgatcactactcgcacctggttttgcagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtagtgttggaaaagtgtgagctgtgggaaaaccgttggatggggacccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggcgcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5885,Drugs,MEG_5885|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111930|WP_063866135.1|NG_050512|1|1|qnrB49|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB49 NG_050512:37-681,3
,ATGCTGTCCAATCAAATTATTAATCAGAGCTTCGCGGAGATTATGGGAAAGCGCTTTGGGGACTATGCCAATCTGGTTATTCTCTCACGCGCGATCCCAGATGCTCGCGATGGACTAAAACCGGTACAGCGCCGTATTTTGTATGCCATGTACCAAGAAGGCAACACGAACGATAAACCATACCGGAAATCAGCGAAAACAGTCGGGTACGTGATGGGTACCTATCACCCGCACGGTGACTCGGCGATTTACGAAACGATGGTGCGGATGGCGCAATGGTGGAAAATGCGACAGGTGCTCATTCAAGGCCACGGAAACTTTGGTAGCTTGGATGCAGATCCGCCAGCCGCTATGCGTTATACCGAATCAAGACTGTCAGCATTGGCCAATGAGCTACTGCGTGATATTGAAAAGGATACGGTTACATTCATCCCGAACTACGACAACTCCGCTCAACAACCGGCAGTATTGCCTTCACGGTTTCCCAATCTTCTCGTGAATGGCGCTGCTGGGATCGCGGTTGGTTTTGCAACAGACATCCCTACTCACAATTTGGGTGAAGTCATCGATGCGGCTGTTGCCCAGATGAAGAACCCGAATATCTCGCTGGATGAGCTGATGCAGCACGTCAAAGGTCCAGATTTTCCAACTGGCGGTATTGTTCAAGGGCTGTCCGGAATTCGCAAGGCGTTTGAGACAGGCCGTGGCCAATTCATCATTCGCGGGAAGACCCATGTAGAGGAGCCAAAAGGCGGCAAGATCAAAAAAATCGTCGTTTCCGAAATCCCTTACGAAGTGGTCAAGTCGAAGCTCGTCGGCCAAATCGATGAGCTTGTGATGGAGCGCAAAATCGAGGGGGCACTGGCGGTTCGCGATGAAACGGGTCGCAAAGAGGCCGAGCAGAAAAAAGTACGCATCGTAGTGGATATTCGCAAAGAAGCGGATGAGCAGGCGATTCTCAACTACCTGTACAAAAATACCGATCTGCAAATCTATTACAATTACAACATGAACGTGATTCATGAGGGGACCATCCGTCAGATGGGACTCAAGGCTTTGTTGGGGGCGTACATCGACCACCAAAAAGAAGTCGTCACGAATCGCTGCCAATATGATCTGGATCGAAAGCAAAGCCGCGAGCATATCGTGGAAGGCTTGATTCGCGCCAAGTCCATTTTGCGTCAGATCGTCGATACGATTATGGATTCGGAAGACCGTGCAGATGCCAAGAAAAACATCATGGAGAAATACGGCTTCACCGACAACCAAGCCGATGCGATCTTGAGCATTCAGCTCGCTTCTTTGACACGCTTGGATATCGTCAAGCTGGAAAAAGAATTGGCTACATTAGCAAAAGAAATCGAGGAACTGAAATCGATTTTGGCAAGCGAGAAAAAGCTGATTCAAGTCATTACAGGCGAGCTGAACGAGATCAAGAAAAAATACGCAGAAGAGCGTCTAACAGAAATCCAGGGCGAGATCGAGGAAATCAAAATCGATATTGCCATGCAAATCAATGCAGAGGATTGTATCGTAACCCTGACGAACGAAGGATATATCAAGCGGACGAGCCCGCGCTCCTTCAAATCAGTGGGGGGAACGCTGGAGACATGTGGGGTAAAAGAAGGCGACCGTGTCCGTTATTTCATGGAGACGAATACGTCTCACACTGCTCTCTTCTTTACCCAGGATGGTAAATACTTTGCCACACTGGTTAACGCCTTCCCGGACGATAAGTGGAAGGATATCGGTTCGGCTCTCGTCAATATCATCCCGTTGGAAAAGAATCAGCGGATCGTTGGCTTTACGATCGTAGAAAACTTCAAACAACCGCTGTATGTATACCATGTAAGTAAAAATGGTTTGATGAAAAAGACGGCGTTGTCCGAATACGAAACCAATCGTTCGAGTGCGTTGGTAGCTGCAAAGCTAAAAGGCGGCGATGACGAGTTTATGAATGTATTCGTGGCGGACGAAGCTGGAGCAATACTCGGTGCGACGAAAGATGGCATGGGCATCCGATTCCAGCGCAGCGAAGTCAGCGCAACGGGTAGAGCGTCGAGCGGGGTAAAAGCGATCGCACTTGCTCCTGGCGATGATGTCATCACGATGCTTCCGATTGAGGAAGTCGATTCGCGTGCCTTTAGCTTGTTGACGGCTGAAGGGGTTGTAAAACGCACAGCCATTGGTGCAATCCCACTTCAGGCTCGCGCAGGCAAAGGGGTACAGTTGATTCGTAAACGAAAAAATAACCCGCATGAGCTTGTTGCGATGTTCCTCGAGGAAACGGTTTATGCCTGGACGTCGCAGAACGAATGGACCCTTGTTGAGACAGAGCAAGTGATCGTCAACGAGCAAGGTGGTATTGGCCGACAACTGATCGAGGGTGGGGTAAAAGCAGTTGCTTTTGAAACCATTTTGCCGACAGATGAACCGAAGGACGAAGCGACGGCAAAAGGCTCAGGAGACGGATCTGGCACAGCAGGGCAACAGAAAACGTCGAATGTCCAGGCTAATTTGTTCGATGGAGATCATCGTAAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5338,Drugs,MEG_5338|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|226092535|dbj|AP008955.1|3483238-3480695,3
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1906,Drugs,MEG_1906|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733572|+|1027-2173|ARO:3002088|CMY-75 [Citrobacter freundii] ,0
,atgatgagaaaaagcgtaaggcgggcgatattaatgacgacagcctgtgtttcgctgctgttggccagtgtgccgctgtgtgcccaggcgaacgatgttcagcaaaagctggcggcgctggagaaaagcagcgggggacgactgggtgtggcgttgattaacaccgccgataacacgcagacgctctaccgcgccgacgagcgttttgctatgtgcagcaccagtaaagtgatggcggcggcggcggtgcttaagcaaagtgaaacgcaaaaagacttactgagtcagcgggttgaaattaagtcatcagacttgattaactacaacccaatcgctgaaaagcacgtcaatggcacgatgacactcggggagctgagcgcggcggcgctgcagtacagcgataatactgccatgaataagctgattgcccatctcggggggccgggtaaagtgacggcatttgctcgtgcgattggcgatgacactttccggctcgatcgtaccgagccgacgctcaacaccgcgatccccggcgacccgcgcgataccaccacgccgttagcgatggcgcagactctacgcaatctcacattgggcaatgccctgggtgacactcagcgtgcgcagctggtgacgtggctgaaaggcaacaccaccggcgctgccagcattcaggcagggctacccacatcgtgggttgtcggggataaaaccggcagcggcgattatggtacgacgaatgatatcgcggttatttggccggaaggtcgcgcgccgctcgttctggtgacttacttcacccagccgaagccgaaggcagagagccgtggtgacgtgctcgctgctgccgccagaattgtcaccgacggttattag,beta-lactamase,antibiotic inactivation,betalactams,MEG_2171,Drugs,MEG_2171|Drugs|betalactams|Class_A_betalactamases|CTX,1270501778|WP_099156053.1|NG_055667|1|1|blaCTX-M-205|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-205 NG_055667:1-876,0
,ATGGAATTAATATTAAAAGCAAAAGACATTCGTGTGGAATTCAAAGGACGCGATGTTTTAGATATAAATGAATTAGAAGTATATGATTATGACCGTATTGGTTTAGTAGGAGCAAATGGTGCTGGAAAAAGCACTTTACTCAGGGTACTTTTAGGAGAATTAACTCCCCCAGGATGTAAAATGAATCGTCTGGGTGAACTTGCCTATATTCCCCAGTTGGACGAAGTAACTCTGCAGGAGGAAAAAGATTTTGCACTTGTAGGCAAGCTAGGTGTTGAGCAATTAAATATACAGACTATGAGCGGTGGTGAAGAAACAAGGCTTAAAATAGCACAGGCCTTATCGGCACAGGTTCATGGTATTTTAGCGGATGAACCTACGAGCCATTTAGACCGTGAAGGAATTGATTTTCTAATAGGACAGCTAAAATATTTTACAGGTGCACTGTTAGTTATTAGCCATGACCGCTATTTTCTTGATGAAATAGTAGATAAAATATGGGAACTGAAAGATGGCAAAATCACTGAGTATTGGGGAAACTATTCTGATTATCTTCGTCAGAAAGAGGAAGAACGTAAGAGCCAAGCTGCAGAATACGAACAATTTATTGCGGAACGTGCCCGATTGGAAAGGGCTGCGGAGGAAAAGCGAAAACAGGCTCGTAAAATAGAACAGAAGGCAAAAGGTTCTTCAAAGAAAAAAAGTACTGAAGACGGAGGGCGTTTAGCTCATCAAAAATCAATAGGAAGTAAGGAAAAAAAGATGTATAATGCTGCTAAAACCCTAGAGCACAGGATTGCGGCCTTAGGAAAAGTAGAAGCTCCGGAAGGCATTCGCAGAATTCGTTTCAGGCAAAGTAAAGCATTGGAGCTCCATAATCCATACCCTATAGTCGGTGCAGAAATTAATAAAGTATTTGGGGATAAGGCTCTGTTTGAAAATGCATCTTTTCAAATTCCGTTAGGAGCAAAAGTGGCGTTAACTGGTGGTAATGGAATCGGAAAAACAACTTTAATCCAAATGATCTTAAACCATGAAGAAGGAATTTCTATTTCGCCTAAGGCAAAAATAGGTTACTTTGCACAGAATGGTTACAAGTACAACAGTAATCAGAATGTTATGGAGTTTATGCAGAAGGATTGTGACTACAATATATCAGAAATTCGTTCAGTGCTAGCATCTATGGGGTTCAAACAGAACGATATTGGAAAAAGTTTATCTGTTTTAAGCGGTGGAGAAATTATAAAATTGTTGCTTGCTAAAATGCTCATGGGTAGATATAACATCCTAATAATGGATGAACCCAGTAACTTCCTTGACATACCAAGTTTAGAGGCTTTGGAAATACTAATGAAGGAGTACACCGGAACTATCGTGTTTATCACCCACGATAAACGATTACTCGAAAATGTAGCAGATGTAGTTTATGAAATTAGAGATAAGAAAATAAATCTGAAACATTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4073,Drugs,MEG_4073|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRD,(MLS)MsrD:AF274302:2462-3925:1464,7
,atggactcggactgggaactccgcggcgacaggatcgtcctccgccccgtcatggccgacgacaccccgaccctccaccgcatcgtccgcgaacccgaggtcgcggcctggtggggcacccccgagggcttcgacgacatgctcgcggtcgtcctcgacggcgaggtgatcgggtccgtccagtacgaggaggaggacgacccggactaccggcacgccggcatcgacctcttcctctccgcccgccaccacggccgcggcctgggcgccgagaccgtccgtacgctggcccgctggctcatcgacgcgcgcggccaccaccgcctgaccatcgaccccgcagccgccaacaccacggccgtccgcagctacacccgcgtcggcttccggcccgtcggcgtcctccgcgcctacgaacgcgacccgctgaccggggactggcgcgacggcctgctcatggatctcctcgccgacgaactcgcctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_196,Drugs,MEG_196|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,739940554|WP_037790839.1|NG_052293|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052293:101-586,2
,atgaagaaatggttttttttattgttattgttattgttaatatacttaggttatgactacattaataaagcactgttttctcaggaaaaagtagaatttcaaaattatgatcaaaatcccaaagaacatttagaaaatagtgggacttctgaaagtacccaaatgaaaacaattacagatgaacaggtttatcaaggaaatctgctattaatcaatagtaaatatcctcttcgtcaagaaagtgtgaaatcagatatcgtgaacttatctaaacatggcgaattaataactggatacgggttgcttgatacgaatatttatatgtcaaaagaaatagcacaaaaattttcagagatgatcaatgatgctgtaaatgggggcgttagtcattttattattaatagtggctatcgagactttgatgagcaaagtgtgctttaccaagaaatgggggatagttatgccttaccagcaggttatagtgaacataattcaggcttatcacttgatgtaggatcaagcttgacgaaaatggaacgagcacctgaaggaaagtggataaaagaaaacgcttggaaatacgggttcattttacgttatccagaggacaaaacagatgtaacaggaattcaatatgaaccatggcatatccgctatgttggtttagcccatagtgcaattatgaaggaaaagaatttcgctctcgaggaatatatggattatctaaaagaagaaaaaattatttctgttagtgtaaatgaggaaaaatatgagatcttttattatcctgttacaaaaaataccaccattcatgtgccttccaatcttcgttgggagatatcaggcaacaatatagatggtgtaattgtgactgtgtttcccgaatcaacataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7592,Drugs,MEG_7592|Drugs|Glycopeptides|VanA-type_accessory_protein|VANYA,1028100706|WP_063856841.1|NG_048517|1|1|vanY-A|vanY-A|D-Ala-D-Ala_carboxypeptidase_VanY-A NG_048517:1-894,5
,TTGACCGTATTGGGAGTTTGAGATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGAATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACTGGTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2401,Drugs,MEG_2401|Drugs|betalactams|Class_A_betalactamases|CTX,gi|56069564|gb|AY822595.1|1-904 gi|548319340|gb|KF308562.1|1-903,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4317,Drugs,MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_8_KT862782 ,1
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccacgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2159,Drugs,MEG_2159|Drugs|betalactams|Class_A_betalactamases|CTX,1028104752|WP_063859998.1|NG_048958|1|1|blaCTX-M-173|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-173 NG_048958:1-876,0
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGAGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6629,Drugs,MEG_6629|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|30314008|gb|AY232670.1|157-972,8
,atgataatcacagaatttgatcgcgaaagcatcgcattaaaaaatcaattaactgatttactggctttaacttggcctaaggattatggagaaacagcttcagagaaagttgaagaattacttaccgataatcggattgccgtagctgctttggaggatgaccagttgattggatttgtaggggcgattccccagtatgcaatgacggggtgggagatgcatcccttggttgtttcttcaacacaaagaggaaatcgaatcggtgcgcgtcttgttcaatatctggaaaaagaagttgcttcaaagggtggacttacgatttatttaggtacagatgatgaaaccaatcaaacaactcttagtgaggatgatttatttgagaatccctttgaaaagattcgacaaattaaaaataaggaaaatcatccctttgaattttatgaaaaacaaggctatcaaattgttggtgttttaccggatgttaatggctggaataaaccggatattttaatggcaaagagggttgggaaaaaagtttccgaatctaatacaaaacagggataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_137,Drugs,MEG_137|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,498462935|WP_010768325.1|NG_052165|1|1|aac(6')_Entco|aac(6')_Entco|aminoglycoside_6'-N-acetyltransferase NG_052165:101-664,2
,ATGCGTTATGTTTGCCTGTGCCTTATCTCACTGGTTGCCGCCCTGCCACTGGCGGTATTCGCCAGCCCTCAGCCGCTTGAGCAGATTAAAATCAGCGAAGGTCAGCTGGCGGGCCGGGTGGGCTATGTTGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCAGTGAGCGCTTTCCGCTGATGAGCACCTTTAAAGTGCTGCTCTGCGGCGCTGTGCTGGCCCGGGTGGATGCCGGCGACGAACAGCTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGCCGACGGGATGACCGTTGGCGAACTCTGCGCCGCCGCCATCACCATGAGCGACAACAGCGCCGGCAATCTGCTGTTGAAGAGCGTCGGCGGCCCCGCGGGATTGACTGCCTTTTTGCGCCAGATCGGTGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTCAATGAGGCGCTTCCCGGCGACGTGCGCGACACCACCACCCCGGCCAGCATGGCCACCACCCTGCGCAAGTTGCTAACCACCCCCTCTCTGAGCGCCCGTTCGCAGCAGCAGCTGCTGCAGTGGATGGTGGACGACCAGGTGGCCGGCCCGTTGATCCGCGCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAAACCGGGGCCGGTGAGCGGGGCTCACGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAAGCGGAGCGTATCGTGGTGATCTATCTGCGGGATACCGCGGCGACCATGGCCGAACGTAACGAGCAGATCGCCGGGATAGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4238,Drugs,MEG_4238|Drugs|betalactams|Class_A_betalactamases|OKP,(Bla)OKP-B-14:DQ149136::47-907:861,0
,atgggtgaattctttcctgcacaaatttccgagcagctatcccacgctcgcggggtgatcgagcgccatctggctgcaacgctggacacaatccacctgttcggatctgcgctcgatggagggttgaagccggacagcgacatcgacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcactaatgctcgacctgctaaaagtctcatcaccgccaggcgatggcggaccatggcgaccgctggaggtgactgttgtcgctcgaagcgaagtagtgccctggcgctatccggcgcgacgtgagcttcagttcggtgagtggctccgccacgacatcctctccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgctctgctaggtccatccgcagtcacgttcttcgagccggtgccgaacgagcatttttccaaggcgcttttcgacacgattgcccagtggaattcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagtgcttcaacgggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccatcatttgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggctgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_900,Drugs,MEG_900|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,490490051|WP_004356282.1|NG_052359|1|1|aadA4|aadA4|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA4 NG_052359:81-869,2
,ATGAAATTAATTGCCAGAGGAAGAGAGCTTAATTTATCTTCACCCCAAGTGATGGGCATTTTAAATGTGACGCCAGATTCATTTTCTGATGGCGGAACGCATAACTCTCTTAATGATGCTATTAACCACGCCGCTAAACTTATTGCTGAAGGGGCTTCTATCATCGATATCGGTGGTGAATCAACAAGGCCGGGTGCCAGTGATGTTTCTGTCGATGAAGAATTACATCGTGTTATTCCTGTGGTCGAAGCTATCCAGCAACGTTTTGATGTGTGGATTTCTGTTGATACATCCAAAGCACAAGTGATCACGGAGTCCGCTCAAGCTGGTGCCTCTATTATCAATGATATACGTTCACTTACCGAACCTGGAGCACTGCAGGCGGCTGCAAAAACGGGGTTACCTGTTTGTATTATGCATATGCAAGGTTTACCTAAAACAATGCAACATTCGCCGCAGTATAAGAATGTGATGATAGAAGTTGATGCTTTTCTAGCAGAGAATATTCAACGTTGTATTGATGCTGGCATCGAGAAAAATCAAATTATTCTTGATCCAGGCTTCGGCTTTGGTAAAAATTTAGCGCATAATTATCAATTATTAGCACATCTAAGTGATTTTCATCACTTTGGTTTACCGATACTCGCCGGAATGTCACGTAAATCAATGGTAGGACAGTTACTCAATGTTCCGCCACAAGAGCGTGTTGCTGGTAGTGTTGCTTGCGCAGTTATTGCTGCAATGCAAGGGGCACAAATTATTCGTGTACACGATGTTAAAGAGACTGTAGATGCGATGAAAGTCGTGCAGGCGACTCTTTCTGCAAAGGAAAATAATGAATGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2946,Drugs,MEG_2946|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|529186758|gb|CP004022.1|3736140-3736982,8
,atgttcaaaacgacgctctgcaccttattaattaccgcctcttgctccacatttgccgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtagcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccacaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatctcgcaacctacaccgctggcggcctgccattgcaggtgccggatgaggtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgaaaactcgtgtcttccagccactcaaactcaatcatacgtggattaatgtaccgtccgcagaagaaaagaactacgcctggggatatcgcgaaggtaaggcagtacatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtgcaaagcaatttaaaaccccttgatatcaatgagaaaacacttcaacaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggtctgggctgggaaatgctggactggccggtaaatcctgacatcatcattaacggcagtgacaataaaattgcactggcagcacgccccgtaaaaccgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacgggggcgaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatcgtgatgctggctaacaaaaactaccccaatccagcgagagtcgccgccgcctggcagattctcaacgctctacagtaa,antibiotic molecule,antibiotic inactivation,betalactams,MEG_1275,Drugs,MEG_1275|Drugs|betalactams|Class_C_betalactamases|BLAEC,485828396|WP_001443153.1|NG_049085|1|1|blaEC-5|blaEC|cephalosporin-hydrolyzing_class_C_beta-lactamase_EC-5 NG_049085:101-1234,0
,atgcgttatgttcgcctgtgccttatctccctgattgccgccctgccactggcggtattcgccagccctcagccgcttgagcagattaaaatcagcgaaagtcagctggcgggccgggtgggctatgttgaaatggatctggccagcggccgcacgctggccgcctggcgcgccagtgagcgctttccgctgatgagcacctttaaagtgctgctctgcggcgcggtgctggcccgggtggatgccggcgacgaacagctggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgccgacgggatgaccgttggcgaactctgcgccgccgccatcaccatgagcgacaacaccgccggcaatctgctgttgaagagcgtcggcggccccgcgggattgaccgcttttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggaactcaatgaggcgcttcccggcgacgtgcgcgacaccaccaccccggccagcatggccaccaccctgcgcaagctgctaaccaccccctctctgagcgcccgttcgcagcagcagctgctgcagtggatggttgacgaccgggtggccggcccgttgatccgcgccgtgctgccggcgggctggtttatcgccgataaaaccggggccggtgagcggggctcacgcggcattgtcgccctgctcggcccggacggcaaagcggagcgtatcgtggtgatctatctgcgtgataccccggcgaccatggtcgagcgtaaccagcagatcgccgggataggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4236,Drugs,MEG_4236|Drugs|betalactams|Class_A_betalactamases|OKP,1028083777|WP_063842745.1|NG_047528|1|1|blaOKP-B|blaOKP-B|OKP-B_family_class_A_broad-spectrum_beta-lactamase NG_047528:47-907,0
,GTGCGCAGCTCTGCCATCATTGCCCTGCTGATCGTGGGTCTTGACGCCATGGGTCTCGGCCTCATCATGCCCGTCCTTCCGACGCTTCTGCGTGAGCTTGTGCCAGCAGAGCAGGTCGCTGGACACTATGGTGCCTTGCTGTCGCTCTATGCATTGATGCAGGTCGTCTTCGCGCCCATGCTTGGACAGCTTTCGGATTCTTACGGTCGGCGTCCGGTACTTCTGGCTTCTCTTGCAGGAGCCGCAGTCGATTACACGATTATGGCATCAGCGCCGGTCTTATGGGTGCTCTATATCGGCCGACTCGTGTCCGGCGTCACGGGCGCAACCGGAGCTGTAGCAGCCTCAACCATTGCCGATTCGACGGGGGAAGGTTCTCGCGCACGCTGGTTCGGCTACATGGGGGCCTGTTATGGGGCGGGCATGATTGCCGGGCCAGCACTTGGTGGCATGCTCGGTGGTATCTCTGCTCATGCCCCGTTTATCGCCGCCGCCCTTCTCAACGGGTTCGCGTTCCTGCTTGCCTGCATTTTCCTCAAGGAGACTCATCACAGCCATGGCGGGACCGGAAAGCCGGTTCGCATCAAACCATTCGTTCTGTTACGGCTGGATGATGCATTGCGCGGGCTAGGTGCGCTTTTCGCAGTTTTCTTCATTATTCAACTGATCGGCCAAGTGCCTGCAGCCCTATGGGTCATATATGGCGAGGACCGTTTTCAGTGGAACACCGCGACCGTTGGTTTGTCGCTCGCGGCGTTTGGGGCAACACATGCGATCTTCCAAGCGTTTGTTACCGGCCCGCTTTCAAGCCGGCTTGGAGAGCGGCGCACGCTGCTGTTTGGCATGGCTGCGGATGCGACTGGCTTCGTTCTTCTGGCTTTTGCCACGCAGGGATGGATGGTGTTCCCGATTCTGTTGCTGCTTGCCGCCGGGGGTGTTGGCATGCCGGCCTTGCAGGCAATGCTCTCAAACAATGTCAGCAGTAACAAGCAAGGGGCTTTGCAAGGAACGCTAACGAGCCTCACCAATCTAAGCTCTATCGCAGGACCGCTTGGCTTCACAGCACTCTATTCTGCCACCGCCGGGGCATGGAACGGTTGGGTTTGGATTGTCGGCGCGATCCTCTATTTAATATGTCTGCCAATACTACGCAGACCATTCGCAACTTCATTGTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7077,Drugs,MEG_7077|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETG,(Tet)TetG:AF133140:757-1932:1176,4
,TCTCCCTGTTAGCCACCCTGCCACTGGCGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCGGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACTGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3566,Drugs,MEG_3566|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AY265889|+|0-458|ARO:3002477|LEN-14 [Enterobacter cloacae] ,0
,ATGCTTCAACTGAAAATGATCGAACTCTTCAAGGAAGGTTGTCATGAGGATGCACGAATAATCGCGGCATTGATGTTCGGCTCATTTGCTATCGGAGAGGGTGACGAGTTCTCTGATATCGAATTCGCAGTGTTCATCCAGGATGACCATTTTGAAAATTTCGATCAGCGCTCGTGGCTTAATGCCGTAAGTCCGGTTGCTGCTTACTTTCCGGACGACTTCGGCCACCACACCGCACTTTTTGAAAACGGCATTCGCGGTGAATTCCATTTCATGCGAAAATCGGACATACCGGTCATTTCCACTTGGCAAGGCTATGGGTGGTTTCCCTCGCTTGAGGCGGCTGTTTTGTTGGACCGATCAGGAGAGTTGTCAAGGTACGCAAGCGCTCTCGTGGGCGGTCCCCCGATACGTGAAGGCGCGCCGCTGGTGGAAGGGCTTGTGTTGAACCTCATCAGCCTGATGCTCTTTGGGGCCAATCTTTTAAATCGGGGAGAGTACGCTCGCGCCTGGGCTTTGCTCAGCAAAGCACATGAAAACCTACTCAAGCTGGTTCGACTCCACGAAGGGGCAACAGACCACTGGCCGACACCTTCACGCGCGCTCGAAAAGGATATCTCGGAGGACTCGTATAATCGCTATCTGGCATGCACAAGCAGTGCAGAACCAAGAGCACTATGTGCAGCCTATCATCAAACGTGGACGTGGAGTCTCGAATTGTTCAAGAGCGTGACAGAACCTCTGAATATCGAGCTTCCGAGAACTGTAATTGCGCAGGCAAAAAGGTTGCTCAATGAGTCTGCGACGCCGCACAACAAGTAA,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3619,Drugs,MEG_3619|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUF,lnu(F)_1_EU118119 ,7
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattataatacaagtgggacttttatagtttttgatggaaaaaattatgcaagtaatgattttaaaagagctaaaaaagctttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgttctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaactatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctagataattctttacaaatttctgcaaaaaatcaagctgatttactttttaaactttcgcaaaattctttacctttttctaaaaaaattcaagaagaagttaaagaaattattctttttaaggaaaataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaattttttcaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4578,Drugs,MEG_4578|Drugs|betalactams|Class_D_betalactamases|OXA,1391852929|WP_109545114.1|NG_057550|1|1|blaOXA-617|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-617 NG_057550:1-774,0
,atgaaaaaaatcgccattatttttggaggcaattcaccggaatacaccgtttctttagcttcagcaactagcgcaatcgaagcactccaatcatctccctatgactacgacctctctttgatcgggatcaccccagatgctatggattggtacttgtatacaggagaactggaaaacatccgacaagacacgtggttgttggatacgaaacataaacagaaaatacagccgctattcgaaggaaacggcttttggctaagtgaagagcagcaaacgttggtacctgatgttttatttcccattatgcatggcaaatatggggaagatggcagtatccaaggattgtttgaattgatgaagctgccttatgtaggttgcggggtggcaggttctgccttatgtatgaacaaatggctgctgcatcaagctgcagcagccattggcgtacaaagtgctcctacgattctcttgacaaatcaagccaaccagcaagaacaaatcgaagcttttatccagacccatggctttccagttttctttaagcctaatgaagcgggctcctcaaaagggatcactaaagtcacctgcgttgaagaaatcgcttctgccttaaaagaagcctttacttattgttccgcagtgctcctacaaaaaaatattgccggtgttgagatcggttgcggtattttgggcaacgactctttgactgtcggtgcttgtgacgccatttcattagtagacggctttttcgattttgaagaaaagtaccagctgatcagcgccaaaatcaccgtccctgcgccattgcctgaaacgattgaaaccaaggtcaaagaacaagctcagctgctctatcgtagtcttggtcttaaaggtcttgctcgcatcgacttttttgtcacggatcaaggagaactatacttgaatgaaatcaatactatgccgggctttacgagtcactcccgctatcctgccatgatggcagcggtcggcttatcctatcaagaactactacaaaaactgcttgtcttagcaaaggaggaagtcaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7357,Drugs,MEG_7357|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100543|WP_063856678.1|NG_048352|1|1|vanC2/3|vanC2/3|D-alanine--D-serine_ligase_VanC2/3 NG_048352:29-1081,5
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCTCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1901,Drugs,MEG_1901|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JN714478|+|1034-2180|ARO:3002079|CMY-66 [Citrobacter freundii] ,0
,ATGCGTTTTATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6497,Drugs,MEG_6497|Drugs|betalactams|Class_A_betalactamases|SHV,gi|975895720|gb|CP014004.1|1087615-1088475 gi|960865004|gb|CP012043.1|2753389-2752529 gi|695172424|gb|CP008929.1|4247745-4246885 gi|23194361|gb|AF538324.1|1-861 gi|83272142|gb|DQ298520.1|22-882,0
,gtgagaacacgtttatttcctttattaagtatatctatttcaatttttttaagtgcgtgctcctctccatttatcgaacctaaagacatcctgcctatttctactactgatcaaactcaacaagcgattggctcctattttgatgaagctcagacacagggtgttattgtcattaaggatgggcacaatattgatacttatggtaatgatttaacccgagccaatacattgtatgtacctgcatcaacttttaagatgttaaatgctttaattggtttggaaaacaataaagctacagtcgatgaagtttttaaatgggatgggaaaaagcgttcatattctatatgggaaaaagatatgaatttgggtgaagccatgaagttatcagcggttcctgtatatcaagaactcgcaaaacggataggcgtagatctaatgcaaaaagaagtaaaaagagtcaaatttggtaattcaaatattgggataaaagttgatgacttttggttggtaggcccattaaagattactcctattcaagaagttgagtttgctgacaaacttgcccatcaagagctaccattcaaacagcaagtacaaaaacaagtccaagatatgctgttaataaaggaagtagagggtaacaaaatttatgcaaagagcgggtggggaatgaatgtcacccctcaagtaggctggttaacaggttgggtggaacaacctaacgggaaaaaaatagctttttcattgaacattgagatgaaaccaaacatgcctggttcagtccgtaatgaaatagctcttaaatcattaaaacgcttaggtattatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4742,Drugs,MEG_4742|Drugs|betalactams|Class_D_betalactamases|OXA,1463920494|WP_116786836.1|NG_061623|1|1|blaOXA-730|blaOXA|class_D_beta-lactamase_OXA-730 NG_061623:1-831,0
,TTGTCAAAATAGCGGGAGTCGCAGATAATCCGCTGCGACTTATCACTCTCAAGGAATCAGAAATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGTTCCGCTGCTGCTGGCGAGCGGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTACGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGCGGCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAGATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5318,Drugs,MEG_5318|Drugs|betalactams|Class_A_betalactamases|OXY,gi|32130558|gb|AY077488.2|100-1031,0
,atgactgatccccgcaaaaacggcgatttgcacgaacccgcgacggcacccgcgacgccctggtccaaaagcgagctggtccggcaattgcgcgacctcggcgtgcgctcaggcgatatggtgatgccgcatgtgtcgttgcgcgccgtcgggccgctggcggacggaccgcagacacttgtcgatgcgctgatcgaggccgtcggccccaccgggaatattctcgccttcgtctcgtggcgcgattcgccctatgaacagacgctgggtcatgatgcgccgcccgccgccatcgcccaaagctggcctgcgttcgaccccgaccatgcgcccgcctaccccggctttggcgcgatcaacgaatttatccgaacctatccggggtgtcggcgcagcgcccatcccgacgcatcgatggcggcgatcgggcccgatgcggcgtggctggtggcgccgcacgagatgggcgccgcttatggcccccgctcgccgatcgcgcgttttctcgcccacgcaggaaaaatcctgtcgatcggcgccgggcccgatgcagtcaccgcgctccattatgccgaagcggtggcgcggatcgagggcaagcgccgcgtcacttattcgatgcccttactgcgcgaaggcaagcgcgtctgggtcaccacgtccgactgggattcgaacggcatcctcgacgaatatgccgcgcccgacggccccgacgcggtcgaacggatcgcccgcgactatctcgcccgcaccagggttgcgcaaggcccggtcggcggcgcgcaatcccggctgatcgacgcggccgatatcgtttccttcggcatcgaatggctcgaggcgcgccacgccgcgccagcggcggcagcgctgaagccgaaacaacgccgcgactga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_39,Drugs,MEG_39|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,446054031|WP_000131886.1|NG_052583|1|1|aac(3)-VIa|aac(3)-VIa|aminoglycoside_N-acetyltransferase_AAC(3)-VIa NG_052583:101-1000,2
,atgcgcaataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacctgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5427,Drugs,MEG_5427|Drugs|betalactams|Class_C_betalactamases|PDC,1408841611|WP_111672884.1|NG_060539|1|1|blaPDC-294|blaPDC|class_C_beta-lactamase_PDC-294 NG_060539:1-1194,0
,AGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGCCCTTCGGGGTACTCGAGTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTCTGGGATAAGCCTGGGAAACTGGGTCTAATACCGGATAGGACCACACACTTCATGGTGAGTGGTGCAAAGCTTTTGCGGTGTGGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTAATGGCCCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGTAGGGACGAAGCGAAAGTGACGGTACCTACAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGCAGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAAGTACCCCGCCTGGGGAGTACGGTCGCAAGACTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGCACAGGACGTACCTAGAGATAGGTATTCCCTTGTGGCCTGTGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCTATGTTGCCAGCGGGTAATGCCGGGGACTCGTAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCAGTACAGAGGGCTGCGAAGCCGTAAGGTGGAGCGAATCCCTTAAAGCTGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCAGTGGCCTAACCTTTTGGAGGGAGCTGTCGAAGGTGGGATCGGCGATTGGGACGAAGTCGTAACAAGGTAGCCGTACCGGAAGGTGCGGCTGGATCACCT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_5,Drugs,MEG_5|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|CU458896.1|+|1462398-1463901|ARO:3003240|Mycobacteroides abscessus 16S rRNA mutation conferring resistance to gentamicin [Mycobacteroides abscessus] ,2
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaaagttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatagttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6679,Drugs,MEG_6679|Drugs|betalactams|Class_A_betalactamases|TEM,1391852874|WP_109545059.1|NG_057472|1|1|blaTEM-232|blaTEM|class_A_beta-lactamase_TEM-232 NG_057472:1-861,0
,CACCACGAGAATAACCATATGCAACAACGACGTGCGCTCGCGCTACTGACGCTGGGTAGCCTGCTGCTAGCCCCTTGTACTTATGCCAGCGGGGAGGCTCCGCTGACCGCCGCTGTGGACGGCATTATCCAGCCGATGCTCAAGGAGTATCGGATCCCGGGGATGGCGGTCGCCGTGCTGAAAGATGGCAAGGCCCACTATTTCAACTATGGGGTTGCCAACCGCGAGAGTGGCCAGCGCGTCAGCGAGCAGACGCTGTTCGAGATTGGCTCGGTCAGCAAGACCCTGACCGCGACCCTCGGTGCCTATGCTGCGGTCAAGGGGGGCTTTGAGCTGGATGACAAGGTGAGCCACCACGCCCCTTGGCTCAAAGGTTCCGCTTTCGATGGTGTGACTATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCTGATGAGGTGGATTCGAATGACAAGATGCAAACTTACTATCGGAGCTGGTCACCGGTTTATCCGGCGGGGACCCATCGCCAGTATTCCAACCCCAGCATAGGCCTGTTTGGTCACCTGGCCGCAAATAGTCTGGGCCAGCCATTTGAGAAACTGATGAGCCAGACCCTGCTGCCCAAGCTTGGTTTGCACCACACCTATATCCAGGTGCCGGAGTCGGCCATGGCGAACTATGCCTACGGCTATTCGAAGGAAGATAAGCCCATCCGGGTCACTCCGGGCGTACTGGCGGCCGAGGCTTACGGGATCAAAACCGGCTCGGCGGATCTGCTGAAGTTTGTCGAGGCAAACATGGGGTATCAGGGAGATGCCGCGCTAAAAAGCGCGATCGCGCTGACCCACACCGGTTTCTACTCGGTGGGAGACATGACCCAGGGACTGGGCTGGGAGAGCTACGCCTATCCGGTGACCGAGCAGGCGTTGCTGGCGGGCAACTCCCCGGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGCTTTGCGGTGCCCAAAGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACCGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATCGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGATCGGTCGAGTTCAAGGCGTCCACATT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3047,Drugs,MEG_3047|Drugs|betalactams|Class_C_betalactamases|FOX,gi|695198169|ref|NG_034922.1|1-1193,0
,atgtccttaataaatgtttcaaatctaactttttcatatgaaggaagttatgacaatatttttgaaaatgtaagttttcagatagatacagattggaaactcggttttattggaagaaacggacgcggtaaaactactttcttaaatttactgcttggcaaatatgcgtattccggcaatataagttctacagttaagtttgagtattttccttatgatgtggaagataagagtctatatacaattgaagtaatgaagagtatttgtacggaatgtatggattgggagatttttcgtgaaatatcattgcttgatgttcaagaagatgctttatatcgtccgtttaatacattgtcaaatggtgagcaaacgaaggtccttcttgcagctttattccttacagcgagttgtttcctgcttattgatgaacctacaaaccatcttgacatcgatgcacgtaatgtagtgcaaaactatttgaaacgcaagaaggggtttattttggtatctcatgatagaagcttacttgatcaatgtgttgaccatatactatctatcaataaaacgaatatcgaaatccaaaagggaaattttacttcttggtgggagaacaaaacgttacaagataattttgaactggcagaaaacaagaaactccttaaagaaataggaaggttgtcttatgcagcaaaacgtagttcaaactggtcaaataaagtagaaaaaagtaaatatggaacaacaaattctggttcaaaactggataagggttatgttggacataaggctgcaaaagcgatgaaacgtgccaaaaatattgagtcaagacatcaggaagccgttttacaaaaatcagaactgctccacaacattgaacaatatgatgacttaaaaatttcaccacttgaatttcacaaagagtgcttaatagaagcgaatgatttatcattgtcttatggagataaagaagtatgcagtaatcttaatttcagagtcaatattggtgatagagttgccattatcggaaaaaatgggagtggtaagtctagtatcctaaaattgattaatggagatgatattaaatttaccggaaattttatgctagcaagtggactaaaaatttcttatatttcgcaagatacttcatatttaaaaggtaatctatctgaatttgcctataataataagatcgatgaaactctatttaaaacgattcttcgtaaactggattttaatagagagcagtttgataagaacatggtggattttagtgctggtcagaaaaagaaagtactaattgctaaaagcctttgtgaaagtgcacatttgtatatatgggatgagccattgaactatattgatattttttcacgtatccaaattgaaaaaatgattttggaatattgtcctacactattgtttgtggagcatgatgatgctttttgcaataacatttgtacgaaaaatattaatttaggtttgtag,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3641,Drugs,MEG_3641|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|LSA,488223305|WP_002294513.1|NG_047935|1|1|lsa(E)|lsa(E)|ABC-F_type_ribosomal_protection_protein_Lsa(E) NG_047935:101-1585,7
,ATGAGAAAAAGTATGGGCATTACTGTTTTTGGATGCGAGCAGGATGAGGCAAATGCTTTCCGCACCTTATCACCAGATTTTCATATTATCCCTACGCTGATCAGTGATGCGATATCGGCAGACAACGCAAAATTGGCCGCTGGCAATCAATGCATTAGCGTAGGCCATAAGTCCGAGGTTTCCGAGGCGACAATTCTTGCGCTGAGAAAGGTCGGGGTAAAATACATTTCTACCCGCAGCATCGGCTGCAATCACATTGATACGACTGCCGCCGAGAGAATGGGGATCTCGGTTGGCACAGTTGCGTATTCGCCGGACAGCGTTGCGGATTATGCTTTGATGCTGATGCTGATGGCCATACGGGGTGCAAAGTCCACCATACACGCCGTGGCGCAACAAAATTTCAGACTGGATTGTGTCCGGGGGAAAGAGCTGCGGGATATGACTGTGGGAGTTATTGGAACCGGCCATATAGGGCAAGCGGTCGTCAAAAGGCTGCGGGGATTTGGATGCCGTGTGCTAGCCTATGATAACAGCCGAAAAATTGAGGCAGATTATGTCCAGCTTGATGAGCTTCTAAAAAACAGCGATATTGTTACGCTCCATGTGCCGCTTTGTGCGGATACCCGCCATCTGATCGGCCAGAGCGAAATCGGAGAGATGAAGCAAGGCGCATTTTTAATCAACACTGGGCGCGGGGCGCTTGTCGATACCGGGTCGCTGGTGGAGGCACTGGGAAGCGGAAAGCTGGGCGGTGCGGCACTGGATGTGTTGGAGGGCGAGGATCAGTTTGTTTATACCGACTGCTCGCAGAAAGTGCTTGACCATCCCTTTTTGTCGCAGCTCCTAAGGATGCCAAATGTGATCATCACACCCCATACGGCGTACTACACCGAGCGTGTGCTGCGAGATACCACAGAAAAAACAATCAGGAATTGTCTTAACTTTGAAAGGAGTTTACAGCATGAATAAAATAAAAGTCGCAATTATCTTCGGCGGTTGCTCGGAGGAACATGATGTGTCGGTAAAATCCGCAATAGAAATTGCTGCGAACATTAATACTGAAAAATTCGATCCGCACTACATCGGAATTACAAAAAACGGCGTATGGAAGCTATGCAAGAAGCCATGTACGGAATGGGAAGCCGATAGTCTCCCCGCCATATTCTCCCCGGATAGGAAAACGCATGGTCTGCTTGTCATGAAAGAAAGAGAATACGAAACTCGGCGTATTGACGTGGCTTTCCCGGTTTTGCATGGCAAATGCGGGGAGGATGGTGCGATACAGGGTCTGTTTGAATTGTCTGGTATCCCCTATGTAGGCTGCGATATTCAAAGCTCCGCAGCTTGCATGGACAAATCACTGGCCTACATTCTTACAAAAAATGCGGGCATCGCCGTCCCCGAATTTCAAATGATTGAAAAAGGTGACAAACCGGAGGCGAGGACGCTTACCTACCCTGTCTTTGTGAAGCCGGCACGGTCAGGTTCGTCCTTTGGCGTAACCAAAGTAAACAGTACGGAAGAACTAAACGCTGCGATAGAAGCAGCAGGACAATATGATGGAAAAATCTTAATTGAGCAAGCGATTTCGGGCTGTGAGGTCGGCTGCGCGGTCATGGGAAACGAGGATGATTTGATTGTCGGCGAAGTGGATCAAATCCGGTTGAGCCACGGTATCTTCCGCATCCATCAGGAAAACGAGCCGGAAAAAGGCTCAGAGAATGCGATGATTATCGTTCCAGCAGACATTCCGGTCGAGGAACGAAATCGGGTGCAAGAAACGGCAAAGAAAGTATATCGGGTGCTTGGATGCAGAGGGCTTGCTCGTGTTGATCTTTTTTTGCAGGAGGATGGCGGCATCGTTCTAAACGAGGTCAATACCCTGCCCGGTTTTACATCGTACAGCCGCTATCCACGCATGGCGGCTGCCGCAGGAATCACGCTTCCCGCACTAATTGACAGCCTGATTACATTGGCGATAGAGAGGTGACCCGTATGGAAAATGGTTTTTTGTTTTTAGATGAAATGTTGCATGGTGTTCGTTGGGATGCCAAGTACGCTACATGGGATAACTTCACGGGAAAACCAGTGGATGGGTATGAGGTGAATCGCATCATCGGCACAAAGGCCGTGGCGCTTGCTCTGCGCGAAGCACAAATCCATGCGGCACGCCTTGGCTACGGCTTGCTTTTATGGGATGGATATCGGCCAAAATCTGCGGTGGACTGTTTCCTGCGTTGGGCGGCGCAGCCGGAGGACAACCTCACAAAAGAAAAATATTACCCCAATATTGAGCGAGCCGAGTTGATTACAAAGGGCTATGTGGCCTCACAATCCAGCCATAGCCGTGGAAGCACAATTGATCTTACGCTCTACCACTTGGATACAGGGGAACTTGTTTCAATGGGAAGCAACTTCGATTTTATGGACGAACGGTCGCACCATACAGCAAAAGGGATAGGGAATGCAGAGGCACAAAATCGAAGATGCTTGCGTAAAATCATGGAAAGCAGCGGATTTCAGTCCTATCGCTTTGAATGGTGGCACTATAAGTTGATTGATGAGCCATACCCCGATACCTATTTTAATTTTGCTGTTTCATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7418,Drugs,MEG_7418|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,VanHBX_2_U35369,5
,ATGACTATACCTGACGCAAATGCAATCTATCCTAACTCAGCCATGATAGAGGTTGTCTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTATCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATTTTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGATTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7629,Drugs,MEG_7629|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|15266479|gb|AY043211.1|1-645,7
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6472,Drugs,MEG_6472|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695210230|ref|NG_035916.1|1-861 gi|2113856|emb|X98103.1|74-934,0
,atggtgacaaagagaatgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgaagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgagatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2174,Drugs,MEG_2174|Drugs|betalactams|Class_A_betalactamases|CTX,1372054669|WP_106924209.1|NG_057473|1|1|blaCTX-M-213|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-213 NG_057473:1-876,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctcattctccacgtttgccgccgccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccactcagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctacacggcaggcggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgtttttatcaaaactggcagccgcaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggtatgagctacgaagaggcaatgaccaaacgcgtcctgcagccattaaaactggcgcatacctggattacgattccgcagaacgaacaaaaagattatgcctggggctatcgcgaatggaagcccgtacacgttactcctggacaacttgatgccgaagcctatggcgtgaaatccagcgttaccgatatggcacgctgggttcaggtcaacatggacgccagccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcaatctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaggctgattcgatcatcaacggcagtgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgccccggcagtgaaagcctcatgggtgcataaaacgggatccactggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1810,Drugs,MEG_1810|Drugs|betalactams|Class_C_betalactamases|CMY,1028104367|WP_063859757.1|NG_048793|1|1|blaCMY-122|blaCMY|class_C_beta-lactamase_CMY-122 NG_048793:1-1146,0
,ATGAAAATCACCATTTTAGCTGTAGGGAAACTAAAAGAGAAATATTGGAAGCAAGCCATAGCAGAATATGAAAAACGTTTAGGCCCATACACCAAGATAGACATCATAGAAGTTCCAGACGAAAAAGCACCAGAAAATATGAGTGACAAAGAAATTGAGCAAGTAAAAGAAAAAGAAGGCCAACGAATACTAGCCAAAATCAAACCACAATCCACAGTCATTACATTAGAAATACAAGGAAAGATGCTATCTTCCGAAGGATTGGCCCAAGAATTGAACCAACGCATGACCCAAGGGCAAAGCGACTTTGTTTTCGTCATTGGCGGATCAAACGGCCTGCACAAGGACGTCTTACAACGCAGTAACTACGCACTATCATTCAGCAAAATGACATTCCCACATCAAATGATGCGGGTTGTGTTAATTGAACAAGTGTACAGAGCATTTAAGATTATGCGAGGAGAAGCATATCATAAATGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_6058,Drugs,MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH,gi|941146344|gb|CP007676.1|33712-34191 gi|941142962|gb|CP007672.1|33712-34191 gi|941139768|gb|CP007657.1|33712-34191 gi|899756207|gb|CP012119.1|1891971-1891492 gi|899750970|gb|CP012120.1|915424-914945 gi|828461663|gb|CP007674.1|33712-34191 gi|828444881|gb|CP007670.1|33698-34177 gi|743649775|gb|CP010300.1|33712-34191 gi|743624649|gb|CP010299.1|33712-34191 gi|743618732|gb|CP010298.1|33712-34191,7
,ATGCAAGATCATTTAGTCAATGAAACAAAAAATATTGTAGAAGTGGGGATTGATTCTTCTATTGAAGAGAGCTATTTGGCTTATTCCATGAGCGTGATCATAGGGCGCGCCTTACCGGACGCTAGAGACGGCTTAAAGCCTGTGCATAGGCGTATTTTGTATGCGATGCATGAATTAGGCCTTACTTCCAAAGTCGCTTATAAAAAAAGCGCTAGGATCGTGGGTGATGTGATTGGTAAATACCACCCTCATGGCGATAACGCAGTTTATGATGCGTTGGTGAGAATGGCGCAAGATTTTTCTATGCGCTTGGAATTAGTGGACGGGCAGGGCAACTTTGGCTCTATTGATGGCGATAACGCCGCAGCGATGCGTTACACTGAAGCCAGAATGACCAAGGCGAGTGAAGAAATTTTAAGGGATATTGATAAAGACACCATTGATTTTGTACCTAATTACGATGACACTTTAAAAGAGCCGGATATTCTACCAAGCCGTCTGCCTAACCTTTTAGTCAATGGGGCTAATGGGATCGCCGTAGGGATGGCGACTTCTATCCCCCCCCACAGGATTGATGAAATCATAGACGCTTTAGCGCATGTCTTAGAAAACCCTAACGCTGAATTAGATGAAATCTTAGAATTTGTCAAAGGGCCTGACTTTCCTACTGGTGGGATCATCTATGGCAAGGCGGGTATTGTTGAAGCCTATAAAACGGGGCGAGGGCGCGTGAAAGTGCGGGCCAAAGTGCATGTGGAAAAGACAAAAAATAAAGAAATCATCGTTTTAGATGAAATGCCTTTTCAAACCAATAAAGCCAAATTAGTGGAACAAATCAGCGATTTAGCACGAGAAAAACAAATTGAAGGCATTAGCGAAGTGCGCGATGAGAGCGATAGAGAGGGAATTAGAGTGGTGATTGAATTAAAAAGAGACGCGATGAGTGAAATTGTCTTAAACCACCTTTACAAACTCACCACCATGGAGACCACTTTTAGCATCATTTTACTCGCTATTTACAATAAAGAGCCTAAGATTTTCACGCTTTTAGAGTTGTTGCGCCTTTTCTTAAACCACAGAAAGACCATTATTATAAGACGCACGATTTTTGAATTAGAAAAGGCTAAGGCCAGAGCGCATATTTTAGAGGGCTATCTGATCGCCTTGGACAATATTGATGAAATCGTGCGACTCATTAAAACAAGCCCAAGCCCAGAAGCGGCTAAAAACGCCTTAATGGAGCGTTTTAGTTTGAGCGAGATCCAAAGCAAAGCCATTTTAGAAATGCGTTTGCAACGCTTGACAGGCCTTGAAAGGGATAAGATCAAAGAAGAATACCAAAACTTATTAGAGCTTATTGATGATCTCAATGGGATTTTAAAGAGCGAAGATCGCTTGAATGAAGTCGTCAAAACAGAGCTTTTAGAAGTCAAAGAGCAGTTTTCTTCTCCAAGGCGCACTGAAATTCAAGAATCTTACGAAAGCATTGACACAGAAGATTTGATCGCTAATGAGCCTATGGTAGTGAGCATGAGCTATAAAGGCTATGTGAAAAGAGTGGATTTAAAAGCCTATGAAAGGCAAAATCGTGGCGGTAAAGGCAAGCTTTCAGGCAGCACTTATGAAGACGATTTCATTGAAAACTTTTTTGTGGCTAACACGCATGATATTTTGCTCTTTATCACCAATAAGGGGCAATTGTATCATTTGAAAGTCTATAAAATCCCAGAAGCGAGCCGGATCGCTATGGGTAAAGCTATTGTGAATTTAATCTCACTCGCTCCTAATGAAAAGATCATGGCAACCCTAAGCACTAAAGATTTTAGCGATGAACGCTCTTTAGCTTTCTTCACAAAAAATGGCGTGGTGAAGCGCACCAATTTGAGCGAATTTGGCGGTAATAGGAGTTATAGCGGTATCAGAGCGATTGTTTTAGATGAAGGCGATGAATTAGTGGGCGCAAAAGTTGTGGATAAAAACGCTAAGCATTTGCTCATCGCATCTTATTTGGGCATGTTCATTAAATTCCCTTTAGAAGACGTGCGCGAAATAGGAAGAACTACTCGTGGGGTTATGGGTATTAGACTGAATGAAAATGATTTTGTTGTCGGCGCGGTCGTCATTAGCGATGATAGCAACAAGCTTTTGAGCGTGAGCGAAAACGGGCTTGGCAAGCAAACTTTAGCCGAAGCGTATAGAGAGCAATCTCGTGGAGGTAAGGGGGTCATTGGCATGAAGCTCACTCAAAAGACCGGTAATTTGGTGAGCGTTATCAGCGTGGATGATGAGAACCTGGATTTAATGATCCTTACTGCGAGCGCGAAAATGATCAGAGTTTCCATTAAAGACATTAGAGAAACCGGAAGAAATGCCAGTGGGGTAAAACTCATAAACACCGCTGATAAAGTCGTGTATGTCAATTCTTGCCCTAAAGAAGAAGAGCCAGAAAATTTAGAAACCTCACGTGCGCAAAATTTGTTTGAGTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3204,Drugs,MEG_3204|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|317013424|gb|CP002332.1|736559-739045,3
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGCGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGATGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6412,Drugs,MEG_6412|Drugs|betalactams|Class_A_betalactamases|SHV,gi|125658593|gb|EF373975.1|1-861,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctaagtggtactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcaatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggtgcagatttccgcggcgcaagctttatgaatatgatcactacacgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagtttacgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcggtcattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5912,Drugs,MEG_5912|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111898|WP_063866105.1|NG_050507|1|1|qnrB44|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB44 NG_050507:37-681,3
,atgagcatcactgctaccatcaggattggtcctgatgagattccggccatgcgggctgtgctcgacctgttcggcagagagtttgaggacatgtccgcctactcggatcgccagccgacaaatgattacttggccaagctcttccgcagcgagacgttcatcgcgctagccgcatttgaccaaggaacagcaataggtgggctcgctgcctacgttttgcccaagttcgagcaagcgcgtagtgagatctacatttatgacttagcagtcgcatccagctatcgacggcaaggaatcgcaacttccctgattagccacctgaagcgtgaggcaatcaagattggggcatatgtgatctatgtgcaagcagactacggagacgaccccgcggtggctctctacaccaagcttggtgttcgggaagatgtcatgcactttgacattgatccaggaaccgccacctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_37,Drugs,MEG_37|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1105502209|WP_071846359.1|NG_052479|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_052479:101-565,2
,atgacagcaatgagcgcaaaggctaaaaaaatgacatggagaactaccagaacacttttacagcctcaaaagctggacttcaatgagtttgagattcttactcccctggttgagggcgcccgaattgtcggccttggcgagggcgctcactttgtcgcggagttttcactggctagagctagtcttattcgctatttggtcgagaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggctatctgaatacctcaactcaacagccggtgctcatgaacttgagcgattttcggatccactgaccttttctttgtatggctcagtgctgatttggattaaatcatatctacgcgaatcaggaagaaaactgcagttagtcggaatcgatttacccaacaccttgaatccaagggacgacctggcacaattggccgaaattatcaaggtcatcgatcacctcattaaaccgcatgttgatgagctgactcacttgttggcatccattgatggtcagtcggcggttatttcatcggcaaaatggggggagatggaaacggctcagcaggagaaagctatctcaggggtaaccagattgaagctacgtttggcatctcttgcccctgtcctgaaaaaacatgtcaacagcgatttgttccgaaaagcctctgatcgaatagagtcgatagagtatacgttggaaaccttgcgtataatgagaactttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtagtggatagaatggttcgagcaaatccggatgtgaagataattctgctggcgcacaacaatcatttacaaaaaactccagtctccttttcgggcgagcttacggctgttcccatggggcagcacctcgcagagagggaggaggaggattaccgtgcgattgcattcacccatcttggatccaccgtgccggaaatgcaattcccatcgcccggcagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtatggaacagtatatcatcgatgcctgtggtacggaggattcatgtctgacattgacagatgcccccatgaaagcaaagcgaatgcggtcccaaagcgcctctgtagaaacgaatttgagcgaggcatttgatgccatcgtctgcgtcccaagcgccggcaaggacggcctggttgacctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2740,Drugs,MEG_2740|Drugs|MLS|Macrolide_esterases|EREA,504872883|WP_015059985.1|NG_047770|1|1|ere(A)|ere(A)|EreA_family_erythromycin_esterase NG_047770:101-1357,7
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagatcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatggagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4632,Drugs,MEG_4632|Drugs|betalactams|Class_D_betalactamases|OXA,1391852900|WP_109545085.1|NG_057503|1|1|blaOXA-630|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-630 NG_057503:1-747,0
,TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAAAAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6878,Drugs,MEG_6878|Drugs|betalactams|Class_A_betalactamases|TEM,gi|157676817|emb|AM087454.1|1-1092 gi|961666360|gb|KT185451.1|87734-87690,0
,GTGACCAACAGCACCGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_343,Drugs,MEG_343|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|294959328|gb|GU966683.1|1450-2004 gi|695221081|ref|NG_039605.1|7564-8118 gi|126635811|gb|EF138817.1|6417-6971 gi|156628070|gb|EU090799.1|1473-2027 gi|88911245|gb|DQ393784.1|2485-3039 gi|4210822|emb|AJ223604.1|2371-2925 gi|1435171|emb|X98393.1|2049-2603,2
,TTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6728,Drugs,MEG_6728|Drugs|betalactams|Class_A_betalactamases|TEM,gb|AF527798.1|+|0-785|ARO:3000879|TEM-7 [Escherichia coli] ,0
,atgtttaaaaaacgaggtcgtcagacggtacttattgccgccgtgctcgctttctttactgccagttcaccgcttttggctcgcacgcagggggagcccacacaggtccaacaaaagctggcagcattagaaaaacaatcgggtggccgactgggcgttgcgctgattaataccgccgatcgttcgcaaattctttatcgcggtgatgagcgctttgccatgtgcagtaccagtaagacgatggtcgctgccgcggtattaaaacagagtgaaactcagcacgatattttgcagcagaaaatggttatcaaaaaagccgatctgacgaactggaatccggtgacggaaaaatatgtcgataaagagatgacattagcggagctaagcgctgccacgctgcaatacagcgataatacggcaatgaataaattacttgagcacctgggcggtaccagtaacgtcacggcttttgcccgctcaattggcgacacgacgtttcgtctggaccggaaagaacccgagctgaacaccgccatccctggcgatgagcgcgacacgacctcgccgctggcgatggcgaaaagcctgcacaaactgacgctgggcgatgcgctggctggcgcacagcgtgcacagcttgtcgaatggttgaaaggcaatacgaccggcggtcagagcattcgtgccggactccctgaagggtgggtggttggcgataaaaccggagcaggtgattacggcacaaccaatgatatcgcggtgatctggcccgaagatcgtgcgccgctgatcctcgtcacctactttacacagccacagcaggatgccaaagggcgtaaagatattctggccgccgctgcaaagattgtgacggaagggctttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6177,Drugs,MEG_6177|Drugs|betalactams|Class_A_betalactamases|SED,1028083937|WP_063842905.1|NG_047543|1|1|blaSED|blaSED|SED_family_class_A_beta-lactamase NG_047543:101-985,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTCCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGAGCGAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7364,Drugs,MEG_7364|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,(Gly)VanC2:L29638:33-1085:1053,5
,ATGAGTGACTTAACTCACGATGGTGCAGAGCGCCTCGCGCTGCATGAATTCACGGAAAACGCCTATCTGAACTACTCCATGTACGTCATCATGGATCGCGCGCTGCCGTTTATCGGCGACGGGCTTAAGCCTGTTCAACGCCGCATCGTCTATGCCATGTCGGAACTGGGGTTGAATGCCAGCGCCAAATTCAAAAAATCCGCCCGTACCGTGGGTGACGTGCTGGGTAAATATCACCCGCACGGCGACAGCGCCTGCTATGAAGCGATGGTGCTGATGGCGCAGCCGTTCTCGTACCGTTACCCGCTGGTGGACGGGCAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCCTTCGCGGCGATGCGTTACACCGAATCGCGTCTCTCTAAATATGCCGAAGTGCTGCTGGGCGAGCTGGGCCAGGGCACTGTGGATTATGTCCCGAACTTCGACGGGACGCTGAACGAGCCGAAAATGCTGCCGGCGCGCCTGCCGAACATTCTGCTGAACGGCACCACGGGCATCGCGGTGGGTATGGCGACGGATATTCCGCCGCACAACCTGCGTGAAGTGGCTAAAGCGGCCGTCAGCCTTATCGACAGCCCGAAAACCACGCTTGATGAACTGCTGGATATCGTGCAGGGCCCGGATTACCCGACCGAAGCGGAAATCATTACCTCCCGCGCTGAAATCCGCAAAATCTACCAGAGCGGCCGCGGCTCGGTGCGTATGCGCGCCGTGTGGAAGAAAGAAGACGGCGCGGTGGTTATTTCCGCGCTGCCGCATCAGGTGTCCGGCGCCCGCGTGCTGGAGCAGATTGCAAGCCAGATGCGCGCCAAAAAGCTGCCGATGGTCGATGACCTGCGCGATGAGTCCGATCACGAGAACCCGACGCGTCTGGTTATCGTGCCGCGCTCTAACCGCGTGGATATGGATCAGGTGATGAACCACCTGTTCGCCACCACCGATCTGGAAAAAAGCTACCGCATTAACCTCAACATGATTGGGCTTGATGGCCGCCCGGCGGTGAAAAACCTGCTGGAGATCCTCACCGAATGGCTGGTGTTCCGTCGCGATACGGTGCGCCGCCGTCTGAACTATCGCCTCGATAAAGTCATGCGTCGCCTGCATATCCTGGAAGGTTTGCTGGTCGCGTTCCTCAATATCGACGAAGTGATTGAGATTATCCGCGGCGAAGATGAGCCGAAGCCGGTGCTGATGAGCCGTTTCGGCATCAGCGAAACGCAGGCGGAAGCTATCCTCGAACTTAAACTGCGCCATCTCGCGAAGCTTGAAGAGATGAAGATCCGCGGCGAGCAGAGCGATCTGGAAAAAGAACGCGATCAGCTCCAGGGCATTCTCGCCTCCGAGCGCAAAATGAATACTCTCCTGAAAAAAGAGATCCAGGCGGATGCCGACGCGTACGGCGACGATCGCCGCTCGCCGCTGCATGAGCGTGAAGAAGCGAAAGCGATGAGCGAGCATGACATGTTGCCGTCCGAGCCGGTCACTATCGTACTCTCCCAGATGGGCTGGGTGCGCAGCGCCAAAGGCCACGACATCGACGCCAAAGCGCTGAGTTATAAAGCAGGCGACAACTGGCTCTCGTCAGCGAAAGGCAAAACCAACCAGCCGGTGGTGTTTATCGACTCCACGGGCCGCAGCTACGCGCTGGATCCGGTATCGCTGCCGTCGGCGCGCGGTCAGGGCGAGCCGCTTACCGGCAAACTGACGCTGCCGCCAGGCGCGGTAGTGGAACATATGCTGATGACCGGCGAAGATCAGAAGCTCCTGATGGCCTCTGACGCGGGTTACGGTTTTGTCTGCACCTTCAACGATCTGGTGGCGCGCAACCGCGCCGGTAAAGCGCTGATTACGCTGCCGGAAAACGCGCATGTGCTCAAACCGCTGGAAATTGAACATGACGACGATATGCTGCTCGCCATTACGGCGGCGGGGCGTATGCTGATGTTCCCGGTGGCCGATCTCCCGCAGCTCTCCAAAGGCAAGGGCAACAAAATTATCTCGATTCCTTCCGCCGATGCGGCGAAGGGCGACGATAAGCTTGCCTATCTCACCATCCTGCCGCCGCAGAGCACCGTGACGCTGCATGTCGGCAAGCGCAAGATCAAACTGCGCCCGGAAGAGTTGCAAAAAGTGCATGGCGAACGCGGGCGTCGCGGTACGCTGATGCGCGGCTTACAACGCATCGACAGCGTCGAAGTGGACGCCCCGTCGCGCCCGAAAGCTGACGACGGCGAGGCGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5342,Drugs,MEG_5342|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|323575285|emb|FN543093.2|3646074-3643804,3
,atgcgatttaaaaaaatttcttgcttacttttaccttctctttttattcttaatacctcaatttatgcaggtaacacctctaaagatcaaggaattaaacaactggtagatcaaaactttaaacccttattagaaaaatataatgtgccgggtatggcagttggtgttattcaaaataataaaaagtatgaaatgtattatggcttgcagtccgttcaagataaaaaagccgtaaatagtaatactatttttgagctaggttctgtcagtaaattatttactgcaaccgcaggtgcctatgccaaaaataaaggaaaaatctcttttgaagacacaccaagtaaatactggaaagaactcaaaaatacgccgattgaccaagttaacctacttcaacttgccacctataccagtggtaaccttgcccttcaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagattggaaacctaaaaacccaattggtgaatatagacaatattcaaacccaagtattggcctatttggaaaaattgtaggcctatcgatgaatcagccttttagtcaggttttagaaaagacaatttttccagaccttggtttaaaacatagctatgtcaatgtgcctaaaactcaaatgcaaaactatgcatttggctataaccaagaaaatcagccgattcgcgttaaccccggtccactcgatgctccagcatatggggttaaatcgacgctaccagatatgctaagttttattcatgccaacctgaacccacagaaatatccaactgatattcaaagcgcaattaatgaaactcacaaaggtttctaccaagtaggcacaatgtatcaagcattaggttgggaagagttctcttatccagcatctttacagactttattagacagtaattcagaacaaatcgtgatgaagcctaataaagtgacagctatttcaaatgaaccttcagttaaaatgtttcacaaaactggttcaaccaatggctttggaacatacgtcgtatttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaacgaagaacgcattaaggcggcttatgctgtgctaaatgcgataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_529,Drugs,MEG_529|Drugs|betalactams|Class_C_betalactamases|ADC,1058243594|WP_068981616.1|NG_051448|1|1|blaADC-84|blaADC|class_C_beta-lactamase_ADC-84 NG_051448:1-1152,0
,atgaatattatgccgatatctgaatcacaattatcagattggctagcattaagaagcttgctctggcctgatcatgacgatgcgcatttacaggaaatgcaccagctacttaaacaaaccgatactttacagttattggcgtattcggaaacgcaacatgcgatagcaatgttggaagcttcgattcgatatgaatatgtgaatggtacagagacatcacccgtggcttttcttgaagggatttatgtattacctgaatatcgacgttcaggcatcgcgactcagttggttcagttcgtagaggaatgggcgaaacaatttgcatgtactgagttcgcttcagatgcagcgctggacaatcatattagccatgcaatgcatcgagcactcggttttcatgaaactgaacgtgtggtgtattttaagaaaaatattggctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_80,Drugs,MEG_80|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,490939600|WP_004801433.1|NG_052396|1|1|aacA-ACI6|aacA-ACI6|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052396:101-541,2
,atgatgaaaaaatcgatatgctgcgcactgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcgggctattccgggtatggccgtggcgattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggataaaaccgaattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggtagtaaaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccggggcaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagcctcgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacaggatccacaggcggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtaatgttggcaaacaaaagctaccccaacccggctcgcgtcgaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1802,Drugs,MEG_1802|Drugs|betalactams|Class_C_betalactamases|CMY,1028104385|WP_063859772.1|NG_048797|1|1|blaCMY-128|blaCMY|class_C_beta-lactamase_CMY-128 NG_048797:1-1146,0
,atgttcaaacttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcactcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacgctacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7708,Drugs,MEG_7708|Drugs|betalactams|Class_B_betalactamases|VIM,1440786789|WP_114699277.1|NG_061404|1|1|blaVIM-60|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-60 NG_061404:1-801,0
,ATGCAGGATAAAAATTTAGTGAATGTCAATCTGACAAAGGAGATGAAGGCAAGTTTTATCGACTACGCCATGAGTGTTATCGTAGCGCGAGCTCTTCCTGATGTTCGAGATGGCTTAAAACCTGTTCACCGTCGCATTCTCTACGGAATGAATGAATTGGGTGTGACCCCAGACAAACCCCATAAAAAATCTGCTCGTATTACAGGGGATGTCATGGGTAAATATCACCCACACGGGGATTCCTCTATTTATGAAGCCATGGTCCGTATGGCTCAATGGTGGAGCTACCGTTACATGCTTGTAGATGGTCATGGGAATTTTGGTTCCATGGATGGAGATAGTGCTGCCGCTCAACGTTATACCGAGGCACGTATGAGCAAGATTGCTCTGGAAATGCTTCGTGATATCAACAAAAATACAGTTGATTTCGTTGATAACTATGATGCCAATGAACGGGAACCCTTGGTCTTGCCAGCGCGTTTTCCAAACCTTTTGGTTAATGGAGCAACTGGTATCGCGGTTGGGATGGCAACCAATATTCCACCTCATAATCTGGGTGAAACCATTGATGCAGTGAAGTTGGTCATGGATAATCCTGAAGTGACTACCAAGGACTTGATGGAAGTCTTGCCTGGACCAGATTTTCCAACTGGTGCTCTTGTCATGGGGAAATCAGGTATCCATAAGGCTTATGAAACAGGTAAAGGTTCGATTGTCCTACGTTCTCGTACAGAGATTGAAACGACTAAGACTGGTCGTGAGCGTATCGTTGTAACAGAATTTCCTTACATGGTCAATAAAACCAAGGTGCATGAGCATATTGTTCGCTTGGTTCAGGAAAAACGCATTGAGGGTATCACAGCAGTACGTGATGAGTCAAACCGTGAAGGTGTTCGATTTGTTATTGAAGTCAAGCGCGACGCCTCAGCCAATGTTATTCTCAATAACCTCTTCAAAATGACCCAAATGCAAACCAATTTTGGTTTCAATATGCTCGCTATCCAAAATGGTATACCGAAAATTTTGTCTCTTCGTCAGATTTTGGATGCTTATATCGAGCACCAAAAAGAAGTGGTTGTTCGTCGTACACGTTTTGATAAGGAAAAAGCGGAAGCGCGCGCTCATATCTTAGAAGGTCTCTTGATTGCGCTAGACCATATCGACGAAGTGATTCGTATCATCCGTGCTAGTGAAACGGATGCGGAAGCTCAAGCTGAGTTGATGAGCAAGTTTAAGCTTTCTGAACGTCAAAGTCAAGCTATCCTTGATATGCGTCTTCGTCGTTTGACAGGTTTGGAACGCGATAAGATTCAATCTGAGTATGATGACCTCTTGGCTCTGATTGCGGATTTAGCAGATATTCTTGCTAAGCCTGAACGTGTTTCTCAAATTATCAAAGACGAATTGGATGAAGTTAAACGTAAATTTTCTGATAAGCGCCGTACAGAGTTGATGATTGGACAGGTCTTGAGTCTCGAGGATGAGGACTTGATTGAAGAATCGGATGTCTTGATTACCCTTTCTAACAGAGGCTACATTAAGCGTTTGGATCAGGACGAGTTCACTGCTCAAAAACGTGGGGGTCGTGGTGTCCAAGGAACGGGAGTGAAAGATGATGACTTTGTTCGTGAGTTAGTGTCAACTAGCACCCATGATCATCTGCTCTTCTTCACAAACAAGGGACGTGTCTATCGTCTTAAAGGTTATGAAATTCCTGAGTATGGTCGGACTGCCAAAGGGCTACCAGTAGTCAATCTCTTGAAATTGGATGAAGACGAAAGTATTCAGACGGTTATCAATGTTGAGTCTGATCGCAGTGATGATGCTTATCTCTTCTTTACAACCCGTCACGGTATTGTGAAGAGAACCAGTGTTAAGGAGTTTGCCAATATTCGTCAAAATGGTCTCAAAGCGCTGAATTTAAAGGATGAAGATGAGTTAATCAATGTCTTGTTGGCAGAAGGAGATATGGATATTATCATTGGTACCAAGTTTGGTTATGCAGTTCGCTTTAATCAATCAGCCGTTCGTGGTATGAGTCGTATCGCCACTGGTGTGAAAGGTGTTAACCTTCGTGAAGGAGACACAGTTGTTGGTGCCAGCTTGATTACTGATCAAGATGAGGTTCTTATTATCACAGAAAAAGGATATGGTAAGCGTACAGTCGCTACTGAATACCCAACAAAAGGTCGTGGTGGTAAGGGAATGCAGACAGCTAAAATTACCGAAAAAAATGGCTTGCTGGCCGGTCTTATGACTGTTCAAGGGGATGAGGATTTGATGATTATCACTGATACAGGTGTCATGATTCGAACCAATCTTGCCAATATTTCACAAACAGGACGTGCAACTATGGGAGTTAAAGTAATGCGCCTGGATCAAGATGCTCAGATAGTGACTTTCACAACGGTTGCGGTGGCAGAAAAAGAAGAAGTTGGGACAGAAAACGAAACAGAAGGTGAAGCATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3225,Drugs,MEG_3225|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|909837468|gb|CP003357.2|992417-994885 gi|556027507|gb|CP006844.1|912912-915380 gi|298237097|gb|CP001993.1|1178899-1181367 gi|225726369|gb|CP000921.1|953680-956148 gi|73916173|gb|DQ175154.1|1-2469,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgtgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5498,Drugs,MEG_5498|Drugs|betalactams|Class_C_betalactamases|PDC,730360199|WP_033998327.1|NG_049916|1|1|blaPDC-43|blaPDC|class_C_beta-lactamase_PDC-43 NG_049916:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6467,Drugs,MEG_6467|Drugs|betalactams|Class_A_betalactamases|SHV,gi|54661907|gb|AY787643.1|1-861,0
,ATGAAAGACGATTTCGTCTTCGTAGACGAGGTTGTGCCCGGAATCCGCTGGGATGCCAAATACGCCACCTGGGACAACTTCACCGGCAAACCGGTGGACGGATATCTGGTGAACCGCGTCGTCGGCACGCGGGCTTTCTGCGCGGCGTTGGAAAAGGCGCGGGAGAAAGCCGAGTCTCTCGGCTTCGGCCTGCTCCTTTGGGACGTCTACCGTCCGCAGCGCGCCGTGGACTGCTTCATGCGCTGGGCGGAACAGCCCGAAGACGGCCGCAAGAAGCTCAGGCACTACCCGAACATCGACCGGCCCCAGATGTTCGAAAAGGGCTACGTGGCCACCAAGTCGGGCCACAGCCGGGGCAGCACGGTGGACCTGACGCTGTACCACTTGGACACCGGTGAACTCGCCGACATGGGTGGCGACCACGACGTGATGGACGTCGTTTCACACCACGGCGCGGCGGGAATCACGCCGGAACAGGAGAAGAACCGTGAACACCTCTGCTCCATCATGGTGGACAGCGGGTTCGGCTCCTATGAGTTCGAGTGGTGGCACTACACCCTG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7550,Drugs,MEG_7550|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Ac2:AY618461:1756-2316:561,5
,atgagaactttattgattttatgtttattcggcactttaaataccgcgtttgcggaagaagcccagccagatttaaaaattgaaaaaatagaagaagggatctatcttcatacatcttttcaagagtacaagggattcggcatcgttaaaaaacaaggcttagtagttcttgacaatcacaaggcatatctcatcgacactccagcttccgcaggagatactgaaaagctagtaaactggctcgaaaaaaatgatttcactgtcaatggaagcatttcaacacatttccacgacgacagtactgctgggatagagtggcttaatacaaagtccatccccacatatgcatctaaattgacaaatgaattgctaaataaaaatggcaaaactcaagccaagcactcttttgataaagagagcttttggttggtcaaaaataaaattgaaattttttatccaggcccaggacacactcaagataacgaagttgtctggatacctaataaaaaaatcctattcgggggctgttttataaaaccgaatggccttggcaatctaagtgacgcaaatttggaagcttggccagactccgcaaaaaaaatgatatcaaaatacagtaaggcaaaacttgttatcccaagccacagtgaaatcggagacgcatcactattgaaactcacatgggaacaggccattaaaggtttaaatgaaagcaaatcaaaaccgccgctcattaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6511,Drugs,MEG_6511|Drugs|betalactams|Class_B_betalactamases|SIM,1028110352|WP_063864722.1|NG_050132|1|1|blaSIM-2|blaSIM|subclass_B1_metallo-beta-lactamase_SIM-2 NG_050132:1-741,0
,atgcgcttcatccacgccctgctgctggccggcatcgcccacagcgcctacgccagcgagaagctgaccttcaagaccgacctggagaagctggagcgcgagaaggccgcccagatcggcgtggccatcgtggacccgcagggcgagctggtggccggccaccgcatggcccagcgcttcgccatgtgcagcaccttcaagttcccgctggccgccctggtgttcgagcgcatcgacagcggcaccgagcgcggcgaccgcaagctgagctacggcccggacatgatcgtggagtggagcccggccaccgagcgcttcctggccagcggccacatgaccgtgctggaggccgcccaggccgccgtgcagctgagcgacaacggcgccaccaacctgctgctgcgcgagatcggcggcccggccgccatgacccagtacttccgcaagatcggcgacagcgtgagccgcctggaccgcaaggagccggagatgggcgacaacaccccgggcgacctgcgcgacaccaccaccccgatcgccatggcccgcaccgtggccaaggtgctgtacggcggcgccctgaccagcaccagcacccacaccatcgagcgctggctgatcggcaaccagaccggcgacgccaccctgcgcgccggcttcccgaaggactgggtggtgggcgagaagaccggcacctgcgccaacggcggccgcaacgacatcggcttcttcaaggcccaggagcgcgactacgccgtggccgtgtacaccaccgccccgaagctgagcgccgtggagcgcgacgagctggtggccagcgtgggccaggtgatcacccagctgatcctgagcaccgacaagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3085,Drugs,MEG_3085|Drugs|betalactams|Class_A_betalactamases|GES,1028105360|WP_063860509.1|NG_049126|1|1|blaGES-23|blaGES|class_A_extended-spectrum_beta-lactamase_GES-23 NG_049126:1-864,0
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCTCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGATTACCCCGCTGATGAAAGCCCAGTCGATTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGTAAACCGCACTATTACACGTTTGGCAAAGCCGATATCGCGGCCAGCAAACCCGTTACGCCTCAGACTCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGGGTTTTAGGAGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGGATTCGTATGCTGGATCTCGCAACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAATGCCGCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGTATCGGTCTTTTTGGCGCGCTGACGGTCAAACCTTCCGGCATGGGCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAACGTTGCTGATGCCTCACTTAAGCAGGGCATCTCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCTGTGGAGGCCAACACGGTGATCGAGGGCAGCGACAGTAAGGTGGCGCTGGCACCGCTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGACGCGCTACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_496,Drugs,MEG_496|Drugs|betalactams|Class_C_betalactamases|ACT,gi|752115649|gb|KM926621.1|650-1897,0
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttgatgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccggtcttgctcgtctcgctggccggcgctgctgtcgactacgccatcatggcgacggcgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacgctccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccggccgttacgccgggaggctctcaacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccggccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgctacgggtggcatcggaatgccggcgctgcaagcaatgttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagcggcgcagggcaacgagccgatcgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7015,Drugs,MEG_7015|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,1028099573|WP_063855983.1|NG_048158|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048158:101-1300,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5497,Drugs,MEG_5497|Drugs|betalactams|Class_C_betalactamases|PDC,730504289|WP_034031407.1|NG_049926|1|1|blaPDC-52|blaPDC|class_C_beta-lactamase_PDC-52 NG_049926:1-1194,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgagacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagggagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcatacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_811,Drugs,MEG_811|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502071|WP_071846223.1|NG_052233|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052233:101-892,2
,TTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGCCATATTATGGAGCCTCATGCTTTTATATAAAATGTGTGACAATCAAAATTATGGGGTTACTTACATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGTACTTTGAATAAATTTTTATTTGGTTCCGCGCTATCTGAAATGAACCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTCACTGGTAATTTACTACGTTCAGTATTGCCGGCGGGATGGAACATTGCGGATCGCTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCAGTTGTGTGGAGTGAGCATCAAGCCCCAATTATTGTGAGCATCTATCTAGCTCAAACACAGGCTTCAATGGCAGAGCGAAATGATGCGATTGTTAAAATTGGTCATTCAATTTTTGACGTTTATACATCACAGTCGCGCTGATAAGGCTAACAAGGCCATCAAGTTGACGGCTTTTCCGTCGCTTGTTTTGTGGTTTAACGCTACGCTACCACAAAACAATCAACTCCAAAGCCGCAACTTATGGCG,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1546,Drugs,MEG_1546|Drugs|betalactams|Class_A_betalactamases|CARB,gi|800908878|gb|KP345882.1|99157-98041 gi|800908878|gb|KP345882.1|65883-65805 gi|777182157|emb|LN829403.1|70501-71617 gi|766547679|gb|KP116299.1|40674-41790 gi|766547679|gb|KP116299.1|20712-20795 gi|742994109|gb|CP010391.1|50897-49781 gi|704485843|gb|KJ186153.1|37177-38293 gi|686483924|gb|KM111262.1|22-1138 gi|675294670|dbj|AB985401.1|878-1994 gi|660573358|gb|CP008790.1|138968-140084 gi|660573358|gb|CP008790.1|155445-155524 gi|628945956|gb|KJ488985.1|12-1128 gi|618631222|gb|CP007581.1|4120474-4121590,0
,ATGGAATTGCCCAATATTATTCAACAATTTATCGGAAACAGCGTTTTAGAGCCAAATAAAATTGGTCAGTCGCCATCGGATGTTTATTCTTTTAATCGAAATAATGAAACTTTTTTTCTTAAGCGATCTAGCACTTTATATACAGAGACCACATACAGTGTCTCTCGTGAAGCGAAAATGTTGAGTTGGCTCTCTGAGAAATTAAAGGTGCCTGAACTCATCATGACTTTTCAGGATGAGCAGTTTGAATTCATGATCACTAAAGCGATCAATGCAAAACCAATTTCAGCGCTTTTTTTAACAGACCAAGAATTGCTTGCTATCTATAAGGAGGCACTCAATCTGTTAAATTCAATTGCTATTATTGATTGTCCATTTATTTCAAACATTGATCATCGGTTAAAAGAGTCAAAATTTTTTATTGATAACCAACTCCTTGACGATATAGATCAAGATGATTTGGACACTGAATTATGGGGAGACCATAAAACTTACCTAAGTCTATGGAATGAGTTAACCGAGACTCGTGTTGAAGAAAGATTGGTTTTTTCTCATGGCGATATCACGGATAGTAATATTTTTATAGATAAATTCAATGAAATTTATTTTTTAGATCTTGGTCGTGCTGGGTTAGCAGATGAATTTGTAGATATATCCTTTGTTGAACGTTGCCTAAGAGAGGATGCATCGGAGGAAACTGCGAAAATATTTTTAAAGCATTTAAAAAATGATAGACCTGACAAAAGGAATTATTTTTTAAAACTTGATGAATTGAATTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1065,Drugs,MEG_1065|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,(AGly)AphA6:JF949760:695-1474:771,2
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaattccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcacagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcgaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcggcttggcatcgcggtgattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5915,Drugs,MEG_5915|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1049330918|WP_065825693.1|NG_051321|1|1|qnrB77|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB77 NG_051321:1-645,3
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatygagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagcsggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcsctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_834,Drugs,MEG_834|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153691|WP_070342371.1|NG_051903|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_051903:101-889,2
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgtcgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6209,Drugs,MEG_6209|Drugs|betalactams|Class_A_betalactamases|SHV,1270501798|WP_099156054.1|NG_055668|1|1|blaSHV-203|blaSHV|class_A_beta-lactamase_SHV-203 NG_055668:1-861,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACTGTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCTTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCAGAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCACAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1839,Drugs,MEG_1839|Drugs|betalactams|Class_C_betalactamases|CMY,(Bla)CMY-36:EU331426:2375-3520:1146,0
,atggaaataggatttacttttttagataaaatagtacacggtgttcgttgggacgctaaatatgccacttgggataatttcaccggaaaaccggttgacggttatgaagtaaatcgcattgtagggacatacgagttggccgaagcgcttttgaaggcaaaggaactggctgctacccaaggttacggattgcttctatgggacggttaccgtccgaagcgtgctgtaaattgttttatgaaatgggctgcacagccggaaaataacctgacaaaggaaatttattttcccaatattgaccgaaccgagatgatttcaaaaggatatgtggcttcaaaatcaagccacagccgcggaagtgccattgatcttaccctttatcatctagacacgggtgagcttgtaccaatggggagcggatttgattttatggatgaacgctctcatcatgcggcaaaaggaatttcaggtaatgaagtgcaaaatcgcagacgtttgcgctccatcatggaaaacagtgggtttgaagcatatagcttcgaatggtggcactatgtattaagagacgaaccatacccaaatagctattttgatttccctattaaataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7548,Drugs,MEG_7548|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,1028100632|WP_063856767.1|NG_048475|1|1|vanX-A|vanX-A|D-Ala-D-Ala_dipeptidase_VanX-A NG_048475:20-628,5
,gtgaaacccaacagacccctgatcgtaattctgagcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgcgatctggttcactcgaacgacgtcaccgcccactatggcattctgctggcgctgtatgcgttgatgcaatttgcctgcgcacctgtgctgggcgcgctgtcggatcgtttcgggcggcggccggtcttgctcgtctcgctggccggcgctgctgtcgactacgccatcatggcgacggcgcctttcctttgggttctctatatcgggcggatcgtggccggcatcaccggggcgactggggcggtagccggcgcttatattgccgatatcactgatggcgatgagcgcgcgcggcacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgggcggtttctccccccacgctccgttcttcgccgcggcagccttgaacggcctcaatttcctgacgggctgtttccttttgccggagtcgcacaaaggcgaacgccggccgttacgccgggaggctctcaacccgctcgcttcgttccggtgggcccggggcatgaccgtcgtcgccgccctgatggcggtcttcttcatcatgcaacttgtcggacaggtgccggccgcgctttgggtcattttcggcgaggatcgctttcactgggacgcgaccacgatcggcatttcgcttgccgcatttggcattctgcattcactcgcccaggcaatgatcaccggccctgtagccgcccggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcacaggctacatcctgcttgccttcgcgacacggggatggatggcgttcccgatcatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaagcaatgttgtccaggcaggtggatgaggaacgtcaggggcagctgcaaggctcactggcggcgctcaccagcctgacctcgatcgtcggacccctcctcttcacggcgatctatgcggcttctataacaacgtggaacgggtgggcatggattgcaggcgctgccctctacttgctctgcctgccggcgctgcgtcgcgggctttggagaaattcttcaaattcccgttgcacatag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7016,Drugs,MEG_7016|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,446726750|WP_000804063.1|NG_048153|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048153:101-1300,4
,ATGAGGACACTTAATAAAGATGAACATAATTATATCAAGCAAATAGCTAATATACATGAGACATTATTGTCGCAAGCAGAATCCAACTATAAATGTACTAAACTGAGTATTGCTCTTAGGTACGAGATGATATGTTCAAGATTAGAACATACAAATGATAAAATTTATATATATGAAAATGAAGGTCAATTAATAGCGTTTATTTGGGGACATTTTAGTAATGAAAAAAGTATGGTTAACATTGAACTGCTATATGTTGAACCACAATTTCGCAAACTGGGAATAGCTACGCAACTGAAGATTGCGCTTGAAAAATGGGCAAAAACTATGAATGCAAAGCGAATAAGCAGTACAATTCATAAAAGTAATTTACCAATGATATCTTTGAATAAAGATTTAGGTTATCAAGTGAGTCATGTAAAAATGTATAAAGATATTGATTAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_47,Drugs,MEG_47|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,(AGly)Aac3-Ik:BX571856:765853-766296:444,2
,gtgaccggcagcgcggccacgatccgcccggccaaggcggccgatgcggtcgcgtgggcgcagctgcgtctgggcctgtggcccgatgccgatgatccgctggagacgctggtggcggcgctggccgaggacgcaggtgcggttttcctggcgtgtgcagcgggtggccaggcgatcggcttcgccgaagtgcgcctgcgccatgactacgtgaacggcaccgattcctcgccggtgggcttcctggagggctggtacgtgcagccgcagtggcaaggctgcggcgtgggccgcgccctgctggcggcggtgcgggcatggacgcgcgacgcgggctgccgcgaactggcttcggacagtcgcgtggaggacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtggtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_246,Drugs,MEG_246|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1032611793|WP_064239013.1|NG_052202|1|1|aac(6')-Iak|aac(6')-Iak|aminoglycoside_N-acetyltransferase_AAC(6')-Iak NG_052202:101-562,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTTAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1401,Drugs,MEG_1401|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_68_NZ_CUHK01000055,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGAAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACTCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGTTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1880,Drugs,MEG_1880|Drugs|betalactams|Class_C_betalactamases|CMY,gb|FN546177|+|0-1146|ARO:3002056|CMY-45 [Proteus mirabilis] ,0
,atggaagcacccaatcccttcactgatggcatgccgctaccgtgggcatggcaggaagcgttggccgatgcgcgcgtcgagcggcagtcgatcggcgtgtcgcgcgcggatgtagcccgtgtgcaacggccggggcaggccgatgccttcgtgaagtcggaagtgatcgacgccttcagtgagctcggtgatgagatcgcgcgcctgcgctggctgcaggaacagggacaaccggcaccaacggtaattgccaccgccgaagaagcgggccggcgctggttgctgatgagcgcgctgcccggccgcgacctggcttcgtcgccggaactcgcgccgcagcagttggtggaactgctggccgacgcgctgcgcgggctgcatgcgttgccgctggcagcctgtccgtttgaccagcgactgcacttgcgactgcaagccgcgcaggcacgggtcgaggcggggttggtggatgccgatgacttcgatgacgaacgcctgggccagagtccgcagcaggtcttcgccgaactgtgcagtacccggcccgatcatgaagacctggtggtcagccatggcgatgcctgcttgccgaacctgatggtggtcgaggggcgtttcagcggtttcatcgactgtgggcgactgggtgttgccgaccgctaccaggacctggcgctggccgcgcgcagcctggtccacaacttcggcgacacgcgttgggtggcgccgttgttccagcgctacggcgcggtggccgacgagcgccggctcgcgttctaccggctgctcgacgagttcttctga,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1036,Drugs,MEG_1036|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,501456554|WP_012479999.1|NG_051214|1|1|aph(3')-IIc|aph(3')-IIc|aminoglycoside_O-phosphotransferase_APH(3')-IIc NG_051214:101-904,2
,atgaacatcaacgatgccctcacctccatcctggcctcaaaaaaataccgcgccctttgcccggataccgttcggcgcatcctgaccgaggaatgggggcggcataaatcccccaaacaggccgtagaggctgcacgcacccggctgcatggaatttgcggggcatatgtcaccccggaatcgctcaaggccgctgccgccgcgctttctgcgggcgatgtaaaaaaggcattgtcgctgcatgcctccaccaaggaaagactggccgagctggataccctgtacgattttatcttttcagccgaaactccccgccgcgtgctggatatcgcctgcggtcttaaccccttggcgctatacgagcgcggggttgcatccgtgtggggctgtgatgtccaccaggggttgggggatgtaatcaccccctttgctagggaaaaagattgggattttacctttgccctgcaggatgtgctgtgtgcgccgcccgccgaaaccggggatctggcgctgatattcaagttactgcccctattggagcgggagcaggccggttctgccatggcacttttacaatccatcaataccccgcgcatggctgtcagttttcccacacgtagtttaggcgggcgtggaaaaggcatggaggcgaactacgccgcatggttcgagggcggcttgcccaccgagtttgagattgaggataaaaagaccatcggaacagaacttatatatttgataaaaaagaatggataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6062,Drugs,MEG_6062|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|RMTB,1028098310|WP_063854854.1|NG_048059|1|1|rmtB2|rmtB|16S_rRNA_(guanine(1405)-N(7))-methyltransferase_RmtB2 NG_048059:1-756,2
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaaccttttgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaggaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_545,Drugs,MEG_545|Drugs|betalactams|Class_C_betalactamases|ADC,488086330|WP_002157727.1|NG_064676|1|1|blaADC-117|blaADC|class_C_beta-lactamase_ADC-117 NG_064676:101-1252,0
,atgaaacaaccaacaactctctcgctgctgacactgggttccctgctgatctcttcattcgcttctgctgcacaggatgctcctctcaccgccatcgtggacggcgccattcaacccgtgctcaaggagtaccggatcccgggaatggcggttgccgtactgaaagatggcaaggcccactacttcaactatggcgttgccaaccgggagagcggtcagcgcgtcagcgagcagaccctgttcgagattggttcggtcagcaagacctatacctccaccctcggcgcctacgccgtggtcaaggggggcttcaagctcgatgacaaggtgagccggcacgcgccctggctcaagggctccgcctttgatggcatcaccatggccgagctcgccacctacagcgcaggcggcttgcccctgcagttccccgatgaggtggaatcggtcgagcagatgcaggcttactatcgccagtggacgccggcctatcagccgggcagccatcgccagtactccaaccccagcatcggtctgttcggctatctggcggcgagctctctgggccaacccttcgagcaactgatgagccagactctgttgccggggctcgcgcttttgcccacacctacctcaaggtgcctgcgcggcatgggtgattacgcctacggctgtgccaaagaggagaaaccgatccgggtcaatccgggagtgctggcggacgaggcctacggcatcaagaccagctcggcggatctgctcgccttcgtgaaggccaatatcagcggtgttgatgacaaggcgttgcagcaggccatctccctgacccaccaagggcgctactcggtaggcgagatgacccagggactgggctgggagagttacgcctatcccgtcagcgagcagacgctgctggcgggcaactcctcggcggtgatttacaatgccaacccggtcaaacctgttgccgcgtcccaagagacggggggggcgcgactctacaacaagaccggctcgaccaacggctttggtgcctatgttgcctttgtcccggccaaggggattggcatcgtcatgctggccaaccgcaactatcccaatgatgcccgggtcaaggcggcttacgccattttgagcaagctggccgactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1799,Drugs,MEG_1799|Drugs|betalactams|Class_C_betalactamases|CMY,1028081080|WP_063840463.1|NG_047381|1|1|blaCMY-FOX|blaCMY-FOX|FOX/MOX_family_class_C_beta-lactamase NG_047381:101-1249,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgcgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccactgagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtatcgttaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaacgggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4609,Drugs,MEG_4609|Drugs|betalactams|Class_D_betalactamases|OXA,739570896|WP_037428895.1|NG_050608|1|1|blaOXA-252|blaOXA-48_like|OXA-48_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-252 NG_050608:101-898,0
,atggacacaacgcaggtcacattgatacaccaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_746,Drugs,MEG_746|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,446303948|WP_000381803.1|NG_052432|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052432:101-634,2
,ATGAAAAACGTAAATACCGGGATCAATCAATTTCGATTGATCGCTGCTTTCATGGTCGTTGCGATTCACTGTTTTCCTTTTCAGTCGTTTAGTAAAACTCTTGATATATTGATTACTTTGACACTCTTTCGAACTGCCGTACCTTTTTTCTTAATGGTCACAGGTTTTTATTTAATTGGACCGATTGCCACTAAGAGAGGCTATCCAGCCTATTTAAAGATAAAAAAATTTTTAAAAAAGCAAGTGAAGCTATATGTGCTTGCTACGCTCATTTATCTTCCACTAGCTTTTTATAGTGGTGTGATCACTTTCAAGACGAGTGTCATTCAATTTTTTCAACTCATCTTTTTCGAAGGAGTTCTTTACCACTTGTGGTATTTTCCAGCATTGATTTTAGGTGTTCTCATCGTTTACTGCTTATTACAGCGGTTCACGCTTCGACAAGTTTTATTAGTGACTTTTCTATTCTATTTACTATGTTTGGGCGGCGATAGCTGGTGGGGGTTAGCTAGACAAATTCCTGTGTTAGAAAAAAGTTATCAAGGGATATTTACGCTCATGATCCATACTCGAAATGGACTATTTTTTGCCCCTTTCTTTTTAACACTCGGTGCTTCGTTCCATCAATCAGAGTGGAACATGCGTACATCTAAAGCCAAGTATTTTTTGTTGATTGCTAGTTTAGGCATGCTAGTGGAAAGCTATTTGCTACACTCCTTTAGTTCACCAAAACATGATAGTGCATACCTATTCTTGCCTGTGGTGATGTTTTTTCTTTTTCCACTTATTTTGAACTGGCAGCCTACACGTGTCATTGCCGACGCTTCGACAATCAGTTTAGGTATTTATGTCCTTCATCCTTATGTCATTGCTGTTGTCCATACTTTAGCCAAAAAAATAACGATACTAAACAATAGTTTAATTTATTATCTCTGCGTTTCCCTTTTAACTAGTTTGATTATTCTTTATGTACACTCTAAGAAAAAGAAAACGACAAAAAATCAGGCTACGTTTGTCCCTAGAACAAAAAAAGTACTCTCTAAGCAAGCAGTTATCCATAATTTGGCACAAATCAATCAAGTGATTCCGAAAACAACGAAAATAATGGCTGTCATAAAAGCCAACGCTTATGGAACTGATGATACAGAATTTGCTCGAATCTTAGAACAACAAGGAGTTGATTTTTTTGCTGTCGCTACCATTGATGAAGGCATTCGTTTGCGAGAAAATGGAATTAAAAGCAAAATCTTAATTCTAGGCTATACACCATCGATACGAATAAAAGAATTAGCTCACTACACATTAATACAAACAATCGTTAGCAAAGAACATGCTTATTCATTAAATCAACAAAAGATACCTATTTCGTGCCATCTAAAAATTGATACTGGCATGCATCGTTTAGGTGTTGAGCCTGTGGTTCAGGAGGTTTCATCCTTATATCGATTACCCTACTTAAATATTCAAGGTATTTATTCTCATCTCGGTTCAGCTGATGATCGAAGTGACAAAGGAATGAAACGCACGAGAAAACAAATTTCGATTTTTGATTATTTATTACATGAACTAGAACTTCAAAAAATCGATGTCGGTGTTACGCATCTGCAAAGTAGCTATGGTATTTTGAATTATCCTGAACTGGTCTATGATTATGTTCGTCCTGGTATTCTTTTATACGGTTATTTAAGTGAACATAATGGAGATTCAAAAATCAACTTAAATTTGCAACCAATTTTAGATGTCCAAGCACTGCTCGTATCAAAAAAATGGGTTGCTGCTGGTGAATATCTTGGCTATAGCCTTGATACTAAACTAGTTTCTCCAAAGCTGATTGGTATCGTCAGCATCGGCTATGCAGACGGTGTTCCTAGAGAGTTATCTCACAATGAGTTTTTATCTTGCTTATCAGGGACAAAATCTACCACAAATCGGACGAATTTGTATGGATATGCTATTAGTGGATTTGACTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7535,Drugs,MEG_7535|Drugs|Glycopeptides|VanN-type_resistance_protein|VANTN,VanT-N_1_JF802084,5
,atgatggaatatcaaaacaataatggaaactatgacaaaaggaatcgtagaaaagccaaaaaaagaaaattgcttttttacagggctgcatgtgtcacactttgtttgctcattgtttctgtaatctttggagttgtgcattttttaggggagagtaaagatcccggccttttatccaaagaaaacacaaaaacagacaagaactattcgtggcttaccgacgatcagaatgaggcagtaccctcagttccagagccagccatatccgaccaggctaacaaaatttcggtaaatatcacagcggcaaacgccattgtaatgaataaagacacaaatgaggtattgtaccagaaaaaaagcacagccaaaattgcgccggccagcactgctaagatgattatggctttgacagcacttgactattgttccccggaggatgaaatgaaagtaggtgcggagattggaatgattcaaagcgattcgtcaaccgcatggcttatgaagggtgatacactgactgtcagacagctcctgattgcccttatgcttccgtccggcaatgatgcagcctatacccttgcagtcaataccggaaaggctattgcaggtgataacagcctgaccagtcagcaagcgattgaagtattcatggataaggtaaatgaaaaagccgtggcccttggcgccacaaactcgaaatttgtagctccggatggatatgatgccgaagggcagtatactacagcttatgaccttgctatcattgcaaaagcatgtttggacaatcctatcatttcggagattgtagcgagttattcatcctatgaaaaatggtcaaacggaagagaggtcacttacaacaattccaatgagcttctcgatccgaacagtccctattaccgtccggaggttatcggtttgaaaacaggaaccagcagtcttggcggcgcatgtattgtttctgcagcggtgatggacggagaaacctatatctgtgtagttatgggttctacaaaggaaagcaggtttcaggacagcgttgatattttagataaaatcaaagcccagtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7599,Drugs,MEG_7599|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,1028100719|WP_063856854.1|NG_048520|1|1|vanY-D|vanY-D|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D NG_048520:101-1171,5
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgctgggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_795,Drugs,MEG_795|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,690411156|WP_031942898.1|NG_052145|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052145:101-892,2
,atgaaattatggttcagtactttaaaactgaaaaaagttgcagctgtgttgcttttctcttgcgtcgcacttgcaggatgcggcagcaatcactcgaatgcctcacattctgccgagaaagatgaaaagacggagatgaaagatgattttgcaaaactcgaggagcaatttgatgcaaaactcgggatctttgcattagatactggtacaaaccgaacggtaacgtatcggccggatgagcgcttcgcttttgcatcgacgattaaggctttaaccgtaggcgtgcttttacaacagaaatcaatagaagatctgaaccagagaataacatatacacgtgatgatcttgtaaactacaacccgattacggaaaagcatgttgatacgggaatgacgcttaaagagcttgcggatgcttcgcttcgatatagtgacaatacggcacagaacctcattcttaaacaaattggcggacctgaaagtttgaaaaaggaactgaggaagattggtgatgaggttacaaatcctgaacgattcgaaccggagttaaatgaagtgaatccgggagaaactcaggataccagtacagcaagagcacttgcgacaagccttcaagcttttgctcttgaagataaacttccaagtgaaaaacgcgagcttttaatcgattggatgaaacgaaataccaccggggacgccttaatccgcgccggtgtgccggaaggctgggaagtggctgataaaactggagcgggatcatatggaacccggaacgacattgccatcatttggccgccaaaaggagatcctgtagttctcgcagtattatccagccgggataaaaaggatgccaagtatgatgataagcttattgcagaggcaacaaaagtggtagtgaaagccttaaacatggaaagcaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1293,Drugs,MEG_1293|Drugs|betalactams|Class_A_betalactamases|BLAP,489270854|WP_003178584.1|NG_051162|1|1|blaP|blaP|class_A_beta-lactamase_BlaP NG_051162:101-1024,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcaacctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5648,Drugs,MEG_5648|Drugs|betalactams|Class_C_betalactamases|PDC,1393270455|WP_109791200.1|NG_057598|1|1|blaPDC-266|blaPDC|class_C_beta-lactamase_PDC-266 NG_057598:1-1194,0
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatgtatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatactggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtataggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2913,Drugs,MEG_2913|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,499772320|WP_011453054.1|NG_047871|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047871:101-1315,6
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttgctacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_839,Drugs,MEG_839|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502126|WP_071846278.1|NG_052325|1|1|aadA3|aadA3|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA3 NG_052325:101-892,2
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgtgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcagttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccacggagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagccagcgtattgtcaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaactggatacgatactaagattggtaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4612,Drugs,MEG_4612|Drugs|betalactams|Class_D_betalactamases|OXA,1270501761|WP_099156052.1|NG_055666|1|1|blaOXA-567|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-567 NG_055666:1-795,0
,ATGTCGAAAATTGAACTAAAACAACTATCTTTTGCCTATGATAATCAAGAAGCGTTGCTTTTTGATCAGGCAAATATCACGATGGATACCAATTGGAAATTAGGATTGATTGGCCGCAATGGCCGTGGGAAAACAACCTTATTAAGATTGTTACAAAAGCAGTTGGATTACCAAGGAGAGATTCTTCATCAAGTCGATTTCGTCTATTTTCCACAAACAGTTGCAGAAGAACAACAGCTCACTTATTATGTCTTACAAGAGGTGACTTCTTTTGAACAGTGGGAATTAGAACGAGAATTAACGCTTTTAAACGTTGATCCTGAAGTTTTATGGCGGCCCTTTTCTTCTTTATCAGGCGGCGAAAAGACGAAAGTTTTATTAGGTCTTCTTTTTATTGAAGAAAAGGCCTTTCCTTTAATTGACGAGCCAACAAATCATTTAGATCTAGCTGGCAGACAACAAGTGGCTGAATATTTGAAGAAAAAGAAACACGGGTTTATTTTAGTCAGCCACGATCGGGCATTTGTTGATGAAGTGGTTGATCATATTTTGGCGATTGAAAAAAGTCAATTGACGCTGTATCAAGGGAATTTTTCTATTTATGAAGAGCAAAAAAAATTAAGAGATGCTTTTGAACTAGCAGAAAATGAAAAAATCAAAAAAGAAGTCAATCGCTTGAAAGAAACCGCTCGTAAAAAAGCGGAATGGTCGATGAACCGTGAAGGTGATAAGTACGGCAATGCTAAAGAAAAAGGAAGCGGGGCGATTTTTGATACAGGAGCCATTGGTGCCCGGGCAACGCGCGTAATGAAGCGCTCGAAACACATTCAACAACGTGCCGAAACACAATTAGCAGAAAAAGAAAAACTATTAAAAGATCTTGAGTATATTGATCCTTTGTCAATGGATTATCAGCCAACGCATCACAAAACATTATTGACGGTGGAAGAGCTTCGTCTAGGCTACGAGAAAAATTGGCTGTTTGCGCCAATTTCTTTTTCAATAAACGCGGGAGAAATTGTTGGAATAACAGGAAAAAATGGCTCAGGAAAATCGAGCTTGATTCAGTATTTGTTGGGGGATTTTTCTGGAGATTCAGAAGGCGAAGCCACTTTGGCTCACCAATTAACCATTTCTTATGTGCGCCAAGATTATGAAGACAATCAAGGAACTTTATCCGAATTTGCAGAGAAAAATCAGTTAGATTACACCCAATTTTTAAATAACTTACGAAAACTTGGGATGGAGCGCGCCGTTTTCACTAATCGAATTGAACAAATGAGTATGGGGCAACGGAAAAAAGTCGAAGTAGCCAAATCATTGTCTCAATCAGCTGAACTTTATATTTGGGATGAACCCCTTAATTACTTGGATGTGTTTAATCATCAACAATTAGAAGCGCTAATCTTATCTGTGAAGCCTGCAATGCTAGTGATTGAGCATGATGCACATTTCATGAAGAAAATAACAGATAAAAAAATTGTCTTGAAATCATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3645,Drugs,MEG_3645|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|LSA,gi|56792345|gb|AY737526.1|312-1808,7
,atgcaacaacgacgtgcgttcgcgctactgacgctgggtagcctgctgctagccccttgtacttatgcccgcggggaggctccgctgaccgccgctgtggacggcattatccagccgatgctcaaggagtatcggatcccggggatggcggtcgccgtgctgaaagatggcaaggcccactatttcaactatggggttgccaaccgcgagagtggtcagcgcgtcagcgagcagaccctgttcgagattggctcggtcagcaagaccctgaccgcgaccctcggtgcctatgctgcggtcaaggggggctttgagctggatgacaaggtgagccagcacgccccctggctcaaaggttccgcctttgatggtgtgaccatggccgagcttgccacctacagtgcgggtggtttgccgctgcagttccccgatgaggtggattcgaatgacaagatgcgcacttactatcggcactggtcaccggtttatccggcggggacccatcgccagtattccaaccccagcataggcctgtttggtcacctggccgcaaatagtctgggccagccatttgagcaactgatgagccagaccctgctgcccaagctgggtttgcaccacacctatattcaggtgccggagtcggccatagcgaactatgcctacggctattcgaaggaagataagcccgtccgggtcactccgggcgtgctggcggccgaggcttacgggatcaagaccggctcggcggatctgctgaagtttaccgaggccaacatggggtatcagggagatgccgcgctaaaaagcgcgatcgcgctgacccataccggtttctactcggtgggagacatgactcaggggctgggttgggagagctacgcctatccgttgaccgagcaggcgctgctggcgggcaactcgagcttccaggccaatccggttacgcgctttgcggtgcccaaagcgatgggcgagcagcggctctataacaagacgggctcgactggcggctttggcgcctatgtggcgttcgtgcccgccagagggatcgccatcgtcatgctggccaatcgcaactatcccatcgaggccagggtgaaggcggctcacgccatcctgagtcagttggccgagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3030,Drugs,MEG_3030|Drugs|betalactams|Class_C_betalactamases|FOX,1028105346|WP_063860495.1|NG_049100|1|1|blaFOX-12|blaFOX|cephalosporin-hydrolyzing_class_C_beta-lactamase_FOX-12 NG_049100:1-1140,0
,AATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGATACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTAAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6939,Drugs,MEG_6939|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695208184|ref|NG_035490.1|1-1105,0
,atggagctgcgcggggatgacgtcgtactgcggccggtgggagacggcgagggtgaggttctcgacaggatcgtgagagagccggaagtcgcggcgtggtggtctcccccggaagactacgagggcatgctcgccattgtcttcgagggcgaggtcatcggcgcggtgcagttcgaggaagagaccgatcccgagttccgccgtgccggcatcgacatcttcctgaccgcacgacatcacgggaaggggctgggtgccgacgcggtgcgcacactggccaggtggctggtgcgggagtgcggccatcaccggctgaccatcgatcctgctgcggccaacaccgcggcgatccgcagttacggcaaggtcgggttcaggccggtggggatcatgcgcgcgtacgggcgcgaccaccagacgggactctggcaggacgcactgttgatggacctgcttgccgaggagttgacctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_198,Drugs,MEG_198|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,746613581|WP_039639671.1|NG_052428|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_052428:101-574,2
,GGCGAGGCCCCGGCGGATCGCCTGAAGGCACTGGTCGACGCCGCCGTACAACCGGTGATGAAGGCCAATGACATTCCGGGCCTGGCCGTAGCCATCAGCCTGAAAGGAGAACCGCATTACTTCAGCTATGGGCTGGCCTCGAAAGAGGACGGCCGCCGGGTGACGCCGGAGACCCTGTTCGAGATCGGCTCGGTGAGCAAGACCTTCACCGCCACCCTCGCCGGCTATGCCCTGACCCAGGACAAGATGCGCCTCGACGACCGCGCCAGCCAGCACTGGCCGGCACTGCAGGGCAGCCGCTTCGACGGCATCAGCCTGCTCGACCTCGCGACCTATACCGCCGGCGGCTTGCCGCTGCAGTTCCCCGACTCGGTGCAGAAGGACCAGGCACAGATCCGCGACTACTACCGCCAGTGGCAGCCGACCTACGCGCCGGGCAGCCAGCGCCTCTATTCCAACCCGAGCATCGGCCTGTTCGGCTATCTCGCCGCGCGCAGCCTGGGCCAGCCGTTCGAACGGCTCATGGAGCAGCAAGTGTTCCCGGCACTGGGCCTCGAACAGACCCACCTCGACGTGCCCGAGGCGGCGCTGGCGCAGTACGCCCAGGGCTACGGCAAGGACGACCGCCCGCTACGGGTCGGTCCCGGCCCGCTGGATGCCGGAGGCTACGGGGTGAAGACCAGCGCGGCCGACCTGCTGCGCTTCGTCGATGCCAACCTGCATCCGGAGCGCCTGGACAGGCCCTGGGCGCAGGCGCTCGATGCCACCCATCGCGGTTACTACAAGGTCGGCGACATGACCCAGGGCCTGGGCTGGGAAGCCTACGACTGGCCGATCTCCCTGAAGCGCCTGCAGGCCGGCAACTCGACGCCGATGGCACTGCAACCGCACAGGATCGCCAGGCTGCCCGCGCCACAGGCGCTGGAGGGCCAGCGCCTGCTGAACAAGACCGGTTCCACCAACGGCTTCGGCGCCTACGTGGCGTTCGTCCCGGGCCGCGACCTGGGACTGGTGATCCTGGCCAACCGCAACTATCCCAATGCCGAGCGGGTGAAGATCGCCTACGCCATCCTCAGCGGCCTGGAGCAGCAGGGCAAGGTGCCGCTGAAGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5731,Drugs,MEG_5731|Drugs|betalactams|Class_C_betalactamases|PDC,gb|KR057749.1|+|0-1116|ARO:3004343|PDC-80 [Pseudomonas aeruginosa] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGTTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACTTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1950,Drugs,MEG_1950|Drugs|betalactams|Class_C_betalactamases|CMY,gb|Y17716.1|+|2373-3519|ARO:3002016|CMY-5 [Klebsiella oxytoca] ,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACACGCGACCGGCGGATTCCACGCGCGCTGCGGCGACCATGCCGCACTGCAACAAAGTCCGGTGA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6613,Drugs,MEG_6613|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|937559777|gb|KT454971.1|367058-366177 gi|937559777|gb|KT454971.1|358200-357382 gi|164521141|gb|DQ914960.2|5778-6659 gi|164521141|gb|DQ914960.2|14636-15454 gi|984881271|gb|CP014215.1|2292203-2291385 gi|984881271|gb|CP014215.1|2304967-2304149 gi|970698242|gb|KT988020.1|22635-23453 gi|970698221|gb|KT988019.1|7447-8265 gi|970698093|gb|KT988018.1|115121-115939 gi|982189197|gb|CP013993.1|5424788-5425606 gi|982189197|gb|CP013993.1|5430539-5431065 gi|974752094|gb|KT164809.1|5954-5136 gi|974751547|gb|KU130294.1|238652-237834 gi|974751547|gb|KU130294.1|233473-234001 gi|974751143|gb|KU238092.1|13028-12210,8
,ATGACTATACCTGACGCAAATGCAATCTATCCTAACCTAGCCATCAAAGAGGTTGTCTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTATCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATTTTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGATTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7627,Drugs,MEG_7627|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|15266470|gb|AY043209.1|1-645,7
,ATGAGCAAAAAATTCATTATCACTTGGGACGCCATGCAAAATTACTGTCGTCAGCTTGCTGAAAAACAGATGCCAGCTGAACAGTGGAAAGGTATTTGGGCGGTGAGCCGTGGCGGTCTAGTACCGGGTGCTATTCTTGCGCGTGAACTTGGTATTCGTCACGTTGATACCATTTGTATCTCTAGCTACGATCATGATCACCAGCGTGATATGACCGTGCTAAAAGCGCCAGAAGGTGATGGCGAAGGTTACCTAATCGTCGAAGACCTAGTGGATAGCGGTGATACAGCGCGTAAACTACGTGAAATGTACCCGAAAGCGAAACTGATTGCTGTTTGCGCTAAGCCATCAGGTGCCACTCTTCTTGATGATTACGTGGTTGATATTGCTCAAGATACATGGATTGAGCAGCCATGGGATACCACAGTGCAATTTGTGGAACCAATTAATCGCAAGCAAAAGTAA,tetracycline-resistant ribosomal protection protein,antibiotic inactivation,Tetracyclines,MEG_6976,Drugs,MEG_6976|Drugs|Tetracyclines|Tetracycline_inactivation_enzymes|TET34,(Tet)Tet-34:AB061440:306-770:465,4
,ttgagcaagggaaaggtgcaagcactctttttatcacttatcggtgcggctctgctcatgacatcaagtttacagacacctacagaagctgaagctgcagagaaaaacataaattcgaaaaagctgaaggttgatgagtttttcacagatctcgacggcacttttatcttgcgggatttaaaaaacgaaaaaacattcgtctacaacgatcagcgcgcaaaacaaagatttgcgccgcagtcgacgtttaaagttcctaatgcgcttatcggattagaaacaggcgctgttaaagatgaatatgacatcaaatactgggatggcgtgaaacgggaacttgacgtttggaaccaagaccatacgctcggctctgctatgagatattcagtggtttggtattaccaagcaatggcccgggacatcggagaagagcgaatgaaggaatggattgaaaaaacaggttacggcaaccaagacatcagcggcggaattgatcaattctggctaagcagcactctcaaaatctctcctttagaacaaacagattttatggaatcgttatacaaagaaaaactaccatttgacaaaagcgtcatgaagacggtaaaacggatgatgattcaagaagacgaagaccactatacgctttatggaaaaaccggttctggctcaggcatcggctggtatgccggctttgttaaaaccgagcacggggcgtacagcttcgtgacaaacattgacggaaccggaacagaagcgaaaagcatcacaatggacattttgaagaaatatgttctgcattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1479,Drugs,MEG_1479|Drugs|betalactams|Class_D_betalactamases|BSU,489328362|WP_003235647.1|NG_050942|1|1|blaBSU-1|blaBSU|class_D_beta-lactamase_BSU-1 NG_050942:101-904,0
,GGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACGGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2420,Drugs,MEG_2420|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695211160|ref|NG_036029.1|1-925,0
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggagagtttattgtataccagtggtgcaattgcagaaccagggagcgtagataaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgtattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagacaatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcaagaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggaaattccaaaccggaacgttatttcccgtttatcacggaagtgctaaaaacaatctggggattcggcagcttaaaaaagggattgccagtaagttttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattaaaatatctgaaaaagagaaaataaaaatcacagagatgtgtgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatgctgttgccgcagagaaaatttattgaaaatcctctccctatgctccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagatggcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaataccatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaaccaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgccccaaggtattgtgcagatattgtaagtactcaggtaaagaatgacgaggtcattctgaaaggagaaatccctgccagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7157,Drugs,MEG_7157|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,1028100269|WP_063856404.1|NG_048261|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048261:101-2020,4
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAAGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2379,Drugs,MEG_2379|Drugs|betalactams|Class_A_betalactamases|CTX,gi|166092025|gb|EU376964.1|1-876,0
,gtgaatggaccaataataatgactagagaagaaagaatgaagattgttcatgaaattaaggaacgaatattggataaatatggggatgatgttaaggctattggtgtttatggctctcttggtcgtcagactgatgggccctattcggatattgagatgatgtgtgtcatgtcaacagaggaagcagagttcagccatgaatggacaaccggtgagtggaaggtggaagtgaattttgatagcgaagagattctactagattatgcatctcaggtggaatcagattggccgcttacacatggtcaatttttctctattttgccgatttatgattcaggtggatacttagagaaagtgtatcaaactgctaaatcggtagaagcccaaaagttccacgatgcgatttgtgcccttatcgtagaagagctgtttgaatatgcaggcaaatggcgtaatattcgtgtgcaaggaccgacaacatttctaccatccttgactgtacaggtagcaatggcaggtgccatgttgattggtctgcatcatcgcatctgttatacgacgagcgcttcggtcttaactgaagcagttaagcaatcagatcttccttcaggttatgaccatctgtgccagttcgtaatgtctggtcaactttccgactctgagaaacttctggaatcgctagagaatttctggaatgggattcaggagtggacagaacgacacggatatatagtggatgtgtcaaaacgcataccattttga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_979,Drugs,MEG_979|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,695346232|WP_032542910.1|NG_047372|1|1|ant(4')-Ia|ant(4')-Ia|aminoglycoside_O-nucleotidyltransferase_ANT(4')-Ia NG_047372:101-862,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGTCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACGGATAAAACCGCATTACTGCACTTTTATCAAAACTGGCAGCCTCAATGGGCTCCGGGCGCTAAGAGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAGCCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGATGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCACGCTGGGTTCAGGCCAACATGGATGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAGGCTGATTCGATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGATTCCCGCCGTTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTATCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1844,Drugs,MEG_1844|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB280919|+|0-1146|ARO:3002048|CMY-37 [Citrobacter freundii] ,0
,TTGTCAAAATAGCGGGAGTCGCATATAGTCCGCTGCGACTTATCACTCTCAAGGAATCAGAAATGATAAAAAGTTCGTGGCGTAAAATTGCAATGCTAGCCGCCGTTCCGCTGCTGCTGGCGAGCGGCGCACTGTGGGCCAGTACCGATGCTATCCATCAGAAGCTGACAGATCTCGAGAAGCGTTCAGGCGGCAGGTTGGGCGTGGCGCTAATCAACACGGCAGATAATTCTCAAATCTTATATCGCGGCGACGAGCGTTTTGCCATGTGCAGCACCAGTAAAGTGATGGCCGCCGCCGCGGTATTAAAACAGAGCGAAAGCAATAAAGAGGTGGTAAATAAAAGGCTGGAGATTAACGCAGCCGATTTGGTGGTCTGGAGTCCGATTACCGAAAAACATCTCCAGAGCGGAATGACGCTGGCTGAGCTAAGCGCGGCGACGCTGCAATATAGCGACAATACGGCGATGAATCTGATCATCGGCTACCTTGGCGGGCCGGAAAAAGTCACCGCCTTCGCCCGCAGTATCGGCGATGCCACCTTTCGTCTCGATCGTACGGAGCCCACGCTGAATACCGCCATCCCGGGCGATGAGCGTGATACCAGCACGCCGCTGGCGATGGCTGAAAGCCTACGCAAGCTGACGCTTGGCGATGCGCTGGGCGAACAGCAACGCGCCCAGTTAGTCACCTGGCTGAAAGGCAATACCACCGGCGGGCAAAGCATTCGCGCGGGCCTGCCTGAAAGCTGGGTGGTCGGCGATAAAACCGGCGCCGGAGATTACGGCACCACCAATGATATTGCGGTTATCTGGCCGGAAGATCACGCTCCGCTGGTATTAGTCACCTACTTTACCCAGCCGCAGCAGGATGCGAAAAACCGCAAAGAGGTGTTAGCCGCAGCGGCAAAAATCGTGACCGAAGGGCTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5317,Drugs,MEG_5317|Drugs|betalactams|Class_A_betalactamases|OXY,gi|32130556|gb|AY077487.2|118-1049,0
,atgaatagaataaaagtcgcaactatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaatgattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtccggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatgggaaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaagagacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccatgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7345,Drugs,MEG_7345|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100424|WP_063856559.1|NG_048332|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048332:1-1029,5
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACCCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGTGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGCATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6451,Drugs,MEG_6451|Drugs|betalactams|Class_A_betalactamases|SHV,gi|313766525|gb|HM751099.1|1-861,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCCAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGGTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACATCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGACAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAACCGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1405,Drugs,MEG_1405|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_117_ACHE01000004,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcaagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_227,Drugs,MEG_227|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1027670681|WP_063612062.1|NG_052358|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052358:29-583,2
,atgactcgacataatgaaattattaaatgtgcagaaaaatatcaattacacatccaacctcaaacaatctcattgaatgaatcgggacttgattttcaagttgcatttggaaaagataaacatggagtagaatgggttttgagactaccaagaagacctgacgtttataaacgaacaaaacccgaaaaacaaacggtagacttcttacagaagaatgtttcatttgaaataccgaagtggaaagtacatgcaaaagaccttattgcttacccaaaacttacaggtaaacccgcagccacaatagatccagaaatacaaaattatgtatgggaaattgaacacaaaccattaccagaaaactttattaacacattagctgaaacactcgtagatttacacaacataccagaagaaaacattaacgttcagcatataaatatcaaaaccatacaagaaataaaaaatgactttcaaagaagaatgaataaagttaaagaaacttatggcgtatcagatgaattatggaacagatggaaacaatggttagaaaacgacgaactatggcctcgacatgcgaccatgatacatggggacttacatccaggacatataatggtagataaccaagcaaacgtcacaggtctcatagactggactgaagcaacccactccgagccatcaatggactttataggacaccatcgtgtattcgacgacgaaggattagagcaacttataacagcatacggtaaagctggaggtgaaatatggccacgaatgaaagagcatataatagaactcaatgcagtattcccaatgtttatcgctgagtttgctatggaatcaggagaatcggcgtatgaaacgatggcattgaaagagttaggtatgaaagagtag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4037,Drugs,MEG_4037|Drugs|MLS|Macrolide_phosphotransferases|MPHC,1028097195|WP_063853892.1|NG_047990|1|1|mph(C)|mph(C)|Mph(C)_family_macrolide_2'-phosphotransferase NG_047990:13-912,7
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTAACCGAAGCATACCGTGCTTTATCTGTCCTTGACGGAGCTGTTTTAGTCATTTCGGCAAAAGACGGCGTACAGGCACAGACGCGTATATTATTCCATGCGCTTCAGAAAATGAACATTCCGACAATTATCTTTATAAATAAGATAGACCAAAATGGAATCGACCTACAGCGTGTTTACCAAAGCATTAAAGACAAACTTACCAGTGATATGATTGTCATGCAGGAGGTTTCCCTGTCGCCCCAAATATCCATGACCGATATTTCTGATTTGGACAAATGGGATATGATTATTTCCGGAAGCGATGAACTATTAGAACGATATGTTGCAGAGGATTCTTTGGATATACAGGAATTACAATATGAAAAGTGCAAAAGAACCAGATGCTGCTCTTTGTTTCCTGTTTATCATGGGAGTGCAAAAGACAATTTAGGAACAGAAAAACTGATTGAAGCGATTACAGAAACTTTCATTACAGAAACAGACGATATTCAGTCTGAATTATGTGGATATGTTTTTAAGGTTGAGTATACAGAGCGGAAAAAACGGCTTTCTTATTTACGCCTGTATCATGGGACGCTCCATTTACGGGATACCCTGCTGCTGTCAAAAAAGGAAAAAATAAAGATTACAGAAATGTGTATTCCGTCAAATGGTGAAATCGTCCCGGCTGACCATGCCTGTCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTGGGAAATGAAAAACTCCTGCCTCACAAAACATGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7171,Drugs,MEG_7171|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/32/O)_1_JQ740052 ,4
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtagctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2207,Drugs,MEG_2207|Drugs|betalactams|Class_A_betalactamases|CTX,1331531446|WP_102607456.1|NG_056173|1|1|blaCTX-M-207|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-207 NG_056173:101-976,0
,ATGAAGAAGAATCAAGGAATTGAGCAGTTTCGGGTGATTTTAGCGATGATGGTGGTGGCGATCCACTGTCTGCCCCTTCATCGATTGTGGCCCAATGGTGATATCCTGATCACATTGACTCTTTTCAGAATCGCCGTCCCCTTCTTTTTTATGATCAGCGGGTATTATGTGTTCAGTGATTTAGCCACCCAAAACAGCTATCCTGCCAGACAACGTATCTGGTTATTTATCAAAAAACAGCTGCAAGTCTATCTCATTGCCACACTGCTCTTTTTGCCGCTTGCTTGGTACAGCGGCATACTAGGATTGAACATGCCACTAGACACTTTTATTCAAACTTTGCTAGTCAACGGCATTCTTTACCATCTTTGGTATTTTCCTGCGATCATTACCGGCGGTCTACTAGTGATGGGCCTCTTGACACGGCTTTCTTTCAAGCAGGTGTTTTTCATTGCTGTCGGTTTGTATGTGGTTGGTTTAGGTGGGGACAGTTGGTCTGGCCTGGCTGCACAAACACCCATCACGCCACTCTATTCACTGATTTTCCAACTATTGGATGGAACTCGCAACGGCATTTTTTTTGCTCCCTTATTTTTGATCTTAGGGGTACTAGCCAGAAGATTTGCCAAAAAACCTGCTTCTCCCCATCGCTATAGTTATCTGATGATTAGTCTTATTTGCTTGCTTTTGGAAAGTTATCTCTTGCATCACTTTACTACACCTAAACATGACAGCATGTATGTCTTTTTGCCCTTCGTTCTCTTGTTTTTATTTCCGATCATTCAGCAATGGCAAGCACCCATGATCTGGAAACAAGCGGGTCGTCTGTCCCTTTGGCTCTATTTGCTCCATCCTTATACCATTGCAGTAACCCATTTTCTTAGTCAAAAGCTACCCTTGCTGCAAAACAATCTGATCAATTTCTTGGTGGTCTTAGGACTGACCATTGGGGTGGTGCATGGTCTCTTTGCTTTGCAAAAGCTGTTGCCGTTTCCGAAAAAAACGCCGCTCCACTTGCAGCGGGCAGCCAAAGAATTCTCAGCCCCCGCCCTGTTGCACAACTTGCAGGAAATCAAACGAGTGATTCCATCCACAACAAAAGTGATGGCGGTGGTTAAAGCAGATGCCTATGGTTGCGATGCACAATTGGTCGCTCGTACCTTAGAAAGAGTAGGCGTCGATTTTTTTGCTGTTGCCACCATAGAAGAAGCCATCGAATTAAGGCGAGCTGGCATTAAAAGTCGCTTACTGATTTTAGGGTACACTTCTGCCCAACGTGCCAAAGAGCTGAACCGATATTCCTTAATTCAAACTATCGTCAGTGAAGCGCATGGACAAGCGTTAGCCCGAACAGGCCTTCCAATCGAATGCCATTTAGCGGTAGATACCGGCATGCATCGTCTAGGCGTTGCCCCTGACCTTGAAACAGTTAGAAGGCTTTATGCCTTGCCATCCCTCAAGATCACAGGCATTTTTTCCCACCTAGGCTCTTCAGATCAGCTAGATACGGCAAGTATCTTACGGACGCAAGCCCAAATCATTTGTTTTGATGATCTATTGGCTGGCTTATCCGCTAGAAATATCGCCTATGGTCTGACGCATCTGCAAAGCAGCTACGGCATTTTGAATTATCCAGAGAAACACTATGATTATGTGCGCCCGGGTATTCTTTTAACTGGTTCCCTGAGTGTCCCGAATGAACCAACAAAACAGAAGATAAACGTACAGCCGATTCTGACCCTAAAAGCCTTACTAGTGGACAAAAAAACAGTCGCCGCTGGTGAAGCGATCGGCTATGGACTAGCCACTGTTTTTGATCGACCTACCACGATTGGGATCGTTAGTATCGGCTACTGTGACGGAGTCCCCCGTGCCCTATCAAATCAAGGATTCCAATTGTCTTATCAAGGGGTTTTACTCCCGCAGGTTGGGTTGATTTGTATGGATATGCTCTTGATCGATTTAACGGACTATCCAGAACTGGCGGTCGAAAGTTGGTTAGAAGTAATCAGCGATTGGACGAATACAGCTGATCAAGCACAAACCATTCCCAATGAATTGATCAGTCGACTAGGTTCCCGCGTCCCTTCAATGTCAAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7528,Drugs,MEG_7528|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,(Gly)VanTc4:EU151753:1647-3749:2103,5
,ATGTCCACCAACTTATCAGTGATAAAGAATCCGCGCGTTCAATCGGACCAGCGGAGGCTGGTCCGGAGGCCAGACGTGAAACCCAACAGACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGATGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCGGTCTTGCTCGTCTCGCTGGCCGGCGCTGCTGTCGACTACGCCATCATGGCGACGGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGCTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACAAAGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCGCTTCGTTCCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCCTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATGTTGTCCAGGCAGGTGGATGAGGAACGTCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7024,Drugs,MEG_7024|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,(Tet)TetA:JX424423:94438-95712:1275,4
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtcggcatgttcttttaataccgtacaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaacagaggaaatctatggcaatgatcttaaaagatcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttctgctattccagtctatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaagaatgtgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacggaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4559,Drugs,MEG_4559|Drugs|betalactams|Class_D_betalactamases|OXA,691059842|WP_032003497.1|NG_049780|1|1|blaOXA-502|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-502 NG_049780:1-822,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAGATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTATTATTCACCAAAGAACAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1352,Drugs,MEG_1352|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_119_NZ_CANQ01000029,0
,ATGAGCGATCTAGCTAAAGAGATCACGCCCGTAAACATCGAAGACGAGCTACGCAGTTCGTATTTGGACTACGCGATGTCGGTTATCGTGGGTCGTGCTCTTCCTGATGTGCGTGATGGCCTTAAACCAGTACACCGACGCGTACTGTTCGCGATGAATGTGCTGGGCAACGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTGGTAGGTGACGTAATCGGTAAATATCACCCTCATGGTGACAGTGCGGTTTACGACACCATCGTGCGTATGGCGCAGCCTTTCTCACTTCGTTACATGTTGGTCGATGGCCAAGGTAACTTTGGCTCGATCGACGGCGACTCCGCGGCGGCAATGCGTTATACCGAAGTTCGTATGTCGAAAATCGCGCACGAACTCTTGGCAGACCTAGACAAAGAAACCGTTGACTACGTTCCGAACTATGACGGCACCGAGCAGATCCCTGCGGTATTGCCGACAAAGATCCCGAACCTGCTGATCAACGGCGCATCTGGTATTGCGGTGGGTATGGCAACCAACATTCCTCCGCACAATTTAGGTGAAGTGATCGATGGCTGTTTAGCCTACATCGATAATGAAGCGATCACCATTGATGAGTTGATGGACTACATTCCTGGTCCAGATTTCCCAACCGCCGCGCTGATCAGTGGCCGTAAAGGCATCATTGACGCGTACAAAACCGGCCGCGGCAAGGTTTACATGCGCTCGAAAGCGGAAATCGAAACCGATAAGAACGGCAAAGAAACCATTATCGTCAGCGAAATCCCTTATCAAGTGAACAAAGCGCGCTTGATCGAAAAAATCGCTGAGTTGGTGAAAGAGAAAAAAGTCGAAGGGATCAGTGCACTGCGTGACGAGTCTGACAAAGACGGTATGCGCATTGTGATTGAGTGTAAGCGTGATGCGGTTGGCGAAGTGGTTTTGAACAACCTGTATGCCAACACTCAGCTGCAAACCACCTTCGGTATCAACATGGTGGCACTCGATAACGGTCAGCCTAAGCTGTTTAACCTGAAAGAGATGCTGAAGTGTTTCGTCGACCACCGCCGCGAAGTGGTGACTCGTCGTACTATTTTTGAACTGCGTAAAGCGCGTGAGCGTGCCCACATCCTTGAAGGTTTGGCACTGGCTCTGGCTAACATTGATGAAATCATTGAACTGATCCGCCGTGCCGCCACGCCTGCAGAAGCAAAAGAAGGCTTAATTGCCCGTGGTTGGGATCTTGGCAACGTTGCGGCAATGCTTGAGCGTGCAGGTACGGATGCGGCGCGTCCTGAGTGGCTTGAGCCACAATACGGCATCCGCGATGGCAAGTACTTCCTGACTGAGCAACAAGCGCAAGCGATTCTGGATCTGCGTCTGCACAAGCTGACTGGTCTAGAGCACGAGAAGATCCTCGATGAGTACAAGCAGCTTCTCGAAGAAATCGCGGCATTGATGCACATTCTGGCGAGCACAGAGCGCTTGATGGAAGTGATCCGTGAAGAGCTAGAAGCGATTCGCGCTGGCTTTAGCGATGCGCGCCGCACTGAAATCACGGCAGCAACGCACGACATCGACATGGAAGAGCTGATCGCTCGTGAAGATGTGGTTGTGACTCTGTCACACGAAGGTTATGTGAAGTATCAATTACTGAGCGACTACGAAGCACAGCGTCGTGGTGGTAAAGGTAAGAGCGCAACCAAGATGAAAGAAGAGGACTACATTGAGCGTCTTCTGGTTGCCAATACTCACGATAACATTCTGCTGTTCTCGACTCGCGGCAAAACTTACCGTATGAAGGTATACCAACTGCCGCTCGCCAGCCGTACTGCGCGTGGTAAGCCAATCGTGAACCTGCTTCCTCTGGAAGAAAACGAGCGCATCACCGCGATTCTGCCAGTGACTGAGTTTAGTGAAGATAAATTCATCTTCATGGCAACCGGTGACGGTACTGTGAAGAAAACATCGCTGGATCAGTTTGCCAACGTTCGTGCGAATGGTTTGATTGCGCTCAACCTGCGTGACGAAGACTCGCTGATTGGTGTGGATATCACCGATGGCGAAAGCGAAATTATGCTGTTCTCTAAATTCGGTAAAGTGGTTCGCTTTAAAGAGTCCGAAGAAACCGCGGTTGTGGATGAAAATGGTCAACCTGTGCTGGATGAAAATGGCCAGCCAGAGATCAAGTTCAAAGGCGTAAGACCAATGGGTCGTACCGCTGCGGGTGTTCGCGGCATGAAACTGGCTGATGGCGACCAAGTGGTATCGCTCATCGTGCCGAAGACCGAAGGTGACGTACTCACCGTAACTGAAAATGGTTACGGCAAACGTACCAGCCTATCTGAATACCCAACCAAAGGTCGTGGAACTCAGGGTGTGGTTTCGATCAAAGTCTCTGAGCGTAACGGCAGCGTTGTGGGTGCAGTACAAGTGGCCGAGGGTGATGAGTTCATGATGATCACCAATGCCGGTACACTGGTACGTACTCGCGTGGCGGAAGTGAGCCAAGTGGGCCGTAATACTCAAGGCGTGACCCTGATCCGTACTTCGGAAGGTGAAAGTGTGGTAGGTCTGCAGCGTATCGATGAAATCGAAGAGTCGGAATTGCCAGAAGGTGAGGAAGCACTTGTCGAGAACGATGCACCTGTTGCACAAGATGATGATGGTGAACAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3216,Drugs,MEG_3216|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|657184927|dbj|AP014524.1|1179549-1182233 gi|378793418|gb|CP003330.1|1327232-1329916 gi|229368777|gb|CP001485.1|2333593-2330909 gi|227011820|gb|CP001235.1|1420096-1422780 gi|227008125|gb|CP001233.1|1287646-1290330 gi|146314918|gb|CP000627.1|888677-891361 gi|12057212|gb|AE003852.1|1330207-1332891 gi|109704606|gb|DQ774257.1|1-2683,3
,ATGATCGTGCAGCTCGGCAAGGCGTCCGTCACGTGGACGCGCGCGGACCTCGAGGCGAAGCTCGCCGGTCACGCGCGCGTGCTCATCGACGTCGGCACGGGCGACGGGCGCTTCGTGTACCGCTCGGCCGGCGCCCACCCGGACACGTACTGCATCGGCGTGGACCCCGCGGGCGAGCGGATGCGCGAGGTGTCGTGGCGCGCCAGCCGCAAGCCCGCCCGCGGCGGCCGGCCGAACGCGCTCTTCGTGGTCGCGTCGGTGCAGGCGCTGCCCGAGGAGCTCGCCGGGCTCGCCCACACCCTGACGCTGAACTTCCCCTGGGCGTCGCTGCTCTCGGCCCTGGTGCTCCCCGAGGCGCCCGTGCTCGAGGCGCTGCGCCGGCTCGTCCGGCCGGGCGGGGAGCTCATCGCGCTGCTCAACCAGAGCGTCTTCGACGACCGGCCCTACGCGGCGCGGCTCGGCCTCCCCGAGCTCTCGGACGCGTGGCTCGACGACGCGCTGCGCCCCGCCTACCGCGCCGCGGGGTTCGAGATCCGGACGAGCGAGATCGTGGACGGGGAGGTCCCGCACCAGACGAGCTGGGGGCAGCACCTCACGCTCGCTTCGGGCCGGCGGACGCGGCTGCTCACGGCCGAGGCGATCGGCGGCTCGGCCAGCGCTGCACCAGGCTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3459,Drugs,MEG_3459|Drugs|Aminoglycosides|16S_rRNA_methyltransferases|KMR,kmr_1_ENA_ACB88605,2
,atgaaacattttcgtctttgccttatccccgtgcttgccgcattttcactgccggtttttgcccacccggcgacgctggataccattaaagatgctgaaagccggctccacggccgagtcggctatgccgagttggatctcgtcagcggaaaaatgatggatagctatcgctctgatgaacgcttccccatgatgagcacctttaaagttattctgtgcggcgcggtgttagcgcgggttgatgccgggcaggaacagcttgatcgccgtatccgctaccgtcagaacgacctggttgagtactcgccggtaacggagaaacatctcgcagaggggatgaacgtgggggaattatgccatgccgcgatcaccatgagcgataacacggcggcaaacctgttgatctctacgctcggcgggccgtcggggctgaccgcatttttgcggaaaacgggtgactcggtgagccgtctcgaccgttgggaaacggcgctgaatgaagcgttgccgggtgacgagcgtgataccaccacgcctgagtccatggcgcggacgctgcataatttgttaacgggcgatgccctgagcgctgagtcacgtcggcaattaatgcgctggatggaaatggataacgtcgccggaccgcttttgcgttcggtgttgccggcagggtggtttattgctgacaaaaccggtgcgggtgagcgtggttcgcgtggcatcgtggcggcgctggggcctgatggtaaaccgtcgcgtatcgtcgtgatttacctgacgggaaccaaggcaacgatggacgagcgcaataagcagatcgccgatatcggcgctgcgctgataaatcactggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6152,Drugs,MEG_6152|Drugs|betalactams|Class_A_betalactamases|RUB,1118555868|WP_072186106.1|NG_054671|1|1|blaRUB-1|blaRUB|class_A_broad-spectrum_beta-lactamase_RUB-1 NG_054671:1-855,0
,gtgaaacccaacagacccctgatcgtaatactgtgcactgtcgcgctcgacgctgtcggcatcggcctgattatgccggtgctgccgggcctcctgcgagatctggttcactcgaacgacgtcaccgcccactatggcattttgctggcgctgtatgcgttgatgcaatttgcctgcgcgcctgtgctgggtgcgctatcggatcgtttcggccggcggccggtcttgctcgtctcgctgtccggcgccgctatcgactacgccatcatggcgacggcgcctttcctttgggttctctatatcgggcgcatcgtggccggcatcaccggggcgactggtgcggtagccggcgcctatattgccgatatcacagatggggatgagcgcgcgcggtacttcggcttcatgagcgcctgtttcgggttcgggatggtcgcgggacctgtgctcggtgggctgatgagcagtttctccccccatgctccgttcttcgccgcagcagccttgaatggcctcaatttcctgatgggcattttccttttgccggagtcgcacaaaggcgaacgtcgaccattacgccgggaggctctcaacccgctcgcttcgttccggtgggtccggggcatgaccgtcatcgccgccctgatggctgtcttcttcatcatgcaactcgtcggacaggcgccggccacgctttgggtcatcttcggcgaggatcgctttcattgggacacgagcttgatcggcatttcgcttgccgcatttggtattctacattcactcgcccaggcaatgatcaccggccctgtaaccaccaggctcggcgaaaggcgggcactcatgctcggaatgattgccgacggcgcaggctacatcctgcttgccttggcgacaaggggatggatggcgttcccgattatggtcctgcttgcttcgggtggcatcggaatgccggcgctgcaagcagtgttgtccaggcaggtagatgaggaacgtcaggggcagcttcaaggatctcttgcggcgctcaccagcctgacctcgatcgtcgggcccctcctcttcacggcgatctatgcggcctctataacaacgtggaacgggtgggcatggattgcaggtgccgccctctacttgctctgcctgccggcgctgcgtcgcgggttttggagcggcgtagggcaacgagccgatcgctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7021,Drugs,MEG_7021|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,690046024|WP_031942321.1|NG_048157|1|1|tet(A)|tet(A)|tetracycline_efflux_MFS_transporter_Tet(A) NG_048157:101-1300,4
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgaattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaatgattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccctgcccggttttacatcgtacagccgctacccacgtatgatggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7346,Drugs,MEG_7346|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100490|WP_063856625.1|NG_048342|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048342:101-1129,5
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgagcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_738,Drugs,MEG_738|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502218|WP_071846368.1|NG_052495|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052495:101-634,2
,ATGGAACAATATACAATTAAATTTAACCAAATCAATCATAAATTGACAGATTTACGATCACTTAACATCGATCATCTTTATGCTTACCAATTTGAAAAAATAGCACTTATTGGGGGTAATGGTACTGGCAAAACCACATTACTAAATATGATTGCTCAAAAAACAAAACCAGAATCTGGAACAGTTGAAACGAATGGCGAAATTCAATATTTTGAACAGCTTAACATGGATGTGGAAAATGATTTTAACACGTTAGACGGTAGTTTAATGAGTGAACTCCATATACCTATGCATACAACCGACAGTATGAGTGGTGGTGAAAAAGCAAAATATAAATTAGCTAATGTCATATCAAATTATAGTCCGATATTACTTTTAGATGAACCTACAAATCACTTGGATAAAATTGGTAAAGATTATCTGAATAATATTTTAAAATATTACTATGGTACTTTAATTATAGTAAGTCACGATAGAGCACTTATAGACCAAATTGCTGACACAATTTGGGATATACAAGAAGATGGCACAATAAGAGTGTTTAAAGGTAATTACACACAGTATCAAAATCAATATGAACAAGAACAGTTAGAACAACAACGTAAATATGAACAGTATATAAGTGAAAAACAAAGATTGTCCCAAGCCAGTAAAGCTAAACGAAATCAAGCGCAACAAATGGCACAAGCATCATCAAAACAAAAAAATAAAAGTATAGCACCAGATCGTTTAAGTGCATCAAAACAAAAAGGCACGGTTGAGAAGGCTGCTCAAAAACAAGCTAAGCATATTGAAAAAAGAATGGAACATTTGGAAGAAGTTGAAAAACCACAAAGTTATCATGAATTCAATTTTCCACAAAATAAAATTTATGATATCCATAATAATTATCCAATCATTGCACAAAATCTAACATTGGTTAAAGGAAGTCAAAAACTGCTAACACAAGTACGATTCCAAATACCATATGGCAAAAATATAGCGCTCGTAGGTGCAAATGGTGTAGGTAAGACAACTTTACTTGAAGCTATTTACCACCAAATAGAGGGAATTGATTGTTCTCCTAAAGTGCAAATGGCATACTATCGTCAACTTGCTTATGAAGACATGCGTGACGTTTCATTATTGCAATATTTAATGGATGAAACGGATTCATCAGAATCATTCAGTAGAGCTATTTTAAATAACTTGGGTTTAAATGAAGCACTTGAGCGTTCTTGTAATGTTTTGAGTGGTGGGGAAAGAACGAAATTATCGTTAGCAGTATTATTTTCAACGAAAGCGAATATGTTAATTTTGGATGAACCAACTAATTTTTTAGATATTAAAACATTAGAAGCATTAGAAATGTTTATGAATAAATATCCTGGAATCATTTTGTTTACATCACATGATACAAGGTTTGTTAAACATGTATCAGATAAAAAATGGGAATTAACAGGACAATCTATTCATGATATAACTTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_4067,Drugs,MEG_4067|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA,(MLS)MsrA:AY591760:274-1740:1467,7
,atgtttgctcgctggtcaaagacctttgcgctggccctcacagcctgtgctttcgtgatgggcgccactcaagcgcacgccgagttgatcgtgcgcgatgaccttaagcgcgtgtttgatgaggccggtgttacgggcaccttcgtgctgatggacatcagtggtaatcgcacctacgttgtggacccggcgcgcgccgcacggcgcatccaccctgcatcaaccttcaagattcccaacagcctgatcgccttcgatacgggtgccgtgcgtgacgatcacgaggtgatcccatacggtggcaagccacagcccttcaaacagtgggagaaggacatggcattgcccgaggcgatccgtgtatccaacgtgcccatctatcaggaagtcgcgcgacgcattggccctgcgcgcatgcaggcctacatggatgcctttgactacggcaaccgccagatcggcagcgtgattgaccagttctggctgcgtggtccattggaaatttccgcatttgaagaggcgcgcttcaccagccgtctggcgctcaagcaactgccggtgaagccgcgcacctgggatctggtccaccgcatgctgatgatcgagagacagggcgatgcctcgctgtacgccaagacgggggtcgccaccgagtatcagcccgagatcggctggtgggtgggctgggtcgagcgtgaggggaaggtgtacgcgttcgccctgaacatcgatatgccgcttgaggccgatatggccaagcgcatcctgctgggcaaacggctgatgcaggcattggacgtgtggccaacaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4740,Drugs,MEG_4740|Drugs|betalactams|Class_D_betalactamases|OXA,1331531452|WP_102607462.1|NG_056179|1|1|blaOXA-570|blaOXA-60_like|OXA-60_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-570 NG_056179:1-816,0
,atgttcatgccgcctgtttttcctgctcattggcacgtttcgcaacctgttctcattgcggacaccttttccagcctcgtttggaaagtttcattgccagacgggactcctgcaatcgtcaagggattgaaacctataaaagacattgctgatgaactgcgcggggccgactatctggtatggcgcaatgggaggggagcagtccggttgctcggtcgtgagaacaatctgatgttgctcgaatatgccggggagcgaatgctctctcacatcgttgccgagcacggcgactaccaggcgaccgaaattgcagcggaactaatggcgaagctgtatgccgcatctgaggaacccctgccttctgcccttctcccgatccgggatcgctttgcagctttgtttcagcgggcgcgcgatgatcaaaacgcaggttgtcaaactgactacgtccacgcggcgattatagccgatcaaatgatgagcaatgcctcggaactgcgtgggctacatggcgatctgcatcatgaaaacatcatgttctccagtcgcggctggctggtgatagatcccgtcggtctggtcggtgaagtgggctttggcgccgccaatatgttctacgatccggctgacagagacgacctttgtctcgatcctagacgcattgcacagatggcggacgcattctctcgtgcgctggacgtcgatccgcgtcgcctgctcgaccaggcgtacgcttatgggtgcctttccgcagcttggaacgcggatggagaagaggagcaacgcgatctagctatcgcggccgcgatcaagcaggtgcgacagacgtcatactag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1084,Drugs,MEG_1084|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH6,446403117|WP_000480972.1|NG_047466|1|1|aph(6)-Id|aph(6)-Id|aminoglycoside_O-phosphotransferase_APH(6)-Id NG_047466:101-937,2
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcaagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgtcgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctgagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_860,Drugs,MEG_860|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1102724720|WP_071593216.1|NG_052038|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052038:101-892,2
,ATGAAAAAATCGTTATCTGCAACACTGATTTCCGCTCTGCTGGCGTTTTCTGCCCCGGGGTTTTCTGCCGCTGATAATGTCGCGGCGGTGGTGGACAGCACCATTAAACCGCTGATGGCACAGCAGGATATTCCCGGGATGGCGGTTGCCGTCTCCGTAAAGGGTAAGCCCTATTATTTCAATTATGGTTTTGCCGATATTCAGGCAAAACAGCCGGTCACTGAAAATACACTATTTGAGCTCGGATCTGTAAGTAAAACTTTCACAGGTGTGCTGGGTGCGGTTTCTGTGGCGAAAAAAGAGATGGCGCTGAATGATCCGGCGGCAAAATACCAGCCGGAGCTGGCTCTGCCGCAGTGGAAGGGGATCACATTGCTGGATCTGGCTACCTATACCGCAGGCGGACTGCCGTTACAGGTGCCGGATGCGGTAAAAAGCCGTGCGGATCTGCTGCACTTCTATCAGCAGTGGCAGCCGTCCCGGAAACCGGGCGATATGCGTCTGTATGCAAACAGCAGTATCGGCCTGTTTGGTGCTCTGACCGCAAACGCGGCGGGGATGCCGTATGAGCAGTTGCTGACTGCACGGATCCTGGCACCGCTGGGGTTATCTCACACCTTTATTACTGTGCCGGAAAGTGCGCAAAGCCAGTATGCGTACGGTTATAAAAACAAAAAACCGGTCCGCGTGTCGCCGGGACAGCTTGATGCGGAATCTTACGGCGTGAAATCCGCCTCAAAAGATATGCTGCGCTGGGCGGAAATGAATATGGAGCCGTCACGGGCCGGTAATGCGGATCTGGAAATGGCAATGTATCTTGCACAGACCCGCTACTATAAAACCGCCGCGATTAACCAGGGGCTGGGCTGGGAAATGTATGACTGGCCGCAGCAGAAAGATATGATCATTAACGGCGTGACCAACGAGGTCGCATTGCAGCCGCACCCGGTAACAGACAACCAGGTTCAGCCGTATAACCGTGCTTCCTGGGTGCATAAAACGGGGGCAACAACTGGTTTCGGCGCCTATGTGGCCTTTATTCCGGAAAAACAGGTGGCGATTGTGATTCTGGCGAATAAAAACTACCCGAATACCGAAAGAGTCAAAGCCGCACAGGCTATTTTGAGTGCACTGGAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2613,Drugs,MEG_2613|Drugs|betalactams|Class_C_betalactamases|DHA,blaDHA-14_1_DQ478687,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTACTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6457,Drugs,MEG_6457|Drugs|betalactams|Class_A_betalactamases|SHV,gi|3769674|gb|AF096930.1|1436-2296 gi|2113860|emb|X98104.1|74-934,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggaaaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_888,Drugs,MEG_888|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695269890|WP_032491959.1|NG_052486|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052486:101-892,2
,atgcctaacgtttcgatcttacctgtgaaagaacaagacgctgccgactggctagcgctgcggaatcttctttggctcgcggatgatcacgcctcggagattgagcagtacttctctggtggacttgaggagcctgtagaagtggtgctcatcgcacgtgatgctaccggcgcggctgttgggcatgtcgaactctcgataagacatgacttggaagaactccaaggaatcaagaccggctacatcgaaggcctttatgtggccccaagccatcgatcaacagaccttgtgaagcgtttcttgcgtgagtccgagaagtgggccctagaacaagggtgcagcgcatttgcctcagacagaagtgatcgggtcatcacgcaccgcaagttcgcaggcagcgccgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_181,Drugs,MEG_181|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,746038502|WP_039110076.1|NG_052220|1|1|aac(6')-29|aac(6')-29|aminoglycoside_6'-N-acetyltransferase_AAC(6')-29 NG_052220:101-508,2
,atgaaaaagaatacgttgttaaaagtaggattatgtgtaagtttactaggaacaactcaatttgttagcacgatttcttctgtacaagcatcacaaaaggtagagcaaatagtaatcaaaaatgagacgggaaccatttcaatatctcagttaaacaagaatgtatgggttcatacggagttaggttattttaatggagaagcagttccttcgaacggtctagttcttaatacttctaaagggctagtacttgttgattcttcttgggataacaaattaacgaaggaactaatagaaatggtagaaaagaaatttcagaagcgcgtaacagatgtcattattacacatgcgcacgctgatcgaattggcggaataacagcgttgaaagaaagaggcattaaagcgcatagtacagcattaaccgcagaactagcaaagaaaagtggatatgaagagccacttggagatttacaaacagttacgaatttgaagtttggcaatacaaaagtagaaacgttctatccagggaaaggacatacagaagataatattgttgtttggttgccacaatatcaaattttagctggaggctgtttagtaaaatctgcggaagctaaaaatttaggaaatgttgcggatgcgtacgtaaatgaatggtccacatcgattgagaatatgctgaagcgatatagaaatataaatttggtagtacctggtcacgggaaagtaggagacaagggattacttttacatacattggatttattaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1203,Drugs,MEG_1203|Drugs|betalactams|Class_B_betalactamases|BCII,1028078998|WP_063839879.1|NG_056058|1|1|BcII|BcII|BcII_family_subclass_B1_metallo-beta-lactamase NG_056058:101-874,0
,ATGTCTAAAATCGAAATAAAAAATCTGACATTCGGCTACGACAGCCAAGGCACATTATTATTTGAACAAGCAAATCTAAATTTTGACACACAATGGAAACTAGGACTTATCGGACGAAACGGTCGAGGAAAGACAACTTTACTGAATATTCTACAAAACAAACTACCTTATCAAGGGCAAGTAATCCATCAGCAAGAATTTGCCTATTTCCCGCAACAGACAAAAGATAAAGAACGTTTAACCTATTACGTGTTAAATGATATTACGGATTTTGAGATATGGGAAATCGAAAGAGAGCTCCAATTGATGCAAACAGATCCTGAAATCTTATGGAGAGAATTCAGCACACTATCGGGGGGAGAGAAGACAAAAGTCCTACTGGCACTTTTATTTGTGGATGACACTCATTTCCCGTTAATCGATGAACCAACGAATCATTTGGATATCTCTGGTAGAAAACAAGTAGCGGCTTATTTGAAAAAGAAAAAACAAGGCTTCATCGTGGTCAGCCATGACCGGGGATTTATCGATGAAGTAGTGGACCATGTTTTAGCAATCGAAAAAAGTCAACTGGAACTTTATCAAGGGAATTTCTCTATCTATGAAGAACAGAAAAAACTTCGTGATGAATTTGAAATGGCTCAAAATGAAAAATTGAAAAAAGAAGTCAGTAGGCTAAAGAAAACAGCAGCTGAAAAAGCCGAATGGTCTCGTTCCCGAGAAGGAGATAAAACAAAGAAACAAGTCGGATTCATCGATACTGAATCTAGACGAGTGAATAAAGGAGCAGTGGGTGCTGATGCTGCACGGACGATGAAACGATCCAAAGCAATCGTGAATCGGATGGAGACCCAGATCAGCGAGAAAGAAAAACTATTAAAAGATATCGAATATATCGATTCTTTGACGATGAATAGCCAAGCGTCTCACCATAAGCGACTTTTAAGCGTAGAAGATCTTCAATTAGGGTATGAAAATCTGTTATTCGAGCCAATTCATTTTACAATCGAGCCTCATCAGCGGGTGGCGATTTCAGGTCCTAACGGTGCAGGAAAGTCATCCATTATCCATTATCTTCTGGGGGCATTCAACGGCAAGGTTATAGGAGAAAAATACCAGCCAAAACATCTGAGCATTAGTTATGCAAGCCAAAATTATGAAGACAATCGAGGAACGTTGGCGGAATTTGCAGAGAAAAACCAAGTAGACTACCAAGCATTTTTGAACAACCTCCGAAAGCTTGGGATGGAAAGAGATGTTTTTCATAACAAGATCGAGCAGATGAGTATGGGCCAACGGAAAAAAGTGGAATTGGCTAAATCTTTATCACAGCCAGCTGAACTATATATATGGGATGAACCATTGAATTATTTGGATGTCTTCAATCAAGAACAATTAGAACAACTGATCTTGAACGTGAAACCTGCCATGTTACTAGTGGAACATGATCAAACCTTCCTGGATAAAGTATCTACTGAGATTATTTCTCTTGAGAGAATCTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_2694,Drugs,MEG_2694|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|EATAV,gb|KF010779.1|+|0-1503|ARO:3003761|eatAv [Enterococcus faecium] ,1
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6887,Drugs,MEG_6887|Drugs|betalactams|Class_A_betalactamases|TEM,gi|21464484|gb|AY101578.1|1-1080,0
,atggatattagaaaaacaatagaagaaaaatgcaatatagtgattgaaagcattaaattgattggagaaggatacgatagtaaagcatatatagtaaataatgaatatgtttttaaaataaagtttagtgctaataagaaaaaaggttatgaaaaagaaaaagcagtatatgattttttgaataaaaaattacatacttctgtaaatattcctaatatagagtattcatacataagtgatgaaatatctatattaggttataaagaaattaaaggaacatttttaacaccagaaatctatttttcaatgtcattggaacaacaagatttattaaaacaagatattgcaatgtttttacgacaaatgcacgatttagattttgatgaaataagttcatatacaatagataataagcaaaatgttttagaagaatatcaattattacgagaaacaatttatgagagtcttactgatatagaaaagcaatatatagaagaatttatgcaaagactatatagtacaactatatttgatggcaaaaaatgtttgtgtcataatgattttagttgtaatcatttattgttagatgataataataggttagttggagtaattgattttggagattctggaataattgatgaatactgtgattttatatatttattagaagatagtgaagaagaaataggagtttcttttggagaagatatacttaaactttatggaaatattgatatttcaaaagcaaaagaatatcaggatgtagtagaacaatattatcctatcgaaactattgtatatggtgtaaaaaataatagagatgattttattgaaaaaggaagaaaagaaatctatttaagaacaagaaaagatgaaaagacaaggaagtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1010,Drugs,MEG_1010|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH2-DPRIME,949781494|WP_057098416.1|NG_047408|1|1|aph(2'')-Ih|aph(2'')-Ih|aminoglycoside_O-phosphotransferase_APH(2'')-Ih NG_047408:1-894,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5671,Drugs,MEG_5671|Drugs|betalactams|Class_C_betalactamases|PDC,1343491216|WP_104009832.1|NG_056389|1|1|blaPDC-234|blaPDC|class_C_beta-lactamase_PDC-234 NG_056389:1-1194,0
,ATGCATAACGACAAAGATCTCTCTACGTGGCAGACATTCCGCCGACTGTGGCCAACCATTGCGCCTTTCAAAGCGGGTCTGATCGTGGCGGGCGTAGCGTTAATCCTCAACGCAGCCAGCGATACCTTCATGTTATCGCTCCTTAAGCCACTTCTTGATGATGGCTTTGGTAAAACAGATCGCTCCGTGCTGGTGTGGATGCCGCTGGTGGTGATCGGGCTGATGATTTTACGTGGTATCACCAGCTATGTCTCCAGCTACTGTATCTCCTGGGTATCAGGAAAGGTGGTAATGACCATGCGTCGCCGCCTGTTTGGTCACATGATGGGAATGCCAGTTTCATTCTTTGACAAACAGTCAACGGGTACGCTGTTGTCACGTATTACCTACGATTCCGAACAGGTTGCTTCTTCTTCTTCCGGCGCACTGATTACTGTTGTGCGTGAAGGTGCGTCGATCATCGGCCTGTTCATCATGATGTTCTATTACAGTTGGCAACTGTCGATCATTTTGATTGTGCTGGCACCGATTGTTTCGATTGCGATTCGCGTTGTATCGAAGCGTTTTCGCAACATCAGTAAAAACATGCAGAACACCATGGGGCAGGTGACCACCAGCGCAGAACAAATGCTGAAGGGCCACAAAGAAGTATTGATTTTCGGTGGTCAGGAAGTGGAAACGAAACGCTTTGATAAAGTCAGCAACCGAATGCGTCTTCAGGGGATGAAAATGGTTTCAGCCTCTTCCATCTCTGATCCGATCATTCAGCTGATCGCCTCTTTGGCGCTGGCGTTTGTTCTGTATGCGGCGAGCTTCCCAAGTGTCATGGATAGCCTGACTGCCGGTACGATTACCGTTGTTTTCTCTTCAATGATTGCACTGATGCGTCCGCTGAAATCGCTGACCAACGTTAACGCCCAGTTCCAGCGCGGTATGGCGGCTTGTCAGACGCTGTTTACCATTCTGGACAGTGAGCAGGAGAAAGATGAAGGTAAGCGCGTGATCGAGCGTGCGACTGGCGACGTGGAATTCCGCAATGTCACCTTTACTTATCCGGGACGTGACGTACCTGCATTGCGTAACATCAACCTGAAAATTCCGGCAGGGAAGACGGTTGCTCTGGTTGGACGCTCTGGTTCGGGTAAATCAACCATCGCCAGCCTGATCACGCGTTTTTACGATATTGATGAAGGCGAAATCCTGATGGATGGTCACGATCTGCGCGAGTATACCCTGGCGTCGTTACGTAACCAGGTTGCTCTGGTGTCGCAGAATGTCCATCTGTTTAACGATACGGTTGCTAACAACATTGCTTACGCACGGACTGAACAGTACAGCCGTGAGCAAATTGAAGAAGCGGCGCGTATGGCCTACGCCATGGACTTCATCAATAAGATGGATAACGGTCTCGATACAGTGATTGGTGAAAACGGCGTGCTGCTCTCTGGCGGTCAGCGTCAGCGTATTGCTATCGCTCGAGCCTTGTTGCGTGATAGCCCGATTCTGATTCTGGACGAAGCTACCTCGGCTCTGGATACCGAATCCGAACGTGCGATTCAGGCGGCACTGGATGAGTTGCAGAAAAACCGTACCTCTCTGGTGATTGCCCACCGCTTGTCTACCATTGAAAAGGCAGACGAAATCGTGGTCGTCGAGGATGGTGTCATTGTGGAACGCGGTACGCATAACGATTTGCTTGAGCACCGCGGCGTTTACGCGCAACTTCACAAAATGCAGTTTGGCCAATGA,ATP-binding cassette (ABC) antibiotic efflux pump,antibiotic efflux,Multi-drug_resistance,MEG_4061,Drugs,MEG_4061|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|MSBA,gb|U00096.3|+|966620-968369|ARO:3003950|msbA [Escherichia coli str. K-12 substr. MG1655] ,1
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccgatgatatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggtatggtaccttccaacgggatgattgttatcaacaaccaccaggcagcgttgctggacacaccgatcaatgacgcacaaacggaaatgctggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggaggactgggttacctgcaaaagaaaggtgtccaatcatacgcgaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagcctggacggcatgcctctccaatgctattatttaggaggcggacatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggtggatgtatgcttaaagacaaccaggcgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcagcccgctacgtcgtgcccggacatggtaactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacctcaaaaccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1662,Drugs,MEG_1662|Drugs|betalactams|Class_B_betalactamases|CFIA,1188444884|WP_085562386.1|NG_054669|1|1|cfiA23|cfiA|subclass_B1_metallo-beta-lactamase_CfiA23 NG_054669:1-750,0
,GTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCACTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_358,Drugs,MEG_358|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|930190865|emb|LN555650.1|261113-260559 gi|930189590|emb|HG530658.1|196821-196267 gi|873463574|gb|KR106190.1|15823-15269 gi|730042884|gb|KJ571202.1|4554-5108 gi|825088700|gb|KP975077.1|106431-105877 gi|821392896|gb|KP873171.1|21087-20533 gi|768032361|gb|KM975294.1|1504-2058 gi|742797756|emb|LK054503.1|13240-13794 gi|636632016|gb|KJ579055.1|150-704 gi|635661965|gb|KJ547703.1|998-1552,2
,ATGAAACTTGTAGCCCAGGGCTCAACCCTCGATCTCTCTCACCCCCACGTGATGGGTATTCTAAATGTGACGCCTGACTCCTTCTCCGATGGCGGCGCCCATAATTCGCTGATTGAGGCGGTGAAGCATGCCAATCTGATGATCAACGCCGGCGCGACCATCATTGATATCGGCGGTGAATCGACGCGGCCAGGGGCGGCTGAGGTTAGTGTGGAAGAGGAGCTTGCGCGGGTGATACCGGTGGTTGAAGCCATTGCCCAGCGCTTTGAGGTATGGATCTCAGTGGATACCTCCAAGGCGGAGGTTATTCGCCAATCGGCCAGGGCCGGGGCGCATATCATCAACGATATTCGTTCGCTGACCGAGCCCGGCGCGCTGCAGGCCGCCGCGGAAACCGGACTGCCAGTGTGTCTGATGCATATGCAGGGACAACCAAAAACCATGCAGGAGGCGCCGAAGTATGAGGACGTCTTCGCCGATGTTGAGCGTTTTTTTAATGAGCACATTGTGCGCTGCGAACAGGCAGGGATCGCAAAAGAAAAATTGCTGCTCGACCCGGGATTCGGTTTCGGTAAAAATCTCTCCCACAATTACCAACTGTTGGCCAGGCTTGGGGAGTTTCATCACTTTGGTCTGCCGCTGCTGGTCGGTATGTCACGTAAGTCGATGGTAGGTCAGTTGCTGAACGTCGGGCCGTCGGAGCGGCTGAACGGCAGCCTGGCGTGTGCCGTCATTGCAGCAATGCAGGGCGCGCAGATTATCCGCGTCCATGATGTCAAAGAAACGGTAGAAGCGCTGCGCGTGGTGGAAGCCACCCTCGCCGCTAAGGGAAAAAAACGTTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2952,Drugs,MEG_2952|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|723234405|gb|CP009863.1|4713480-4712632 gi|499527875|emb|FO203501.1|4893434-4892586 gi|150953431|gb|CP000647.1|3948486-3947638,8
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAATCAGCAGTAACTAGAGTGAAAGCGATGATGGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCCGGCCATGAAATGATTTCATTAGAAGAAGAGCTGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTGAAAATTTCGGTTGATACTTTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATTATTAATGATCAATGGGCAGGCCTTTATGATCATCGCATGTTTCAAGTTGTAGCCAAATACGATTCGGAAATTGTTTTAATGCATAATGGCAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATCTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCTGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAGAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2956,Drugs,MEG_2956|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|82655308|emb|AJ938182.1|512315-513118,8
,AGGAGGTGATCCAACCGCAGGTTCACTACGGTTACCTTGTTACGACTTCACCCCAGTCGCTGTGTGTGCCGTGGGCAGTAGCCAATTTAGCATCCTGACTTAAGGCAAACACAACTCCCATGGTGTGACGGGCGGTGAGTACAAGACCCGGGAACGTATTCACCGCAACATGGCTGATTTGCGATTACTAGCGATTCCAGCTTCATGCAGGCGAGTTGCAGCCTACAATCCGAACTGAGAGGTGTTTTGAAGATTGGCTCCATTCGCAGTATTGCTTCTCTTTGTGCACCCCATTGTAGCACGTGTGTAGCCCTAGGCGTAAGGGCCATGATGACTTGACGTCGTCCCCACCTTCCTNCCCTTACGGAGGCAGTATCCTTAGAGTTCTCAGCATAACCTGTTAGCAACTAAGAAAAGGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCAGCACCTGTTTTCAAGGTCTGGCAAGCCAGACACTCCACTATTTCTAGCGGATTCTCTCAATGTCAAGCCTAGGTAAGGTTCTTCGTGTATCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTCCCCGTCTATTCCTTTGAGTTTTAATCTTGCGACCGTACTCCCCAGGCGGGATGCTTAATGCGTTAGCTGCATTACTGGAGAGACTAAGCCCTCCAACAACTAGCATCCATCGTTTAGGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCAACMGCTTTCGCGCAATCAGCGTCAGTAATGTTCCAGCAGGTCGCCTTCGCAATGAGTATTCCTCTTGATCTCTACGGATTTTACCCCTACACCAAGAATTCCACCTACCTCTCCCACACTCTAGAATAGTAGTTTCAAATGCAGTTCTATGGTTAAGCCATAGGATTTCACACCTGACTGACTATCCCGCCTACGCGCTCTTTACGCCCAGTGATTCCGAGTAACGCTTGCACCCTCCGTATTACCGCGGCTGCTGGCACGGAGTTAGCCGGTGCTTATTCGTTAGATACCGTCATTATCTTCTCTAACAAAAGGAGTTTACAATCCTAAAACCTTCATCCTCCACGCGGCGTTGCTGCTTCAGGGTTTCCCCCATTGAGCAATATTCCCTACTGCTGCCTCCCGTAGGAGTCTGGACCGTGTCTCAGTTCCAGTGTGTCCGTTCACCCTCTCAGGCCGGATACCCGTCATAGCCTTGGTAAGCCATTACCTTACCAACAAGCTGATAGGACATAGGCTGATCTCTTAGCGATAAATCTTTCCCCCGTAGGAGTATCTGGTATTAATCATCGTTTCCAATGGCTATCCCAAACTAAGAGGCACATAACCTATGCGTTACTCACCCGTGCGCCACTAATCAGCACTCTAGCAAGCTAGAAGCTTCATCGTTCGACTTGCATGTATTAGGCACGCCGCCAGCGTTCACTCTGAGCCAGGATCAAACTCTCCATAAAA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Tetracyclines,MEG_6963,Drugs,MEG_6963|Drugs|Tetracyclines|Tetracycline-resistant_16S_ribosomal_subunit_protein|TET16S,gb|CP003904.1|-|1511156-1512657|ARO:3003510|Helicobacter pylori 16S rRNA mutation conferring resistance to tetracycline [Helicobacter pylori 26695] ,4
,atgaattttaataataaaacaaagtatggtaaaatacaggaatttttaagaagtaataatgagcctgattatagaataaaacaaataaccaatgcgatttttaaacaaagaattagtcgatttgaggatatgaaggttcttccaaaattacttagggaggatttaataaataattttggagaaacagttttgaatatcaagctcttagcagagcaaaattcagagcaagttacgaaagtgctttttgaagtatcaaagaatgagagagtagaaacggtaaacatgaagtataaagcaggttgggagtcattttgtatatcatcacaatgcggatgtaattttgggtgtaaattttgtgctacaggcgacattggattgaaaaaaaacctaactgtagatgagataacagatcaagttttatacttccatttattaggtcatcaaattgatagcatttcttttatgggaatgggtgaagctctagccaaccgtcaagtatttgatgctcttgattcgtttacggatcctaatttatttgcattaagtcctcgtagactttctatatcaacgattggtattatacctagtatcaaaaaaataacccaggaatatcctcaagtaaatcttacattttcattacactcaccttatagtgaggaacgcagcaaattgatgccaataaatgatagatacccaatagatgaggtaatgaatatactcgatgaacatataagattaacttcaaggaaagtatatatagattatatcatgttgcctggtgtaaatgattctcttgagcatgcaaacgaagttgttagccttcttaaaagtcgctataaatcagggaagttatatcatgtaaatttgatacgatacaatcctacaataagtgcacctgagatgtatggagaagcaaacgaagggcaggtagaagccttttacaaagttttgaagtctgctggtatccatgtcacaattagaagtcaatttgggattgatattgacgctgcttgtggtcaattatatggtaattatcaaaatagccaatag,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Multi-drug_resistance,MEG_1681,Drugs,MEG_1681|Drugs|Multi-drug_resistance|MDR_23S_ribosomal_RNA_methyltransferase|CFRA,695269285|WP_032491462.1|NG_047632|1|1|cfr|cfr|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr NG_047632:101-1150,1
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgattagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgacgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6676,Drugs,MEG_6676|Drugs|betalactams|Class_A_betalactamases|TEM,920081298|WP_052944427.1|NG_050261|1|1|blaTEM-32|blaTEM|inhibitor-resistant_class_A_broad-spectrum_beta-lactamase_TEM-32 NG_050261:101-961,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttgacattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcaccacgcgcacctggttttgtagcgcatatatcacgaatacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtacccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggggttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5907,Drugs,MEG_5907|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1049330928|WP_065825703.1|NG_051323|1|1|qnrB80|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB80 NG_051323:1-645,3
,ATCTTATAAGTCTTATGAACATTAAAACACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGTACACACTAAGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTGCAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCGGTTCACTTTTACCATTTTGATCTGGGCCATTGCCTATTTTCAAAACTGATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5231,Drugs,MEG_5231|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389151|gb|KF986258.1|1-907,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1390,Drugs,MEG_1390|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_32_JINH01000005,0
,ATGAATTATCAAATTGTGAATATTGCGGAATGCAGCAATTATCAGTTAGAAGCAGCAAATATACTAACAGAAGCGTTCAATGATCTTGGTAACAATTCATGGCCAGATATGACGAGTGCAACAAAAGAAGTAAAAGAATGTATTGAGAGTCCAAACCTTTGTTTCGGTCTGCTAATAAATAACTCCTTAGTTGGCTGGATAGGCTTAAGGCCAATGTACAAGGAAACGTGGGAATTGCATCCATTGGTTGTCAGACCAGATTATCAAAATAAAGGTATTGGCAAGATCCTGCTTAAGGAATTAGAAAACAGAGCTAGAGAGCAAGGTATTATTGGAATCGCTTTAGGAACAGATGATGAATACTATAGAACAAGTCTCTCTTTAATAACTATAACAGAAGATAATATATTTGATTCAATAAAAAATATTAAAAATATTAATAAACATCCATATGAGTTTTATCAGAAGAATGGTTATTATATTGTTGGAATAATTCCAAATGCCAATGGTAAAAACAAACCAGATATTTGGATGTGGAAAAGTTTAATCAAAGAGTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_337,Drugs,MEG_337|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|155023|gb|M86913.1|TRNTN21CAS|2775-3332,2
,atgacgaattattttgagagtcccttcaaagggaagcttctgactgagcaggtgaagaatccgaacatcaaggtagggcggtatagctactattccggctattaccatgggcactcgtttgatgattgtgctcgctaccttctaccagaccgtgatgacgttgatcagctgattatcggcagcttctgctccatcggatcaggcgcagcttttattatggctgggaatcaaggccaccgatatgattgggtctcttctttccctttcttctacatgaacgaggagcccgcgtttgcaaaatcagtcgatgcattccagcgggctggcgacacagttataggaagtgatgtgtggatcggttcggaggccatgatcatgcccgggatcaagatcgggcatggagcggtgataggtagccgcgctttggttgccaaagacgtggaaccctacaccatagtggggggaaaccctgcaaagtcgattaggaagcgcttttctgaagaagaaatttctatgcttttagatatggcttggtgggattggccgctggaacaaatcaaggaagcaatgccttttctttgttcgtctggcattgccagcctgtatcgtcgctggcaaggcacaagcgcctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1618,Drugs,MEG_1618|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,501453942|WP_012477387.1|NG_047602|1|1|catB2|catB2|type_B-2_chloramphenicol_O-acetyltransferase_CatB2 NG_047602:101-733,6
,ATGGAAAAAAACAGAAAAAAACAAATCGTAGTTTTGAGTATAGCTTTAGTTTGCATTTTCATCTTGGTATTTTCATTGTTCCATAAATCAGCGACAAAAGGTAGCGCAAATCCTCCTTTAACAAATGTTTTGACTGATAGCATTTCTCAAATTGTCTCAGCTTGTCCTGGCGAAATTGGTGTGGCGGTTATTGTTAATAACAGAGATACGGTTAAGGTCAATAATAAGAGTGTTTATCCTATGATGAGTGTGTTTAAGGTTCATCAGGCATTAGCTCTTTGTAATGACTTTGACAATAAAGGAATTTCACTTGATACCTTAGTAAATATAAATAGGGATAAACTTGACCCAAAGACTTGGAGTCCTATGCTGAAAGATTATTCAGGGCCAGTCATATCATTGACAGTGAGAGATTTGCTGCGTTATACTCTTACTCAGAGTGACAACAATGCAAGCAACCTTATGTTTAAGGATATGGTTAATGTCGCTCAAACAGATAGTTTTGTAGCCACACTCATTCCTCGTTCAAGTTTTCAGATAGCTTATACGGAAGAGGAAATGTCGGCTGACCATAACAAGGCTTACTCTAACTATACATCTCCTCTTGGTGCTGCAATGTTGATGAATCGTTTGTTTACTGAAGGTCTTATCGATGATGAGAAACAAAGTTTCATTAAGAATACGTTAAAAGAATGCAAAACAGGTGTAGATAGGATAGCAGCTCCACTTCTTGATAAAGAAGGGGTTGTTATAGCGCATAAGACAGGTTCAGGTTATGTTAATGAAAATGGTGTTCTTGCAGCTCACAATGATGTTGCCTATATATGTCTGCCTAATAATATCAGTTATACCTTAGCGGTATTTGTTAAGGATTTCAAGGGAAATGAATCACAAGCGTCACAATATGTTGCGCATATATCAGCTGTAGTATATTCTTTATTAATGCAAACTTCAGTAAAATCTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1691,Drugs,MEG_1691|Drugs|betalactams|Class_A_betalactamases|CFX,(Bla)cfxA2:AF504910:1-966:966,0
,CAGCAAATTTTAATTATTTCTCCATAAAAATTATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTGGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACTATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGCGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTACGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAACGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAATGAAATATGCTCAGGCTACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGTCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAATGTAAGACATTAAAATGGTTCGGAAAAAATCGAAAGATTTTATAAAGCCTATTATTTATACTTAAAAAATCCCGAATGAAAATTCGGGATTTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3428,Drugs,MEG_3428|Drugs|betalactams|Class_B_betalactamases|IND,gi|302357573|dbj|AB563173.1|1-858 gi|270266461|gb|GU186045.1|771-800,0
,ATGAGCAAGTTATTTGTATTCTTTATGTTTTTGTTTTGTAGCATTACTGCCGCAGGAGAGTCTTTGCCAGATTTAAAAATTGAGAAGCTTGACGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGTTGGGGTGTTATTCCTAAACACGGCTTGGTGGTTCTTGTAAATACTGATGCCTATCTGATAGACACTCCATTTACTGCTAAAGATACTGAAAATTTAGTTAATTGGTTTGTTGAGCGCGGCTATAGAATAAAAGGCAGTATTTCCTCACATTTCCATAGCGACAGCACGGGTGGAATAGAGTGGCTTAATTCTCAATCTATCCCCACGTATGCATCTGAATTAACAAATGAACTTCTTAAAAAAGACGGTAAGGTACAAGCTAAATATTCATTTAGCGGAGTTAGCTATTGGCTAGTTAAGAAAAAGATTGAAGTTTTTTATCCTGGTCCAGGGCACGCTCCAGATAACGTAGTGGTTTGGCTGCCTGAAAATAGAGTTTTGTTCGGTGGTTGTTTTGTTAAACCCTACGGTCTAGGTAATTTGGGTGACGCAAATTTAGAAGCTTGGCCAAAATCCGCCAAGTTATTAATGTCAAAATATAGTAAGGCAAAACTGGTTGTACCAAGTCATAGTGACATAGGAGATTCGTCGCTCTTGAAGCTTACATGGGAGCAGACGGTAAAAGGATTCAATGAAAGCAAAAAAAGTACTACTGCACATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3399,Drugs,MEG_3399|Drugs|betalactams|Class_B_betalactamases|IMP,blaIMP-9_1_FJ655384,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCAAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGTATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6409,Drugs,MEG_6409|Drugs|betalactams|Class_A_betalactamases|SHV,gi|124053914|gb|EF035563.1|1-861,0
,atgatgaaaaaatcgatatgctgcgcgctgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggtatggccgtggcgattatctacgaggagaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgaattagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctaccgctgcagatccccgatgaagttacggataaagccgcattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggcggtgaaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgttactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacgggatccacaggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatagtgatgctggcaaacaaaagctaccccaacccggctcgcgtcgaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1804,Drugs,MEG_1804|Drugs|betalactams|Class_C_betalactamases|CMY,696362634|WP_032937778.1|NG_054963|1|1|blaCMY-152|blaCMY|class_C_beta-lactamase_CMY-152 NG_054963:1-1146,0
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTCCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCACCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCAGAAAAACGTATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATCGAATTGATTCGTAGCTCTAAAAACAAGTGTGACGCTAAAGAAAACCTTATCGAAGTATACGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAACACTGATATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAAGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGACAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCGTCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATTGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAATGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5345,Drugs,MEG_5345|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|47118312|dbj|BA000033.2|1358315-1360717,3
,ATGGACATGTACTTGCCGGCAGTGCCGTTTATGCCAAACGCGCTTGGTACGACAGCGAGCACAATTCAGCTTACGCTGACAACGTACTTGGTCATGATTGGTGCCGGTCAGCTCTTGTTTGGACCGCTATCGGACCGACTGGGGCGCCGCCCCGTTCTACTGGGAGGTGGCCTCGCCTACGTTGTGGCGTCAATGGGCCTCGCTCTTACGTCATCGGCTGAAGTCTTTCTGGGGCTTCGGATTCTTCAGGCTTGTGGTGCCTCGGCGTGCCTTGTTTCCACGTTTGCAACAGTACGTGACATTTACGCAGGTCGCGAGGAAAGTAATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGCAGCGTGGCGATTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGGCAATTGCCATGGTGTTTACAGCTCGTTTTATGGGGCGTGTAATACCCAAGTGGGGCAGCCCAAGCGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTCGCAGTCCGTGTTAGGCTTTATTTCTCCAATGTGGCTAGTGGGTATTGGTGTCGCCACAGCGGTATCTGTGGCGCCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACACGGCTTGGCCGGTTGTCGTGTACTGTTTGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGCGGAGGGCTCTCGCGGCCAGGGGGAGCATGATGTGGTCGCGCTACAAAGTGCGGAAAGTACGTCAAATCCCAATCGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1770,Drugs,MEG_1770|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,gi|765098769|dbj|LC031883.1|7618-8790 gi|374095356|gb|JN651402.1|1004-2176 gi|364524682|gb|JN108884.1|1015-2187 gi|335335057|gb|HQ634775.2|4155-5327 gi|330885969|gb|HQ880268.1|1017-2189 gi|330885964|gb|HQ880266.1|1023-2195 gi|330885950|gb|HQ880261.1|1022-2194 gi|329885280|gb|JF701188.1|1530-2702 gi|308826678|emb|FQ482074.1|78323-77151 gi|300391777|gb|HM175873.1|937-2109,6
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcactgcgctcggcgctgtggcccaccagcccgttggaagaacaccgcgcagaaatgcgcgagatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgagatcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccagtggcgtttttggaagggatttacaccgtcgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcagcaggggtgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgcagaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_94,Drugs,MEG_94|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,757522614|WP_042785406.1|NG_052415|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052415:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacacccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5440,Drugs,MEG_5440|Drugs|betalactams|Class_C_betalactamases|PDC,1463920492|WP_116786834.1|NG_061620|1|1|blaPDC-304|blaPDC|class_C_beta-lactamase_PDC-304 NG_061620:1-1194,0
,ATGCAACAACGACGTGCGTTCGCGCTACTGACGCTGGGTAGCCTGCTGTTAGCCCCTTGTACCTATGCCAGCGGGGAGGCCCCGCTGACCGTCACTGTGGACGGCATTATCCAGCCGATGCTCAAGGCGTATCGGATCCCGGGGATGGCGGTCGCCGTACTGAAAGATGGCAAGGCCCACTATTTCAACTATGGGGTTGCCAACCGCGAGAGTGGTCAGCGCGTCAGCGAGCAGACCCTGTTCGAGATTGGCTCGGTCAGCAAAACCCTGACCGCGACCCTTGGCGCTTATGCAGCGGTCAAGGGAGGCTTTGAGCTGGATGACAAGGTGAGCCAGCACGCCCCCTGGCTGAAAGGTTCCGCCTTTGATGGGGTGACCATGGCCGAGCTTGCCACCTACAGTGCGGGTGGTTTGCCGCTGCAGTTCCCCGAAGAGGTGGATTCGAATGACAAGATGCGCACTTACTATCGGAGTTGGTCACCGGTTTATCCGGCGGGGACCCACCGTCAGTACGCCAATACCAGTATCGGTCTGTTCGGCTATCTGGCTGCCAACTCCCTGGGCCAGTCATTTGAGCAACTGATGAGCCAGACCCTGCTGCCCAAGCTGGGTTTGCACCACACCTATATCCAGGTGCCGGAGTCGGCCATGGCGAACTATGCCTACGGCTATTCGAAGGAAGAGAAGCCCATCCGGGTCACTCCGGGCATGCTGGCGGCCGAGGCTTACGGGATCAAGACCGGTTCGGCGGATCTGCTGAAGTTTGCCGAGGCAAACATGGGGTATCAGGGAGATGCCGCGGTAAAAAGCGCGATCGCGCTGACCCACACCGGTTTCTACTCGGTGGGAGACATGACTCAGGGGCTGGGCTGGGAGAGTTACGACTATCCCGTCACCGAGCAGGTGCTGCTGGCGGACAACTCACCAGCGGTGAGCTTCCAGGCCAATCCGGTTACGCGTTTTGCTGTGCCCAAAGCGATGGGCGAGCAGCGGCTCTATAACAAGACGGGCTCGACCGGCGGCTTTGGCGCCTATGTGGCGTTCGTGCCCGCCAGAGGGATAGCCATCGTCATGCTGGCCAATCGCAACTATCCCATCGAGGCCAGGGTGAAGGCGGCTCACGCCATCCTGAGTCAGTTGGCCGAGTGATTTCCCTTTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3045,Drugs,MEG_3045|Drugs|betalactams|Class_C_betalactamases|FOX,gi|340937393|gb|JF896803.1|1-1159,0
,atgcccgcgagcacatccgttgtgaccctgcgcctgatgaccgagcacgacctgccaatgctccacgaatggctgaaccggccgcacatcgtcgagtggtggggcggcgaggaagagcgccccagtcttgacgaagtccgcgagcactatcttccgagagtcttggctgaagaggcggttacgccgtacatcgcaatgctggacggcgaggcaattggctacgcccagtcttacgtcgcactgggaagcggcgatgggtggtgggaagacgaaactgatccgggagtacgagggattgaccagtcgctggccaaccccacacagttgagccggggcctcggaacgcagcttgtccgtgcgctcgtagagatgctgttctccaaccccgccgtgactaaaattcagaccgatcccgatcccaagaacctacgtgcaatccggtgctatgagaaggcagggtttgtacagcagaaggtcatcaccacgcccgatggccccgccgtctacatggttcaaacgcgcaacgcgttcgagagttcgcgcagtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_180,Drugs,MEG_180|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,895944069|WP_049031504.1|NG_052221|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052221:101-655,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgacctcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5545,Drugs,MEG_5545|Drugs|betalactams|Class_C_betalactamases|PDC,1393270450|WP_109791195.1|NG_057593|1|1|blaPDC-261|blaPDC|class_C_beta-lactamase_PDC-261 NG_057593:1-1194,0
,TTCTAATCGTTAAGGGATCAACTTTGGNAGAGAGTTCAAAATTGATCCTTTTTTTATAACAGGAATTCCCTATAGTGAGTCGTATTAAATTCGAGCTCGGTACCCGGGGATCCAAATTGAGTGTTGCTCTGTGGATAACTTGCAGAGTTTATTAAGTATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTTGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGGACTATTCATGTTGTTGTTATTTCGTATCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCAGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACTGCAAAAGTGCTGTCGCCCACCTGCGCTTGCGCATACCAGGCCATAAGCTCCGTGGTTCCTGGTTCTCCTTCCGCTGGAGCCCAGTGCGCATAGTCATCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2424,Drugs,MEG_2424|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695225979|ref|NG_041449.1|1-1414,0
,atgttcaaatttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7717,Drugs,MEG_7717|Drugs|betalactams|Class_B_betalactamases|VIM,1625655429|WP_136512106.1|NG_064783|1|1|blaVIM-48|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-48 NG_064783:1-801,0
,atgaacattaaagcacccttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatatatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcattataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattccccgaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtattggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4693,Drugs,MEG_4693|Drugs|betalactams|Class_D_betalactamases|OXA,1625655412|WP_136512089.1|NG_064756|1|1|blaOXA-798|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-798 NG_064756:1-825,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACAGAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGTTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGAATGTTTGAATTGATGAAGCTACCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGTTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCACGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGTTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACTAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGACTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGGTTATCCTATCAAGAACTACTACAAAAACTACTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAGCCGCCTCATTTAGTCCTTGCTGCCTTCAGTGAAGACGAGGTTTACTTGCAACCAGAAGCAGCCAAACAATGGAAACGGCTAGTCAAAGCTTTAAAGCTTGAAGACGAGATCTGCTTATTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCATTGCCCGGGTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAAGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCGGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCCCATAGTCAAATCATCGCCAGCCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACGGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7379,Drugs,MEG_7379|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC3XY_1_AY033764,5
,AGATCAAAATGGTAAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAGCTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTTTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACTGGAATAGCGGAAGCTTTCATGGCATCGCCTAGGGTCATGTCCTTTTCCCATTCTCGGAATAACCTTTTTTTACCATCCCACTTAAATACTTCTGTGGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAACAAGATCATTACCATAGCTTTGTTGAGTTTGGCCTTGTTGGATAACTAAAACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCGCTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGCTTTAATGTTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5229,Drugs,MEG_5229|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389147|gb|KF986256.1|1-867,0
,TTGACAATCATACAAATTTAATATATACTCCGCAAAAATATCAAGGATTATAAATGTCTAAAAAAAATTTTATATTAATATTTATTTTTGTTATTTTAATATCTTGTAAAAATACAGAAAAAATATCAAATGAAACTACATTAATAGATAATATATTTACTAATAGCAATGCTGAAGGAACATTAGTTATATATAATTTAAATGATGATAAATATATAATTCATAATAAAGAAAGAGCTGAACAAAGATTTTATCCAGCATCAACATTTAAAATATATAATAGTTTAATAGGCTTAAATGAAAAAGCAGTTAAAGATGTAGATGAAGTATTTTATAAATATAATGGCGAAAAAGTTTTTCTTGAATCTTGGGCTAAGGACTCTAATTTAAGATATGCAATTAAAAATTCGCAAGTACCGGCATATAAAGAATTAGCAAGAAGAATAGGTCTTAAAAAGATGAAAGAGAATATAGAAAAACTAGATTTTGGTAATAAAAGTATAGGTGATAGTGTAGATACTTTTTGGCTTGAAGGACCTTTGGAAATAAGTGCGATGGAGCAAGTTAAATTATTAACTAAATTAGCTCAAAATGAATTACCGTATCCTATAGAAATACAAAAAGCTGTTTCTGATATTACTATACTAGAGCAAACTTACAATTATACGCTTCATGGAAAAACTGGATTAGCTGATTCTAAAAACATGACAACTGAGCCTATTGGTTGGTTCGTAGGCTGGCTTGAAGAAAATGATAATATATATGTCTTTGCTTTAAATATTGATAATATCAATTCAGATGACCTTGCAAAAAGGATAAATATAGTAAAAGAAAGTTTAAAAGCATTAAATTTATTAAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5215,Drugs,MEG_5215|Drugs|betalactams|Class_D_betalactamases|OXA,gi|300687338|gb|CP002025.1|1473162-1472300 gi|158634575|gb|EU086830.1|36-898,0
,gtggacgagaaggaactgatcgagcgcgccggcggccccgtcacccgcggccggctcgtgcgcgacctcgaggcactcggcgtcggcgccggcgacaccgtcatggtgcacacccgcatgtcggcgatcggctacgtcgtgggcggcccgcagaccgtgatcgacgcgctccgcgacgccgtcggcgccgacggcaccctcatggcctactgcggctggaacgacgccccgccctacgacctcgccgagtggccccccgcgtggcgggaggccgcacgcgccgagtggcccgcctacgacccgctgctcagcgaggccgaccggggcaacggccgggtccccgaggccctgcgccaccagcccggcgcggtccgcagccggcaccccgacgcgagcttcgtcgcggtcgggccggccgcccacccgctcatggacgaccacccctgggacgacccgcacggaccggacagcccgctcgcccggctcgccggggccggcggacgggtactgctgctcggcgccccgctggacaccctgacgctgctgcaccacgcggaggcactggccgaggcccccggcaagcggttcgtcgcgtacgagcagcccgtgaccgtcggcgggcgacgggtctggcggcgcttccgcgacgtcgacaccgagaaccgaggcgtcccctacgggcgggtggtgcccgagggggtctggccgttcaccgtcatcgcccaggacatgctcgccgccgggatcggccggaccggccgggtcgccgccgccccctgccacctcttcgaggccgccgacgtggtccgcttcggcgtcgagtggatcgagagccggatggggggcgcggccggcggcgcgtga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_33,Drugs,MEG_33|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080887|WP_063840270.1|NG_047259|1|1|aac(3)-VIII|aac(3)-VIII|aminoglycoside_N-acetyltransferase_AAC(3)-VIII NG_047259:101-964,2
,atggattataagaacattaacggaaattacgataacaggaacaggagaaaatcaaaaaagaaaaaaagagtttattacagaactgtatgtatcgtgctcggtttactcatagccgttgcagcacttgggattgtgaatctgataaggggcgacaaagaaactccctcccccggcaaaaacgaggcttattctctggtagatggcgaacaaaacgagacagtcttcccctctcttgactctgctgaaaattctctttccgtaaacattacggcagcaaatgcgattgtaatcaacgctgatacaaatgagacattgtatcagaaaaaaagtacagataaaattgcgccggccagcacagctaagatgattacagccttgacggtgctggattactgttccccgaacgatgaaatgagggtgggcgcggaaattgaattgatgcatgatgattcgtcaagggcatggcttatgcagggcgataccctgaccgtcagacagctcttagttgcccttatgcttccttctggcaatgatgcggcgtatacgcttgctgtgaataccggaaagaaaattgccggagataacggcctgtcaaatgcacagtccattgatgtgttcatggataaagtaaaccaaaaggcaaaatcgcttggagcggaaaactcgaattttgtagtcccggacggatatgacgccgatgggcagtatactacggcctacgatctcgccgttattgcaaaggcatgtttggatgacccttatatttcagagatcgtggcaagctactcgtcttatgaaagatggccgaatggccgggaggtcacttacaacaatacaaacgaacttctcaatccaaacagcccgtattatcggccagaagtgatcggcctaaaaacgggaaccagcagtctcggcggtgcctgtatcgtttctgctgctgtcattaacgggaacacctatatctgtgcagtcatgggctccactgagaacgacaggttccaggacggcatcgatataattgatgcaataaaattacaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7601,Drugs,MEG_7601|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,1028100736|WP_063856871.1|NG_048522|1|1|vanY-D|vanY-D|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D NG_048522:101-1141,5
,atgaacaaaaatataaaatattctcaaaactttttaacgagtgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaatcgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggaatattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccatgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaagagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatatacgtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccgttacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2795,Drugs,MEG_2795|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,1028086180|WP_063844619.1|NG_047796|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047796:101-838,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5506,Drugs,MEG_5506|Drugs|betalactams|Class_C_betalactamases|PDC,1343491240|WP_104009856.1|NG_056419|1|1|blaPDC-227|blaPDC|class_C_beta-lactamase_PDC-227 NG_056419:1-1194,0
,atgcgttcgttcgccatatcgactgtgttggtgatgtcctcactgttagcgtcgtcaatcattgccgccccgacttttgcctcaacagcggtgaagaaggagtggcaagaaacccgtagttgggatgccatttttactcagcaccaagttgaaccgcaacaagctaaactgcaaaaaactaagctccaacaaacctcgggcgtggtagcactatggaacgaaaacaagcaacagggatataccaacaatcttaaacgtgccaatcaaggttttttacctgcatcgacctttaaaatccctaacagtctgattgcgctagatctcggtgtggtgaaggatgaacatcaagtgtttaagtgggatggtaaaagccgtgatattgccacttggaatcgtgaccacaacttgattaccgggatgaagtattcggttgtgccagtctatcaagagtttgcccgccaaattggtgaggcgcgaatgtcgaagatgatcgcctctttcgattatggtaatgagactatctcgggtaacttagatagcttttggcttgatggtggtattcggatatcggctactgagcaaattgatttcctgcgccggctttatcacaacaaggtacacgcttcagagcgcagtcaacgcatcgttaagcaagccatgctcaccgaggcgaattctgactatattatccgcgcaaaaaccggttatgcggtcagagctgagccaagcattggctggtgggttggttgggtagagctcgatgataatgtgtggttttttgcaatgaatatggatatccccgacgctgcaggtttgccattgcgtcaagccattactaaggaagtattaaaactggaacacgtaattccttag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4624,Drugs,MEG_4624|Drugs|betalactams|Class_D_betalactamases|OXA,1201190423|WP_087587943.1|NG_054957|1|1|blaOXA-552|blaOXA-548_like|OXA-548_family_class_D_beta-lactamase_OXA-552 NG_054957:1-873,0
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaaaccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttctatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattgctagaaaaatatctagcaatcataacaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4586,Drugs,MEG_4586|Drugs|betalactams|Class_D_betalactamases|OXA,919540973|WP_052858477.1|NG_057490|1|1|blaOXA-637|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-637 NG_057490:1-750,0
,atgagtattcaacattttcgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgctgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgctgccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgagatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6682,Drugs,MEG_6682|Drugs|betalactams|Class_A_betalactamases|TEM,1028110632|WP_063864910.1|NG_050264|1|1|blaTEM-35|blaTEM|inhibitor-resistant_class_A_broad-spectrum_beta-lactamase_TEM-35 NG_050264:14-874,0
,atgaaaaaattaatcatagccatcgtggttgtaatcattgttgtagcttcaagcatatttttttatgcatcaaaaaacagccaaataaacgatacactagatgccattgaagacaaaaatgttaagcaagtgttcaaagatagtacttaccaatctaaaaatgataatggcgaagtggaaatgacagaccgccctattaagatttatgacagtctaggtgtcaaagctatcaacattaaagatcgtgatatcaaaaaggtttcaaaaaacaaaaaacaagtcactgcaaaatatgaactgcaaacaaattacggcaaaattaatcgtgacgttaaattaaactttattaaagaagataaagattggaaattagattggaatcaaagtgtcatcattccaggcatgcagaaaaatcaatccatcaatattgaaccattgaaatcagaacgaggtaagattttagaccgaaataatgtagaattagccactacaggaacagcacatgaagttggcattgttcctaataatgtttcgacaagtgattacaaagcaatcgctgaaaaattagacctttcagaatcgtatattaaacaacaagctgaacaggattgggttaaagatgatacattcgtccctctcaagactgttcaaaatatgaatcaagacacaaagcgttttgttgaaaagtatcatctcacaacacaagaaacagaaagtcgacagtatccgcttgaagaagcaacaacgcacttgcttggttatgttggccctattaactcagaagaattaaagcaaaaagcatttaaaggttataaaaaagatgccatcgtcggtaaaaaaggaatcgaaaaactttacgataaagaccttcaaaataaagacggatatcgggtcacaataattgataataataaagttattgatacattaataaagaaaaagaaaaaagatggcaaagatattaaattaaccatcgattctagagtccaaaaaagtatttataacaacatgaaagatgactacggttcaggtacagctattcatccacaaacaggcgaactgttagcacttgtcagcacaccatcttacgatgtttatccatttatgaatggaatgagtgatgaagattataagaaattaacggaagatgataaagaaccacttcttaataagttccaaatcacgacatcacctggttcgactcaaaaaatattaacagctatgattggcttaaataataagactttagacgacaaaacaagttataaaattaacggaaaaggatggcaaaaagataaatcttggggtgactacaacgttacaagatatgaagttgttaatggtgatatcgatttaaaacaagctattgaatcatcagataatatcttctttgcgagagttgcacttgaattaggaagcaaaaaattcgaagaaggtatgaaacgtctaggcgttggtgaagatatcccgagtgattatccattctataatgcacaaatttcaaataagaacttagataatgaaatattgttagctgactcaggttatggacaaggcgaaatattgattaatcctgttcaaattctttcaatatatagcgcattagagaataaaggtaatgtaaatgcaccacatgtactcaaagatacgaaaaataaagtctggaagaagaacatcatttcccaggaaaatattaaattgttaacagacggcatgcaacaagtcgtgaacaaaacacatagagaagatatttatagatcatatgccaacttagttggtaaatcaggcacagctgaactcaagatgaaacaaggtgagacaggacaacaaataggttggttcatttcttataataaagataatccaaatatgatgatggctattaatgtgaaagatgtacaagataaaggtatggcaagttacaatgccaaaatatctggaaaagtgtatgacgatttatatgataacggtaagaaaacatataatattgataaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3767,Drugs,MEG_3767|Drugs|betalactams|Penicillin_binding_protein|MECA,969850952|WP_058611717.1|NG_047950|1|1|mecA1|mecA1|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA1 NG_047950:20-2017,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggaaagatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaagacgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_892,Drugs,MEG_892|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695263573|WP_032490443.1|NG_052252|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052252:101-892,2
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggctctgggcgcaggcgcttgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5699,Drugs,MEG_5699|Drugs|betalactams|Class_C_betalactamases|PDC,1343491246|WP_104009862.1|NG_056425|1|1|blaPDC-233|blaPDC|class_C_beta-lactamase_PDC-233 NG_056425:1-1194,0
,ATGAGCAAGTTATCTGTATTCTTTATATTTTTGTTTTGCAGCATTGCTACCGCAGCAGAGTCTTTGCCAGATTTAAAAATTGAAAAGCTTGATGAAGGCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGGTGGGGCGTTGTTCCTAAACATGGTTTGGTGGTTCTTGTAAATGCTGAGGCTTACCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACTTGGTTTGTGGAGCGTGGCTATAAAATAAAAGGCAGCATTTCCTCTCATTTTCATAGCGACAGCACGGGTGGAATAGAGTGGCTTAATTCTCGATCTATCCCCACGTATGCATCTGAATTAACAAATGAACTGCTTAAAAAAGACGGTAAGGTTCAAGCCACAAATTCATTTAGCGGAGTTAACTATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCGGGACACACTCCAGATAACGTAGTGGTTTGGTTGCCTGAAAGGAAAATATTATTCGGTGGTTGTTTTATTAAACCGTACGGTTTAGGCAATTTGGGTGACGCAAATATAGAAGCTTGGCCAAAGTCCGCCAAATTATTAAAGTCCAAATATGGTAAGGCAAAACTGGTTGTTCCAGGTCACAGTGAAGTTGGAGACGCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAACCATCAAAACCAAGCAACTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3398,Drugs,MEG_3398|Drugs|betalactams|Class_B_betalactamases|IMP,blaIMP-6_1_AB753460,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccacatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacttgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_891,Drugs,MEG_891|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1102724709|WP_071593205.1|NG_052031|1|1|aadA1bt|aadA1bt|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1bt NG_052031:101-892,2
,atgcccctccgactccctttgcgcgccctcggcgcggccctgtccctgttcgcgctggccggcgcccccgcccgcgcggcggttttgtgcaccgtggtggccgacgccgccgacggccgcatcgtgttccagcaaggcacgcaggcggcctgcgccgagcgctacacgcccgcctcgaccttcaagctgccgatcgcgctgatgggcgcggacgcgggcatcctgcaaggcccgcacgcgccagtctggaactaccagccgggctaccccgactggggcggcgacgcctggcgccagccgacggacccggcgcgctggatcaagtattcggtggtctggtactcacaactgaccgcccgggcgctggggcaggagcgcttccagcgctacgcctcggccttccagtacggcaacgaggacgtctcgggcgagcccggcaagcacaacggcctggacggcgcgtggatcaactcgtcgctgcgcatttcgccgctggagcaactggcgttcctgcgcaagctggtcaaccgccaattgccgctcaagcccgcggcctacgatctggccgagacgctgttcgacgccggcgaggccggcggctggcgcctgtatggcaagaccggcaccggctcgccgggcagcaacggcgtctacacgccggacaacgcctacggctggttcgtcggctgggcgcgcaaggacggccgccaactggtgttcgcgcgcctgctgcaggacgagaaagccacccggcccaatgccggcctgcgcgcccgcgacaagctgttgcgcgagtggccagccatggccgacgcgccccgccagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4602,Drugs,MEG_4602|Drugs|betalactams|Class_D_betalactamases|OXA,1625655406|WP_136512083.1|NG_064748|1|1|blaOXA-787|blaOXA-364_like|OXA-364_family_class_D_beta-lactamase_OXA-787 NG_064748:1-828,0
,atggacacaacgcaggtcacattgatacaccaaattctagttgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctccaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccaatggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_750,Drugs,MEG_750|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502163|WP_071846314.1|NG_052384|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052384:59-592,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccctggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5562,Drugs,MEG_5562|Drugs|betalactams|Class_C_betalactamases|PDC,1393270443|WP_109791188.1|NG_057586|1|1|blaPDC-254|blaPDC|class_C_beta-lactamase_PDC-254 NG_057586:1-1194,0
,atgtcgatacgaattctacttgtcgaggatgatgatcatatctgtaatacagtaagggcgtttctggctgaggcaggatatcaggtggatgcctgcacagatggaaatgaggcatacaccaagttttacgaaaacacttatcaactggttattcttgatattatgctgcccggtatgaacgggcatgaacttttgcgtgaatttcgtgcgaaaaatgatactcccattctgatgatgacagccctgtcggatgacgaaaaccaaatccgggcgtttgatgcagaggcagacgactatgtaacaaagccattcaagatgcagattttactaaagcgggtggaagccctgctgcggcgcagcggtgcgctggcaaaggaaatccgtgtcggcaggctgacacttctgccggaggatttcacggtactttgtgacggtacagagctgcccctgacacgaaaagaatttgaaatccttttgctgctggtgcagaacaaaggcagaaccttaacgcatgaaatcattttgtcacgtatatggggatatgactttgagagtgatggcagcacagtccacactcatatcaaaaatttgcgggccaagctgccggaaaatatcatcaaaaccattcgcggtgtaggataccgattggaggaatcataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7461,Drugs,MEG_7461|Drugs|Glycopeptides|VanB-type_regulator|VANRB,1028100588|WP_063856723.1|NG_048417|1|1|vanR-B|vanR-B|VanB-type_vancomycin_resistance_response_regulator_transcription_factor_VanR NG_048417:69-728,5
,ATGAAAAATAAAGCTTTAGCAATTTTAATTATATGTATTTGCCTTTTAATAGCATATAATTTTGTGAAAAAAGATGAAGTTGATAAAATATTTGATGCTATTGAATTAAGGGATTCGGAATATCTGAATGAACATGCGACATTCTTATCTAAAAGTCTTTACGACAAAGATCAGAGATATAAAAGAATGGATAAGATTGATGCTTCTCTTGGTATTAAAGAAGTGAAAGTTAGTAATGTACGACTCGTGCAAAAGAAAAAAAATAAACGTCAATATAGTGCAAATTTAAATTTTAGAACTAAATATGGTAATTTTTCTAGAGAAGGGAACTATTCTTTTGAAAAGGATGAAATAACAAAAAAATGGCTTTTGGATTGGTCACCTGAGGTTATAATACCGGGATTGACTGATAGAAATCAAATCAGTATAGAAACCTTGGAATCTTTCAGAGGGAAAATACTAGACAGAAACGGGATTGATATAGCGAAAGACGGAATTCATTACGAAGTTGGAATAGATATTAAAAATTTAAATAAAAAAAATAAGAAAAATATTTCAAAATTGTTATCAATAAGTGAATCGACACTAAATAAAAAGTTAAAACAAACATGGGTAAAAGAAGGTGTTTTTTTACCTTTAAAATCGTACATAGAGTTGGATGATGAACTTAAATTGGGTATCCAAAAATATCATTTGACGGTTAATCAAACAAAAGGTAGGGTTTATCCATTAAGAGAAGCAACAGTACATCTTTTAGGGTATGTTGGAGAAATTAATGCTGAAGAATTAAAGAATAAAAAGTTTAAGGATTATGATGAACACTCAATCGTAGGAAAAAGTGGTATCGAACTACAATATGATAAACAATTGCAAAATAAAGATGGTTATAAAGTTGTCATAACTAGTGATGATGCATTAAATAATGATGAAGATGTCTTGTTAGAAAAGAAACCAAAAAATGGACAGGACATTATATTAACAATTGATAGCAAAGTACAAAGAAGTATATATAGTCATTTAAAAGAAGATAATGGTTCAGGAGTAGCCATGAATCCTAAAACTGGTGAATTATTAGCTTTAGTTAGTTATCCTGCATATGACCCCTATGAGTTTATGTTCGGCATTTCCGACGAAAACTACAAAAAGATAGTTAATGATAAGAAAGAGCCCCTGTTAAATAAATTTCAGACAACCTCTTCCCCAGGATCTACTCAGAAATTAATAACATCTATCATAGGTTTGAAAAATGGGACTATAGACGCATCAACCAGCTACAACATAGTAACTAAGGGATGGCAGAGAAATTCTTCATGGGGAGGATATGAAGTTACAAGGTTTGAGGAAGTTAATGGAGATATTGATTTAGAAAAAGCGATAGCACATTCTGATAATATATTTTTTGCAAGAGCTACCCTCGATATGGGTTCCGAAAAATTTATTAAGGGCATGAAAGCTTTAGACATTGGGAGAAATATTCCTTCTGATTATTATTTTCAAAAAGGACAAATTGCAAATCCAGAAAGTTTAAAAAATAATTTTAAAAATGAAATATTACTAGCTGATTCAGGATATGGCCAGGGAGAAATACTTATAAGTCCAGTACAAATATTATCTATTTATAGTTCTTTAATTAATGAAGGTAAAATGATGAAACCTAAATTATTTGAAACAACAAAAGAAGATATTTGGAAAAATCATATTATTTCAAAAGATGACGTAGATATATTAACAAGAAGCATGAGAAAAGTAGTTACTGGGACACATAGATTGGATGCAGAAAGAAATTATGCACAGTTTGCTGGAAAAACTGGCACTGCAGAATTGAAAACCTCTAGAGAAGAGGGGTTAGGAGCTCAAATCGGTTGGTTTGTTGGATATGATCAAAATAATCCCAATATGATGTTAGGTATAAGTGTGAAGAATGTAGAGAATAAAGGTATGTCGAGTTATAATGCAAGAAAGTTTGCCGAGATAATGGATGAATTATATGAAAATGGAACGAAAAAATATGAAATAGATAGGTGA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3796,Drugs,MEG_3796|Drugs|betalactams|Penicillin_binding_protein|MECB,gb|AB498758|+|3738-5762|ARO:3003440|mecB [Macrococcus caseolyticus] ,0
,TAAGTCTTATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATAAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGATGGTAAAAAAAGGTTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGATGCCATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAGTTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCGGTTCACTTTTTACCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5253,Drugs,MEG_5253|Drugs|betalactams|Class_D_betalactamases|OXA,gi|88697140|gb|DQ392963.1|1-865,0
,atggctctggcactcgttggcgataaaattgacagaaaccgtttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaattccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaaatgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctttccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagctggacaactaccaggcgtcgttgctcatggagcgacttggcatcgcggtgattggtagctaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5918,Drugs,MEG_5918|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111878|WP_063866087.1|NG_050504|1|1|qnrB41|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB41 NG_050504:37-684,3
,TTATGCCGCACCCACCCCTATGGAGTCTTGATGTTAAAAGTTATTAGTAGTTTATTGGTCTACATGACCGCGTCTGTCATGGCTGTCGCAAGTCCGTTAGCCCATTCCGGGGAGCCGAGTGGTGAGTATCCGACAGTCAACGAAATTCCGGTCGGAGAGGTCCGACTTTACCAGATTGCCGATGGTGTTTGGTCGCATATCGCAACGCAGTCGTTTGATGGCGCGGTCTACCCGTCCAATGGTCTCATTGTCCGTGATGGTGATGAGTTGCTTTTGATTGATACAGCGTGGGGTGCGAAAAACACAGCGGCACTTCTCGCGGAGATTGAAAAGCAAATTGGACTTCCCGTAACGCGTGCAGTCTCCACGCACTTTCATGACGACCGCGTCGGCGGCGTTGATGTCCTTCGGGCGGCTGGGGTGGCAACGTACGCATCACCGTCGACACGCCGGCTAGCCGAGGCAGAGGGGAACGAGATTCCCACGCATTCTCTAGAAGGACTCTCATCGAGCGGGGACGCAGTGCGCTTCGGTCCAGTAGAGCTCTTCTATCCTGGTGCTGCGCATTCGACCGACAATCTGGTTGTATACGTCCCGTCAGCGAACGTGCTATACGGTGGTTGTGCCGTTCATGAGTTGTCAAGCACGTCTGCGGGGAACGTGGCCGATGCCGATCTGGCTGAATGGCCCACCTCCGTTGAGCGGATTCAAAAACACTACCCGGAAGCAGAGGTCGTCATTCCCGGGCACGGTCTACCGGGCGGTCTAGACTTGCTCCAGCACACAGCGAACGTTGTCAAAGCACACAAAAATCGCTCAGTCGCCGAGTAGCAGATGCGGCATAACAAATCGTTGGAGCGGGACTTTTGCTACGCAGGCTGCGCCTACTCCGCAAAAGCCCCTCAACTCAGGCGTTAGGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_7768,Drugs,MEG_7768|Drugs|betalactams|Class_B_betalactamases|VIM,gi|941350200|gb|KT345946.1|25770-26689 gi|930190865|emb|LN555650.1|262051-261132 gi|930189590|emb|HG530658.1|197759-196840 gi|887516996|gb|KR338351.1|1151-2070 gi|825088700|gb|KP975077.1|107369-106450 gi|821393026|gb|KP873172.1|23993-23074 gi|821392896|gb|KP873171.1|22025-21106 gi|821392896|gb|KP873171.1|20472-19556 gi|821392896|gb|KP873171.1|19558-18713 gi|768032361|gb|KM975294.1|566-1485 gi|768032333|gb|KM514484.1|566-1485 gi|742797756|emb|LK054503.1|12302-13221,0
,atgcgcgataccagattcccctgcctgtgcggcattgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5684,Drugs,MEG_5684|Drugs|betalactams|Class_C_betalactamases|PDC,730491770|WP_034028067.1|NG_049930|1|1|blaPDC-56|blaPDC|class_C_beta-lactamase_PDC-56 NG_049930:1-1194,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTAAGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTCCTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4308,Drugs,MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_14_KX620941 ,1
,ATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACCATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGTGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTATGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAACGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCAGGCTACTCTGGTAATCCCGGGACACGACGAATGGAAAGGCGGTGGCCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3405,Drugs,MEG_3405|Drugs|betalactams|Class_B_betalactamases|IND,(Bla)IND-2c:GU186042::57-788:732,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcaacctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5454,Drugs,MEG_5454|Drugs|betalactams|Class_C_betalactamases|PDC,1028110213|WP_063864583.1|NG_049932|1|1|blaPDC-58|blaPDC|class_C_beta-lactamase_PDC-58 NG_049932:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatatcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4654,Drugs,MEG_4654|Drugs|betalactams|Class_D_betalactamases|OXA,1391852922|WP_109545107.1|NG_057541|1|1|blaOXA-582|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-582 NG_057541:1-774,0
,AAGACTTTCAGTCGATCCGGAAAACAGCAAATTTTAATTATTTCTCCATAAAAATTATGAAAAAAAGTATTCAGCTTTTGATGATGTCAATGTTTTTAAGCCCATTGATCAATGCCCAGGTTAAAGATTTTGTAATTGAGCCGCCTGTTAAACCCAACCTGTATCTTTATAAAAGTTTCGGAGTTTTCGGGGGTAAAGAATATTCTGCCAATGCTGTATATCTTACCACTAAGAAAGGAGTTGTCTTATTTGATGTCCCATGGCAAAAGGAACAATATCAAACCCTTATGGACACTATACAAAAGCGTCATCACCTTCCTGTAATTGCTGTATTTGCCACCCACTCTCATGATGACAGAGCGGGCGATCTAAGCTTTTACAATCAAAAAGGAATTAAAACATATGCGACCGCCAAGACCAATGAACTGTTGAAAAAAGACGGAAAAGCAACCTCAACCGAAATTATAAAAACAGGAAAACCTTACAAAATTGGTGGTGAAGAATTTATGGTAGACTTTCTTGGAGAAGGACATACAGTTGATAATGTTGTTGTATGGTTCCCCAAATATAAAGTACTGGACGGAGGATGTCTTGTAAAAAGCAGGACAGCCACTGACCTGGGATATACCGGTGAAGCAAACGTAAAACAATGGCCGGAAACCATGCGAAAACTAAAAACGAAATATGCTCAGGCCACTCTGGTAATCCCGGGACACGAGGAATGGAAAGGCGGTGGCCATGTACAGCATACTCTGGATCTTCTGGATAAGAATAAAAAGCCGGAATAATGTAAGACATTAAAATGGTTCGGAAAAAATCGAAAGATTTTTATAAAGCCTATTATTTATACTTAAAAAATCCCGAATTTTCATTCGGGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3426,Drugs,MEG_3426|Drugs|betalactams|Class_B_betalactamases|IND,gi|300510843|gb|HM245381.1|1-878 gi|11095175|gb|AF219130.1|AF219130|1-732,0
,ATGATGGAATATCAAAACAATAATGGAAACTATGACAAAAGGAATCGTAGAAAAGCCAAAAAAAGAAAATTGCTTTTTTACAGGGCTGCATGTGTCATACTTTGTTTGCTCATTGTTTCTGTAATCTTTGGAGTTGTGCATTTTTTAGGGGAGAGTAAAGATCCCGGCATTTTATCCAAAGAAAACACAAAAACAGACAAGAACTATTCGTGGCTTACCGACGATCAGAAGGAGGCAGTACCCTCAGTTTCAGAGCCAGCCATATCCGACCAGGCTAACAAAATTTCGGTAAATATCACGGCAGCAAACGCCATTGTAATGAATAAAGACACAAATGAGGTATTGTACCAGAAAAAAAGCACAGCCCAAATTGCGCCGGCCAGCACTGCTAAGATGATTATGGCTTTGACAGCACTTGACTATTGTTCCCCGGAGGATGAAATGAAAGTAGGTGCGGAGATTGAAATGATTCAAAGCGATTCGTCAACCGCATGGCTTATGAAGGGTGATACACTGACTGTCAGACAGCTCCTGATTGCCCTTATGCTTCCATCCGGTAATGATGCAGCCTATACCCTTGCAGTCAATACTGGAAAGAAGATTGCAGGAGATAAAAGCCTGACCCATCAGCAAGCGATTGAAGTATTCATGGATAAGGTAAATGAAAAAGCCGTGGACCTTGGCGCCACAAACTCGAAATTTATAGCTCCGGATGGATATGATGCCGAAGGGCAGTATACTACAGCTTACGACCTTGCTATCATTGCAAAAGCATGTTTGGACAATCCTATCATTTCGGAGATTGTAGCGAGTTATTCATCCTATGAAAAATGGCCAAACGGAAGAGAGGTCACTTACAGCAATTCCAATGAGCTTCTCGATCCGAACAGTCCCTATTACCGTCCGGAGGTTATCGGCCTGAAAACCGGGACCAGCAGCCTTGGCGGCGCATGTATTGTTTCTGCAGCGGTGATTGACGGAGAAACCTATATCTGCGTAGTTATGGGCTCTACAAAGGAAAGCAGGTTTCAGGACAGTGTTGATATTTTAGATAAAATCAAAGCCCAGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7605,Drugs,MEG_7605|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,gi|5759260|gb|AF175293.1|AF175293|2025-3095,5
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgcgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccattacccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaatgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtgggattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7645,Drugs,MEG_7645|Drugs|betalactams|Class_A_betalactamases|VEB,1028110889|WP_063865157.1|NG_050325|1|1|blaVEB-17|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-17 NG_050325:1-900,0
,atgaagaaaaaaaatcataagtacagaggaaaaaagttaaaccgcggggaatctccgaatttttccggacagcatttgatgcataataaaaaattaattgaagaaattgtggatcgggcaaatattagcatagacgatacggttttagagttaggagcgggaaaaggggctttgacaactgtgctaagtcaaaaagccggtaaggtattggcagtggaaaacgattctaaattcgttgatatactcacacgtaaaacggcacagcattcaaatacgaaaattattcatcaagatatcatgaagattcatttaccaaaagaaaagtttgtggtggtctctaatattccctatgccatcacaacccccatcatgaaaatgcttttgaacaatcctgcaagcggatttcaaaaagggatcatcgtaatggaaaaaggggctgctaaacgtttcacatcaaaattcattaaaaattcctatgttttagcttggagaatgtggtttgatattggcattgtcagagaaatatcgaaagagcatttttctccccctccaaaagtggactcggcaatggtcagaataacacgaaaaaaagacgcgcctctatcacataaacattatattgcgtttcggggacttgccgaatacgcgctaaaggagccgaatatccctctctgtgttgctttacgcggaatttttaccccgcgtcaaatgaaacacttgagaaaaagtctaaaaatcaacaatgaaaaaaccgttggaacgctcaccgaaaaccaatgggcggtcatttttaacacgatgactcagtatgtaatgcatcacaaatggccaagagcaaataagcgaaaacccggagaaatataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2824,Drugs,MEG_2824|Drugs|MLS|23S_rRNA_methyltransferases|ERMD,647502401|WP_025811090.1|NG_047820|1|1|erm(D)|erm(D)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(D) NG_047820:101-964,7
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4433,Drugs,MEG_4433|Drugs|betalactams|Class_D_betalactamases|OXA,1028109747|WP_063864150.1|NG_049786|1|1|blaOXA-508|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-508 NG_049786:1-825,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAACCGGTAAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6694,Drugs,MEG_6694|Drugs|betalactams|Class_A_betalactamases|TEM,(Bla)TEM-24:GQ293500:4033-4893:861,0
,ATGATGAAAGGTTGGATAAAGTACGGGCTGGCCGGGGCCCTGGTGCTGGTGGCGAGTTTCTGGGGCGGCAGCGTGCATGCGGCGGCGATCTCCCTCACTCAGGTGAGCGGCCCCGTGTATGTCGTAGAGGATAACTACTACGTCAAAGAGAACTCCATGGTCTATTTCGGGGCCAAGGGGGTGACTGTGGTGGGGGCGACCTGGACGCCTGATACCGCCCGCGAGCTGCACAAGCTGATCAAACGGGTCAGCAACAAGCCTGTGCTGGAGGTGATCAACACCAACTACCACACGGACAGGGCAGGGGGGAACGCCTACTGGAAGTCCATCGGTGCCAAGGTGGTATCGACCCGCCAGACCCGGGATCTGATGAAGAGCGATTGGGCCGAGATCGTCGCCTTTACCCGCAAGGGGCTGCCGGAGTACCCGGACTTGCCGCTGGTGCTGCCGAACGTGGTGCACGACGGCGACTTTACCCTGCAAGAGGGCAAGGTTCGCGCCTTCTACTTGGGCCCGGCCCACACGCCGGACGGCATCTTTGTCTACTTTCCCGATCAGCAGGTGCTCTATGGTAACTGCATCCTCAAGGAGACGCTTGGCAACCTGAGCTTTGCCGATGTGAAGGCGTATCCGCAGACGCTGGAGCGACTCAGGGCGATGAAGCTGCCGATCAAGATTGTGGTTGGCGGTCATGACTCGCCACTGCACGGCCCAGAGCTTATCGATCACTACGAAGAGCTGATCAAGGCAAGCCCTCATTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2109,Drugs,MEG_2109|Drugs|betalactams|Class_B_betalactamases|CPHA,gi|33150463|gb|AY261376.1|1-765,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGAAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1386,Drugs,MEG_1386|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_71_NZ_CUGR01000082,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcgaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccgaagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3093,Drugs,MEG_3093|Drugs|betalactams|Class_A_betalactamases|GES,1407696517|WP_111273849.1|NG_060521|1|1|blaGES-36|blaGES|class_A_beta-lactamase_GES-36 NG_060521:1-864,0
,atgttcgctagcctgatcgcacttacgctcgccgcccagcaaatcatcgtcccgctcggcaagacgcctcgcccgatcgaacgcccgcgcgcaccgatcgagacggccggtccgctatgggccgaggcatgcggcgattccaccgattgggaccagcccgcgccgccggtgcgaatccatggcaacacctatctggtcggcacctgcggcatttccgcgatcctcgtgaccggcagcgacggccacgtcctgatcgacggcgggacagagaagggcgccgaagtgatcgccgccaatatccgcgagctcggcttcgacctgaaggacatcaagtttctcctcatcagtcatgagcatttcgaccatgtcggcgggatcgcgcagctacaaaaattgaccggcgcaacgctggtcgcgtccgccccggcagcgaaggtgatgaacagcggcctgccgggcaccgacgacccgcagtccggcatgcacccgcccttcgcccccgcgaacgtcggccgggtggtgaaggacagcgaggatgtccgcttcggcaatctgatgctgaccgcaatgaccacgcccggccatacgccgggcgcgttgagctggcgctgggagagttgcgacggcggggtttgcaggacgatggtctacgccgatagcctctcgcctgtcagccgcgacgattacaagttttccggccatccagcctatctcgccgcctaccgcgcctcgatcgccaaggtcgctgccacccgctgcgaaatcttgctcacaccgcacccttcggccagcgcgatgaaggagcgcatgaccggcaaacaggccttgttcgatgccgacggctgccgggattatgccgccgcgcttacccggcgcctcgacgagcgactggccaaggagaaagcgaaatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2123,Drugs,MEG_2123|Drugs|betalactams|Class_B_betalactamases|CRD,1509794522|WP_122630831.1|NG_062235|1|1|blaCRD3-1|blaCRD3|subclass_B3_metallo-beta-lactamase_CRD3-1 NG_062235:1-912,0
,atgaacaaaaatataaaatattctcaaaactttttaacgaatgaaaaagtactcaaccaaataataaaacaattgaatttaaaagaaaccgataccgtttacgaaattggaacaggtaaagggcatttaacgacgaaactggctaaaataagtaaacaggtaacgtctattgaattagacagtcatctattcaacttatcgtcagaaaaattaaaactgaatactcgtgtcactttaattcaccaagatattctacagtttcaattccctaacaaacagaggtataaaattgttgggagtattccttaccatttaagcacacaaattattaaaaaagtggtttttgaaagccatgcgtctgacatctatctgattgttgaagaaggattctacaagcgtaccttggatattcaccgaacactagggttgctcttgcacactcaagtctcgattcagcaattgcttaagctgccagcggaatgctttcatcctaaaccaaaagtaaacagtgtcttaataaaacttacccgccataccacagatgttccagataaatattggaagctatatacgtactttgtttcaaaatgggtcaatcgagaatatcgtcaactgtttactaaaaatcagtttcatcaagcaatgaaacacgccaaagtaaacaatttaagtaccgttacttatgagcaagtattgtctatttttaatagttatctattatttaacgggaggaaataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2789,Drugs,MEG_2789|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,1028086162|WP_063844601.1|NG_047793|1|1|erm(B)|erm(B)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B) NG_047793:101-838,7
,atgttaaaagttattagtagtttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7704,Drugs,MEG_7704|Drugs|betalactams|Class_B_betalactamases|VIM,1509794519|WP_122630828.1|NG_062231|1|1|blaVIM-53|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-53 NG_062231:1-801,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagcttgagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatctggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6230,Drugs,MEG_6230|Drugs|betalactams|Class_A_betalactamases|SHV,1442602489|WP_115196748.1|NG_062282|1|1|blaSHV-210|blaSHV|class_A_beta-lactamase_SHV-210 NG_062282:1-861,0
,atggttaaaaaatcattacgccagtttgcgctgttggccgcgacggtctttccgctgctggcaagcagcgtatcgctacaggcacaaacgctaagcgtagagcagaaacttgcggctttagagcagcgttcagggggacggcttggggtcgcgttgatagatactgcggatggttcgcaaattctctatcgtggcgatgagcgtttcgcgatgtgtagtaccagcaaagtgatggccgctgccgcggtgctaaagcaaagtgaaagtcagcacgatcttttaaatcagcgcattgagatcaaaaagggtgacctgactaactataacccgattgcggaaaaacatgtcggtgggtcgatgtcgttgtctgagctcagcgccgcggccttgcagtacagcgataacgtggcgatgaataagcttatcgctcaactgggtggcccgcagggggttaccgcgtttgcccgtaagattggggatgagacgtttcgtctcgatcgcacggaaccgacgctgaacactgcaattcccggcgatccacgcgataccacatcaccacgggctatggcacaaacgctgcgcaacctgacgctgggaaaagcgcttggtgacgctcaaagggcgcagttggtgacctggatgaaagggaatacgactggaacggccagtattcaggctggactaccggcttcgtgggtggtgggcgataaaaccggcagcggtgattacggcaccaccaacgacattgcggtgatttggccgaaagatcgtgcaccattggttttggttacctacttcacgcagcctcagcctgaggcggaaagccgtcgtgatgtattagcctcggcggcgaaaatcgtcactgagggattatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3455,Drugs,MEG_3455|Drugs|betalactams|Class_A_betalactamases|KLUC,1293382091|WP_100663667.1|NG_062249|1|1|blaKLUC-5|blaKLUC|class_A_extended-spectrum_beta-lactamase_KLUC-5 NG_062249:101-976,0
,gtgatcgccagcgcgcccacgatccgccaggccacgccggccgatgcgggcgcgtgggcgcagttgcgtctcggcctgtggactgatgccgatgatccgctggaggaactgacgcagtcgctggcagatgccgaaggtgctgtgttcttggcctgtgcggcggatggcgaggcggttggtttcgctgaagtgcgcctgcgccatgactacgtgaacggcaccgagtcttcgccggtggggttcctggagggctggtgcgtgcagccgcagtggcaaggccgcggcgtcggccgcgccctgctgacggcggtgcaggcgtggacgcgcgatgcgggctgccgcgaactggcctcggacagtcgcgtggaagacgtgcaggctcacgccgcgcatcgggcctgcggcttcgaagagaccgaacgggtcgtctatttccgcatgccgctggagccatcggcgtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_262,Drugs,MEG_262|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502159|WP_071846310.1|NG_052377|1|1|aac(6')-Iz|aac(6')-Iz|aminoglycoside_N-acetyltransferase_AAC(6')-Iz NG_052377:101-562,2
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatgctggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcatccaaagcctgatagtcagtatcgtcgggacattggcggtgacgctgttaaacggcgatacagcgtggcccgtgatttgttacgccacggcaatggcagtgctggtgtcgttggggctggcgctccttcgatcccgtgatgctgccaccgagaagtcgccagtcgtctag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2922,Drugs,MEG_2922|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,487652940|WP_001747811.1|NG_047861|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047861:101-1315,6
,atgaaaaatttacagttgggactcatcgtcctcattacaaccttcggttccgcatgtacaacaataagcccctccgtagaaacagctaaaaaccaacatcagcaaagcgcgcagcagcagatccaacaagccttcgatcaactccaaaccactggggtgattgtcattaaggacaagtatggcttacacagctacggcaatgacttgagccgtgctcagacaccctatgtaccggcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcaccgaggtgtttaaatgggatggtcaaaagcgtagtttccctgcctgggaaaaagacatgactttagggcaagccatgcaagcatctgctgttcccgtttatcaggagcttgcacggcgcattggtctagacctgatgcaaaaagaagtacagcgcattggatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacacctgttcaagaagtcctttttgtagagaagctggccaatacacaactcgcttttgagccagatgtgcaacataccgtacaagacatgttgctgattgaacaaaaaccgaattataaactctacgccaaatctggttggggcatggacctagaaccgcaagtgggctggtggacaggctgggtcgaaacagcaacaggtgaaaaagtgtattttgctttgaatatgcagatgaaaacaggaatttcagccagcgtgcgtgagcaactggtcaaacaaagtctaacagcactggggataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4672,Drugs,MEG_4672|Drugs|betalactams|Class_D_betalactamases|OXA,972002245|WP_058951457.1|NG_059327|1|1|blaOXA-652|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-652 NG_059327:101-925,0
,atgcgttattttcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagtcgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgtaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6236,Drugs,MEG_6236|Drugs|betalactams|Class_A_betalactamases|SHV,1209144264|WP_088245226.1|NG_055284|1|1|blaSHV-198|blaSHV|class_A_beta-lactamase_SHV-198 NG_055284:1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcacccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcacgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5484,Drugs,MEG_5484|Drugs|betalactams|Class_C_betalactamases|PDC,1559613015|WP_128268280.1|NG_063888|1|1|blaPDC-317|blaPDC|class_C_beta-lactamase_PDC-317 NG_063888:1-1194,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGAACAAAAAAGTTAAACAACGTCTAAAAGGACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1428,Drugs,MEG_1428|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_63_NZ_JUMX01000103,0
,atgaaagcatatttcatcgccatacttaccttattcacttgtatagctaccgtcgtccgggcgcagcaaatgtctgaacttgaaaaccggattgacagtctgctcaatggcaagaaagccaccgttggtatagccgtatggacagacaaaggagacatgctccggtataacgaccatgtacacttccccttgctcagtgtattcaaattccatgtggcactggccgtactggacaagatggataagcaaagcatcagtctggacagcattgtttccataaaggcatcccaaatgccgcccaatacctacagccccctgcggaagaagtttcccgaccaggatttcacgattacgcttagggaactgatgcaatacagcatttcccaaagcgacaacaatgcctgcgacatcttgatagaatatgcaggaggcatcaaacatatcaatgactatatccaccggttgagtatcgactccttcaacctctcggaaacagaagacggcatgcactccagcttcgaggctgtataccgcaactggagtactccttccgctatggtccgactactgagaacggctgatgaaaaagagttgttctccaacaaggagctgaaagacttcttgtggcagaccatgatagatactgaaaccggtgccaacaaactgaaaggtatgttgccagccaaaaccgtggtaggacacaagaccggctcttccgaccgcaatgccgacggtatgaaaactgcagataatgatgccggcctcgttatccttcccgacggccggaaatactacattgccgccttcgtcatggactcatacgagacggatgaggacaatgcgaacatcatcgcccgcatatcacgcatggtatatgatgcgatgagatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1636,Drugs,MEG_1636|Drugs|betalactams|Class_A_betalactamases|CBLA,492386200|WP_005827792.1|NG_047624|1|1|cblA|cblA|CblA_family_class_A_beta-lactamase NG_047624:101-991,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgtctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_579,Drugs,MEG_579|Drugs|betalactams|Class_C_betalactamases|ADC,746200996|WP_039258389.1|NG_064701|1|1|blaADC-146|blaADC|class_C_beta-lactamase_ADC-146 NG_064701:66-1217,0
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTTATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTATTAGCCAATGGTGCATCAGGTATCGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAGCAATCTTAGCTGATGAAGAAGTGTTATTACAGTTAGTTAGAGATGAATTGACTGAAATTAGAGATCGTTTCGGTGATGATCGTCGTACAGAAATTCAATTAGGTGGATTTGAAAACTTAGAGGACGAAGACTTAATTCCAGAAGAACAAATAGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTACGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGCTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3223,Drugs,MEG_3223|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|899750970|gb|CP012120.1|942104-939441 gi|743649775|gb|CP010300.1|7032-9695 gi|743624649|gb|CP010299.1|7032-9695 gi|743618732|gb|CP010298.1|7032-9695 gi|743615870|gb|CP010297.1|7032-9695 gi|743612995|gb|CP010296.1|7032-9695 gi|743602172|gb|CP010295.1|7032-9695 gi|675300911|gb|CP007499.1|7032-9695 gi|584463070|gb|CP007176.1|7032-9695 gi|479274824|emb|HF937103.1|4902-7565,3
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtatcgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2201,Drugs,MEG_2201|Drugs|betalactams|Class_A_betalactamases|CTX,1209144263|WP_088245225.1|NG_055283|1|1|blaCTX-M-204|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-204 NG_055283:1-876,0
,atgaaaaaattatttgttttatgtatctttttgttttgtagcattactgccgcaggagagtctttgcctgatttaaaaattgagaagcttgaagacggtgtttatgttcatacatcgtttgaagaagttaacggttggggtgtttttactaaacacggtttggtgtttcttgtaaacacagacgcctatctgattgacactccatttgctgctaaagacactgaaaagttagtaaattggtttgtggagcgcggttataaaataaaaggcagtatttcctcacattttcatagcgacagctcgggtggaatagaatggcttaactctcaatctattcccacgtatgcatctgaattaacaaacgaacttcttaaaaagaacggtaaggtgcaagctaaaaactcatttagcggagttagttattggctacttaaaaataaaattgaaattttttatccgggccctgggcacactcaagataatgtagtggtttggttgcctgaaaagaaaattttatttggtgggtgttttgttaaaccgtacggtcttggaaatctcgatgatgcaaatgttgaagcgtggccacattctgctgaaatattaatgtctaggtatggtaatgcaaaactggttgttccaagccatagtgacgtcggagatgcgtcgctcttgaagcttacatgggagcaggctgttaaagggctaaaagaaagtaaaaaaccatcacagccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3319,Drugs,MEG_3319|Drugs|betalactams|Class_B_betalactamases|IMP,1393270462|WP_109791207.1|NG_057606|1|1|blaIMP-74|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-74 NG_057606:1-741,0
,ttgagcgtttcgatcttacctgtgaaagaacaagacgctgccgactggctagcgctgcggaatcttctttggctcgcggatgatcacgcctcggagattgagcagtacttctctggtggatttgaggagcctgcagaagtgctcatcgcccgtgatgctaccggcgcggctgttgggcatgtcgaactctcgataagacatgacttggaagaactccaaggaatcaagaccggctacatcgaaggcctttatgtggccccaagccatcgatcaacagaccttgtgaggcgtttcttgcgtgagtccgagaagtgggccctagaacaagggtgcagcgcatttgcctcagacagaagtgatcgggtcatcacgcaccgcaagttcgcaggcagcgccgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_268,Drugs,MEG_268|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1031994774|WP_064190969.1|NG_048576|1|1|aac(6')-29b|aac(6')-29|aminoglycoside_N-acetyltransferase_AAC(6')-29b NG_048576:101-502,2
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaatgttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcagaaagggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcacagcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7110,Drugs,MEG_7110|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100160|WP_063856391.1|NG_048227|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048227:101-2020,4
,atgcgttttctgttcattctgcttgctagcactttatttactcacttagccgtagcgcaggcggcccagaagccgccgctgcgagtgagtcggttgagcgatcgggtgtttgtccatacgacttacggcatgtatcagggcgagccggtgccgtccaacgggctcattgtccgcaccgacgacggcgtggtgctgctggacacgggctgggataccgagggtaataccgacaacacccggcagctactccgctgggtggccgacagtctgcgcctccccgtccggctgtgcatcgtgacgcactcccacgacgataaagtgggcggcatcgtcgagctgcaaaaggcgggtatccgggtggtgagtacgccgctgactgcgcagaaaactgtgaaacagggctatccctcgcccgacggcatcctgcccgccgacactacgtttacgatcggcaatgtacccatccgcacttattttccgggtgaaggccatacggtcgacaacatcgtggtgtggctcccgagcgagcgcattctgcacggcggctgcttcgtcaagagtgtggcggccttcgggatgggctacgtcggcgagtcgaacctgaccgcctggagtggctcgatccggaacgtaaaaaagcgtttcggcaacgcccgcatcgtcgtgcccggccacgaagaatggactggcccgcaggcgctcgaccacacgttgcgcctattggaaaaatacaacgccaatcgtcattga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2908,Drugs,MEG_2908|Drugs|betalactams|Class_B_betalactamases|FIA,752588961|WP_041258349.1|NG_057437|1|1|blaFIA-1|blaFIA|subclass_B1_metallo-beta-lactamase_FIA-1 NG_057437:101-850,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGTGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1876,Drugs,MEG_1876|Drugs|betalactams|Class_C_betalactamases|CMY,gb|EU515250|+|0-1146|ARO:3002038|CMY-27 [Escherichia coli] ,0
,atgatgaaaaaatccctttgctgcgccctgctgctgggcctctcttgctctgctctcgccgcgccagtatcagaaaaacagctggcggaggtggtcgcgaatacgattaccccgctgatgaaagcccagtctgttccaggcatggcggtggccgttatttatcagggaaaaccgcactattacacgtttggcaaggccgatatcgcggcgaataaacccgttacgcctcagaccctgttcgagctgggttctataagtaaaaccttcaccggcgttttaggtggggatgccattgctcgcggtgaaatttcgctggacgatccggtgaccagatactggccacagctgacgggcaagcagtggcagggtattcgtatgctggatctcgccacctacaccgctggcggcctgccgctacaggtaccggatgaggtcacggataacgcctccctgctgcgcttttatcaaaactggcagccgcagtggaagcctggcacaacgcgtctttacgccaacgccagcatcggtctttttggtgcgctggcggtcaaaccttccggcatgccctatgagcaggccatgacgacgcgggtccttaagccgctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggctatcgtgacggtaaagcggtgcgcgtttcgccgggaatgctggatgcacaagcctatggcgtgaaaaccaacgtgcaggatatggcgaactgggtcatggcaaacatggcgccggaaaaggttgccgatgcctcacttaagcagggcatcgcgctggcgcagtcgcgctactggcgtatcgggtcaatgtatcagggtctgggctgggagatgctcaactggcccgtggaggccaacacggtggtcgaaggcagcgacagtaaggtagcgctggcgccgttacccgtggcagaagtgaatccaccggctcccccggtcaaagcgtcctgggtccataaaacgggttctactggcgggtttggcagctacgtggcctttattcctgaaaagcagatcggtattgtgatgctcgcgaataaaagctatccgaacccggcacgcgttgaggcggcataccatatcctcaaggcgcttcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_430,Drugs,MEG_430|Drugs|betalactams|Class_C_betalactamases|ACT,1423319031|WP_112017656.1|NG_061387|1|1|blaACT-61|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-61 NG_061387:1-1146,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGCACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTATCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAACTGACAGAGGGGTCCGGTAAATCGGACCTCCTTTCTTGCTCTTTTTTCCCTGCTGTCATCTACACTTAACAAAAAACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1968,Drugs,MEG_1968|Drugs|betalactams|Class_C_betalactamases|CMY,gi|388564859|gb|JQ733579.1|1028-2255,0
,ATGAGCGTTATCGTATCCCGGGCGCTTCCGGATGTGCGTGACGGTCTGAAGCCGGTTCACAGGCGGATTTTGTACGCAATGAATGATTTAGGCATGACCAGTGACAAACCATATAAAAAATCTGCCCGTATCGTCGGTGAAGTTATCGGTAAGTACCACCCGCACGGTGACTCAGCGGTTTACGAATCAATGGTCAGAATGGCGCAGGATTTTAACTACCGCTACATGCTTGTTGACGGACACGGCAACTTCGGTTCGGTTGACGGCGACTCAGCGGCCGCGATGCGTTACACAGAAGCGAGAATGTCAAAAATCGCAATGGAAATCCTCCGGGATATTACGAAAGATACGATTGATTATCAAGATAACTATGACGGCGCAGAAAGAGAACCTGTCGTCATGCCTTCGAGATTTCCGAATCTGCTCGTAAACGGAGCTGCCGGTATTGCGGTCGGAATGGCGACAAATATTCCTCCGCATCAGCTTGGGGAAGTCATTGAAGGCGTGCTTGCCGTAAGCGAGAATCCTGAGATTACAAACCAGGAGCTGATGGAATACATCCCGGGCCCGGATTTTCCGACTGCAGGTCAGATTTTGGGCCGGAGCGGCATCCGCAAGGCATATGAATCCGGACGGGGATCAATCACAATCCGGGCTAAGGCTGAAATCGAAGAGACATCATCGGGAAAAGAAAGAATTATTGTCACAGAACTTCCTTATCAGGTGAACAAAGCGAGATTAATTGAAAAAATCGCAGATCTTGTCCGGGACAAAAAAATCGAAGGAATTACGGATCTGCGAGACGAATCCGACCGTAACGGAATGAGAATCGTCATTGAGATCCGCCGTGACGCCAATGCTCACGTCATTTTGAATAACCTGTACAAACAAACGGCCCTGCAGACGTCTTTCGGAATCAACCTGCTGGCGCTCGTTGACGGACAGCCGAAGGTACTAAGCCTGAAACAATGTCTGGAGCATTATCTTGATCACCAAAAGGTTGTGATCCGGCGCAGAACGGCTTACGAACTCCGCAAAGCGGAAGCGAGAGCTCACATTCTGGAAGGTTTAAGAATTGCTCTCGATCATTTAGATGCCGTTATTTCTCTTATCCGCAATTCCCAGACGGCTGAAATTGCGAGAACAGGTTTGATCGAACAATTCTCACTGACTGAAAAACAAGCGCAAGCCATTCTGGATATGCGCCTTCAGCGATTAACCGGTCTGGAGCGCGAAAAGATTGAAGAGGAATATCAATCACTTGTTGCGCTTATCGCCGAGCTGAAAGATATTTTAGCCAATGAAGCAAGAGTTCTTGAGATCATTCGTGAAGAGCTCAATGAAATCAAAGAGCGTTTCAATGATGAGAGACGCACTGAAATCGTGACGTCCGGTCTTGAAACAATTGAAGATGAAGATCTTATCGAGAGAGAAAATATCGTCATCACACTGACCCATAACGGCTATGTTAAACGGCTCCCAGCGTCCACATACCGCAGCCAAAAACGGGGCGGAAAAGGCGTACAGGGAATGGGAACGAATGAAGATGACTTTGTGGAACATTTAATTTCCACATCAACGCACGATACGATCCTGTTCTTCTCTAATAAAGGGAAGGTATACCGTTCTAAAGGATATGAAATCCCTGAATACGGCCGTACGGCAAAAGGCATTCCGATTATTAACCTTCTGGAGGTTGAAAAAGGCGAATGGATTAATGCCATTATTCCGGTCAGCACGTTTGATGAGGAGCAATACCTCTTCTTTACGACCAAACAAGGGGTGTCGAAACGTACGGCACTGTCCCAGTTTGCGAATATACGGAATAACGGGCTGATCGCCCTAGGTCTCCGGGAAGACGATGAACTGATGGCCGTCCGCCTGACTGACGGCAAGAAACAAATCATCATCGGAACGAAGAACGGTTTGCTGATCCGTTTCCCTGAAGAAGATGTAAGACAAATGGGACGCACAGCTGCGGGTGTTAAAGGCATCACGCTGACAGACGATGATGTTGTGGTAGGCATGGAGATTCTTGAAGAAGACTCCCACGTCCTCATAGTGACAGAAAACGGCTACGGCAAACGCACACCGGCTTCAGAATACAGAGTTCAAAGCCGGGGCGGAAAAGGCCTTAAAACATGTAAAATCACTGACAGCAACGGTCCGTTAGTAACCGTGAAAGCAACAAAAGGCGAAGAGGACTTAATGATTATTACGGCAAGCGGCGTGTTAATCAGAATGGATATTAATGATATCTCCACTACGGGACGCGTAACACAAGGCGTCCGTCTGATCCGCATGTCTGATCAAGAGCATGTAGCCACTGTGGCGCTTGTGGAAAAGAATGAAGAAGAGCCGGAAGAAACGGAAGAAGTATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3211,Drugs,MEG_3211|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|556017688|gb|CP006845.1|7081-9462 gi|154350369|gb|CP000560.1|7081-9462,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5470,Drugs,MEG_5470|Drugs|betalactams|Class_C_betalactamases|PDC,1201190453|WP_087587973.1|NG_054994|1|1|blaPDC-209|blaPDC|class_C_beta-lactamase_PDC-209 NG_054994:1-1194,0
,CTTTTAAACCGATCGATTTATTAGTATTGGTCAGCTCAACGTATTACTACGCTTACACCTCCAACCTATCAACCTCATAGTCTATAAGGAATCTCAAGGGAATACTTATCTCTGAGGAGGCTTCCCACTTAGATGCTTTCAGCGGTTATCCTTTCCGTACTTAGCTACCCAGCTATGCTCCTGGCGGAACAACTGGAACACCAGTGGTACGTCCACTCCGGTCCTCTCGTACTAAGAGCGGCTCTCATCAATATTCCAACGCCCACATCAGATAGGGACCAAACTGTCTCACGACGTTTTGAACCCAGCTCGCGTACCGCTTTAATGGGCGAACAGCCCAACCCTTGGAACCGACTCCAGCTCCAGGATGCGATGAGCCGACATCGAGGTGCCAAACCTTGCCGTCGATGTGATCTCTTGGGCAAGATAAGCCTGTTATCCCCAGGGTAACTTTTATCCGTTGAGCGACTGCCATTCCACAATGTACAGCCGGATCACTAAGTCCTGCTTTCGCACCTGCTCGACTTGTAAGTCTCACAGTCAAGCACACTTCTACCTTTGCGCTCTACATACGGTTTCTGACCGTACTGAGTGTACCTTTGAACGCCTCCGTTACTCTTTAGGAGGCGACCGCCCCAGTCAAACTACCCGTCACGCACTGTCCACCCACCTGATGATGATGGCATGTTAGAAACTCAATATACCAAGGGTGGTATTTCAAGGATGACTCCACGAGAACTAGCGTCCTCGCTTCAAAGTCTCCCACCTATCCTACACATGTTAGACCAAGTTCCAATACGAAACTGTAGTAAAGCTCCATGGGGTCTTTTCGTCTTGATGCGGGTACCCAGCGTTTTCACTGGGACCATAATTTCACCGAGTCTAGTGTTGAGACAGTTGAGAGATCATTGCGCCTTTCGTGCAGGTCAGTATTTAGCCGACAAGGAATTTCGCTACCTTAGGACCGTTATAGTTACGGCCGCCGTTCACCCGGGCTTCATTTCAACGCTTCGCAAATGCTAACGCATCCACTTAACCTTCGGGCACTGGGCAGGCTTCACCCCCTATACATCACCTTGCGGTTTAGCAGAGAGCTGTGTTTTTGATAAACAGTTGCCCCTCATAATTTACTGTGGCCTAAGTGTTACCTTAGGCGCCCCTTCTTGCGAACTTACGGGGTCATTTTGCAGAGTTCCTTAACACTAGTTTTCTCGCTCGCCTTAGAATACTCATCTCGGGGACGTGTGTCCGTTCTCGGTACAGGTTTCCATAATATTAAGTTTAGAAGCTTTTCTTGGAAGTGTGGAATCATCTAATTCGGTTTGACCCTATGCATCACGCCTCCCGGTTATAGACTGCGGATTTGCCTACAGTCACCAGTGAACGCTTACCCCACAATCCAGTAAGTGGTAAGATTATCCTCCTCCGTCACTCCATCACTATTATAGAAAGTACAGGAATATTAACCTGTTGTCCATCGGCTACGCTTTTCAGCCTCGTCTTAGGTCCTGACTAACCCTGGGTGGACGAACCTTGCCCAGGAAACCTTCCCCAATAGGCGTCGTAGATTCTCACTACGAATCGTTACTCATACCGGCATTCTCACTTCCTAGCGCTCCACCAGTCCTCACGGTCTGACTTCATTGCCCTAGGAACGCTCCTCTAACGTAAATATAATTACCCGCGGCTTCGGTATCGTGTTTTAGTCCCGTTAAATTGTTGGCGCAAGGTCTCTTGACTAGTGAGCTATTACGCACTCTTTAAAAGGTGGCTGCTTCTGAGCCAACTTCCTAGTTGTTTATGAAACCTCACAACCTTTCTCACTTAACACGATTTTGGGACCTTAGCCGGCGATCTGGGTTGTTGCCCTCGCGAGCCGGGACGTTAGCACCCCGGTTCCGACTGCATAGCAATACATAGCGGTATTCGGAGTTTGATTATAGTCAGTACCCCTAGGCGAGGCCATTCCATATTCAGTGCTCTACCACCACTACTTAACACTACACGCTAGCCCTAAAGCTATTTCGAGGAGAACCAGCTATCTCCAAGTTCGATTGGAATTTCTCCACTATTCACAAGTCATCCGGGCACTTTTCAGCGTACTACGGTTCGGCCCTCCGCTTGGGGTTAGCCAAGTTTCAGCCTGCTCATGAATAGATCACATGGTTTCGGGTATATGACAACATACTAAGACGCCCTATTAAGACTCGATTTCTCTACGGCTCCGCTTTTTTCTGCTTAACCTCGCATGCTGTCATAACTCGCCGGTCCATACTGCAAGATGTACGCCATCACCCATAAACGGGCTCTGACTAATTGTAAGTAAGTGGTTTCAGAATCTATTTCACTCCCCTCTCGGGGTTCTTTTCACCTTTCCCTCACGGTACTAGTTCACTATCGGTGTCTGATTAGTATTTAGCCTTACCGGGTGGTCCCGGCAGATTCAGACAGGGTTCCACGTGCCCCGCCCTACTCAGGATACGATCAGAAGACTTAACAATTTCACATACGGGGGTATCACCCTCTATGCCGCTTCTTCCCAAAAGCTTCTGCTATCATTAAGTTTTGTAACTTCATGTAGATCGTCCTACAACCCCCATTGCTGGGTTTGGGCTCTTTCTCGTTCGCTCGCCGCTACTAAAGAAATCATTGTTTATTTTCTCTTCCTCTTGCTACTAAGATGTTTCAGTTCACAAGGTGTCTCACTCAAGTTCCTATGAATTCAGAACAAGGCAACTAGGCATTACCCTAGTTAGGTTTCCCCATTCGGAAATCCCCGTTTCATAGCATATTTCCGGCTCCACGAGGCTTATCGCAGGTAATCACGTCCTTCATCGACTTTCAGACCCAAGGCATCCACCACAAACTCTTCCTTATTTAAAAGTA,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3983,Drugs,MEG_3983|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NC_021002.1|-|901870-904756|ARO:3004177|Mycoplasma fermentans 23S rRNA with mutation conferring resistance to macrolide antibiotics [Mycoplasma fermentans PG18] ,7
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACACTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6622,Drugs,MEG_6622|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|1477693|gb|U57647.1|PMU57647|1422-2237 gi|1477693|gb|U57647.1|PMU57647|127-266,8
,atggttaaaaaatcactgcgtcagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggaagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgtggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgacttggttaactataatccgattgcggaaaagcacgtcgatgggacgatgtcactggttgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgatttctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcgtaatctgacgctgggtaaagcattgggtgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccaacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2214,Drugs,MEG_2214|Drugs|betalactams|Class_A_betalactamases|CTX,1028104727|WP_063859973.1|NG_048951|1|1|blaCTX-M-166|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-166 NG_048951:1-876,0
,ATGATGACAAAATCCCTAAGCTGTGCCCTGCTGCTCAGCGTCGCCAGCGCTGCATTCGCCGCACCGATGTCCGAAAAACAGCTGGCTGAGGTGGTGGAACGTACCGTTACGCCGCTGATGAACGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTCAGCCACACTACTTTACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCCGTCACCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGCGTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCCGGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTCGCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTGCCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGTACCACGCGTCTTTACGCTAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTTAAACCTTCCGGCATGAGCTATGAGCAGGCCATGACGACGCGGGTCTTTAAACCCCTCAAGCTGGACCATACCTGGATTAACGTCCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGTGAGGGTAAAGCGGTCCACGTTTCGCCAGGGATGCTGGACGCGGAAGCCTATGGCGTAAAAACTAACGTGAAGGATATGGCGAGCTGGCTGATAGCCAACATGAAGCCGGATTCTCTTCAGGCTCCCTCACTCAAGCAAGGCATTGCTCTGGCGCAGTCTCGCTACTGGCGCGTGGGGGCTATGTATCAGGGGCTGGGCTGGGAGATGCTCAACTGGCCGGTCGATGCCAAAACCGTCGTCGGAGGCAGTGATAACAAGGTGGCGCTGGCACCATTGCCCGTGGCAGAAGTGAATCCACCCGCGCCGCCGGTCAAAGCCTCCTGGGTCCATAAAACAGGCTCGACGGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGCATTGTGATGCTGGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCGTATCCTCGACGCGCTGCAGTAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3973,Drugs,MEG_3973|Drugs|betalactams|Class_C_betalactamases|MIR,gi|591542788|gb|KJ207200.1|547-1693,0
,atgaaccagaaaaaccctaaagacacgcaaaattttattacttctaaaaagcatgtaaaagaaatattgaatcacacgaatatcagtaaacaagacaacgtaatagaaatcggatcaggaaaaggacattttaccaaagagctagtcaaaatgagtcgatcagttattgctatagaaattgatggaggcttatgtcaagtgactaaagaagcggtaaacccctctgagaatataaaagtgattcaaacggatattctaaaattttccttcccaaaacatataaactataagatatatggtaatattccttataacatcagtacggatattgtcaaaagaattacctttgaaagtcaggctaaatatagctatcttatcgttgagaagggatttgcgaaaagattgcaaaatctgcaacgagctttgggtttactattaatggtggagatggatataaaaatgctcaaaaaagtaccaccactatattttcatcctaagccaagtgtagactctgtattgattgttcttgaacgacatcaaccattgatttcaaagaaggactacaaaaagtatcgatcttttgtttataagtgggtaaaccgtgaatatcgtgttcttttcactaaaaaccaattccgacaggctttgaagcatgcaaatgtcactaatattaataaactatcgaaggaacaatttctttctattttcaatagttacaaattgtttcactaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2783,Drugs,MEG_2783|Drugs|MLS|23S_rRNA_methyltransferases|ERMA,446994941|WP_001072197.1|NG_047791|1|1|erm(A)|erm(A)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(A) NG_047791:101-832,7
,gtggttaagcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagcgggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6239,Drugs,MEG_6239|Drugs|betalactams|Class_A_betalactamases|SHV,1509794530|WP_122630839.1|NG_062245|1|1|blaSHV-202|blaSHV|class_A_beta-lactamase_SHV-202 NG_062245:1-867,0
,atgtcacttaatgcaaaaccaagtagaataggcatcctgtttagctcttgtttagttttaatatcatttttctcacaagccaatacaaagggcatcgatgagattaaaagccttgagacagatttcaatgggaggattggtgtctacgctttggacactggctcgggtaaatcattttcgtacagagcaaatgaacgatttccattatgtagttcttttaaaggttttttagctgctgctgtattaaaaggttctcaagataatcaacttaatcttaatcagatcgtaaactatagcacaagaagtttagagttccattcccccattacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagcgacaatggtgctactaatattatccttgaacgttttatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagtttttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgatacatctacacctgcagcaataggtaagagcctggaaaaccttgctctgggtaacatacttagtgaacgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggcgcaacgcgtattcgtgctagcgtaccaagcgattgggttgttggcgataaaactggtagttgcggggcatacggtacggcaaatgattatgcagtagtgtggccaaagaaccgggctcctcttataatttctgtatacactacaaaaaaccaaaaagaagctaagcatgacgataaagtaatagcagaagcttcaagaattgcaattgacaaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3300,Drugs,MEG_3300|Drugs|betalactams|Class_A_betalactamases|IMI,1226997332|WP_094009809.1|NG_055491|1|1|blaIMI-13|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-13 NG_055491:1-879,0
,ATGAAAAAAATCGCAATCATTTTTGGAGGCAATTCACCAGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATACACAGAAAATAAAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTCCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAATTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGATGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGAAACGGCTCGTCAAAGCCTTAAAGCTTGAAAACGAGATCTGCTTGTTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCATTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAGATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7375,Drugs,MEG_7375|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC2XY_2_EU151755,5
,atgaagaaaaaaaatcataagtacagaggaaaaaagttaaaccgcggggaatatccgaatttttccggacagcatttgatgcataataaaaaattaattgaagaaattgtggatcgggcaaatattagcatagacgatacggttttagagttaggagcgggaaaaggtgctttgacaactatgctaagtcaaaaagccggtaaggtattggcagtggaaaacgattctaaattcgttgctatactcacacgtaaaacagcacagcatccaaatacgaaaattattcatcaagatatcatgaagattcatttaccaaaagaaaagtttgtggtggtctctaatattccctatgccatcacaactcccatcatgaaaatgctcttgaacaatcctgcaagcggatttcaaaaagggatcatcgtaatggaaaaaggggctgctaaacgtttcacatcaaaattcattaaaaattcctatgttttagcttggagaatgtggtttgatattggcattgtcagagaaatatcgaaagagcatttttctccccctccaaaagtggactcggcaatggtcagaataacacgaaaaaaagacgcgcctctatcacataaacattacattgcgtttcttgggcttgccgaatatgcgctaaaggagccgcaagcccctttctgtgttgctttacgcggaatttttactccgcgtcaaatgaaacacttaagaaaaagtctaaaaattaacaatgaaaaaaccgttggaacgctcaccgaaaaccaatgggcggttatttttaacacgatgactcaatatgtgatgcaccacaaatggccaagagcaaataagcgaaaacccggagaaatataa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2823,Drugs,MEG_2823|Drugs|MLS|23S_rRNA_methyltransferases|ERMD,489276093|WP_003183781.1|NG_047818|1|1|erm(D)|erm(D)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(D) NG_047818:101-964,7
,ATGCCGACGATCCACGTCTCAATAGTATCGTTCAGCAACTCTTTCGCGTACTCCGGGGGTTACATGACTGAAGAGTGCGGGGAAATTGTTTTCTGGACGCTGCGAAAAAAGTTTGTCGCCAGTAGCGACGAGATGCCGGAACACAGCTCCCAGGTAATGTATTACTCGCTGGCTATCGGTCATCACGTTGGCGTGATTGATTGTCTGAATGTCACCTTCCGCTGCCCACTGACGGAATACGAAGATTGGCTTGCACTGGTCGAAGAGGAGCAAGCCCGACGTAAGATGCTGGGGGTGATGACTTTTGGTGAGATTGTTATTGACGCCAGCCACACCGCCCTGTTGACCCGGGCATTCGCGCCACTGGCAGATGACGCGACGTCTGTGTGGCAAGCGCGTAGCATTCAATTCATTCATCTGTTGGATGAAATTGTGCTGGAACCGGCTATCTATCTGATGGCCAGAAAAATTGCGTGA,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4033,Drugs,MEG_4033|Drugs|MLS|Macrolide_phosphotransferases|MPHB,gb|AE005174.2|+|3397370-3397847|ARO:3000318|mphB [Escherichia coli O157:H7 str. EDL933] ,7
,ATGCAGTTAATATCTTTACCAAAGCAGATTTTACAGTGTGGACAGCTTCAATTAGATTTATCTCAGCCCCATGTTATGGGTATCTTAAACGTCACTCCTGATTCTTTCAGTGATGGTGGCAAACATAACCAATTAGACCAAGCGGTTGACCATGCACTTAGTATGATTGAGCAAGGCGCGACTATTATTGATATTGGGGGGGAGTCTACCCGTCCTGGTGCTTCAGAAGTTGCAGTAGAAGAAGAAGTGCGTCGTGTGGTACCTGTCGTCGAGGCTTTATCTCACCATAACGTTATTTTGTCGATCGACACGAGTCAGCCAGAAGTTATTCGCGCAGCAAAAGCAGCAGGGGCACATATCTGGAATGATGTTCGTGCCTTAACAGGTCCCAATGCTTTAAAAACTGCCGTAGAGTTAGATATACCTGTAGTAATTATGCATATGCGCGGTGAGCCAACGACAATGAATCAGTTGGATCAGTACACTGATGTAACACTCGATGTGATGCAAGAGCTGCAACAGCGTATTGATGAGGCTTTGGCTGCTGGGGTAAAAAAGCACAATATTATTGTTGATCCTGGATTTGGCTTTGCGAAAAATGCTCAGCAAAATTTAAAACTATTAAAAGAATTTTGGAAACTTAATGAACTTGGTTATCCAATTTTATCTGGCCTTTCTCGTAAACGTTTCATAGGTGAAGCTTTACAAGGCGCTCCTGCAGATCAACGTGCTGTGGGAAGTGTAACTGGGCATTTGCTTAGTATTCAGCAGGGAGCATCTATTGTAAGAGCGCATGATGTAAAGGAAATGCATGAAGCAATTTTAGTTTGGAAAGCGATGCAGCAAGCCTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2938,Drugs,MEG_2938|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|169150821|emb|CU468230.2|742749-743600,8
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggtgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgatgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6664,Drugs,MEG_6664|Drugs|betalactams|Class_A_betalactamases|TEM,1398001652|WP_110174956.1|NG_059898|1|1|blaTEM-235|blaTEM|class_A_beta-lactamase_TEM-235 NG_059898:101-961,0
,GGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATCAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6485,Drugs,MEG_6485|Drugs|betalactams|Class_A_betalactamases|SHV,gi|74422854|gb|DQ174306.1|1-865,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcgccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggtgtacctgggtagcgaggacggcgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_911,Drugs,MEG_911|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502044|WP_071846196.1|NG_052154|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052154:101-889,2
,TAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGTCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACATGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6886,Drugs,MEG_6886|Drugs|betalactams|Class_A_betalactamases|TEM,gi|209974341|gb|FJ360884.1|1-1074,0
,atggaaatcaaaaagttaagcagtgctaatattaacttatggatagcgctaagagagcagttatggccgcatcaccctgaaaatgcaaatagatctgatggcaaaaatattattctgtctgatgaattggcttcatttattgctgtagatgaggatgggctaggtattggtttcgctgatgcatccatacggaatgattatgtgaatggctgtattcatagccctgttgccttccttgaaggcatttttattgtcccatcctctcggcgtggtggtgttgccaaacagttagttgatgctgtgcaagcatgggggttagaaaagggctgtcaggagctggcgtctgataccgcattggacaacgttttatcacagcaagtccatgaagctttgggatttaaggaaactgagagagtcgtttactaccgcaaagcctcacttagctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_188,Drugs,MEG_188|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,902809117|WP_049677835.1|NG_052199|1|1|aac(6')_Yersi|aac(6')_Yersi|aminoglycoside_6'-N-acetyltransferase NG_052199:101-547,2
,atgaccgttcgacgtttttcgtgcgccctgggcgcagccctttccctgtccgcgctggcgggcgtccccgcccgcgcggcggttttgtgcaccgtggtggccgacgccgccgacggccgcatcgtgttccagcaaggcacgcaggcggcctgcgccgagcgctacacgccggcctcgaccttcaagctgccgatcgcgctgatgggcgcggacgcgggcatcctgcaaggcccgcacgcgccggtctggaactaccagccgggctaccccgactggggcggcgacgcctggcgccagccgacggacccggcgcgctggatcaagtattcggtggtctggtattcgcagctgaccgccagggcgctggggcaggagcgcttccagcgctacgcctcggccttccagtacggcaacgaggacgtctcgggcgagcccggcaagcacaacggcctggatggcgcgtggatcaactcgtcgctgcgcatttcgccgctggagcaactggcgttcctgcgcaagctggtcaaccggcaattgccgctcaagcccgcggcctacgatctggccgagacgctgttcgacgccggcgaggccggcggctggcgcctgtatggcaagaccggcaccggctcgccgggcagcaacggcgtctacacgccggacaacgcctacggctggttcgtcggctgggcgcgcaaggacggccgccagctggtgttcgcccgcctgctgcaggacgagaaggccaccaaacccaacgccggcctgcgcgcccgcgatgacctgatgcgcgactggccggccatggccgacgcgccccgccagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4548,Drugs,MEG_4548|Drugs|betalactams|Class_D_betalactamases|OXA,1028109791|WP_063864194.1|NG_049790|1|1|blaOXA-513|blaOXA-364_like|OXA-364_family_oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-513 NG_049790:1-828,0
,atggaaagaaaagggattttcattaaggttttttcctatacgatcattgtcctgctactgcttgtcggtgtaacagcaacactgtttgcacagcaatttgtgtcttatttcagagtgatggaattacagcaaacagtaaaatcctatcagccattggtggaactgattcagaatagcgataggcttgatattcaagaggtggcagggctgtttcactacaataaccaatcctttgagttttatattgaagataaagagggaagcgtactctatgccacaccaaatgccaatacatcaaatagttttagacccgactttctttatgtggtacatagagatgataatatttcgattgttgctcaaggcaaggcaggtgtgggattgctttatcaagggctgacaattcggggaattgttatgattgcgataatggttgtattcagccttttatgcgcgtatatctttgcgcggcaaatgacaacgccgatcaaagccttagcggacagtgcgaataaaatggcaaacctgaaagatgtaccgccgccgctggagcgaaaggatgagcttggcgcactggctcatgatatgcattccatgtatgtcaggctgaaagaaaccatcgcaaggctggaggatgaaatcgcaagggaacatgagttggaggaaacacagcgatatttctttgcggcagcttctcatgagctaaaaacgcccatcgcggctacaagcgttctgttggagggaatgcttgaaaatatcggtgactacaaagatcattctaagtatctgcgcgaatgcatcaaaatgatggataggcagggcaaaatcatttccgaaatactggagcttgtcagcctgaatgatgggagaatcgtacccatagctgaaccgttggacatagggcgcacggttgccgagttgctgcccgattttcaaaccttggcagaggcaaacaaccagcggttcgtcacagatattccagccgggcaaattgtcctgtccgatccgaggctgctccaaaaggcactatccaatgtcatattgaatgcagttcagaacacgccgcagggaggcgaggtacggatatggagtgagcctggtgctgaaaaatgccgcctttttgttttgaacatgggcgttcacattgatgatactgcgcttccaaggctgttcaccccattctatcgcattgatcaggcgcgaagcagaaaaagtgggcgaagcggtttaggacttgccatcgtacaaaaaacgctggatgccatgagcctccagtatgcgctggaaaacacctcggatggcgttttgttctggctggatttaccgctcacatcaacattgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7492,Drugs,MEG_7492|Drugs|Glycopeptides|VanB-type_regulator|VANSB,1028100604|WP_063856739.1|NG_048439|1|1|vanS-B|vanS-B|VanB-type_vancomycin_resistance_histidine_kinase_VanS NG_048439:101-1444,5
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcactgcgctcggcgctgtggcccacctgcccgttggaagagcaccgcgcggaaatgcgcgagatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttctggaagggatttataccgtcgaacgcgcccgccgccagggctgggccacgcgcttgatcgcacaggtgcaggaatgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaacctggactcccaacgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_95,Drugs,MEG_95|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,896196408|WP_049204401.1|NG_052192|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052192:101-541,2
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAATCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1339,Drugs,MEG_1339|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_106_FQHX01000011,0
,atgtcacttaatgtaaaaccaagtagaatagccatcttgtttatctcttgtttattttcaatatcatttttctcacaggccaatacaaagggtatcgatgagattaaaaaccttgaaacagatttcaatggtagagttggtgtctacgctttagacactggctcaggtaaatcattttcgtacaaagcaaatgaacgatttccattatgtagttctttcaaaggctttttagctgctgctgtattaaaaggctctcaagataatcaactcaatcttaatcagatcgtgaattacaatacaagaagtttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagcgacaatggtgctactaatattattcttgaacgttatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagattttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgacacatctacacctgcagcagtagctaagagcctgaaaactcttgctctgggtaacatacttagtgagcgtgaaaaggaaacctatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtactgcaaatgattatgcggtagtctggccaaagaaccgggctcctcttataatttctgtatacacaacaaaaaacgaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3307,Drugs,MEG_3307|Drugs|betalactams|Class_A_betalactamases|IMI,1028105427|WP_063860570.1|NG_049168|1|1|blaIMI-6|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-6 NG_049168:101-979,0
,ATGAAAGAAAAGGTAGTTGTTGATAAAGCGATTTCACTCTATACCGAATCATTCGGCGACCCGGCCCATGAACCCATTATTCTGATCATGGGGGCAATGTCGTCTGCGGTGTGGTGGCCTGATGAGTTTTGTTCCCAACTTGCCAAAATGGGTCGCTATGTGATCCGGTACGACCACCGTGATACCGGGAAATCAACAAGCTATGAGCCAGGTCAGGCTCCATATTCCGTTGAAGAATTAGCAGATGATGTGGTTCGCGTCATTGATGGTTATGGTCTGGAAGCTGCTCATTTAGTCGGCATGTCTTTGGGGGGATTTCTTTCCCAGCTTGTAGCTCTCAAGTATCCGAAACGTGTGAAGAGCTTGACGCTGATTGCTTCAGAACGGCTTGCAGATGCAGATCCGGATATGCCCGCTTTTGATCCTGCCATCATTGAGTATCACCAACGGGCGGAATCGCTGGATTGGTCTGATAGAGATGCTGTCGTCGCGTATCAGGTCGGAGCGTGGCGAATCAACTCAGGTACTGCGCATGCTTTTGACGCTGAGAAGATACAAAACATCGCTGAGTTAAATTTTGATCGCACTCCGAATATCCTGACAACATTCAACCACACTACTTTAGGTGGTGGCGAGAGATGGCTCGGGAGATTAAATGAGATAGCTGTACCAACTTTGATCATTCACGGCACGGAGGATCCTGTACTTCCTTATGTGCATGGGTTGGCACTGAAAGATGCGATTCGTGGTTCAAAAATGCTGACACTCGAAGGCACGGGACATGAGTTGCATCATGAAGACTGGCCGAGGATTATCCAGGCGATTAAGGGGCAAACGTCATAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5254,Drugs,MEG_5254|Drugs|betalactams|Class_D_betalactamases|OXA,gi|937637492|gb|KT334335.1|98367-97525 gi|928083869|gb|CP012682.1|75273-74431 gi|828971497|gb|CP011644.1|25581-26423 gi|743008998|gb|CP010362.1|66627-65785 gi|742999823|gb|CP010396.1|9100-8258 gi|660582341|gb|CP008800.1|52487-53329 gi|587656709|gb|KF921569.1|615-1457 gi|587656699|gb|KF921568.1|615-1457 gi|587656689|gb|KF921567.1|615-1457 gi|587656679|gb|KF921566.1|615-1457,0
,atgaagaaaaaactcgttttctgcgccctgcttctcggcgtttcatgctcagccctcgcgtcctccctgtcagaaaaagagctggcaaaggtggtgaagcgcaccgtgacgcctctgatgaaagcacagtccattccgggcatggcggtggcggtgatctatcagggccagccgcactacttcaccttcggcaaagccgatgttgctgcaaacacacccgtcacgccgcagaccttatttgagctgggctctgtcagtaaaactttcaccggagtgctgggcggcgatgccattgcccgcggcgaaatttcgcttaacgatccggtgacgaggtactggcctgaactgaccggcaagcagtggcagggcattcgcctgctggatctcgccacctacaccgccggtggcctgccgttacaggtgccggataacgtcaccgacccggccgcactgctgaacttctatcaaacgtggcagccgcagtggaaaccgggcaccacgcgcctgtatgccaattccagcatcggcctctttggggcgctggcggtcaagccctctggaatgggctttgagcaggccatgaccacgcgcgtcctgaagccgctgaagctcgatcatacctggatccaggttccgaaatccgaagagcagcattacgcctggggctatcgcgacggcaaagcggtccacgtttcaccgggtatgctggacggcgaagcctatggcgtaaaaagcaacgccgaagacatggcgagctgggtgatggtaaacatggcaccggagcgcgttcaggctacatcacttaaacagggtattgccctggcacagtcacgctactggcgcgttgggtcgatgtatcaggggctgggctgggagatgctgaactggccggtcgatggcaaaacgattatcgatggcagtgataataagatcgcgctggcagcgttacccgcgcgagaagtaaaccctccggcaccaccggttaaggcctcatgggtccataaaacgggctcaaccggtgggttcggcagctacgtggccttcattcccgagaagcaactggggatcgtgatgctggcgaacaagagctatccgaaccctgcccgggtagaagcggcttaccagatccttaacgcactgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1800,Drugs,MEG_1800|Drugs|betalactams|Class_C_betalactamases|CMY,493180650|WP_006178946.1|NG_047383|1|1|CMY2-MIR-ACT-EC|CMY2-MIR-ACT-EC|CMY2/MIR/ACT/EC_family_class_c_beta-lactamase NG_047383:101-1246,0
,GGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTAAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6867,Drugs,MEG_6867|Drugs|betalactams|Class_A_betalactamases|TEM,gi|110610032|gb|DQ679961.1|1-1118 gi|926539378|gb|CP012632.1|40436-40469 gi|909636816|emb|LN850165.1|2743-2776 gi|704486155|gb|KM083064.1|117173-117206 gi|566129968|gb|KF705206.1|16369-16402 gi|566129838|gb|KF705205.1|22199-22232 gi|356472769|gb|HQ659758.1|4038-4005 gi|353233769|emb|HE603110.1|32196-32163 gi|695224810|ref|NG_041152.1|1324-1291 gi|228480787|gb|EU935740.1|5715-5682,0
,atgaatattatgcctgtatctgaatccctgatggcagattggttgggattgagaaaactgctctggcctgatcatgacgaggcacatttacagcaaatgcagcagctacttcaacagacacaaagcttgcagctacttgcatattcagatactcaacaagcgattgccatgctggaagcatcgattcgatatgaatatgtaaatggcacgcaaacttcaccagttgcatttcttgaaggaatttatgtccttcctgattatcgacgttcaggcatcgcaacacatctgattcaacaagtagaagcatgggcaaaaccgtttggatgtactgaatttgcctcggatgcagccctcgacaatcgtattagccatgcgatgcatcaggcgcttggttttcatgaaactgaacgtgtggtttatttcaagaaacacattggctga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_119,Drugs,MEG_119|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491385602|WP_005243483.1|NG_052525|1|1|aacA-ACI3|aacA-ACI3|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052525:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgttggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5473,Drugs,MEG_5473|Drugs|betalactams|Class_C_betalactamases|PDC,1001043515|WP_061189306.1|NG_055478|1|1|blaPDC-114|blaPDC|class_C_beta-lactamase_PDC-114 NG_055478:1-1194,0
,atgcgccatgcgacaatcctcaacctgtgcggcctcgccgcttccaccctgttcttcgcgacaacatcggccttcgccacggaggcgccggcggagcgcctgaaggctctggtggacgccgccgtgcaaccggtcatgaaggccaatgatatcccgggactggccgtcgccatcactctcaagggcgaaccgcattacttcagttatggggtggcctcgaaggaggacgcccgcaaggtgacccccgagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctacgccctggcccaggacaagatgcgcctcgacgaccgcgccagccggcactggcccgccctgcagggcagccgcttcgacggtatcagcctgctcgacctcggcacctacaccgctggcggcctgccgctacagttccccgatgtggtgcagaaggatccggcgcagatccgcgactattaccgccagtggcaaccgacctacgccccgggcagccaccgccagtactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccattcgagcgcagcatggaacggcagctgttcccggcgctcggcctggagcacacctttatccgggtgcccaccgcgcagcaggggctgtacgcccagggctacggcaaggacgaccacccgctgcgggtcggacccggtccgctggacgccgaggcctacgggctgaagtccagcgctgcggacctgctgcgcttcgtcgaggccaacctgcaccccgagcgcctggagaagccctgggcgcaggccctcgacgccacccatcgcggctactacaaggtgggcgacatgacccagggcctgggctgggaagcctacgattggccgatcgacctgaagcgcctgcaggcgggcaactcggcgccgatggcgctgcaggcgcacaaggtcgccaggttgccggcgccgcaagccctggacggccagcgcctgctgaacaagaccggctccaccaacggtttcggcgcctacctggcgttcatcccgggacgcgacgtcggcctggtgatcctggccaatcgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggaacagcaggccaaggtaccgctggtgcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5431,Drugs,MEG_5431|Drugs|betalactams|Class_C_betalactamases|PDC,927333323|WP_053816671.1|NG_050824|1|1|blaPDC-151|blaPDC_var|class_C_beta-lactamase_PDC-151 NG_050824:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6436,Drugs,MEG_6436|Drugs|betalactams|Class_A_betalactamases|SHV,gi|256862159|gb|GQ389702.1|1-861,0
,atgaaaatcatgcctgtaaccgagccgttattggccgactggctgcaattaagaatattactctggcctgatcatgaagacgcgcatttactggaaatgcggcagctactcgaacaaccacatactttgcaattattaagctataacgatcagcagcaagcaattgccatgctggaagcgtctattcgatatgaatatgtaaatggtacacaaacctcacctgtggcttttctggaaggcatttatgtcttgcctgaatatcgacgttcaggtgttgctaccactttggtgcagcaagtagaagactgggcaaagcaattttcctgtaccgaatttgcttcagatgcagcaattgataatacaatcagtcatgccatgcatcgcgcgctgggttttcaggaaaccgaacgtgtggtttattttaagaaaaagatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_108,Drugs,MEG_108|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,835265496|WP_047426753.1|NG_052421|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052421:101-541,2
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGGCATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1456,Drugs,MEG_1456|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_49_CVLS01000543,0
,atggctaaaatgagaatatcaccggaattgaaaaaactgatcgaaaaataccgctgcgtaaaagatacggaaggaatgtctcctgctaaggtatataagctggtgggagaaaatgaaaacctatatttaaaaatgacggacagccggtataaagggaccacctatgatgtagaacgggaaaaggacatgatgctatggctggaaggaaagctgcctgttccaaaggtcctgcactttgaacggcatgatggctggagcaatctgctcatgagtgaggccgatggcgtcctttgctcggaagagtatgaagatgaacaaagccctgaaaagattatcgagctgtatgcggagtgcatcaggctctttcactccatcgacatatcggattgtccctatacgaatagcttagacagccgcttagccgaattggattacttactgaataacgatctggccgatgtggattgcgaaaactgggaagaagacactccatttaaagatccgcgcgagctgtatgattttttaaagacggaaaagcccgaagaggaacttgtcttttcccacggcgacctgggagacagcaacatctttgtgaaagatggcaaagtagtggctttattgattcttgggagaagcggcagggcggacaagtggtatgacattgccttctgcatccggttgatcagggaggatatcggggaagaacagtatgtcgagctattttttgacttactggggatcaagcctgattgggagaaaataaaatattatattttactggatgaattgttttag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1038,Drugs,MEG_1038|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,695269603|WP_032491780.1|NG_047421|1|1|aph(3')-IIIa|aph(3')-IIIa|aminoglycoside_O-phosphotransferase_APH(3')-IIIa NG_047421:101-895,2
,GTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGGTGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6938,Drugs,MEG_6938|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695200318|ref|NG_035427.1|1-950 gi|943457735|gb|KT818627.1|74996-74889 gi|943457735|gb|KT818627.1|136587-136480 gi|959195734|gb|CP013326.1|60879-60772 gi|959190351|gb|CP013324.1|110333-110226,0
,atgcaacaacgacgtgcgttcgcgctactgacgctgggtagcctgctgctagccccttgtacttatgccggcggggaggctccgctgaccgccgctgtggacggcattatccagccgatgctcaaggagtatcggatcccggggatggcggtcgccgtgctgaaagatggcaaggcccactatttcaactatggggttgccaaccgcgagagcggccagcgggtcaatgagcagaccctgttcgagattggctcggtcagcaagaccctgacagcgaccctcggagcctatgccgcggtcaaggggggctttgagctggatgacaaggtgagccagcacggcccttggctcaaaggttccgccttggatggtgtgaccatggccgagcttgccacctacagtgcgggtggtttgccgctgcagttccccgatgaggtagattcgaatgacaagatgcgcacttactatcagagctggtcaccggtttatccggcagggacccatcgccagtattccaaccccagcataggcctgtttggtcacctggccgcaaatagtctgggccagccatttgagcaactgatgagccagaccctgctgcccaagctgggtttgcaccacacctatatccaggtgccggagtcggccatggtgaactatgcctacggctattcgaaggaagataagcccgtccgggtcactccgggtgtgctggcggccgaggcttacgggatcaagaccggctcggcggatctgctgaagtttgtcgaggccaacatggggtatcagggagatgccgcggtaaaaagcgcaatcgcgctgacccacaccggtttctactcggtgggagaaatgacccagggattaggatgggagagttatgcctatccggtgaccgagcagacattgctggcgggcaattcaccagcggtgagcttccaggccaatccggttacgcgctttgcggtgcccaaagcgatgggcgagcagcggctctataacaagacgggctcgactggcggctttggcgcctatgtggcgttcgtgcccgccagagggatagccatcgtcatgctggccaatcgcaactatcccatcgaggccagggtgaaggcggctcacgccatcctgagtcagttgaacgagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3031,Drugs,MEG_3031|Drugs|betalactams|Class_C_betalactamases|FOX,1028105347|WP_063860496.1|NG_049101|1|1|blaFOX-13|blaFOX|cephalosporin-hydrolyzing_class_C_beta-lactamase_FOX-13 NG_049101:1-1149,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacagttgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcatagaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7651,Drugs,MEG_7651|Drugs|betalactams|Class_A_betalactamases|VEB,1559613021|WP_128268286.1|NG_063894|1|1|blaVEB-20|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-20 NG_063894:1-900,0
,ttgaacaaacagaaagcggtagaaatagcaagaaagtatggtttggaagttaaagatgagtccatcatattcaacgagtccggtttagattttctggttgcttatgcagaagacgataaaggcgaagaatgggtgctaaggtttccgagacgggacgatgtgatgccaaggacgatagtggagaagaaagcactggatcttgtaaataaatatgccacttttcaggttccagtctggtcggtttatgaaggcgatctaatagcttataaaaagttaatcggagtgccagcaggcacgattgatccggagattcaaaactatgtgtgggagatggattatgaaaatgtgcctgaacaatttcaccagacattagccaaagcgttggcttcgctacacacagttccgaaaacagaggctcttaaagtaggcctgtttgtccagacagcagaagaggcaagaaaatcgatgattgagcgtatgaaaaaggttaaagcgaagtttggcgtaggcgaatccttatggaaccgctggcaggcctgggtaaaaaatgaggaattgtggcctcagagaacaggtctgattcatggggatgttcatgctggccacacgatgattgataaagatgctaacttaacaggttttatcgactggaccgaagcaaaagtaacggatgtatcaaatgactttgttttccagtaccgggtattcggggaggcagccctggagaaactgatcaactattaccggcaagcaggtgggatttactggcctgccatgaaagagcacgtcattgaacttaatgcggcataccctgttgcgatagctgagtttgcgattatctcaggcttggaagaatatgagcagatggcgaaagaaacattggaagtgaatgaccgctag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4032,Drugs,MEG_4032|Drugs|MLS|Macrolide_phosphotransferases|MPHB,506987367|WP_016078774.1|NG_055771|1|1|mph(B)|mph(B)|Mph(B)_family_macrolide_2'-phosphotransferase NG_055771:101-1000,7
,ATGCAGGAAAAAATAGATATTACGGTTTTTGGGTGTGAGCGGGATGAAGCGGCGGTATTCCGTAAACTTTCATCTGAGTATGGCGTCACAGTTTCGCTCATCGAAGATGTCGTATCAGAGCACAATGCAAAATTAGCGGACGGATGCCAGTGTGTCAGCGTAAGCCATAAGGCGGAGCTGTCGGAGCAGCTTCTCCTTGCGCTGAAACACGCAGGAGTGAAATACATCAGTACCCGGAGCATTGGATTCAACCATATTGATATACAGGCTGCAGGTCAGTTGGGTATGGCTGTTGGCACAGTGGCATACTCACCGGGAAGCGTGGCCGATTATACCGTCATGCTGATGCTCATGCTGCTGCGCGGCACAAAGTCGGTTCTACGAGGAACCCAGAAGCAGAATTATTGTCTGAATGACTGCCGTGGAAAAGAACTGCAGGATTTGACGGTTGGCGTCCTGGGAACCGGACGAATCGGACAGGCAGTCATGGAACGCCTGGAGGGATTCGGCTGCAAGGTGTTGGCCTATGACCGAACTCACAAAGCCGGAGCAAATTATGTTTCGTTTTGTGAATTATTGAAGAGCAGCGACATTGTTACGCTGCATGTGCCTCTGGCAGAGGATACCCGCCATATGATTGGGCGCGAGCAGCTAGAGATGATGAAGAGGGAGGCACTTCTGATCAACACGGCACGGGGGGCTTTAGTGGATACGGCTGCACTGGTTGCTGCGCTGAAAGAACAAAAAATCGGCGGAGCCGCCTTAGATGTCCTGGAAGGGGAAGAAGGCATCTTTTACCATGAATGCACACAAAAAACGATAGGGCATCCTTACCTCTCCGTTTTGCAGAAAATGCCCAATGTCATTGTTACGCCGCATACGGCCTATCATACGGATCGGGTACTGGTCGATACCGTGAGCAATACCATCCGAAATTGTCTGAATTTTGAAAGGAGTCTTGGAAATGTATAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7426,Drugs,MEG_7426|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,gi|109240378|dbj|AB242319.1|3045-4016 gi|54114872|dbj|AB183866.1|1-79,5
,atgtcacgcaccggtcgactgtctgtatttttctctgccatatttcccctgttgactctgactaatatggcggaggcggcgtcccaacccccacaagtaacagtggataaattgaaaagattggaaaatgattttggagggcgaattggggtttatgctattgatactggctcaaataaaacttttggttatagagctaacgagcgttttcctctctgtagttcatttaaaggcttccttgctgcggcagtattatcgaaaagccagcagcaagagggcttactgaaccagcgaattcgctatgacaatcgagttatggagcctcattctcctgtgactgaaaaacagattacgaccggcatgacagttgccgagttgtctgctgccactctgcagtacagtgataatggagccgccaacctgttgctcgaaaagcttattggtggccctgaaggaatgacgtcgtttatgcgttccattggtgacaatgtatttcgtctggaccgatgggaactggagttgaattccgccattcctggtgatgatagagatacatcaacacccaaagctgttgcagaaagtatgcaaaagctggcatttggaaatgtgcttggattaacggagcgccaccaactgatggattggtttaaagggaatacaacaggaggagcaagaatacgtgcaagcgtacctgcaaactgggtggttggagacaaaacgggtacttgtggtgtctatggtacagccaacgattatgcagtgatctggcctgtagggcatgcgccaattgttctggctgtctatacatcaaaaccagacaaaaattccaaacacagcgatgctgttatagcagatgcatcgcgcattgttcttgaaagctttaatattgacgcattacgtatggctacaggaaagtctatcggcttctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6182,Drugs,MEG_6182|Drugs|betalactams|Class_A_betalactamases|SFC,639192161|WP_024531321.1|NG_049980|1|1|blaSFC-1|blaSFC|carbapenem-hydrolyzing_class_A_beta-lactamase_SFC-1 NG_049980:82-1011,0
,ATGTTCGTTTTAAACAAGTTCTTTACCAATTCACATTATAAAAAGATTGTACCTGTCGTATTACTTTCATGCGCGACACTGATAGGCTGTTCTAATAGTAATACGCAATCAGAATCAAATAAACAAACAAATCAAACCAATCAAGTTAAGCAAGAAAATAAACGTAATCATGCTTTTGCTAAACTTGAAAAAGAATATAACGCTAAACTTGGTATTTACGCACTGGACACAAGTACGAATCAGACTGTTGCTTACCATGCAGATGATCGTTTTGCATTTGCCTCTACATCTAAATCATTAGCAGTGGGAGCTCTTTTACGTCAGAATTCAATAGAAGCTCTTGATGAAAGAATTACGTATACACGTAAAGACCTATCTAATTATAATCCAATTACTGAAAAGCATGTGGATACAGGAATGACGTTAAAAGAACTTGCAGATGCTTCTGTTCGATATAGTGACAGTACGGCACATAATTTAATTCTTAAAAAGTTAGGTGGTCCATCCGCATTTGAAAAAATCTTGAGGGAAATGGGTGATACTGTTACTAACTCCGAGCGATTTGAACCTGAATTAAATGAAGTAAATCCAGGAGAAACACATGATACGAGTACACCAAAAGCAATCGCTAAGACGCTTCAATCTTTTACATTAGGAACTGTACTACCATCTGAGAAACGTGAACTGTTAGTAGATTGGATGAAGAGAAATACGACTGGGGATAAATTAATTCGTGCGGGTGTACCAAAAGGATGGGAAGTAGCTGATAAAACAGGTGCAGGATCTTATGGAACAAGGAATGATATCGCAATTATTTGGCCACCAAATAAAAAGCCGATTGTTCTTTCCATCCTTTCTAATCATGATAAAGAAGATGCAGAATACGATGATACACTTATTGCAGACGCTACGAAAATCGTGTTAGAAACTCTAAAGGTTACGAATAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1412,Drugs,MEG_1412|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_12_M15195,0
,atgagtaataacatatttaaaataaaaagcagtgtattgatcatcctgagtagtttggctttttcaggttgtgtttcgaagcttaatttgtatgatccagcttcatcacaaagaacaagtgaaattccgttgttgtttaattatgcgcaaactcaagccgtctttgtgacttatgacggaactcaatttaaacgctatgggaatgatttaaatagagccaagactgcgtatattccagcctctacttttaaaatgttgaatgccttaattggtttgcaacatgcgaaaacgacaaatacagaagtatttaagtggaatggtgaaaaaagatcttttcctgcttgggaaaaagatatgaccttggcaggagcaatgcaggcttccgccgtacctgtatatcaggagttggcacgacgtattggtttggatttgatgagtcaagaagtcaaacgtgttggttttggtaatacacaaattggtcaacaggtggataatttctggttggttggtccattgaaaatcaccccagagcaagaagctaaatttgcttatcaattggcaaagaaaacattgccttttgatgatgctgtacaacagcaagtcaaagatatgctttatgtcgaaagacgtggtgattccaagctctatgccaaaagtggctggggaatggatgttgagccacaagtgggttggtatacaggatggatagaacagccgaatggtcagatcaccgcttttgctttaaatatgcacatgcagacaggggatgatcctgctgaacgtaagcaactgacattaagtatcttagataaattaggcttattcttttatttgagataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4589,Drugs,MEG_4589|Drugs|betalactams|Class_D_betalactamases|OXA,947856904|WP_056517622.1|NG_062227|1|1|blaOXA-669|blaOXA-274_like|OXA-274_family_class_D_beta-lactamase_OXA-669 NG_062227:101-940,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaggtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcggtgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaaccgtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_585,Drugs,MEG_585|Drugs|betalactams|Class_C_betalactamases|ADC,1625655375|WP_136512052.1|NG_064669|1|1|blaADC-109|blaADC|class_C_beta-lactamase_ADC-109 NG_064669:101-1252,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1822,Drugs,MEG_1822|Drugs|betalactams|Class_C_betalactamases|CMY,1693892930|WP_140423307.1|NG_065422|1|1|blaCMY-164|blaCMY|class_C_beta-lactamase_CMY-164 NG_065422:1-1149,0
,atgagcaagttatctgtattctttatatttttgttttgtagcattgctaccgcagcagagcctttgccagatttaaaaattgaaaaacttgatgaaggcgtttatgttcatacttcgtttgaagaagttaacgggtggggcgttgttcctaaacatggtttggttgttcttgtagatgctgaagcttatctaattgacactccatttacggctaaagatactgaaaagttagtcacttggtttgtggaacgtggctataaaataaaaggcagtatttcctctcattttcatagtgacagcacgggcggaatagagtggcttaattctcaatccatccccacgtatgcgtctgaattaactaatgagctgcttaaaaaagacggtaaggttcaagctaaaaattcatttggcggggttaactattggctagttaaaaataaaattgaagttttttatccaggcccaggacacactccagataacctagtagtttggctgcctgaaaggaaaatattattcggtggttgttttattaaaccgtacggtctaggttatttgggtgacgcaaatttagaagcttggccaaagtccgctaaattattaatatccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagctggagacgcatcactcttgaaacttacattagagcaggcggttaaagggttaaacgaaagtaaaaaaccatcaaaactaagcaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3337,Drugs,MEG_3337|Drugs|betalactams|Class_B_betalactamases|IMP,1226997328|WP_094009805.1|NG_055477|1|1|blaIMP-59|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-59 NG_055477:1-741,0
,ATGCCGATCTTGCCTGAATTATTACGGTCATTGGCTGGAGCTGAAGCAGGCGGTGTTCACTATGGTGCTTTATTAGCTGTGTATGCTCTGATGCAGTTCATTTTTGCACCTATCCTTGGAGCGTTGAGTGACCGATTTGGACGTCGACCTGTATTAATTATTTCAATTGCTGGTGCAACGGCTGATTATCTCCTAATGGCTGCTGCTCCTTCTCTATTGTGGCTATATATTGGTCGTATTTTTGCGGGAATTACAGGTGCCAACATGGCTGTTGCAACAGCTTATGTTTCAGATATTACTCCAGCCCATGAGCGTGCAAAAAGGTTTGGTCTCCTTGGAGCTGTCTTTGGTATTGGGTTTATAGCGGGTCCGGTAATAGGTGGAGTTTTGGGTGAATGGAACTTACATGCACCGTTCTTTGCTGCTGCTTTTATGAATGGGATTAATTTAATAATGACAGCAGTCTTATTAAAAGAATCAAAACACAGCAATAAAATGACTGAGAAGGTTCAGGAGCAATCAATATTAAAGAAATTATCCTATTTGATCACTCAACCTAATATGGCTCCATTGCTTGGTATCTTTTTAATTATCACATTGGTTTCACAAGTCCCCGCAACTTTATGGGTTATCTATGGGCAGGATCGTTATGGCTGGAGTATATTTATTGCAGGTGTTTCCCTTGCTAGTTATGGAATATGCCATTCTATTGCACAGGCTTTTGCTATCGCCCCTATGGTAAAGAGGTTTGGAGAGAAAAATACGTTGTTATGTGGAATAGCTTGCGATGCAATTGGTTTACTTCTTTTATCTATTGCTGTTGAAGAATGGGTGCCTTTTGCGTTGTTACCATTGTTTGCCCTTGGTGGAGTAGCCGTTCCTGCTTTGCAAGCAATGATGTCCAGAGGTATTAGTGATGAAAGACAAGGTGAATTACAAGGGCTATTAAGCAGTTTTAATAGTCTGGGGGCTATAATTGGTCCTGTATTAGTTACTAGCCTCTATTTTATGACTCAGGCATCAGCTCCTGGAATGGTATGGGCATTAGCTGCAATACTTTATGTAATCACCCTACCCTTATTGCTTAAGTATCGCCTGAATAAATATTCTGGAGTTCCATAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_6990,Drugs,MEG_6990|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TET39,tet(39)_1_KT346360 ,4
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccacaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatctcgcaacctacactgctggcggcctgccattgcaggtgccggatgaggtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctacatgggcgccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaacacgtgtcttccagccactcaaactcaaccatacgtggattaatgtacctcccccagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtacgaagcaatatgaatccccgtgatatcaacgacaaaacacttcagcaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggcagtggcaataaaattgcactggcagcacaccctgtaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcaaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatagtgatgctggctaacaaaaactatcccaatccagcgagattcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1279,Drugs,MEG_1279|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105071|WP_063860256.1|NG_049083|1|1|blaEC-18|blaEC|class_C_extended-spectrum_beta-lactamase_EC-18 NG_049083:101-1234,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccagcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2163,Drugs,MEG_2163|Drugs|betalactams|Class_A_betalactamases|CTX,1343491231|WP_104009847.1|NG_056408|1|1|blaCTX-M-178|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-178 NG_056408:1-876,0
,GGGCGAATTGAATTTAGCGGCCGCGAATTCGCCCTTGTATGGATCCTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGAATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTAGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCAGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAGTAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6885,Drugs,MEG_6885|Drugs|betalactams|Class_A_betalactamases|TEM,gi|20805893|gb|AF506748.1|1-899 gi|45332239|gb|AY524415.2|1-899,0
,GTGAAACCCAACATACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGGTGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCAATCTTGCTCGTCTCGCTGGCCGGCGCCACTGTCGACTACGCCATCATGGCGACAGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGCTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACAAAGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCGCTTCGTTCCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCCTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATGTTGTCCAGGCAGGTGGATGAGGAACGTCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7033,Drugs,MEG_7033|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|984658883|dbj|LC121523.1|5455-4256 gi|961494512|gb|KT950741.1|13358-14557 gi|961494501|gb|KT950740.1|12725-13924 gi|788321380|gb|KM116512.1|8110-9309 gi|788321347|gb|KM116511.1|7931-9130 gi|788321324|gb|KM116510.1|7982-9181 gi|788321306|gb|KM116509.1|7890-9089 gi|788321290|gb|KM116508.1|7888-9087 gi|788321263|gb|KM116507.1|8082-9281 gi|788321242|gb|KM116506.1|7917-9116,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtctcgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5604,Drugs,MEG_5604|Drugs|betalactams|Class_C_betalactamases|PDC,1028110206|WP_063864576.1|NG_049898|1|1|blaPDC-25|blaPDC|class_C_beta-lactamase_PDC-25 NG_049898:1-1194,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcatgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5693,Drugs,MEG_5693|Drugs|betalactams|Class_C_betalactamases|PDC,553777894|WP_023109643.1|NG_055486|1|1|blaPDC-122|blaPDC|class_C_beta-lactamase_PDC-122 NG_055486:1-1194,0
,ATGCTAAATTTAACCGTTTGTCAGGCACTGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCCCTTTGCTGCGCCCTGCTGCTCGGCATTTCTTGCTCTGCTCTCGCCACGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCTGTTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGAAAACCGCACTATTACACGTTTGGCAAGGCCGATATCGCGGCGAATAAACCCGTTACGCCTCAGACCCTGTTCGAGCTGGGTTCTATAAGTAAAACCTTCACCGGCGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTGACGGGCAAGCAGTGGCAGGGTATTCGTATGCTGGATCTCGCCACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAACGCCTCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGTCTGGCACAACGCGTCTTTACGCCAACGCCAGCATCGGTCTTTTTGGTGCGCTGGCGGTCAAACCTTCTGGCATGCCCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTGCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGTATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAACGTTGCTGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGGTCGAGGGCAGCGACAGTAAGGTAGCGCTGGCGCCGTTGCCCGTGGTAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACGTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATACAAGCTATCCGAACCCGGCACGTGTTGAGGCGGCATACCATATCCTCGAGGCGCTACAGTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_487,Drugs,MEG_487|Drugs|betalactams|Class_C_betalactamases|ACT,gi|407731538|gb|JX440356.1|653-1899,0
,TTGATTTATAAAAATTACAACTGTAATATCGGAGGGTTTATTTTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAACCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAGCAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1408,Drugs,MEG_1408|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_78_KU607301,0
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctcagcgcaatccccactgttaaaagagcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctgggctccgataatgaaagcgtatcagggagacgagtttagtgttccagtgcagcaactgctgcaatactcggtctcggacagcgataacgtggcctgtgatttgttatttgaactggttggtggaccagctgctttgcatgactatatccagtctatgggtataaaggagaccgctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaaaggtgctgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccaccacaggaccagagcggttaaaaggtttgttaccagctggtactgtggtcgcacataaaactggtacttcgggtatcaaagccggaaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggttgctcagactgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5758,Drugs,MEG_5758|Drugs|betalactams|Class_A_betalactamases|PER,447023496|WP_001100752.1|NG_059319|1|1|blaPER-10|blaPER|class_A_extended-spectrum_beta-lactamase_PER-10 NG_059319:101-1027,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgcttccagatcgtgaggacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcagcatgactgggcatcatccttccccttcttctatatgcaagaggagcctgctttctcaagagcactcgacgccttccaaagagcaggtgataccgtcattggcaatgatgtctggataggctcggaggcaatgattatgcctggcatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagagccttatgccatcatcgggggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactagataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1604,Drugs,MEG_1604|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1028084263|WP_063843231.1|NG_047618|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_047618:101-733,6
,atgagtaagttgaaaatcgcaattatcttcggaggctgttccgaagaacatcccgtctccgttaaatctgctggggaggtggccaaaaacctggatctcgaaaagtatgaacccttctatatcgggattacgaaagatggggtttggcagctttgtcactaccctgaggccaattgggaaaagggcagttgccgtccggctatcctgtcaccggacagaagcgtccagggattgcttgttctggagcaggggcaataccaaaggatccccttggatctggtgtttcccgttctgcatggcaaatttggcgaggatggcgcgatacagggtttgttggagctttccggcatcccctatgtgggctgcgatatcccgagttcggctctgtgcatggacaaatccctggcttatatcgtcgctggaaaggcaggaattgccacgccaaagttccggacggtcactgcgaaggagactattgacgccgaacggcttgcttatcccgtttatgtcaagccggcccgttcgggttcatccttcggcgtcactaaggtatgccgccaagaagaattgctgagtgcggtggaaatcgccagacagtatgactcgaaggtgctgattgaagaggctgtcgtcggcagcgaggtaggctgtgcgatatttggaaacgatctggatttgatggccggtgaggtcgatcagatctgtctgtctcatggctttttcagaatccatcaggagaatgagccggaaaagggttccgaaaactcaacactaatcgttcccgccgacatttccccagaggcgcgctcgcgggttcaggagacggcaaaagccatctatcgcgctttgggctgcaggggactggcgcgggtggatatgtttctgaaagaagatggaacagtaatcctcaacgaggtgaatactttgcccggcatgacctcatacagccgttttccgagaatgatggcggccgcaggcttgccctttgccgaagtgatcgaccggcttgtctcgttggccttttaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7441,Drugs,MEG_7441|Drugs|Glycopeptides|VanI-type_resistance_protein|VANI,506423864|WP_015943583.1|NG_050602|1|1|vanI|vanI|D-alanine--(R)-lactate_ligase_VanI NG_050602:101-1126,5
,CCACGAGTATGTGGTTATGCGTCATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACAAGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTTACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6469,Drugs,MEG_6469|Drugs|betalactams|Class_A_betalactamases|SHV,gi|666914763|gb|KJ776406.1|1-877,0
,ATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAAATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1061,Drugs,MEG_1061|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,(AGly)Aph3-Ia:HQ840942:23569-24384:816,2
,ATGGCTGAATTACCTCAATCAAGAATAAATGAACGAAATATTACCAGTGAAATGCGTGAATCATTTTTAGATTATGCGATGAGTGTTATCGTTGCTCGTGCATTGCCAGATGTTCGTGACGGTTTAAAACCAGTACATCGTCGTATACTATATGGATTAAATGAACAAGGTATGACACCGGATAAATCATATAAAAAATCAGCACGTATCGTTGGTGACGTAATGGGTAAATATCACCCTCATGGTGACTCATCTATTTATGAAGCAATGGTACGTATGGCTCAAGATTTCAGTTATCGTTATCCGCTTGTTGATGGCCAAGGTAACTTTGGTTCAATGGATGGAGATGGCGCAGCAGCAATGCGTTATACTGAAGCGCGTATGACTAAAATCACACTTGAACTGTTACGTGATATTAATAAAGATACAATAGATTTTATCGATAACTATGATGGTAATGAAAGAGAGCCGTCAGTCTTACCTGCTCGATTCCCTAACTTGTTAGCCAATGGAGCATCAGGTATAGCGGTAGGTATGGCAACGAATATTCCACCACATAACTTAACAGAATTAATCAATGGTGTACTTAGCTTAAGTAAGAACCCTGATATTTCAATTGCTGAGTTAATGGAGGATATTGAAGGTCCTGATTTCCCAACTGCTGGACTTATTTTAGGTAAGAGTGGTATTAGACGTGCATATGAAACAGGTCGTGGTTCAATTCAAATGCGTTCTCGTGCAGTTATTGAAGAACGTGGAGGCGGACGTCAACGTATTGTTGTCACTGAAATTCCTTTCCAAGTGAATAAGGCTCGTATGATTGAAAAAATTGCAGAGCTCGTTCGTGACAAGAAAATTGACGGTATCACTGATTTACGTGATGAAACAAGTTTACGTACTGGTGTGCGTGTCGTTATTGATGTGCGTAAGGATGCAAATGCTAGTGTCATTTTAAATAACTTATACAAACAAACACCTCTTCAAACATCATTTGGTGTGAATATGATTGCACTTGTAAATGGTAGACCGAAGCTTATTAATTTAAAAGAAGCGTTGGTACATTATTTAGAGCATCAAAAGACAGTTGTTAGAAGACGTACGCAATACAACTTACGTAAAGCTAAAGATCGTGCCCACATTTTAGAAGGATTACGTATCGCACTTGACCATATCGATGAAATTATTTCAACGATTCGTGAGTCAGATACAGATAAAGTTGCAATGGAAAGCTTGCAACAACGCTTCAAACTTTCTGAAAAACAAGCTCAAGCTATTTTAGACATGCGTTTAAGACGTCTAACAGGTTTAGAGAGAGACAAAATTGAAGCTGAATATAATGAGTTATTAAATTATATTAGTGAATTAGAAACAATCTTAGCTGATGAAGAAGTATTACTACAATTAGTTAGAGATGAATTAACAGAAATTCGAGATCGTTTCGGTGATGATCGTCGTACTGAAATCCAATTAGGTGGATTTGAAGATTTAGAAGATGAAGATCTCATTCCAGAAGAACAAATTGTAATTACACTAAGCCATAATAACTACATTAAACGTTTGCCGGTATCTACATATCGTGCTCAAAACCGTGGTGGTCGTGGTGTTCAAGGTATGAATACATTGGAAGAAGATTTTGTCAGTCAATTGGTAACTTTAAGTACACATGACCATGTATTGTTCTTTACTAACAAAGGTCGTGTATACAAACTTAAAGGTTATGAAGTGCCTGAGTTATCAAGACAGTCTAAAGGTATTCCTGTAGTGAATGCTATTGAACTTGAAAATGATGAAGTCATTAGTACAATGATTGCTGTTAAAGACCTTGAAAGTGAAGACAACTTCTTAGTGTTTGCAACTAAACGTGGTGTCGTTAAACGTTCAGCATTAAGTAACTTCTCAAGAATAAATAGAAATGGTAAGATTGCGATTTCGTTCAGAGAAGATGATGAGTTAATTGCAGTTCGCTTAACAAGTGGTCAAGAAGATATCTTGATTGGTACATCACATGCATCATTAATTCGATTCCCTGAATCAACATTACGTCCTTTAGGCCGTACAGCAACGGGTGTGAAAGGTATTACACTTCGTGAAGGTGACGAAGTTGTAGGGCTTGATGTAGCTCATGCAAACAGTGTTGATGAAGTATTAGTAGTTACTGAAAATGGTTATGGTAAACGTACGCCAGTTAATGACTATCGTTTATCAAATCGTGGTGGTAAAGGTATTAAAACAGCTACGATTACTGAGCGTAATGGTAATGTTGTATGTATCACTACAGTAACTGGTGAAGAAGATTTAATGATTGTTACTAATGCAGGTGTCATTATTCGACTAGATGTTGCAGATATTTCTCAAAATGGTCGTGCAGCACAAGGTGTTCGCTTAATTCGCTTAGGTGATGATCAATTTGTTTCAACGGTTGCTAAAGTAAAAGAAGATGCAGAAGATGAAACGAATGAAGATGAGCAATCTACTTCAACTGTATCTGAAGATGGTACTGAACAACAACGTGAAGCGGTTGTAAATGATGAAACACCAGGAAATGCAATTCATACTGAAGTGATTGATTCAGAAGAAAATGATGAAGATGGACGTATTGAAGTAAGACAAGATTTCATGGATCGTGTTGAAGAAGATATACAACAATCATCAGATGAAGATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3236,Drugs,MEG_3236|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|984671414|emb|LT009690.1|6489-9158 gi|927048389|gb|CP010890.1|7005-9674 gi|925190036|gb|CP012593.1|7005-9674 gi|595636499|gb|CP007454.1|1109826-1107157 gi|262073980|gb|CP001781.1|7005-9674 gi|47118324|dbj|BA000018.3|7005-9674,3
,GTGTTATCATCTTTTTTAATGTTAAGTATAATCAGTTCATTGCTCACGATATGTGTAATTTTTTTAGTGAGAATGCTCTATATAAAATATACTCAAAATATTATGTCACATAAGATTTGGTTATTAGTGCTCGTCTCCACGTTAATTCCATTAATACCATTTTACAAAATATCGAATTTTACATTTTCAAAAGATATGATGAATCGAAATGTATCTGACACGACTTCTTCGGTTAGTCATATGTTAGATGGTCAACAATCATCTGTTACGAAAGACTTAGCAATTAATGTTAATCAGTTTGAGACCTCAAATATAACGTATATGATTCTTTTGATATGGGTATTTGGTAGTTTGTTGTGCTTATTTTATATGATTAAGGCATTCCGACAAATTGATGTTATTAAAAGTTCGTCATTGGAATCGTCATATCTTAATGAACGACTTAAAGTATGTCAAAGTAAGATGCAGTTCTACAAAAAGCATATAACAATTAGTTATAGTTCAAACATTGATAATCCGATGGTATTTGGTTTAGTGAAATCCCAAATTGTACTACCAACTGTCGTAGTCGAAACCATGAATGACAAAGAAATTGAATATATTATTCTACATGAACTATCACATGTGAAAAGTCATGACTTAATATTCAACCAGCTTTATGTTGTTTTTAAAATGATATTCTGGTTTAATCCTGCACTATATATAAGTAAAACAATGATGGACAATGACTGTGAAAAAGTATGTGATAGAAACGTTTTAAAAATTTTGAATCGCCATGAACATATACGTTATGGTGAATCGATATTAAAATGCTCTATTTTAAAATCTCAGCACATAAATAATGTGGCAGCACAATATTTACTAGGTTTTAATTCAAATATTAAAGAACGTGTTAAGTATATTGCACTTTATGATTCAATGCCTAAACCTAATCGAAACAAGCGTATTGTTGCGTATATTGTATGTAGTATATCGCTTTTAATACAAGCACCGTTACTATCTGCACATGTTCAACAAGACAAATATGAAACAAATGTATCATATAAAAAATTAAATCAACTAGCTCCGTATTTCAAAGGATTTGATGGAAGTTTTGTGCTTTATAATGAACGGGAGCAAGCTTATTCTATTTATAATGAACCAGAAAGTAAACAACGATATTCACCTAATTCTACTTACAAAATTTATTTAGCGTTAATGGCATTCGACCAAAATTTACTCTCATTAAATCATACTGAACAACAATGGGATAAACATCAATATCCATTTAAAGAATGGAACCAAGATCAAAATTTAAATTCTTCAATGAAATATTCAGTAAATTGGTATTACGAAAATTTAAACAAACATTTAAGACAAGATGAGGTTAAATCTTATTTAGATCTAATTGAATATGGTAATGAAGAAATATCAGGGAATGAAAATTATTGGAATGAATCTTCATTAAAAATTTCTGCAATAGAACAGGTTAATTTGTTGAAAAATATGAAACAACATAACATGCATTTTGATAATAAGGCTATTGAAAAAGTTGAAAATAGTATGACTTTGAAACAAAAAGATACTTATAAATATGTAGGTAAAACTGGAACAGGAATCGTGAATCACAAAGAAGCAAATGGATGGTTCGTAGGTTATGTTGAAACGAAAGATAATACGTATTATTTTGCTACACATTTAAAAGGCGAAGACAATGCGAATGGCGAAAAAGCACAACAAATTTCTGAGCGTATTTTAAAAGAAATGGAGTTAATATAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3786,Drugs,MEG_3786|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|985566378|dbj|LC068959.1|25887-27644 gi|985563902|dbj|AB721404.1|39037-40794 gi|974161314|gb|CP012018.1|71036-72793 gi|974158397|gb|CP012015.1|71040-72797 gi|974155539|gb|CP012013.1|71037-72794 gi|974152716|gb|CP012012.1|71252-73009 gi|974149849|gb|CP012011.1|72396-74153 gi|955659783|emb|LN864705.1|6025-7782 gi|937132516|gb|KT316803.1|6469-8226 gi|758371776|dbj|AB983237.1|38178-39935,0
,AATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCTCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGCGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2395,Drugs,MEG_2395|Drugs|betalactams|Class_A_betalactamases|CTX,gi|375313994|gb|JN790863.1|233-1108,0
,ATGGTGACAAAGAGAATGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCAAAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGAGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAACT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2417,Drugs,MEG_2417|Drugs|betalactams|Class_A_betalactamases|CTX,gi|695200145|ref|NG_035388.1|1-878,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtgttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggcagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_512,Drugs,MEG_512|Drugs|betalactams|Class_C_betalactamases|ADC,447082505|WP_001159761.1|NG_061392|1|1|blaADC-176|blaADC|class_C_beta-lactamase_ADC-176 NG_061392:1-1167,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccagggcaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccactattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5547,Drugs,MEG_5547|Drugs|betalactams|Class_C_betalactamases|PDC,1393270452|WP_109791197.1|NG_057595|1|1|blaPDC-263|blaPDC|class_C_beta-lactamase_PDC-263 NG_057595:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggctcgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5501,Drugs,MEG_5501|Drugs|betalactams|Class_C_betalactamases|PDC,1209144259|WP_088245221.1|NG_055279|1|1|blaPDC-216|blaPDC|class_C_beta-lactamase_PDC-216 NG_055279:1-1194,0
,CTTAATTATGAATTATTTCATGAGTTATCTATTTTTGTCGTGTACAGAGCTCTTTTTTATTTTCTATTGATCTGGTGTTTAAAATGAATAAATATTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTTAATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTTTGATGAAAAAAACACCTCAGGTGTGCTGGTTATTCAAACAGATAAAAAAATTAATCTATATGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTTGAATGCCCTGATCGGATTGGAGAACCAGAAAACGGATATTAATGAAATATTTAAATGGAAGGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAAGCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCAAAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTTCTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATTAGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCTTTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCAATGGATATAAAACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTGTTGCATTAAATATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGATGAAATCATTAAAACAGCTGAATATTATTTAAGAGCTTGACAGACACTCTCATTTTATAAAATGCTCATTTGAGATAAATGGGTCCTTTTATAATCTGACTAATAATGAAACCTGATCAATTTTTCTAGTTTAAAATTTTACAGTGCTTTAGATTGTTTGTGAACGACGATACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5252,Drugs,MEG_5252|Drugs|betalactams|Class_D_betalactamases|OXA,gi|817490722|gb|KP264125.1|1-1048,0
,atgaactttcaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaattacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaataatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgataggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtattggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatatctagctctgttcgaaaagagattacttatagaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4512,Drugs,MEG_4512|Drugs|betalactams|Class_D_betalactamases|OXA,1509794576|WP_122630885.1|NG_062305|1|1|blaOXA-683|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-683 NG_062305:14-838,0
,gtgaccaacagcaccgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_242,Drugs,MEG_242|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,502019073|WP_012695458.1|NG_051697|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_051697:101-655,2
,ATGGCAATCCGAATCTTCGCAATACTTTTCTCCACTTTTGTTTTTGGCACGTTCGCGCATGCACAAGAAGGCATGCGCGAACGTTCTGACTGGCGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAACAGATCGTGTCATATTGGTTTTTGATCAGGTGCGGTCAGAGAAACGCTACTCGCCGGCCTCGACATTCAAGATTCCACATACACTTTTTGCACTTGACGCAGGCGCTGCACGTGATGAGTTTCAAGTTTTCCGATGGGACGGCATCAAAAGAAGCTTTGCAGCTCACAACCAAGACCAAGACTTGCGATCAGCAATGCGGAATTCTACTGTCTGGATTTATGAGCTATTTGCAAAAGAGATCGGTGAAGACAAGGCTCGACGCTATTTGAAGCAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGATGGCAATCTTGCTATCGCGGCACAAGAACAGATTGCATTTCTCAGGAAGCTCTATCATAACGAGTTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGACCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGCGCAAAGACGGGCTGGGAAGGCCGCATGGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCCCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGGATGGATGACCTTTTCAAAAGGGAGGCAATAGTGCGGGCAATCCTTCGCTCTATCGAAGCGTTGCCGCCCAACCCGGCAGTCAACTCGGACGCAGCGCGATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5267,Drugs,MEG_5267|Drugs|betalactams|Class_D_betalactamases|OXA,blaOXA-21_1_AB626885,0
,atggcactggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatagtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagattttcgcggcgcaagttttatgaatatgatcactactcgcacctggttttgcagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgttggatgggggcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggcgcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5884,Drugs,MEG_5884|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,851969414|WP_048236419.1|NG_059323|1|1|qnrB85|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB85 NG_059323:101-745,3
,atgtccgtgtcgatcaggtgcctgggccgatccgacgtttccgtcctgcggcagatgaacgccttgttcggggatgccttcgacgatcccgacacctacctgggagagccgccggacgacgcctatctgagcggccttctggccggggatcatctcatcgcgctggcggccatggacggcgccgtcgtcgtcggcggcctgatcgcctacgagctcgagaaatttgagcgggcgcgttcggaaatctacatctacgatcttgctgtcgccgagacccaccggcgccagggcatagccaccgcgctcatcggtaccttgcaacggatcgcggccgaacggggcgcctgggtggtttacgttcaggccgattacggggatgagccggccattgccctctataccgggcttggaaagcgcgaggacgtcctgcatttcgacattccggtcgatgcgggatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_31,Drugs,MEG_31|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,500073597|WP_011749610.1|NG_048572|1|1|aac(3)-Ih|aac(3)-I|aminoglycoside_N-acetyltransferase_AAC(3)-Ih NG_048572:101-559,2
,ATGAAGAAAAAGATTGATATTACTGTTTTTGGATGTGAGCCGGACGAAGCGACAGTTTTCCGTAAACTGTCCCATGAATTTGGTGTTACGGTCTCACTCGTAAGAGAAGCAGTATCGGAGGACAATGCAAAAGTAGCCGATGGATGCCAGTGTGTCAGCATAAGCCATAAAGCGGAGCTGTCGGAGCCTCTCCTTCTCGCGTTGAAAGACGCCGGAGTGAAATATATCTGCACCCGGAGCATCGGTTATAACCATATTGATATACAGGCGGCCGGTCAAATGGGAATGACCATCGGCACAGTAGCCTACTCGCCGGGGAGCGTCGCCGACTATGCCATTATGCTGATGCTTATGCTGATGCGTGGAACAAAATCCGTAATACACAGAACTGAAAAACAGGATTATTGCCTGAATAGCCTTCGCGGGAAGGAATTGCGGGATATGACGGTTGGCGTATTAGGGGCGGGACGGATCGGACAGGCTGTTATGGAACGCTTGAAAGGATTCGGCTGTACGGTGCTGGCATATGACCGTAATCATAAAGCCGGAGCAGATTATGTTTCATTTTGTGAGCTGCTGCAAAGAAGCGACATCATTACGCTTCATGTTCCGCTGGCAGAAGATACTTTCCATATGATTGGGCGCGAGCAATTAGAAATGATGAAGAAAGAGGCGCTTCTTATCAATACGGCGCGGGGCGCTTTAGTGGACACCGGGGCATTGGTAGAGGCACTGGCAGATGGGAAAATTGGAGGCGCCGCTTTAGATGTACTGGAAGGCGAAGAAGGGTTTTTTTATTATGACTGCACGTACAAGGCGGTAGAACATCCCTTTTTATCGACCCTACAAAGGATGCCAAATGTAATTGTTACGCCGCATACTGCCTACCATACGGAACGGGTGTTGGTTGACACCGTGAGCAATACGATTCGGAATTGTCTGAACTTTGAAAGGAGTCTTGGAAATGTATAGGATTAACGTTGCGGTCCTGTTTGGGGGCTGCTCAGAAGAACATACTGTATCAATAAAGTCTGCAATGGAGCTTGCGGCAAACATTGATACGGAAAAATATCAGCCTTTTTATATCGGGATCACAAAATCCGGTGTTTGGAAATTGTGTGAAAAGCCCTGCCTGGATTGGGAACAATATGCAAAATATCCGGTCGTCTTTTCGCCGGGCAGAAATACGCATGGTTTTCTGATACAAAAAGAGGATAGATATGAAATCCAACCTGTAGATGTAGTGTTCCCCATCATTCATGGAAAATTCGGAGAAGATGGCTCAATACAGGGGCTGCTCGAATTATCGGGTATTCCCTATGTTGGCTGTGATATTCAAAGCTCCGTGATTTGCATGGATAAATCGCTTGCTTATACTACCGTAAAAAATGCAGGTATTGAAGTCCCTGATTTTCAGATTATCCAGGACGGTGACAGCCCGAAAACCGAGTGCTTTAGCTTTCCTCTTTTTGTGAAACCTGCACGCTCTGGTTCTTCTTTTGGAGTAAATAAAGTAGATAAAGCGGAGGATTTATGCGCTGCCATAAACGAAGCAAGGCAATATGACAGAAAAGTATTGATTGAGCAGGCCGTTTCTGGAAGTGAGGTTGGCTGCGCCGTATTGGGAACCGGTACGGACCTAATTGTCGGAGAGGTCGATCAGATTAGCCTAAAACATGGCTTTTTTAAGATTCATCAGGAAGCACAGCCTGAAAAGGGGTCTGAAAATGCAACGATCGAAGTGCCGGCTGATCTTCCGGCAAAGGTAAGAGAGCGGATTCAGAAAACAGCTAAGAAGATTTATCAGGTGCTCGGCTGCAGAGGACTGGCCCGTATTGATTTGTTTTTGCGGGAGGACGGGCATATTGTCCTCAATGAAGTGAATACCATGCCCGGTTTTACTTCGTATAGCCGCTATCCCTGTATGATGACTGCGGCAGGCTTTACCCTTTCGGAACTCATTGATCGTTTGATTGAACTGGCGCTCAGGAGGTAGACATGATGAAACAGAATTTTATTTTTTTAGACGAAGTGCTGCCTGGTATTCGTTGGGATGCCAAATATGCCACATGGGATAATTTTACAGGCAAACCGGTGGACGGATATGAGGTAAACCGTATTGTAGGAACCAAAGAGCTGGGAGCTGCTTTACGCAAAGCTCAAAAACTTGCCATGAAACAGGGATATGGGCTGCTCTTATGGGATGGTTATCGCCCTCAGCGTGCCGTGGATTGTTTTCTGCATTGGGCGTCACTACCGGAGAATAATCTAACGAAAAACCGGTATTACCCTAATATAAAGCGGAATGAAATGGTGACAAAGGGATATGTGGCCTCACAGTCCAGCCATAGCCGCGGAGGCGCAGTTGATCTCACGATTTTTTATTTAGATACCGGTATGCTTGTTCCTATGGGCGGAGATTTTGATTTTATGGATGAACGGTCCCATCATGCTGCAAGCGGACTGACGGAGGAAGAATCCAGAAACCGGGAATGTCTGCGCCATATCATGGGAAGGAGCGGCTTTGAAGCCTATTGTAACGAATGGTGGCATTATGTCCTGGCAGATGAACCATACCCAAATACATATTTCAATTTTTGCATTGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7430,Drugs,MEG_7430|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_6_DQ172830,5
,TCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAAGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGGGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6874,Drugs,MEG_6874|Drugs|betalactams|Class_A_betalactamases|TEM,gi|14700043|gb|AY039040.1|1-1022,0
,ATGGCAGAAAAAATAATTGTTGTTGATGATGAAAAAGAAATCGCGGAGTTAGTCACGACGTTTCTAAGGAATGAAGGCTTCCAAGTAGAACCTTTTTATGATGGAACGAGCGCTTTGGCTTATCTTGAAAAAGAAACGGTCGACGTGGCGGTTTTAGATGTGATGCTGCCGGATATCGACGGCTTTCAGCTGCTGCAGCAAATTCGTAAGACCCACTTTTTCCCAGTACTGATGCTCACGGCAAAAGGGGAAGACTTGGATAAAATCACCGGTCTAAGCCTTGGGGCAGATGATTATGTGACCAAGCCCTTCAATCCTTTAGAAGTCGTTGCTCGGGTCAAAACGCAGCTGCGGCGATACCAGCGTTACAACCAGTCAGCGAATCCCCAGAAGATTGAAGAATACGAAAAGGAAGGCTTACTGTTGAAAATCAACAGCCACCAATGTTTTCTTTATGGCAAAGAGGTTTTCTTGACCCCCATCGAATTTAAAATCTTGCTTTACTTATTTGAACACCAAGGATCGGTCGTTGCCTCGGAAACCCTTTTTGAAGCAGTTTGGAAAGAAAAGTATCTAGACAACAATAACACAGTGATGGCACATATCGCCCGTTTGCGGGAAAAACTGAATGAACAACCCCGCAAACCGAAATTAATCAAAACCGTATGGGGGGTCGGCTATATCATTGAAAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7472,Drugs,MEG_7472|Drugs|Glycopeptides|VanC-type_regulator|VANRC,(Gly)VanRc3:AY033764:3846-4541:696,5
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3477,Drugs,MEG_3477|Drugs|betalactams|Class_A_betalactamases|KPC,1044690746|WP_065419571.1|NG_051167|1|1|blaKPC-25|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-25 NG_051167:1-888,0
,atggctaagttattaataatgagcatagtaagcttttgttttatatttctattgttattattttttaggtacatattaaaacgctattttaattatatgttaaattataaagtttggtatctaactcttcttgcaggattaattcctttcattcctattaaattctctctttttaaatttaataatgtgaataatcaagcgcccacagttgaaagtaagtcacacgacttgaaccataacataaataccaccaaacctattcaagagttcacaacagatatccataagtttaattgggattcaattgataatatctgcacagttatttggatagttttagttattattttaagttttaaatttttgaaagccttattatatcttaaatatttaaagaaacagtcactttatctaaacgaaaatgaaaaaaataaaatagatacgatacttttcaaccatcaatataaaaaaaatattgtgattcgaaaagcagagactattcaatctccaataactttttggtatgggaaatatattattttgattcctagttcatattttaaaagtgtaattgacaaaagactaaaatatataatattgcatgaatatgctcatgctaaaaatagagatactttacatttaattatctttaatatcttctctattattatgagttacaatccattagtacatattgtaaaaagaaagataattcatgacaatgaagtagaagccgatagatttgtccttaataatattaacaaaaatgaatttaaaacttatgcggaatctattatggactccgtattaaatgttccattttttaataaaaatatattaagccattcatttaatggtaaaaagtcattactcaaaagaagattaattaatataaaagaagccaatctgaaaaaacagtccaaattaattctaatttttatttgtatttttacttttttgctcatggtaattcaaagccagtttttgatggggcaatccataactgattataattataaaaagcccttacacaacgattaccaaattttagataaaagtaaaatttttggttcaaatagtggatctttcgtcatgtacagcatgaagaaagacaaatactatatttataacgaaaaagaaagtagaaaaaggtattctcctaattcaacttataaaatttatttagctatgtttggacttgaccgacatattataaatgatgaaaattcacgtatgtcatggaatcataagcattacccttttgatgcttggaataaggaacaagatttaaatacagcaatgcaaaattcagttaattggtacttcgaacgtattagcgatcaaataccaaagaactatactgcgactcaactcaagcaattaaattatggtaataaaaatttgggaagttataaaagctattggatggaagatagtttgaaaatatctaatcttgaacaagtaatagtttttaaaaatatgatggaacaaaataaccattttagtaaaaaagcaaagaatcaattatcttcttcattattgattaagaaaaatgaaaagtatgaactgtatgggaaaacaggtacaggtatagtaaacgggaagtataataatgggtggtttgtaggttacgtaattacaaatcatgataagtattattttgctacacatttatcagatggaaagccatctgggaaaaatgctgaattaatcagtgaaaaaatattaaaagaaatgggtgttttaaatggccaataa,beta-lactamase,antibiotic target alteration,betalactams,MEG_1302,Drugs,MEG_1302|Drugs|betalactams|Penicillin_binding_protein_regulator|BLAR,447019120|WP_001096376.1|NG_047539|1|1|blaR1|blaR1|beta-lactam_sensor/signal_transducer_BlaR1 NG_047539:101-1858,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6494,Drugs,MEG_6494|Drugs|betalactams|Class_A_betalactamases|SHV,gi|943457735|gb|KT818627.1|89545-88685 gi|943457735|gb|KT818627.1|151138-150278 gi|746616805|gb|KJ187752.1|63128-62268 gi|667713574|gb|CP006801.1|57446-58306 gi|257043735|gb|GQ407109.1|1-861,0
,ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTATTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTGGAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAGATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCCGCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATCAAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATGACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAGCTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGATGAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCGCGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAAGCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGTAGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGCGGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTGGTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGGCGTCGGGATATTCTGGCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGATGCAATAAATGGAGCGAGGTATCGCTCCATTTACGTTAAATATGTGCTCCTGAACTTCAGTCTTGTCTTGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2373,Drugs,MEG_2373|Drugs|betalactams|Class_A_betalactamases|CTX,gi|1435024|dbj|D37830.1|ECOBELA|91-1037,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCTGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAATAAAAGCTATCCTAACCCTGCCCGCGTCGAGGCGGCCTGGCGTATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1894,Drugs,MEG_1894|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ336940|+|0-1146|ARO:3002064|CMY-53 [Escherichia coli] ,0
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTTAAGAACTCTTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCGGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTATTGGGCAATGACTGGAACAAAGCCTATAAAAAATCAGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCACCCGCACGGCGACTACGCGGTATACGACACCATCGTGCGTATGGCGCAGCCGTTCTCGCTGCGTTACATGCTGGTGGACGGCCAGGGTAACTTTGGTTCCATCGACGGCGACTCCGCCGCGGCGATGCGTTATACCGAAATTCGTCTGGCGAAAATCGCTCATGAGCTGATGGCCGATCTTGAAAAAGAGACGGTCGATTTCGTCGACAACTATGACGGTACGGAGCGTATTCCGGACGTCATGCCGACCAAAATTCCTAACCTGCTGGTGAACGGCGCCTCCGGGATCGCCGTAGGGATGGCCACCAACATACCGCCACATAACCTGACGGAAGTGATTAACGGCTGTCTGGCGTATGTTGACGATGAAGACATCAGCATTGAAGGGCTGATGGCGCATATTCCTGGCCCTGATTTCCCGACCGCCGCCATTATCAATGGCCGTCGCGGCATCGAAGAGGCCTATCGCACCGGTCGCGGTAAAGTGTACATTCGCGCGCGCGCGGAAGTGGAAGTGGACGCGAAATCCGGCCGCGAAACCATCATCGTGCACGAAATTCCGTATCAGGTGAACAAAGCGCGCCTGATCGAGAAAATCGCCGAGCTGGTCAAAGAAAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAGTCTGATAAAGACGGGATGCGCATCGTGATTGAAGTGAAGCGCGATGCGGTAGGGGAAGTGGTGCTTAACAACCTCTATTCCCAGACCCAGCTGCAGGTCTCCTTCGGCATCAACATGGTAGCTCTGCACCATGGTCAGCCGAAGATCATGAACCTGAAGGACATCATCGCCGCGTTTGTACGCCACCGCCGTGAAGTGGTGACCCGTCGTACGATTTTCGAACTGCGCAAAGCGCGCGACCGGGCGCATATCCTCGAAGCGCTGGCCGTTGCGCTGGCCAACATCGACCCGATTATCGAACTGATCCGTCGCGCGCCGACCCCGGCAGAAGCGAAAACGGCGCTGGTTGCCCAGGCGTGGGATCTCGGTAACGTTGCGGCGATGCTGGAGCGCGCCGGGGATGACGCCGCGCGTCCGGAATGGCTGGAACCAGAGTTCGGCGTGCGCGACGGTAAATACTACCTGACCGAGCAGCAGGCTCAGGCGATTCTGGATCTGCGTCTGCAGAAACTGACCGGCCTTGAGCATGAAAAACTGCTCGACGAATATAAAGAGCTGCTGGAGCAGATCGCAGAGCTGCTGCACATTCTCGGCAGCGCCGACCGTCTGATGGAAGTGATTCGCGAAGAGCTGGAGCTGATCCGCGACCAGTTCGGCGACGAACGTCGTACCGAAATCACCGCCAACAGCGCTGATATTAACATCGAAGATCTGATCAACCAGGAAGATGTGGTGGTCACCCTGTCGCATCAGGGGTATGTGAAGTATCAGCCGCTGACCGACTACGAAGCACAGCGTCGTGGCGGTAAAGGCAAATCGGCAGCGCGCATTAAAGAAGAAGACTTTATCGACCGCCTGCTGGTGGCTAACACCCATGACACCATCCTCTGCTTCTCAAGCCGCGGCCGTCTGTACTGGATGAAGGTCTATCAGCTGCCGGAAGCCAGCCGCGGCGCGCGCGGTCGGCCGATCGTCAACCTGCTGCCGCTGGAAGCCGATGAGCGCATTACCGCCATCCTGCCGGTCCGCGAGTACGAAGAGGGCGTCAACGTCTTTATGGCGACCGCCAGCGGTACCGTGAAGAAAACCGCGCTGACCGAGTTCAGCCGTCCGCGTTCCGCCGGTATCATCGCGGTCAACCTGAACGAAGGCGATGAGCTGATCGGCGTCGATCTGACCTCTGGTCAGGATGAAGTGATGCTGTTCTCCGCGGCCGGTAAGGTTGTACGCTTCAAAGAAGACGCCGTTCGCGCCATGGGCCGTACCGCCACCGGCGTACGCGGTATTAAGCTTGCGGAAAACGACAGCGTCGTCTCGCTGATTATTCCACGCGGCGAAGGCGCGATCCTGACGGTGACGCAAAACGGTTACGGTAAACGTACCGCGGCGGCGGAGTATCCGACCAAGTCGCGTGCCACCCAGGGCGTTATTTCGATCAAAGTCACCGAGCGTAACGGTTCCGTGGTCGGCGCCGTGCAGGTGGATGACTGCGATCAGATCATGATGATCACCGACGCCGGGACGCTGGTGCGTACCCGCGTTTCCGAAGTGAGCATCGTGGGCCGTAACACCCAGGGCGTGATCCTCATCCGCACCGCGGAAGATGAAAACGTGGTAGGTCTGCAGCGCGTGGCTGAGCCGGTGGATGATGAAGAGCTGGATGCCATCGACGGTAGCGCGGCAGAAGGCGATGATGATATCGCCCCGGAAGCGGATACCGATGACGACATCGCCGAAGACGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3189,Drugs,MEG_3189|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|150953431|gb|CP000647.1|2905657-2903024,3
,atgaaaattgataatgtaacagaaaaggatttattttatattttagacttatttgaaaaaatggaagtaactcattggttagatggaggctggggcgtagatgtattaactggaaaacaacaaagagaacacagagatatagatatagattttgacgctcaacacactcaaaaagttataaaaaaattagaagatataggatacaaaatagaagttgattggatgccttcacgtatggaacttaaacataaagaatatggatatttagatattcatcctataaatttaaatgatgatggttccattactcaagcaaacccagaaggtggcaattacatctttcaaaatgaatggttttcagaaactaattataaaggtcgaaaaataccatgcatttccaaagaagctcaacttctttttcattccggttatgaattaacagaaaaagaccattttgatataaaaaatttaaaatcaataacttaa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3604,Drugs,MEG_3604|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,499748145|WP_011428879.1|NG_050416|1|1|lnu(A)'|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A)' NG_050416:101-586,7
,atgtcacttaatgtaaaaccaagcagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgatattaaaaaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggtaaatcattttcgtacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaacgctctcaagataatcaactcagtcttaatcagatcgtgaattacaatacaagaactttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagtgacaatggtgctactaatattattcttgaacgttatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagattttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgacacatctacacctgcagcagtagccaagagcctgaaaaccattgctctgggtaacatacttagtgagcgtgaaaaggaaacatatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtactgcaaatgattatgcggtagtctggccaaagaaccgggctcctcttataatttctgtatacactacaaaatacgaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3302,Drugs,MEG_3302|Drugs|betalactams|Class_A_betalactamases|IMI,1226997339|WP_094009816.1|NG_055504|1|1|blaIMI-16|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-16 NG_055504:1-879,0
,TTATTCATCTATATCGTATTTTTTATTACCGTTCTCATATAGCTCATCATACACTTTACCTGAGATTTTGGCATTGTAGCTAGCCATTCCTTTATCTTGTACATCTTTAACATTAATAGCCATCATCATGTTTGGATTATCTTTATCATATGATATAAACCACCCAATTTGTCTGCCAGTTTCTCCTTGTTTCATTTTGAGTTCTGCAGTACCGGATTTGCCAATTAAGTTTGCATAAGATCTATAAATATCTTCTTTATGTGTTTTATTTACGACTTGTTGCATACCATCAGTTAATAGATTGATATTTTCTTTGGAAATAATATTTTTCTTCCAAACTTTGTTTTTCGTGTCTTTTAATAAGTGAGGTGCGTTAATATTGCCATTATTTTCTAATGCGCTATAGATTGAAAGGATCTGTACTGGGTTAATCAGTATTTCACCTTGTCCGTAACCTGAATCAGCTAATAATATTTCATTATCTAAATTTTTGTTTGAAATTTGAGCATTATAAAATGGATAATCACTTGGTATATCTTCACCAACACCTAGTTTTTTCATGCCTTTTTCAAATTTCTTACTGCCTAATTCGAGTGCTACTCTAGCAAAGAAAATGTTATCTGATGATTCTATTGCTTGTTTTAAGTCGATATTACCATTTACCACTTCATATCTTGTAACGTTGTAACCACCCCAAGATTTATCTTTTTGCCAACCTTTACCATCGATTTTATAACTTGTTTTATCGTCTAATGTTTTGTTATTTAACCCAATCATTGCTGTTAATATTTTTTGAGTTGAACCTGGTGAAGTTGTAATCTGGAACTTGTTGAGCAGAGGTTCTTTTTTATCTTCGGTTAATTTATTATATTCTTCGTTACTCATGCCATACATAAATGGATAGACGTCATATGAAGGTGTGCTTACAAGTGCTAATAATTCACCTGTTTGAGGGTGGATAGCAGTACCTGAGCCATAATCATTTTTCATGTTGTTATAAATACTCTTTTGAACTTTAGCATCAATAGTTAGTTGAATATCTTTGCCATCTTTTTTCTTTTTCTCTATTAATGTATGTGCGATTGTATTGCTATTATCGTCAACGATTGTGACACGATAGCCATCTTCATGTTGGAGCTTTTTATCGTAAAGTTTTTCGAGTCCCTTTTTACCAATAACTGCATCATCTTTATAGCCTTTATATTCTTTTTGTTTTAATTCTTCAGAGTTAATGGGACCAACATAACCTAATAGATGTGAAGTCGCTTTTCCTAGAGGATAGTTACGACTTTCTGTTTCATTAGTTGTAAGATGAAATTTTTTTGCGAAATCTCTTAAATATTCATCCATTTTTTTAACGGTTTTAAGTGGAACGAAGGTATCATCTTGTACCCAATTTTGATCCATTTGTTGTTTGATATAGTCTTCAGAAATACTTAGTTCTTTAGCGATTGCTTTATAATCTTTTTTAGATACATTCTTTGGAACGATGCCTATCTCATATGCTGTTCCTGTATTGGCCAATTCCACATTGTTTCGGTCTAAAATTTTACCACGTTCTGATTTTAAATTTTCAATATGTATGCTTTGGTCTTTCTGCATTCCTGGAATAATGACGCTATGATCCCAATCTAACTTCCACATACCATCTTCTTTAACAAAATTAAATTGAACGTTGCGATCAATGTTACCGTAGTTTGTTTTAATTTTATATTGAGCATCTACTCGTTTTTTATTTTTAGATACTTTTTTTATTTTACGATCCTGAATGTTTATATCTTTAACGCCTAAACTATTATATATTTTTATCGGACGTTCAGTCATTTCTACTTCACCATTATCGCTTTTAGAAATATAACTGCTATCTTTATAAACTTGTTTGAAATTTTTATCTTCAATTGCATCAATAGTATTATTAATTTCTTTATCTTTTGAAGCATAAAAATATATACCAAACCCGACAACTACAACTATTAAAATAAGTGGAACAATTTTTATCTTTTTCATCAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3783,Drugs,MEG_3783|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|961572904|gb|CP013619.1|47565-49574 gi|961570270|gb|CP013616.1|47558-49567 gi|959165045|gb|CP009828.1|47917-49926 gi|937305921|gb|CP012756.1|1393480-1395489 gi|928189965|dbj|AP014944.1|52490-54499 gi|841330217|emb|LN866849.1|427183-429192 gi|807232188|gb|CP011116.1|35985-33976 gi|760495145|gb|CP010944.1|2706000-2703991 gi|760491253|gb|CP010943.1|2710136-2708127 gi|760463627|gb|CP010940.1|2728511-2726502,0
,atgactactaaacttccagaatcgatagcagaccaattatccgatacgctatcaattttagaaaaccatcttggtgaaactattcaggcggttcatctgtttggttctgcagttgatggcggtttaaaaccatttagtgatatagacctgttgatcactgtgagtactcctttaggcgaatcaactagggtggcattgatgtccgacctgctgttggtatcagcttttccaggcaccgatgctaagcgccgtgcacttgaggtgactatattggcacaaaaagacgtggtgccgtggcgatatccggcgagacggcaaatgcaatttggtgaatggttgcgtcacgatatcaatgcaggtatttttgagccggcaatgacggaccacgacctagctatcttgttgacgaaggtgaggctgcatagcctagctttgtatggtccagcagctcaagagtttttcgatgagattcctgctattgatgtgcaacgttcactgctggaaacgttggcgctctggactacagaggcagattgggagggagatgaaagaaacatagttcttgccttagtacgtatttggtacactgcgatgaccggagatattgcgtctaaggatgccgctgctgattgggctcttcagcgtctgcccagcgagcacaagcacatcgttattgccgcaagagatgggtatcttggactgggaacagtcgatctggcagcctatccacaagagcgggcggaacttctgaactacatccggtctagcgtgacgacgaagctgcaatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_870,Drugs,MEG_870|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,665824776|WP_031192893.1|NG_057462|1|1|aadA31|aadA31|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA31 NG_057462:101-889,2
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaaggactatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttgtttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4384,Drugs,MEG_4384|Drugs|betalactams|Class_D_betalactamases|OXA,1391852908|WP_109545093.1|NG_057527|1|1|blaOXA-596|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-596 NG_057527:1-774,0
,ATGAAAATACTGTTAGAGGGACTTCATATAAAACATTATGTTCAAGATCGTTTATTGTTGAACATAAATCGCCTAAAGATTTATCAGAATGATCGTATTGGTTTAATTGGTAAAAATGGAAGTGGAAAAACAACGTTACTTCACATATTATATAAAAAAATTGTGCCTGAAGAAGGTATTGTAAAACAATTTTCACATTGTGAACTTATTCCTCAATTGAAGCTCATAGAATCAACTAAAAGTGGTGGTGAAGTAACACGAAACTATATTCGGCAAGCGCTTGATAAAAATCCAGAACTGCTATTAGCAGATGAACCAACAACTAACTTAGATAATAACTATATAGAAAAATTAGAACAGGATTTAAAAAATTGGCATGGAGCATTTATTATAGTTTCACATGATCGCGCTTTTTTAGATAACTTGTGTACTACTATATGGGAAATTGACGAGGGGAGAATAACTGAATATAAGGGGAATTATAGTAACTATGTTGAACAAAAAGAATTAGAAAGACATCGAGAAGAATTAGAATATGAAAAATATGAAAAAGAAAAGAAACGATTGGAAAAAGCTATAAATATAAAAGAACAGAAAGCTCAACGAGCAACTAAAAAACCGAAAAACTTAAGTTTATCTGAAGGCAAAATAAAAGGAGCAAAGCCATACTTTGCAGGTAAGCAAAAGAAGTTACGAAAAACTGTAAAATCTCTAGAAACCAGACTAGAAAAACTTGAAAGCGTCGAAAAGAGAAACGAACTTCCTCCACTTAAAATGGATTTAGTGAACTTAGAAAGTGTAAAAAATAGAACTATAATACGTGGTGAAGATGTCTCGGGTACAATTGAAGGACGGGTATTGTGGAAAGCAAAAAGTTTTAGTATTCGCGGAGGAGACAAGATGGCAATTATCGGATCTAATGGTACAGGAAAGACAACGTTTATTAAAAAAATTGTGCATGGGAATCCTGGTATTTCATTATCGCCATCTGTCAAAATCGGTTATTTTAGCCAAAAAATAGATACATTAGAATTAGATAAGAGTATTTTAGAAAACGTTCAATCTTCTTCACAACAAAATGAAACTCTTATTCGAACTATTCTAGCTAGAATGCATTTTTTTAGAGATGATGTTTATAAACCAATAAGTGTTTTAAGTGGTGGAGAGCGAGTTAAAGTAGCACTAACTAAAGTATTCTTAAGTGAAGTTAATACGTTGGTATTAGATGAACCAACAAACTTTCTTGATATGGAAGCTATAGAGGCGTTTGAATCTTTGTTAAAGGAATATAATGGCAGTATAATCTTTGTATCTCACGATCGTAAATTTATCGAAAAAGTAGCCACTCGAATAATGACAATTGATAATAAAGAAATAAAAATATTTGATGGCACATATGAACAATTTAAACAAGCTGAAAAGCCAACAAGGAATATTAAAGAAGATAAAAAACTTTTACTTGAGACAAAAATTACAGAAGTACTCAGTCGATTGAGTATTGAACCTTCGGAAGAATTAGAACAAGAGTTTCAAAACTTAATAAATGAAAAAAGAAATTTGGATAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7687,Drugs,MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,vga(A)_3_JQ312422,1
,TCCACCTTCAAACAAGGAATATCGTTGATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAAGGCTCTGAAAATCATCTATTGGCCCACCACCGCCGCCCTTGCGGGCGGCATGGATTA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3507,Drugs,MEG_3507|Drugs|betalactams|Class_A_betalactamases|KPC,gi|873464424|gb|KR014106.1|9873-10838 gi|962148899|gb|KU176944.1|36826-37791 gi|961666360|gb|KT185451.1|86357-85392 gi|966624506|gb|CP012000.1|12143-13108 gi|966624404|gb|CP011999.1|28799-27834 gi|959190550|gb|CP013325.1|38384-37419 gi|941349957|gb|KP726894.1|3999-3034 gi|918463219|gb|KP987218.1|19767-18802 gi|918462945|gb|KP987215.1|6205-7170 gi|817046807|gb|KP893385.1|125849-124884,0
,atgcgatttaacaaaatttcttgcttacttttatcccctctttttatttttaatacctcaatttatgcaggtaatacaccaaaagagcaagaaattaagaaactggttgatcaaaactttaaaccgttattagaaaaatatgatgtacccggtatggctgttggcgtcatccaaaataataaaaagtatgaaacgtattatggtttacaatccgttcaagataaaaaagccgtaaatagcagtaccatttttgagctcggttcagttagtaaattatttaccgctacagcaggtgcttatgctaaaaacaagggaaaaatctcttttaaagacacacctggaaaatattggaaagaattaaaaaacacaccgattgatcaagttaacttacttcaacttgcaacatatacaagtggcaaccttggcttacagtttccagatgaagtccaaacagatcagcaagttttaacttttttcaaagactggaagcctaagagctcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaactatttttccagatcttagcttaaaacatagttatgtaaatgtgcctaaaactcagatgcaaaactatgcatttggctataaccaacaaaatcagccgattcgagttaaccccggccccttagatggtccagcttacggcgttaaatcgacactaccagacatgttggggtttgttcatgccaatctgaacccgcagcaatatcctgctgatattcaacgtgcaattaatgagacacacaaaggtttctatcaagtaggtacgatgtatcaggcgcttggttgggaagagttttcttatccggcaacattacaaactctattagacagtaattctgaccaaattgtgatgaaacctaataaagtcactgctatttctaaagaaccttcagttaagattttccacaaaactggttcaaccaatggcttcggaacatacgtcgtatttattcctaaagagaatattggtttagtcatgttaaccaataaacgtattccaaacgaagaacgcattaaagcagcgtatgcggtgttgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_626,Drugs,MEG_626|Drugs|betalactams|Class_C_betalactamases|ADC,1058243603|WP_068981617.1|NG_051449|1|1|blaADC-85|blaADC|class_C_beta-lactamase_ADC-85 NG_051449:1-1152,0
,GCCACCCTGCCACTGGCGGTAGACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCAGGGGTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTACCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCGCTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACATATCGCCGGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3555,Drugs,MEG_3555|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AJ635425|+|0-789|ARO:3002457|LEN-7 [Klebsiella pneumoniae] ,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacaattgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaatgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtgggattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7649,Drugs,MEG_7649|Drugs|betalactams|Class_A_betalactamases|VEB,1028110878|WP_063865150.1|NG_050318|1|1|blaVEB-10|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-10 NG_050318:1-900,0
,ATGTATAAGCTTAAAATTGCAGTCCTGTTTGGAGGCTGCTCAGAGGAACATGATGTTTCAGTGAAATCTGCGATGGAGGTTGCAGCAAATATAAACAAGGAAAAATACCAGCCGTTTTATATTGGAATCACAAAATCCGGCGCATGGAAACTATGCGATAAGCCCTGCCGGGACTGGGAGAACTATGCGGGATACCCGGCTGTGATTTCTCCGGACAGAAGGATCCATGGCCTGCTGATACAAAAGGACGGCGGATATGAGAGCCAGCCTGTAGACGTGGTGCTTCCGATGATTCATGGAAAATTTGGCGAGGACGGAACCATACAGGGTCTGCTTGAGCTGTCCGGCATTCCTTATGTGGTATGCGACATTCAAAGTTCTGTAATCTGTATGGATAAGTCGCTCGCTTATATGGTTGTGAAAAATGCGGGAATTGAGGTACCTGGGTTTCGAGTTCTACAAAAGGGGGACAGCCTGGAAGCAGAGACGCTCTCGTATCCGGTCTTTGTAAAGCCTGCCCGTTCCGGCTCCTCTTTTGGCGTGAATAAGGTATGCCGGGCAGAGGAACTGCAGGCAGCGGTCACAGAGGCGGGTAAGTATGACAGCAAAATATTGGTTGAGGAGGCCGTTTCCGGGAGTGAGGTAGGATGTGCCATACTGGGAAACGGAAACGATCTCATCACCGGCGAGGTCGATCAGATTGAATTGAAACACGGGTTTTTTAAGATCCATCAGGAAGCACAGCCGGAAAAGGGGTCTGAAAATGCTGTGATTAGAGTTCCAGCCGCCCTGCCGGATGAAGTTAGGGAGCAGATTCAGGAAACGGCGAAGAAGATTTACCGGGTACTTGGCTGCAGAGGTCTGGCCCGCATTGATTTGTTTTTACGGGAGGATGGAAGCATTGTCCTGAATGAAGTGAACACCATGCCTGGATTTACTTCCTATAGCCGTTATCCACGCATGATGACAGCAGCAGGGTTTACGCTTTCTGAAATATTGGACCGCTTGATTGGACTTTCACTTAGGAGGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7387,Drugs,MEG_7387|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,gi|109240378|dbj|AB242319.1|4009-5040 gi|54114872|dbj|AB183866.1|72-1103,5
,ATGATGAAAAAATCGTTATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1937,Drugs,MEG_1937|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087838|+|0-1146|ARO:3002129|CMY-118 [Citrobacter freundii] ,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGGGTAATGATACCAACGTGTTGATTTCGTATTTTCACTGACACCAGGATCATCCTGATGTTACAAGGATTGAATGACTACAGATTAAAATAGTCATCAACAGGTTGACAGCATTACCCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6915,Drugs,MEG_6915|Drugs|betalactams|Class_A_betalactamases|TEM,gi|41816|emb|X57972.1|1-1200 gi|970697516|gb|KT935445.1|6140-6305 gi|943457735|gb|KT818627.1|32855-33020 gi|943457735|gb|KT818627.1|72074-71909 gi|943457735|gb|KT818627.1|75121-74956 gi|943457735|gb|KT818627.1|133665-133500 gi|943457735|gb|KT818627.1|136712-136547 gi|943457735|gb|KT818627.1|74964-74889 gi|943457735|gb|KT818627.1|136555-136480 gi|959195734|gb|CP013326.1|57957-57792 gi|959195734|gb|CP013326.1|61004-60839 gi|959195734|gb|CP013326.1|60847-60772 gi|959190351|gb|CP013324.1|107411-107246 gi|959190351|gb|CP013324.1|110458-110293 gi|959190351|gb|CP013324.1|110301-110226 gi|973743069|gb|KT894025.1|2234-2395 gi|948549813|dbj|LC094340.1|8524-8441 gi|948549806|dbj|LC094339.1|8146-8063 gi|948549800|dbj|LC094338.1|5089-5006 gi|948549794|dbj|LC094337.1|5413-5330,0
,atgaaaaactactttaacagccctttcaaaggggaacttctttctgagcaagtgaaaaatccaaatatcagagtaggccggtatagctattactctggctactatcacgggcactcatttgatgaatgcgcgcgatacttgtttccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1609,Drugs,MEG_1609|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502055|WP_071846207.1|NG_052180|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052180:97-729,6
,ATGAGAAAAAGTATGGGCATTACTGTTTTTGGATGCGAACAGGATGAGGCAAATGCTTTCCGCGCTTTATCGCCAGATTTTCATATTATCCCTACGCTGATTAGCGATGCGATATCGGCAGACAACGCAAAATTGGCCGCTGGCAATCAATGCGTTAGCGAAGGCCATAAGTCCGAGGTTTCCGAGGCGACAATTCTTGCGCTGAGAAAGGTCGGGGTAAAATACATTTCTACCCGCAGCATCGGCTGCGATCACATTGATACGACTGCCGCCGAGAGAATGGGAATCTCGGTTGGCACGGTTGCGTATTCGCCGGACAGCGTTGCGGATTATGCTTTGATGCTGATGCTGATGGCCATACGGGGTGCAAAACCCACCATGCACGCCGTGGCGCAACAAGATTTCAGATTGGATCGTATCCGGGGGAAAGAACTGGGGGATATGACTGTGCGAGTTATTGGAACCGGCCATATCGGGCAAGCGGTCGTCAAAAGGCTGCGGGGATTTGGATGCCATGTGCTGGCCTATGATAACAGCCGAAAAATGGATGCAGATTATGTCCAGCTTGATGAGCTTCTAAAAAACAGCGGTATTGTTACGCTCCATGTGCCGCTTTGTGCGGATACCCGCCATCTGATCGGTCAGAAGCAAATTGGAGAGATGAAGCAAGGCGCATTTTTAATCAACACCGGGCGCGGAGCGCTTGTCGATACCGGGGCGCTGGTGGAGGCGTTGGAAAGCGGAAAGCTGGGTGGTGCGGCACTGGATGTGTTGGAGGGCGAGGATCAGTTTGTTTATACCGATTGCTCGCAGAAAGTGCTTGACCATCCCTTTTTGTCGCAGCTTTTAAGGATGCCGAATGTGATCATCACACCCCATACGGCGTACTACACTGAGCGTGTGCTGCAGGATACTACAGAAAAAACAATCAGGAATTGTCTCAATTTTGAAAGGAGTTTACAGCATGAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7416,Drugs,MEG_7416|Drugs|Glycopeptides|VanB-type_resistance_protein|VANHB,(Gly)VanH-B:AF192329:27871-28842:972,5
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGTCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTATCAGAAAACTGAAGGAACCTCCATTGAATCGAACTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6630,Drugs,MEG_6630|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|306485939|gb|HM486907.1|1663-2514 gi|229904977|gb|FJ670543.1|3981-3130 gi|975007785|gb|CP010832.1|3652-3615 gi|954666075|gb|KT962845.1|18735-18698 gi|971339514|gb|CP006662.2|54069-54032 gi|943457735|gb|KT818627.1|109771-109734,8
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataaggtattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4661,Drugs,MEG_4661|Drugs|betalactams|Class_D_betalactamases|OXA,488946471|WP_002857546.1|NG_057515|1|1|blaOXA-592|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-592 NG_057515:1-774,0
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgcccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttataactatgggttagcggcaaaacagcctcagcagccggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgctgccaccttggcgtcctatgcgcaggtgagcggtaagctgtccttggatcaaagcgttagccattacgttccagagttgcgtggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtatgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtgaatatggagattttgggtaacgaagcttatggtatcaaaaccacttccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaaatcgggtgagattactcaggatctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttccgccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcgttggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_383,Drugs,MEG_383|Drugs|betalactams|Class_C_betalactamases|ACC,1028101849|WP_063857697.1|NG_048590|1|1|blaACC-1b|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-1b NG_048590:1-1173,0
,atgactaaaaacgaaagctattctggcattgattattttagatttattgcagccttattgattgttgctattcatacttcgcctctcttttcttttagtgaaacaggcaactttatatttacacgcattgtagcccctgtagccgttccgttcttttttatgacatctggattttttctgatttccagatatacctgtaatgccgaaaagctgggagcttttataaaaaagacaaccttaatttacggggttgcaatactcttatacatacctatcaatgtttataacggttatttcaaaatggacaaccttttgccaaatatcataaaagatattgtatttgatggtactttatatcacttgtggtatcttcctgcatctattatcggagctgcgattgcttggtatctggtaaagaaagttcattatcgcaaagcctttttgatagcttctatactctatatcataggcttatttggagatagttattatggaattgtgaaaagcgtttcctgcttaaatgttttttacaatctaatcttccaattaacagattacacaagaaacggaatattttttgccccaatcttttttgtgcttggtggatatatctctgatagtccaaacagatatcgtaaaaagaattatattaggatttatagtttgttttgccttatgtttggcaaaacccttactttacaacattttgatatacagaaacatgacagtatgtatgtgcttttacttccgagtgtgtggtgcttatttaatcttctgctgcactttagaggaaaacgccgcacaggattacggacaatatcattagatcagctatatcattcatccgtttatgattgttgtaatacgattgtttgcgcagaattactgcatctgcaaagcctgcttgttgaaaacagccttgttcattatattgcggtctgctttgcatcggtagtattagcagtggttataacagcgttattgagcagtctgaaaccgaaaaaggcaaaacataccgccgatacggatagagcgtatttggaaatcaacctaaataatttagagcataatgtaaacactttgcaaaaagcaatgtcacctaaatgtgaattgatggcggttgtaaaagcggaagcctatggtcacggtatgtatgaagtgacgacatattttgagccgataggagttttttatttggcggtagctaccattgatgaaggtatccgattgagaaaatatggcatttttagcgaaatcctaattttaggctatacatcgccttcaagggcgaaagaactttgtaagtttgagctgacccaaaccttgatagattataggtatttgttgcttttgaataaacagggatatgacattaaagcacatattaaaattgacacaggtatgcatagacttggatttagcacagaagataaggataaaatccttgcagctttttttttgaagcacatcaaagttgcgggaatttttacacatttgtgtgcggctgacagccttgaagaaaaagaagttgcatttacaaacaagccaataggcagtttttataaagtgcttgattggccgaaaagcagcggtttgaatatacctaaagtaaatatccaaactagttatggattatggaatatccagagctggaatgtgatatatcagagtggtgttgctctgtatggtgttttaaggtctactaatgacaaaacaaaattagaaactgatttaagagcctgtagcttcttgaaagcaaaagttgttttaattcggaagataaagcagggcggaagtgttggttatagcagggcttttactgcaacccgagatagtttaattgccatattaccaattggatatgcagatggttttccaagaaatctgtcttgtggaaatagttatgtgctgattggtggacgacaagcccctattgtcggaaaaatctgtatggatcaacttgcagttgatgtaacagatattcccaatgttaagactggaagtattgcaacgctgattggtaaagatggaaaggaagaaattacagcaccgatggtagctgaaagtgcagaaagcataaccaatgaattgttaagccgtatggaacacagattaaatattattcgtagagcgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7531,Drugs,MEG_7531|Drugs|Glycopeptides|VanG-type_resistance_protein|VANTG,1028100617|WP_063856752.1|NG_048455|1|1|vanT-G|vanT-G|membrane-bound_serine_racemase_VanT-G NG_048455:101-2236,5
,atgaaaaaatcgttatctgcaacactgatttccgctctgctggcgttttccgccccggggttttctgccgctgataatgtcgcggcggtggtggacagcaccattaaaccgctgatggcacagcaggatattcccgggatggcggttgccgtctccgtaaagggtaagccctattatttcaattatggttttgccgatattcaggcaaaacagccggtcactgaaaatacactatttgagctcggatctgtaagtaaaactttcacaggtgtgctgggtgcggtttctgtggcgaaaaaagagatggcgctgaatgatccggcggcaaaataccagccggagctggctctgccgcagtggaaggggatcacattgctggatctggctacctataccgcaggcggactgccgttacaggtgccggatgcggtaaaaagccgtgcggatctgctgaatttctatcagcagtggcagccgtcccggaaaccgggcgatatgcgtctgtatgcaaacagcagtatcggcctgtttggtgctctgaccgcaaacgcggcggggatgccgtatgagcagttgctgactgcacggatcctggcaccgctggggttatctcacacctttattactgtgccggaaagtgcgcaaagccagtatgcgtacggttataaaaacaaaaaaccggtccgcgtgtcgccgggacagcttgatgcggaatcttacggcgtgaaatccgcctcaaaagatatgctgcgctgggcggaaatgaatatggagccgtcacgggccggtaatgcggatctggaaatggcaatgtatctcgcccagacccgctactataaaaccgccgcgattaaccaggggctgggctgggaaatgtatgactggccgcagcagaaagatatgatcattaacggtgtgaccaacgaggtcgcattgcagccgcatccggtaacagacaaccaggttcagccgtataaccgtgcttcctgggtgcataaaacgggcgcaacaactggtttcggcgcctatgtcgcctttattccggaaaaacaggtggcgattgtgattctggcgaataaaaactacccgaataccgaaagagtcaaagctgcacaggctattttgagtgcactggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2585,Drugs,MEG_2585|Drugs|betalactams|Class_C_betalactamases|DHA,490356613|WP_004236386.1|NG_049055|1|1|blaDHA-1|blaDHA|class_C_beta-lactamase_DHA-1 NG_049055:101-1240,0
,atggaaaaaatattatctagaggattgctagctttatatttagtgacactaatctggttagtgttattcaaattacaatacaatattttgtcagtatttcattatcaccaaagaagtcttaacttgattccatttgctgcacatggaagtctcagagagatgatagataatattatcatctttatcccttttggcttgcttttgaatgtcaatttcaaaaaagttggatttttactcaagtttgcttttatattagttttaagtcttacttttgaattaatacaatttatcttcgcaattggagcgacagatatgacagatgtaattacaaatactgttggaggctttcttggactgaaattatatggtttaagcaataagcacataaataataaaaaattagacagaattattatttttgtaggtatacttttgctcgtattattgctctattaccgtacccatttaaaaattaaatattcttag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7616,Drugs,MEG_7616|Drugs|Glycopeptides|VanA-type_accessory_protein|VANZA,1028100790|WP_063856925.1|NG_048533|1|1|vanZ-A|vanZ-A|glycopeptide_resistance_protein_VanZ-A NG_048533:1-486,5
,TTGAAAAAGTTAATACTTTTAATTGCAATTACTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATACTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTACAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1416,Drugs,MEG_1416|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_53_NZ_JUXQ01000001,0
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGTTCTCTGTTCCCTCTTTATCATGGAAGTGCAAAAAGTAATATAGGGATTGATAACCTTATAGAAGTTATTACTAATAAATTTTATTCATCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAAAAAAGACAACGTCTTGCATATATACGTCTTTATAGTGGAGTACTACATTTACGAGATTCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATCGATAAGGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGTTAAATAGTGTTCTTGGAGATACAAAACTATTGCCACAGAGAAAAAGAATTGAAAATCCGCACCCTCTACTACAAACAACTGTTGAACCGAGTAAACCTGAACAGAGAGAAATGTTGCTTGATGCCCTTTTGGAAATCTCAGATAGTGATCCGCTTCTACGATATTACGTGGATTCTACGACACATGAAATTATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGATTAGTGCACTGTTGCAAGAAAAGTATCATGTGGAGATAGAACTAAAAGAGCCTACAGTCATTTATATGGAGAGACCGTTAAAAAATGCAGAATATACCATTCACATCGAAGTGCCGCCAAATCCTTTCTGGGCTTCCATTGGTTTATCTGTATCACCGCTTCCGTTGGGAAGTGGAATGCAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGGATACGCTATGGTTGCGAACAAGGATTATATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTCTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCGCCACAGGAATATCTTTCACGAGCATACAACGATGCTCCTAAATATTGTGCGAACATCGTAGACACTCAATTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7135,Drugs,MEG_7135|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|1470075|gb|U58985.1|GVU58985|228-2147,4
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttagcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_784,Drugs,MEG_784|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502193|WP_071846343.1|NG_052440|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052440:101-892,2
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacgtcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcagtttggagaatggcagcgcaatgacactcttgcaggtatcttcgagccagccacgattgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcagaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtgtcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_787,Drugs,MEG_787|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502144|WP_071846296.1|NG_052354|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052354:101-892,2
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTGCGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCCAAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGCGGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTAGGAAATGAAAAACTCCTGCCTCATAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTGCATTTTGACATTGATACTGTTACACATGAGATTATGTTATCTTTTTTGGGAAAAGTACAGTTAGAAGTTATTTGTTCGCTATTAGAAGAAAAATATCATGTGGGCGTGGCTATGAAAGAGCCTTCGGTTATTTATCTGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAAGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTAATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7235,Drugs,MEG_7235|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,tet(W/32/O)_3_AM710603 ,4
,atggttaaaaaatcactgagccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2191,Drugs,MEG_2191|Drugs|betalactams|Class_A_betalactamases|CTX,1028104725|WP_063859971.1|NG_048948|1|1|blaCTX-M-163|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-163 NG_048948:1-876,0
,ATGATGAAAAGTTGGATGAAGTGTGGATTGGCCGGGGCCGTGGTGCTGATGGCGAGTTTCTGGGGTGGCAGCGTGCGGGCGGCGGGGATCTCCCTTAAGCAGGTGAGCGGCCCTGTTTACGTGGTTGAAGATAACTACTACGTAAAGGAAAACTCCATGATCTATTTCGGGGCCAAGGGGGTGACGGTGGTGGGGGCGACCTGGACGCCGGATACCGCCCGCGAGCTGCACAAGCTGATCAAGCGGGTCAGCAGCAAGCCGGTGCTGGAGGTGATCAACACCAACTACCACACCGATCGGCGGGCCGGTAACGCCTACTGGAAGTCCATCGGGGCCAAGGTGGTGGCGACGCGCCAGACCAGGGATCTGATGAAGAGCGACTGGGCCGAGATTGTCGCCTTTACCCGCAAGGGGCTGCCGGAGTACCCGGATCTGCCGCTGGTGCTGCCCAACGTGGTGCACGATGGCGACTTCACCCTGCAAGAGGGCAAGGTGCGCGCCTTCTACGCGGGCCCGGCCCATACGCCGGACGGCATCTTTGTCTACTTCCCCGACGAGCAGGTGCTCTATGGCAACTGCATCCTCAAGGAGAAGCTGGGCAACCTGAGCTTTGCCAATGTGAAGGCCTATCCGCAGACCATCGAGCGACTGAAAGCGATGAAGTTGCCGATCAAGACGGTGATCGGCGGTCACGACTCACCGCTGCACGGGCCGAGCTTGATTGATCACTATGAAGCGCTGATCAAGGCAAGCCCTCATTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2110,Drugs,MEG_2110|Drugs|betalactams|Class_B_betalactamases|CPHA,gi|33150465|gb|AY261377.1|1-765,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTTGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGTTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6933,Drugs,MEG_6933|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6634544|emb|AJ251946.1|520-1380,0
,atggttaaaaaatcactgcgccagttcacgctcatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccagcagcggtgactatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcagcggctaaaatcgtcaccgacggttcgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2194,Drugs,MEG_2194|Drugs|betalactams|Class_A_betalactamases|CTX,1343491232|WP_104009848.1|NG_056409|1|1|blaCTX-M-187|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-187 NG_056409:1-876,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgctatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3475,Drugs,MEG_3475|Drugs|betalactams|Class_A_betalactamases|KPC,1121408346|WP_073668892.1|NG_055494|1|1|blaKPC-31|blaKPC|inhibitor-resistant_carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-31 NG_055494:101-982,0
,ATGACCTACAGCGAACCAGCGCGATCAGCTGCCCCCCGCACCGGATCGCCGGCGTCCGCCTCCTCCTCGGCCGTCTTGGCGAGGGGAATCACGATTTATGGTTGCGGATCGGACGAGGCCGCCTTGTTCCGGGAGATGGCTCCTCGTTTCGGCGTAATGCCGACCATTGTGGACGAGCCGGTATCCGAGGCGAATATCGGGCTGGTCTCCGGAAATCGATGCATCAGTATCGGTCACAAGACCAAGGTCACGAATTCCATTCTTCTCGCCCTCGCCGAAGCGGGCGTGGAATACATCTCCACCAGGAGCATCGGCTTCAACCACATCGATGTGGAATACGCGGCGAGCGTCGGTATCACCGTGGGCAATGTCGCCTACTCGCCCGACAGCGTCGCCGACTTCACGCTGATGCTGATGCTGATGGCGGTGCGCGACGCCAAGTCCATCATCCGCCGCACCGAGGTGCACGACTACCGGCTGAACGAGGTGCGCGGGAAAGAGCTGCGCGATCTGACCGTCGGAGTGGTCGGAACAGGGCGGATCGGGGTCGCGGTGCTGGACCGGCTGCGTGGTTTCGGCTGCCGGGTGCTGGCCTACGACACGCTGCTGACCGCCTCGGCCGATTACGTTCCGCTCGACGAATTGCTCCAGCAGAGCGACATCGTGACGCTCCATGTGCCGCTCAACAACGATACCTATCATCTTCTCGACCGGAAGAACATCGAGCGGATGAAGGACGGCGCGTACATCATCAACACCGGACGTGGCCCGCTCATCGAAACCGAAGCCCTCATTTCGGCACTGGAAGACGGCAAACTGGGCGGAGCGGCATTGGACGTCGTCGAAGGAGAGGAAGGCATCTTCTACGCCGACTGCCGGAACAAGCCGCTCGAGAGCGAAACGTTGCTGCGGCTGGAAAAGCTGCCGAACGTGCTCATCAGTCCGCATACCGCCTATTACACGGACCACGCACTGAGTGACACTGTTGAAAACTCCATCATCAATTGTCTCCAATTCGAAAGCGGGAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7401,Drugs,MEG_7401|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,(Gly)VanH-Ao2:HQ679900:1-1032:1032,5
,GTGAGTTTGGCGCCAGTGCAGGTTATTGGGGTTTTGAACGTCACTGACAATTCGTTCTCAGATGGCGGACGTTACCTTGATCCTGACGATGCTGTCCAGCACGGCCTGGCAATGGTCGCGGAAGGCGCGGCGATTGTCGACGTCGGTGGCGAATCGACCCGGCCCGGTGCCATTAGGACCGATCCTCGAGTTGAACTCTCTCGTATCGTTCCTGTCGTAAAAGAACTTGCAGCACAGGGGATTACAGTAAGTATCGATACTACGCGCGCTGATGTTGCACGGGCGGCGCTGCAAAGCGGCGCACGGATCGTCAACGATGTGTCTGGTGGGCGAGCAGATCCCGCGATGGCTCCTCTGGTGGCTGAAGCCGGTGTTGCGTGGGTGTTGATGCACTGGCGACTGATGTCGGCTGAACGGCCGTATGAGGCTCCGAATTACCGCGACGTGGTGGCTGAAGTGCGTGCCGACCTACTGGCTGGTGTCGATCAGGCTGTGGCCGCAGGTGTTGATCCTGGGAGTCTAGTGATCGATCCCGGGCTTGGATTCGCCAAGACGGGACAGCACAATTGGGCGCTGCTGAATGCGTTACCGGAGTTGGTGGCTACTGGGGTCCCGATTCTACTTGGCGCCTCGCGTAAACGGTTCCTGGGTAGGTTATTAGCTGGGGCTGATGGCGCGGTACGACCGCCGGACGGACGTGAGACGGCGACCGCGGTGATTTCCGCACTTGCTGCCCTACACGGGGCTTGGGGTGTTCGGGTGCACGATGTGCGTGCCTCGGTCGACGCACTCAAGGTCGTCGGGGCTTGGCTGCATGCTGGGCCGCAGATTGAAAAGGTTAGATGTGATGGCTGA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2935,Drugs,MEG_2935|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gb|AL450380|+|296695-297550|ARO:3003389|Mycobacterium leprae folP with mutation conferring resistance to dapsone [Mycobacterium leprae TN] ,8
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtgtcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_800,Drugs,MEG_800|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502091|WP_071846243.1|NG_052266|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052266:101-892,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgacgaggccccggcagatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttctccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactaccccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5628,Drugs,MEG_5628|Drugs|betalactams|Class_C_betalactamases|PDC,1034011075|WP_064483999.1|NG_050790|1|1|blaPDC-134|blaPDC|class_C_beta-lactamase_PDC-134 NG_050790:1-1194,0
,TTGATAATCCGATTTCTAGCACTGCTTTTCTCAGCTGTTGTACTTGTCTCTCTTGGTCATGCACAAGAAAAAACGCATGAGAGCTCTAATTGGGGGAAATACTTTAGTGATTTCAACGCTAAAGGTACAATAGTTGTAGTAGATGAACGCACAAACGGTAATTCCACATCGGTTTATAATGAATCCCGGGCTCAGCAGCGCTATTCGCCTGCGTCCACATTCAAGATTCCGCATACCCTTTTTGCGCTGGATGCAGGGGCGGTTCGCGATGAGTTTCATGTTTTTCGATGGGACGGCGCTAAAAGAAGCTTTGCAGGTCACAATCAAGACCAAAACCTACGATCGGCAATGCGCAATTCTACCGTTTGGGTCTATCAACTATTCGCAAAAGAAATAGGCGAAAACAAAGCACGAAGCTACCTAGAAAAATTAAACTACGGCAATGCAGACCCCTCGACCAAGAGCGGTGACTACTGGATAGATGGAAATCTTGCAATTTCAGCAAATGAACAAATTTCCATCCTAAAGAAGCTTTATCGAAATGAGCTTCCTTTTAGGGTAGAGCACCAACGCTTGGTTAAAGACTTGATGATTGTCGAAGCCAAACGCGATTGGATACTACGTGCCAAAACAGGCTGGGATGGTCAAATGGGTTGGTGGGTCGGTTGGGTAGAGTGGCCTACAGGCCCAGTATTTTTTGCGTTAAATATCGACACGCCAAACAGGATGGAAGACCTTCATAAACGAGAGGCAATTGCGCGTGCTATTCTTCAATCCGTCAATGCTTTGCCACCCAACTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_4747,Drugs,MEG_4747|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-20:AF024602:1238-2038:801,0
,ATGATGAAGCGCAATATTCTGGCAGTGGTGATCCCTGCCCTGCTGGTAGCCGGTGCAGCCAACGCTGCAGAAATCTATAACAAAAACGGCAACAAACTGGACTTCTATGGAAAAATGGTCGGCGAGCACGTCTGGACCACCAATGGCGACACCAGCAGCGACGATACCACCTATGCCCGTATCGGCCTGAAAGGCGAAACTCAGATCAACGATCAGCTGATCGGCTACGGCCAGTGGGAATACAACATGGACGCGTCCAATGTTGAAGGTTCCCAGACCACAAAAACCCGTCTGGCGTTCGCGGGCCTGAAAGCGGGCGAATACGGTTCATTCGACTATGGCCGTAACTACGGCGCGATCTACGACGTCGAAGCGGCAACCGATATGCTGGTTGAATGGGGCGGTGACGGCTGGAACTATACCGACAACTACATGACCGGTCGTACCAACGGCGTCGCAACCTACCGTAACTCCGACTTCTTCGGTCTGGTTGACGGTCTGAGCTTCGCGCTGCAGTACCAGGGTAAAAACGACCATGACCGTGCGATTCGCAAGCAGAATGGCGACGGCTTCAGCACCGCAGCCACCTACGCGTTCGACAACGGTATCGCACTGTCTGCAGGCTACTCCAGCTCTAACCGTAGCGTCGATCAGAAAGCTGACGGCAATGGCGACAAAGCCGAAGCCTGGGCGACCTCTGCAAAATATGACGCTAACAACATCTATGCGGCCGTCATGTACTCCCAGACTTACAACATGACTCCGGAAGAAGATAACCACTTCGCCGGTAAAACTCAGAACTTTGAAGCAGTTGTACAGTATCAGTTTGACTTCGGCCTGCGTCCGTCCATCGGCTACGTACAGACCAAAGGGCAAGGACCTGCAGTCGCGTGCTGGCTTCTCCGGCGGCGATGCGGATCTGGTTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,Multi-drug_resistance,MEG_4286,Drugs,MEG_4286|Drugs|Multi-drug_resistance|MDR_mutant_porin_proteins|OMPF,gi|150953431|gb|CP000647.1|1081235-1080309,1
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttatccacgtttgccgccgccaaaacagaaccacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggctgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcaccaataaccacccagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctacacggcaggcggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgtttttatcaaaactggcagccgcaatgggccccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaaggctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggtcaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcaatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggatccactggaggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccttgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1811,Drugs,MEG_1811|Drugs|betalactams|Class_C_betalactamases|CMY,1226997325|WP_094009802.1|NG_055473|1|1|blaCMY-155|blaCMY|class_C_beta-lactamase_CMY-155 NG_055473:1-1146,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaaaatataaaggaaattttttatcattataagggcgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcttatggaaatgcaaaaatttcaaaaatcgataccttttggctggataattctttgcaaatttctgcaaaaaatcaagctgatttactttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaacttcttctttttaaagaaaataaaatacaaaaaatttatgccaaaacaggttttaatgataatataaatttagcttggattgttggattcgtaaagactaaaaacaaaattttatcttttgctttaaatgttgatataaagcacattaaaaatattaaaataagagaagaattgctagaaaaatatctagcaattataacaaattag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4659,Drugs,MEG_4659|Drugs|betalactams|Class_D_betalactamases|OXA,1559613013|WP_128268278.1|NG_063884|1|1|blaOXA-783|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-783 NG_063884:1-750,0
,atgaaaaactactttgacagccctttcaaaggggagcttctttctgagcaagtgaaaaatccaaacatcaaagtaggccgttatagctattactctggctactatcacggccactcatttgatgaatgcgcgcgatacttgcatccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttctatatgcaagaggaacctgctttctcaagcgcactcgatgccttccaaagagcaggtgataccgccattggcaatgatgtctggataggctcggaggcaatgattatgcccggaatcaaaattggagacggtgccgtgataggtagtcgctcgttggtgacaaaagatgtagtgccttatgccatcatcggaggaagtcccgcaaagcaaattaagaagcgcttctccgatgaggaaatctcattgctcatggagatggagtggtggaactggccactggataaaattaagacagcaatgcctctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgtcgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1610,Drugs,MEG_1610|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,873902158|WP_048608591.1|NG_047615|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_047615:34-666,6
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGGTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6635,Drugs,MEG_6635|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|695211084|ref|NG_036020.1|2766-3605,8
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccgatgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaataccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgtaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6211,Drugs,MEG_6211|Drugs|betalactams|Class_A_betalactamases|SHV,1393270467|WP_109791212.1|NG_057611|1|1|blaSHV-204|blaSHV|class_A_beta-lactamase_SHV-204 NG_057611:1-861,0
,GGAGACACTTCAGCATGCATCCCGGCGTTGTTACTCTGCGTCCGATGACCGAAGACGACATCGGTATGCTTCACGAATGGTTGAATCGGCCGCACATTGTCGAATGGTGGGGTGGTGAGCGGCCCTCGCTCGAAGAGGTGAAAGAGGACTATCGGCCCAGCGCGTTGGCCGAAGAAGGAGTGACGCCGTACATCGGTTTGCTTGACGGAACTCCATTCGCGTTCGCACAGTCGTACGTTGCGCTCGGGTCGGGTGGTGGATGGTGGGAGGAAGAGACCGATCCTGGTGTCCGCGGAATCGATCAATCAATCGCCGATTCCGGGCTTCTCGGAAGAGGTTACGGCACTCGGCTGGTGCAGGCGCTTGTTGATTTGCTGTTCGCCGACCCGCAGGTATCCAAGGTTCAGACGGACCCCTCCCCGAACAACATGCGCGCGATACGCTGCTATGAGAAGGCAGGCTTCCGGAAGGTCAAGGTCGTTTCAACACCGGATGGGCCGGCCATGTACATGTTGCACGAGCGTCCGTTGGTGAACGGTTTGCGCAGTGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_336,Drugs,MEG_336|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|150950|gb|L06163.1|PSEAAC|518-1074,2
,GGCTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAAAGCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6465,Drugs,MEG_6465|Drugs|betalactams|Class_A_betalactamases|SHV,gi|5002313|gb|AF148851.1|AF148851|1-871 gi|675218243|emb|FO818745.1|22123-21261 gi|295917911|gb|GU732836.1|11-873 gi|110264421|gb|DQ449578.1|81849-80987 gi|695200097|ref|NG_035376.1|1439-2301 gi|43789|emb|X53433.1|929-1791 gi|150488|gb|M95179.1|P60BETALAC|185-1047 gi|695210228|ref|NG_035915.1|1-861,0
,atggacacaacgcaggtcacattgatacaccaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccaatggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_745,Drugs,MEG_745|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,489251152|WP_003159209.1|NG_052363|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052363:101-634,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgatgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagctgcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5444,Drugs,MEG_5444|Drugs|betalactams|Class_C_betalactamases|PDC,1028110196|WP_063864566.1|NG_049878|1|1|blaPDC-110|blaPDC|class_C_beta-lactamase_PDC-110 NG_049878:1-1194,0
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGTTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGAGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGAAGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6600,Drugs,MEG_6600|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695210449|ref|NG_035943.1|3369-4208,8
,ATGGCCCAGATCATAATGGTAAAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAACTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTCTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCGCCTAGGGTCATGTCCTTTTCCCATTCTGGGAACAGCCTTTTTTGCCCGTTCCACTTAAATACTTCTGTGGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGACCTTGATGGATAACTAAAACACCCGTAGTGTGTGCTTCGGTAAATAAATTTTTAATTTTCTCTGCTTTGTCATCAGATTTTGAAGCACTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGCTTTAATGTTCATAAGACTTATAAAAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5237,Drugs,MEG_5237|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389163|gb|KJ135342.1|1-887,0
,AAGGAGATTATGAATGAAAGCTAAAAGTAATAATTATAGAGGAAAAGTTGATATTAGTGTATCGCAAAATTTTATTACTAGTAAAAATACTATATATAAATTAATAAAAAAAACAAATATATCCAAAAATGATTTTGTTATTGAAATTGGACCAGGAAAAGGTCATATAACAGAAGCTTTATGTGAAAAAAGTTATTGGGTTACAGCTATAGAACTAGATAGAAGTTTATATGGAAATTTAATAAATAAATTTAAAAGTAAAAATAATGTTACTCTTATTAATAAAGATTTTTTAAATTGGAAATTACCTAAAAAAAGAGAATATAAGGTATTTTCTAATATTCCTTTTTATATAACAACAAAGATTATTAAGAAATTATTATTAGAAGAGTTAAATTCACCAACTGATATGTGGCTAGTTATGGAGAAAGGTTCCGCAAAAAGATTTATGGGAATACCTAGAGAGAGTAAATTATCATTACTTTTAAAAACTAAATTTGATATTAAGATAGTGCACTATTTTAATAGAGAAGACTTCCATCCCATGCCTAGTGTAGATTGCGTCTTAGTATATTTTAAAAGAAAATATAAATATGATATATCTAAAGATGAATGGAATGAATATACAAGTTTTATATCTAAGTCTATTAATAACTTAAGAGATGTATTTACAAAAAATCAAATTCATGCAGTAATTAAATACCTAGGTATAAATCTTAATAATATTAGTGAAGTTTCTTATAATGATTGGATACAGTTATTTAGATATAAACAAAAGATAGATTAG,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2842,Drugs,MEG_2842|Drugs|MLS|23S_rRNA_methyltransferases|ERMQ,gi|457207|gb|L22689.1|CLOERMQ|249-1035,7
,ATGCGTTATATTCGCCTGTGTATTATCTCCTTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6444,Drugs,MEG_6444|Drugs|betalactams|Class_A_betalactamases|SHV,gi|262212666|gb|GU083599.1|1-861,0
,atgaacattatcaatatcgggattcttgcccatgtagacgctggaaagacaaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgcttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggtgtgcaggcccagacccgtattctgttccatgccctgcggaaaatggacattcccaccgttatctttatcaataagatcgaccaggctggcgttgatttgcagggcgtgtatcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgaattattggaaaagtatatcgcaggagaaccaatcagccgggaagaacttgcgcaggaggaacagcggcgggttcaagacgcctccctgttcccggtctatcatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgacgccctatgcggcagcgttttcaaggtggagtatacagattgtggccagcggctcatctatttgcggctatacagcggaacgctgcgcctgcgggatacggtggctctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgttcagtaagatcactggttga,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7225,Drugs,MEG_7225|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100287|WP_063856422.1|NG_048295|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048295:101-2023,4
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacgacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_218,Drugs,MEG_218|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502223|WP_071846373.1|NG_052503|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052503:101-658,2
,ATGACGCGTAGCTATATCCCTCTTAACTCGCTGCGGGCTTTTGAAGCCGCGGCCAGACATCTCAGTTTTACCCGCGCCGCGATTGAGCTCAACGTGACGCATTCTGCCATCAGTCAGCATGTAAAAGCGCTGGAGCAGCAGCTAAATTGTCAGCTTTTTGTGCGCGGTTCTCGTGGATTAATGTTGACGACTGAAGGGGAAAGTCTGTTACCTGTACTTAATGACTCTTTCGATCGTATGGCGGGGATGCTGGATCGTTTTGCCACCAAACAGACCCAGGAAAAACTTAAAATTGGCGTGGTGGGGACCTTTGCGGCTGGGTGTCTGTTTCCTCTACTGGGCGATTTTAAGCGCAGTTACCCGCATATTGATTTGCATATTTCTACCCATAATAACCGCGTGAATCCCGCTGCCGAAGGGCTGGATTATACCATTCGCTACGGAGGGGGAGCCTGGCACGATACCGACGCGCAATATTTATGTAGCGCGTTGATGTCTCCACTGTGTTCGCCAACATTGGCTTCGCAGATTCAAACGCCTGCGGACATCCTGAAATTTCCGTTATTACGATCGTATCGGCGGGATGAATGGACGCTTTGGATGCAGGCCGCCGGAGAGGCGCCCCCGTCACCGACGCACAACGTGGTGGTGTTTGATTCGTCCGTCACCATGCTGGAAGCCGCGCAGGCGGGGATCGGTGTGGCAATTGCACCAGTCAGAATGTTCACGCATTTACTCAGTAGGGAACGAATCGTTCAACCGTTTTTAACGCAGATTGATTTGGGAAGTTACTGGATAACGCGTTTGCAATCGCGTCCGGAGACACCCGCGATGCGTGAATTTTCCCGTTGGTTGACAGGAATGCTGCACAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1992,Drugs,MEG_1992|Drugs|betalactams|Class_C_betalactamases|CMY,gi|695210321|ref|NG_035929.1|4918-5793,0
,ATGAATAGAATAAAAGTTGCAATATTGTTTGGGGGTTGCTCAGAGGAGCATGACGTATCTGTAAAATCCGCAATAGAAATAGCCGCTAACATTGATAAAGAAAAATACGAGACGTTATACATTGGGATTACCAAATCTGGTGTATGGAAAATGTGTGAAAAACCGTGCGTGGAATGGGAAAACGACAATTGCTGTTCAGCAGTACTCTCGCCGGATAAAAAAATGCACGGATTACTTGTTAAAAAGAACCATGAATATGAAATCGACCACGTTGATGTAGCATTTTCGGTTTTGCACGGCAAGTCGGGTGAAGATGGATCAATACAAGGTCTTTTTGAATTGTCCGGTATCCCCTTTGTAGGCTGCGATATTCAAAGCTCAGCGATTTGTATGGACAAATCACTGACATACATCGTTGCGGAAAATGCTGGCATAGCTACTCCCGAATTTTGGGTTTTTAATAAAGACGATAAGCCGATGGCAGATACGTTTACCTATCCTGTTTTTGTTAAGCCTGCGCGTTCAGGCTCATCCTTTGGCGTGAAAAAGGTCAATGGAGCAGACGAATTGGACGCCGCAATTGAATTGGCTGGACAATATGACAGCAAAATCTTAATTGAGCAGGCTGTTTTGGGCTGTGAGGTCGGTTGTGCCGTATTGGGAAACAGTTCCGCTTTTGTTGTTGGCGAGGTAGACCAAATCAGACTGCAGCACGGAATCTTTCGTATTCATCAGGAAGCCGAGCCGGAAAAAGGCTCTGAAAACGCAGTTATAACCGTTCCCGCAGACCTGTCGGCAGAGGAGCGAGGACGGATACAGGAAACGGCAAAAAAAATATATAATGCGCTCGGCTGTAGAGGTCTAGCCCGTGTCGATATGTTTTTACAAGATAACGGCCGCATTGTACTGAACGAAGTCAATACCCTGCCCGGTTTCACTTCATACAGCCGTTATCCTCGTATGATGGCCGCTGTAGGTATTGCATTTCCCGAATTGATTGACCGCTTGATTGTATTAGCGTTAAAGGGGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7337,Drugs,MEG_7337|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,(Gly)VanHA-Bc:Y15704:23-1054:1032,5
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaagtataccgttctttatccgcattagacggagcagtattattagtttctgcaaaggatggcatacaggcacagacccgtatactgtttcatgcactacagataatgaagattccgacaatttttttcatcaataaaattgaccaagaggggattgatttgccaatggtatatcgggaaatgaaagcaaagctttcttcggaaattatagtgaagcaaaaggttgggcagcatccccatataaatgtaacggacaatgacgatatggaacagtgggatgcggtaattatgggaaacgatgaactattagagaaatatatgtcagggaaaccgtttaaaatgtcagaactggaacaggaagaaaacaggagattccaaaacggaacgttatttcccgtttatcacggaagcgctaaaaacaatctggggattcggcagcttatagaagtaattgccagtaaattttattcatcaacgcctgaaggtcaatctgaactatgcgggcaggtttttaagattgaatattcagagaaaaggcggcgttttgtttatgtgcgtatatatagcggaacattgcatttgagggatgttattagaatatctgaaaaagagaaaataaaaatcacagagatgtatgttccgacaaacggtgaattatattcatccgatacagcctgctctggtgatattgtaattttaccaaatgatgttttgcagctaaacagtattttggggaacgaaatactgttgccgcagagaaaatttattgaaaatcctctccctatgatccaaacaacgattgcagtaaagaaatctgaacagcgggaaatattgcttggggcacttacagaaatttcagattgcgaccctcttttaaaatattatgtggatactacaacgcatgagattatactttcttttttggggaatgtgcagatggaagtcatttgtgccatccttgaggaaaaatatcatgtggaggcagaaataaaagagcctactgttatatatatggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7151,Drugs,MEG_7151|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,488999204|WP_002909882.1|NG_048263|1|1|tet(O)|tet(O)|tetracycline_resistance_ribosomal_protection_protein_Tet(O) NG_048263:101-2020,4
,atgcgcgataccagatttccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggctctgggcgcaggcgcttgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccacggccgagcgggtgaagatcgcctacaccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5702,Drugs,MEG_5702|Drugs|betalactams|Class_C_betalactamases|PDC,1028110200|WP_063864570.1|NG_049883|1|1|blaPDC-13|blaPDC|class_C_beta-lactamase_PDC-13 NG_049883:1-1194,0
,CAGACCAAGTTAATAAGAGCTATTGGTGGATGCCTTGGCATTGACAGGCGAAGAAGGACGCGAATACCTGCGAAAAGCTCCGGCGAGCTGGTGATAAGCAAAGACCCGGAGGTATCCGAATGGGGAAACCCGGTAGAGTAATAGACTACCATTGCATGCTGAATACATAGGTATGCAAAGCGACACCTGCCGAACTGAAACATCTTAGTAAGCAGAGGAAAAGAAATCGAAGAGATTCCCTGTGTAGCGGCGAGCGAAAGGGGAATAGCCTAAACCGAGCTGATAAGGCTCGGGGTTGTAGGATTGAGGATAAAGGATCAGGACTCCTAGTTGAACACATCTGGAAAGATGGATGATACAGGGTGATAGTCCCGTAGACGAAAGGAGAGAAAGACCGACCTCAACACCTGAGTAGGACTAGACACGTGAAACCTAGTCTGAATCTGGGGAGACCACTCTCCAAGGCTAAATACTAGTCAATGACCGATAGTGAACCAGTACTGTGAAGGAAAGGCGAAAAGAACCCTTGTTAAGGGAGTGAAATAGAACCTGAAACCAGTAGCTTACAAGCGGTCGGAGACCAATGGCCCGTAAGGGTCAAGGTTGACGGCGTGCCTTTTGCATGATGAGCCAGGGAGTTAAGCTAAACGGCGAGGTTAAGGGATATACATTCCGGAGCCGGAGCGAAAGCGAGTTTTAAAAGAGCGAAGAGTCGTTTGGTTTAGACACGAAACCAAGTGAGCTATTTATGACCAGGTTGAAGCATGGGTAAAACTATGTGGAGGACCGAACTAGTACCTGTTGAAAAAGGTTTGGATGAGTTGTGAATAGGGGTGAAAGGCCAATCAAACTTGGAGATATCTTGTTCTCTCCGAAATAACTTTAGGGTTAGCCTCGGATAATAAGCTTTTGGGGGTAGAGCACTGAATTCTAGCGGGGGCCTACCGGCTTACCAACGGAAATCAAACTCCGAATACCAGAAGCGAGTCCGGGAGATAGACAGCGGGGGCTAAGCTTCGTTGTCGAGAGGGGAACAGCCCAGACCGCCGATTAAGGTCCCTAATTTTATGCTAAGTGGGTAAGGAAGTGATGATTCGAAGACAGTTGGAATGTTGGCTTAGAGGCAGCAATCATTTAAAGAGTGCGTAACAGCTCACCAATCGAGAATCATTGCGCCGATAATAAACGGGACTAAGCATAAAACCGACATCGCGGGTGTGTCGATAAGACACGCGGTAGGAGAGCGTAGTATTCAGCAGAGAAGGTGTACCGGAAGGAGCGCTGGAGCGGATACTAGTGAAGATCCATGGCATAAGTAACGATAAAGGGAGTGAAAATCTCCCTCGCCGTAAGCCCAAGGTTTCCAGGGTCAAGCTCGTCTTCCCTGGGTTAGTCGGCCCCTAAGTTGAGGCGTAACTGCGTAGACGATGGAGCAGCAGGTTAAATATTCCTGCACCACCTAAAACTATAGCGAAGGAATGACGGAGTAAGTTAAGCACGCGGACGATTGGAAGAGTCCGTAGAGCGATGAGAACGGTTAGTAGGCAAATCCGCTAACATAAGATCAGGTCGCGATCAAGGGGAATCTTCGGGGGAACCGATGGTGTGGAGCGAGGCTTTCAAGAAATAATTTCTAGCTGTTGATGGTGACCGTACCAAAACCGACACAGGTGGGCGAGATGAATATTCTAAGGCGCGCGAGATAACTTTCGTTAAGGAACTCGGCAAATTATCCCCGTAACTTCGGAATAAGGGGAGCCTTTTAGGGTGACTATGGAACGATAGGAGCCCCGGGGGGCCGCAGAGAAATGGCCCAGGCGACTGTTTAGCAAAAACACAGCACTATGCAAACCTCTAAGGGGAAGTATATGGTGTGACGCCTGCCCAATGCCAAAAGGTTAAAGGGATATGTCAGCTGCAAAGCGAAGCATTGAACCTAAGCCCTGGTGAATGGCCGCCGTAACTATAACGGTGCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGTGTAACGATCTGGGCACTGTCTCAACGAAAGACTCGGTGAAATTGTAGTAGCAGTGAAGATGCTGTTTACCCGCGAAAGGACGAAAAGACCCCGTGAACCTTTACTGTACTTTGGTATTGATTTTTGGTTTGTTATGTGTAGGATAGCCAGGAGACTAAGAACACTCTTCTTCAGGAGAGTGGGAGTCAACGTTGAAATACTGGTCTTAACAAGCTGGGAATCTAACATTATTCCATGAATCTGGAAGATGGACATTGCCAGACGGGCAGTTTTACTGGGGCGGTATCCTCCTAAAAAGTAACGGAGGAGCCCAAAGCTTATTTCATCGTGGTTGGCAATCACGAGTAGAGCGTAAAGGTATAAGATAGGTTGACTGCAAGACCAACAAGTCGAGCAGAGACGAAAGTCGGGCTTAGTGATCCGGCGGTGGAAAGTGGAATCGCCGTCGCTTAACGGATAAAAGGTACTCCGGGGATAACAGGCTGATCGCCACCAAGAGTTCATATCGACGTGGCGGTTTGGCACCTCGATGTCGGCTCATCGCATCCTGGGGCTGGAGAAGGTCCCAAGGGTTTGGCTGTTCGCCAATTAAAGCGGTACGCGAGCTGGGTTCAAAACGTCGTGAGACAGTTTGGTCTCTATCCTTCGTGGGCGCAGGATACTTGAGAGGAGCTGTTCCTAGTACGAGAGGACCGGAATGGACGAACCAATGGTGTGTCGGTTGTTTTGCCAAGGGCATAGCCGGGTGGCTCACGTTCGGAAAGGATAAGCATTGAAAGCATCTAAATGCCAAGCCTCCCTCAAGATAAGGTATCCCAATGAGACTCCATGTAGACTACGTGGTTGATAGGTTGGAGGTGTAAGCACAGTAATGTGTTCAGCTAACCAATACTAATAAGTCCAAAGACTTGGTCTT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3986,Drugs,MEG_3986|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NR_076160.1|+|0-2940|ARO:3004174|Chlamydia trachomatis 23S rRNA with mutation conferring resistance to macrolide antibiotics [Chlamydia trachomatis] ,7
,atgaaaaaccaacgtcttacgcccctagcagctttcttacttttaatcagtgtggctgctacggctcacactctcccatcacaaggtacagaaacaaaaggtgcagaaacaaatagtcccgccatcacctcactgacagggtgcggtccatcctcagctatcaaccaatttttcaaccaatttggaagcagcggtaaaatgcctgccgaacttggacgttggctgaatgatgcaaaggcccaggccgtcgaaccctatcaggtatttgacaatgtttattatgtcggcatttgttgggtctcagcctggctcatcaaaaccagcgaaggcccagtactaatagatacgctgtatggagaatttacagaccagcttatggataacattaaaaaaatcggcgtcgagccatcagatatcaaaatggtactgctaacacacggacattttgatcatgtaggcggcgtatctaaactcaagtcgttaaccaacgcacgttttgtcatgtctgaggaaggatggaaggaagcgcaggctgatgcaaaaaaaacactggggaaacctagcgcatgggcaatgcctgacccagccaccacagatatcttggtgaaagacggcgatgcgttgacggtgggtgatactacatttcatgcctacattaccccaggccacacttggggcaccacatcttatgtgcttgatgtcaaagagaggaataacacctatcacgcgattactattggcggattaggattaaatgctatagacggtccgcaacaggttgaggcctacatccgaagcatagaccgtattaaggtgatggtggaagattctaagcaccccattacagtccatctcaccgcgcatccttttagtaacggtcaaattgaaatgcaaaatcaactaaaagtacatcagcctgaccaaccacaccccatggtagatgcaaaagggctcctcaaacagttggcgacactccgcgcaggagcaatagaacgactggccgttgaacaggcacggattcaaaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1250,Drugs,MEG_1250|Drugs|betalactams|Class_B_betalactamases|BLAB,499406915|WP_011094382.1|NG_048712|1|1|blaCAR-1|bla-B3-CAR|subclass_B3_metallo-beta-lactamase_CAR-1 NG_048712:101-1129,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6439,Drugs,MEG_6439|Drugs|betalactams|Class_A_betalactamases|SHV,gi|257043769|gb|GQ407126.1|1-861,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGATATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATTATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTCCTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4316,Drugs,MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_17_ALZI01000051 ,1
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTCAACATTGAGGAAGAGCTGAAGAGCTCCTATCTGGATTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCAGATGTCCGAGATGGCCTGAAGCCGGTACACCGTCGCGTACTTTACGCCATGAACGTACTAGGCAATGACTGGAACAAAGCCTATAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGACTCGGCAGTTTATGACACGATCGTCCGTATGGCGCAGCCATTCTCGCTGCGTTACATGCTGGTAGACGGTCAGGGTAACTTCGGTTCCATCGACGGCGACTCTGCGGCGGCAATGCGTTATACGGAAATCCGTCTGGCGAAAATTGCCCATGAACTGATGGCCGATCTCGAAAAAGAGACGGTCGATTTCGTTGATAACTATGACGGCACGGAAAAAATTCCCGACGTCATGCCAACCAAAATTCCTAACCTGCTGGTGAACGGTTCTTCCGGTATCGCCGTAGGTATGGCAACCAACATCCCGCCGCACAACCTGACGGAAGTCATCAACGGTTGTCTGGCGTATATCGATGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGGCCGGACTTCCCGACGGCGGCAATCATTAACGGTCGTCGCGGTATTGAAGAAGCTTACCGTACCGGTCGCGGCAAGGTATATATCCGCGCCCGTGCTGAAGTGGAAGTTGACGCCAAAACCGGACGTGAAACCATTATCGTCCACGAAATCCCGTATCAGGTAAACAAAGCGCGCCTGATCGAGAAGATTGCGGAACTGGTAAAAGAAAAACGCGTGGAAGGCATCAGCGCGCTGCGTGACGAGTCTGACAAAGACGGTATGCGCATCGTGATTGAAGTGAAACGCGATGCGGTCGGTGAAGTTGTGCTCAACAACCTCTACTCCCAGACCCAGTTGCAGGTTTCTTTCGGTATCAACATGGTGGCATTGCACCATGGTCAGCCAAAGATCATGAACCTGAAAGACATCATCGCGGCGTTTGTTCGTCACCGCCGTGAAGTGGTGACCCGTCGTACTATTTTCGAACTGCGTAAAGCTCGCGATCGTGCTCATATCCTTGAAGCATTAGCCGTGGCGCTGGCGAACATCGACCCGATCATCGAACTGATCCGTCATGCGCCGACGCCTGCAGAAGCGAAAACTGCGCTGGTGGCTAATCCGTGGCAGCTGGGCAACGTTGCCGCGATGCTCGAACGTGCTGGCGACGATGCTGCGCGTCCGGAATGGCTGGAGCCAGAGTTCGGCGTGCGTGATGGTCTGTACTACCTGACCGAACAGCAAGCTCAGGCAATTCTGGATCTGCGTTTGCAGAAACTGACCGGCCTTGAGCACGAAAAACTGCTCGACGAATACAAAGAGCTGCTGGATCAGATCGCGGAACTGCTGCGTATTCTTGGTAGCGCCGATCGTCTGATGGAAGTGATCCGTGAAGAGCTGGAGCTGGTTCGTGAACAGTTCGGTGACAAACGTCGTACTGAAATCACCGCCAACAGCGCAGACATCAACCTGGAAGATCTGATCACCCAGGAAGATGTGGTCGTGACGCTCTCTCACCAGGGCTACGTTAAATATCAGCCGCTTTCTGAATACGAAGCGCAGCGTCGTGGCGGGAAAGGTAAATCTGCCGCACGTATTAAAGAAGAAGACTTTATCGACCGACTGCTGGTGGCGAACACGCACGACCATATTCTGTGCTTCTCCAGCCGTGGTCGCGTCTATTCGATGAAAGTTTACCAGTTGCCGGAGGCCACTCGTGGCGCGCGCGGTCGTCCGATCGTCAACCTGCTGCCGCTGGAGCAGGACGAACGTATCACCGCGATCCTGCCGGTGACCGAGTTTGAAGAAGGCGTGAAAGTCTTCATGGCGACCGCTAACGGTACTGTGAAGAAAACCGTCCTCACCGAGTTCAACCGTCTGCGTACCGCCGGTAAAGTGGCGATCAAACTGGTTGAAGGCGATGAGCTGATCGGCGTTGACCTGACCAGCGGCGAAGACGAAGTAATGCTGTTCTCCGCCGAAGGTAAAGTGGTGCGCTTTAAAGAGTCTTCTGTCCGTGCGATGGGCTGCAACACCACCGGTGTTCGCGGTATTCGTTTAGGCGAAGGTGATAAAGTCGTCTCTCTGATCGTGCCTCGTGGCGATGGCGCAATCCTCACCGCAACGCAGAACGGTTATGGTAAACGTACCGCAGTGGCGGAATACCCGACTAAGTCGCGTGCGACGAAAGGGGTTATCTCCATCAAGGTTACCGAACGTAACGGTTTAGTTGTTGGCGCGGTACAGGTAGATGACTGCGACCAGATCATGATGATCACCGATGCCGGTACGCTGGTACGTACTCGCGTTTCAGAAATCAGCATCGTGGGCCGTAACACCCAGGGCGTGATCCTCATCCGTACTGCGGAAGATGAAAACGTAGTGGGTCTGCAACGTGTTGCTGAACCGGTTGACGAGGAAGATCTGGATACCATCGACGGCAGTGCCGCGGAAGGGGACGATGAAATCGCTCCGGAAGTGGACGTTGACGACGAGCCAGAAGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3227,Drugs,MEG_3227|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|937297913|gb|CP012802.1|2937681-2935054 gi|667689599|gb|CP008957.1|3153509-3150882 gi|386794017|gb|CP001925.1|2993275-2990648 gi|209765559|gb|EU898541.1|1-2628 gi|47118301|dbj|BA000007.2|3065190-3062563,3
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATTATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACTATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4310,Drugs,MEG_4310|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_3_KT862780 ,1
,atgaaaaagttatcagtattctttatgtttttgttttgtagcattgctgcctcaggagaggctttgccagatttaaaaattgagaagcttgacgaaggcgtttatgttcatacttcgtttgaggaagttaacggctggggcgtggctcctaaacacggcttggtggttcttgtaaatactgacgcttatttgattgacactccatttacagctaaagatactgaaaagttagttacttggtttgtagagcgcggctataaaataaaaggcagtatctcctctcattttcatagcgacagcacgggcggaatagagtggcttaattctcaatctattccaacatatgcatctgaattaacaaatgaacttcttaaaaaagacggtaaggtacaagctaaaaattcatttagcggagccagctattggttagttaagaaaaagattgaaattttttatcctggcccagggcacactccagataacgtagtggtttggctacctgaacatagagttttgtttggtggttgttttgttaaaccgtatggtctaggtaatttgggtgacgcaaatttagaagcttggccaaagtctgccaaattattagtgtccaaatatggtaaggcaaaactggttgttccaagtcacagtgaagttggagatgcatcactcttgaaacgtacattagaacaggctgttaaaggattaaacgaaagtaaaaagctatcaaaaccaagtaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3325,Drugs,MEG_3325|Drugs|betalactams|Class_B_betalactamases|IMP,1391852868|WP_109545053.1|NG_057463|1|1|blaIMP-73|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-73 NG_057463:1-741,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2227,Drugs,MEG_2227|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-79:GU125702:1-876:876,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1426,Drugs,MEG_1426|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_136_NZ_ALWE01000009,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgagaccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcagccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5601,Drugs,MEG_5601|Drugs|betalactams|Class_C_betalactamases|PDC,1034011053|WP_064483996.1|NG_050787|1|1|blaPDC-131|blaPDC|class_C_beta-lactamase_PDC-131 NG_050787:1-1194,0
,atgagggactcagtgaccgccgaaatttcgacgcaactatccaaggtgcttagtgttatcgagcaccatctggaaccgacgttgcttgccgtacatttgtacggctccgcagtggatggcggcctgaagccatacagtgatattgatttgctggttactgtgaccgcaaggcttgatgacacaacgcggcgagctttgttcaacgatcttttggaggtttcggctttcccaggcgagagtgagattctccgcgctatagaagtcaccattgtcgtgcacgaagacattaggccgtggcgttatccagccaagcgcgaactgcaatttggagaatggcagcgtaatgacattcttgcgggtatcttcgagccagccacgatcgacatcgatctggctatcttgctaacgaaagcgagagaacatagcgtggctttggtaggtccggcggcggaggaactctttgatccagttcctgaacaagatctaatcaaggcgctgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgctgtcccgcatttggtacagcgcagcaactggtaaaatcgcgccgaaggatgtcgctgccgactgggcaatggaacatctacctgcccagcataagtctgtcttgcttgaagctagacaggcttatcttgggcaagaggaagatcgctcggtcttgcgcgcagataagttggaagaatttattcacttcatgaaaagcgagatcaccaaggtgctcggcaatgatgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_851,Drugs,MEG_851|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,501382614|WP_012414180.1|NG_047335|1|1|aadA13|aadA13|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA13 NG_047335:101-898,2
,atgagggactcagtgaccgccgaaatttcgacgcaactatccaaggtgcttagtgttatcgagcaccatctggaaccgacgttgcttgccgtacatttgtacggctccgcagtggatggcggcctgaagccatacagtgatattgatttgctggttactgtgaccgcaaggcttgatgacacaacgcggcgagctttgttcaacgatcttttggaggtttcggctttcccaggcgagagtgagattctccgcgctatagaagtcaccattgtcgtgcacgaagacattatgccgtggcgttatccagccaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcgggtatctccgagccagccatgatcgacgttgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagctgcggaggaactctttgatcccgttcctgaacaggatctattcgaggcactgaatgaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_852,Drugs,MEG_852|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502111|WP_071846263.1|NG_052304|1|1|ant(3'')-Ia|ant(3'')-Ia|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA NG_052304:101-892,2
,atgatgactaaatccctttgctgcgccctgctgctcagcacctcctgctcggtattggctgcaccgatgtcagaaaaacagctggctgagatggtggaacgtaccgttacgccgctgatgaaagcgcaggccattccgggtatggcggtggcggtgatttatcagggtcagccgcactactttaccttcggtaaagccgatgttgcggcgaacaaacctgtcaccccacaaaccttattcgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgctcggggtgaaatatcgctgggcgatccggtgaccaaatactggcctgaactgacaggcaagcagtggcaggggatccgcatgctggatctggcaacctataccgcaggaggtttgccgttacaggtaccggatgaggtcacggataacgcctctctgctgcgcttttatcaaaactggcagcctcagtggaagccgggcaccacgcgtctttacgccaacgccagcatcggtctttttggcgcgctggcggtcaaaccttccggcatgagctatgagcaggccataacgacgcgggtctttaagcggctcaagctggaccatacctggattaacgttccgaaagcggaagaggcgcattacgcctggggataccgcgacggtaaggcggtacacgtttcgccaggaatgctggacgctgaagcctatggcgtaaaaaccaacgtgaaggatatggcaaactgggtgatggtcaacatgaagccggactcgcttgaggatagttcactcaggaaaggccttaccctggcgcagtctcgctactggcgcgtgggtgccatgtatcaggggttaggctgggaaatgcttaactggccggtcgatgcaaaaaccgtggttgaaggtagcgacaataaggtggcgctggcaccgctgcctgcgagagaagtgaatccaccggcgcccccggtcaatgcgtcatgggtccataaaacaggctctaccggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_442,Drugs,MEG_442|Drugs|betalactams|Class_C_betalactamases|ACT,1236136932|WP_094935119.1|NG_061418|1|1|blaACT-57|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-57 NG_061418:1-1146,0
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcaaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaatgagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtacctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3090,Drugs,MEG_3090|Drugs|betalactams|Class_A_betalactamases|GES,1331531450|WP_102607460.1|NG_056177|1|1|blaGES-34|blaGES|class_A_beta-lactamase_GES-34 NG_056177:1-864,0
,ATGCGTAAAAAAATGCAGAACACATTGAAGCTGTTATCCGTGATTACCTGTCTGGCAGCAACTGCCCAAGGTGCTCTGGCTGCTAATATCGATGAGAGCAAAATTAAAGACACCGTTGATGACCTGATCCAGCCGCTGATGCAGAAGAATAATATTCCCGGTATGTCGGTCGCAGTGACCGTCAACGGTAAAAACTACATTTATAACTATGGGTTAGCGGCAAAACAGCCTCAGCAGTCGGTTACGGAAAATACGTTATTTGAAGTGGGTTCGCTAAGTAAAACGTTTGCTGCCACCTTGGCGTCCTATGCGCAGGTGAGCGGTAAGCTGTCTTTGGATCAAAGCGTTAGCCATTACGTTCCAGAGTTGCGTGGCAGCAGCTTTGACCACGTTAGCGTACTCAATGTGGGCACGCATACCTCAGGCCTACAGCTATTTATGCCGGAAGATATTAAAAATACCACACAGCTGATGGCTTATCTAAAAGCATGGAAACCTGCCGATGCGGCTGGAACCCATCGCGTTTATTCCAATATCGGTACTGGTTTGCTAGGGATGATTGCGGCGAAAAGTCTGGGTGTGAGCTATGAAGATGCGATTGAGAAAACCCTCCTTCCTCAGTTAGGCATGCATCACAGCTACTTGAAGGTTCCGGCTGACCAGATGGAAAACTATGCGTGGGGCTACAACAAGAAAGATGAGCCAGTGCACGTGAATATGGAGATTTTGGGTAACGAAGCTTATGGTATCAAAACCACCTCCAGTGACTTGTTACGCTACGTGCAAGCCAATATGGGGCAGTTAAAGCTTGATGCTAATGCCAAGATGCAACAGGCTCTGACTGCCACCCACACCGGCTATTTCAAATCGGGTGAGATTACTCAGGATCTGATGTGGGAGCAGCTGCCATATCCGGTTTCTCTGCCGAATTTGCTCACCGGTAACGATATGGCGATGACGAAAAGCGTGGCTACGCCGATTGTTCCCCCGTTACCGCCACAGGAAAATGTGTGGATTAATAAGACCGGATCAACTAACGGCTTCGGTGCCTATATTGCGTTTGTTCCTGCTAAGAAGATGGGGATCGTGATGCTGGCTAACAAAAACTACTCAATCGATCAGCGAGTGACGGTGGCGTATAAAATCCTGAGCTCATTGGAAGGGAATAAGTAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_394,Drugs,MEG_394|Drugs|betalactams|Class_C_betalactamases|ACC,blaACC-1d_1_ADCU02000001,0
,ATGTCTCCGATCGAGCCCGCGGCGTCTGCGATCTTCGGACCGCGGCTTGGCCTTGCTCGGCGGTACGCCGAAGCGTTGGCGGGACCCGGTGTGGAGCGGGGGCTGGTGGGACCCCGCGAAGTCGGTAGGCTATGGGACCGGCATCTACTGAACTGCGCCGTGATCGGTGAGCTCCTCGAACGCGGTGACCGGGTCGTGGATATCGGTAGCGGAGCCGGGTTGCCGGGCGTGCCATTGGCGATAGCGCGGCCGGACCTCCAGGTAGTTCTCCTAGAACCGCTACTGCGCCGCACCGAGTTTCTTCGAGAGATGGTGACAGATCTGGGCGTGGCCGTTGAGATCGTGCGGGGGCGCGCCGAGGAGTCCTGGGTGCAGGACCAATTGGGCGGCAGCGACGCTGCGGTGTCACGGGCGGTGGCCGCGTTGGACAAGTTGACGAAATGGAGCATGCCGTTGATACGGCCGAACGGGCGAATGCTCGCCATCAAAGGCGAGCGGGCTCACGACGAAGTACGGGAGCACCGGCGTGTGATGATCGCATCGGGCGCGGTTGATGTCAGGGTGGTGACATGTGGCGCGAACTATTTGCGTCCGCCCGCGACCGTGGTGTTCGCACGACGTGGAAAGCAGATCGCCCGAGGGTCGGCACGGATGGCGAGTGGAGGGACGGCGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_3135,Drugs,MEG_3135|Drugs|Aminoglycosides|Aminoglycoside-resistant_gidB|GIDB,gb|AL123456|-|4407527-4408202|ARO:3003470|Mycobacterium tuberculosis gidB mutation conferring resistance to streptomycin [Mycobacterium tuberculosis H37Rv] ,2
,atgatgaaaaaatccctaagttgtgccctgctgctcagcgttgcctgctctgccttcgccgcccccatgtcagaaaaacagctggctaaggtggtggagcgtgccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccgcactactttacctttggtaaagcggatgtcgcggcgaataaacctgttacgcctcaaaccttgttcgagctgggctctataagtaaaaccttcaccggcgtattgggtggcgatgcgattgctcgcggtgaaatctcactgggtgatccagtgacaaggtactggcctgaactgacaggaaaacagtggcagggcattcgcatgctggatctggcaacctataccgcaggggggttgccgttacaggtaccggatgacgtcactgataacgcctctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttatgccaacgccagcatcggtctttttggtgctctcgcggttaaaccctccggcatgagttttgaagaggccatgacgaagcgggtctttaagccgctcaggctcgaccatacgtggattaacgtaccaaaagcggaagaggcgcattacgcctggggataccgtgacggtaaagcggtacacgtttctccagggatgctggacgctgaagcctatggcataaaaaccaacgtgaaagatatggcgagctgggtggtggcaaacatggcccccgatgcccttcaggatagctctctcaaacaagggatagccctggcacagtcccgctactggcgcgtgggtgccatgtatcaggggttaggctgggaaatgctgaactggccggtcgatgccaaaaccgtggtcgggggcagcgacaataaggtggcgctggcgccgttgcctgccagagaagtcaatcccccggtaccgccggttaaggcctcctgggtacacaaaacgggttcaaccggtgggtttgggagctacgtggcatttattcctgaaaaacagctcggcattgtgatgctggcgaataaaagctatccgaatccggcacgcgttgagacggcataccgtatcctcgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_420,Drugs,MEG_420|Drugs|betalactams|Class_C_betalactamases|ACT,772675957|WP_045286607.1|NG_050713|1|1|blaACT-50|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-50 NG_050713:1-1146,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcgtccaaattaaacgaagacatatccatcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgataagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1516,Drugs,MEG_1516|Drugs|betalactams|Class_A_betalactamases|CARB,658998526|WP_029834158.1|NG_048732|1|1|blaCARB-29|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-29 NG_048732:1-852,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcgagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagtatcaacatttaagatccccagcgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagctgttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtgacattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4422,Drugs,MEG_4422|Drugs|betalactams|Class_D_betalactamases|OXA,1270501124|WP_099156044.1|NG_055653|1|1|blaOXA-368|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-368 NG_055653:101-901,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaattcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtgggttggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4492,Drugs,MEG_4492|Drugs|betalactams|Class_D_betalactamases|OXA,1559612981|WP_128268246.1|NG_063851|1|1|blaOXA-747|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-747 NG_063851:26-850,0
,ATGATGAAAGGTTGGATAAAGTGCGGGCTGGCCGGGGCCGTGGTGCTGATGGCGAGTTTCTGGGGGGGCAGCGTGCGGGCGGCGGGGATGTCGCTGACGCAGGTGAGCGGCCCTGTGTATGTGGTGGAGGACAACTACTACGTACAGGAAAACTCCATGGTCTATTTCGGGGCCAAGGGGGTGACGGTGGTGGGGGCGACCTGGACGCCGGATACCGCCCGCGAGCTGCACAAGCTGATCAAACGGGTCAGCAGCAAGCCCGTGCTGGAGGTGATCAACAACAACTACCACACCGACCGGGCAGGCGGTAACGCCTACTGGAAGTCCATCGGTGCCAAGGTGGTATCGACCCGCCAGACCCGGGAGCTGATGAAGAGCGACTGGGCCGAGATCGTCGCCTTTACCCGCAAGGGGTTGCCGGAGTATCCGGACTTGCCGCTGGTGCTGCCCAACGTGGTGCACGATGGCGACTTCACCCTGCAAGAGGGCAAGCTGCGCGCCTTCTACGCGGGCCCGGCCCATACCCCGGACGGCATCTTTGTCTACTTCCCCGATGAGCAGGTGCTCTATGGCAACTGCATTCTCAAGGAGAAGCTGGGCAACCTGAGCTTTGCGGATGTGAAGGCCTATCCGCAGACACTTGAGCGGCTGAAAGCGATGAAGCTGCCAATCAAGACGGTGGTGGGTGGTCACGACTCGCCGCTGCACGGCCCTGAGCTGATTGATCACTACGAAGCGCTGATCAAGGCGGCAACTCATTCATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2111,Drugs,MEG_2111|Drugs|betalactams|Class_B_betalactamases|CPHA,gi|33150469|gb|AY261379.1|1-765,0
,atggacacaacgcaggtcacattgatacaccaaattctagctgcggcagatgagcgaaatctgcggctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccactagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_749,Drugs,MEG_749|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,959847528|WP_058133312.1|NG_051895|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_051895:101-634,2
,ATGAGGGAAGCGGTGATCGCCGAAGTATCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCCGTACATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCACACAGTGATATTGATTTGCTGGTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGGAAACTTCGGCTTCCCCTGGAGAGAGCGAGATTCTCCGCGCTGTAGAAGTCACCATTGTTGTGCACGACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCAGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTGACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACTCTTTGATCCGGTTCCTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACTCGCCGCCCGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGTAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCCAGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGGCCTCCCGCGCAGATCAGTTGGAAGAATTTGTTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_973,Drugs,MEG_973|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|984881271|gb|CP014215.1|2293499-2292708 gi|984881271|gb|CP014215.1|2306263-2305472 gi|974751547|gb|KU130294.1|205907-205116 gi|974022331|gb|CP013924.1|1440234-1441025 gi|973715451|gb|CP013836.1|109167-108376 gi|969995259|gb|KT317079.1|2315-3106 gi|969995242|gb|KT317078.1|4201-4992 gi|969995220|gb|KT317076.1|5176-5967 gi|969995200|gb|KT317075.1|7062-7853 gi|969972869|gb|KT354506.1|6167-6958 gi|953773532|gb|CP013224.1|40675-39884,2
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgcgaaagatggcgtgcaggcccagacccgtattctgctccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgatgcattattggaaaagtatatcgcaggagaaccaatcagccaggaaaaacttgcgcgggaggaacagcggcgggttcaagaagcctccctgtttccggtctatcatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacaggactgttccaaccgattggggaacaagggggcgccgccctatgcggcagcgttttcaaggttgagtacaccgattgcggccagcggcgtgtctatctgcggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggcgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggatcaaacccggctccctcgtaaaaggtggcgcgaggcccccctccccatgctgcggacgacgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaagtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggtcgtttccgctttgctgtcggaaaaatacaagattgaaacagtggtaaaggaacccaccgtcatttatacggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatctatcggactgtctgttacaccactcccgcttggctccggcgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccagtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcggggacgcagctgctggaaccttatctctccttcaccctctatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaggaatacaggaacgatttaacttatttcacaaatgagcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7206,Drugs,MEG_7206|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100286|WP_063856421.1|NG_048294|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048294:100-2019,4
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcaccgcgctgtggccgtccggctcgcctgaagagcaccgcgcggaaatgcgcgagatattggcttcgccgcaccataccgcgtttatggcgcgggggctggacggcgctttcgttgcctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgccgaacgcgcccgccgccagggctgggccgcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgatatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggagcgagtagtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_157,Drugs,MEG_157|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,835583607|WP_047570454.1|NG_052420|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052420:101-541,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatggattgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4459,Drugs,MEG_4459|Drugs|betalactams|Class_D_betalactamases|OXA,1188444910|WP_085562412.1|NG_054702|1|1|blaOXA-558|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-558 NG_054702:1-825,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCTTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATAAACAGAAAATCCAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATATGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGTTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTCCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGAATCCCTATCTACAGTTAGTTAGCAAAGAATTTCCGTTAGAAAAAAACCAAGAACCCCCTCATTTAGTCCTTGCTGCCTTCAGCGAAGACGAGGTTTACTTGCAGCCAGAAGCAGCCAAACAATGGGAACGGCTCGTCAAAGCCTTAAAGCTTGAAAACGAGATCTGCTTGTTAGATGGCTACCGAACCGAAAAGCAGCAACGGTATTTATGGGAATATTCCTTGAAAGAAAATGGGCTAGCCTATACGAAACAATTTGTGGCGTTGCCCGGTTGCAGTGAACATCAGTTAGGCTTAGCGATCGATGTTGGTTTAAAGGGCAGCCAGGATGATTTGATCTGCCCACGATTTCGTGACAGCGCAGCCGCTGATTTATTTACCCAGGAAATGATGAACTATGGGTTTATTTTACGCTATCCCGCAGACAAACAGGAAATTACAGGGATTGGCTATGAACCATGGCATTTTCGTTATGTCGGTCTGCCTCATAGTCAAATCATCGCCAGTCAACAGTGGACCTTGGAAGAATACCATCAATACCTTGAACAAACTGCGAGGCAGTTCGCATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7381,Drugs,MEG_7381|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,VanC2XY_5_EU151760,5
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGAGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6477,Drugs,MEG_6477|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695220756|ref|NG_039549.1|77-937 gi|124053916|gb|EF035564.1|1-861,0
,atgagtaaagatattaaacaagtaatcgagatagcaaaaaaacacaatctttttctaaaagaagaaacgatacagtttaatgaatcagggcttgattttcaagctgtttttgcacaagataataatggaattgattgggttctaagattgcctagacgggaagatgtgatgcctagaacaaaggtagaaaaacaagctttggatttggtaaataagtacgctatatcctttcaggcaccaaactggatcatttacacagaggaactaatagcttataaaaagttagatggtgtgccagcaggtacgatagatcataacataggtaactatatttgggagatagacataaataatgttccagaattatttcacaagtcgctaggcagggtgttagcagagcttcatagcatacctagtaataaagccgcagcgcttgatcttgtagtacacacaccagaagaagcaagaatgtcaatgaagcagcgtatggatgcagtaagagcaaagttcggagtaggtgagaatctatggaacagatggcaagcgtggttgaatgatgatgatatgtggcctaagaaaactggactgattcatggagatgtacatgccggacatactatgattgataaggatgccaatgtgactggattaatcgattggactgaagcgaaggttacagatgtttcgcatgactttattttcaactatagagcttttggggaagaagggttagaagctttaattctcgcttataaggaaattggtggatattactggcctaaaatgaaagagcatattatcgaacttaatgcagcatacccagtttcaatcgctgagtttgcattagtgtctggaattgaggaatatgagcagatggcaaaggaagcattggaagtacaaggttcgtaa,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4031,Drugs,MEG_4031|Drugs|MLS|Macrolide_phosphotransferases|MPHB,445953162|WP_000031017.1|NG_047988|1|1|mph(B)|mph(B)|Mph(B)_family_macrolide_2'-phosphotransferase NG_047988:101-1009,7
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcgcccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2197,Drugs,MEG_2197|Drugs|betalactams|Class_A_betalactamases|CTX,1028104768|WP_063860014.1|NG_048961|1|1|blaCTX-M-176|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-176 NG_048961:1-876,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctcgaaccgacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_855,Drugs,MEG_855|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1102724723|WP_071593219.1|NG_052041|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052041:31-822,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccgtaaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4698,Drugs,MEG_4698|Drugs|betalactams|Class_D_betalactamases|OXA,1625655411|WP_136512088.1|NG_064755|1|1|blaOXA-797|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-797 NG_064755:1-825,0
,atgcatacgcggaaggcaataacggaggcaattcgaaaactcggagtccaaaccggtgacctgttgatggtgcatgcctcacttaaagcgattggtccggtcgaaggaggagcggagacggtcgttgccgcgttacgctccgcggttgggccgactggcactgtgatgggatacgcgtcgtgggaccgatcaccctacgaggagactctgaatggcgctcggttggatgacaaagcccgccgtacctggccgccgttcgatcccgcaacggccgggacttaccgtgggttcggcctgctgaatcaatttctggttcaagcccccggcgcgcggcgcagcgcgcaccccgatgcatcgatggtcgcggttggtccgctagctgaaacgctgacggagcctcacgaactcggtcacgccttggggaaagggtcgcccgtcgagcggttcgtccgccttggcgggaaggccctgctgttgggtgcgccgctaaactccgttaccgcattgcactacgccgaggcggttgcggatatccccaacaaacgatgggtgacgtatgagatgccgatgcttggaagaaacggtgaagtcgcctggaaaacggcatcagaatacgattcaaacggcattctcgattgctttgctatcgaaggaaagccggatgcggtcgaaactatagcaaatgcttacgtgaagctcggtcgccatcgagaaggtgtcgtgggctttgctcagtgctacctgttcgacgcgcaggacatcgtgacgttcggcgtcacctatcttgagaagcacttcggagccactccgatcgtgccagcacacgaagccgcccagcgctcttgcgagccttccggttag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_41,Drugs,MEG_41|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,487991691|WP_002063884.1|NG_047247|1|1|aac(3)-IIa|aac(3)-IIa|aminoglycoside_N-acetyltransferase_AAC(3)-IIa NG_047247:101-961,2
,atggatataaaaaagattatagaagaaaaatgcaagatagttgttgatagtataaagttgattggcgaggggtatgacagtaaagcatacattgtaaataatgaatatgtttttaaaattaaatttagtgctaataagaaaaaaggatatgaaaaagaaaaagcaatatatgatttcttaaacaaaaaattaaatacaacaataaatattcctaatattgaatattcatatataagtgatgatatatctatattggggtataaggaaattaaaggaacttttttaacaccagagatttattttactttatcaaaagagaaacaagatttgttgaaacaagatattgctatgtttttaaaacaaatgcacaatttagattatagtgaaataagttcatatacgatagacaataaacaaaatgttttagaagaatatcaattactaaaagaaacaatatatgatagttttactgatattgaaaaacaatatgtagaaaattttatgcaaatattacataatacgactatatttgatggcagaaaatgtttatgtcataatgattttagttgtaatcatttattacttgatgataatagattagttggagtaattgattttggagattctggaattatagatgagtattgtgattttatatatttattagaagatagtaaagaagaaattggtgtatcttttggagaagatatattaagattatacggaaatattgatatttcaaaagcaaaagaatatcaagatgtagtagaacaatattatcctattgaaactattgtatatggtattaaaaataataaacctgattttatagaaaaaggtagaaaagagatttatataagaacacacaaagaagaaaaattaaggaagtga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_1009,Drugs,MEG_1009|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH2-DPRIME,1028081341|WP_063840675.1|NG_047406|1|1|aph(2'')-If|aph(2'')-If|aminoglycoside_O-phosphotransferase_APH(2'')-If NG_047406:1-891,2
,ATGGGCATCATTCGCACATGTAGGCTCGGTCCGGACCAAGTGCAATCCATGCGGGCTGCTCTTGATCTCTTCGGTCGTGAGTTCGGAGACGTAGCCAGCTACTCCCAACATCAGCCGGACTCCGATTACCTCGCGAAATTGCTCCACAGCAGGACATTCATCGCGCTTGCCGCGTTCGACCAAGAATCGGTTGTTGGCGCTCTTGCCGCCTACGTTTTGCCAAAGTTTGAGCAAGCACGTAGCGAGATCTACATCTATGATCTCGCAGTCTCCGGCGAGCACCGGCGGCAAGGCATAGCCACCGCGCTCATCAATCTCCTCAAGCAAGAGGCCAATGCGCTTGGTGCTTACGTGATCTATGTGCAAGCTGACTACGGTGACGATCCCGCAGTGGCCCTCTACACAAAGTTGGGCATACGGGAAGACGTCATGCACTTTGATATCGACCCAAGTACCGCCACCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_43,Drugs,MEG_43|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,(AGly)Aac3-I:AJ877225:5293-5757:465,2
,atgaaaataattaacttaggcattctggctcacgttgacgcaggaaagacaacattaacggaaagtttattgtataccagtggtgcaattgcagaactagggagcgtagatgaaggcacaacaaggacagatacaatgaatttggagcgtcaaaggggaatcactatccagacagcagtgacatcttttcagtgggaggatgtaaaagtcaacattatagatacgccaggccatatggattttttaaccgaagcataccgctctttatctgtccttgacggagctgttttagtcatttcggcaaaagacggcgtacaggcacagacgcgtatattattccatgcgcttcagaaaatgaacattccgacaattatctttataaataagatagaccaaaatggaatcgacctacagcgtgtttaccaaagcattaaagacaaacttaccagtgatatgattgtcatgcaggaggtttccctgtcgccaaagataaccatgaccgatatttctgatttggacaaatgggatatgattatttccggaagcgatgaactattagaacgatatgttgcagaggattctttggatatacaggaattacaatatgaaaagtgcaaaagaaccagatgctgctctttgtttcctgtttatcatgggagtgcaaaagacaatttaggaacagaaaaactgattgaagcgattacagaaactttcattacagaaacagacgatattcagtctgaattatgtggatatgtttttaaggttgagtatacagagcggaaaaaacggctttcttatttacgcctgtatcatgggacgctccatttacgggataccctgctgctgtcaaaaaaggaaaaaataaagattacagaaatgtgtattccgtcaaatggtgaaatcgtcccggttgaccatgcctgtccgggagaaattgttattttagctgatgatactttgaaactgaacgacattctgggaaatgaaaaactcctgcctcacaaaacacggattgataatcccatgccattacttcggacaacggtagagccgcaaaagccggagcaaagggaagccctgttaaatgccctcacagagattgctgatacagaccctcttttgcattttgacattgatactgttacacatgagattatattatcttttttgggaaaagtacagttagaagttatttgttcgctattagaagaaaaatatcatgtgggcgtggctatgaaagagccttcggttatttatctggaaagaccgcttagaaaagcagaatataccatccacatagaagtcccgccaaatcctttctgggcttctgtcgggttgtccatagagccgctccctattggaagcggagtgcagtatgaaagcagagtttcacttggatatttaaatcaatcgttccaaaatgcggttatggagggggttctttatggctgcgagcaggggctgtatggatggaaagtgacagactgtaaaatctgttttgaatatggattgtattatagtcctgtaagtacccccgcagactttcggctgctttcccctatcgtattggagcaggctttaaaaaaagcagggacagaactattagagccatatctccactttgaaatttatgcaccgcaggaatatctctcacgggcgtatcatgatgctccaaggtattgtgcagatattgtaagtactcagataaagaatgacgaggtcattctgaaaggagaaatccctgctagatgtattcaagaatacaggaacgatttaacttatttcacaaatgggcagggagtctgcttgacagagttaaaaggataccagccagctattggtaaatttatttgccaaccccgccgcccgaatagccgtatagataaggttcggcatatgttccacaagttagcttaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_6969,Drugs,MEG_6969|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET32,505385954|WP_015573056.1|NG_048124|1|1|tet(32)|tet(32)|tetracycline_resistance_ribosomal_protection_protein_Tet(32) NG_048124:101-2020,4
,AACCTTTTAATGCTATGGGGGATTGGCATAATTATGCCTGTCTTGCCGGCGTTATTACGGGAGTTTGTTGGAAAGGCTAATGTTGCAGAGAACTACGGTGTTTTATTGGCGCTGTATGCAATGATGCAAGTGATTTTTGCCCCTCTTCTCGGCCGCTGGTCAGATCGCATAGGTCGTCGCCCTGTATTGTTACTTTCACTTTTAGGTGCAACACTGGACTACGCATTAATGGCAACAGCCAGCGTAGTGTGGGTGTTGTATTTGGGACGCTTAATTGCTGGTATTACCGGTGCGACTGGAGCTGTTGCAGCCTCAACAATTGCCGATGTCACACCTGAGGAATCCAGGACACATTGGTTTGGTATGATGGGTGCCTGTTTTGGTGGCGGTATGATTGCTGGACCAGTCATTGGTGGTTTTGCCGGTCAACTTTCGGTACAGGCACCGTTTATGTTCGCTGCTGCTATTAACGGGCTGGCATTTCTGGTCTCCCTATTCATTTTACATGAGACCCATAATGCTAATCAGGTTAGTGACGAGTTAAAGAATGAAACAATCAATGAAACCACATCCTCCATACGCGAGATGATCTCCCCATTATCGGGATTGTTAGTTGTCTTTTTCATCATTCAATTGATTGGCCAAATCCCCGCAACATTATGGGTTTTATTCGGAGAAGAGCGCTTCGCATGGGATGGCGTAATGGTCGGTGTTTCATTGGCTGTGTTCGGGCTGACACACGCACTGTTTCAAGGACTTGCTGCTGGTTTTATCGCTAAACATTTGGGAGAACGGAAAGCTATAGCGGTTGGCATTTTGGCTGACGGTTGTGGCCTATTTTTATTGGCGGTCATTACACAAAGCTGGATGGTTTGGCCGGTTTTGCTGTTACTAGCTTGTGGTGGCATCACACTTCCCGCCTTGCAGGGAATTATATCTGTTCGTGTCGGTCAGGTAGCACAGGGACAATTACAAGGGGTGCTGACCAGTTTGACCACCTGACAGGTGTAATCGGGCCACTTGTTTTTGCATTTTTGTATAGTGCACCCCCCAAACGTGAAATGAATGGGTATGAATATTGGCCGCCGATATATGTAGTTGCATTGATATACTGAAGTTTTTCCTCCCGGTAGGGTACCCCCCCATAATAAACGCGGTTTTCCCCCAAAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7075,Drugs,MEG_7075|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETE,gi|146335259|gb|EF471995.1|1-1170 gi|327195566|gb|HQ399593.1|1-273 gi|296044842|gb|HM041202.1|195-1 gi|296044846|gb|HM041204.1|189-1,4
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAAAATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1447,Drugs,MEG_1447|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_17_JDDF01000008,0
,atgagtaattaccgatttaaatctaaaataaaaagcagtgtattgatcattctgagtagtgtggcattttcaggttgtgtttctaatgccaatttgcatgatccagcgtcatcacaaagaataagtgaaatcccgttgttgtttaattatgcgcaaactcaagccgtctttgtgacttatgatggaactcaatttaaacgttatgggaatgatttaaatagagccaagactgcctatattccagcctctacttttaaaatgttgaatgccttaattggtttgcaacatgcgaaagcgacgaatacagaagtatttaagtggaatggagaaaaaagatcttttcctgcatgggaaaaagatatgaccttggcacaagcaatgcaggcttcagccgtacctgtatatcaggagttggcacgacgtattggcttggatttgatgagtaaagaagtcaagcgtgttggttttggcaatacacaaattggtcaacaggtagataatttctggctagtcggcccattgaaaattaccccagaacaagaagctaaatttgcttatcaattggcaaacaaaacattgccttttgatgatgctgtacagcaacaagttaaagatatgctctatgtcgaaagacggggtgattccaagctttatgccaaaagtggatggggaatggatgtggagccacaagtggggtggtacacaggatgggtggaacagccgaatggtcagatcactgcttttgctttaaacatgcacatgcagacaggggatgatcctgctgaacgcaagcaactgacattaagtatcttggataaattaggcttattcttttatttgagataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4591,Drugs,MEG_4591|Drugs|betalactams|Class_D_betalactamases|OXA,1248237514|WP_096735335.1|NG_062225|1|1|blaOXA-667|blaOXA-274_like|OXA-274_family_class_D_beta-lactamase_OXA-667 NG_062225:101-946,0
,TATCATCAATAAAATTGAGTGTTGCTCTGTGGATAACTTGCAGAGTTTATTAAGTATCATTGCAGCAAAGATGAAATCAATGATTTATCAAAAATGATTGAAAGGTGGTTGTAAATAATGTTACAATGTGTGAGAAGCAGTCTAAATTCTTCGTGAAATAGTGATTTTTGAAGCTAATAAAAAACACACGTGGAATTTAGGGACTATTCATGTTGTTGTTATTTCGTATCTTCCAGAATAAGGAATCCCATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTATCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAATAGCGGAAACGGAATGGGGAAACTCATTCCGTTTTTGTTTATCGCCTTAGACGGCAAAAGTGCTGTCGCCCACCTGCGCTTGCGCATACCAGGCCATAAGCTCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_2393,Drugs,MEG_2393|Drugs|betalactams|Class_A_betalactamases|CTX,gi|323709060|gb|HQ398214.1|1-1229 gi|971338783|gb|CP006659.2|2745071-2744871 gi|958102843|emb|LN824133.1|127563-127763 gi|958102843|emb|LN824133.1|1153883-1154083 gi|958102843|emb|LN824133.1|3347240-3347040 gi|828906158|gb|CP011578.1|655943-656143 gi|828906158|gb|CP011578.1|849699-849499,0
,atgaaatctaacaatgcgctcatcgtcatcctcggcaccgtcaccctggatgctgtaggcataggcttggttatgccggtactgccgggcctcttgcgggatatcgtccattccgacagcatcgccagtcactatggcgtgctgctagcgctatatgcgttgatgcaatttctatgcgcacccgttctcggagcactgtccgaccgctttggccgccgcccagtcctgctcgcttcgctacttggagccactatcgactacgcgatcatggcgaccacacccgtcctgtggatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgcggctgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgggggactgttgggcgccatctccttgcatgcaccattccttgcggcggcggtgctcaacggcctcaacctactactgggctgcttcctaatgcaggagtcgcataagggagagcgtcgaccgatgcccttgagagccttcaacccagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgtcgcttgcggtattcggaatcttgcacgccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgccggcatggcggccgacgcgctgggctacgtcttgctggcgttcgcgacgcgaggctggatggccttccccattatgattcttctcgcttccggcggcatcgggatgcccgcgttgcaggccatgctgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgctcgcggctcttaccagcctaacttcgatcattggaccgctgatcgtcacggcgatttatgccgcctcggcgagcacatggaacgggttggcatggattgtaggcgccgccctataccttgtctgcctccccgcgttgcgtcgcggtgcatggagccgggccacctcgacctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7057,Drugs,MEG_7057|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,499388698|WP_011076165.1|NG_048179|1|1|tet(C)|tet(C)|tetracycline_efflux_MFS_transporter_Tet(C) NG_048179:101-1291,4
,atgaagcaaatattaatttttctgttagcggtattcattccgacaagctttgtttttgctggtgatccgctgccagatttgaaaatcaagcagctggatgacggcgtttatctgcatacgtctttccaggtttttagtggggttgtgatgggctcgaatggattggtggtgctggatcacaatgatgcctatatcgtcgatacgccatggtctgcggaagacacggaaaagcttctgagttggattaaggcgaatggcttttccgttaaaggcagcatttcgacccattcgcacgatgatcgaaccgccggtattgcattgctcaattcgaaagccattcccacatacgcttcgaaaatgaccaatggatttcttgagaaagccggtaaggcgcaggccaaaaattcattcgatagcaaggatttctggtgggtaaaagaccaagtggaagtcttctaccccggtgcaggtcacgcacccgacaatttggttgtgtggctgcccaagcaaaaaattctatttggcggctgtctgattcgcgcaaaagaagctaaaaatcttggcaatgtcgccgatgcagttattggggagtggcctaggtcggccgaaaaactgcaggaaaaatatggaaacgccaaggtcgtcgttccggggcacggtgaggttggcgatgtatcgttgttggagcacacaaaggagctggctgcggcgagtgctagaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3170,Drugs,MEG_3170|Drugs|betalactams|Class_B_betalactamases|GRD,1509794526|WP_122630835.1|NG_062239|1|1|blaGRD23-1|blaGRD23|subclass_B1_metallo-beta-lactamase_GRD23-1 NG_062239:1-726,0
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgcgcggcgctgtggccatccagctcgcctgaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggccggatggcgtttttgtcgcctttgccgaggtcgcgctgcgctacgattatgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaacgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggccaagcaacagggatgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgccgcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_98,Drugs,MEG_98|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,763150745|WP_044030410.1|NG_052336|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052336:101-541,2
,atgaaaataatgttagagggacttcatataaaacattatgttcaagatcgtttattgttgaacataaatcgcctaaagatttatcagaatgatcgtattggtttagttggtaaaaatggaaatggaaaaacaacgttacttcacatattatataaaaaaattgtgcctgaagaaggtattgtaaaacaattttcacattgtgaacttattcctcaattgaagctcatagaatcaactaaaagtggtggtgaagtaacacgaaactatattcggcaagcgcttgataaaaatccagaactgctattagcagatgaaccaacaactaacttagataatgactatatagaaaaattagaacaggatttaaaaaattggcatggagcatttattatagtttcacatgatcgcgcttttttagataacttgtgtactactatatgggaaattgaagaaggaagaataactgaatataaggggaattatagtaactatgttgaacaaaaagaattagaaagacatcgagaagaattagaatatgaaaaatatgaaaaagaaaagaagcgattggaaaaagctataaatataaaagaacagaaagctcaacgagcaactaaaaaaccgaaaaacttaagttcatctgaaagcagaataaaaggaacaaagccatactttgcaggtaagcagaagaagttacgaaaaactataaaatctctagaaaccagactagaaaaacttgaaagcgtcgaaaagagaaacgaacttcctccacttaaaatggatttagtgaatttagaaagtgtaaaaaatagaactataatacgtggtgaagatgtctcgggcacaattgaaggacgggtattgtggaaagcaaaaagttttagtattcgtggaggagacaagatggcaattatcggatctaatggtacaggaaagacaacgtttattaaaaaaattgttcatgggaatcatggtatttcattatcgccatctgtcaaaatcggttattttagccaaaaaatagatacattagaattagataagagtattttagaaaatgttcaatcttcttcacaacaaaatgaaactcttattcgaactattctagctagaatgcatttttttagagatgatgtttataaaccaataaatgtcttaagtggtggagagcgagttaaagtagcactaactaaagtattcttaagtgaagttaacacgttagtactagatgaaccaacaaactttcttgatatggaagctatagaggcgtttgaatctttgttaaaggaatataatggcagtataatctttgtatctcacgatcgtaaatttatcgaaaaagtagccactcgaataatgacaattgataataaagaaataaaaatatttgatggtacatatgaacaatttaaacaagctgaaaagccaacaaggaatattaaagaagataaaaaacttttacttgagacaaaaattacagaagtactcagtcgattgagtattgaaccttcggaagaattagaacaagagtttcaaaacttaataaatgaaaaaagaaatttagataaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_7677,Drugs,MEG_7677|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA,488371242|WP_002440627.1|NG_048557|1|1|vga(A)|vga(A)|ABC-F_type_ribosomal_protection_protein_Vga(A) NG_048557:101-1669,1
,ATGCTAAATTTAACCGTTTGTCAGGCACAGTCAAATCCAACAGACTACGCCTGTCTGACGGGCCCGGACATCCCCTTGACTCGCTATTACGGAAGATTACTGATGATGAAAAAATCTCTTTGCTGCGCCCTGCTGCTCGGCATCTCTTGCTCTGCTCTCGCCGCGCCAGTGTCAGAAAAACAGCTGGCGGAGGTGGTCGCGAATACGGTTACCCCGCTGATGAAAGCCCAGTCGATTCCAGGCATGGCGGTGGCCGTTATTTATCAGGGTAAACCGCACTATTACACGTTTGGCAAAGCAGATATCGCGGCTAATAAACCCGTTACGCCTCAGACTCTGTTCGAGCTGGGCTCTATAAGTAAAACCTTCACCGGGGTTTTAGGTGGGGATGCCATTGCTCGCGGTGAAATTTCGCTGGACGATCCGGTGACCAGATACTGGCCACAGCTAACGGGCAAGCAGTGGCAGGGGATTCGTATGCTGGATCTCGCAACCTACACCGCTGGCGGCCTGCCGCTACAGGTACCGGATGAGGTCACGGATAATGCCGCCCTGCTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCTGGCACAACGCGTCTTTACGCCAACGCCAGTATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGGGCTATGAGCAGGCCATGACGACGCGGGTCCTTAAGCCGCTCAAGCTGGACCATACCTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGCTATCGTGACGGTAAAGCGGTGCGCGTTTCGCCGGGAATGCTGGATGCACAAGCCTATGGCGTGAAAACCAACGTGCAGGATATGGCGAACTGGGTCATGGCAAACATGGCGCCGGAGAAGGTTGCTGATGCCTCACTTAAGCAGGGCATCGCGCTGGCGCAGTCGCGCTACTGGCGTATCGGGTCAATGTATCAGGGTCTGGGCTGGGAGATGCTCAACTGGCCCGTGGAGGCCAACACGGTGATCGAGGGCAGCGACAGTAAGGTGGCGCTGGCACCGCTGCCCGTGGCAGAAGTGAATCCACCGGCTCCCCCGGTCAAAGCGTCCTGGGTCCATAAAACGGGCTCTACTGGCGGGTTTGGCAGCTACTTGGCCTTTATTCCTGAAAAGCAGATCGGTATTGTGATGCTCGCGAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCATATCCTCGACGCGCTACAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_485,Drugs,MEG_485|Drugs|betalactams|Class_C_betalactamases|ACT,gi|407731530|gb|JX440354.1|655-1902,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCCTTCGGTAAGACCCTTAATAAACTTATCGCCAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1324,Drugs,MEG_1324|Drugs|betalactams|Class_A_betalactamases|BLAZ,gi|695196521|ref|NG_034440.1|140-985,0
,GGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGCTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2332,Drugs,MEG_2332|Drugs|betalactams|Class_A_betalactamases|CTX,gb|JF274245|+|0-863|ARO:3001968|CTX-M-108 [Shigella sp. SH223] ,0
,AGAAGGAAGAAACAAAGTTGGAATGCTCACTTTACTGAACATAAATCACAGGGCGTAGTTGTGCTCTGGAATGAGAATAAGCAGCAAGGATTTACCAATAATCTTAAACGGGCGAACCAAGCATTTTTACCCGCATCTACCTTTAAAATTCCCAATAGCTTGATCGCCCTCGATTTGGGCGTGGTTAAGGATGAACACCAAGTCTTTAAGTGGGATGGACAGACGCGCGATATCGCCACTTGGAATCGCGATCATAATCTAATCACCGCGATGAAATATTCAGTTGTGCCTGTTTATCAAGAATTTGCCCGCCAAATTGGCGAGGCACGTATGAGCAAGATGCTACATGCTTTCGATTATGGTAATGAGGACATTTCGGGCAATGTAGACAGTTTCTGGCTCGATGGTGGTATTCGAATTTCGGCCACTGAGCAAATCAGCTTTTTAAGAAAGCTGTATCACAATAAGTTACACGTATCGGAGCGCAGCCAGCGTATTGTCAAACAAGCCATGCTGACCGAAGCCAATGGCGACTATATTATTCGGGCTAAAACGGGATACTCGACTAGAATCGAACCTAAGATTGGCTGGTGGGTCGGTTGGGTTGAACTTGATGATAATGTGTGGTTTTTTGCGATGAATATGGATATGCCCACATCGGATGGTTTAGGGCTGCGCCAAGCCATCACAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5217,Drugs,MEG_5217|Drugs|betalactams|Class_D_betalactamases|OXA,gi|308055643|gb|HM755942.1|1-691,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAATAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1433,Drugs,MEG_1433|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_67_NZ_CTTL01000039,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccactacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaaacgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4465,Drugs,MEG_4465|Drugs|betalactams|Class_D_betalactamases|OXA,1058244149|WP_068981647.1|NG_051482|1|1|blaOXA-532|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-532 NG_051482:1-825,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgattaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccgcaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4429,Drugs,MEG_4429|Drugs|betalactams|Class_D_betalactamases|OXA,1509794595|WP_122630904.1|NG_062324|1|1|blaOXA-702|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-702 NG_062324:14-838,0
,atgcgtgtattagccttatcggctgtgtttttggtggcatcgattatcggaatgcctgcggtagcaaaggaatggcaagaaaacaaaagttggaatgctcactttactgaacataaatcacagggcgtagttgcgctctggaatgagaataagcagcaaggatttaccaataatcttaaacgggcgaaccaagcatttttacccgcatctacctttaaaattcccaatagcttgatcgccctcgatttgggcgtggttaaggatgaacaccaagtctttaagtgggatggacagacgcgcgatatcgccacttggaatcgcgatcataatctaatcaccgcgatgaaatattcggttgtgcctgtttatcaagaatttgcccgccaaattggcgaggcacgtatgagcaagatgctacatgctttcgattatggtaatgaggacatttcgggcaatgtagacagtttctggctcgacggtggtattcgaatttcggccattgagcaaatcagctttttaagaaagctgtatcacaataagttacacgtatcggagcgcagtcagcgcatcgtgaaacaagccatgctgaccgaagccaatggcgactatattattcgggctaaaactggatactcgactagaatcgaacctaagattggctggtgggtcggttgggttgaacttgatgataatgtgtggttttttgcgatgaatatggatatgcccacatcggatggtttagggctgcgccaagccatcacaaaagaagtgctcaaacaggaaaaaattattccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4610,Drugs,MEG_4610|Drugs|betalactams|Class_D_betalactamases|OXA,1201190425|WP_087587945.1|NG_054959|1|1|blaOXA-546|blaOXA-48_like|OXA-48_family_class_D_beta-lactamase_OXA-546 NG_054959:1-798,0
,ATGACTATTTCAAACACAACAGACTTGCCTGCTCCCTTAATGCCATCACAGCAACACAATGGCAAATTTAGAAATACGCGTCCGAACCAACACAAGCCTTCTTTTGGCAAAACGCTTCAACTCATGTGGAAGTTTCTATTTAACAAACCTAAAAATACCGTTCCAAACAGAGAAATTCCTGTTTTAAGTTTGTCAAAAGAACAGCTTTTAAGTGCGCCTGACCGTTCTCTATTTCGTTTGGGTCACTCAACTATCCTGTTAAAACTGCAAGATGAATTTTGGTTAACTGACCCTGTTTTTTCAGAGCGTGCATCACCTTTTCAATGGCTTGGACCAAAACGTTTCCATCAGCCCCCAATTAGTATTGCCGAATTACCACCCATTAAAGGCGTGATTTTGTCGCATAACCACTACGACCACCTCGATTACCATGCGGTCATGCAGCTTAACGATAAAGTTGAGCACTTCTTAACACCGCTTGGTGTGGGTGATACACTCATTAAATGGGGAATTCCAGCAGAAAAGGTTCAGCAGCTCGACTGGTGGGGTACCACACAGGTAGATGGACTAAAATTAGTTGCTACCCCTGCCCATCATTTTTCAGGCCGTGGTATGGGTGATAGCAATGCGACACTTTGGGCATCGTGGGTGATTATTGATAATGATTTACGTGTATTTTTTAGTGGAGATACGGGCTATTTTGACGGGTTTAAAGAAATCGGTCTTCGTTATGGACCTTTCGATCTGACCATGTTAGAAACGGGTGCTTACGACCCCGAATGGCCTGATGTTCACATGCAACCAGAGCAAACTTTACAAGCTCATATCGATTTAAAAGGACGTCATTTGTTGCCTGTGCACAACGGTACTTTTGACTTGGCACTTCATGCTTGGGACGACCCTTTTGAACGTATCGTCGCTTTGGCTCAACAAAATAATTTAGCGATTAGCACACCGCAAATGGGACAAATTTTGAACTTAAACGAGCCGAATGTTGAAAATTATTGGTGGCGTTCGTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1246,Drugs,MEG_1246|Drugs|betalactams|Class_A_betalactamases|BLAA,(Bla)BlaA1:NC_010410:1803480-1804499:1020,0
,ATGAGCGTATCGGAAATCCGACCGATTGCCATTGAGGACGAACTCAAGCATTCATATTTAGATTACGCGATGAGTGTAATTGTATCTCGTGCATTGCCGGATGTGAGAGACGGTCTTAAACCTGTTCACCGTCGTGTGCTTTATGCCATGCACGAATTGGGCAATGACTATAACAAAGCCTACAAGAAATCTGCTCGTGTCGTTGGGGACGTAATCGGTAAATATCACCCGCATGGTGACTTAGCTGTTTATGAAACCATTGTTCGTATGGCTCAAGACTTTAGCTTACGTTATTTATTGGTTGATGGTCAGGGTAACTTCGGTTCGATCGATGGTGATAGCGCTGCGGCAATGCGTTATACCGAAGTCCGTATGACTAAGCTGGCACATGAGCTTCTTGCAGATTTAGAAAAAGACACAGTTGACTGGGAAGATAACTACGACGGTTCGGAACGTATCCCTGAAGTACTTCCGACACGTGTTCCAAACTTATTAATTAACGGTGCTGCTGGTATTGCTGTAGGTATGGCAACTAACATGGCACCACACAACATGACAGAAGTTGTGAATGCTTGTTTGGCTTATGCTGACAATCCGAATATCTCGATTGAAGGATTGATGGAATACATTACTGGTCCTGACTTCCCTACAGGCGGTATTATTTACGGTAAATCAGGTATTGTTGATGCCTACCGTACCGGTAAAGGTCGTTTACACATTCGTGGTAAATACCATTTCGAAGAAGATGAAAAGACAGGTCGTACAACCATCGTCTTTACTGAAATTCCATATCAAGTAAACAAAGCAAGAGTTATTGAACGTATTGCCGAGTTAGTAAAAGAGAAAAAGCTTGAAGGTATTTCAGAACTTCGTGATGAGTCTGATAAAGAAGGTATGCGTATTGCAATTGACTTGAAACGCGGTGAAAACGCAGAAGTCGTTGTAAATAACTTATTCTTAAATACCCAGCTTGAAAACTCATTCAGCATCAACATGGTTTGTCTAGACAATGGACAACCAAAATTGATGAATCTAAAAGATATTATTGCGGCATTTATTCGTCACCGCCAAGAAGTTGTGACACGCCGTACCATGTTCGAATTACGTAAAGCACGTGAACGTGGTCATATCTTGGAAGGCTTGACAGTTGCCTTAGCCAATATTGATGAAATTATTGAAACCATCAAAACTTCTGCAAACCCTGCTGAAGCGCGTGAGCGTTTACTTGCGGGTGAGTGGGCAGGTGGTGGCGTTGTTGCACTACTTGAAAAAGCTGGTGCAATTTCTGTTCGCCCAGATGAAATTGAAGGTGAAGATCCAAATCGTCCATTTGGTTTAAGTGATTCATTTTATCGTCTGTCACCAACACAAGTAGGCGCAATTTTAGAATTACGTTTACACCGTTTAACTGGTCTTGAACAAGACAAGTTACATGCGGAATATACTGAAATTTTAGGTCAAATTGCTGAACTTACTGCAATTTTAAATGACTTTAACTTGTTAATGGGTGTTATTCGCGAAGAGTTGGCACAAGTTTTACAACAATATGGCGATGCACGTCGTACCGAAATTGTTGAATCTCGTGTGGATTTCTGCCGTGAAGATTTAATTCCTGAAGAGCAAGTGGTATTAACGGTTTCGCAAACGGGTTATGCAAAAACTCAACCTCTTTCAGACTATCAGGCACAGCGCCGTGGTGGACGTGGTAAGTCTGCAACCTCAATGAAAGATGATGACTTTATTCAACATCTGATTGTGGCATCGAACCATGCGACCGTACTTTGCTTTACCAATGTGGGTAAAGTGTACCGTCTGAAAGTATTTGAAGTTCCTCAAGCATCACGTGGGGCAAAAGGCCGTCCAATCGTGAACTTGTTACCTCTAGATGCAACAGAAACCGTAACCGCAATCTTGCCGTTAACCGAGTTCCCGGAAAACCACTATGTGTTTATGGCGACAGCTTCTGGTACGGTTAAGCGTGTTGAGTTAGAGCAATTTGCAAACATTCGTTCAAATGGTCTACGTGCTATTGAACTTAATGAAGAAGATACTTTAATTGGTGTTGCGATTACTGATGGTAATCAGCAAATCATGTTGTTCTCTAACGAAGGTAAGGCAATTCGTTTTGCTGAAACTGACGTACGTGCAATGGGTCGTACAGCGAAAGGTGTACGCGGTATGCGCGTGAGTTTTGCAAGCAGCACCTTAAGTGAAGAAGATGCAGATGTTGAAAATGATGATTCAGATGATAATGATGATTCAACAGATTCAAGTCTAGTAAGTCGCATCGTATCGCTTGTTGTTGTACCTGAGACAGGCGAAGTACTGTGTGCGAGTGCCAACGGTTATGGTAAACGTACTCCAGTAAATGACTTCCCGACCAAGAAACGTGGTGGTAAGGGTGTTATTGCGATCAAGACAAGTGAACGTAACGGTGAGCTAGTTGGTGCAGTTTCTATTGATGAAACCAAAGAGTTATTATTAATTTCTGATGGTGGTACGCTTGTTCGTACGCGTGCTGCAGAAGTTGCAATGACAGGCCGTAATGCTCAAGGTGTTCGTCTGATCCGTTTAAGCGAAGAAGAAACGCTCGTTGGCGTAGTTTCAATTGAAGCTGTAGAAGACGAAGAAGAACTTCTTGAAGGTGAAGTAGATACGACTGAAACTGATAGCGAAGAAGCTGTATCTAATAATGAAGATACTTCTGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3192,Drugs,MEG_3192|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|169147133|emb|CU459141.1|924612-927326 gi|88758889|emb|CT025946.2|1-2715,3
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaatagccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatccgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_838,Drugs,MEG_838|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1693892902|WP_140423279.1|NG_065406|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_065406:101-892,2
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcatgagttgtcaagcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacgctacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7699,Drugs,MEG_7699|Drugs|betalactams|Class_B_betalactamases|VIM,1440786795|WP_114699283.1|NG_061412|1|1|blaVIM-59|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-59 NG_061412:94-894,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccattagggagcggagtgcagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattcaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7131,Drugs,MEG_7131|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100174|WP_063856395.1|NG_048234|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048234:1-1920,4
,atggctctagcgctcgtgggcgaaaaaattgacagaaaccgtttcaccggtgaaaaaattgaaaatagtacattttttaactgtgatttttcaggagcggacctgagcggcactgagtttatcggctgccaattttatgatcgtgaaagccagaaaggctgtaattttagccgtgcgatgttaaaggatgctatttttaaaagctgcgatttatccatggccgattttcgcaatgcaagcgccctgggtattgagattcgtcattgtagggctcagggtgcagattttcgcggcgcaagctttatgaacatgattaccacgcgaacttggttctgcagcgcgtatatcacgaatacgaatctgtcttatgccaatttttcgaaagcagtgttggagaagtgtgaattatgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcaactttcgactggcgagcagcaaactttacacattgcgatctcacaaattcggagttgggtgacttagatattcgtcgggttgatttacaaggcgttaagttggacaactaccaggcttcgttgctcatggagcgacttggcatcgcgataattggatga,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5886,Drugs,MEG_5886|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111959|WP_063866162.1|NG_050516|1|1|qnrB53|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB53 NG_050516:37-681,3
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTTCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCATCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCTGAAAAACGTATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATTGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATTCGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAACACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAGGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGGCAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCGTCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATTGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAATGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5344,Drugs,MEG_5344|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|408436493|emb|HE579073.1|1334624-1337026 gi|408434508|emb|HE579071.1|1334575-1336977 gi|408432519|emb|HE579069.1|1334801-1337203 gi|408430526|emb|HE579067.1|1334760-1337162 gi|408428537|emb|HE579065.1|1334762-1337164 gi|408426549|emb|HE579063.1|1334766-1337168 gi|408424560|emb|HE579061.1|1334811-1337213 gi|408422572|emb|HE579059.1|1334819-1337221 gi|262073980|gb|CP001781.1|1369090-1371492 gi|156720466|dbj|AP009324.1|1434054-1436456,3
,atgttttttttaaaaaaaagtgcaagtacatttgtttttttgctctgtcttccattgaactcattcgcctcccaggaaagtaatggtgttgagcaaatgaaggaattggaaaattcttttggggggcggataggtgtttatattttaaacacaaaaaatgggaaagaattttcctacagacaagatgagagatttcctttatgtagttcatttaaggcgttcctcgctgcatccgtattaaaaagaactcaggataaatctgtttctcttgatgatatgatggaatattctggacgtgttatggaaaagcattctcctgtatcagaaaaataccgcgaaacaggagcaagcgtgcagactttggccaaggcagcaattcagtatagtgacaatggagcttctaatctattaatggaaagatacataggaggtcctgagggtttgactgcatttatgcggtcaacgggagacactgacttcaggcttgatcgttgggaattagaattaaactcagctattccaggcgatgaacgtgatacttccactccaaaaacagtggctatgagccttaataatattgcttttggttcagtactcgatgctaaaaataaatccttgctacaggattggcttaaaggcaacactactggtaatgcgcgaattagagctgctgttccagataagtgggttgttggcgataaaacaggcacctgtggtttttatggtacagccaatgatattgctattttatggccagatgccaattcacctgcagttatggctgtctacacaacacgtcctaatcaaaacgacaaacatgacgaaacagttataaaaaatgctgcaaaaatagctataaatgcagtgtatggaagtactaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3054,Drugs,MEG_3054|Drugs|betalactams|Class_A_betalactamases|FRI,1693892932|WP_140423309.1|NG_065424|1|1|blaFRI-9|blaFRI|carbapenem-hydrolyzing_class_A_beta-lactamase_FRI-9 NG_065424:101-985,0
,TTGAAAAATAGAAATAAAACCAGTCATGAAGATGACTATTTACTTTTTAAAAACAGATTGTCCGTTAAAATACTGCTTATGATGGTATATTCCATTCTGATTATTGCGGGCGTTTATCTGTTTATCTTAAAAGATAATTTTGCAAATGTCGTGGTAGCTATTTTAGACAGTTTTATCTATCATGATCGGGATGAGGCGGTGGCTGTTTATCTGAGAACCTTTAAGGCGTATGAGATATGGCTTTTCCTGATAGCGGTTATGGGCGTGTTTTTTATGATCTTCCGCCGTTATCTGGACAGTATTTCAAAATATTTTAAGGAGATCAACCGGGGGATCGATACTTTGGTGAATGAGGATGCCAACGATATTGGGCTGCCTCCGGAGTTGGCTTCGACCGAAAGAAAAATCAATTCCATACGGCATACCCTGACGAAACGGAAAACGGACGCCGAGCTTGCGGAACAGCGGAAAAACGACCTTGTCATGTACCTGGCTCATGACTTGAAGACTCCGCTTTCATCGGTCATAGGATATTTGAACCTGTTAAGGGATGAGAATCAGATCTCCGAGGAACTCCGGGAAAAATATCTGTCCATTTCACTGGATAAGGCTGAACGTCTGGAAGAGCTGATCAATGAGTTTTTTGAAATTACGAGGTTTAATCTTTCAACATCACGCTTGTGTACAGCAAAATCAATCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7510,Drugs,MEG_7510|Drugs|Glycopeptides|VanD-type_regulator|VANSD,gi|5759260|gb|AF175293.1|AF175293|759-1460,5
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacatttaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtctggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgttgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcgaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaaccacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcagctgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1495,Drugs,MEG_1495|Drugs|betalactams|Class_A_betalactamases|CARB,670464736|WP_031413517.1|NG_048727|1|1|blaCARB-24|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-24 NG_048727:1-852,0
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCCGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTCCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCAGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCATCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCTGAAAAACATATGCATATCGTCGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATCGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATACGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAACACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAAGATATTGGTTTAAAAGATGGTGATAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGGCAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATAATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCATCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACTGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATAGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAACGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAGCAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5354,Drugs,MEG_5354|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|82655308|emb|AJ938182.1|1321963-1324365,3
,CACACTGATTGCGTCTGACGGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGGAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1990,Drugs,MEG_1990|Drugs|betalactams|Class_C_betalactamases|CMY,gi|641682562|emb|HG941718.1|4940343-4941549 gi|93277247|gb|DQ463751.1|15-1221 gi|90568484|gb|DQ438952.1|100-1306,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggtgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttactttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4401,Drugs,MEG_4401|Drugs|betalactams|Class_D_betalactamases|OXA,488901283|WP_002812372.1|NG_057512|1|1|blaOXA-578|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-578 NG_057512:1-774,0
,GTGATTGAGGTGTATAAATTAACACAAAGAAAAAGACTAACGCAGTTGTTTCCTTTTTTGCTACCTCTCCGCAAATGGCAAAGAAAAAAATATTTTTATTTCAAAATGAAATTTGACGGCAATAGATACGCAAAAAAGACATCTGAGAAATTGTTACCAAACACAGTATTTGAAACATCATCACTTATGCTAAATGAAAATAGTGGATTTGATATGAAGTACCAAATCAATAAGGTACACAACCTAAAACTTGCCGCAAAAACAATCAATAAAGTGATTATTGAGCCGAAAGAAACATTTTCATTTTGGCAGCTTGTACGATGGGCAGACCGTCACGAGAAATATAAGGACGGATTAAATCTTGTTAATGGAAAGATTGTAGGCTCTTATGGCGGAGGTTTGTGTCAATTGAGTAATATGCTATTTTGGCTTTTTTTACACACGCCGCTTGTTATTGTCGAGCGACACGGACACGCAGTTGAGTCTTTCCCATCAACAACCGAAGATTTGCCCTGCGGTACTGATGCTACGATTAACGAAGGTTGGTTAGACCTAAAACTCCGTAACGACACGGACAATACTTTCCAGATTGAGATTAGTTTTGATGACAACTTTATGTATGGTCGAATTTTGTCGCAAAGCTCCGTAAATATTGAATATACGGTTTTTAATTCGTCTGTTTCCTATTTCAAGCGAGAGGAAAAAGTATATCAAATAGCTTCTGTTTGTCGTACAGAAAAAGACAAAATGACTGGTAGTCAGACGGAAAAAGAATTGTATGTCAACCAATGTAAAATAGCCTATAAGCTACCCGATGATGTAAAAATTGAAGAAAGAGGTGTGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7544,Drugs,MEG_7544|Drugs|Glycopeptides|VanG-type_accessory_protein|VANWG,gi|33355827|gb|AY271782.1|20202-21047,5
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccgcaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgaagtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtacctcccccagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtacgaagcaatatgaatccccgtgatatcaacgacaaaacacttcagcaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggcagtggcaataaaattgcactggcagcacaccctttaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcaaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatagtgatgctggctaacaaaaactatcccaatccagcgagagtcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1281,Drugs,MEG_1281|Drugs|betalactams|Class_C_betalactamases|BLAEC,1028105047|WP_063860233.1|NG_049080|1|1|blaEC-14|blaEC|class_C_extended-spectrum_beta-lactamase_EC-14 NG_049080:101-1234,0
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatgtgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctctttatcatggaagtgcaaaaagtaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagatccggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7106,Drugs,MEG_7106|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100185|WP_063856398.1|NG_048239|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048239:101-2020,4
,atgcgttattttcgcctgtgtattatctccctgttagccaccctgccgctgcgggtacacgccggaccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggcagcgtaggcatgatagaaatggatctggccaggcccggcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcaggtctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccgacaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctgccagccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccgcccgcagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggacgtttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcgccggggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4233,Drugs,MEG_4233|Drugs|betalactams|Class_A_betalactamases|OHIO,1028105871|WP_063860895.1|NG_049352|1|1|blaOHIO-1|blaOHIO|class_A_extended-spectrum_beta-lactamase_OHIO-1 NG_049352:101-961,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacactctacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcaaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4692,Drugs,MEG_4692|Drugs|betalactams|Class_D_betalactamases|OXA,1058244127|WP_068981645.1|NG_051480|1|1|blaOXA-530|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-530 NG_051480:1-825,0
,atgcccctccgactccctttgcgcgccctcggcgcggccctgtccctgttcgcgctggccggcgcccccgcccgcgcggcggttttgtgcaccgtggtggccgacgccgccgacggccgcatcgtgttccagcaaggcacgcaggcggcctgcgccgagcgctacacgcccgcctcgaccttcaagctgccgatcgcgctgatgggcgcggacgcgggcatcctgcaaggcccgcacgcgccagtctggaactaccagccgggctaccccgactggggcggcgacgcctggcgccagccgacggacccggcgcgctggatcaagtattcggtggtctggtactcacaactgaccgcccgggcgctggggcaggagcgcttccagcgctacgcctcggccttccagtacggcaacgaggacgtctcgggcgagcccggcaagcacaacggcctggacggcgcgtggatcaactcgtcgctgcgcatttcgccgctggagcaactggcgttcctgcgcaagctggtcaaccgccaattgccgctcaagcccgcggcctacgatctggccgagacgctgttcgacgccggcgaggccggcggctggcgcctgtatggcaagaccggcaccggctcgccgggcagcaacggcgtctacacgccggacaacgcctacggctggttcgtcggctgggcgcgcaaggacggccgccaactggtgttcgcgcgcctgctgcaggacgagaaagccacccggcccaatgccggcctgcgcgcccgcgacgagctgttgcgcgagtggccagccatggccgacgcgccccgccagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4603,Drugs,MEG_4603|Drugs|betalactams|Class_D_betalactamases|OXA,935682093|WP_054500785.1|NG_064750|1|1|blaOXA-789|blaOXA-364_like|OXA-364_family_class_D_beta-lactamase_OXA-789 NG_064750:1-828,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaaatatttaagtgggacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggtgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcctaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4452,Drugs,MEG_4452|Drugs|betalactams|Class_D_betalactamases|OXA,1058244138|WP_068981646.1|NG_051481|1|1|blaOXA-531|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-531 NG_051481:1-825,0
,TCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGCCATATTATGGAGCCTCATGCTTTTATATAAAATGTGTGACAATCAAAATTATGGGGTTACTTACATGAAGTTTTTATTGGCATTTTCGCTTTTAATACCATCCGTGGTTTTTGCAAGTAGTTCAAAGTTTCAGCAAGTTGAACAAGACGTTAAGGCAATTGAAGTTTCTCTTTCTGCTCGTATAGGTGTTTCCGTTCTTGATACTCAAAATGGAGAATATTGGGATTACAATGGCAATCAGCGCTTCCCGTTAACAAGTACTTTTAAAACAATAGCTTGCGCTAAATTACTATATGATGCTGAGCAAGGAAAAGTTAATCCCAATAGTACAGTCGAGATTAAGAAAGCAGATCTTGTGACCTATTCCCCTGTAATAGAAAAGCAAGTAGGGCAGGCAATCACACTCGATGATGCGTGCTTCGCAACTATGACTACAAGTGATAATACTGCGGCAAATATCATCCTAAGTGCTGTAGGTGGCCCCAAAGGCGTTACTGATTTTTTAAGACAAATTGGGGACAAAGAGACTCGTCTAGACCGTATTGAGCCTGATTTAAATGAAGGTAAGCTCGGTGATTTGAGGGATACGACAACTCCTAAGGCAATAGCCAGTACTTTGAATAAACTTTTATTTGGTTCCGCGCTATCTGAAATGAACCAGAAAAAATTAGAGTCTTGGATGGTGAACAATCAAGTCACTGGTAATTTACTACGTTCAGTATTGCCGGCGGGATGGAACATTGCGGATCGCTCAGGTGCTGGCGGATTTGGTGCTCGGAGTATTACAGCAGTTGTGTGGAGTGAGCATCAAGCCCCAATTATTGTGAGCATCTATCTAGCTCAAACACAGGCTTCAATGGCAGAGCGAAATGATGCGATTGTTAAAATTGGTCATTCAATTTTTGACGTTTATACATCACAGTCGCGCTGATAAGGCTAACAAGGCCATCAAGTT,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1542,Drugs,MEG_1542|Drugs|betalactams|Class_A_betalactamases|CARB,gi|233319|gb|S46063.1|S46063|1-1060 gi|766547679|gb|KP116299.1|20688-20795 gi|660573358|gb|CP008790.1|155421-155524 gi|800908878|gb|KP345882.1|65907-65805 gi|481190437|gb|JX121641.1|52141-52243,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatcgcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcatttggttataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgaatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaacgggcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaccggtttcggaacatatgtagtgtttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctggatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_583,Drugs,MEG_583|Drugs|betalactams|Class_C_betalactamases|ADC,1058243656|WP_068981620.1|NG_051453|1|1|blaADC-89|blaADC|class_C_beta-lactamase_ADC-89 NG_051453:1-1152,0
,ATGAAAAATAAAGGAATCGATCAATTTCGTGTGATTGCAGCCATGATGGTGGTTGCGATCCATTGTCTTCCCCTTCACTATTTATGGCCAGAAGGCGATATCCTAATCACATTGACGATTTTTCGAGTAGCTGTTCCTTTCTTTTTTATGATCAGTGGTTACTATGTGTTTGCAGAACTTGCTGTGGCCAATAGTTATCCTTCGCGACAACGAGTATTCAACTTTATCAAAAAACAGCTAAAAGTCTATCTATTAGCCACACTAATGTTTTTACCATTAGCACTCTACAGTCAAACGATCGGCTTCGATCTACCAGTTGGAACATTAGTACAATCACTTTTGGTCAATGGCATTCTTTATCATCTTTGGTACTTTCCGGCTTTGATTACTGGGAGCCTGCTCCTAACAAGTTTGCTGATACATGTCTCCTTCAAAAAAGTGTTCTGGCTTGCGGCTGGATTGTACCTGATTGGATTAGGTGGTGATAGTTGGTTTGGACTGATCCAACAGACACCAATCGAACCATTCTATACTGCTGTGTTCCACCTATTAGATGGTACCCGCAACGGTATTTTCTTTACACCATTGTTTTTGTGCTTAGGTGTGCTGGTCAGAAAACAATCAGTGAAAAGAAGTTTATCCAAAACAGCTCTCTTCTTTTTGATCAGTCTTATCGGATTGCTTATTGAGAGTGCGTACTTGCATGGGTTTTCTATACCTAAACATGACAGTATGTATCTCTTCTTGCCTGTTGTACTCTTTTTCTTATTTCCACTGATCTTGCGCTGGCATCCCCACAGGACTTGGAAGCATCCGGGACAGCTATCTTTATGGCTTTACCTTTTGCATCCTTATACAATTGCCGGCACACACTTTTTGAGCCAAAAAATCAGCATTCTGCAAAACAATCTAATCAACTATTTGGTTGTTTTGATCTTGACGATTGGATTCATTTGCCTCTTTTTAAGACAACAACACTCATGGTTTAGACACAAACAAACAACGCCCGTTAAAAGGGTCGTAAAAGAATTCTCAAAGACAGCCCTTTTGCATAATCTACAGGAGATCCAGCGGATCATCTCACCGAAAACAAAAGTGATGGCAGTCGTTAAAGCCGATGCCTACGGCTGTGGTGCCAAGGAAGTTGCTCCTGTTTTAGAACAAGCCGGAATTGATTTTTTTGCGGTGGCTACGATTGATGAAGGTATTCAATTGCGGAAAAATGCTGTCAAAAGCCCCATCTTGGTCTTGGGATATACCTCTCCAAAACGCATAAAAGAACTTCGTCGCTACTCATTGACCCAATCGATCATCAGCGAAGGTCATGCTGTAGCATTGTCACAAAGAAAAGTAGCGATTGACTGTCATTTAGCCATCGATACTGGGATGCATCGGTTAGGTGTAACACCGACTATCGATTCGATTCTTTCGATTTTCGATTTGCCCTTCTTGACGATCAGTGGTGTTTATTCTCATCTTGGTTCGGCAGATCGCTTAAATCCTGATAGTATGATTCGCACTCAGAAGCAGATTGCCTGCTTCGATCAGATTCTCCTAGAGCTGGATCAGAGACAGATTTCTTATGGTATCACACACTTACAAAGCAGTTATGGTATTTTGAATTATCCAGACTTAAACTATGATTATGTGCGTCCGGGGATTTTATTGACAGGATCCCTCAGTGATACGAACGAGCCTACAAAACAACGAGTAAGCTTACAGCCTATTCTGACCCTCAAAGCACAGTTGATCACTAAGCGAGTCGTTGCCAAAGGGGAAGCGATCGGTTATGGGCAAACCGCCGTCGCGAATCAAGAAACAACTGTTGGTGTTGTGAGCATCGGCTATTGTGACGGACTGCCCCGTTCTCTATCAAATCAAGAGTTTTGTCTTTCCTATCGCGGTCAGTCCTTGCCGCAGATCGGCTTGATCTGCATGGATATGCTTTTGATAGACTTGAGCCATTGTCCTACGATCCCAATTGAAAGTGAAATTGAAATTCTGACAGATTGGAGCGATACTGCCGAGCAAGTACAAACTATAACCAATGAGTTGATTTGTCGGATCGGTCCACGAGTCAGTGCTAGGATCAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7526,Drugs,MEG_7526|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,(Gly)VanTc:DQ022190:1802-3898:2097,5
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5610,Drugs,MEG_5610|Drugs|betalactams|Class_C_betalactamases|PDC,1408841621|WP_111672894.1|NG_060551|1|1|blaPDC-281|blaPDC|class_C_beta-lactamase_PDC-281 NG_060551:1-1194,0
,ATGAGTGAAAAAGTGCCCGCCGAGATTTCGGTGCAACTATCACAAGCACTCAACGTCATCGGGCGCCACTTGGAGTCGACGTTGCTGGCCGTGCATTTGTACGGCTCCGCACTGGATGGCGGATTGAAACCGTACAGTGATATTGATTTGCTGGTGACTGTAGCTGCACCGCTCAATGATGCCGTGCGGCAAGCCCTGCTCGTCGATCTCTTGGAGGTTTCAGCTTCCCCTGGCCAAAACAAGGCACTCCGCGCCTTGGAAGTGACCATCGTCGTGCACAGTGACATCGTACCTTGGCGTTATCCGGCCAGGCGGGAACTGCAGTTCGGAGAGTGGCAGCGCAAAGACATCCTTGCGGGCATCTTCGAGCCCGCCACAACCGATTCTGACTTGGCGATTCTGCTAACAAAGGCAAAGCAACATAGCGTCGTCTTGGCAGGTTCAGCAGCGAAGGATCTCTTCAGCTCAGTCCCAGAAAGCGATCTATTCAAGGCACTGGCCGATACTCTGAAGCTATGGAACTCGCCGCCAGATTGGGCGGGCGATGAGCGGAATGTAGTGCTTACTTTGTCTCGTATCTGGTACACCGCAGCAACCGGCAAGATCGCGCCAAAGGATGTTGCTGCCACTTGGGCAATGGCACGCTTGCCAGCTCAACATCAGCCCATCCTGTTGAATGCCAAGCGGGCTTATCTTGGGCAAGAAGAAGATTATTTGCCCGCTCGTGCGGATCAGGTGGCGGCGCTCATTAAATTCGTGAAGTATGAAGCAGTTAAACTGCTTGGTGCCAGCCAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_921,Drugs,MEG_921|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA7:AF224733:32-829:798,2
,atggtgacaaagagagtgctacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcgccgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcggctacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2189,Drugs,MEG_2189|Drugs|betalactams|Class_A_betalactamases|CTX,1028104759|WP_063860005.1|NG_048959|1|1|blaCTX-M-174|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-174 NG_048959:1-876,0
,gtgaatacgtcttattcacaatcaaatttacgacacaaccaaattttaatttggctttgcgttctatctttttttagcgtattaaatgaaatggttttgaacgtctcattacctgatattgcaaatgattttaataaatcaccggcgagtacaaactgggtgaacacagcctttatgttaaccttttctattggaacagctctatatggaaagctatctgatcagctaggcattaaaaggttactcctatttgggattataataaattgcttcggatcggtaattgggtttgttggacattctttttttcccatacttattctggctcgatttattcaaggagctggtgcagctgcatttccagcactcgtgatggttgtagttgcgcgctatattccaaaggaaaataggggtaaagcgtttggtcttattggctccatagtagctatgggagaaggtatcggtccagctattggtggaatgatagctcattttatccattggtcttatcttctgctcattccaatgatgacaattatcactgttccgttccttattaaattgttgaaaaaagaagtaaggataaaaggtcattttgatattgtaggaattatactaatgtcagtgggcattgtattttttatgctgtttacaacatcttataacatttcttttctgatcatcagtattctgtcattcctgatatttgtaaaacatattaggaaagtaacagaaccttttgttgaacctgcactggggaaaaatatttcttttataattggtgtcctttgtggaggacttatatttggtacagtagcagggtttatctctatggttccttacatgatgaaagatgtacatcaactaagtactgctgcaattggcagtgtgattattttccctggagcaatgagcgttattatcttcggttacattggtggattacttgttgatagaaaaggtccattgtacgtgttaaccattggagttacatttctttccgttagctttttaattgctgccttttttttagaagtaacaccatggttactgacaattatattagtttttgtttttggtgggctgtcattcaccaaaacagttatatctacaattgtttcaagtagtttgaaacaaaaggaagctggtgccggaatgagtttgcttaattttaccagttttttatcagagggaataggtattgcaattgttggtggtttattatctgtacgcttactgaatcagaagttgctacctatggaccttgatcaatccacttatttgtatagtaatatgctattcctttttacaggagtcgttgttactagttggctgatcaccttgaatgtatataaacgaagacaaattcaatttaaaagttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7094,Drugs,MEG_7094|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,501454005|WP_012477450.1|NG_048209|1|1|tet(L)|tet(L)|tetracycline_efflux_MFS_transporter_Tet(L) NG_048209:101-1483,4
,atgtccgttaaagcgctgttcgcggccctgcccttgctcatcgctgcttgcgcggcaattccagcaccgcaagttgaagatgcggacgcgccgccctcgcccgcgccaacggaaacggtggtgaacgcccacgagatgcagatggcgtttctcgatgcgtgcgagccgtgggacgagtgggacaagcccgctccaccgttccaattgatgggcaacagctggtatgtcggcacctgcggtatctcggcagtcctgattaccggcgaagacggacacatcctgatcgacagcggcgtccccgaggccgccccgctggtcctcgcgaacatcgcctcgctcggtttcgatgcgaaggatgtgcgctatctcctgatgagccatgagcatttcgaccatgtcggcgcgcatgccgcaatcaaggaagcgacaggtgcgcaagtgttggcttcggtaagagccaagcccgtgctcgaaacggggaaagtcgccgccgacgatccgcaggccgcatccggccatccagacatgaccccggtaaaggtcgaccgcgtgatcggcgatggggaaatactcgatctcggcaacctgcgcgttacggctcatgaaacgcccggccattcgcccggggcgctcagctggacatggtggtcgtgttcgctccctggcgagccgcccgtgtgcaaccgcttcgcctatgtcgacagcctgtccgcggtttccgcagacgattaccgcttcaccgatcacccggagatggttcgcgcattccggaccagcatcgacaaggcacgcatgctccagtgtgagtttctggtgacaccgcacccctcggccgggtccatgctcgacctgatgagcggagaacacgggctctacctgcacaagggctgcggcttctatgcaaagcggcttagcaaacgcctcgatgagcgcttggccaaggaagctgccgagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1274,Drugs,MEG_1274|Drugs|betalactams|Class_B_betalactamases|BLAEAM,1509794516|WP_122630825.1|NG_062208|1|1|blaEAM-1|blaEAM|subclass_B3_metallo-beta-lactamase_EAM-1 NG_062208:1-957,0
,ATGGTTAAAAAATCACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCTGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGACTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCGACGGTTTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2221,Drugs,MEG_2221|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-38:AY753197:1-876:876,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1900,Drugs,MEG_1900|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JF780936|+|63-1209|ARO:3002078|CMY-65 [Citrobacter sp. 913] ,0
,atgaaaaaattatttgttttatgtgtattcttcctttgcaacattgctgctgcagatgattctttgcctgatttaaaaattgagaagcttgaaaaaggcgtttatgttcatacttcgtttgaagaagttaaaggttggggtgtattcgcaaaacacggtttagtggttcttgtaaagaatgatgcttatctgatagatactccaattaccgctaaagatactgaaaaattagttaattggtttattgagcacggctatagaatcaaaggcagtatttccacacatttccatggcgacagtacggctggaatagagtggcttaattctcaatctatctccacgtatgcctctgaattaacaaatgaacttctaaaaaaagacaataaggtgcaagctacaaattcttttagtggagttagttattcacttatcaaaaacaaaattgaagttttctatccaggtccaggacacactcaagataacgtagtggtttggttacctgaaaagaaaattttattcggtggttgctttgttaaaccggacggtcttggaaatttaggggatgcaaatttagaagcttggccaaagtccgctaaaatattaatgtctaaatatggtaaagcaaaactggttgtttcaagtcatagtgaaattggaaacgcatcactcttgcagcgcacatgggagcaggctgttaaagggttaaatgaaagtaaaaaaccgttacagccaagtagctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3322,Drugs,MEG_3322|Drugs|betalactams|Class_B_betalactamases|IMP,1343491236|WP_104009852.1|NG_056414|1|1|blaIMP-71|blaIMP|subclass_B1_metallo-beta-lactamase_IMP-71 NG_056414:1-741,0
,atgcacgccagcgactccaaagtcactctgcgcttgatgaccgagcgtgacctgccgatgctgcacgaatggctgaatcggcctcatattgtcgagtggtggggtggagaggacgaacgcccgactctcgacgaggtacttcggcactacatgccaagagttttatctgaagcgtccgtcactgcctacatcgcgatgctgggagacgaacccattggctacgcccagtcgtatgtcgcccttcgaagtggtgatggatggtgggccgacgaaactgatcctggagttcgcgggattgatcagtctctggctgacccggcgcaattgaacaaggggctgggaacaatgctcgtccgtgcccttacgagcatgctcttctcggacccgacagtgacaaagattcaaaccgaccccgcgccccacaaccacagggccatccgttgctacgagaaggcggggtttgttcagcaaaaggtagtcaccacgcctgacggtcccgctgtttatatggttcaaacacgcgaggccttcgagaggtcgtgcagtgccacctag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_177,Drugs,MEG_177|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,518484846|WP_019655053.1|NG_052534|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052534:101-655,2
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgcaggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgctgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctgtggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_873,Drugs,MEG_873|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502156|WP_071846308.1|NG_052375|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052375:62-853,2
,atgaccactaccattagcttcgtcactctgcgcctcatgaccgagcacgaccttccgatgctccatgactggctaaaccggcctcacatcgttgagtggtggggcggagaagaaacacgtccaacacttgctgaagtgctggagcaatacctaccaagtgccctggcgaaagagtccgtcactccctacatcgcaatgctggatgaagaaccgattgggtacgctcagtcgtacattgcactcggaagcggtggcggatggtgggaagacgaaaccgatccaggagtacgcggaatagaccagtctctggcgaatccatcgcagctgggcaagggcttgggaaccaagctcgttcgcgcgctcgttgagatgctgttcaaagacgctgaggtaaccaagatccaaacggacccgtcgccgaacaacttacgcgcaatccggtgctacgagaaggcgggttttgtggcgcaaagaaccataaccaccccagatggaccggccgtatacatggttcaaacacgtcaggcgttcgagcaggcgcgcagtgccgtctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_128,Drugs,MEG_128|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,959688383|WP_058124867.1|NG_052214|1|1|aac(6')-31|aac(6')-31|aminoglycoside_N-acetyltransferase_AAC(6')-31 NG_052214:101-655,2
,TGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCGGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGGGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGCACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3490,Drugs,MEG_3490|Drugs|betalactams|Class_A_betalactamases|KPC,gb|AY700571|+|0-879|ARO:3002314|KPC-4 [Enterobacter sp. E624] ,0
,atgaaaatcatgcctgtaaccgagccgttcttggctgactggctgcagttaagacgattactctggcctgatcatgaagacgcgcatttactggaaatgcggcagttactcgaacaaacacagaccctgcaattattaagctataacgatcagcagcaagcaattgccatgctggaagcgtctattcgatatgaatatgtaaatggcacacaaagctcaccggtggcttttctggaaggtatttatgtgttgccagaatatcgacgttcaggtgttgctagcgcgttggtacagcaagtagaacactggtccaagcagtttgcatgtaccgaatttgcttcggacgctgcgctggataatacgatcagtcatgccatgcatcgcgcgctgggctttcaggaaaccgagcgtgtggtttattttaagaaaaacatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_111,Drugs,MEG_111|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,497196670|WP_009510932.1|NG_052258|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052258:101-541,2
,GTAATTCGGGGCAGAATTGGTAAAGAGAGTCGTGTAAAATATCGAGTTCGCACATCTTGTTGTCTGATTATTGATTTTTCGCGAAACCATTTGATCATATGACAAGATGTGTATCCACCTTAACTTAATGATTTTTACCAAAATCATTAGGGGATTCATCAGTGCCCGGCAGTGGTTGCAGGGGATTGAGAGGGCAAGCGCATTTTTGTTTTTTACTTTTTGTGCTGACTGTGAATACTTCAGCCACACGGATTCAATTTTCAGGAGTTTGAGATGATGAGACATCGCGTTAAGCGGATGATGCTAATGACAACGGCCTGTATTTCGCTGTTGCTGGGGAGTGCGCCGCTGTATGCGCAGGCGAACGACGTTCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGGGGGCGGTTGGGAGTGGCGCTGATTGACACCGCCGATAACGCACAGACGCTCTACCGCGCCGATGAGCGCTTTGCCATGTGCAGCACCAGTAAGGTGATGGCGGCAGCGGCTGTGCTCAAGCAAAGTGAAACGCAAAAGAAGGTGTTGAGTCAGAAGGTTGAGATTAAATCTTCAGACCTGATTAACTACAATCCCATTACTGAAAAACACGTCAACGGCACGATGACGCTGGCGGAATTGAGCGCCGCGGCGTTGCAGTACAGCGACAATACGGCCATGAACAAGCTGATTGCCCATCTTGGGGGGCCGGATAAAGTGACGGCGTTTGCCCGTGCGATTGGGGATAACACCTTCCGGCTCGATCGTACTGAGCCGACGCTCAACACCGCGATCCCCGGCGACCCGCGCGATACCACCACGCCATTAGCGATGGCGCAGACGCTTCGCAATCTGACGTTGGGCAGTGCCTTAGGTGAAACTCAGCGTGCGCAACTGGTAACGTGGCTGAAAGGCAATACCACCGGCGCTGCCAGCATTCAGGCTGGGCTACCCACATCGTGGGTTGTCGGGGATAAAACCGGCAGCGGTGATTATGGTACGACGAATGACATCGCCGTTATCTGGCCGGAAGGGCGTGCGCCGCTTATTCTGGTCACTTACTTCACCCAGCCAGAGCAGAAGGCAGAAAGTCGTCGTGACGTACTCGCGGCTGCCGCGAAAATCGTCACCGACGGTTATTAATTCTAAAAAATGTGGAGCGCTCTGTCGCTCCACTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_2434,Drugs,MEG_2434|Drugs|betalactams|Class_A_betalactamases|CTX,gi|970697631|gb|KT935446.1|131552-132735 gi|695199311|ref|NG_035199.1|1-1184 gi|288872162|dbj|AB543595.1|1019-2157 gi|958572031|gb|KT001474.1|1591-2696 gi|958571981|gb|KT001472.1|1575-2680 gi|958571965|gb|KT001471.1|1571-2676 gi|958572015|gb|KT001473.1|1574-2663 gi|573008382|emb|HG798900.1|1-876,0
,atgaacattaaaacactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagtacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacggacaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4686,Drugs,MEG_4686|Drugs|betalactams|Class_D_betalactamases|OXA,1559613005|WP_128268270.1|NG_063875|1|1|blaOXA-771|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-771 NG_063875:36-860,0
,ATGAGCGACCTTGCGAGAGAAATTACACCGGTTAACATCGAGGAAGAGCTGAAGAGCTCCTATCTGGACTATGCGATGTCGGTCATTGTTGGCCGTGCGCTGCCGGACGTCCGCGATGGCCTGAAGCCGGTACACCGTCGCGTACTATACGCCATGAACGTATTGGGCAATGACTGGAATAAAGCCTACAAAAAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGATTCCGCGGTGTACGACACCATCGTTCGTATGGCGCAGCCTTTCTCGCTGCGTTACATGCTGGTAGATGGTCAGGGTAACTTTGGTTCTATCGACGGCGACTCCGCCGCGGCAATGCGTTATACGGAAATCCGTCTGGCGAAAATTGCCCATGAGCTGATGGCCGACCTGGAAAAAGAGACGGTTGATTTCGTTGATAACTACGATGGCACGGAAAAAATTCCTGACGTCATGCCAACGAAGATCCCTAACCTGCTGGTGAACGGTTCGTCCGGTATCGCCGTAGGGATGGCGACCAACATTCCGCCGCACAACATCACCGAAGTGATCAACGGCTGCCTGGCCTATATCGACGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGCCCGGACTTCCCGACGGCGGCCATCATCAACGGTCGTCGTGGTATTGAAGAAGCGTACCGCACCGGTCGCGGCAAGATTTACATCCGTGCCCGCGCCGAAGTGGAAGCAGATGCCAAAACCGGCCGTGAAACCATCATTGTTCACGAGATCCCGTATCAGGTGAACAAAGCGCGACTGATTGAAAAAATCGCCGAGCTGGTAAAAGAAAAACGTGTTGAAGGCATCAGCGCGCTGCGTGACGAGTCTGATAAAGACGGTATGCGCATCGTGATTGAAATCAAACGCGACGCGGTGGGCGAGGTTGTGCTGAACAACCTGTACTCTCAGACCCAGCTGCAGGTCTCCTTCGGTATCAACATGGTTGCACTGCACCATGGTCAGCCGAAGATCATGAACCTGAAAGAGATCCTGAGCGCGTTTGTCCGTCACCGCCGCGAAGTGGTGACCCGTCGTACCATTTTCGAACTGCGCAAAGCGCGTGACCGTGCCCACATCCTTGAGGCACTGGCCGTGGCGCTGGCCAACATCGACCCGATCATTGAACTGATCCGTCGCGCGCCAACCCCGGCGGAAGCGAAAACCGCGCTGATTTCCCGTCCGTGGGATCTGGGCAACGTTGCGGCAATGCTGGAGCGTGCCGGTGATGACGCCGCGCGTCCTGAGTGGCTGGAACCTGAATTCGGCGTGCGTGATGGTCAGTACTACCTGACTGAACAGCAAGCCCAGGCGATTCTGGATCTGCGTCTGCAGAAACTGACCGGCCTTGAGCATGAAAAACTGCTCGACGAATATAAAGAGCTGCTGGAGCAGATCGCTGAACTGCTGCACATCCTGGGCAGCGCAGAGCGCCTGATGGAAGTGATCCGCGAAGAGCTGGAGCTGATCCGCGATCAGTTCGGCGATGAGCGTCGCACCGAAATCACCGCCAACTCCGCAGATATCAACATCGAAGACCTGATCAACCAGGAAGACGTTGTTGTGACCCTGTCTCACCAGGGCTACGTGAAGTATCAGCCGTTAACTGACTACGAAGCACAGCGTCGTGGTGGTAAAGGCAAATCTGCGGCACGTATTAAAGAAGAAGACTTTATTGACCGTCTGCTGGTGGCGAACACCCATGACACCATCCTCTGCTTCTCCAGCCGGGGTCGTCTGTACTGGATGAAGGTCTACCAGTTGCCGGAAGCGAGCCGTGGTGCACGTGGTCGTCCGATCGTTAACCTGCTGCCGCTGGAAGCGAACGAACGTATCACCGCCATTCTGCCGGTACGCGAGTACGAAGAGGGCGTGAACGTCTTTATGGCGACCGCCAGCGGTACCGTGAAGAAAACCGCGCTGACCGAGTTCAGCCGTCCACGTTCTGCCGGTATCATCGCGGTGAACCTGAACGAAGGCGATGAGCTGATTGGCGTCGATCTGACTTCAGGCAAAGATGAAGTCATGCTCTTCTCCGCAGCCGGTAAAGTGGTGCGCTTCAAAGAAGACGCCGTCCGCGCAATGGGTCGTACCGCAACGGGCGTTCGCGGTATCAAACTGGCGGGCGAAGACAGCGTCGTTTCTCTGATTATTCCGCGCGGGGAAGGGGCTATCCTGACCGTGACGCAGAATGGTTACGGTAAACGTACCGCGGAAGGGGAATACCCAACCAAGTCGCGTGGCACGCAGGGCGTTATCTCTATCAAGGTGACCGAGCGCAACGGTTCCGTTGTGGGCGCGGTGCAGGTAGACGATGCCGACCAGATCATGATGATCACCGATGCCGGTACGTTGGTGCGTACCCGCGTGTCGGAGATTAGCGTGGTGGGTCGTAATACCCAGGGCGTTATCCTCATCCGTACGGCGGAAGATGAAAACGTGGTGGGTCTGCAACGTGTTGCTGAGCCAGTGGACGACGAAGAGCTCGACTCCATCGACGGTAGCGTCGCGGAAGGTGATGATGATATCGCACCGGAAGTGGACACCGACGATGATGCAGCGGATGATGCTGACGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3201,Drugs,MEG_3201|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|295054830|gb|CP001918.1|3612829-3610193,3
,TTTTCTTACTCGCCTTTATCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATTTTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCAGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGTGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGGATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAACCCGGCGGTGGCCGCGCGCGTTATCCGGCTCGTAGCA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6473,Drugs,MEG_6473|Drugs|betalactams|Class_A_betalactamases|SHV,gi|695210936|ref|NG_035980.1|1-946,0
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAATCAGCAGTAACTAGAGTGAAAGCGATGATGGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCCGGCCATGAAATGATTACTGTGGAAGAAGAGTTGAATAGAGTATTACCAGTTGTTGAAGCGATTGTCGGTTTTGATGTAAAAATTTCGGTTGATACTTTTCGTAGTGAAGTTGCTGAAGCTTGTTTAAAGCTAGGTGTTGATATTATTAATGATCAATGGGCAGGCCTTTATGATCATCGCATGTTTCAAGTTGTAGCCAAATACGATGCGGAAATTGTTTTAATGCATAATGGCAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAGAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATTTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2951,Drugs,MEG_2951|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|703576232|gb|CP009554.1|497697-498500 gi|701162461|emb|LN626917.1|2115506-2114703 gi|685631213|gb|CP009361.1|503794-504597 gi|312436391|gb|CP002110.1|10309-9506 gi|49240382|emb|BX571856.1|554802-555605 gi|2058355|emb|Z84573.1|133-936,8
,TATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATACTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGGTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6916,Drugs,MEG_6916|Drugs|betalactams|Class_A_betalactamases|TEM,gi|444746817|gb|KC292503.1|4217-5195 gi|392513885|gb|JQ783055.1|2643-2841 gi|981191958|emb|LN999997.1|2513351-2513298 gi|975048878|gb|CP013962.1|4121749-4121696 gi|973715451|gb|CP013836.1|137699-137752 gi|973705327|gb|CP013832.1|76000-76053 gi|971339514|gb|CP006662.2|50761-50814 gi|943457735|gb|KT818627.1|33005-33058 gi|970338578|gb|KT725789.1|75398-75451 gi|970338460|gb|KT725788.1|80658-80711,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataatacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4461,Drugs,MEG_4461|Drugs|betalactams|Class_D_betalactamases|OXA,1058244003|WP_068981635.1|NG_051470|1|1|blaOXA-510|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-510 NG_051470:1-825,0
,TTCAATAATATTGAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6943,Drugs,MEG_6943|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695212971|ref|NG_036530.1|183-1123,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagagggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacggccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5543,Drugs,MEG_5543|Drugs|betalactams|Class_C_betalactamases|PDC,1035157530|WP_064511495.1|NG_050817|1|1|blaPDC-144|blaPDC|class_C_beta-lactamase_PDC-144 NG_050817:1-1194,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagccgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2158,Drugs,MEG_2158|Drugs|betalactams|Class_A_betalactamases|CTX,1028104747|WP_063859993.1|NG_048957|1|1|blaCTX-M-172|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-172 NG_048957:1-876,0
,GTGGTCGGCGTGGGGCTGAGGGAGCGCAAGAAACTGGACACCCGGCGGGCGCTGAGTGACGCCGCGCTGAGGCTGATGTTCGAGCGCGGCCTGGAGAACGTCACGCGCGAAGACATCGCCAACCTGGCGGGCGTCTCCTTGCGCACGTTCACCAACTACTTCAACGGCAAGTACGACGCATTGGCGTACCGCCAGGTCGAACGCATGCGGCGCAGCATCGAGACGCTGCGCAATCGTCCGGTCGGTGAGCCGTTGTGGACGTCGGTCATTGAGGCCGTGTTGGAGCCGCTCGACGAGGACTTCGAGGACATGTATGGAGCGGAGAACGTCCTGCCCACTCGCCAGCAGCTCGCCGAGGTCCGAAAACTGTTGATGGTGCCGGAGATCCGCGATGCGACGTTCCGTGCGATGTTCGACGAATGGGTTGCGGTCATCGCCGAACGTACCGGCACCGATCCCGCACATGACATGTATCCACGACTCGTGGTGGCCGTCGTCCGCGCGGTGGGCGACGTCGCGATGGACCAGTACGCGAACGCCGATCCACCGGTGTCCTTCACCGAACTACTGCGTCAGGGGTTCGCGGCCGTCACCGCGGGACTGCCTGAACCCGAGAGGAAGAAATGA,tetR,antibiotic target alteration,Tetracyclines,MEG_7193,Drugs,MEG_7193|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|45758644|gb|AY570506.1|1820-1194,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcgagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5572,Drugs,MEG_5572|Drugs|betalactams|Class_C_betalactamases|PDC,1201190439|WP_087587959.1|NG_054976|1|1|blaPDC-190|blaPDC|class_C_beta-lactamase_PDC-190 NG_054976:1-1194,0
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctcagcgcaatccccactgttaaaagagcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctgggctccgataatgaaagcgtatcagggagacgagtttagtgttccagtgcagcaactgctgcaatactcggtctcgcacagcgataacgtggcctgtgatttgttatttgaactggttggtggaccagctgctttgcatgactatatccagtctatgggtataaaggagaccgctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaaaggtgctgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccacctcaggaccagagcggttaaaaggtttgttaccagctggtactgtggtcgcacataaaactggtacttcgggtatcaaagccggaaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggttgctcagactgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5761,Drugs,MEG_5761|Drugs|betalactams|Class_A_betalactamases|PER,1625655428|WP_136512105.1|NG_064782|1|1|blaPER-13|blaPER|class_A_extended-spectrum_beta-lactamase_PER-13 NG_064782:1-927,0
,TGGACATAAGCCTGTTCGGTTCGTAAACTGTAATGCAAGTAGCGTATGCGCTCACGCAACTGGTCCAGAACCTTGACCGAACGCAGCGGTGGTAACGGCGCAGTGGCGGTTTTCATGGCTTGTTATGACTGTTTTTTTGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGACATCATGAGGGTAGCGGTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGACCTTATGGAGGCTTCGGCTTTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCACTACGTGAAAGGCGAGATCACCAAGGTAGTCGGCAAATAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_952,Drugs,MEG_952|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|213958578|gb|AF047479.2|1035-2087 gi|573013567|dbj|AP013064.1|28857-28601 gi|973585379|gb|KP054476.2|32479-32732,2
,ATGATGACTCTGGCGTTAGTTGGCGAAAAAATTGACAGAAACAGGTTCACCGGTGAAAAAGTTGAAAATAGCACATTTTTCAACTGTGATTTTTCGGGTGCCGACCTTAGCGGCACTGAATTTATTGGCTGCCAGTTTTATGATCGAGAAAGTCAGAAAGGATGTAATTTTAGTCGCGCTAACCTGAAAGATGCCATTTTCAAAAGTTGTGATCTCTCCATGGCTGATTTCAGGAATATCAATGCGCTGGGAATCGAAATTCGCCACTGCCGGGCACAAGGGTCAGATTTTCGCGGCGCAAGTTTTATGAATATGATCACCACCCGCACCTGGTTTTGTAGCGCCTATATCACCAATACCAACTTAAGCTACGCCAACTTTTCAAAAGTCGTACTGGAAAAGTGCGAGCTGTGGGAAAACCGCTGGATGGGTACTCAGGTGCTGGGCGCAACGTTCAGTGGATCAGACCTCTCTGGCGGCGAGTTTTCATCCTTCGACTGGCGAGCAGCAAACGTTACGCACTGTGATTTGACCAATTCGGAACTGGGCGATTTAGATATCCGCGGGGTTGATTTGCAAGGCGTCAAACTGGACAGCTACCAGGCATCGTTGCTCCTGGAACGTCTTGGTATCGCTGTCATGGGTTAA,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_5932,Drugs,MEG_5932|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gb|DQ303921|+|0-648|ARO:3002718|QnrB4 [Escherichia coli] ,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgtaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgcttttccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4702,Drugs,MEG_4702|Drugs|betalactams|Class_D_betalactamases|OXA,1509794535|WP_122630844.1|NG_062257|1|1|blaOXA-733|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-733 NG_062257:1-825,0
,atggaaacctacaatcatacatatcggcaccacaacttttcacataaagacttaagtgatctcaccttcaccgcttgcacattcattcgcagcgactttcgacgtgctaacttgcgtgatacgacattcgtcaactgcaagttcattgaacagggtgatatcgaaggctgccactttgatgtcgcagatcttcgtgatgcaagtttccaacaatgccaacttgcgatggcaaacttcagtaatgccaattgctacggtatagagttccgtgcgtgtgatttaaaaggtgccaacttttcccgaacaaactttgcccatcaagtgagtaatcgtatgtacttttgctcagcatttatttctggatgtaatctttcctatgccaatatggagagggtttgtttagaaaaatgtgagttgtttgaaaatcgctggataggaacgaacctagcgggtgcatcactgaaagagtcagacttaagtcgaggtgttttttccgaagatgtctgggggcaatttagcctacagggtgccaatttatgccacgccgaactcgacggtttagatccccgcaaagtcgatacagcaggtatcaaaattgcagcctggcagcaagaactgattctcgaagcactgggtattgttgtttatcctgactaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_6017,Drugs,MEG_6017|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRS,1245933209|WP_096170112.1|NG_059279|1|1|qnrS14|qnrS|quinolone_resistance_pentapeptide_repeat_protein_QnrS14 NG_059279:101-757,3
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctggctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgaggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagtacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3464,Drugs,MEG_3464|Drugs|betalactams|Class_A_betalactamases|KPC,1142971250|WP_077064886.1|NG_052862|1|1|blaKPC-27|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-27 NG_052862:1-882,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctacttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2195,Drugs,MEG_2195|Drugs|betalactams|Class_A_betalactamases|CTX,1625655387|WP_136512064.1|NG_064720|1|1|blaCTX-M-225|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-225 NG_064720:73-948,0
,atgaaaattattaatattggaattttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcaaaatgagtttttgaagttaaatagtgttcttggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaactaaaagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtttatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcatttcaaaatgcagttatggaagggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7116,Drugs,MEG_7116|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,758866324|WP_043029018.1|NG_048244|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048244:101-2020,4
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5687,Drugs,MEG_5687|Drugs|betalactams|Class_C_betalactamases|PDC,1201190444|WP_087587964.1|NG_054984|1|1|blaPDC-199|blaPDC|class_C_beta-lactamase_PDC-199 NG_054984:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagattacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4646,Drugs,MEG_4646|Drugs|betalactams|Class_D_betalactamases|OXA,919248567|WP_052788887.1|NG_057517|1|1|blaOXA-581|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-581 NG_057517:1-774,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_792,Drugs,MEG_792|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1080153686|WP_070342366.1|NG_051891|1|1|aadA15|aadA15|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA15 NG_051891:101-892,2
,ATGACCTTCTCCTCGACCTCCTCGGCCCCTCCACCGTCACCGCTCCTCCCGGCAACGAGAATCACGGTTTACGGCTGCGGGCGGGACGAGGCCGCCTTGTTCCGCCGGACGGCACCCCGTTTCGGCGTCGAGGCGACTCTCACGGAGGCCGCCGTATCCGAAGAGAACGCCGAGATGGCGGCCGGAAACCAATGCATCAGCATTGACCACAAGACCCCGGTCACACCTGCCACTCTCCGCGCTCTCCACCGGGCCGGCGTGACGTACATATCCACCCGGAGTATCGGTTACAACCACATCGATGTGACATACGCGGCCGGCGTGGGGATATCCGTCGAGAACGTCACCTACTCCCCCGCCGGCGTGGCCGACTACACCCTGATGCTCATGCTGATGGCGGTGCGCAACGCGAAATCCACCGTCCGCCGCGCGGAGCTGCACGACTACCGGCTGAACGAGATACGCGGTAAGGAGCTGCGCGACCTGACCGTCGGAGTGATCGGGACGGGGCGTATCGGTGCGGCGGTCGTGGACAGGCTGCGGGGTTTTGGCTCCCGGGTACTGGCCTACGGAAAACGGCCCACCATCGCGGCAGATTACGTCTCTCTCGACGAGTTGCTGCGGTCGAGCGACATCGTGTCGCTGCACGTACCGCTGACCCCGGACACGCATCACCTTCTCGATCAAAGCCGTATCCGGCGGATGAAAAGTGGCGCTTTCGTCATCAACACCGGACGCGGCCCGCTCATCGACACCGAAGCGCTGGTACCGGCGTTGGAGAGCGGCAGGTTGAGCGGTGCGGCGCTGGATGTCATCGAGGGCGAGGAAGGGATCTTCTACGCCGACTGCAGAAACAGAACCATCGAAAGCACGTGGCTCCCGCGGCTGCAGAAAATGCCGAACGTACTCATCAGCCCGCACACCGCCTATTACACCGACCACGCCCTGATGGACACGGTCGAGAACTCCATCATCAACTGCCTTAATTTCGGAAGCAGGAAACAGCATGGCTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7406,Drugs,MEG_7406|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,gi|24427162|emb|AL939117.1|53343-54356,5
,ATGGAGGAAATAAAATTGAAAATTATTAATATCGGTATCTTAGCACATGTTGATGCAGGAAAAACTACTTTGACAGAAAGCTTACTATACAGTAGCGGAGCAATTAAAGAGTTAGGAAGTGTAGATAGCGGTACAACGAAAACGGATACTATGTTTTTGGAACGCCAGAGAGGTATTACTATTCAGACCGCAATAACATCTTTTCAACGGGAAAATGTTAAAGTAAATATTGTAGATACTCCTGGACACATGGATTTTTTGGCAGATGTATACCGTTCATTATCTGTTTTGGATGGAGCTATTTTGCTAATCTCTGCAAAAGATGGAGTACAGTCACAAACTCGTATACTATTCCATGCACTTAGAAAGATGAACATACCTATAATATTTTTTATTAACAAAATTGATCAAAATGGAATAAATTTGCCAGATGTTTATCAAGATATTAAGGACAAACTTTCTGACGACATCATAATTAAGCAGACTGTGAATCTAAATTTGAAACCTTATGTAATAGATTATACTGAACCAGAACAATGGGAGACAGTAATTGTGGGAAATGATTATTTATTAGAAAAATATACCATTGGGAAAACATTGAATATTGCAGAACTTGAAAAGGAGGAAAACGAAAGAATTCAAAGTTGCTCCTTATATCCTGTTTATCACGGAAGTGCAAAGAATAATATTGGAATTAAACAACTTATAGAGGTAATTACTAGCAAATTATTTTCACCCACACAACTCAATTCAGATAAACTTTGTGGAAATGTTTTTAAAGTAGAATATTCAGATGATGGTCAACGGCTTGTCTATGTACGTCTTTATAGTGGAACGCTACATTTGCGAGACTCAGTCAATATATCAGAAAAGGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGAGAATTACGCCAGATAGATAAGGCAGAGCCTGGTGAGATTATTATTTTAAAAAATGAGCTTTTAAAACTAAATAACGTACTTGGAGATAAAAAAAGATTACCACATAGAGAAATTCTTGAGAATCCTCTTCCTATGTTACAAACAACAATTGAACCATGTAAATCAGTACAAAGAGAAAAGTTACTAGATGCACTTTTTGAAATATCCGATAGTGATCCCCTTCTACAATATTATGTAGATACAGTAACTCACGAAATTGTGCTATCTTTTTTAGGTGAGGTCCAAATGGAGGTAACTTGTACTCTGATTCAAGAAAAATATCATATTGAGATAGAAACAAGAAAACCAACTGTCATTTATATGGAAAGACCATTAAAAAAATCTGAATTTACCATTGATATCGAAGTACCTCCAAATCCTTTCTGGGCTTCTATTGGTTTATCTGTAACACCACTTCCTTTGGGTAGTGGCATTCAGTATGAGAGCCTGGTTTCTCTAGGTTATTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGTATACGCTATGGGTGTGAACAAGGATTGTACGGTTGGAAATTAACAGACTGTAAGATCTGTTTTAAGTATGGTCTATATTACAGCCCTGTCAGTACGCCAGCAGATTTCCGAATGCTTGCGCCTATTGTACTAGAGCAGGCTTTTAGAAAGAGTGGTACAGAGTTATTAGAGCCATATCTTAGCTTCGAAATTTATGTACCACAAGAATATCTTTCGAGAGCATATAATGATGCTTCCAAATATTGTGCAAATATTTTAAATACTAAGTTAAAAGGTAACGAGGTCATTCTCATTGGTGAAATCCCTGCTCGGTGTATTCAAGAATATCGTAGTGATTTAACTTTCTTTACAAATGGACGTAGTGTTTGTTTAACAGAGTTAAAAGGGTACCATGTTACTACCGGTGAACCTGTTTGCCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7147,Drugs,MEG_7147|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,tet(S/M)_2_AY534326 ,4
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGCATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGTGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGTTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCCCTGGCGGTCAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTGTTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAACGGACAAGGAGGCCCTGGATATTGGGCTTCCTTTCTTTCTCTTTTTTTCCTGCTGTCATCTACACTTAACAAAAATCCAGCAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1986,Drugs,MEG_1986|Drugs|betalactams|Class_C_betalactamases|CMY,gi|595583473|gb|KF992025.1|1027-2255,0
,ATGTACAGCATCGTGACCAACAGCACCGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_275,Drugs,MEG_275|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,(AGly)AacA4:AF416297:2738-3304:567,2
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcatgagttgtcactcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7700,Drugs,MEG_7700|Drugs|betalactams|Class_B_betalactamases|VIM,1693892950|WP_140423327.1|NG_065447|1|1|blaVIM-64|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-64 NG_065447:1-801,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCCGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTAACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAACTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1859,Drugs,MEG_1859|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AM931008|+|0-1146|ARO:3002049|CMY-38 [Proteus mirabilis] ,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTTCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1368,Drugs,MEG_1368|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_135_AB811795,0
,TGGAAACCTACAATCATACATATCGGCACCGCAACTTTTCACATAAAGACTTAAGTGATCTCACCTTCACCGCTTGCACATTCATTCGCAGCGACTTTCGACGTGCTAACTTGCGTGATACGACATTCGTCAACTGCAAGTTCATTGAACAGGGTGATATCGAAGGCTGCCACTTTGATGTCGCAGATCTTCGTGATGCAAGTTTCCAACAATGCCAACTTGCGATGGCAAACTTCAGTAATGCCAATTGCTACGGTATAGAGTTCCGTGCGTGTGATTTAAAAGGTGCCAACTTTTCCCGAACAAACTTTGCCCATCAAGTGAGTAATCGTATGTACTTTTGCTCAGCATTTATTTCTGGATGTAATCTTTCCTATGCCAATATGGAGAGGGTTTGTTTAGAAAAATGTGAGTTGTTTGAAAATCGCTGGATAGGAACGAACCTAGCGGGTGCATCACTGAAAGAGTCAGACTTAAGTCGAGGTGTTTTTTCCGAAGATGTCTGGGGGCAATTTAGCCTACAGGGTGCCAATTTATGCCACGCCGAACTCGACGGTTTAGATCCCCGCAAAGTCGATACATCAGGTATCAAAATTGCAGCCTGGCAGCAAGAACTGATTCTCGAAGCACTGGGTATTGTTGTTTATCCTGACT,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6022,Drugs,MEG_6022|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRS,gb|EU077611|+|0-654|ARO:3002792|QnrS3 [Escherichia coli] ,3
,atgcgtcaatatcgattcgcccttctcccattgttagccgccctggcgctccccggttgggcgcatcaagctacggtgacgacggttaaacaagccgaaagccagcttcagggccgggtcggctacgccgaactggatttagcttccgggcaactgctggccggctatcgttctgacgaacggttcccgatgatgagcacttttaaagttctgctctgcggcgcagtcttgtcgcgtgtcgatgccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatattcgccggtgacggaaaagcatcttaccgatgggctcaccgtgggcgaactgtgcgctgccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccagcttcctgcgccacagcggcgaccagacttcgcggcttgaccgttgggaaacggaactcaatgaagcgcggccgggcgacgtgcgagataccacaactccgcaagcgatggccaggacactgcgaaatctgttgaccggtcgcgtgctttccagcgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgatcggtgctgccggcaggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcgggatcatcgctgctctcgggccggacggtaaagctgcgcgcatcgtggtgatttatttgaccgggacccccgccacaatggatgaacgcaataaacagattgcggccatcggcgcaacgctggtcacgcactggtccgcagacgagaacagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5789,Drugs,MEG_5789|Drugs|betalactams|Class_A_betalactamases|PLA,835809808|WP_047664983.1|NG_049970|1|1|blaPLA-2a|blaPLA|class_A_beta-lactamase_PLA-2a NG_049970:101-976,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtagctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacctgacatgctgagttttattcatgccaatctgaacctacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaagcctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_595,Drugs,MEG_595|Drugs|betalactams|Class_C_betalactamases|ADC,1058243669|WP_068981621.1|NG_051454|1|1|blaADC-90|blaADC|class_C_beta-lactamase_ADC-90 NG_051454:1-1152,0
,atggaaaaatatataaattggaaatttaagttttatactatatgggcagggcaggcggtatctttaatcactagtgccatcctgcaaatggcgataattttttaccttacagaaaaaacaggatctgcgatggttttgtctatggcttcactagtagggtttttaccctatgcggtctttggaccagccattggtgtattagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatagcagcagctggagcagtgctcgctattgttgcattgtatacggagttatctgtatggatggttatggtagtattgtttatccgtagcattggaacggcttttcattctccggctctcaatgcggttacgccgcttttagtaccagaagaacagcttacgaaatgtgcaggttatagtcagtctttgcagtcgataagttatattattagtccggctgctgcggcattgttatactccgtttggaaattaaatgcaattattgctatcgatatattgggtgctatgattgcatctattacggtagcaattgtaagtattcctaagctgggcgatcaagtgcaaagtttgaaaccaaatttcttaagagaaatgaaagaaggaattgtcgcattgagacaaaacaaaggcttatttgccttattactcttaggaacgctatatacgtttgtgtatatgccaattaatgcactatttcctttaattagcatggaatattttaatggaacacctgtgcatatttccattaccgaaatcgcttttgcatctggaatgctagtaggcggtctactattaggaaggttggggaactttgaaaagcgtgtattgctaataacaggttcattctttataatgggagccagtttagccgtttcaggattacttccgccaagtggatttgttatatttgtagcttgctgtgcagtaatggggctttcggtgccattttatagcggtgtgcaaacagctctttttcaggagaagattaagcctgaatatttaggacgtgtattttctttgaccggaagtattatgtcatttgcaatgccaattggattaattctttctggattctttgctgatagaattggtgtaaatcattggtttttactatcaggtattttaattattggcattgctatagtttgcccgatgataacagaggttagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3822,Drugs,MEG_3822|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,969896723|WP_058621816.1|NG_047965|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047965:101-1318,7
,ATGAAAAGATTAAAAGGATTATTGGTTCTGGCTTTAGGTTTTACAGGACTACAGGTTTTTGGACAGCAAAATCCTGATATTAAAATTGAAAAATTAAAAGATAATTTATACGTCTATACAACCTATAATACCTTTAAAGGAACTAAATATGCGGCTAATGCGGTATATATGGTAACGGATAAAGGAGTAGTGGTGATAGACTCTCCATGGGGAGAAGATAAATTTAAAAGTTTTACAGACGAGATTTATAAAAAGCACGGAAAGAAAGTCATCATGAACATTGCTACCCATTCTCATGACGATAGAGCCGGAGGTCTTGAATATTTTGGTAAACTAGGTGCAAAAACTTATTCTACTAAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCAAAGTACACTTTTGATAATAATAAATCTTTTAAAGTAGGAAACACTGAGTTCCAGGTCTATTATCCGGGAAAAGGTCATACAGCAGATAATGTGGTTGTGTGGTTCCCTAAAGACAAAGTATTAGTAGGAGGCTGCATTGTAAAAAGCGGTGATTCGAAAGACCTTGGGTTTATTGGAGAAGCTTATGTAAACGACTGGACACAGTCCATACACAACATTCAGCAGAAATTTCCCGATGTTCAGTATGTCGTTGCAGGTCACGATGACTGGAAGGATCAAACATCAATACAGCATACACTGGATTTAATCAGTGAATATCAACAAAAACAAAAGGCTTCAAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1262,Drugs,MEG_1262|Drugs|betalactams|Class_B_betalactamases|BLAB,(Bla)B-6:AF189302:1-747:747,0
,gtggatagagcgcctgggttgggcgttcgcctcaaactcactctcagttatgccgggttcctcatgctcgctggtgtcttgctccttgcggcggtttgggttttcctgctgagagggcggtccacgaatttccaattccctgctctggccgactttgcccgggtcttcgacccgagcaacttcggtcccgtggtgtttgtcccggcagcgatcttggcgctcgggttcttgctggtgttcggccttgtgggtggttggattctcgcgggccgaatgcttgccccgttggcgcgcattacgcgcgccgcgcgggaggcggggagtggctcgctgtcgtaccggatcgaactggagggacgcaacgacgagttccgtgaacttgccgatgccttcgacgccatgctcgcacggctcgaagcacgagacgccgcgcagcagcgattcgccgccaacgcctcccacgagttgcgcaccccgctggcgatcacacaaacccttctcgatgtcgcccgcaacgatccgaaccgcgacggcggcgagctcgacgaacgcctccgcgctgtcaacgcacgggcgatcgagctcaccgaggcattgctcctgctcagccgtaccgaccaacggtccttcagccgagaagacgtcgatctgtcgctcatcgcggaagaagccgccgagacactcctcccgttcgcggagaagcacggcgtcagcatcgagacctccggggacatcgcgccggtcatcggctcacacgcactcttgctgcagttgactacgaaccttctgcacaatgcgatcgtccacaatgtccccgagcacggcagcgtgcagatcagcaccgccatcggctccgagtccgtcatgctcacggtcgagaacaccggcgacaagctcagtccacagttggtctcgacactcaccgagccgtttcagcgcggcactgctcgcacccgcggggacgatgcgagggtgggccttggcctggcgatcgtcaagagcatcacgcaggcacacgacggatccctcacgctcagcccccgagctgccggcgggctctccgtagcagtgcgactgcccgccgctcagcgacgaccgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7522,Drugs,MEG_7522|Drugs|Glycopeptides|VanO-type_regulator|VANSO,1073722253|WP_070064533.1|NG_051735|1|1|vanS-O|vanS-O|VanO-type_vancomycin_resistance_histidine_kinase_VanS NG_051735:101-1201,5
,atgacgaaaatgaaccgcctggcggcagcgctgatcgccgcactgatcttgccgaccgcgcaggccgcgcagcagcaggatatcgacgccgttattcagccgctgatgaaaaaatatggcgtaccgggcatggcgatcgccgtgtcggtcgacggcaaacagcagatttacccatatggcgtcgcctcgaagcagaccggcaaaccgatcaccgaggagacgctgttcgaagtgggctcgctgagcaaaacctttaccgcgacgctggcggtctatgcgcagcagcagggcaagctgtcgttcaatgatccggccagccgctacctgcccgagctgcgcggcagcgccttcgacggcgtcagcctgctgaatctggcgacgcatacctccggcctgccgctgttcgtgccggacgacgtcaccaacaacgcccagctgatggcctactaccgggcctggcagccgaaacacccggcgggcagctaccgggtctattccaacctcggcatcggcatgctgggcatgatcgccgccaagagcctcgaccagccgtttatccaggcgatggaacaggggatgctgccggcgctgggcatgagccacacctacgttcaggtgccggcggcgcagatggctaactatgcgcagggttacagcaaggacgataagccggtgcgggtcaatcccggcccgctggacgccgaatcttacggcatcaagtccaacgctcgcgatctgattcgctatctggacgccaacctgcagcaggtgaaggtggcgcagccgtggcgcgacgcgctggccgcgacgcacgtcgggtattacaaggcgggcgcgttcacgcaggatctgatgtgggagaactacccgtatccagtgaaactgtcgcgtttgattgaaggcaacaacgccgggatgatcatgaacggcacgccagccaccgccatcacgccgccgcagccggaattgcgcgccggctggtataacaaaaccggctccaccggcggcttctccacctacgcggtatttatcccggcgaaaaatattgccgtggtgatgctggccaacaagtggttcccgaacgacgatcgcgtcgaggcggcttaccacatcgtccaggcgctggagaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6567,Drugs,MEG_6567|Drugs|betalactams|Class_C_betalactamases|SRT,835578460|WP_047567658.1|NG_047546|1|1|blaSRT|blaSRT|SRT/SST_family_class_C_beta-lactamase NG_047546:33-1169,0
,ATGAAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAGAGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACGAGGACGGACACCATGTTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACTTCCTTCCAGTGGCACAGATGTAAAGTTAACATTGTGGATACGCCCGGCCACATGGATTTTTTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCTAAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATTCCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTTCAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCCCCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAATAACGATGAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGCGCGGGAGGAACAGCAGCGGGTTCAAGACGCCTCCCTGTTCCCAGTCTATCATGGCAGCGCCAAAAATGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATTGGGGAACAGGGGGGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTTGAGTACACCGATTGCGGCCAGCGGCGTGTCTATCTACGGTTATACAGCGGAACGCTGCGCCTGCGGGATACGGTGGCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAAATTGTTCGGACAGACACCGCTTATCAGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTGAGGTTAAACGATGTATTAGGGGACCAAACCCGGCTCCCTCGTAAAAGGTGGCGCGAGGACCCCCTCCCCATGCTGCGGACGGCGATTGCGCCGAAAACGGCAGCGCAAAGAGAACGGCTGCTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGTTGCGAAGTGGATTCCATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCTTTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCTCCGTCATTTATATGGAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAACCCGTTTTGGGCATCCATAGGACTGTCTGTTACACCACTCTCGCTTGGCTCCGGTGTACAATACGAGAGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATCCGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTTGAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCGATTGTATTGGAACAGGCATTGAAGGAATCGGGGACGCAGCTGCTGGAACCTTATCTCTCCTTCATCCTCTATGCGCCCCAGGAATACCTTTCCAGGGCTTATCATGATGCACCGAAATACTGTGCCACCATCGAAACGGCCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATTCCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCGGAGCGTATGCCTTACAGAGCTGAAAGGATATCAGGCCGCTGTCGGTCAGCCGGTCATCCAGCCCCGCCGTCCAAACAGCCGCCTGGACAAGGTGCGCCATATGTTTCAGAAGGTAATGTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7231,Drugs,MEG_7231|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,gi|602249396|gb|KJ512988.1|1-1920 gi|602249394|gb|KJ512987.1|7446-9365 gi|166362177|gb|DQ060146.3|2244-4163,4
,atgaacattaaagcactctcacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4694,Drugs,MEG_4694|Drugs|betalactams|Class_D_betalactamases|OXA,1058244099|WP_068981643.1|NG_051478|1|1|blaOXA-528|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-528 NG_051478:1-825,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgagggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaagcgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_903,Drugs,MEG_903|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502205|WP_071846355.1|NG_052474|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052474:101-889,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5487,Drugs,MEG_5487|Drugs|betalactams|Class_C_betalactamases|PDC,1201190445|WP_087587965.1|NG_054985|1|1|blaPDC-200|blaPDC|class_C_beta-lactamase_PDC-200 NG_054985:1-1188,0
,atgactaaaaaagctcttttctttgccattggtacgatgtttttgtctgcatgttcttttaatacggtagaacaacatcaaatacagtcaatttctaccaataaaaactcagagaaaattaaatcgttgtttgatcaagcacaaactacaggtgttttagttataaaacatgggcaaacagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttgtttcctgattgggaaaaggacatgactctaggcgatgcgatgaaagcttctgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatgtgcaagaacaagttcaatctatggtgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaacctcaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggcatacctagttctattcgaaaagaaattgcttataagggattggaacaactcggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4567,Drugs,MEG_4567|Drugs|betalactams|Class_D_betalactamases|OXA,1028109710|WP_063864113.1|NG_049779|1|1|blaOXA-501|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-501 NG_049779:1-822,0
,ATGACTAAAACAAAAATTATGGGCATATTAAACGTCACACCTGATTCATTCTCAGATGGTGGAAAATTTAATAATGTTGAATCAGCTATAAATAGAGTGAAAGCCATGATAGATGAAGGTGCTGACATTATAGATGTTGGAGGTGTTTCAACGAGACCAGGTCATGAAATGGTTTCATTAGAAGAAGAGATGAACAGAGTATTACCTGTTGTTGAAGCTATTGTCGGTTTTGATGTAAAAATTTCAGTCGATACATTTCGAAGTGAGGTTGCTGAAGCATGTTTAAAATTAGGCGTTGATATGATTAATGATCAATGGGCGGGTCTGTATGATCATCGTATGTTCCAAATTGTAGCTAAATATGACGCGGAAATTATTTTAATGCATAATGGAAATGGTAATCGTGATGAACCGGTTGTCGAAGAAATGTTAACATCTTTGTTAGCACAAGCACATCAAGCTAAAATAGCTGGTATACCTTCAAATAAAATTTGGCTAGATCCAGGTATAGGTTTCGCTAAAACTAGAAATGAAGAAGCCGAAGTTATGGCAAGACTGGATGAACTTGTTGCAACAGAATATCCAGTTTTATTAGCGACAAGCCGGAAACGTTTCACTAAAGAGATGATGGGTTATGATACAACACCGGTTGAAAGAGATGAAGTAACTGCAGCTACGACTGCATATGGTATTATGAAAGGCGTTAGAGCAGTACGCGTTCATAATGTCGAGTTGAATGCTAAATTAGCTAAAGGTATAGATTTTTTAAAGGAGAATGAAAATGCAAGACACAATCTTTCTTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2945,Drugs,MEG_2945|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|47118312|dbj|BA000033.2|530596-531399,8
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataggcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_596,Drugs,MEG_596|Drugs|betalactams|Class_C_betalactamases|ADC,447133956|WP_001211212.1|NG_056172|1|1|blaADC-169|blaADC|class_C_beta-lactamase_ADC-169 NG_056172:1-1152,0
,atgatgactcagagcattcgccgctcaatgttaacggtgatggcgacgctacccctgctatttagcagcgcaacgctgcatgcgcaggcgaacagcgtgcaacagcagctggaagccctggagaaaagttcgggaggtcggcttggcgttgcgctgattaacaccgccgataattcgcagattctctaccgtgccgatgaacgttttgcgatgtgcagtaccagtaaggtgatggcggccgcggcggtgcttaaacagagcgagagcgataagcacctgctaaatcagagcgttgaaatcaagaagagcgacctggttaactacaatcccattgcggagaaacacgttaacggcacgatgacgctggctgagcttggcgcagcggcgctgcagtatagcgacaatactgccatgaataagctgattgcccatctgggtggtcccgataaagtgacggcgtttgctcgctcgttgggtgatgagaccttccgtctggacagaaccgagcccacgctcaataccgccattccaggcgacccgcgtgataccaccacgccgctcgcgatggcgcagaccctgaaaaatctgacgctgggtaaagcgctggcggaaactcagcgggcacagttggtgacgtggcttaagggcaatactaccggtagcgcgagcattcgggcgggtctgccgaaatcatgggtagtgggcgataaaaccggcagcggagattatggcaccaccaacgatatcgcggttatctggccggaaaaccacgcaccgctggttctggtgacctactttacccaaccggagcagaaggcggaaagccgtcgggatattctggctgcggcggcgaaaatcgtaacccacggtttctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_2168,Drugs,MEG_2168|Drugs|betalactams|Class_A_betalactamases|CTX,1044690743|WP_065419568.1|NG_051164|1|1|blaCTX-M-171|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-171 NG_051164:1-876,0
,AGAAAGGAGGTGATCCAGCCGCACCTTCCGGTACGGCTACCTTGTTACGACTTCGTCCCAATCGCCGATCCCACCTTCGACGGCTCCCTCCACAAGGGTTAGGCCACCGGCTTCGGGTGTTACCGACTTTCATGACGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGCGTTGCTGATCTGCGATTACTAGCGACTCCGACTTCACGGGGTCGAGTTGCAGACCCCGATCCGAACTGAGACCGGCTTTGAAAGGATTCGCTCCACCTCACGGCATCGCAGCCCTTTGTACCGGCCATTGTAGCATGTGTGAAGCCCTGGACATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCCGAGTTGACCCCGGCAGTCTCTCACGAGTCCCCACCATAACGTGCTGGCAACATGAGACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGCACACAGGCCACAAGGGAACCGACATCTCTGCCGGCGTCCTGTGCATGTCAAACCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAATCCACATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGGCGGGGTACTTAATGCGTTAGCTACGGCACGGATCCCAAGGAAGGAAACCCACACCTAGTACCCACCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTTACTGCCCAGAGACCCGCCTTCGCCACCGGTGTTCCTCCTGATATCTGCGCATTCCACCGCTACACCAGGAATTCCAGTCTCCCCTGCAGTACTCTAGTCTGCCCGTATCGCCCGCACGCCCACAGTTAAGCTGTGAGTTTTCACGAACAACGCGACAAACCACCTACGAGCTCTTTACGCCCAGTAATTCCGGACAACGCTCGGACCCTACGTATTACCGCGGCTGCTGGCACGTAGTTGGCCGGTCCTTCTTCTGCACATACCGTCACTTGCGCTTCGTCTGTGCTGAAAGAGGTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTGCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTATCTCAGTCCCAGTGTGGCCGGTCACCCTCTCAGGCCGGCTACCCGTCGTCGCCTTGGTAGGCCATCACCCCACCAACAAGCTGATAGGCCGCGGGCCCATCCCACACCGCAAAAGCTTTCCCCTACCAGGCCATGCGACCAGCAGGGTGTATTCGGTATTAGACCCAGTTTCCCAGGCTTATCCCAAAGTGCAGGGCAGATCACCCACGTGTTACTCACCCGTTCGCCACTCGAGTACCCCCGAAAGGGCCTTTCCGTTCGACTTGCATGTGTTAAGCACGCCGCCAGCGTTCGTCCTGAGCCAGGATCAAACTCTCCAAACAAAAAC,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_6145,Drugs,MEG_6145|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|RRSA,gb|NC_008596.1|-|3823614-3825143|ARO:3003544|Mycolicibacterium smegmatis 16S rRNA mutation in the rrsA gene conferring resistance to neomycin [Mycolicibacterium smegmatis MC2 155] ,2
,ATTGTAATATTATTTATTTATAAAAATTACAATTGTAATATTGGAGGGTTTATTTTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1413,Drugs,MEG_1413|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_29_JDXN01000019,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccatactgctgttcgccaccaccccggccattgccgacgaggccccggcagatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttctccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaagcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5681,Drugs,MEG_5681|Drugs|betalactams|Class_C_betalactamases|PDC,1028110198|WP_063864568.1|NG_049880|1|1|blaPDC-112|blaPDC|class_C_beta-lactamase_PDC-112 NG_049880:1-1194,0
,TTGAATCGAACTAATATTTTTTTTGGTGAATCGCATTCTGACTGGTTGCCTGTCAGAGGCGGAGAATCTGGTGATTTTGGTTTTCGACGTGGTGACGGGCATGCCTTCGCGAAAATCGCACCTGCTTCCCGCCGCGGTGAGCTCGCTGGAGAGCGTGACCGCCTCATTTGGCTCAAAGGTCGAGGTGTGGCTTGCCCCGAGGTGATCAACTGGCAGGAGGAACAGGAGGGTGCATGCTTGGTGATAACGGCAATTCCGGGAGTACCGGCGGCTGATCTGTCTGGAGCGGATTTGCTCAAAGCGTGGCCGTCAATGGGGCAGCAACTTGGCGCTGTTCACAGCCTATCGGTTGATCAATGTCCGTTTGAGCGCAGGCTGTCGCGAATGTTCGGACGCGCCGTTGATGTGGTGTCCCGCAATGCCGTCAATCCCGACTTCTTACCGGACGAGGACAAGAGTACGCCGCAGCTCGATCTTTTGGCTCGTGTCGAACGAGAGCTACCGGTGCGGCTCGACCAAGAGCGCACCGATATGGTTGTTTGCCATGGTGATCCCTGCATGCCGAACTTCATGGTGGACCCTAAAACTCTTCAATGCACGGGTCTGATCGACCTTGGGCGGCTCGGAACAGCAGATCGCTATGCCGATTTGGCACTCATGATTGCTAACGCCGAAGAGAACTGGGCAGCGCCAGATGAAGCAGAGCGCGCCTTCGCTGTCCTATTCAATGTATTGGGGATCGAAGCCCCCGACCGCGAACGCCTTGCCTTCTATCTGCGATTGGACCCTCTGACTTGGGGTTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1054,Drugs,MEG_1054|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|695208275|ref|NG_035510.1|1-804,2
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaatgattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataacggtatagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccttcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4636,Drugs,MEG_4636|Drugs|betalactams|Class_D_betalactamases|OXA,1391852894|WP_109545079.1|NG_057496|1|1|blaOXA-631|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-631 NG_057496:1-747,0
,ATGTCACCACCATCCCCGGTGCTGAAGAATTTCGAAGCATGGACGATGCGTTGCGTGCACTGCGGGGTCGGTATCCCGGTTGTGAGTGGGTTGTTGTGGAGGATGGGGCCTCGGGGGCTGGTGTTTATCGGCTTCGGGGTGGTGGGCGGGAGTTGTTTGTCAAGGTGGCAGCTCTGGGGGCCGGGGTGGGCTTGGGTGAGGCTGAGCGGCTGGTGTGGTTGGCGGAGGTGGGGATTCCCGTACCTCGTGTTGTGGAGGGTGGTGGGGACGAGAGGGTCGCCTGGTTGGTCACCGAAGCGGTTCCGGGGCGTCCGGCCAGTGCGCGGTGGCCGCGGGAGCAGCGGCTGGACGTGGCGGTGGCGCTCGCGGGGATCGCTCGTTCGCTGCACGGCGCTGGACTGGGAGCGGTGTCCGTTCGATCGCAGTCTCGCGGTGACGGTGCCGCAGGCCCGTGCTGTCGCTGAAGGGAGCGTCGACTTGGAGGATCTGACGAGGAGCGGAAGGGGTGGTCGGGGGAGCGGCTTCTCGCCGAGCTGGAGCGGACTCGGCCTGCGGACGAGGATCTCGGTTTGCCACGGTGACCTGTGCCCGGACAACGTGCTGCTCGACCCTCGTACCTGCGAGGTGACCGGGCTGATCGACTGGGGCGGGTCGGCCGTGCGGACCGGCACTCCGATCTCGCGCGGTGCTGGCGTCGCGCGAGCTGCGCGGGTGGGTCGGGGGCGGTGCAATCGGAGGAAAAGCTGCGTTTACCGGCTGTTGGACGAGTTCTTCTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1062,Drugs,MEG_1062|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,(AGly)Aph3-Va:U24442:680-1456:780,2
,atgaaaatcatgcctgtaaccgagccgttattggccgactggctgcaattaagaatattactctggcctgatgatgaagatgcacatttactggaaatgcggcagctactcgaacaaccacatactttgcaattattaagctataacgatcagcagcaagcaattgccatgctagaagcgtctattcgatatgaatatgtaaatggtacacaaacctcacctgtggcttttctggaaggcatttatgtcttgcctgaatatcgacgttcaggtgttgctaccactttggtacagcaagtagaagactgggcaaagcaattttcctgtaccgaatttgcttcagatgcagcaattgataatacgatcagtcatgccatgcatcgcgcgctgggttttcaggaaaccgaacgtgtggtttattttaagaaaaagatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_109,Drugs,MEG_109|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491401196|WP_005259042.1|NG_052526|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052526:101-541,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccactgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5518,Drugs,MEG_5518|Drugs|betalactams|Class_C_betalactamases|PDC,1035157542|WP_064511507.1|NG_050830|1|1|blaPDC-157|blaPDC|class_C_beta-lactamase_PDC-157 NG_050830:1-1194,0
,GCCGTCTAGTTCTGCTGTCTTGTCTCTCATGGCCGCTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATGACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCGCGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACCTGCGGAGCGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCTATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGG,beta-lactamase,antibiotic inactivation,betalactams,MEG_3495,Drugs,MEG_3495|Drugs|betalactams|Class_A_betalactamases|KPC,gb|FJ624872|+|0-851|ARO:3002319|KPC-9 [Escherichia coli] ,0
,ATGTCTGCATACGGACACGGCCGTCACGAGCATGGCCAAAATTTTCTCACCAACCACAAGATCATCAACTCCATCATCGACCTTGTGAAACAAACCTCCGGCCCCATCATTGAGATCGGACCAGGAAGCGGTGCCCTCACTCACCCGATGGCCCACTTGGGGAGGGCGATAACGGCAGTTGAAGTGGACGCAAAACTAGCTGCCAAAATCACACAAGAAACCTCCTCGGCGGCGGTCGAAGTGGTCCATGATGATTTCCTTAACTTCCGGTTACCCGCCACTCCCTGCGTCATTGTGGGAAACATTCCCTTTCACCTCACCACTGCCATTCTTCGAAAGTTGCTGCATGCGCCAGCATGGACTGACGCTGTACTCCTCATGCAGTGGGAAGTCGCTCGCCGCCGGGCCGGGGTAGGCGCAAGCACGATGATGACGGCTCAGTGGTCCCCATGGTTCACATTTCACCTGGGTTCTCGGGTACCAAGGCCTGCTTTCCGGCCACAGCCAAACGTTGACGGGGGGATCTTAGTGATCCGCCGGGTGGGTGACCCGAAGATTCCGATAGAGCAGCGCAAAGCCTTTCAGGCGATGGTGCACACCGTTTTCACTGCCCGGGGACGCGGGATAGGGGAAATTCTCCGAAGGCAGGGTTGTTTTCATCACGTTCAGAAACACAATCATGGTTGCGCTCGCGAGGAATCGACCCCGCGACCCTACCTCCCAGATTGCACACCAACGACTGGATCGATCTCTTCCAGGTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2861,Drugs,MEG_2861|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,gi|9945780|gb|AF024666.2|2969-2208 gi|695198883|ref|NG_035107.1|4849-5610,7
,ATGACTGATAAACAAAAACAACGCCCCGCGTGGGCCTATACGCTGCCGGCAGCACTGCTGCTGATGGCTCCTTTCGACATCCTCGCTTCACTGGCGATGGATATTTATCTCCCTGTCGTTCCAGCGATGCCCGGCATCCTGAACACGACGCCCGCTATGATCCAACTCACGTTGAGCCTCTATATGGTGATGCTCGGCGTGGGCCAGGTGATTTTTGGTCCGCTCTCAGACAGAATCGGGCGACGGCCAATTCTACTTGCGGGCGCAACGGCTTTCGTCATTGCGTCTCTGGGAGCAGCTTGGTCTTCAACTGCACCGGCCTTTGTCGCTTTCCGTCTACTTCAAGCAGTGGGCGCGTCGGCCATGCTGGTGGCGACGTTCGCGACGGTTCGCGACGTTTATGCCAACCGTCCTGAGGGTGTCGTCATCTACGGCCTTTTCAGTTCGATGCTGGCGTTCGTGCCTGCGCTCGGCCCTATCGCCGGAGTATTGATCGGCGAGTTCTTGGGATGGCAGGCGATATTCATTACTTTGGCTATACTGGCGATGCTCGCACTCCTAAATGCGGGTTTCAGGTGGCACGAAACCCGCCCTCTGGATCAAGTCAAGACGCGCCGATCTGTCTTGCCGATCTTCGCGAGTCCGGCTTTTTGGGTTTACACTGTCGGCTTTAGCGCCGGTATGGGCACCTACTTCGTCTTCTTCTCGACGGCTCCCCGTGTGCTCATAGGCCAAGCGGAATATTCCGAGATCGGATTCAGCTTTGCCTTCGCCACTGTCGCGCTTGTAATGATCGTGACAACCCGTTTCGCGAAGTCCTTTGTCGCCAGATGGGGCATCGCAGGATGCGTGGCGCGTGGGATGGCGTTGCTTGTTTGCGGAGCGGTCCTGTTGGGGATCGGCGAACTTTACGGCTCGCCGTCATTCCTCACCTTCATCCTACCGATGTGGGTTGTCGCGGTCGGTATTGTCTTCACGGTGTCCGTTACCGCGAACGGCGCTTTGGCAGAGTTCGACGACATCGCGGGATCAGCGGTCGCGTTCTACTTCTGCGTTCAAAGCCTGATAGTCAGCATTGTCGGGACATTGGCGGTGGCACTTTTAAACGGTGACACAGCGTGGCCCGTGATCTGTTACGCCACGGCGATGGCGGTACTGGTTTCGTTGGGGCTGGTGCTCCTTCGGCTCCGTGGGGCTGCCACCGAGAAGTCGCCAGTCGTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2930,Drugs,MEG_2930|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,gi|343916452|gb|JF268688.1|4316-3093 gi|820773184|gb|KM877269.1|106985-108188 gi|833127931|gb|KP696484.1|1069-2272 gi|678222149|gb|KJ909290.1|24367-25570 gi|440575351|emb|HF545434.1|42519-41316 gi|305670530|gb|HQ023861.1|30385-31588 gi|695213834|ref|NG_036692.1|12-1215,6
,ATGAATATAGTTGAAAATGAAATATGTATAAGAACTTTAATAGATGATGATTTTCCTTTGATGTTAAAATGGTTAACTGATGAAAGAGTATTAGAATTTTATGGTGGTAGAGATAAAAAATATACATTAGAATCATTAAAAAAACATTATACAGAGCCTTGGGAAGATGAAGTTTTTAGAGTAATTATTGAATATAACAATGTTCCTATTGGATATGGACAAATATATAAAATGTATGATGAGTTATATACTGATTATCATTATCCAAAAACTGATGAGATAGTCTATGGTATGGATCAATTTATAGGAGAGCCAAATTATTGGAGTAAAGGAATTGGTACAAGATATATTAAATTGATTTTTGAATTTTTGAAAAAAGAAAGAAATGCTAATGCAGTTATTTTAGACCCTCATAAAAATAATCCAAGAGCAATAAGGGCATACCAAAAATCTGGTTTTAGAATTATTGAAGATTTGCCAGAACATGAATTACACGAGGGCAAAAAAGAAGATTGTTATTTAATGGAATATAGATATGATGATAATGCCACAAATGTTAAGGCAATGAAATATTTAATTGAGCATTACTTTGATAATTTCAAAGTAGATAGTATTGAAATAATCGGTAGTGGTTATGATAGTGTGGCATATTTAGTTAATAATGAATACATTTTTAAAACAAAATTTAGTACTAATAAGAAAAAAGGTTATGCAAAAGAAAAAGCAATATATAATTTTTTAAATACAAATTTAGAAACTAATGTAAAAATTCCTAATATTGAATATTCGTATATTAGTGATGAATTATCTATACTAGGTTATAAAGAAATTAAAGGAACTTTTTTAACACCAGAAATTTATTCTACTATGTCAGAAGAAGAACAAAATTTGTTAAAACGAGATATTGCCAGTTTTTTAAGACAAATGCACGGTTTAGATTATACAGATATTAGTGAATGTACTATTGATAATAAACAAAATGTATTAGAAGAGTATATATTGTTGCGTGAAACTATTTATAATGATTTAACTGATATAGAAAAAGATTATATAGAAAGTTTTATGGAAAGACTAAATGCAACAACAGTTTTTGAGGGTAAAAAGTGTTTATGCCATAATGATTTTAGTTGTAATCATCTATTGTTAGATGGCAATAATAGATTAACTGGAATAATTGATTTTGGAGATTCTGGAATTATAGATGAATATTGTGATTTTATATACTTACTTGAAGATAGTGAAGAAGAAATAGGAACAAATTTTGGAGAAGATATATTAAGAATGTATGGAAATATAGATATTGAGAAAGCAAAAGAATATCAAGATATAGTTGAAGAATATTATCCTATTGAAACTATTGTTTATGGAATTAAAAATATTAAACAGGAATTTATCGAAAATGGTAGAAAAGAAATTTATAAAAGGACTTATAGGGGTCCCGAGCGCCTACGAGAAATTTGTATCGATAAGAAATAG,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_352,Drugs,MEG_352|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|695227123|ref|NG_041616.1|3848-5323 gi|222121345|dbj|AP009486.1|44169-45644 gi|974700633|dbj|AP017321.1|1566-2997 gi|937637449|gb|KT601170.1|53744-52313 gi|908234448|gb|CP010309.1|342355-340924 gi|841330217|emb|LN866849.1|1591032-1592463 gi|822490352|gb|CP003939.1|1724076-1722645 gi|807232188|gb|CP011116.1|1632281-1630850 gi|756766642|gb|KJ922127.1|19639-18208 gi|748807120|gb|CP010526.1|59777-61208,2
,ATGACTATACCTGACGCAAATGCAATCTATCCTAACCTAGCCATCAAAGAGGTTGTCTTTATCAAGAACGTGATCAAAAGTCCCAATATTGAAATTGGGGACTACACCTATTATGATGACCCAGTAAATCCCACCGATTTTGAGAAACACGTTACCCATCACTATGAATTTCTAGGCGACAAATTAATCATCGGTAAATTTTGTTCTATCGCCAGTGGCATTGAATTTATCATGAACGGTGCCAACCACGTAATGAAAGGTATTTCGACTTATCCATTTAATATTTTAGGTGGCGATTGGCAACAATACACTCCTGAACTGACTGATTTGCCGTTGAAAGGTGATACTGTAGTCGGAAATGACGTGTGGTTTGGGCAAAATGTGACCGTCCTACCAGGCGTAAAAATAGGTGACGGTGCCATTATCGGAGCAAATAGTGTTGTAACAAAAGACGTCGCTCCATATACAATTGTCGGTGGCAATCCAATTCAACTCATCGGACCAAGTTTTGAACCGGAAGTTATTCAAGCATTAGAAAATCTGGCATGGTGGAATAAAGATATTGAATGGATAACTGCTAATGTTCCTAAACTAATGCAAACAACACCCACACTTGAATTGATAAACAGTTTAATGGAAAAATAA,streptogramin inactivation enzyme,antibiotic inactivation,MLS,MEG_7628,Drugs,MEG_7628|Drugs|MLS|Streptogramin_A_O-acetyltransferase|VATE,gi|15266475|gb|AY043210.1|1-645,7
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagtggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagtttttcctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7043,Drugs,MEG_7043|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,488173588|WP_002244796.1|NG_048164|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048164:101-1306,4
,atgtcatccatcgttcgcggcgttcgcgccgccgtcgtcgcatccgccatttctcttgcagccgcgttcgcctgcctgccgctcgccgcggcggatgcgacgcgcgagcccgtcctcccgcaaagcggtcgctacgaagtgccggacagttggcgccagccgattgccccggtccgcatcgccgaccacacctggtacatcggcaccgagaacctgagtgcggtgctcgtcacgacgccgcagggcgcggtgctgatcgacggcggcatgccgcaggccgcggacatgctgttgcaacgcatgcgcgacgtcggcatcgcgcccggcgacctgcgctggatcctggtgtcgcacgcgcacgcggaccatgccggccccgtcgcgaaggtcaagcgcgcgaccggagcccgcatcgccgccaacgccgaatccgccgcgatgctcgcgcgcggcggtaccgacgacatccacttcggcgacgacatcaccttcccgcccgcgcaggccgatcgcctgctgcaggacgacgaagtcgtgcaggtcggcggcatcgcgctcaccggtcacgtcacgcccgggcacacgccgggcagcacgagctggacgtggaccgacacgaaggacggcaagccggtgcgcatcgcgtacgcggacagcctgtccgcgccgggctacaagctcatcggcaatccgcgcatgccgcgcatcgtcgagatgtacgaggccacgttcgcgaaggtgcgcgccctgccctgcgacctgctgctcacgccgcatccggatgcgagcgggtggacgcccgcggatgcggcgaacccgcatccctcgccgaaaacctgcgcggcctacgccgacgaaatggaagcgaagttcgacgccgaactcgcgaaacaacgtgcggcgaagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2648,Drugs,MEG_2648|Drugs|betalactams|Class_B_betalactamases|DHT,1509794520|WP_122630829.1|NG_062233|1|1|blaDHT2-1|blaDHT2|subclass_B3_metallo-beta-lactamase_DHT2-1 NG_062233:1-909,0
,atgaaaattattaatattggagttttagctcatgttgatgcgggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacagaggtacaacgaaaacggataatacgcttttagaacgtcagagaggaattacaattcagacggcgataacctcttttcagtggaaaaatactaagataaacatcatagacacgccaggacatatggattttttagcagaagtatatcgttcattatcagtattagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattgtttcatgcacttaggaaaataggtattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgcggaaattgtaatcaaacagaaggtagaactgcatcctaatatgcgtgtaatgaactttaccgaatctgaacaatgggatatggtaatagaaggaaatgattaccttttggagaaatatacgtctgggaaattattggaagcattagaactcgaacaagaggaaagcataagatttcataattgttccctgttccctgtttatcacggaagtgcaaaaaacaatatagggattgataaccttatagaagtgattacgaataaattttattcatcaacacatcgaggtcagtctgaactttgcggaaaagttttcaaaattgagtattcggaaaaaagacagcgtcttgcatatatacgtctttatagtggcgtactgcatttgcgagattcggttagaatatcggaaaaggaaaaaataaaaattacagaaatgtatacttcaataaatggtgaattatgtaaaatcgataaggcttattccggggaaattgttattttgcagaatgagtttttgaagttaaatagtgttcttggagatacaaagctattgccacagagagagagaattgaaaatcccctccctctgctgcaaacgactgttgaaccgagcaaacctcaacaaagggaaatgttacttgatgcacttttagaaatctccgacagtgacccgcttctgcgatattatgtggattctgcgacacatgaaatcatactttctttcttagggaaagtacaaatggaagtgacttgtgctctgctgcaagaaaagtatcatgtggagatagaaataaaagagcctacagtcatttatatggaaagaccgttaaaaaaagcagagtataccattcacatcgaagttccaccgaatcctttctgggcttccattggtctatctgtagcaccgcttccattagggagcggagtacagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7112,Drugs,MEG_7112|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,488345309|WP_002414694.1|NG_048235|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048235:1-1920,4
,ATGTCCTACAGAGACCTGGGTTTGATCGACAGCGAAGTGATCGCGGAGCGACGCGTCCGAGCGCTCGACGATTCGTCACCCTCGGCCGTCCCGACCACTGGGGTCAGAGTTTTCGGATGCGGTCACGACGAAGCCGTTTTGTTCCGCGAGATGGGAACCCGCCTCGGGATAACGCCAAGCATCACCGAGGAAGCGATCAGTGAAACCAACGCTGAACTGGCGCGTGGCAACCGATGCATCAGCGTGAGCCACAAGACGCAGATCGACAATTCCACGCTGCTGGCGCTGAGCCGAGTCGGAGTGGAGTACATCTCCACCAGAAGCGTCGGGTACAACCACATCGACGTGGAATTCGCGGCGAGCATCGGCATCTCGGTCGGCAACGTCGACTACTCGCCCGACAGCGTGGGCGACTACACACTGATGTTGATGCTGATGACCGTACGCCACGCGAAATCAATTGTCCGCCGCGCCGATACGCATGATTACCGGCTGAATGACACGCGCGGCAGGGAGCTGCGCGACTTGACCGTCGGGGTGATCGGAACAGGGCGCATCGGCACAGCAGTCATCGACCGGCTGCAGGGATTTGGCTGCCGCGTGCTGGCACATGACAGCGGGCCTCACGCCTCCGCCGACTACGTTCCGCTCGATGAACTGCTGCGGCAGAGCGACATTGTCACGCTCCACACTCCACTCACCGCGGACACACACCATCTCCTCGATCGCCAACGCATCGACCAGATGAAGCACGGCGCGTACATCGTCAACACGGGTCGCGGACCGCTGCTCGATACCGAGGCCCTCCTCTCCGCATTGGAGAGCGGCCGGTTGGGCGGCGCGGCGCTCGATGTCGTCGAAGGAGAGGAAGGGATCTTCTACGCCGACTGCAGGAACAGGCTCATCGAGAACAAGGCCCTGGTGCGGCTACAGCGCCTGCCGAATGTGCTGATCAGTCCGCACTCCGCCTACTACACAGACCACGCCCTGAACGACACCGTCGAAAACAGCCTCGTCAACTGCCTGAACTTTGAAAGTGGGAGAACAGCATGAGCAGATTGAAGGTCGGGGTCATCTTCGGAGGGGCTTCCGAAGAACATCCCGTCTCCATCAAGTCGGCGCGAGAGGTGGCAAGAAGTCTCGACACGGAGAAGTACGAACCGTTCTGGATCGGCATCACGACCGGCGGCGAGTGGAAGCTCTGTGACGGCCCCGACGCGGATTGGGAGAATCGCAGCGCCCGTCCCGCCGTGCTGTCACCCGATCGAAGTGTGCACGGCCTGCTGGTCATGGAGCAGGGGGGCTACGAAACCGTGCGCCTCGACCTCGTCTTCCCCGTACTTCACGGCAAGCTCGGCGAAGACGGCGCGATCCAAGGCCTGTTGGAGCTCGCCGGCATCCCCTACGTCGGCTGCGACATCCAGGGCTCGGCTGTGTGCATGGACAAGGCCCTGGCCTACATCGTGGCCAAGAGCGCGGGAATCGCCACGCCGAGCTTTTGGGTTGTCGCGGAGAACGAGAAGGTCGACGCCGATCACCTTCGCTATCCGGTCTTCGTGAAGCCGGCCCGTTCGGGTTCATCTTTCGGCGTCAGCAAGGTCACCCGAGAAGACGAGCTGCCGAACGCGCTGAGCGCGGCGCGACAGTACGACTCGAAGGTCCTGATCGAAGAAGCCGTGGCCGGCAGCGAGATCGGCTGCGCGGTCATGGGTGAACTATTCGGCCTGATCACTGGGGAGGTGGACCGCGTCGACCTCTCGCACGGATTCTTCAGGATCCACCAGGAGGACTCACCCGAAACCGGATCGGAGAACTCGACGTTCATCGTTCCCGCCGACATCTCCGACGAATCGCGCCGGCTCGTCCAAGAGACCGCCAAGGCCATCTACCGCACCCTGGGCTGCAAGGGACTTGCCCGCGTTGACATGTTCCTCACCGACGACGGACGGGTGGTCCTCAACGAGGTCAACACCATGCCCGGCATGACGTCGTACAGCCGGTACCCGCGGATGATGGCCGCCGCGGGACTGCCGATCTCCGACATGATCGACCGGCTCATCTCGATGACAATGCACGGGAAGAAGCGATGAACGACGACTTCGTCTACGTCGACGACTGGGTGCCCGGAGTCCGCTGGGATGCCAAGTACGCCACGTGGGACAACTTCACCGGCAAACCGGTAGACGGCTACCTCGCGAATCGAATCGTCGGCACCCGGGCTTTGTGCGCGGCCCTCGAGCAAGCACGCGAGAAGGCAGCTTCCCTCGGCTTCGGATTGCTTCTCTGGGACGGCTACCGTCCTCGACGCGCCGTCGACAGCTTCCTACGCTGGTCAGAACAGCCGGAGGATGGCCAGACGAAGCAGCGACACTATCCCAATATCGACAGACCCGAGATGCTCGAAAAGGGATACGTGGCAACCCAGTCGGGCCACAGTAGGGGCGGCGCCGTTGACCTGACGCTCTATCACCTTGCGACCGGTGAACTTGCTCCTATGGGTGGCGACCACGACCTCATGGACCCGATCTCACATCATCGAGCGCGAGGAATCAAGCCAATCGAGTCCAAGAATCGTGAGCTTCTTCGTTCCATCATGGAGGACTGCGGATTTGATCGGTACGACTGCGAGTGGTGGCACTACACGCTGAAACGCGAACCATATCCAGATGTCTACTTCGACTTTCCGATCACGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7438,Drugs,MEG_7438|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHOX_1_KF478993,5
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaaatgggatggggaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattctggtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctctaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4707,Drugs,MEG_4707|Drugs|betalactams|Class_D_betalactamases|OXA,1028109735|WP_063864138.1|NG_049785|1|1|blaOXA-507|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-507 NG_049785:1-825,0
,atggaaaatggttttttgtttttagatgaaatgttgcatggcgtccgttgggatgccaagtacgccacatgggataacttcacaggaaaaccggtggatgggtatgaggtgaatcgcatcatcggcacaaaggccgtggcgtttgctctgcgcgaggcacaaatccatgcggctgcgcttggctatggcttgcttttatgggatggatatcggccaagaactgcggtggactgcttcctgcgttgggcagcgcaaccggaggacaagctcacaaaagaaaaattttaccccaatatagagcgagccgagttgattacaaagggttatgtggcctcacaatccagccatagccgtggaagcgcaattgatcttacgctctaccacctggatacaggggaacttgtttcaatgggaagtaacttcgattttatggacgaacggtcgcatcatacagcaaaagggataggggatgcagaggcacaaaatcgaagatgcttgcgtaaaatcatggaaagcagcggatttcagtcttatcgctttgaatggtggcactataagttgattgatgagccataccccgatacctattttaattttcccgtttcataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7559,Drugs,MEG_7559|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,501574714|WP_012579102.1|NG_048486|1|1|vanX-B|vanX-B|D-Ala-D-Ala_dipeptidase_VanX-B NG_048486:101-709,5
,atggaaaagcactttatcaatgaaaagttttcacgggatcaatttacggggaatagagttaaaaatattgccttttcaaattgtgatttttcaggggttgatttaactgatactgaatttgttgattgtagcttttacgacaggaatagcctggtagggtgtgattttaatagagccaaactaaaaaacgccagctttaaaagctgcgatttatcaatgagtaattttaaaaacattagcgccttaggtcttgagattagtgagtgtttagctcaaggagttgattttcgaggggctaattttatgaatatgataactacaaggtcatggttttgtagtgcttatataaccaagacaaatcttagttacgctaatttttctagagtcatattagaaaagtgcgaactgtgggaaaatcgctggaatggcactgtgataactggcgccgtgtttcgtggttccgatctttcttgtggggagttttcatcgtttgattggtctttggctgattttactggttgtgatttaacgggtggggtgcttggcgagcttgatgcaagacgaactaatttagatggcgtgaagttggatggagagcaggcgcttcagcttgttgagagtttaggtgttattgttcaccgataa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_6012,Drugs,MEG_6012|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRD,1391852860|WP_109545045.1|NG_057448|1|1|qnrD3|qnrD|quinolone_resistance_pentapeptide_repeat_protein_QnrD3 NG_057448:1-645,3
,atgaaaaacatcggcattaccgtttatggatgtaatcaggatgaggcagatgcattccgtgctctttcgccacaatttggcattatgccctcgattattaacgccgacgtgtcggaagctaacgccatatccgcccctttaaatcaatgtatcagtgtgggacacaaatccgagatttccgcgtctattcttgttgcgctgaagagaggcggtgtgaaatatatctctacccgaagcatcggctgcaatcatatagatacaattgccgctaagagaatcggcatcactgtcggcaatgtggcgtattcgccggatagcgttgctgattttaccatgatgctgatgcttatggcagtacgcaacacgaaatctatcgtacggtctgtggaaaaacatgatttcaggctggacagcgttcgggggaaggtactgagcgagatgacagttggcgtggtgggaacaggtcagataggcaaagcggttattgagcggctgcgaggatttggatgtaaagtgttggcttatagtcacagcaaaagtatagaggtatactatgttccgtttgatgagttgttgcaaaatagcgatatcgttacccttcatgtgccgctccatacggatacgcactatatcatcggtcacgaacaaatacagagaatgaagaaaggagcgtttattatcaatactagtcgcggtccacttgtagatacctatgcgttggttaaagcattagaaaacggaaaactgggcggtgccgcattggatgtattggagggagaagaagagtttttctactctgattgtacccaaagacccattgataatcaatttttacttaaacttcaaaaaatgcctaacgtgataatcacaccgcatacggcttattataccgagcaagcgttgcgtgataccgttgaaaaaaccattacaaactgtttggattttgaaaggagactggagcatgaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7398,Drugs,MEG_7398|Drugs|Glycopeptides|VanA-type_resistance_protein|VANHA,1028100562|WP_063856697.1|NG_048371|1|1|vanH-A|vanH-A|D-lactate_dehydrogenase_VanH-A NG_048371:101-1069,5
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccaccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5688,Drugs,MEG_5688|Drugs|betalactams|Class_C_betalactamases|PDC,564975097|WP_023874922.1|NG_049890|1|1|blaPDC-19b|blaPDC|class_C_beta-lactamase_PDC-19b NG_049890:1-1194,0
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTTTTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGGTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGACCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6944,Drugs,MEG_6944|Drugs|betalactams|Class_A_betalactamases|TEM,gi|695213005|ref|NG_036534.1|1-1075,0
,TTATTTCCTCCCGTTAAATAATAGATAACTATTAAAAATAGACAATACTTGCTCATAAGTAATGGTACTTAAATTGTTTACTTTGGCGTGTTTCATTGCTTGATGAAACTGATTTTTAGTAAACAGTTGACGATATTCTCGATTGACCCATTTTGAAACAAAGTACGTATATAGCTTCCAATATTTATCTGGAACATCTGTGGTATGGCGGGTAAGTTTTATTAAGACACTGTTTACTTTTGGTTTAGGATGAAAGTATTCTCTAGGGATTTTACTTAATATGGATATATCAACTTCTGTCATTAAAAATAGTGCTAGTGAACGATTTGTATTTAGCAACCTTTTAGCAAATCCATATTCCACTATTAAATAACTTTCTGTAGCTGTGCTTTCAAAAACAATTTTTCGAATTATATCTGTACTTATATTGTAGGGTATACTTCCAAATATCTTATATGACTTATTTTTAGGAAACTTAAATTGTAAAATATCTTTATTGATAACCTGGAAGTTCTCATATTCAATAAGTTTGTTTTTAGTTATCCTACATAATTTAGGATCTATTTCAATGGCGGTTACATAATTACACCTTTTAGCTAATTCAAACGTGAAATGACCTTTCCCTGAACCAATCTCAATAATATTATCATTTGTATTTAAATGTACATTTCTCAAAATTTCATTTATATGATGCTTTGAAGTAATAAAGTTTTGACTATCTTTTATATTTTTGTTCAT,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2847,Drugs,MEG_2847|Drugs|MLS|23S_rRNA_methyltransferases|ERMT,gi|28273038|emb|AJ488494.2|10767-11504,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctgaccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccgggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcccacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5629,Drugs,MEG_5629|Drugs|betalactams|Class_C_betalactamases|PDC,1693892948|WP_140423325.1|NG_065445|1|1|blaPDC-333|blaPDC|class_C_beta-lactamase_PDC-333 NG_065445:1-1194,0
,atgatcgtcatctgcgaccacgacaacctcgacgcctggctggcgctgcgcacggcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaatgcgcccgccgccagggctgggcggcgcgtttgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaacctggactcccaacgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgtaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_163,Drugs,MEG_163|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,983383199|WP_060560340.1|NG_054690|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_054690:101-541,2
,atgcctaccaaagcgatcgctgtcaccttacgcgccatgaccgaggatgatcttccgatgctgtacgactggctcaaccgaccccacatcgttgaatggtggggaggcgaggggcagcgtcccaccctctcagacgtggtggagcactaccggccacgagtcttggcagaagagcgcgtcacgccgtacatcgccatgcttggcaatgaaccaatcggctatgcgcagtcgtacattgctctcgggagtggcgaaggttggtggcaggacgaaactgaccctggagttcgcggcatcgatcaatcgcttgccaatcccctccagttgaacaaaggtctcggaacggagcttgtgcgatcactcgtcgaactgttgttcttggatcccgaggtaaccaagattcagactgatccggctcctactaaccatcgtgcaatcaggtgctacgaaaaagcagggtttgtggtgcagaacacaatcactacccccgatggtccggccgtctatatggttcaaactcgtcacgacttcgagcgagcgcgctgtgctgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_182,Drugs,MEG_182|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,654299991|WP_027814019.1|NG_052056|1|1|aacA38|aacA38|aminoglycoside_6'-N-acetyltransferase_AacA38 NG_052056:101-655,2
,CCTATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATTGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6934,Drugs,MEG_6934|Drugs|betalactams|Class_A_betalactamases|TEM,gi|68137405|gb|DQ075245.1|1-1078 gi|961666360|gb|KT185451.1|87741-87690,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaaacacacactacgggtgttttagttatccatcaaggtcaaactcaacaaagctacggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4438,Drugs,MEG_4438|Drugs|betalactams|Class_D_betalactamases|OXA,1559612979|WP_128268244.1|NG_063849|1|1|blaOXA-745|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-745 NG_063849:34-858,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGAGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGTTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCGGCTCGCGTAGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1886,Drugs,MEG_1886|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HM046998|+|1039-2185|ARO:3002058|CMY-47 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTTGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1860,Drugs,MEG_1860|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AY513266|+|164-1310|ARO:3002028|CMY-17 [Escherichia coli] ,0
,ATGCCCAAGGTGCTCTCTGATGAAGACGTCGGTGAATTCCGTCAACGGCTCCTGAAAACCGCGGAAGCCGCGTTCGCCACGCACGGCGTCGACGGGGTTTCGATGCGCCAGCTCGCGCAGCAACTGGGGTGCAGCGCGACAACCCCTTATCGCTATTTCAAGAACAAGGACGAGATCCTCGCGGCGGTCACGGCCGCGGCCTTGAACCGGTTCTCCGCAACGCTCGAAAAGGCGTTCGCCGCCAAGGGCAGCAGCGCCGAGAAGGCGGTCGCGGTGCGCAAGGCCTACATCCGCTTCGCCTTCAAGAACCCCAAGGCCTATAGGCTGATGTTCGATGCGCCGCATCCGAGCCTGCTGGACTACGCCGATCTTTCAGAAGCCTCCAGCCGCGCGGACCGGATCATGGCCGCGCCCCTGGCTCTTCTGGCGCAAGAGGGCATCGTCAAGGGCGACTCCCGGCTCCTGGGGCGCGTGTTCTGGAGCGCGATCCACGGCGCGGTTTCGCTGCAACTGGCCGGCAAGCTCGCGGCGAAACCCACATTCGAAGCCGTTCTCGAACAGACATTGCAGCTGATCATGGCCGGCGCCATGGCGACCCGTCATTCCGCTTGA,tetR,antibiotic target alteration,Tetracyclines,MEG_7189,Drugs,MEG_7189|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|169647622|gb|EU408346.1|4730-4119,4
,AAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAGCTTTTATAAGTAATCTCTTTTCGAACAGAGCTAGGTATTCCTTTTTTCATTTCTAAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTTTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGCTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAACACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCGCCTAGGGTCATGTTCTTTTCCCATTCTGGGAATAGCCTTTTTTGCCCGTCCCACTTAAATACTTCTGTGGTGGTTGCCTTATGGTGCTCAAGGCCGATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGGCCTTGTTGGATAACTAAAACACCCGTAGTGTGTACTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCGCTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGTGTTTTAATGTTCATAAGACTTATAAGATTGAATTTGAAGTTTAGCTAATTAATGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5235,Drugs,MEG_5235|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389159|gb|KF986262.1|1-895,0
,ATGGACAGAAAAAGATTGACACAGCGTTTCCCGTTCCTGCTTCCAATGAGACGGGCGCAGAGAAAAATGTGCTTTTATGCGGGAATGAGATTTGACGGCTGTCGCTATGCGCAGACGATAGGGGAAAAATCGCTTTCCCATTTGCTCTTTGAAACGGATTGCGCATTATACAACCACAATACCGGATTTGACATGATATACCAGGAAAACAAGGTGTTCAACTTAAAGCTGGCAGCAAAGACCTTAAACGGCTTATTGATAAGACCGGGGGAAACCTTTTCTTTCTGGTGGCTGGTACGCCATGCGGACAAAGATACCCCCTATAAAGACGGCCTTACGGTGACCAATGGTAAACTCACCACCATGTCGGGCGGCGGTATGTGCCAGATGAGCAATTTACTATTTTGGATGTTCCTGCATACGCCATTGACAATTATCCAGCGCAGAGGTCACGAAGTAAAGGAGTTTCCAGAGCCAAACAGTGACGAGATTAAAGGGGTGGATGCAACCATTTCAGAGGGCTGGATTGATTTAAAAGTGCGAAACGATACCGACTGCACCTACCAAATATGGGTGACCTTAGATGATGAGAAAATCATCGGTCAGGTGTCCGCCGACAAAGAGCCCCAAGCATTATACAAAATTACAAATGGCAGTATCCAGTATGTCCGTGAAAGTGGCGGGATTTATGAATATGCCCAGGTTAAACGGATGCAAGTTGCCTTAGGTACCGGGGAAATAATAGATTGCAAGCTGCTTTATACAAACAAATGCAAAATCTGTTATCCCCTCCCGGAAAGTGTGGATATTCAGGAGGAGAACCAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7540,Drugs,MEG_7540|Drugs|Glycopeptides|VanB-type_accessory_protein|VANWB,(Gly)VanW-B:AY655721:3069-3896:828,5
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCTTCGTTCTCCACGTTTGCCGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCGCTGATGCAGGAGCAGGCAATTCCGGGCATGGCCGTTGCGATTATCTATCAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCGTCCAGTCACTCAACAAACGCTGTTTGAACTCGGATCGGTCAGTAAAACGTTCAACGGTGTGCTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGTTCAGCGATCCGGTCACGCATTACTGGCCTGAACTGACTGGTAAGCAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTTCAGGTTCCGGACGACGTTACGGATAAAGCCGCGTTACTACGCTTTTATCAAAACTGGCAGCCGCAATGGGCCCCAGGCGCTAAACGTCTTTATGCTAACTCCAGCATTGGTCTGTTTGGTGCCCTGGCGGTCAAACCCTCAGGCATGAGCTACGAAGAGGCGATGACCAAACGCGTCCTGCGCCCCTTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAGCGAACAAAAAGATTATGCCTGGGGTTATCGCGAAGGAAAGCCAGTGCATGTATCCCCTGGCCAACTTGATGCCGAAGCCTACGGGGTGAAATCGAGCGTTATCGATATGACCCGTTGGGTTCAGGCCAACATGGACGCCAGCCAGGTTCAGGAGAAAACGCTCCAGCAGGGCATCGAGCTTGCGCAGTCACGTTACTGGCGTGTTGGCGATATGTACCAGGGCCTGGGCTGGGAGATGCTGAACTGGCCGGTGAAAGCCGACTCGATAATTAGCGGTAGCGACAGCAAAGTGGCACTGGCAGCGCTTCCTGCCGTTGAGGTAAACCCGCCCGCGCCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGCGGATTCGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAGAGCTACCCAAACCCTGTTCGCGTCGAGGCCGCCTGGCGCATTCTTGAAAAACTGCAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1929,Drugs,MEG_1929|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KF992025|+|1026-2172|ARO:3002106|CMY-93 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCACAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGAGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTACCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGTTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1847,Drugs,MEG_1847|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB429270|+|14-1160|ARO:3002052|CMY-41 [Citrobacter freundii] ,0
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcaccggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcagaaagggtgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagtgccttgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaatactaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctgtgggaaaaccgctggatggggactcaggtactgggtgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacagctaccaggcatcgttgctcatggagcggcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5883,Drugs,MEG_5883|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111939|WP_063866143.1|NG_050513|1|1|qnrB5|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB5 NG_050513:37-681,3
,atgcaacgccggcattttttacaaaaaaccttattggcactacctattattttttctggcaatttattaactggatgtaaaacgaatttatctgatgattatttgcccgatgataagataacaaacaatccaaatttattacaaaataaattaaaagagatattgccaatttgggaaaataaatttaatgccaaaattggtatgacgattattgctgacaatggtgaactatccagtcatcgtggtaatgaatattttcctgttaatagtaccattaaagcctttattgcaagtcatatattattacttgtagataaagaaaaattggatttaaacgaaaaaatcatcattaaagaaagcgatttgatagaatattctcctgtctgtaaaaaatactttgatgagaataaaccaatttctattagtgaattgtgcgaagctaccataacactgagtgataatggttctgctaatatcttgttggataaaattgggggtttgactgcattcaatcaatttttgaaagagattggggcggatatggtgctggcaaataatgagcctttattaaatcgctcacattatggtgaaaccagtgataccgcaaaaccaattccttacacaaaaagcctaaaagcactgattgtaggcaatatcctatccaatcaaagcaaagaacagttgataacttggcttatcaatgataaagttgctgataatttattgagaaaatatttaccaaaaaattggcgaattggcgacaaaacaggcacaggtagtgaatcaaaaaatatcattgctgtgatttggaatgaaaataataaaccttattttatcagcctatttatcacccagccccatgatggtaaatcccttgattttaaaaatcaaaaagatgaaataatggcacaaattggtaaagaaatttatccatttttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1473,Drugs,MEG_1473|Drugs|betalactams|Class_A_betalactamases|BRO,489753004|WP_003657002.1|NG_048711|1|1|blaBRO-1|blaBRO|class_A_beta-lactamase_BRO-1 NG_048711:101-1042,0
,atgataatcagtgaatttgaccgtaataatccagtattgaaagatcagctttctgatttactgagactgacttggccgaaagaatatggagacagctcggcagaagaagtagaagaaatgatgaatccagaacggatcgcggtagcagcggttgaccaagatgagttagtaggatttattggtgcaatccctcaatacggtataacaggttgggaattgcatccattagttgtagaaagctcccgacgaaagaaccaaataggtactcgattagtcaattacttagaaaaagaagtagcttccagaggaggaataacgatttatttaggtacggatgatttagaccatggaacaacgttaagtcaaacggacctgtatgagcatacgtttgataaagtggcctccatccagaaccttcgtgaacatccatatgagttctatgaaaaattaggttataaaatcgtaggtgtcttaccaaatgcaagtggttgggacaaaccggatatttggatggcaaaaacgattattcctcgaccagattctcaataa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_140,Drugs,MEG_140|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,639458212|WP_024635824.1|NG_052447|1|1|aacA-ENT1|aacA-ENT1|aminoglycoside_6'-N-acetyltransferase NG_052447:101-649,2
,atggctctggcactcgttggcgaaaaaattgacagaaaccgtttcaccggtgagaaaattgataatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgctgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggcgcaagttttatgaatatgatcactactcgcacctggttttgtagtgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgctggaaaagtgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatctctccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggggacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgttgctcatggaacgtcttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5893,Drugs,MEG_5893|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111993|WP_063866193.1|NG_050521|1|1|qnrB58|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB58 NG_050521:37-681,3
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgccgctattccaacccgagcatcgacctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcaacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatgacgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcatcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5512,Drugs,MEG_5512|Drugs|betalactams|Class_C_betalactamases|PDC,1393270458|WP_109791203.1|NG_057601|1|1|blaPDC-270|blaPDC|class_C_beta-lactamase_PDC-270 NG_057601:1-1194,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAATGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1425,Drugs,MEG_1425|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_108_FQPO01000005,0
,atgacttttaatattatcaaattagaaaattgggatagaaaagaatattttgaacactattttaaccagcaaactacgtatagcattactaaagaaattgatattactttgtttaaagatatgataaaaaagaaaggatatgaaatttatccttctttgatttatgcaattatggaagttgtaaataaaaataaagtgtttagaacaggaattaatagtgagaataaattaggctattgggataagttaaatcctttgtatacagtttttaataagcaaactgaaaaatttactaacatttggactgaatctgataacaacttcacttctttttataataattataaaaatgacttgtttgaatataaagataaagaagaaatgtttcctaaaaaaccgatacctgaaaacaccataccgatttcaatgattccttggattgattttagttcatttaatttaaacattggtaacaatagcagctttttattgcctattattacgataggtaaattttatagtgagaataataaaatttatataccagttgccttacagcttcatcatgctgtatgtgatggttaccatgcttcattatttataaatgaatttcaagatataattaataaggtagatgattggatttag,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1570,Drugs,MEG_1570|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,695261501|WP_032488460.1|NG_047565|1|1|catA7|catA7|type_A-7_chloramphenicol_O-acetyltransferase NG_047565:101-748,6
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAGCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCAGCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6430,Drugs,MEG_6430|Drugs|betalactams|Class_A_betalactamases|SHV,gi|2113850|emb|X98101.1|74-1018,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcccctttctccacgtttgccgcagccaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcaccaataaccacccagtcacgcagcaaactctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatcagcctgctgcacttagccacctacacggcaggcggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgtttttatcaaaactggcagccgcaatgggccccgggcgctaagcgtctttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacagttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaaggctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagtgttattgatatggcccgctgggttcaggtcaacatggacgccaaccgcgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcaatcatcaacggtagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcctgcccccgctgtgaaagcctcatgggtgcataaaacgggatccactggaggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1790,Drugs,MEG_1790|Drugs|betalactams|Class_C_betalactamases|CMY,1028104391|WP_063859777.1|NG_048798|1|1|blaCMY-129|blaCMY|class_C_beta-lactamase_CMY-129 NG_048798:1-1146,0
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTTACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAATTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAAAAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATGGGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTATCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATTAAAATACTTTTAACAAAGCCAGATATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGCTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGACAAGTGTTAAGTGTTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGATGGTGCGTCAGCATTGTCCGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTATTAATCTTAGATGAGCCGACAAACCACATGGATATTATTGGCAAAGAGAACTTAGAGAATATCTTATGCAGTTATAAAGGCACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTGCTTGTTTTTGATAAGGATGGTGTAGAGTTTGTAGAATCCACTTATGGTGAGTACGAGAAAAAAAGGTTGAATTCCGAAAAGCCATTTAATTACATTAATGTTGAGAAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCTATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTCAACCAAACAATTCTTCTGATTATATAGTACTGACGGAATTACAAAAATCAATTGATGAAGTTAAAAGGTGTCAGGGTATTTATTTTAATGAATGGGAACAGTTGATGGGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4322,Drugs,MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_9_KT892063 ,1
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAGAGTTTATTGTATACCAGTGGTGCAATTGCAGAACCAGGGAGCGTAGATAAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAAGTATACCGTTCTTTATCCGTATTAGACGGAGCAGTATTATTAGTTTCTGCAAAGGATGGCATACAGGCACAGACCCGTATACTGTTTCATGCACTACAGACAATGAAGATTCCGACAATTTTTTTCATCAATAAAATTGACCAAGAGGGGATTGATTTGCCAATGGTATATCAAGAAATGAAAGCAAAGCTTTCTTCGGAAATTATAGTGAAGCAAAAGGTTGGGCAGCATCCCCATATAAATGTAACGGACAATGACGATATGGAACAGTGGGATGCGGTAATTATGGGAAACGATGAACTATTAGAGAAATATATGTCAGGGAAACCGTTTAAAATGTCAGAACTGGAACAGGAAGAAAACAGGAGATTCCAAAACGGAACGTTATTTCCCGTTTATCACGGAAGTGCTAAAAACAATCTGGGGATTCGGCAGCTTATAGAAGTGATTGCCAGTAAGTTTTATTCATCAACGCCTGAAGGTCAATCTGAACTATGCGGGCAGGTTTTTAAGATTGAATATTCAGAGAAAAGGCGGCGTTTTGTTTATGTGCGTATATATAGCGGAACATTGCATTTGAGGGATGTTATTAAAATATCTGAAAAAGAGAAAATAAAAATCACAGAGATGTGTGTTCCGACAAACGGTGAATTATATTCATCCGATACAGCCTGCTCTGGTGATATTGTAATTTTACCAAATGATGTTTTGCAGCTAAACAGTATTTTGGGGAACGAAATGCTGTTGCCGCAGAGAAAATTTATTGAAAATCCTCTCCCTATGCTCCAAACAACGATTGCAGTAAAGAAATCTGAACAGCGGGAAATATTGCTTGGGGCACTTACAGAAATTTCAGATGGCGACCCTCTTTTAAAATATTATGTGGATACTACAACGCATGAGATTATACTTTCTTTTTTGGGGAATGTGCAGATGGAAGTCATTTGTGCCATCCTTGAGGAAAAATACCATGTGGAGGCAGAAATAAAAGAGCCTACTGTTATATATATGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAACCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCCCCAAGGTATTGTGCAGATATTGTAAGTACTCAGGTAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCCAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7162,Drugs,MEG_7162|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,gi|920768663|gb|CP011419.1|1142579-1140660 gi|821177616|gb|CP002007.2|1201193-1203112 gi|295092884|emb|FP929039.1|815149-817068 gi|1532066|emb|Y07780.1|125-2044,4
,atgaccaccacacgccccgcgtgggcctatacgctgccggcagcactgctgctgatggctcctttcgacatcctcgcttcactggcgatggatatttatctccctgtcgttccagcgatgcccggcatcctgaacacgacgcccgctatgatccaactcacgttgagcctctatatggtgatgctcggcgtgggccaggtgatttttggtccgctctcagacagaatcgggcgacggccaattctacttgcgggcgcaacggctttcgtcattgcgtctctgggagcagcttggtcttcaactgcaccggcctttgtcgctttccgtctacttcaagcagtgggcgcgtcggccatgctggtggcgacgttcgcgacggttcgcgacgtttatgccaaccgtcctgagggtgtcgtcatctacggccttttcagttcgatactggcgttcgtgcctgcgctcggccctatcgccggagcattgatcggcgagttcttgggatggcaggcgatattcattactttggctatactggcgatgctcgcactcctaaatgcgggtttcaggtggcacgaaacccgccctctggatcaagtcaagacgcgccgatctgtcttgccgatcttcgcgagtccggctttttgggtttacactgtcggctttagcgccggtatgggcaccttcttcgtcttcttctcgacggctccccgtgtgctcataggccaagcggaatattccgagatcggattcagctttgccttcgccactgtcgcgcttgtaatgatcgtgacaacccgtttcgcgaagtcctttgtcgccagatggggcatcgcaggatgcgtggcgcgtgggatggcgttgcttgtttgcggagcggtcctgttggggatcggcgaactttacggctcgccgtcattcctcaccttcatcctaccgatgtgggttgtcgcggtcggtattgtcttcacggtgtccgttaccgcgaacggcgctttggcagagttcgacgacatcgcgggatcagcggtcgcgttctacttctgcgttcaaagcctgatagtcagcattgtcgggacattggcggtggcacttttaaacggtgacacagcgtggcccgtgatctgttacgccacggcgatggcggtactggtttcgttggggctggtgctccttcggctccgtggggctgccaccgagaagtcgccagtcgtctaa,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_2917,Drugs,MEG_2917|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|FLOR,544574424|WP_021038045.1|NG_047866|1|1|floR|floR|chloramphenicol/florfenicol_efflux_MFS_transporter_FloR NG_047866:101-1315,6
,atgaacattatcaatatcgggattcttgcccatgtagatgcgggcaagacgacactgacagaaagcctgctgtatgccagcggaaccatttcagagccggggagcgtcgaaaaagggacaacgagaacggacactatgtttttggagcggcagcgtggaattaccattcaaacggcagtcacttctttccagtggcacagttgtaaagtcaatattgtggatactcccggccacatggatttcttggcagaggtataccgctctctggctgttttggacggggccatcttggtgctctccgctaaagatggcgtgcaggcccagacccgtgttctgttccatgccctacggaaattgaacatccccaccattatctttatcaacaagatcgaccaggttggcattgatttggagagcgtatatcagtctgttcgggataagctctccgctgatattatcatcaagcagacagtgtcgctgtcctcgaaaataactctgacagaaaacactagtgcagaggtttgggattcggtcatcgaaaataacgatgagttattggcaaagtatatcgcaggagaatcaatcagtcagaaagaacttgcgcaagaagaacagcggcgagttcaagacgcctccctgctcccggtctatcatggtagcgccaaaaacggccttggcattcaacagttgatggatgcggtgatagggctgttccaatcgaccaaggaacaggggagcgccgccctgtgcggtagagtttttaaggtggagtatacagattgcggccagaggcttgtctatctgcggctatacagcggaacgctgcgtctgcgggatacggtggccctagccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggagattgttcggacagataccgcccataagggcgaaattgtcatccttcccagcgacagcttgagattaaacgatatattgggggacaaaacccaacttcctcgtgaaatgtggagtgatgttcccttccctatgctgcggacgacgattacgccaaaaacggcagagcaaagagaccggttgctggacgctcttacgcaaattgcggatactgacccgcttttgcactacgaggtggattccaccacccatgagatcattctttcttttttgggtcggatgcagttggaggttgtttccgctttgctgacggaaaaatacaagattgaaacagcagtgaaggaacccaccgtcatttatttagagcggccgctcaaagtggccagtcacaccatccatatcgaggtgccgcctaacccgttttgggcatctatcggactgtctgttacaccgctcccgcttggctccggtgtaaaatacgagagccgggtttccctgggatacctgaaccagagttttcaaaacgctgtcatggatggtatccgttacggtttggggcaaggcttgtgtggctggaacgtaacggactgtaagatttgctttgaatacggactttactatagcccggtcagtacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaagaaatctgggacgcagttgctggaaccttatctctccttcaccctctatgcgccccaggaatacctttccagggcttatcatgatgcgccgaaatactgtgccaccatcgaaacggcccagataaaaaaggatgaagttgtctttactggcgagattcccgcccgttgcatacaggcataccgtactgatttggccttttacaccaacgggcggagtgtgtgcctgacggaactgaaagggtatcaggccactgtcggcgagccaatcatccagccccgtcgtccaaacagccgtttggataaggtgcgccatatgttcagtaagattccttga,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7226,Drugs,MEG_7226|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,499845527|WP_011526261.1|NG_055990|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_055990:101-2020,4
,ATGAAAATAATTAACTTAGGCATTCTGGCTCACGTTGACGCAGGAAAGACAACATTAACGGAAAGTTTATTGTATACCAGTGGTGCAATTGCAGAACTAGGGAGCGTAGATGAAGGCACAACAAGGACAGATACAATGAATTTGGAGCGTCAAAGGGGAATCACTATCCAGACAGCAGTGACATCTTTTCAGTGGGAGGATGTAAAAGTCAACATTATAGATACGCCAGGCCATATGGATTTTTTGGCGGAAGTATACCGTTCTTTATCCGTATTAGACGGAGCAGTATTATTAGTTTCTGCAAAGGATGGCATACAGGCACAGACCCGTATACTGTTTCATGCACTACAGATAATGAAGATTCCGACAATTTTTTTCATCAATAAAATTGACCAAGAGGGGATTGATTTGCCAATGGTATATCGGGAAATGAAAGCAAAGCTTTCTTCGGAAATTATAGTGAAGCAAAAGGTTGGGCAGCATCCCCATATAAATGTAACGGACAATGACGATATGGAACAGTGGGATGCGGTAATTATGGGAAACGATGAACTATTAGAGAAATATATGTCAGGGAAACCGTTTAAAATGTCAGAACTGGAACAGGAAGAAAACAGGAGATTCCAAAACGGAACGTTATTTCCCGTTTATCACGGAAGCGCTAAAAACAATCTGGGGATTCGGCAGCTTATAGAAGTAATTGCCAGTAAATTTTATTCATCAACGCCTGAAGGTCAATCTGAACTATGCGGGCAGGTTTTTAAGATTGAATATTCAGAGAAAAGGCGGCGTTTTGTTTATGTGCGTATATATAGCGGAACATTGCATTTGAGGGATGTTATTAGAATATCTGAAAAAGAGAAAATAAAAATCACAGAGATGTGTGTTCCGACAAATGGTGAAATCGTCCCGGCTGACCATGCCTGTCCGGGAGAAATTGTTATTTTAGCTGATGATACTTTGAAACTGAACGACATTCTGGGAAATGAAAAACTCCTGCCTCACAAAACACGGATTGATAATCCCATGCCATTACTTCGGACAACGGTAGAGCCGCAAAAGCCGGAGCAAAGGGAAGCCCTGTTAAATGCCCTCGCAGAGATTGCTGATACAGACCCTCTTTTAAAATATTATGTGGATACTACAACGCATGAGATTATACTTTCTTTTTTGGGGAATGTGCAGATGGAAGTCATTTGTGCCATCCTTGAGGAAAAATATCATGTGGAGGCAGAAATAAAAGAGCCTACTGTTATATATATGGAAAGACCGCTTAGAAAAGCAGAATATACCATCCACATAGAAGTCCCGCCAAATCCTTTCTGGGCTTCTGTCGGGTTGTCCATAGAGCCGCTCCCTATTGGAAGCGGAGTGCAGTATGAAAGCAGAGTTTCACTTGGATATTTAAATCAATCGTTCCAAAATGCGGTTATGGAGGGGGTTCTTTATGGCTGCGAGCAGGGGCTGTATGGATGGAAAGTGACAGACTGTAAAATCTGTTTTGAATATGGATTGTATTATAGTCCTGTAAGTACCCCCGCAGACTTTCGGCTGCTTTCCCCTATCGTATTGGAGCAGGCTTTAAAAAAAGCAGGGACAGAACTATTAGAGCCATATCTCCACTTTGAAATTTATGCACCGCAGGAATATCTCTCACGGGCGTATCATGATGCTCCAAGGTATTGTGCAGATATTGTAAGTACTCAGATAAAGAATGACGAGGTCATTCTGAAAGGAGAAATCCCTGCTAGATGTATTCAAGAATACAGGAACGATTTAACTTATTTCACAAATGGGCAGGGAGTCTGCTTGACAGAGTTAAAAGGATACCAGCCAGCTATTGGTAAATTTATTTGCCAACCCCGCCGCCCGAATAGCCGTATAGATAAGGTTCGGCATATGTTCCACAAGTTAGCTTAA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7165,Drugs,MEG_7165|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETO,tet(O/32/O)_5_FP929050 ,4
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccaggtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_566,Drugs,MEG_566|Drugs|betalactams|Class_C_betalactamases|ADC,765465338|WP_044718369.1|NG_064702|1|1|blaADC-147|blaADC|class_C_beta-lactamase_ADC-147 NG_064702:85-1236,0
,atgagcaactctatacacaccggaatctcaaggcagcttcaggcacgcgatgtaattaaacgccatttggcatcaacgctgaaagccatacacttgtatggttctgcaattgatggtggcctcaaaccatatagcgacattgatctgctggttaccgtggatgcacgcttggatgaagctaccagacgctccctgatgctcgatttcttgaatatctcggcaccaccatgcgaaagctcaatactccggccgctagaggtaactgttgttgcatgcaacgaagtagtgccttggcgttatccggcacgacgagaactgcagttcggggagtggctgcgggaggatattcttgaaggtgtcttcgagccagccgccttggacgccgaccttgcaattctaataacgaaagctaggcaacacagcatcgctttagtaggtccagtggctcaaaaagtcttcatgccggtgccagagcatgactttctccaggtgctttccgatacccttaagctgtggaatactcatgaggattgggaaaatgaggagcggaacatcgtactcacgttagctcggatctggtatagcactgaaactggaggaatcgtccccaaggatgtggccgccgaatgggttttagagcgcttgccagctgagcataagccaatactggttgaggcgcggcaagcctatcttgggctttgcaaggatagtcttgctttgcgtgcagatgagacttcggcgttcattggctatgcaaagtctgcggtcgctgatttgctcgaaaagcgaaaatctcaaacttcgcatatttgcgatggcgccaagaacgtctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_766,Drugs,MEG_766|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1028081076|WP_063840459.1|NG_047370|1|1|aadA9|aadA9|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA9 NG_047370:101-934,2
,ATGATGACTAAATCCCTTTGCTGCGCCCTGCTGCTCAGCACCTCCTGCTCGGTATTGGCTACCCCGATGTCAGAAAAACAGCTGGCTGAGGTGGTGGAACGGACCGTTACGCCGCTGATGAAAGCGCAGGCCATTCCGGGTATGGCGGTGGCGGTGATTTATGAGGGTCAGCCGCACTACTTCACCTTCGGTAAAGCCGATGTTGCGGCGAACAAACCTGTCACTCCACAAACCTTGTTCGAACTGGGTTCTATAAGTAAAACCTTCACCGGCGTACTCGGTGGCGATGCCATTGCTCGCGGTGAAATATCGCTGGGCGATCCGGTGACAAAATACTGGCCTGAGCTGACAGGCAAGCAGTGGCAGGGGATCCGCATGCTGGATCTGGCAACCTATACCGCAGGAGGTTTGCCGTTACAGGTACCGGATGAGGTCAAGGATAACGCCTCTCTGTTGCGCTTTTATCAAAACTGGCAGCCGCAGTGGAAGCCGGGCACCACGCGTCTTTACGCCAATGCCAGCATCGGTCTTTTTGGCGCGCTGGCGGTCAAACCTTCCGGCATGAGCTATGAGCAGGCCATAACGACGCGGGTCTTTAAGCCGCTCAAGCTGGACCATACGTGGATTAACGTTCCGAAAGCGGAAGAGGCGCATTACGCCTGGGGATACCGCGACGGTAAAGCAGTACACGTTTCGCCAGGAATGCTGGACGCTGAAGCCTATGGCGTAAAAACCAACGTGCAGGATATGGCAAGCTGGGTGATGGTCAACATGAAGCCGGACTCCCTTCAGGATAATTCACTCAGGAAAGGCCTTACCCTGGCGCAGTCTCGCTACTGGCGCGTGGGGGCCATGTATCAGGGGTTAGGCTGGGAAATGCTTAACTGGCCGGTCGATGCCAAAACCGTGGTTGAAGGTAGCGACAATAAGGTTGCACTGGCACCGCTGCCTGCGAGAGAAGTGAATCCACCAGCGCCCCCGGTCAACGCATCCTGGGTCCATAAAACAGGCTCTACCGGCGGGTTTGGCAGCTACGTGGCATTTATTCCTGAAAAGCAGCTCGGTATTGTGATGCTGGCAAATAAAAGCTATCCGAACCCGGCACGCGTTGAGGCGGCATACCGTATTTTGAGCGCGCTGTAGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_483,Drugs,MEG_483|Drugs|betalactams|Class_C_betalactamases|ACT,gi|323541267|gb|HQ235646.1|659-1804 gi|323541257|gb|HQ235645.1|1087-2232 gi|4827074|gb|U58495.2|KPU58495|31-1176,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6240,Drugs,MEG_6240|Drugs|betalactams|Class_A_betalactamases|SHV,(Bla)SHV-1:AF148850:6-866:861,0
,GGCTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAAAAGCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6464,Drugs,MEG_6464|Drugs|betalactams|Class_A_betalactamases|SHV,gi|5002311|gb|AF148850.1|AF148850|1-871 gi|562889800|gb|KF585134.1|46-908 gi|695220752|ref|NG_039547.1|75-937 gi|133905277|gb|CP000603.1|142442-141580 gi|4337047|gb|AF124984.1|AF124984|197-1059 gi|94502885|gb|DQ478720.1|1-861,0
,atgcgttatattcgcctgtgtattatctccctgttacccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaacaaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6188,Drugs,MEG_6188|Drugs|betalactams|Class_A_betalactamases|SHV,1509794559|WP_122630868.1|NG_062285|1|1|blaSHV-213|blaSHV|class_A_beta-lactamase_SHV-213 NG_062285:1-861,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactgacgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcattgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1814,Drugs,MEG_1814|Drugs|betalactams|Class_C_betalactamases|CMY,1028104452|WP_063859815.1|NG_048807|1|1|blaCMY-139|blaCMY|class_C_beta-lactamase_CMY-139 NG_048807:1-1146,0
,atgaaaaatttacagttgggactcatcgtcctcattacaaccttcggttccgcatgtacaacaataagcccctccgtagaaacagctaaaaaccaacagcaacaaagtgctcagcagcagatccaacaggccttcgatcaactccaaaccacgggggtgattgtcattaaggataagcatggcttacacagctacggcaatgacttgagccgtgctcagacaccctatgtacccgcctctacctttaaaatgctgaatgccttaatcggactagaacatggtaaagcaaccagcaccgaggtatttaaatgggatggtcaaaagcgcagcttccctgcttgggaaaaagacatgactttagggcaagccatgcaagcatctgccgttcccgtttatcaggagctagcacggcgcattggcctagacctgatgaaaaaagaagtgcaacgcattggatatggcaatcaacagattggcaccgttgtcgataatttttggttagtcggtccactgcaaattacgcctgttcaagaagtcctttttgtagagaagctggccaatacacaactcgcttttaagccagatgtgcaacataccgtacaagacatgctgctgattgaacaaaaaccgaattataaactctacgccaaatctggttggggcatggacctagaaccgcaagtgggctggtggacaggctgggtcgaaacagcaacaagtgaaaaagtgtattttgctttgaatatgcatatgaaaacgggaatttcagccagcgtacgtgagcaactggtcaaacaaagtctgacagcactggggataatttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4671,Drugs,MEG_4671|Drugs|betalactams|Class_D_betalactamases|OXA,1693892936|WP_140423313.1|NG_065430|1|1|blaOXA-644|blaOXA-211_like|OXA-211_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-644 NG_065430:1-825,0
,ATGAGAAATTTTGCTACACTGTTTTTCATGTTCATTTGCTTGGGCTTGAATGCTCAGGTAGTAAAAGAACCTGAAAATATGCCCAAAGAATGGAACCAGACTTATGAACCCTTCAGAATTGCAGGTAATTTATATTACGTAGGAACCTATGATTTGGCTTCTTACCTTATTGTGACAGACAAAGGCAATATTCTCATTAATACAGGAACGGCAGAATCGCTTCCAATAATAAAAGCAAATATCCAAAAGCTCGGGTTTAATTATAAAGACATTAAGATCTTGCTGCTTACTCAGGCTCACTACGACCATACAGGTGCATTACAAGATCTTAAAACAGAAACCGGTGCAAAATTCTATGCCGATAAAGCAGATGCTGATGTCCTGAGAACAGGGGGGAAGTCCGATTATGAAATGGGAAAATATGGGGTGACATTTAAACCTGTTACTCCGGATAAAACATTGAAAGATCAGGATAAAATAACACTGGGAAATACAATCCTGACTTTGCTTCATCATCCGGGACATACAAAAGGTTCCTGTAGTTTTATTTTTGAAACAAAAGACGAGAAGAGAAAATATAGAGTTTTGATAGCTAATATGCCCTCCGTTATTGTTGATAAGAAATTTTCTGAAGTTACCGCATATCCAAATATTCAGTCCGATTACGCATATACTTTCAAAGCAATGAAGAATCTAGATTTTGACCTTTGGGTGGCATCACATGCAAGTCAGTTCGATCTGCATGAAAAACGTAAAGAAGGAGATCCGTACAATCCGCAATTGTTTATGGATAAGCAAAGCTATTTCCAAAACCTTAATGATTTGGAAAAAAGCTATCTCGACAAAATAAAAAAAGATTCCCAAGATAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3165,Drugs,MEG_3165|Drugs|betalactams|Class_B_betalactamases|GOB,gi|126571830|gb|EF394442.1|1-873,0
,atgcgtcaatatcgattcgcccttctcccattgttagccgccctggcgctccccggttgggcgcatcaagctacggtgacgacggttaaacaagccgaaagccagcttcagggccgggtcggctacgccgaactggatttagcttccgggcaactgctggccggctatcgttctgacgaacggttcccgatgatgagcacttttaaagttctgctctgcggcgcagtcttgtcgcgtgtcgatgccggtgaagaacagctcgatcgccgtatccattaccggcagcaggatctggtggaatattcgccggtgacggaaaagcatcttaccgatgggctcaccgtgggcgaactgtgcgctgccgccattaccctgagcgataatacggcggcaaacctgctgttgaccactctcggcggcccgcaggggctgaccagcttcctgcgccacagcggcgaccagacttcgcggcttgaccgttgggaaacggaactcaatgaagcgcggccgggcgacgtgcgagataccacgactccgcaagcgatggccaggacactgcgaaatctgttgaccggccgcgtgctttccagcgcctcgcagcagcagttgcaacgctggatggtagaggacaaagttgcggggccgctgttgcgatcggtgctgccggcgggctggtttattgccgataagaccggagccggcaatcgcggctcgcgcgggatcatcgctgctctcggtccggacggtaaagctgcgcgcatcgtggtgatttatttgaccgggacccccgccacaatggatgaacgcaataaacagattgcggccatcggcgcaacgctgatcaggcactggtccgcagacgagaacagaccctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_5790,Drugs,MEG_5790|Drugs|betalactams|Class_A_betalactamases|PLA,695776964|WP_032699754.1|NG_049969|1|1|blaPLA-1|blaPLA|class_A_broad-spectrum_beta-lactamase_PLA-1 NG_049969:101-976,0
,atgaaaatcatgcctgtaagcgagccgttcttggccgactggctgcaattaagaatattactctggcctgatcatgaagacgcgcatttactggaaatgcggcagttactcgaacaaccacataccctgcaattattaagctataacgatcagcagcaagcagttgcgatgctggaagcgtcgattcgatatgaatatgtgaatggcacgcaaagctcaccggtggcttttctggaaggtatttatgtgttgccagaatatcgacgtttaggtgttgctagcacgttggtacagcaggtagaacactgggccaagcagtttgcatgtaccgaatttgcttcagatgctgcgctggataatacgatcagtcatgccatgcatcgcgcgctgggctttcaggaaaccgagtgtgtggtttattttaagaaaaacatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_113,Drugs,MEG_113|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,696304861|WP_032880374.1|NG_052531|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052531:101-541,2
,ATGAGCGAATCCCTCGATCTGAGCCTGGAAGGGGTCGAACGCCGGTCGTTGGCCGAGTTCACCGAGCAGGCCTATCTGAACTATTCCATGTACGTGATCATGGACCGCGCCCTGCCGCATATCGGCGACGGCCTGAAACCGGTGCAGCGACGCATCGTCTACGCCATGAGCGAACTGGGGCTGGATGCCGATTCCAAGCACAAGAAGTCGGCGCGCACCGTCGGCGACGTGCTCGGCAAGTTCCACCCGCACGGCGACTCGGCCTGCTACGAGGCCATGGTGCTGATGGCGCAGCCGTTCTCCTATCGCTATCCGCTGGTGGACGGCCAGGGCAACTGGGGGGCTCCGGACGATCCCAAGTCCTTCGCCGCCATGCGTTATACCGAGGCGCGCCTGTCGCGCTATTCCGAGGTGCTGCTCAGCGAACTGGGCCAGGGTACCGTGGACTGGGTACCGAACTTCGACGGCACCCTCGACGAGCCGGCCGTGCTGCCGGCCCGCCTGCCCAACCTGCTGCTCAACGGCACCACCGGCATCGCGGTGGGCATGGCCACCGACGTGCCGCCGCACAACCTGCGGGAAGTCGCGTCGGCCTGCGTGCGCCTGCTCGACCAGCCGGGCGCGACGGTCGCCGAATTGTGCGAACACGTGCCGGGCCCGGACTTCCCCACCGAAGCCGAGATCATCACCCCGCGCGCCGACCTGCAGAAGGTCTACGAGACCGGCCGCGGTTCGGTGCGCATGCGCGCGGTGTACCGCGTCGAGGACGGCGATATCGTCATCCACGCCCTGCCGCACCAGGTGTCCGGTTCCAAGGTGCTGGAACAGATCGCCGGGCAGATGCAGGCCAAGAAGCTGCCGATGGTGGCCGACCTGCGCGACGAGTCGGACCACGAGAACCCGACCCGCATCGTCATCATCCCGCGTTCGAACCGGGTCGATGTCGAAGAGCTGATGACCCATCTGTTCGCCACCACCGACCTGGAGACCAGCTACCGGGTCAACCTGAACATCATCGGCCTCGACGGCAAGCCGCAGGTCAAGGACCTGCGCCAGTTGCTCTCGGAGTGGCTGCAGTTCCGCATCGGCACCGTGCGTCGACGCCTGCAGTTCCGCCTGGACAAGGTCGAGCGCCGCCTGCATCTGCTGGATGGCTTGCTGATCGCCTTCCTCAACCTCGACGAGGTGATCCACATCATCCGCACCGAGGACCAGCCCAAGGCGGTGCTGATGGAGCGCTTCGAACTCAGCGAGGTGCAGGCCGACTACATCCTCGACACCCGCCTGCGCCAGTTGGCACGCCTGGAAGAGATGAAGATCCGCGGCGAGCAGGAAGAGTTGCTGAAGGAGCAGAAGCGCCTGCAGACCCTGCTCGGCAGCGAGGCCAAGCTGAAGAAGCTGGTGCGCGAGGAGCTGATCAAGGACGCCGAGACCTACGGCGACGACCGCCGTTCGCCGATCGTCGCCCGCGCCGAGGCCCGCGCGCTGTCGGAAACCGAGCTGATGCCCACCGAACCGGTGACCGTGGTGCTCTCGGAAAAAGGCTGGGTGCGTTGCGCCAAGGGCCACGACATCGACGCCGCCGGCCTCTCCTACAAGGCCGGCGACGGCTTCAAGGCCGCCGCGCCGGGACGCTCGAACCAGTATGCGGTGTTCATCGACTCCACCGGGCGCAGCTACTCGCTGCCGGCCCACAGCCTGCCGTCCGCGCGAGGCCAGGGCGAGCCACTCAGCGGCCGGCTGACGCCGCCGCCGGGGGCCAGCTTCGAATGCGTGCTGCTGCCGGACGACGATGCGCTGTTCGTGATCGCTTCCGACGCCGGCTATGGTTTCGTGGTCAAGGGCGAGGACCTGCAGGCCAAGAACAAGGCCGGCAAGGCCCTGCTCAGCCTGCCCAACGGCTCCGCCGTGGTGGCGCCGCGCCCGGTGCGCGATGTGGAGCAGGATTGGCTGGCGGCCGTGACGACCGAGGGCCGTCTGCTATTGTTCAAGGTCTCCGACCTGCCGCAGCTCGGCAAGGGCAAGGGCAACAAGATCATCGGCATCCCCGGCGAACGCGTGGCCAGCCGCGAGGAATACCTCACCGACCTGGCTGTTCTGCCAGCCGGGGCGACGTTGGTCCTGCAGGCCGGAAAGCGTACCCTGTCGCTCAAGGGCGACGACCTGGAACACTACAAGGGGGAGCGAGGCCGGCGAGGCAACAAGCTGCCGCGCGGTTTCCAGCGCGTCGACAGCCTGCTGGTGGATATTCCGCCACAGGATTGA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5357,Drugs,MEG_5357|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|926451317|emb|LN871187.1|5586548-5584284 gi|553895034|gb|CP006832.1|5574481-5572217 gi|553886202|gb|CP006831.1|5575566-5573302 gi|543879514|gb|CP006705.1|5354067-5351803 gi|110227054|gb|AE004091.2|5574486-5572222,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagaaaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcaacaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4710,Drugs,MEG_4710|Drugs|betalactams|Class_D_betalactamases|OXA,949688834|WP_057053864.1|NG_049632|1|1|blaOXA-340|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-340 NG_049632:1-825,0
,ATGCGCATTCTGCCTGTTATTGCCGCAGTAACAGCCGCGTTTTTAGTGGTTGCTTGCAGTTCCCCTACTCCTCCGCCTAGCGTCACGGTAGTCAGTAATTTCGACGCTCAGCGCTTCCTCGGCACCTGGTATGAAATCGCCCGAATGGACCATCAGTTCGAACGGGGCTTAGAGAAGGTCACGGCCAGCTACAGCGCGAGGGATGACGGCGGGATCCAGGTCATTAACCGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_497,Drugs,MEG_497|Drugs|betalactams|Class_C_betalactamases|ACT,gi|752115662|gb|KM926622.1|1493-1724,0
,atggaattgcccaatattatgcacccggtcgcgaagctgagcaccgcattagccgctgcattgatgctgagcgggtgcatgcccggtgaaatccgcccgacgattggccagcaaatggaaactggcgaccaacggtttggcgatctggttttccgccagctcgcaccgaatgtctggcagcacacttcctatctcgacatgccgggtttcggggcagtcgcttccaacggtttgatcgtcagggatggcggccgcgtgctgttggtcgataccgcctggaccgatgaccagaccgcccagatcctcaactggatcaagcaggagatcaacctgccggtcgcgctggcggtggtgactcacgcgcatcaggacaagatgggcggtatggacgcgctgcatgcggcggggattgcgacttatgccaatgcgttgtcgaaccagcttgccccgcaagaggggctggttgcggcgcaacacagcctgactttcgccgccaatggctgggtcgaaccagcaaccgcgcccaactttggcccgctcaaggtattttaccccggccccggccacaccagtgacaatatcaccgttgggatcgacggcaccgacatcgcttttggtggctgcctgatcaaggacagcaaggccaagtcgctcggcaatctcggtgatgccgacactgagcactacgccgcgtcagcgcgcgcgtttggtgcggcgttccccaaggccagcatgatcgtgatgagccattccgcccccgatagccgcgccgcaatcactcatacggcccgcatggccgacaagctgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4142,Drugs,MEG_4142|Drugs|betalactams|Class_B_betalactamases|NDM,1391852864|WP_109545049.1|NG_057455|1|1|blaNDM-20|blaNDM|subclass_B1_metallo-beta-lactamase_NDM-20 NG_057455:1-813,0
,atggtgacaaagagagtgcaacggatgatgttcgcggcggcggcgtgcattccgctgctgctgggcagcgcggcgctttatgcgcagacgagtgcggtgcagcaaaagctggcggcgctggagaaaagcagcggagggcggctgggcgtcgcgctcatcgataccgcagataatacgcaggtgctttatcgcggtgatgaacgctttccaatgtgcagtaccagtaaagttatggcggccgcggcggtgcttaagcagagtgaaacgcaaaagcagctgcttaatcagcctgtcgagatcaagcctgccgatctggttaactacaatccgattgccgaaaaacacgtcaacggcacaatgacgctggcagaactgagcgcggccgcgttgcagtacagcgacaataccgccatgaacaaattgattgcccagctcggtggcccgggaggcgtgacggcttttgcccgcgcgatcggcgatgagacgtttcgtctggatcgcactgaacctacgctgaataccgccattcccggcgacccgagagacaccaccacgccgcgggcgatggcgcagacgttgcgtcagcttacgctgggtcatgcgctgggcgaaacccagcgggcgcagttggtgacgtggctcaaaggcaatacgaccggcgcagccagcattcgggccggcttaccgacgtcgtggactgtgggtgataagaccggcagcggcgactacggcaccaccaatgatattgcggtgatctggccgcagggtcgtgcgccgctggttctggtgacctattttacccagccgcaacagaacgcagagagccgccgcgatgtgctggcttcagcggcgagaatcatcgccgaagggctgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2188,Drugs,MEG_2188|Drugs|betalactams|Class_A_betalactamases|CTX,1188444899|WP_085562401.1|NG_054687|1|1|blaCTX-M-198|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-198 NG_054687:1-876,0
,ATGAGGGATGATTTCGTCTTCGTCGACGAGGTCGTCTCCGGAATCCGCTGGGACGCCAAGTACGCCACGTGGGACAACTTCACCGGCAAGCCGGTGGACGGCTACCTGGTGAACCGCGTCGTCGGCACACGTGCGTTCTGCGCGGCGCTGGAAAAGGCGCGGGACAAGGCCGCGGAACTCGGCTTCGGGCTGCTTCTTTGGGACGTGTACCGCCCGCAGCGCGCGGTGGACCGCTTCATGCGCTGGGCGGAAGAGCCCGAAGACGGCCGGAAGAAGGCCAGGCACTACCCGAACATCGAGCGGCCCCAGATGTTCGAACAGGGCTACGTGGCCACCAAGTCCGGGCACAGCCGGGGCAGCACGGTGGACCTGACGCTCTACCGCCTGGACACCGGTGAGCTCGCCGACATGGGCGGTGACCACGACCTGATGGACGTCGTCTCGCACCACGGTGCCGACGGGGTGCCGGAAGAGGCCGCGAAGAACCGCGCGCACCTGTGCGCGATCATGGAAGGTTCCGGCTTCAGCTCCTACGAGTGCGAGTGGTGGCACTACAACCTGAAGGACGAGCCTTACCCGGACACCTATTTCGATTTTCCCATCGAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7552,Drugs,MEG_7552|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Ao2:HQ679900:2070-2678:609,5
,ATGCGCGATACCAGATTCCCCTGCCTGTGCGGCATCGCCGCTTCCACACTGCTGTTCGCCACCACCCCGGCCATTGCCGGCGAGGCCCCGGCGGATCGCCTGAAGGCACTGGTCGACGCCGCCGTACAACCGGTGATGAAGGCCAATGACATTCCGGGCCTGGCCGTAGCCATCAGCCTGAAAGGAGAACCGCATTACTTCAGCTATGGGCTGGCCTCGAAAGAGGACGGCCGCCGGGTGACGCCGGAGACCCTGTTCGAGATCGGCTCGGTGAGCAAGACCTTCACCGCCACCCTCGCCGGCTATGCCCTGGCCCAGGACAAGATGCGCCTCGACGACCGCGCCAGCCAGCACTGGCCGGCGCTGCAGGGCAGCCGCTTCGACGGCATCAGCCTGCTCGACCTCGCGACCTATACCGCCGGCGGCTTGCCGCTGCAGTTCCCCGACTCGGTGCAGAAGGACCAGGCACAGATCCGCGACTACTACCGCCAGTGGCAGCCGACCTACGCGCCGGGCAGCCAGCGCCTCTATTCCAACCCGAGCATCGGCCTGTTCGGCTATCTCGCCGCGCGCAGCCTGGGCCAGCCGTTCGAACGGCTCATGGAGCAGCAATTGTTCCCGGCACTGGGCCTCGAACAGACCCACCTCGACGTGCCCGAGGCGGCGCTGGCGCAGTACGCCCAGGGCTACGGCAAGGACGACCGCCCGCTACGGGTCGGTCCCGGCCCGCTGGATGCCGAAGGCTACGGGGTGAAGACCAGCGCGGCCGACCTGCTGCGCTTCGTCGATGCCAACCTGCATCCGGAGCGCCTGGACAGGCCCTGGGCGCAGGCGCTCGATGCCACCCATCGCGGTTACTACAAGGTCGGCGACATGACCCAGGGCCTGGGCTGGGAAGCCTACGACTGGCCGATCTCCCTGAAGCGCCTGCAGGCCGGCAACTCGACGCCGATGGCGCTGCAACCGCACAGGATCGCCAGGCTGCCCGCGCCACAGGCGCTGGAGGGCCAGCGCCTGCTGAACAAGACCGGTTCCACCAACGGCTTCGGCGCCTACGTGGCGTTCGTCCCGGGCCGCGACCTGGGACTGGTGATCCTGGCCAACCGCAACTATCCCAATGCCGAGCGGGTGAAGATCGCCTACGCCATCCTCAGCGGCCTGGAGCAGCAGGGCAAGGTGCCGCTGAAGCGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5745,Drugs,MEG_5745|Drugs|betalactams|Class_C_betalactamases|PDC,gi|20135559|gb|AY083592.1|45-1238,0
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccacggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagcgagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2155,Drugs,MEG_2155|Drugs|betalactams|Class_A_betalactamases|CTX,1058243948|WP_068981632.1|NG_051467|1|1|blaCTX-M-188|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-188 NG_051467:1-876,0
,atgaatattaaaccagcatcagaagcttcatttaaagattggttaaaactaagaataaagctttggaatgatcttgaagaatcacatttgcaagagatgcatcagttattggctgaaaagcatgcattacaattattagcctattcggatgatcacgcggttgcgatgctagaagcatctattcgctatgaatatgtaaacgggacagagacttctcccgtggcatttctagaaggcatttatgtacttccagaatatcgtcgcttaggtgtagcaactttacttgttcgtcaggttgaggcgtgggcaaaacaattttcttgtactgagtttgcatctgatgcggcattggacaatgtcattagtcatgcaatgcatcgtgcattgggttttcaagaaacggaaagcgttgtttattttagtaaaaaaatagattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_114,Drugs,MEG_114|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491339916|WP_005197871.1|NG_052400|1|1|aacA-ACI4|aacA-ACI4|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052400:101-538,2
,atgttcaaatttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagccagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7716,Drugs,MEG_7716|Drugs|betalactams|Class_B_betalactamases|VIM,1028110984|WP_063865196.1|NG_050374|1|1|blaVIM-46|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-46 NG_050374:1-801,0
,atgaaaatcatgcctgtaaccgagccgttattggccgactggctgcaattaagaatattactctgccctgatcatgaagacgcgcatttactggaaatgcggcagctactcgaacaaccacatactttgcaattattaagctataacgatcagcagcaagcaattgccatgctggaagcgtcgattcgatatgaatatgtaaatggcacacaaacctcacctgtggcttttctggaaggcatttatgtcttgcctgaatatcgacgttcaggtgttgcttccactttggtacagcaagtagaagactgggcaaagcaattttcctgtaccgaatttgcttcagatgcagcaattgataatacgatcagtcatgccatgcatcgcgcgctgggttttcaggaaaccgaacgtgtggtttattttaagaaaaagatcagttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_107,Drugs,MEG_107|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,490908402|WP_004770322.1|NG_052395|1|1|aacA-ACI5|aacA-ACI5|AAC(6')-Ighjkrstuvwx_family_aminoglycoside_N-acetyltransferase NG_052395:101-541,2
,atggaatacaaaatagtagatattgcacttgatagtaagctggtgaaagttgcagcagagattttgttttatactttttctgaaattaataatgaatcttggccaacaattaactctgccactgaggaagtgaaagaatgtatagaagataagaatatttgtattggagttttggtagaagacaagctggtaggttggattggattacgtccaatgtatgaaaatacttgggaattacatccaatggtggttttatcaaaatggcaaggcaaaggattagggaaaatattaatatttgaattagaaaaaagagcaaaagaacaaggaataaacggaattgttttaggaactgacgatgagacatttcgaacatctttatctatgaaagaattggataaaaatgatctatttgaagaaataaaaaacattaaaaatattaatcatcatccgtatgagttttatcagaaatgtggatataaaattattggagtaatcccagatgctaatggtaagaataaaccggatatttggatgtggaagaaaataatgtag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_194,Drugs,MEG_194|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,798836135|WP_045890872.1|NG_051492|1|1|aacA56|aac(6')_Ia_fam|AAC(6')-Ia_family_aminoglycoside_6'-N-acetyltransferase_AacA56 NG_051492:101-652,2
,TTGGCAATGAATAAACAAAATAATTATTCAGATGATTCAATACAGGTTTTAGAGGGGTTAGAAGCAGTTCGTAAAAGACCTGGTATGTATATTGGATCAACTGATAAACGGGGATTACATCATCTAGTATATGAAATTGTCGATAACTCCGTCGATGAAGTATTGAATGGTTACGGTAACGAAATAGATGTAACAATTAATAAAGATGGTAGTATTTCTATAGAAGATAATGGACGTGGTATGCCAACAGGTATACATAAATCAGGTAAACCGACAGTCGAAGTTATCTTTACTGTTTTACATGCAGGAGGTAAATTTGGACAAGGCGGCTATAAAACTTCAGGTGGTCTTCACGGCGTTGGTGCTTCAGTTGTAAATGCATTGAGTGAATGGCTTGAAGTTGAAATCCATCGAGATGGTAATATATATCATCAAAGTTTTAAAAACGGTGGTTCGCCATCTTCTGGTTTAGTGAAAAAAGGTAAAACTAAGAAAACAGGTACCAAAGTAACATTTAAACCTGATGACACAATTTTTAAAGCATCTACATCATTTAATTTTGATGTTTTAAGTGAACGACTACAAGAGTCTGCGTTCTTATTGAAAAATTTAAAAATAACGCTTAATGATTTACGCAGTGGTAAAGAGCGTCAAGAGCATTACCATTATGAAGAAGGAATCAAAGAATTTGTTAGTTATGTCAATGAAGGAAAAGAAGTTTTGCATGACGTGGCTACATTTTCAGGTGAAGCAAATGGTATAGAGGTAGACGTAGCTTTCCAATATAATGATCAATATTCAGAAAGTATTTTAAGTTTTGTAAATAATGTACGTACTAAAGATGGTGGTACACATGAAGTTGGTTTTAAAACAGCAATGACACGTGTATTTAATGATTATGCACGTCGTATTAATGAACTTAAAACAAAAGATAAAAACTTAGACGGTAATGATATTCGTGAAGGTTTAACAGCTGTTGTGTCTGTACGTATTCCAGAAGAATTACTACAATTTGAAGGACAAACGAAATCTAAATTGGGTACTTCTGAAGCAAGAAGTGCTGTTGATTCAGTAGTTGCAGACAAATTACCATTCTATTTAGAAGAAAAAGGACAATTGTCTAAATCACTTGTAAAAAAAGCAATTAAAGCACAACAAGCAAGGGAAGCTGCACGTAAAGCTCGTGAAGATGCTCGTTCAGGTAAGAAAAACAAGCGTAAAGACACTTTGCTATCTGGTAAATTAACACCTGCACAAAGTAAAAATACAGATAAAAATGAATTGTATTTAGTCGAAGGTGATTCTGCGGGAGGTTCAGCAAAACTTGGACGAGACCGCAAATTCCAAGCGATATTACCATTACGTGGTAAGGTAATTAATACAGAGAAAGCACGTCTGGAAGATATTTTTAAAAATGAAGAAATTAATACAATTATCCACACAATCGGGGCAGGCGTTGGTACTGACTTTAAAATTGAAGATAGTAACTATAATCGTGTAATTATTATGACTGATGCTGATACTGATGGTGCGCATATTCAAGTGCTATTGTTAACATTCTTCTTCAAATATATGAAACCGCTTGTTCAAGCAGGTCGTGTATTTATTGCTTTACCTCCACTTTATAAATTGGAAAAAGGTAAAGGCAAAACAAAGCGAGTTGAATACGCTTGGACAGACGAAGAGCTTAATAAATTACAAAAAGAACTTGGTAAGGGCTTCACGTTACAACGTTACAAAGGTTTGGGTGAGATGAACCCTGAACAATTATGGGAAACGACGATGAACCCAGAAACACGAACTTTAATTCGTGTACAAGTTGAAGATGAAGTGCGTTCATCTAAACGTGTAACAACATTAATGGGTGACAAAGTACAACCTAGACGTGAATGGATTGAAAAGCATTTTGAGTTTGGTATGCAAGAGGACCAAAGTATTTTAGATAATTCTGAAGTACAAGTGCTTGAAAATGATCAATTTGATGAGGAGGAAATCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5395,Drugs,MEG_5395|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PAREF,gb|BX571856.1|+|1417762-1419760|ARO:3003315|Staphylococcus aureus parE conferring resistance to fluoroquinolones [Staphylococcus aureus subsp. aureus MRSA252] ,3
,atgactaaaaaagctcttttctttgccattagtaccatatttttgtcagcatgttctttcaatacagtacaacagcaccaaatacacgctatttctacacataaaaattcagaagaaataaaatcactgtttgatcaagcacagaccacaggtgttttggttattaagcgcggaaatacagaggaaatttatgggaatgatctaaaaagggcatcaaccgaatatgtccctgcatctacctttaaaatgctaaatgctttaattggtcttgaacatcataaagcaacaacaactgaagtgttcaaatgggatggacaaaagcgtttattttttgattgggaaaaggatatgactctgggtgatgccatgaaagcttctgctattcccgtgtatcaagaactagctcgacgaattggccttgatcttatgtccaaagaggtcaagcgtattggtttcggtaatgctgatattggttcaaaagtagataatttttggcttgtcggtccactcaaaattacgcctcaacaggaagcacagtttgcttatgaattagcacataaaactcttccttttagcaaaaatgtacaagaacaagttcaatctatggtgttcgtagaagaaaaaaacggacgtaaaatttacgctaaaagcggttggggatgggatgtggaacctcaagtgggctggttaacaggctgggtcgttcaaccacaaggagaaattgtagcgttctcactcaatttagaaatgaaaaaaggaacacctagttctattcgaaaagaaattgcttataaaggattagagcagctaggtattttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4550,Drugs,MEG_4550|Drugs|betalactams|Class_D_betalactamases|OXA,1509794551|WP_122630860.1|NG_062273|1|1|blaOXA-678|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-678 NG_062273:1-822,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaggcacgcaacaggcctgcgccgagcgctacacgccagcttcgaccttcaagctggccattgccctgatgggcgccgacgccgacatcctgcaaggcccgcacgagccggtctggaactaccagcctgcctatcccgactggggcggcgacgtctggcgccagcccaccgacccggcgcgctggatccagtattcggtggtctggtattcacagctgatcgccaaggcgctgggacaggaccgcttccagcgctacaccagcgcattcggctacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaggctggtgaaccggcaattgccagtcaaggccgccgcctatgagctggccgacaacttgttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcagcgatggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccatggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4539,Drugs,MEG_4539|Drugs|betalactams|Class_D_betalactamases|OXA,1134169699|WP_076412384.1|NG_064737|1|1|blaOXA-114p|blaOXA-114_like|class_D_beta-lactamase_OXA-114p NG_064737:1-828,0
,ATGTACACCAAGAATGCCGCAATAGTTCTGCGCCTCATGACTGAGAGCGATCTGCCAATGCTCCATGCGTGGCTGAACCGGCCCCACATAGTCGAGTGGTGGGGAGGAGAAGATAAACGCCCCACACTTGGCGAAGTTTTAGAACATTATTCGCCCCGAGTTCTCGCAGAGCAAGCAGTAGTACCCTACATCGCAATGCTAGATGATGAACCCATTGGCTACGCGCAGTCCTACACCGCCCTTGGAAGTGGCGATGGATGGTGGGAAGACGAAACTGATCCAGGGGTCCGTGGCATTGACCAGTCATTGGCCAATCCGTCGCAGCTAAACAAGGGCCTTGGAACAACGCTCGTACGCTCACTGGTTGAACTCCTGTTCAGTGATCCGGCCGTGTCGAAGATCCAAACTGATCCTTCTCCTAACAACCATCGCGCTATCCGCTGTTACGAAAAAGCCGGGTTCGCACAAGACAAAATCATCCTGACGCCTGACGGCCCTGCGGTGTATATGGTTCAAACACGCCAAGCGTTCGAAAGCCAGCGCAATGCTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_355,Drugs,MEG_355|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|765098769|dbj|LC031883.1|6608-7162 gi|599206606|gb|KJ138219.1|999-1553,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcaccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5460,Drugs,MEG_5460|Drugs|betalactams|Class_C_betalactamases|PDC,1034011026|WP_064483993.1|NG_050784|1|1|blaPDC-128|blaPDC|class_C_beta-lactamase_PDC-128 NG_050784:1-1194,0
,atgaccgttcgacgcctttcgtgcgcccttggcgcagccctttccctgtccgcgctgggcggcggccccgtccaggccgccgtcctgtgcaccgtggtggccgacgccgccgacggccgcatcctgttccagcaaagcacgcagcaggcctgcgccgagcgctacacgccggcctcgaccttcaagctggccatcgccctgatgggcgccgacgccggcatcctgcaaggcccgcacgagccggtctggaactaccagcccgcctatcccgactggggcggcgacgcctggcgccagcccaccgatccggcgcgctggatcaagtattcggtggtctggtattcacagctgacggccaaggcgctgggacaggaccgcttccagcgctacaccagcgcgttcggatacggcaatgcggacgtctcgggcgagcccggcaagcacaacggcaccgacggcgcgtggatcatctcgtcgctgcgcatttcgccgctggaacaactggctttcctgcgcaagctggtgaaccggcaattgccggtcaaggccgccgcctatgagctggccgaaaacctcttcgaggtgggccaggccgatggctggcgcctgtatggcaagaccggcaccggttcgcccggcagcaacggcgtctacacggcggccaatgcctacggctggttcgtcggctgggcgcgcaaggatggccgccagctggtgtacgcccgcctgctgcaggatgagcgcgccacccggcccaacgccggcctgcgcgcccgcgacgagctggtgcgcgactggccggccaaggccggcgcgtggcgcccgtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4537,Drugs,MEG_4537|Drugs|betalactams|Class_D_betalactamases|OXA,1625655398|WP_136512075.1|NG_064738|1|1|blaOXA-114q|blaOXA-114_like|class_D_beta-lactamase_OXA-114q NG_064738:1-828,0
,ATGAAATCTAACAATGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGCATCGCCAGTCACTATGGCGTGCTGCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTACTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCTATACCTTGTCTGCCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7067,Drugs,MEG_7067|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,gi|961454907|gb|KT991389.1|1319-129 gi|961454907|gb|KT991389.1|3654-3683 gi|627769342|gb|KF195927.1|6879-5689 gi|669174522|dbj|AB775653.1|58-1248 gi|507466429|dbj|AB777650.1|496-1686 gi|507466429|dbj|AB777650.1|2190-2283 gi|507466429|dbj|AB777650.1|2337-2280 gi|507466420|dbj|AB777647.1|2256-1066 gi|507466420|dbj|AB777647.1|562-469 gi|507466420|dbj|AB777647.1|415-472 gi|496543269|gb|KC820641.1|3902-5092 gi|496543253|gb|KC820640.1|3901-5091 gi|448967488|gb|KC562906.1|5363-6553 gi|358444205|gb|JN381160.1|86-1276 gi|325965637|gb|JF420888.1|8876-7686 gi|325965637|gb|JF420888.1|6585-6555,4
,TCGGCCCTCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCGCCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGTGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGAAGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAACGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATCGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6420,Drugs,MEG_6420|Drugs|betalactams|Class_A_betalactamases|SHV,gi|160948442|emb|AM176551.2|1-891 gi|124263629|gb|EF210158.1|5-895,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgagcggggtgcgcgcggcattgtcgtcctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6224,Drugs,MEG_6224|Drugs|betalactams|Class_A_betalactamases|SHV,1028110266|WP_063864636.1|NG_050025|1|1|blaSHV-150|blaSHV|class_A_beta-lactamase_SHV-150 NG_050025:1-861,0
,atggaaaaatacaacaattggaaacttaagttttatacaatatgggcagggcaagcagtatcattaatcactagtgccatcttgcaaatggcgattattttttaccttacagaaaaaactggatccgcgatggtcttgtctatggcttcactattaggttttttaccctatgcggtctttggacctgcaattggtgtgttagtggatcgtcatgataggaagaagataatgattggtgctgatttaattatcgcagcagctggttcggtgcttactattgttgcattctatatggagctacctgtctggatggttatgatagtattgtttatccgtagcattggaacagcttttcacaccccggctctcaatgcggttacgccacttttagtaccagaagaacagcttacgaaatgtgcaggctatagtcagtctttgcagtctataagctatattgttagtccggcggttgcagcactcttatactccgtttgggaactaaatgctattattgccatcgatgtattgggtgctgtgattgcatctattacggtagcaattgtacgtattcctaagctgggtgatcgcgtgcaaagtttggacccaaatttcataagagaaatgaaagaaggaatggctgtactacggcaaaataaaggattatttgctttattactcgttggaacattatatatgtttgtttatatgcccattaatgcactattccctttaattagcatggattactttaatggaacacctgtgcatatttctattacggaaatttcctttgcatctggaatgttgatagggggtctattattagggttatttgggaattaccaaaagcgaatcttattaataacggcatccatttttatgatggggataagcttaaccatttcaggattacttccccaaagtggatttttcatttttgtagtctgctgtgcaataatggggctttctgttccgttttacagcggtgtgcaaacagctctttttcaggagaaaattaagcctgaatatttaggacgtgtattttctttaactggaagtatcatgtctcttgctatgccaattggattaattctttctgcactctttgctgatagaatcggtgtaaatcattggtttttactatcaggtattttaattatttgcattgcaatagtttgcccaatgataaatgagattagaaaattagatttaaaataa,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3814,Drugs,MEG_3814|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,517185988|WP_018374806.1|NG_047961|1|1|mef(A)|mef(A)|macrolide_efflux_MFS_transporter_Mef(A) NG_047961:1-1218,7
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgattcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4445,Drugs,MEG_4445|Drugs|betalactams|Class_D_betalactamases|OXA,1188444908|WP_085562410.1|NG_054700|1|1|blaOXA-556|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-556 NG_054700:1-825,0
,atgaatagttcgacaaagatcgcattggtaattacgttattcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggttattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaaaccgacaagatccaagaatga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7046,Drugs,MEG_7046|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,502644960|WP_012881330.1|NG_048171|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048171:101-1309,4
,TCCAGTGGAATGGATGGATAGATTATCAGTTTTAAAATAGCAATGGCCCAGATCATAATGGTAAAAAGTGAACTGGGCTATAAACTAACTCTATAAAATACCTAATTGTTCTAAACTTCTATAAGTAATCTCTTTTCGAACAGAGCTAGATATTCCTTTTTTCATTTCTGAGTTAAGGGAGAACGCTACAATATTCCCTTGAGGCTGAACAACCCATCCAGTTAACCAGCCTACTTGTGGGTTTACATCCCATCCCCAACCACTTTTTGCGTATATTTTATTTCCATTCTTTTCTTCTATGAATAGCATGGATTGCACTTCATCTTGGACTTTTTGGCTAAATGGAAGCGTTTTATTAGCTAGCTTGTAAGCAAATTGTGCCTCTTGTTGAGGAGTAATTTTTAAAGGACCCACCAGCCAAAAATTATCGACTTGGGTACCGATATCTGCATTGCCATAACCAATACGCTTCACTTCATTAGACATGAGTTCAAGTCCAATACGACGAGCTAAATCTTGATAAACCGGAATAGCGGAAGCTTTCATAGCATCGCCTAGGGTCATGTTCTTTTCCCATTCTGGGAATAGCCTTTTTTGCCCGTCCCACTTAAATACTTCTGTAGTGGTTGCCTTATGGTGCTCAAGGCCTATCAAAGCATTAAGCATTTTGAAGGTCGAAGCAGGTACATACTCGGTCGAAGCACGAGCAAGATCATTACCATAGCTTTGTTGAGTTTGGCCTTGTTGGATAACTAAAACACCCGTAGTGTGTGCTTCGTTAAATAAATTTTTAATTTTCTCTGCTTTTTCATCAGATTTTGAAGCACTGTGATTTGGATTAGCAGTCACTATATAAGGTGAGCAGGCTGAAATAAAAATAGCGCTTGTTATAAGTAAGAGGGCTTGAATGTTCATAAGACTTATAAGATTGAATTTGAAGTTTAGCTAAATTAATGTAACT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5236,Drugs,MEG_5236|Drugs|betalactams|Class_D_betalactamases|OXA,gi|591389161|gb|KF986263.1|1-961,0
,atgaatccctatctacagttagttagcaaagaatttccgttagaaaaaaaccaagaaccccctcatttagtccttgctgccttcagcgaagacgatgtttacttgcagccagaagcagccaaacaatggaaacggctcgtcaaagccttaaagcttgaaaacgagatctgcttgttagatggctaccgaaccgaaaagcagcaacggtatttatgggaatattccttgaaagaaaatgggctagcctatacgaaacaatttgtggcattgcccggttgcagtgaacatcagttaggcttagcgatcgatgttggtttaaagggcagccaggatgatttgatctgcccacgatttcgtgacagcgcagccgctgatttatttacccaggaaatgatgaactatgggtttattttacgctatcccgcagacaaacaggagattacagggattggctatgaaccatggcattttcgttatgtcggtctgcctcatagtcaaatcatcgccagtcaacagtggaccttggaagaataccatcaataccttgaacaaactgcgaggcagttcgcatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7576,Drugs,MEG_7576|Drugs|Glycopeptides|VanC-type_resistance_protein|VANXYC,1028100670|WP_063856805.1|NG_048509|1|1|vanXY-C|vanXY-C|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C NG_048509:101-673,5
,GTGAATACGTCTTATTCACAGTCAACTTTACGGCACAATCAAGTTTTGATTTGGCTTTGTGTTCTATCATTTTTCAGCGTATTAAATGAAATGGTTCTGAACGTCTCATTACCTGATATTGCCAACGAGTTTAATAAACTGCCAGCAAGTGCAAACTGGGTGAATACAGCCTTTATGTTAACCTTCTCCATTGGAACAGCTCTATATGGAAAGCTATCAGACCAGCTGGGCATCAAAAATCTGCTTCTATTTGGGATTATGGTAAATGGCTTAGGGTCGATCATTGGATTTGTTGGACACTCTTTCTTTCCTATTCTCATTCTAGCCCGATTTATTCAAGGAATTGGTGCAGCCGCATTCCCAGCTCTTGTGATGGTTGTCGTTGCGCGCTATATTCCAAAAGAGAACAGGGGGAAAGCATTTGGCCTGATCGGGTCCCTGGTAGCAATGGGAGAAGGTGTTGGGCCAGCTATTGGCGGAATGGTTGCTCATTATATCCATTGGTCGTATTTGCTGCTTATTCCAACTGCAACAATTATCACCGTTCCATTCCTTATAAAATTGTTGAAAAAGGAAGAGAGAATAAGAGGACACATTGATATGGCAGGGATTATATTGATGTCTGCAGGTATCGTATTTTTTATGCTGTTTACAACATCTTATAGATTTTCTTTTCTGATCATCAGTATCCTTGCTTTCTTCATATTTGTGCAACACATTAGGAAAGCTCAGGACCCTTTTGTTGACCCTGAATTAGGGAAAAACGTCTTTTTTGTGATTGGAACCCTTTGCGGAGGACTAATATTTGGTACAGTAGCAGGATTTGTCTCTATGGTTCCTTACATGATGAAAGATGTTCACCATTTAAGTACTGCAGCAATTGGAAGCGGCATTATTTTCCCCGGAACAATGAGTGTCATCATCTTTGGTTACATTGGGGGATTGCTTGTTGATCGGAAAGGTTCCTTGTATGTACTAACTATTGGAAGTGCCTTGCTTTCTTCCGGCTTTTTAATCGCTGCCTTTTTTATAGATGCAGCACCATGGATCATGACAATTATAGTAATTTTTGTTTTTGGGGGGCTATCTTTCACAAAAACAGTTATATCTACAGTTGTGTCTAGCAGTTTGAAAGAAAAGGAAGCGGGCGCTGGAATGAGTTTGCTTAATTTCACGAGCTTTTTATCAGAGGGAACGGGTATTGCGATTGTAGGCGGTTTATTATCTATCGGCTTCCTAGACCATAGGCTGCTGCCTATTGACGTTGATCACTCTACCTATTTGTATAGCAATATGCTCATACTTTTTGCAGGAACCATTGTTATTTGTTGGCTAGTAATCTTGAATGTATATAAACGTTCGCGGAGGCATCGCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7099,Drugs,MEG_7099|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,gi|532329|dbj|D12567.1|BACTETBSR|546-1922,4
,atgcgatttaacaaaatttcttgcttacttttattccctctttttatttttaatacctcaatttatgcagggaatacaccaaaagagcaagaaattaagaaactggttgatcaaaattttaaaccgttattagaaaaatataatgtgccgggtatggcggtaggtgttattcaaaacaataaaaaatatgaaatgtattatggccttcaatctgttcaagataaaaaagctgtaaatagcagtaccatttttgagctaggttctgtcagtaaactatttaccgctacagcaggtgcttatgctaagaataagggaaaaatctcttttgaagataaaccaagtaaatactggaaagagctaaaaaacaccccgattgatcaggtcaatttacttcaacttgctacttataccagtggtaatcttgcgctacagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaagcctaaaaatccaattggtgaatatagacaatattccaacccaagtattggcctatttggaaaagttgtaagcttgtcaatgaatcagccttttagtcaggttttagaaaaaaccatttttccagaccttggcttaaaacatagttatgtcaatgtacctaaaactcaaatgcaacattatgcatttggctataaccaacaaaatcagccgattcgagtcaaccctggtcccttagatggtccagcttacggcgttaaatcgactcttccagacatgttggggtttgttcatgccaacctgaacccgcagcaatatcctgctgatattcaacgtgcaattaatgagacacatcaaggtttctatcaagtagataccatgtatcaggcgcttggttgggaagagttttcttaccctgcaaccttacaaactttattagacagtaattctgaccagattgtgatgaagcctaataaagtcactgctatttctaaagaaccttcaattaaaatgtttcacaaaactggttcaaccaatggctttggaacatacgtcgtatttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaacgaagaacgcattaaggcggcttatgctgtgctaaatgcgataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_627,Drugs,MEG_627|Drugs|betalactams|Class_C_betalactamases|ADC,490838130|WP_004700205.1|NG_064689|1|1|blaADC-133|blaADC|class_C_beta-lactamase_ADC-133 NG_064689:101-1252,0
,atgaactttaataaaattgatttagacaattggaagagaaaagagatatttaatcattatttgaaccaacaaacgacttttagtataaccacagaaattgatattagtgttttataccgaaacataaaacaagaaggatataaattttaccctgcatttattttcttagtgacaagggtgataaactcaaatacagcttttagaactggttacaatagcgacggagagttaggttattgggataagttagagccactttatacaatttttgatggtgtatctaaaacattctctggtatttggactcctgtaaagaatgacttcaaagagttttatgatttatacctttctgatgtagagaaatataatggttcggggaaattgtttcccaaaacacctatacctgaaaatgctttttctctttctattattccatggacttcatttactgggtttaacttaaatatcaataataatagtaattaccttctacccattattacagcaggaaaattcattaataaaggtaattcaatatatttaccgctatctttacaggtacatcattctgtttgtgatggttatcatgcaggattgtttatgaactctattcaggaattgtcagataggcctaatgactggcttttataa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1563,Drugs,MEG_1563|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,446933131|WP_001010387.1|NG_047564|1|1|catA9|catA9|type_A-9_chloramphenicol_O-acetyltransferase NG_047564:101-751,6
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATGCTAAAGAGTTAAATAATTTAGAAAAGAAATATAATGCTAATATTGGTGTCTATGCATTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAACGAAATCGGTGGAATCAAAAAAATTAAAAAACGTTTAAAAAAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAAATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCCCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTGTTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1435,Drugs,MEG_1435|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_89_FKPS01000007,0
,gtgaccaacagcaacgattccgtaacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaagcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_214,Drugs,MEG_214|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,550552027|WP_022631162.1|NG_052535|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052535:101-655,2
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcaaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccatcggactgtctgttacaccactcccgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggcctcttacaccaacgggcagagcgtatgccttacagaactgaaagggtatcaggccgctgtcggcaagccagtcatccagccccgccgtccaaacagccgcctggacaaggtgcgctatatgtttcagaagataatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7211,Drugs,MEG_7211|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,489768696|WP_003672618.1|NG_048296|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048296:1-1920,4
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaaggccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5535,Drugs,MEG_5535|Drugs|betalactams|Class_C_betalactamases|PDC,1035157536|WP_064511501.1|NG_050823|1|1|blaPDC-150|blaPDC|class_C_beta-lactamase_PDC-150 NG_050823:1-1194,0
,ATGCCTCGACTTCGCTGCTGCCCAAGGTTGCCGGGTGACGCACACCGTGGAAACGGATGAAGGCACGAACCCAGTGGACATAAGCCTGTTCGGTTCGTAAGCTGTAATGCAAGTAGCGTATGCGCTCACGCAACTGGTCCAGAACCTTGACCGAACGCAGCGGTGGTAACGGCGCAGTGGCGGTTTTCATGGCTTGTTATGACTGTTTTTTTGGGGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGACGGGCGTACAAAGATAATTTCCATCTCAAGGGATCACCATGCGCTTCATTCACGCACTATTACTGGCAGGGATCGCTCACTCTGCATATGCATCGGAAAAATTAACCTTCAAGACCGATCTTGAGAAGCTAGAGCGCGAAAAAGCAGCTCAGATCGGTGTTGCGATCGTCGATCCCCAAGGAGAGATCGTCGCGGGCCACCGAATGGCGCAGCGTTTTGCAATGTGCTCAACGTTCAAGTTTCCGCTAGCCGCGCTGGTCTTTGAAAGAATTGACTCAGGCACCGAGCGGGGGGATCGAAAACTTTCATATGGGCCGGACATGATCGTCGAATGGTCTCCTGCCACGGAGCGGTTTCTAGCATCGGGACACATGACGGTTCTCGAGGCAGCGCAACTGGCGGTGCAGCTTAGCGACAATGGGGCTACTAACCTCTTACTGAGAGAAATTGGCGGACCTGCTGCAATGACGCAGTATTTTCGTAAAATTGGCGACTCTGTGAGTCGGCTAGACCGGAAAGAGCCGGAGATGGGCGACAACACACCTGGCGACCTCAGAGATACAACTACGCCTATTGCTATGGCACGTACTGTGGCTAAAGTCCTCTATGGCGGCGCACTGACGTCCACCTCGACCCACACCATTGAGAGGTGGCTGATCGGAAACCAAACGGGAGACGCGACACTACGAGCGGGTTTTCCTAAAGATTGGGTTGTTGGAGAGAAAACTGGTACCTGCGCCAACGGGGGCCGGAACGACATTGGTTTTTTTAAAGCCCAGGAGAGAGATTACGCTGTAGCGGTGTATACAACGGCCCCGAAACTATCGGCCGTAGAACGTGACGAATTAGTTGCCTCTGTCGGTCAAGTTATTACACAACTCATCCTGAGCACGGACAAATAGTTGACGCCCGTCTAACAATTCGTTCAAGCCGACGTTGCTTCGTGGCGGCGCTTGCGTGCTACGCTAAGCTTCGCACGCCGCTTGCCACTGCGCACCGCGGCTTAACTCAGGCGTTAGATGCACTAAGCACATAATTCGTCACAGCCAAACTATCAGGTCAAGTCTCGTTAAGCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3129,Drugs,MEG_3129|Drugs|betalactams|Class_A_betalactamases|GES,gi|13310176|gb|AF329699.1|1-1410,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAAAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAATACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGATGGTGTTTCAAAAGACTGTAAGGTGGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTATTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1448,Drugs,MEG_1448|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_91_FKQH01000022,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacattgcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_804,Drugs,MEG_804|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502207|WP_071846357.1|NG_052477|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052477:101-892,2
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCATTCTCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCATTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTACAGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTACTCCTGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAACGTTACCGATATGGCCCGTTGGATTCAGGTCAACATGGACGCCAGCCGCGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGTAGTGACAGCAAAGTGGCATTGGCAGCGCTTCACACCGTTGAGGTAAACCCGCCCGCCCCGGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCATTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1884,Drugs,MEG_1884|Drugs|betalactams|Class_C_betalactamases|CMY,gb|GQ402541|+|0-1146|ARO:3002060|CMY-49 [Citrobacter freundii] ,0
,atgatgaaaaaatcgttatgctgcgcgctgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggcatggccgtggcaattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagttagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcaacgacccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctacacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggataaagccgcattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggcggtgcaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacgggatccacaggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatagtgatgctggcaaacaaaagctatcctaacccggctcgcgtagaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1808,Drugs,MEG_1808|Drugs|betalactams|Class_C_betalactamases|CMY,1028104567|WP_063859888.1|NG_048885|1|1|blaCMY-87|blaCMY|class_C_beta-lactamase_CMY-87 NG_048885:1-1146,0
,atggacacaacgcaggtcacattgatacaccaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgctgggcggccagtccgttgtaacagctggggggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_747,Drugs,MEG_747|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1028081124|WP_063840507.1|NG_047389|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_047389:101-634,2
,gtgcgtaccctgaccaccctcggccttgccctgctgctggcccaacccgccgtggccgcccaggccgtcctgccgcaactgcagccctacaccgcaccggccgcctggctgaccccggtggcaccgctgcgcatcgccgacaacacctggcacatcggcaccgccagcatcaccgcgctgctggtgaagacgccggaaggcgccgtgctgctggacggcggcatgccccaggtggccgatcacctgctggccaacatgcgcgagctgggtgtggcgccgggcgacctcaagctgatcctgcacagccacgcccacatcgatcacgtgggcccgctggccgccatcaagaaggccaccggcgcgcaactggtgagcaacgccgaatcggccgtgctgctgcaacgcggcgacagccaggacatccacttcggcgacgacatggtcttcgccccggtgcaggtggaccgcctggtgcaggacggcgagacggtggaactgggcggcatgaccttcaccgcccacttcacccccgggcacacccccggcagcctgagctggacctggaccgaccgccgcgacggcaagcccctgcgcatcgcctacagcgacagcctgagcgcccccggctacagcctgtggatgaacccgcgcttcccgaagatcgccgaagccttccgcagcggcttcgccgccgtccgcgccctgccctgcgacctgctgatcaccccccacgccgaggccagcggctgggactacaccaacgccgaacaccccaacccgtcgcccatgagctgcaaggcctacgccgacaaggccgaggccgccttcgacgcgcaactgaagaagcagcgcagcggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5806,Drugs,MEG_5806|Drugs|betalactams|Class_B_betalactamases|POM,1693892949|WP_140423326.1|NG_065446|1|1|blaPOM-2|blaPOM|subclass_B3_metallo-beta-lactamase_POM-2 NG_065446:1-861,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacctgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccaatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcagccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5609,Drugs,MEG_5609|Drugs|betalactams|Class_C_betalactamases|PDC,1028110218|WP_063864588.1|NG_049953|1|1|blaPDC-96|blaPDC|class_C_beta-lactamase_PDC-96 NG_049953:1-1194,0
,GTGGAACGTCAAAATAACAATGAAAACCAGTATGGAAGGAATCGCAGAAAAGACAAAAGAAAAAAATTGTTTTTTTACAGAGCAGCATGTGCCATGCTCGGTCTGCTCATAGTCTGTGTAATTTTTGGAGCTGTGTATTTTCTCAGAGAGAGTAAAGATCCGGTTCTTCCATCCAAAGAAAATACAAAGACAGGCAAGGACTATTCATTTTTGGCCGACGGTCAGAGTGAGGATGAGTCTCCGATTTCGGAGCCAGCCATATCCAACCGGGCGAATGCGATTGACCTGAACATCATAGCAGCAAATGCCATTGTGATGAATAAAGACACCGATGCGTTATTGTATCAAAAAAAACGGCACGGACAGAATTGCGCCGGCCAGTACAGCAAAGATGATTACGGCGTTGACCGTGCTTGAATATTGTTCTCCGGAGGAGGAGATGAGAGTCGGTGCAGAGATTGAAATGATCCATAGTGATTCGTCAACCGCATGGCTTATGAAAGGCGATACCCTGACTGTCAGGCAGCTCCTGATTGCCCTGATGCTTCCGTCCGGCAATGATGCAGCTTATACCCTTGCAGTCAATACCGGAAAGGTTATTGCAGGCGATAACAGCCTGTCCAATCAGCAGGCCATTCAGATATTCATGGATAAGGTAAATGAGAAGGCCAGGGCAATTGGTGTTACAGACTCGAATTTTGTGGTTCCGGATGGGTATGATGCCGAGGGGCAGTATACCACGGCCTATGATCTTGCCATCATTGCAAAGGCATGTTTGGAGGATCCCATTATTTCAGAAATTGTGGCGAGCAATACGTCGTATGAAAAATGGCCGAACGGCAGGGAGGTCACTTACAACAATTCCAATGAGCTTCTTGATCCGAACAGTCCCTATTACCGTCCGGAGGTCATCGGACTGAAAACAGGGACCAGCAGCCTTGGCGGCGCCTGTGTGGTCTCTGCGGCAGTGATTGACGGAGAAACCTATATTTGCGTAGTCATGGGCTCTACGAAAGAAAGCAGGTTTCAGGACAGCGTTGCCATTTTGGATAAAATCAAGGCCCAGTGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7604,Drugs,MEG_7604|Drugs|Glycopeptides|VanD-type_accessory_protein|VANYD,gi|27461214|gb|AY082011.1|3849-4917,5
,atgatgaaaaaatcgatatgctgcgcgctgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggtatggccgtggcgattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcatgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggataaagccgaattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggcggtgaaatcttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaactatgcctggggctatctcgaagggaagcctgtgcacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagtgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacgggatccacaggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatagtgatgctggcaaacaaaagctatcctaacccggctcgcgtagaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1805,Drugs,MEG_1805|Drugs|betalactams|Class_C_betalactamases|CMY,1188444918|WP_085562420.1|NG_054711|1|1|blaCMY-151|blaCMY|class_C_beta-lactamase_CMY-151 NG_054711:1-1146,0
,ATGTTGATTAAGAGTGAATATAAGCCCCGGATGCTGCCCAAAGAAGAGCAGGTCAAAAAGCCGATGACCAGTAACGGACGGATCAGCTTCGTCCTGATGGCAATAGCGGTCTTGTTTGCCGGTCTGATTGCCCGCGGACTGTATCTGCAGACGGTAACGTATAACTTTTTGAAAGAACAGGGCGACAACCGGATTGTGCGGACTCAAACATTGCCGGCTACACGCGGTACGGTTTCGGACCGGAACGGTGCGGTTTTGGCGTTGAGTGCGCCGACGGAGTCCCTGTTTGCCGTGCCTAAAGAGATGAAGGAAATGCCGTCTGCCGCACAATTGGAACGCCTGTCCGAGCTTGTCGATGTGCCGGTTGATGTTTTGAGGAACAAGCTCGAACAGAAAGGCAAGTCGTTTATCTGGATTAAGCGGCAGCTCGATCCCAAGGTTGCCGAAGAGGTCAAAGCCTTGGGTTTGGAAAACTTTGTATTTGAAAAAGAATTAAAACGCCATTACCCGATGGGCAACCTGTTTGCACACGTCATCGGATTTACCGATATTGACGGCAAAGGTCAGGAAGGTTTGGAACTTTCGCTTGAAGACAGTTTGCATGCTGAAGAAGGTGCGGAAGTCGTATTGCGGGATCGGGAAGGCAATATTGTGGACAGTTTGGATTCTCCGCGTAATAAAGCCCCGCAAAACGGCAAAGACATTATTCTTTCTCTGGATCAGAGGATTCAGACTTTGGCTTATGAAGAGTTGAATAAGGCGGTCGAATACCATCAGGCAAAAGCCGGAACGGTGGTGGTGTTGGATGCCCGTACTGGGGAAATCCTCGCATTGGTCAATACGCCTGCCTATGAGCCCAACAAACCCGGTCAGGCAGACAGCGAACAGAGGCGCAACCGCGCCGTAACCGATATGATTGAACCCGGTTCTGCCATGAAGCCGTTTACCATTGCCAAAGCATTGGATTCAGGCAAAGTGGATGCAACCGATACGTTCAATACCCTGCCTTACAAAATCGGTCCGGCTACCGTACAAGATACCCATGTTTATCCTACTTTGGATGTGCGCGGCATTATGCAAAAATCTTCCAACGTCGGTACCAGTAAACTTTCTGCCATGTTTACGCCTAAAGAAATGTACGATTTCTATCACGATTTAGGTGTGGGCGTGCGTATGCATTCAGGCTTTCCCGGCGAGACTGCAGGTTTGTTGAGAAGCTGGCGCAGATGGCAAAAAATCGAACAGGCAACCATGTCTTTCGGTTATGGCCTGCAATTAAGCTTATTGCAATTGGCGCGTGCCTATACTGTCTTGACCCATGACGGTGAATTGTTGCCGGTCAGCTTTGAAAAACAAGCGGTTGCACCTAAAGGCAAGCGTGTTATCAAAGCCTCTACTGCGAAAAAAGTGCGCGAGTTGATGGTTTCCGTTACTGAACCCGGCGGTACGGGTACGGCGGGTGCGGTAGATGGTTTCGACGTCGGCGCAAAAACCGGTACGGCGCGTAAGTTGGTCAACGGGCGTTACGTCGATAACAAACACGTTGCCACTTTCATCGGTTTTGCACCTGCCAAAAATCCCCGTGTGATTGTGGCGGTAACCATCGACGAACCGACTGCAAACGGTTACTACGGCGGCGTAGTGACAGGGCCGCCCTTCAAAAAAATTATGGGCGGCAGCCTGAACATCTTGGGCGTTTCCCCGACCAAGCCCCTGACCGCCGCAGCCGTCAAAACACCGTCTTAA,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_5405,Drugs,MEG_5405|Drugs|betalactams|Penicillin_binding_protein|PBP2|RequiresSNPConfirmation,penA_1_AF515059 ,0
,atgagccccggcgttgtcaccttgcggagcatgaccgaagaggatctcggtatgcttcacgactggttgaaccggccccacatcgtcgaatggtggggtggcgagcgtccttcgcttgaggaggtgcaagagcactatcacccttgtgcccttgcagaagccaacgtgactccgtacgtcgggatgctcgatgggcggccttttgcatatgcacagtcgtatgtcgccctgggatcgggagatgggtggtggcaggacgaaaccgatccgggcatacgtggtatcgaccagtcaattggcgagtccgcgcttctagggcaaggttacggtacgttgctggtacgcgcgctcgttgatctgctcttcgccgacccgcgcgtatcgaaagttcagacagatccttctccccggaacttgcgcgccatacgatgctatgagaaggctggcttccgcaggatcaagaccattgagacacctgatggaccagcgatatacatgttgcacgagcgcccatag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_132,Drugs,MEG_132|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502107|WP_071846259.1|NG_052300|1|1|aac(6')-set_A|aac(6')-set_A|aminoglycoside_6'-N-acetyltransferase NG_052300:101-616,2
,ATGACCAATTTCTTCGAAAGCCCGTTCAAGGGCATCCCGCTCGATCAGCAGGTGACGCATCCCAACATCGTCGTCGGGCGGCACAGCTATTATTCGGGCTATTATCACGGGCACGGTTTTGACGACTGCGCGCGGTATGTGTTGCCCGATGCCGATGCCGACCGGCTGATCATCGGCGCGTTCTGTTCGATCGGCTCGGGCGCGGCGTTCATCATGGCGGGCAATCAGGGGCACCGCCATGAATGGGTGAGCACATTCCCCTTCTTCTATGCGAACGAGAGCTGGCAGCAGGCGCAGGCGGCGGACGGCTATCTGCCCGCCGGAGACACGGTGATCGGCAATGATGTGTGGATCGGCAGCGAGGCGATCATCATGCCCGGCGTGCGCGTGGGCGACGGCGCGATCATCGGCACGCGTGCGCTGGTGACGCGCGATGTCGAGCCCTATGCGATTGTCGGCGGCAACCCGGCACGGGTGCTGCGCAAGCGGTTCGACGAAGACCGGATCGCGCTGCTGCTCGAGATGCGGTGGTGGGACTGGCCCGATGCCGCGATCGAGGCGACGATGCCGCTGATGACGAGCGGCGATATCGAGGGGCTGCACGCCGCCTGGCAGCGCCAGACGCGGCGGTGA,chloramphenicol acetyltransferase (CAT),antibiotic inactivation,Phenicol,MEG_1629,Drugs,MEG_1629|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB,gi|958108507|emb|LN824138.1|12203-11571 gi|958102843|emb|LN824133.1|2817474-2816842 gi|957647579|dbj|AP017302.1|2612956-2612324 gi|550602065|gb|KF295829.1|123424-122792 gi|443299869|gb|JQ955744.1|4652-4020 gi|695214903|ref|NG_036913.1|8188-7556 gi|493665175|dbj|AP012055.1|50915-51547 gi|695226706|ref|NG_041561.1|4660-4028,6
,atgaatcattctccgttacgccgctcgctgctcgttgcagccgtttccgcaccgctcgccggcgcatgtgcgccgctgcgcggcaactcgaaaaacgtcgccgccgagcggcaattgcgcgaactcgaatcgacgttcgacggccgcctcggcttcgtcgcgctcgataccgcgacaggcgcgcgcatcgcgcatcgcgccgatgagcgctttccgttctgcagcacgttcaagatgatgctctcggctgcggtactcgcgcgcagcgccgacgacgccgcgctgctgcagcgacggattccgtacgcgaagcgcgacctcgtccgctattcgccgatcaccgagcggcacgtgggcgccggcatgacggtcgccgagctgtgcgcggcgacgctccagtacagcgacaacaccgcggcgaacctgctgatcgatctgctcggcggcccgcaggccgtcaccgcgtatgcgcgctcgatcggcgacgcgacgttccgcctcgatcgccgcgagaccgagctgaacacggcgattcccggcgacgagcgcgatacgacgacgcccgccgcgatggccgcgagcgtgcgccggctgctcgcgggcgatgcgctcggggccgcgcagcgcgcgcagctcaacgcgtggatgctcggcaacaagacgggcgacgcgcggctccgcgcgggcgtgccggccggctggcgcgtcgccgacaagacgggcacgggcgattacgggacggggaacgacatcggcgtcgcgtatccgccggatcgcgcgccgatcgtgttcgtcgtctacacgacgatgcgcagtcagaacgcgccggtgcgcgacgacgtgatcgcggcggcggcgcggatcgccgcgcgggcattcgcctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5754,Drugs,MEG_5754|Drugs|betalactams|Class_A_betalactamases|PENI,492896975|WP_006027381.1|NG_048032|1|1|penI_Bp|penI_Bp|PenI_family_class_A_extended-spectrum_beta-lactamase NG_048032:101-985,0
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATGCCGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAAGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATTGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTGTAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1348,Drugs,MEG_1348|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_122_NZ_AJGE01000057,0
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTTACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4315,Drugs,MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_19_ALMN01000021 ,1
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtacgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcattaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgcccctgcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccggctgatattcaaagggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacaaattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacgtatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_542,Drugs,MEG_542|Drugs|betalactams|Class_C_betalactamases|ADC,1058243552|WP_068981612.1|NG_051444|1|1|blaADC-105|blaADC|class_C_beta-lactamase_ADC-105 NG_051444:1-1152,0
,atgtctgcatacggacacggccgtcacgagaatggccaaaattttctcaccaaccacaagatcatcaactccatcatcgaccttgtgaaacaaacctccggccccatcattgagatcggaccaggaagcggtgccctcactcacccgatggcccacttggggagggcgataacggcagttgaagtggacgcaaaactagctgccaaactcacacaagaaacctcctcggcggcggtcgaagtggtccatgatgatttccttaacttccggttacccgccactccctgcgtcattgtgggaaacattccctttcacctcaccactgccattcttcgaaagttgctgcatgcgccagcatggactgacgctgtactcctcatgcagtgggaagtcgctcgccgccgggccggggtaggcgcaagcacgatgatgacggctcagtggtccccatggttcacatttcacctgggttctcgggtaccaaggactgctttccggccacagccaaacgttgacggggggatcttagtgatccgccgggtgggtgacccgaagattccgatagagcagcgcaaagcctttcaggcgatggtgcacaccgttttcactgcccggggacgcgggataggggaaattctccgaagggcagggttgttttcatcacgttcagaaacacaatcatggttgcgctcgcgaggaatcgaccccgcgaccctacctcccagattgcacaccaacgactggatcgatctcttccaggtgactggttcctctctacctcaccatcgacccatttcaccatcgggaagtagtcaacgacctcctcaacggaaaaaccgaagccggcggcgttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2854,Drugs,MEG_2854|Drugs|MLS|23S_rRNA_methyltransferases|ERMX,1028086548|WP_063844922.1|NG_047854|1|1|erm(X)|erm(X)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(X) NG_047854:101-955,7
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcatggctggcaatcaggggcatcggtgcgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1601,Drugs,MEG_1601|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,695270614|WP_032492683.1|NG_047606|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_047606:101-733,6
,atgcgatttaacaaaatttcttgcttacttttatcccctctttttatttttaatacctcaatttatgcagagaatacacccaaagagcaagaaattaagaaactggttgatcaaaattttaaacctttattagaaaaatatgatgtgcccggtatggctgttggcatcatccaaaataataaaaagtatgaaatgtattatggtctacaatccgttcaagataaaaaagccgtaaatagcagtaccatttttgagctcggttcagtcagtaaattatttactgctacagcaggtggatatgcaaaaacaaaaggaataatttcttttaaagacactcccggaaaatattggaaagaattaaaaaacacaccgattgaccaagttaacttacttcaacttgctacttatacaagtggcaaccttggcttacagtttccagatgaagtccaaacaaatcagcaagttttaacttttttcaaagactggaagcctaaaaactcaatcggtgaatatcgacaatattcaaatccaagcattggtttatttggaaaagttgttgctttgtctatgaacaaacctttcgaccaagtcttagaaaaaaccatttttccagatcttggcttaaaacatagctatgtaaatgtgcctaaaactcaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccgctagatgcacctgcgtacggcgttaaatcgaccttacctgatatgctgagtttcgttaatgccaatctaaatccacaaaaatatccagcagatattcaacgcgcaattaatgaaacacatcaaggtttctaccaagtgggtacgatgtatcaagcattaggttgggaagagttctcttatccagcaccattacagactttattagacagtaattcagagcaaatcgtaatgaaatctaataaagtgacagctatttcgaaagaaccttcagttaagatgttccacaaaactggttcgaccaacggttttggaacatatgttgtctttattccaaagcaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaagctgcctatgcagtgttgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_624,Drugs,MEG_624|Drugs|betalactams|Class_C_betalactamases|ADC,490929086|WP_004790939.1|NG_064691|1|1|blaADC-135|blaADC|class_C_beta-lactamase_ADC-135 NG_064691:101-1252,0
,atgaaaattctgattttgctacctttactgagttgcttgggcctgacagcgtgtacctcacctgtttcatctttcccttctcagatcacttcaactcaatcgactcaagccattgcccaattatttgatcaggcgcaaagttctggcgttttagtgattcagcgtggtcaaaaagtacaggtctatggcaatgatttaagccgtgcaggtaccgaatatgttccagcctctactttcaaaatgctcaatgccctgattggtctacaacatggtaaagccacaaccaatgagatttttaaatgggatggcaagaaacgcagttttgcagcctgggaaaaagacatgacgctcggcgaagccatgcaagcttctgctgtacccgtctatcaggaactggcacgtcatattggtttggaattaatgcagcaggaagtacaacgcatccaatttggtaatcagcagattggtcagcaggtcgataacttctggttggtaggtcctttgaaaatcactccaaaacaggaagtcgaatttgtctctgctctagcccgagagcaactagcctttgatcctcaagtccagcagcaagtcaaagccatgttacttctacaggaacggcaagcttatcgcctgtatgccaaatccggttggggcatggatgtagaaccgcaagtcggctggctcaccgggtgggtcgaaacaccgcaggctgaaatcgtggcattttctctaaatatgcaaatgcaaaccaatatgaatccagccattcgccttgaaattttacagcaggctctgggcgaattagggctttacccaaaagtggggcagcaaagcaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4425,Drugs,MEG_4425|Drugs|betalactams|Class_D_betalactamases|OXA,748644458|WP_039902635.1|NG_065432|1|1|blaOXA-646|blaOXA-134_like|OXA-134_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-646 NG_065432:1-840,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacagtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcatcgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacctgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccctctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5707,Drugs,MEG_5707|Drugs|betalactams|Class_C_betalactamases|PDC,1343491241|WP_104009857.1|NG_056420|1|1|blaPDC-228|blaPDC|class_C_beta-lactamase_PDC-228 NG_056420:1-1194,0
,TTGAAAAATAAAAATATGACCAGTTATGAGGATGACTATTTACTTTTTAAAAACAGACTGTCCGTTAAAATACTGCTGATGATGGCGTGCTCCATTCTGATTATATCGGTGGTTTATCTGTTCGTCTTAAAGGATAATTTTGCAAATGTGGTGGTAGCCATATTGGACCGTTTCATTTATCATGACCGGGATGAAGCGGTGGCTGTTTACCTGAGAACCTTTAAGGCGTATGAGATATGGCTTTTCCTGATCGCCGTCATGGGTGTGTTTTTCGTTATTTTTCGTCGTTATCTGGACAGCATCTCAAAGTATTTTAAGGAGATCAACCGGGGGATTGATACACTGGTGCATGAAGATACCAATGATATCGCCCTGCCTCCGGAACTGGCTTCGACCGAAAGGAAAATCAATTCCATACGGCATACCCTGACGAAGCGGAAAACAGACGCCGAGCTTGCGGAACAGCGGAAAAACGACCTTGTCATGTACCTGGCTCATGACTTGAAGATCCCGCTTTCATCGGTCATAGGGTATTTGAACCTGTTAAGGGATGAGAAGCAGATCTCCGAGGAACTCCGGGAAAAATATCTGTCCATTTCACTGGATAAGGCGGAACGTCTGGAAGAGCTGATCAATGAGTTTTTTGAAATTACGAGGTTTAATCTTTCAAACATCACGCTTGTGTACAGCAAAATCAATCTGACGATGATGCTGGAACAGCTGGGGCACGAGTTTAAGCCGATGCTGGCCGGGAAAAATCTCAAATGTGAATTTGATATTCAGCCGGACATGCTGCTGTCCTGTGATGCCAACAAGCTGCAGAGAGTGTTTGATAATCTGCTGAGAAATGCCGTCAGCTACTGTTATGAGAACACCACCATTCAGGTGAATGCCAGGCAGGCGGAAGATCATGTGCTCATCAAAATCATAAACGAAGGGGATACGATTCCGCGGGAAAGGTTAGAAAGAATCTTTGAGCAGTTTTATCGCCTTGATATGTCGCGAAGCTCAAGCACCGGCGGAGCCGGTCTGGGACTTGCGATTGCAAGGGAGATTGTGGAACTGCACCATGGACAGATCACTGCCCGCAGCGAAAACGGTATCACCAGTTTTGAGGTTACATTGCCCACCGTAGGAAAATCGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7507,Drugs,MEG_7507|Drugs|Glycopeptides|VanD-type_regulator|VANSD,(Gly)VanS-D:AB242319:689-1834:1146,5
,GTGGACGAGTTGGAGCAGTTTTATCAATTAGGGTGGACACTTGATTCAGCAGGTGGTGCATCTGGTGAAGCATATATGGCTGAACAAGATGGACAAAAGTTGTTTTTAAAACGAAATTCAAATCCATTTATTGCGGCATTATCAGCAGAAGGTATTGTGCCCAAATTAGTATGGACGAAACGCATAGAAACAGGCGAGGTTGTTACAGCACAACATTGGAAAAATGGGCGTGAACTATCTTCAAACGAAATGAAGCAAACAAGAGTTGCACATTTATTAAAGAAGATACACAATTCTAGACCTTTATTAAGTATGTTAAAGCGTATGGAAATGGAACCTATTACTCCTGAGATTATGCTTAATAAAATTAATGCCTCTTTATCAAGAGAAGTTTTAACACATCATATTGTGAGAAAATCATTAACCTATTTAGAAGAGCATATACCGAGTTTAGATTCGCGTTTTTTCACTGTTGTACATGGTGATGTGAATCATAATAATTGGTTATTATCCGATCGAGATGAACTATTTTTAGTTGATTGGGAAGGTGCAATGATTGCAGACCCGGCAATTGATATCGGAATGCTGCTTTACAACTATGTTCCACAACAACAATGGTCTGAATGGCTTGAAACATATGGTGTTCAAGAGAGCTTGAATTTAAATAAACGTATGAAATGGTATACGGTAATTCAATCTATAGGTCTTGTTCAATGGTATGAAGAGCAAAAAAGATATAAGGATATGAACACTTGGCTTAAATTCCTAAATGAAGTTATGAATAGTAACATGTTTATTTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1060,Drugs,MEG_1060|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-PRIME,(AGly)APH-Stph:HE579073:1778413-1779213:801,2
,atgcgttatattcgcctgtgtattatctccctgttagcccccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctactggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcaagcggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcgcattgtggtgatttatctgcgggataccccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6235,Drugs,MEG_6235|Drugs|betalactams|Class_A_betalactamases|SHV,1028110282|WP_063864652.1|NG_050041|1|1|blaSHV-165|blaSHV|class_A_beta-lactamase_SHV-165 NG_050041:1-861,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatctggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttgcgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcggatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_808,Drugs,MEG_808|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502116|WP_071846268.1|NG_052309|1|1|aadA12|aadA12|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA12 NG_052309:101-892,2
,ATGAAAATTATTAATATTGGAGTTTTAGCTCATGTTGATGCAGGAAAAACTACCTTAACAGAAAGCTTATTATATAACAGTGGAGCGATTACAGAATTAGGAAGCGTGGACAAAGGTACAACGAGGACGGATAATACGCTTTTAGAACGTCAGAGAGGAATTACAATTCAGACAGGAATAACCTCTTTTCAGTGGGAAAATACGAAGGTGAACATCATAGACACGCCAGGACATATGGATTTCTTAGCAGAAGTATATCGTTCATTATCAGTTTTAGATGGGGCAATTCTACTGATTTCTGCAAAAGATGGCGTACAAGCACAAACTCGTATATTATTTCATGCACTTAGGAAAATGGGGATTCCCACAATCTTTTTTATCAATAAGATTGACCAAAATGGAATTGATTTATCAACGGTTTATCAGGATATTAAAGAGAAACTTTCTGCCGAAATTGTAATCAAACAGAAGGTAGAACTGTATCCTAATATGTGTGTGACGAACTTTACCGAATCTGAACAATGGGATACGGTAATAGAGGGAAACGATGACCTTTTAGAGAAATATATGTCCGGTAAATCATTAGAAGCATTGGAACTCGAACAAGAGGAAAGCATAAGATTTCAGAATTGCTCCTTGTACCCTGTTTATCATGGAAGCGCAAAAAGCAACATAGGGATTGAGCAGCTTATAGAAGTGATAACGAATAAATTTTATTCATCAACATACAGAAAGAAGTCTGAACTTTGCGGAAATGTCTTCAAAATTGAATATTCGGAAGAAAGACAACGTCTTGCATATGTACGCCTTTATGGCGGAATCCTGCATTTGCGGGATTCGGTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGTGAATTATGTAAAATTGATAAGGCTTATTCCGGGGAAATTGTTATTTTGCAAAATGAGTTTTTGAAGCTAAATAGTGTTCTTGGAGATACAAAGCTATTGCCACAGAGAGAGAGAATTGAAAATCCGCTCCCTCTGCTGCAAACAACTGTTGAACCGAGCAAACCTCAACAAAGGGAAATGTTACTTGATGCACTTTTAGAAATCTCCGACAGTGACCCGCTTCTACAATATTATGTGGATTCTACGACACATGAAATCATACTTTCTTTCTTAGGGAAAGTACAAATGGAAGTGACTTGTGCTCTATTGCAAGAAAAGTATCATGTGGAGGTAAAAATAAAAAAGCCTACAGTCATTTATATGGAAAGACCGTTAAAAAAAGCAGAGTATACCATTCACATCGAAGTGCCACCGAATCCCTTCTGGGCTTCCATTGGTCTTTCTGTAGCACCGCTTCCATTAGGGAGCGGAGTACAGTATGAGAGCTCGGTTTCTCTTGGATACTTAAATCAATCGTTTCAAAATGCAGTTATGGAAGGGATACGATATGGCTGTGAACAAGGATTGTATGGTTGGAATGTGACGGACTGTAAAATCTGTTTTAAGTATGGCTTATACTATAGCCCTGTTAGTACCCCAGCAGATTTTCGGATGCTTGCTCCTATTGTATTGGAACAAGTTTTAAAAAAAGCTGGAACAGAATTGTTAGAGCCATATCTTAGTTTTAAAATTTATGCACCACAAGAATATCTTTCACGAGCATATAACGATGCTCCCAAATATTGTGCAAATATCGTAAATACTCAACTGAAAAATAATGAGGTCATTCTTAGTGGAGAAATTCCTGCTCGGTGTATTCAAGAATATCGTAATGATTTAACTTTCTTTACAAATGGACGTAGCGTTTGTTTAACAGAGTTAAAAGGGTACTATGTTACTACTGGTGAATCTGTTTGTCAGCCCCGTCGTCCAAATAGTCGGATAGATAAAGTACGATATATGTTCAATAAAATAACTTAG,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7144,Drugs,MEG_7144|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,gi|962094922|gb|KT281952.1|1-1920 gi|962094920|gb|KT281951.1|1-1920 gi|158264372|gb|EU182585.1|1-1920,4
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccgagaaattaaaaaactggtagatcaaaactttaaacctttattagataaatatgatgtgccgggtatggccgtgggcgttattcagaataataaaaaatatgaaacgtattatggtcttcaatctgttcaagataaaaaatccgtaagtagcagtaccatttttgaactaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcaacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagaatggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccgggccttggcttaaaacatagctatgtaaatgtaccgaagacccagatgcaaaactatgcttttggctataatcaagaaaatcagccaattcgtgttaaccccggtccgctagatgctccagcatacggtgttaaatcgaccttacctgatatgctgagtttcattaatgccaatataaatccacaaaaatatccgaaagatactcaacgtgcaattaatgaaacacatcaaggtttctaccaagtcggcacgatgtatcaggcacttggttgggaagaattttcttatccagcgcctttacaaactttattagacagtaattcagagcaaatcgtgatgaagcctaataaagtgactgccatttccaaagaaccttcagttaagatgttccacaaaactggctcaacaaatggctttggatcttatgtggtgtttattccaaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagtattaaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_605,Drugs,MEG_605|Drugs|betalactams|Class_C_betalactamases|ADC,516050127|WP_017480710.1|NG_051317|1|1|blaADC-70|blaADC|class_C_extended-spectrum_beta-lactamase_ADC-70 NG_051317:101-1252,0
,GTGGAAGTCGCCAATGTGCCACGGCGTCATTGCTGCCTTTTTGCTCGCCCGATCCCCATCGTGGAAGTCGCTGCGGAGGCCGACGCCATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2964,Drugs,MEG_2964|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|971497891|gb|CP012901.1|4102945-4103871 gi|957647579|dbj|AP017302.1|424019-424945 gi|957647579|dbj|AP017302.1|412063-411165 gi|957647579|dbj|AP017302.1|116888-116001 gi|751410783|gb|CP010781.1|272091-273017 gi|751410783|gb|CP010781.1|293752-294650 gi|702084791|gb|JN409449.3|54428-55354 gi|702084791|gb|JN409449.3|74145-75043 gi|685193060|gb|JN968482.3|21238-22164 gi|685193060|gb|JN968482.3|42899-43797 gi|672940400|gb|HM590877.5|48637-49563 gi|672940400|gb|HM590877.5|62675-63573 gi|469481726|gb|CP004038.1|62060-61134 gi|325301733|gb|JF262166.1|247-1173 gi|297185510|gb|HM357806.1|6255-7181 gi|213054530|gb|CP001182.1|283659-284585,8
,atggacgtacgtaaacacaaggctagtttttttagcgtagtaattacttttttatgtctcacgctatcattaaatgctaatgcaacagactcagtacttgaagcggttaccaatgctgaaactgaattaggcgctagaattggtctagctgtgcatgatttggaaacgggaaaacgttgggaacataaatctaatgaacgttttcctctaactagtacctttaaaacacttgcctgtgcaaacgttcttcaaagagttgatctaggtaaagaaagaattgatagagttgtgagattctctgaaagcaatctcgttacatactcacctgtaacagaaaaacatgtgggtaaaaaagggatgtcgctcgcagagctgtgtcaggccacattatcaaccagtgataattcagctgccaattttattctacaagcgattggtggacctaaggctctaacgaaatttttgcgttccattggcgacgatactacgcgccttgatcgctgggaaacagaacttaacgaagcggtgcctggagataagcgagacacgacaacaccaattgcaatggtaacgacacttgaaaagttactaattgacgaaacactatctatcaaatctcgtcaacaactagaatcttggcttaaaggtaatgaggttggcgatgcattgtttcgtaaaggcgttccaagtgactggatagtagcagatagaacaggcgctggtggttatgggtcgcgtgctattactgcggtgatgtggcctccaaatcgcaagcctatcgtagccgctctatacattacagagacagacgcctcgtttgaagaaagaaatgctgtcattgcaaaaattggtgagcaaatagcgaagacagtattaatggagaatagccgtaactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6150,Drugs,MEG_6150|Drugs|betalactams|Class_A_betalactamases|RTG,1058243929|WP_068981631.1|NG_051466|1|1|blaCARB-49|blaRTG|RTG_family_carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-49 NG_051466:1-897,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5486,Drugs,MEG_5486|Drugs|betalactams|Class_C_betalactamases|PDC,1001056857|WP_061196139.1|NG_049954|1|1|blaPDC-97|blaPDC|class_C_beta-lactamase_PDC-97 NG_049954:1-1194,0
,ATGAAACTCTTCGCTCAGGGCGCCACGCTCGATCTCACTCATCCGCATGTTATGGGGATCCTGAACGTAACGCCGGATTCGTTCTCCGACGGCGGCGCGCATAACACGCTGATTGAGGCGGTGAAACATGCGAATTTAATGGTGAATGCCGGGGCGACAATTATTGATGTGGGGGGGGAATCAACGCGACCAGGCGCGGCAGAAGTGAGCGTGGAAGAAGAGCTGGATCGCGTTATTCCGGTACTGGAAGCAATCGCGCAACGTTTTGAAGTGTGGATTTCTGTGGATACCTCTAAACCCGAGGTGATCCGTGAAGCGGCAAGGGCGGGCGCGCATATTATCAATGATGTCCGTTCACTCTCCGAACCCGGCGCGTTGGAAGCGGCAGCGGAAACCGGCTTGCCGGTCAGTCTTATGCACATGCAGGGCAACCCCAAAACCATGCAGGAGGCGCCGAAATATGACGATGTCTTTGCCGAGGTGAATCGCTACTTTATTGAGCAAATAGCACGTTGTGAGAAGGCCGGCATCGCAAAAGAGAAATTGTTGCTCGACCCAGGATTCGGTTTCGGTAAAAATCTCTCTCACAATTATACCTTACTGGCGCGACTGGGTGAGTTTCATCATTTTAACCTGCCGCTGCTGGTGGGCATGTCACGTAAAACGATGGTTGGTCAGTTACTTAACGTGGGACCATCAGACCGTCTGAACGGCAGCCTTGCGTGCGCGGTAATTGCCGCGATGCAGGGCGCGCAGATCATTCGCGTCCATGACGTCAAAGAAACCGTAGAGGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGGAAACAAACGCTATGAGTAA,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2966,Drugs,MEG_2966|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|981191958|emb|LN999997.1|1907400-1908248 gi|973795115|gb|AE006468.2|3464592-3463744 gi|928084184|gb|CP012681.1|3417132-3416284 gi|821161554|gb|CP011428.1|3492819-3491971 gi|808186398|gb|CP007523.1|4149048-4148200 gi|777181114|emb|LN829402.1|552874-553722 gi|764057510|gb|CP007235.1|4236272-4235424 gi|674281104|gb|CP009102.1|3400488-3399640 gi|669110799|gb|CP007804.2|3371060-3370212 gi|661245796|dbj|AP014565.1|3628207-3627359,8
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaaaccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttctatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaattttttccaacaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4585,Drugs,MEG_4585|Drugs|betalactams|Class_D_betalactamases|OXA,1391852926|WP_109545111.1|NG_057547|1|1|blaOXA-613|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-613 NG_057547:1-753,0
,atgaaaaaaatcgccattatttttggaggcaattcatcggaatacaccgtttctttagcctcagcaactagcgcaatcgaagcactccaatcatctccctatgattacgacctctctttgatcgggatcgccccagatgctatggattggtatttgtacacaggagaactagaaaacatccgacaagacacatggttgttggatacgaaacatacacagaaaatccagccactttttgaagaaaacggcttttggctaagtgaagcgcagcaaacgttggtacctgatgttttatttcccattatgcatggcaaatacggggaagatggcagtatccaaggattgtttgaattgatgaagcttccttatgtaggctgcggggtggcagcctctgccttatgtatgaacaaatggctgctgcatcaagctgcagcagcgattggagtacaaagcgcccctacgattctcttgacaaatcaagacaaccaacagcaacaaatcgaagccttcatccagacccatggctttccagttttctttaagcctaatgaagcgggctcctcaaaagggatcacaaaagtaacttgtgttgaagaaatcgctcctgccttgaaggaagcattcgcttattgttccgcagtgctcttacaaaaaaatatcgctggcgttgagattggttgcggtatcttaggcaacgactctttgactgtcggtgcttgtgacgctatttcattagtagaaggctttttcgattttgaagaaaagtaccaattgattagcgccaagatcaccgttcctgcaccattgcctgaaacgattgaaaccaaggtcaaagaacaagctcagctgctctatcacagtcttggtcttaaaggacttgctcgcatcgacttttttgtcacggatcaaggagaactatacttgaatgaaatcaatactatgccgggctttactagtcactcccgctatcctgccatgatggcagcaatcggcttatcctatcaagaactactacaaaaactgcttgtcttagcaaaggaggaaggcaaatga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7359,Drugs,MEG_7359|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,1028100531|WP_063856666.1|NG_048349|1|1|vanC2/3|vanC2/3|D-alanine--D-serine_ligase_VanC2/3 NG_048349:29-1081,5
,TTGTCCGAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGATTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTACTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATGGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4313,Drugs,MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_2_KT862781 ,1
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTACTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCGGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGCCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCGTTTGCCCCCTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGTGTCAACCCTGGCATGCTGGCGGACGAGGCCTATGGCATCAAGACCAGCTCGGCGGATCTGCTGCGTTTTGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACCAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCGCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTACCCCAACGAGGCGCGCATCAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1947,Drugs,MEG_1947|Drugs|betalactams|Class_C_betalactamases|CMY,gb|X92508|+|332-1481|ARO:3002012|CMY-1 [Klebsiella pneumoniae] ,0
,atgggtgaatttttccctgcacaagttttcaagcagctgtcccacgctcgcgcggtgatcgagcgccatctggctgcgacactggacacaatccacctgttcggatctgcgatcgatggagggctgaagccggacagcgacatagacttgctcgtgaccgtcagcgccgcacctaacgattcgctccggcaggcgctaatgctcgatttgctgaaagtctcatcaccgccaggcgatggcggaacatggcgaccgctggagctaactgttgtcgctcgaaacgaagtagtgccttggcgctatccggcgcggcgtgagcttcagttcggtgagtggctccgccacgacatcctttccggaacgttcgagcctgccgttctggatcacgatcttgcgattttgctgaccaaggcgaggcaacacagccttgcgcttctaggcccatccgcagccacgtttttcgagccggtgccgaaggagcatttctccaaggcgcttttcgacactattgcccagtggaatgcagagtcggattggaagggtgacgagcggaacgtcgttcttgctcttgctcgcatttggtacagcgcttcaactggtctcattgctcctaaggacgttgctgccgcatgggtatcggagcgtttgcctgccgagcatcggcccctcatctgcaaggcacgcgcggcgtacctgggtagcgaggacgacgacctagcaatgcgcgtcgaagagacggccgcgttcgttcgatatgccaaagcaacgattgagagaatcttgcgttga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_830,Drugs,MEG_830|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502134|WP_071846286.1|NG_052333|1|1|aadA5|aadA5|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA5 NG_052333:101-889,2
,ATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGTAGCGCATATATCACGAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCGAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGCTGGACAACTACCAGGCGTCGTTGCTCATGGAGCGGCTTGGCATCGCGGTGATTGGTTAG,quinolone resistance protein (qnr),antibiotic target alteration,Fluoroquinolones,MEG_6008,Drugs,MEG_6008|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,qnrB6_2_EF523819 ,3
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggacagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactgactggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacactgtttttgcgctctattggcgacaaagcaacgcgacttgaccgattggagccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacacaccttgatggaagataacgccctatcttacgagtcacgcacacaactgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctaccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1502,Drugs,MEG_1502|Drugs|betalactams|Class_A_betalactamases|CARB,646998191|WP_025623492.1|NG_048730|1|1|blaCARB-27|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-27 NG_048730:1-852,0
,ATGAAAGTTAAAGTACTGTCCCTCCTGGTACCAGCACTGCTGGTAGCGGGCGCAGCAAATGCGGCTGAAATTTATAACAAAGACGGCAACAAATTAGACCTGTACGGTAAAATCGACGGTCTGCACTACTTCTCTTCCGACGACAGCGTCGACGGCGACCAGACCTACATGCGTATCGGCGTGAAAGGCGAAACCCAGATCAACGACCAGCTGACCGGTTACGGCCAGTGGGAATACAACGTTCAGGCGAACAACACTGAAAGCTCCAGCGACCAGGCGTGGACTCGTCTGGCCTTCGCGGGTCTGAAATTCGGCGACGCGGGTTCTTTCGACTACGGTCGTAACTACGGCGTTGTTTACGACGTAACTTCCTGGACCGACGTTCTGCCGGAATTCGATGGCGACACCTACGGTTCCGACAACTTCCTGCAGTCCCGTGCTAACGGCGTTGCCACCTACCGTAACTCTGACTTCTTCGGTCTGGTTGACGGCCTGAACTTTGCTCTGCAGTACCAGGGTAAAAACGGCAGCGTGAGCGGCGAAGATCAGACCAACAACGGTCGCGGCTTCCAGAAACAGAACGGCGAAGGCTTCGGCACCTCCGTGACTTATGAGATCTGGGACGGCATCAGCGCTGGTTTCGCGTACTCCAGCTCTAAACGTACCGATGAGCAGAACAACTCTACTTATTTTTCTAAGTCCTATCAGCGTACATACGGTGTTCTGGGTGAAGGCGATCACGCTGAAACCTATACCGGTGGTCTGAAATATGACGCCAACAACATTTACCTGGCGACTCAGTACACCCAGACCTACAACGCAACTCGCACTGGCGACATCGGTTTTGCTAACAAAGCGCAGAACTTCGAAGTGGTTGCTCAGTACCAGTTCGACTTCGGTCTGCGTCCGTCCGTGGCTTACCTGCAGTCTAAAGGTAAAGACATGGGCCGTTACGGCGACCAGGACATCCTGAAATATGTTGACCTGGGTGCGACCTACTACTTCAACAAAAACATGTCCACCTACGTTGATTACAAAATCAACCTGCTGGACGACAACAAGTTCACTAAAGATGCAAGCATCTCTACTGACAACGTTGTGGCTCTGGGCCTGGTTTACCAGTTCTAA,General Bacterial Porin (GBP),reduced permeability to antibiotic,betalactams,MEG_4279,Drugs,MEG_4279|Drugs|betalactams|Mutant_porin_proteins|OMP36,gi|13384116|gb|AF336095.1|1-1128,0
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgacagtctccccgccatactctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgttcccgaatttcaaatgattgataaaggtgacaagccggaggcgggtgcgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacggtacggaagaacttaacgctgcgatagaagcggcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcgggtgtgcggtcatggggaacgaggatgatttgattgtcggcgaagtggatcaaatccggctgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagaaaatgcgatgattacagttcccgcagacattccggtcgaggaacgaaatcgggtgcaggaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgcccgtgttgatctttttttgcaggaggatggcggcatcgttctaaatgaggtcaataccatgcccggttttacatcgtacagccgctacccacgtatggtggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7347,Drugs,MEG_7347|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,984659310|WP_060763488.1|NG_048337|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048337:1-1029,5
,ATGAAAAAAATCGCAATCATTTTTGGAGGCAATTCACCAGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTACGACCTCTCTTTGATCGGGATCGCCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATACACAGAAAATAAAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTCCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGCCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACGCCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAATTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7365,Drugs,MEG_7365|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,(Gly)VanC2/3:EU151755:29-1081:1083,5
,atgactaaaaaagctcttttctttgccattggtacgatgtttttatcggcatgttcttttaatacggtagaacagcatcaaacacagtcaatttctaccaataaaaactcagagaaaattaaatcattgtttgatcaagcacaaactgaaggtgttttagttataaaacgtgggcaaatagaggaagtctatggcaatgatcttaaaagagcatcaaccgaatatgttcccgcctctacctttaaaatgttaaatgctttgattggacttgagcatcataaagcaacaccaactgaagtgtttaaatgggatgggcaaaagcgtttatttcccgattgggaaaaagacatgacattaggcgatgcgatgaaagcttatgctattccagtttatcaggaactagctcgacgaattggccttgatcttatgtctaaagaggtaaaacgcattggtttcggtaatgctgatattggttcaaaagtagatgatttttggcttgttggtccacttaaaattacacctcaacaagaagcccagtttgcttatgaactagcccataaaactcttccttttagcaaaaatatgcaagaacaagttcaatctatgctgttcatagaagaaaaaaatggacgaaaaatttatgccaaaagtggttggggatgggatgtggagcctcaagtgggctggttaacaggctgggtcgttcaaccacaaggagaaattatagctttctcacttaatttagaaatgaaaaaaggcatacctagctctattcgaaaagaaattgcttataagggattggaacaactcggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4553,Drugs,MEG_4553|Drugs|betalactams|Class_D_betalactamases|OXA,1693892942|WP_140423319.1|NG_065437|1|1|blaOXA-826|blaOXA-213_like|OXA-213_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-826 NG_065437:1-822,0
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtagctagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccggctttaccagattgctgatggtgtttggtcgcatatctcaacgcagtcgtttgatggcgcggtctacccatccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcccttctcgcggagattgagaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcggaaggctggagtggcaacgtacgcatcaccgtcgacacgccggctagccgaggcagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcccggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcttgcgttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcacagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7696,Drugs,MEG_7696|Drugs|betalactams|Class_B_betalactamases|VIM,1028110986|WP_063865198.1|NG_050376|1|1|blaVIM-49|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-49 NG_050376:1-801,0
,atgagggaagcgatgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagggagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_769,Drugs,MEG_769|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502088|WP_071846240.1|NG_052257|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052257:101-892,2
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgtcttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataagacaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattcccagaatgggaaaaggacatgaccctaggcgacgctatgaaagcttccgctattctggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagcccaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcattctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4501,Drugs,MEG_4501|Drugs|betalactams|Class_D_betalactamases|OXA,1028109755|WP_063864158.1|NG_049787|1|1|blaOXA-509|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-509 NG_049787:1-825,0
,ATGCAACAACGACAATCCATCCTGTGGGGGGCCGTGGCCACCCTGATGTGGGCCGGTCTGGCCCATGCAGGTGAGGCTTCACCGGTCGATCCCCTGCGCCCCGTGGTGGATGCCAGCATCCAGCCGCTGCTCAAGGAGCACAGGATCCCGGGCATGGCGGTGGCCGTGCTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGAGAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGAGCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCGATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATCCGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAGGCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGCGCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCAGTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCCTGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTCGGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTATGCCTATGGCTATTCGAAAGAGGACAAGCCCATCCGGGTCAACCCTGGCATGCTGGCGGACGAGGCCTACGGCATCAAGACCAGCTCGGCGGATCTGCTCGCCTTCGTGAAGGCCAACATCGGCGGGGTTGATGACAAGGCGTTGCAGCAGGCCATCTCCCTGACCCACAAAGGGCATTACTCGGTAGGCGGGATGACCCAGGGGCTGGGTTGGGAGAGTTACGCCTATCCCGTCACCGAGCAGACATTGCTGGCGGGCAATTCGGCCAAGGTGATCCTCGAAGCCAATCCGACGGCGGCTCCCCGGGAGTCGGGGAGCCAGGTGCTCTTCAACAAGACCGGCTCGACCAATGGCTTTGGCGCCTATGTGGCCTTCGTGCCGGCCAGGGGGATCGGCATCGTCATGCTGGCCAATCGCAACTATCCCATCCCGGCCAGGGTGAAGGCGGCCCACGCCATCCTGGCGCAGTTGGCCGGTTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1851,Drugs,MEG_1851|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AF167990|+|612-1761|ARO:3002019|CMY-8 [Klebsiella pneumoniae] ,0
,atgatcgtcaactgcgaccacgacaaccttgatgcctggctggcgctgcgctcggcgctgtggcccacctgcccgctggaagagcaccgcgcggagatgcacgaaatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgttttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggctgcgaatcgtcgccggtcgcgtttctggaagggatttacaccgtcgaacgcgcccgccgccagggctgggcggcgcgattgatcgcacaggtgcaggaatgggccaagcagcaaggctgcagcgagctggcgtcggataccgacatcgccaatctggactcccagcgcctgcatgcggcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_149,Drugs,MEG_149|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,491075553|WP_004937175.1|NG_052389|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052389:101-541,2
,atgaaaaagataaaaattgttccacttattttaatagttgtagttgtcgggtttggtatatatttttatgcttcaaaagataaagaaattaataatactattgatgcaattgaagataaaaatttcaaacaagtttataaagatagcagttatatttctaaaagcgataatggtgaagtagaaatgactgaacgtccgataaaaatatataaaagtttaggcgttaaagatataaacattcaggatcgtaaaataaaaaaagtatctaaaaataaaaaacgagtagatgctcaatataaaattaaaacaaactacggtaacattgatcgcaacgttcaatttaattttgttaaagaagatggtatgtggaagttagattggaatcatagcgtcattattccaggaatgcagaaagaccaaagcatacatattgaaaatttaaaatcagaacgtggtaaaattttagaccgaaacaatgtggaattggccaatacaggaacagcatatgagataggcatcgttccaaagaatgtatctaaaaaagattataaagcaatcgctaaagaactaagtatttctgaagactatatcaaacaacaaatggatcaaaattgggtacaagatgataccttcgttccacttaaaaccgttaaaaaaatggatgaagatttaagtgatttcgcaaaaaaatttcatcttacaactaatgaaacagaaagtcgtaactatcctctagaaaaagcgacttcacatctattaggttatgttggtcccattaactctgaagaattaaaacaaaaagaatataaaggctataaagatgatgcagttattggtaaaaagggactcgaaaaactttacgataaaaagctccaacatgaagatggctatcgtgtcacaatcgttgacgataatagcaatacaatcgcacatacattaatagagaaaaagaaaaaagatggcaaagatattcaactaactattgatgctaaagttcaaaagagtatttataacaacatgaaaaatgattatggctcaggtactgctatccaccctcaaacaggtgaattattagcacttgtaagcacaccttcatatgacgtctatccatttatgtatggcatgagtaacgaagaatataataaattaaccgaagataaaaaagaacctctgctcaacaagttccagattacaacttcaccaggttcaactcaaaaaatattaacagcaatgattgggttaaataacaaaacattagacgataaaacaagttataaaatcgatggtaaaggttggcaaaaagataaatcttggggtggttacaacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggcagtaagaaatttgaaaaaggcatgaaaaaactaggtgttggtgaagatataccaagtgattatccattttataatgctcaaatttcaaacaaaaatttagataatgaaatattattagctgattcaggttacggacaaggtgaaatactgattaacccagtacagatcctttcaatctatagcgcattagaaaataatggcaatattaacgcacctcacttattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccaaagaaaatataaatctattaactgatggtatgcaacaagtcgtaaataaaacacataaagaagatatttatagatcttatgcaaacttaattggcaaatccggtactgcagaactcaaaatgaaacaaggagaaactggcagacaaattgggtggtttatatcatatgataaagataatccaaacatgatgatggctattaatgttaaagatgtacaagataaaggaatggctagctacaatgccaaaatctcaggtaaagtgtatgatgagctatatgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3770,Drugs,MEG_3770|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095738|WP_063852626.1|NG_047941|1|1|mecA|mecA|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA NG_047941:1-2007,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttaccttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4647,Drugs,MEG_4647|Drugs|betalactams|Class_D_betalactamases|OXA,1391852916|WP_109545101.1|NG_057535|1|1|blaOXA-598|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-598 NG_057535:1-771,0
,ATGATGACTGATCCCCGCAAAAACGGCGATTTGCACGAACCCGCGACGGCACCCGCGACGCCCTGGTCCAAAAGCGAGCTGGTCCGGCAATTGCGCGACCTCGGCGTGCGCTCAGGCGATATGGTGATGCCGCATGTGTCGTTGCGCGCCGTCGGGCCGCTGGCGGACGGACCGCAGACACTTGTCGATGCGCTGATCGAGGCCGTCGGCCCCACCGGGAATATTCTCGCCTTCGTCTCGTGGCGCGATTCGCCCTATGAACAGACGCTGGGTCATGATGCGCCGCCCGCCGCCATCGCCCAAAGCTGGCCTGCGTTCGACCCCGACCATGCGCCCGCCTACCCCGGCTTTGGCGCGATCAACGAATTTATCCGAACCTATCCGGGGTGTCGGCGCAGCGCCCATCCCGACGCATCGATGGCGGCGATCGGGCCCGATGCGGCGTGGCTGGTGGCGCCGCACGAGATGGGCGCCGCTTATGGCCCCCGCTCGCCGATCGCGCGTTTTCTCGCCCACGCAGGAAAAATCCTGTCGATCGGCGCCGGGCCCGATGCAGTCACCGCGCTCCATTATGCCGAAGCGGTGGCGCGGATCGAGGGCAAGCGCCGCGTCACTTATTCGATGCCCTTACTGCGCGAAGGCAAGCGCGTCTGGGTCACCACGTCCGACTGGGATTCGAACGGCATCCTCGACGAATATGCCGCGCCCGACGGCCCCGACGCGGTCGAACGGATCGCCCGCGACTATCTCGCCCGCACCAGGGTTGCGCAAGGCCCGGTCGGCGGCGCGCAATCCCGGCTGATCGACGCGGCCGATATCGTTTCCTTCGGCATCGAATGGCTCGAGGCGCGCCACGCCGCGCCAGCGGCGGCAGCGCTGAAGCCGAAACAACGCCGCGACTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_65,Drugs,MEG_65|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,aac(3)-VIa_2_NC_009838,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccagcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5653,Drugs,MEG_5653|Drugs|betalactams|Class_C_betalactamases|PDC,1509794537|WP_122630846.1|NG_062259|1|1|blaPDC-308|blaPDC|class_C_beta-lactamase_PDC-308 NG_062259:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6415,Drugs,MEG_6415|Drugs|betalactams|Class_A_betalactamases|SHV,gi|158518994|gb|EF653399.1|353-1213,0
,TTGAAAAAGTTAATACTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAACCAGTTCACATTCTAAAGAGTTAAATAATTTAGAAAAAAAATATAATGCTAATATTGGTGTCTATGCTTTAGACACTAAAAGTGGTAAGGAAGTAAAATATAATGCTGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCCATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGAAGTATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATAGGTGGAATCAAAACAATTAAAAAACGCTTAAAAGAATTGGGAGATAAAGTAACAAATCCAGTTAGATATGAGATTGAATTGAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTAAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAAGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTAGCTTTTATTTATCCTAAGAACCAATCTGAACCTATTATTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAACCTAATGATAAATTGATAAGTGAAACCGCCAAGAATGTAATAAACAAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1444,Drugs,MEG_1444|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_42_CCEE01000006,0
,ATGTTACGCAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGCCGCATGGACACAACGCAGGTCACATTGATACACAAAATTCTAGCTGCGGCAGATGAGCGAAATCTGCCGCTCTGGATCGGTGGGGGCTGGGCGATCGATGCACGGCTAGGGCGTGTAACACGCAAGCACGATGATATTGATCTGACGTTTCCCGGCGAGAGGCGCGGCGAGCTCGAGGCAATAGTTGAAATGCTCGGCGGGCGCGTCATGGAGGAGTTGGACTATGGATTCTTAGCGGAGATCGGGGATGAGTTACTTGACTGCGAACCTGCTTGGTGGGCAGACGAAGCGTATGAAATCGCGGAGGCTCCGCAGGGCTCGTGCCCAGAGGCGGCTGAGGGCGTCATCGCCGGGCGGCCAGTCCGTTGTAACAGCTGGGAGGCGATCATCTGGGATTACTTTTACTATGCCGATGAAGTACCACCAGTGGACTGGCCTACAAAGCACATAGAGTCCTACAGGCTCGCATGCACCTCACTCGGGGCGGAAAAGGTTGAGGTCTTGCGTGCCGCTTTCAGGTCGCGATATGCGGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_754,Drugs,MEG_754|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,gi|372292616|gb|JQ004409.1|49235-48639 gi|320091601|gb|HQ148722.1|63-659 gi|226934274|gb|FJ855133.1|64-660 gi|695211084|ref|NG_036020.1|1672-2268,2
,atgatgaaaaaatcgatatgctgcgcactgctgctgacagcctctttctccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggtatggccgtggcgattatctacaaggggaaaccttattactttacctggggtaaagccgatatcgccaataaccacccagtcacgcagcatacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacattacggataaagccgcattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggcggtgaaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaactatgcctggggctatcgcgaagggaagcctgtgcacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccactgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagcacctgccgtgaaagcctcatgggtgcataaaacaggatccacaggcggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatcgtaatgttggcaaacaaaagctatcccaacccggctcgcgtcgaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1801,Drugs,MEG_1801|Drugs|betalactams|Class_C_betalactamases|CMY,696373628|WP_032948363.1|NG_048779|1|1|blaCMY-109|blaCMY|class_C_beta-lactamase_CMY-109 NG_048779:1-1146,0
,ATGATGAAAAAATCGATATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATTGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGTTGGTGGTAAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1902,Drugs,MEG_1902|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JN714480|+|1039-2185|ARO:3002081|CMY-68 [Citrobacter freundii] ,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtccccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgttgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_231,Drugs,MEG_231|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502056|WP_071846208.1|NG_052181|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052181:101-655,2
,GTGAATACATCCTATTCACAATCGAATTTACGACACAACCAAATTTTAATTTGGCTTTGCATTTTATCTTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTCTCATTACCTGATATTGCAAATGATTTTAATAAACCACCTGCGAGTACAAACTGGGTGAACACAGCCTTTATGTTAACCTTTTCCATTGGAACAGCTGTATATGGAAAGCTATCTGATCAATTAGGCATCAAAAGGTTACTCCTATTTGGAATTATAATAAATTGTTTCGGGTCGGTAATTGGGTTTGTTGGCCATTCTTTCTTTTCCTTACTTATTATGGCTCGTTTTATTCAAGGGGCTGGTGCAGCTGCATTTCCAGCACTCGTAATGGTTGTAGTTGCGCGCTATATTCCAAAGGAAAATAGGGGTAAAGCATTTGGTCTTATTGGATCGATAGTAGCCATGGGAGAAGGAGTCGGTCCAGCGATTGGTGGAATGATAGCCCATTATATTCATTGGTCCTATCTTCTACTCATTCCTATGATAACAATTATCACTGTTCCGTTTCTTATGAAATTATTAAAGAAAGAAGTAAGGATAAAAGGTCATTTTGATATCAAAGGAATTATACTAATGTCTGTAGGCATTGTATTTTTTATGTTGTTTACAACATCATATAGCATTTCTTTTCTTATCGTTAGCGTGCTGTCATTCCTGATATTTGTAAAACATATCAGGAAAGTAACAGATCCTTTTGTTGATCCCGGATTAGGGAAAAATATACCTTTTATGATTGGAGTTCTTTGTGGGGGAATTATATTTGGAACAGTAGCAGGGTTTGTCTCTATGGTTCCTTATATGATGAAAGATGTTCACCAGCTAAGTACTGCCGAAATCGGAAGTGTAATTATTTTCCCTGGAACAATGAGTGTCATTATTTTCGGCTACATTGGTGGGATACTTGTTGATAGAAGAGGTCCTTTATACGTGTTAAACATCGGAGTTACATTTCTTTCTGTTAGCTTTTTAACTGCTTCCTTTCTTTTAGAAACAACATCATGGTTCATGACAATTATAATCGTATTTGTTTTAGGTGGGCTTTCGTTCACCAAAACAGTTATATCAACAATTGTTTCAAGTAGCTTGAAACAGCAGGAAGCTGGTGCTGGAATGAGTTTGCTTAACTTTACCAGCTTTTTATCAGAGGGAACAGGTATTGCAATTGTAGGTGGTTTATTATCCATACCCTTACTTGATCAAAGGTTGTTACCTATGGAAGTTGATCAGTCAACTTATCTGTATAGTAATTTGTTATTACTTTTTTCAGGAATCATTGTCATTAGTTGGCTGGTTACCTTGAATGTATATAAACATTCTCAAAGGGATTTCTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7095,Drugs,MEG_7095|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETL,(Tet)TetL:FN435329:1-1377:1377,4
,ATGAAGAAGAATCAGGGAATCGATCAGTTTCGGGTGATTCTAGCGATGATGGTGGTGGCGATCCACTGTCTGCCCCTTCATCGATTGTGGCCCGATGGTGATATCCTGATCACATTGACGCTTTTCAGAATCGCCGTCCCCTTCTTTTTTATGATCAGCGGATATTACGTGTTCAGCGACTTGGCCACCCAAAACAGCTATCCTGCCAGACAGCGTGTCTGGCATTTTATTAAAAAGCAGCTACAAGTCTATCTCATAGCCACACTGCTCTTTTTGCCGCTTGCTTGGTACAGCGGCATGTTAGGATTGAACATGCCCCTAGGCACTTTTATTCAAACTTTGCTAGTCAATGGCATCCTTTATCATCTATGGTATTTTCCTGCGATCATTACCGGCAGTCTTTTAGTGATGGGCCTCTTGACACGTCTTTCTTTCAAGCAGGTGTTTTTCATTGCTGTCGGTTTGTATGTGGTTGGTTTAGGTGGGGACAGTTGGTCTGGCCTGGCTGCCCAAACACCCCTCGCGTCACTCTATTCACTGATTTTCCAACTATTGGCTGGAACTCGCAACGGCATTTTCTTTGCTCCCTTGTTTTTGCTCTTAGGGGTACTAGCCAGAAGATTTGCCCAAAAACCTGCTTCTCCCCATCGCTATAGTTATCTAATGATTAGTCTGATTTGCTTGCTTTTGGAAAGTTACCTTTTGCATCACTTTACCACGCCGAAACATGACAGCATGTATGTTTTTTTGCCCTTCGTCCTATTGTTTTTATTTCCGATCATCCAGCAATGGCAAGCACCCATGATCTGGAAACAAGCGGGTCGACTGTCCCTTTGGCTCTATTTGCTCCATCCTTATACCATTGCGGTGACCCATTTTCTTAGTCAGAAACTGCCCTTGCTGCAAAACAATTTGATCAATTACATTGTGGTCTTAGGGCTGACCATCGGGTTGATTTATGGTCTCTTTGCTTTGCAAAAGCTGTTCTCGTTTCCGAAAAAAACGCCGCCCCACTTGCAACGGGCAACCAAAGAATTTTCAGCCCCCGCCTTGCTGCACAACTTGCAGGAAATCAAACGAGTGATTCCATCCACAACAAAAGTGATGGCGGTGGTTAAAGCGGATGCCTATGGTTGTGATGCGAAGACGGTCGCAGGCACCCTAGAAAGAGCCGGCGTCGATTTCTTTGCCGTTGCTACCATTGAAGAAGCCATTGAATTGCGGCGAGCTGGCATCAAAAGTCGCTTACTGATTTTAGGGTACACTTCTGCCCAACGTGCCAAAGAGCTGAACCGATATTCTTTAATTCAAACCGTCGTTAGTGAAGCACATGGACAAGCGTTAGCCCGAACAGGCCTTCCAATCGAGTGCCATTTAGCGGTAGATACCGGTATGCATCGTCTGGGTGTTGCCCCTGACCTCGAAACAGTTAGAAAGCTTTTCGCCTTGCCATCCCTCAAGATCACAGGCATTTTTTCCCATCTAGGCTCTTCAGATCAGCTAGATACGGCAAGTATCTTGCGGACACAAGCCCAAATCACTTGTTTTGATGATCTATTGGCTGGTTTGTCTGCTAGAAATATCGCCTACGGTCTGACGCATCTGCAAAGCAGCTACGGAATATTGAATTACCCAGAGAAACACTATGATTATGTGCGCCCAGGTATTCTTCTAACTGGTTCATTGAGCGTCCCGAACGAACCAACGAAGCAGAAGATAAACGTACAGCCGATTTTGACACTCAAAGCCTTACTGGTAGACAAAAAAACAGTTGCAGCCGGAGAAGCGATCGGCTATGGACTAGGCACTGTTTTTGATCGACCAGCCACGATCGGGATCGTTAGTATCGGCTACTGCGACGGGGTCCCCCGTGCCCTATCAAATCAAGGATTCCAATTGTCTTATCAAGGGGTTTTACTCCCGCAGATTGGGTTGGTTTGTATGGACATGCTCTTGATCGATTTAACGGACTATCCAGAACTGGCGGTCGAAAGTTCGCTCGAAGTAATCAGCGATTGGACGACTGCAGCTGATCAAGCACAAACCATTACCAATGAATTGATCAGCCGCCTAGGTTCCCGCATCACCTCTAGTGCAAAGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7529,Drugs,MEG_7529|Drugs|Glycopeptides|VanC-type_resistance_protein|VANTC,gi|161779845|gb|EU151752.1|1647-3749,5
,atggtctcgttggttgttcgttcctgttccgttgctgctgttgcagtcggtctgctgtttcccgcctgcgctgcgcctgtcggcgccaccgccaccactgcccccgttgccgagttagacagcgtgccgcaagttagcagtggtcgcttaggcgtggcgattctggatttccagacgtcgaaaacgtatcacataaacggcaaagatcggttcccgatgcagagcgtgtttaaggcgatgtcggcggtggtggtgatgcgggaggtggatgaggggaagctgacgctggatcaggagattccggtggggccagatgatatctcggtttactggagtcccatcgcggaggaatttaaaggtaccacgcagacatatacggttcgtgaactactggagaagtcagtgggcatgagcgataacaccgcggcggatgtgctgatggaactgacgggcggtccgcaggcggtgacgcagttgctgaaggatgccggtattgagggcgtgcgggtagaccgctatgagcggcagttccaggcggaactggaaggcctgccgccgtttgagctgggtgaggtgatcaaccgaaaagcatttgtcgaagcggcgaaggcggtgccggctgaggtaaagcgcccgatattggaacgctacgtggctggcaaggatgagcgcgatacggccactcccctgggcgccgtggatttcctggtgaagctgcaggagggcaagctgctctcggcagaatcgacgcgggtgctgctgcagatcatgacggatgtgaagactggggctgggagactaaaagctggattgcccgagggcagtaagctggcgcataagacgggcaccggcggcgacatcctgggcgtgaacacagcgacgaacgacatcgggatcgcaaccctgccggacgggcggaagttcgccgtggcggtgtttctgacggggtcgaaggagtcggaagagaagcgagacgccatccacgcagacgtggtgcggcagtttgtagatcagctgctggcggaagcgaaagagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1243,Drugs,MEG_1243|Drugs|betalactams|Class_A_betalactamases|BLAA,1028083121|WP_063842277.1|NG_047487|1|1|bla-A|bla-A|class_A_beta-lactamase NG_047487:101-1138,0
,atgcgcgataccggattcccctgcctgtgcggcatcgccgcctccacactgctgttcgccgccacctcggccattgccggcgaggccccggcggatcgcctgaagacactggtcgacgccgccgtacaaccggtgatgaaggccaatgatattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcttcgaaagaggacggtcgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagcctgcactggccggcgctgcaaggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaagaccaggcacagatccgcgactactaccgccagtggcagccgacctacacgccgggcagccagcgcctctactccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggatcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccctctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaagccctgggcgcaggcgctcaatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggcgggcaactcgacgccgatggcgctgcaaccgcacaggatcgccagactgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcatcccaggccgcgacctgggcctggtgatcctggccaaccgcaattatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5709,Drugs,MEG_5709|Drugs|betalactams|Class_C_betalactamases|PDC,1209144257|WP_088245219.1|NG_055277|1|1|blaPDC-214|blaPDC|class_C_beta-lactamase_PDC-214 NG_055277:1-1194,0
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacagttgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacagcaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7652,Drugs,MEG_7652|Drugs|betalactams|Class_A_betalactamases|VEB,1028110883|WP_063865153.1|NG_050321|1|1|blaVEB-13|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-13 NG_050321:1-900,0
,ATGAAAAAAATCGCCATTATTTTTGGAGGCAATTCACCGGAATACACCGTTTCTTTAGCCTCAGCAACTAGCGCAATCGAAGCACTCCAATCATCTCCCTATGACTATGACCTCTCTTTGATCGGGATCACCCCAGATGCTATGGATTGGTACTTGTATACAGGAGAACTGGAAAACATCCGACAAGACACGTGGTTGTTGGATACGAAACATAAACAGAAAATACAGCCGCTATTCGAAGGAAACGGCTTTTGGCTAAGTGAAGAGCAGCAAACGTTGGTACCTGATGTTTTATTTCCCATTATGCATGGCAAATACGGGGAAGATGGCAGTATCCAAGGATTGTTTGAATTGATGAAGCTGCCTTATGTAGGCTGCGGGGTGGCAGGTTCTGCCTTATGTATGAACAAATGGCTGCTGCATCAAGCTGCAGCAGCCATTGGCGTACAAAGTGCTCCTACGATTCTCTTGACAAATCAAGCCAACCAGCAAGAACAAATCGAAGCTTTTATCCAGACCCATGGCTTTCCAGTTTTCTTTAAGCCTAATGAAGCGGGCTCCTCAAAAGGGATCACTAAAGTCACCTGCGTTGAAGAAATCGCTTCTGCCTTAAAAGAAGCCTTTACTTATTGTTCCGCAGTGCTCCTACAAAAAAATATTGTCGGTGTTGAGATCGGTTGCGGTATTTTGGGCAACGACTCTTTGACTGTCGGTGCTTGTGACACCATTTCATTAGTAGACGGCTTTTTCGATTTTGAAGAAAAGTACCAGCTGATCAGCGCCAAAATCACCGTCCCTGCGCCATTGCCTGAAACGATTGAAACCAAGGTCAAAGAACAAGCTCAGCTGCTCTATCGTAGTCTTGGTCTTAAAGGTCTTGCTCGCATCGACTTTTTTGTCACGGATCAAGGAGAACTATACTTGAATGAAATCAATACTATGCCGGGCTTTACGAGTCACTCCCGCTATCCTGCCATGATGGCAGCGGTCGGCTTATCCTATCAAGAACTACTACAAAAACTGCTTGTCTTAGCAAAGGAGGAAGTCAAATGA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7369,Drugs,MEG_7369|Drugs|Glycopeptides|VanC-type_resistance_protein|VANC,gi|161779857|gb|EU151754.1|29-1081,5
,ATGACATGGAGAACGACCAGAACACTTTTACAGCCTCAAAAGCTGGAGTTCAATGAGTTTGAGATTCTTAATCCCGTAGTTGAGGGCGCCCGAATTGTCGGCATTGGCGAGGGTGCTCACTTTGTCGCGGAGTTCTCACTGGCTAGAGCTAGTCTTATTCGCTATTTTGTCGAGAGGCATGATTTTAATGCGATTGGTTTGGAATGTGGGGCGATTCAGGCATCCCGGCTATCTGAATGGCTCAACTCAACAGCCGGTGCTCATGAACTTGAGCGATTTTCGGATACCCTGACCTTTTCTTTGTATGGCTCAGTGCTGATTTGGGTTAAATCATATCTACGCGAATCAGGAAGAAAACTGCAGTTAGTCGGAATCGATTTACCCAACACCTTGAATCCAAGGGACGACCTAGCGCAATTGGCCGAAATTATCCAGGTCATCGACCACCTCATGAAACCCCACGTTGATGCGCTGACTCAGTTGTTGACGTCCATTGATGGCCAGTCGGCGGTTATTTCATCGGCAAAATGGGGGGAGTTGGAAACGGCTCAGCAGGAGAAAGCTATCTCAGGGGTAACCAGATTGAAGCTCCGTTTGGCGTCGCTTGCCCCTGTCCTGAAAAATCACGTCAACAGCGATTTTTTCCGAAAAGCCTCTGATCGAATAGAGTCGATAGAGTATACGTTGGAAACCTTGCGTGTAATGAAAGCTTTCTTCGATGGTACCTCTCTTGAGGGAGATACTTCCGTACGTGACTCGTATATGGCGGGCGTGGTGGATGGAATGGTTCGAGCGAATCCGGATGTAAGGATAATTCTGCTGGCGCACAATAATCATTTACAAAAAACTCCAGTTTCCTTTTCAGGCGAGCTTACGGCTGTTCCCATGGGACAGCATCTCGCAGAGAGGGAGGAGGGGGATTACCGTGCGATTGCATTCACCCATCTTGGACTCACCGTGCCGAAAATGCATTTCCCATCGCCCGACAGTCCTCTTGGATTCTCTGTTGTGACCACGCCTGCCGATGCAATCCGTGAGGATAGTGTGGAACAGTATGTCATCGATGCCTGTGGTAAGGAGGATTCATGCCTGACATTGACAGATGACCCCATGGAAGCAAAGCGAATGCGGTCCCAAAGCGCCTCTGTAGAAACGAATTTGAGCGAGGCATTTGATGCCATCGTCTGCGTTCCCAGCGCCGGCAAGGACAGCCTGGTTGCCCTATAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2749,Drugs,MEG_2749|Drugs|MLS|Macrolide_esterases|EREA,gi|14582735|gb|AF326209.1|76-1302 gi|954629879|gb|CP013215.1|280834-280647 gi|948288909|gb|KR259328.1|932-1119 gi|908266278|gb|CP012170.1|140874-141061 gi|659224503|gb|KJ668707.1|918-1105,7
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccacccccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggctgcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccactcatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5564,Drugs,MEG_5564|Drugs|betalactams|Class_C_betalactamases|PDC,510932648|WP_016252988.1|NG_060538|1|1|blaPDC-286|blaPDC|class_C_beta-lactamase_PDC-286 NG_060538:1-1194,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggagagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgtatcgaacacgcttgtgaggccgccatgttgatgagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgctgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgataagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattctctcatgcgctctgttctgccaaaaggctggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatctggaaagacaactacaagccggtttacatcagtatttacgtcacagacactgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1494,Drugs,MEG_1494|Drugs|betalactams|Class_A_betalactamases|CARB,646459295|WP_025535332.1|NG_048737|1|1|blaCARB-33|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-33 NG_048737:1-852,0
,AGGAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA,rRNA with mutation conferring antibiotic resistance,antibiotic inactivation,Phenicol,MEG_1593,Drugs,MEG_1593|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,gi|985700753|dbj|LC122351.1|1649-2319 gi|973776294|gb|KT833851.1|162657-163327 gi|973743057|gb|KT894021.1|4129-3459 gi|974004808|dbj|LC030201.1|1364-2034 gi|974004804|dbj|LC030200.1|1364-2034 gi|971497742|gb|CP012903.1|56765-57435 gi|970697631|gb|KT935446.1|80626-81296 gi|937637950|gb|KT203286.1|5910-5240 gi|941350020|gb|KT163018.1|10773-10103 gi|941350015|gb|KT163017.1|4081-3411,6
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGCTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1382,Drugs,MEG_1382|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_73_CYNA01000004,0
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGAGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGAGACAACTTGGCGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1952,Drugs,MEG_1952|Drugs|betalactams|Class_C_betalactamases|CMY,AKG51729.1 KP281294.1:1-1146,0
,atggcttctcagtactacgttcatcacctcgggcaggatgactcagagttgatgaacgcccttttgtcagtgttcggcgcggccttcaatgaagtggagacctatgttggaaagcggccgggccccgaatatatacgcaggctcctgggcagcgactacttcatagctttggcggcgctcgaggacaacgaggtcgtaggcggaatcgccgcctaccacctaaaaaagttcgagcaggaacgcaaggaaatctatatctccgatctggctgtcgcggaagagcacaggcgcaaaggaatagcaacaggcttgatccggaagctcaggaagattgcagccgctcgcggggcttacgtaatcttcgtacaggccgatacgggcgtcgaggatgagccagccattgcgttatacaccaagctgggagtacgtgaggatgttctgcattttgatatagcagtggaagacggcgatgacgctgcggctcatgctaacgaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_24,Drugs,MEG_24|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3,1028080877|WP_063840260.1|NG_047240|1|1|aac(3)-I|aac(3)-I|AAC(3)-I_family_aminoglycoside_3-N-acetyltransferase NG_047240:101-598,2
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAAGATGTTTATGA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6634,Drugs,MEG_6634|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|695209907|ref|NG_035903.1|915-1733 gi|975007785|gb|CP010832.1|4504-3697 gi|954666075|gb|KT962845.1|19587-18780 gi|971494279|gb|CP010355.1|2154-2961 gi|971339514|gb|CP006662.2|54921-54114 gi|943457735|gb|KT818627.1|110623-109816 gi|969995276|gb|KT317085.1|2977-2170 gi|969868918|gb|CP013690.1|3395295-3396102 gi|959153704|gb|CP012993.1|20101-20908 gi|959147947|gb|CP012988.1|73119-72312,8
,ATGTTTGCTAAAAATTCAAAGGCATATTCTGTCTACCTGCTGTTCCGATTTGTCTGTTCCCTGGCGGTTTCTATGTCCACAGTGCTTTCCATCGTGTACCACCTGGAGGTGGTGCAGCTGGATGCTTTCCAGCTTGTCCTGGTAGGGACGGTTCTGGAGACCTCCTGCTTTCTGTTCGAGATACCCACCGGTGTGGTGGCGGATTTGTATAGCCGTCGGCGCTCGGTGCTGATTGGAATGTTCCTCTACGGCCTGGGCTTTCTGATGGAGGGTGCGCTACCGTGGTTCGCGCCGGTTCTGCTGGCCCAGGTTGTCTGGGGTTGCGGTGATACCTTCATCACCGGCGCTCTGGAGGCGTGGATTGCCTCGGAGGAAGAGGACAAACCCATAGACAAGGTGTTCCTGCGGGGCAGTCAAATGGGGCAAATCGGCGGCGTTCTGGGCGTGGTGCTGGGCACACTGCTGGGAAACATAAACCTGCAAATGCCTGTCATCTTGGGGGGCAGTTTGTGCTTGTTGTTGGGGCTGGTGATGGTTCGCATCATGCCAGAAACCAACTTCTCCCCTGCTATTGAGGAACGGCAGGGCTTGCTTAAAGACTTTGTCTGCCTGTTCAAGCTCAACCTGGGCTTTGTGAAAGGCGCACCTGTGTTGCTGGCGCTCTTAGCAATCACACTATGCGGGGGACTTGCCAGTGAAGGCTTTGACCGGCTCTCCACCGCTCATTTTCTGGATGACACGGTAATACCCGTTATCGGGCCGCTGAACAGCGTCACTTGGTTCGGTGTTATCAGTCTTATCGGCAACGGCTTAGGTATTCTGGCTTCTCAGTTGCTCATCGCCCGCATGGAGAAAAAAGGGACTGTCAGCCGAACCAGTGTGGTCATGTCCACCAGCGCCGGGTATATCCTGTGCCTGGTTCTCTTCGCGGTGGGGCGGAGCTTTTGGTTCATGTTGTTGGTGTTCCTGCTGGCGGGGCTTATGCGCACCATCAAGGAGCCTGTGCTGGCCGCCTGGATGAACGACCATGTGGATGAGAAAATGCGCGCCACAGTCTTTTCCACCAGCGGACAGCTGGACTCTTTCGGGCAGATCATCGGCGGGCCTATTGTGGGGCTGGTAGCCCAGCAGGTGTCCATACCCTGGGGGCTGGTCTGTACCGCTTTCCTGCTGTTGCCCGCGCTGTTCTTAGTGCCGGTGGCGGGAAAGAAGCGGGATTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic target protection,Tetracyclines,MEG_6994,Drugs,MEG_6994|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET40,gi|576941992|gb|KC790466.1|1971-3191 gi|204789639|gb|FJ158002.1|1889-3109 gi|204789615|gb|FJ157999.1|1889-3109 gi|379125718|gb|JQ280445.2|3221-3296,4
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttaatacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagtgctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtagcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttgatgccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaattaggaaccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcccaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagaacgcattaaggcagcgtatgcagttttaaatgcaataaaggaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_532,Drugs,MEG_532|Drugs|betalactams|Class_C_betalactamases|ADC,491280291|WP_005138362.1|NG_054996|1|1|blaADC-154|blaADC|class_C_beta-lactamase_ADC-154 NG_054996:1-1152,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacgaccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5645,Drugs,MEG_5645|Drugs|betalactams|Class_C_betalactamases|PDC,1028110201|WP_063864571.1|NG_049887|1|1|blaPDC-17|blaPDC|class_C_beta-lactamase_PDC-17 NG_049887:1-1194,0
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactgacgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgagacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1794,Drugs,MEG_1794|Drugs|betalactams|Class_C_betalactamases|CMY,1408841633|WP_111672906.1|NG_060564|1|1|blaCMY-163|blaCMY|class_C_beta-lactamase_CMY-163 NG_060564:1-1146,0
,ttgcccaggcgcctgatattcgcggccctgctgctcgccgccccggcggccgcgcagcaggaagcgccgcgcccgtcgctgctcccgccgccgcctcgctatatggtcagcgaatccgccatgaggtcggtccgcaatcccaaggagatcgagaccgaaagcggcggccggctgggcgtggcgctggtcgacggcaagggcgcgctgatccttggtttcaaccgggacgagcgtttcgccatgtgctcgaccttcaaggcgccgctcgccgccgccgtgctggcgggcgcggaaggcggcaagttcgggctggaggggcagatcagcttcgccaaggccgatctgctggactatgccccggtcgtcaggaagaatgtgaagcgcggccgcatgtcgatggaggaactcgccgccgccgccgtggaagtcagcgacaacagcgcggccaacctgctgctgccgatggtcggcgggccggagggcctgacccgcttcatccgcgcccatgatgacatggtgacgcggctcgaccgcaatgagccgtctctcaacgagaatgcggagggcgacgagcgcgacaccaccagccccgccgccatggccggcctgatgggccgcctgatcttccgcgacctcgctccggaaagcgccggaaagctgcgcggctggctcaatgccagcaccaccggcgccaaccggatcaaggcgggcctgcccaagggctggacctccggcagcaagacgggaagctgcggcaccgcctataatgacgtggcgctggtgaaggccccgtcgggcgaggaatatatcctggccatctatctcgaccgcccgacggtcgacgccaaggccgccgaagccgccatagccgaaaccgcccgcgccgcgctggatttcgtggataaggcgcagaagaccgggctggaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1307,Drugs,MEG_1307|Drugs|betalactams|Class_A_betalactamases|BLASGM,494962766|WP_007688792.1|NG_052647|1|1|blaSGM-3|blaSGM|class_A_beta-lactamase_SGM-3 NG_052647:101-1030,0
,gtgcgctcaaaaaactttagttggcggtactcccttgccgccacggtgttgttgttatcaccgttcgatttgctggcatcactcggcatggacatgtacttgccggcagtgccttttatgccaaacgcgcttggcacgacagcgagcacagttcagcttacgctggcaacgtacttggtcatgatcggtgccggtcagctcttgtttggaccgctatcggaccgactggggcgccgccccgttctactgggaggtggcctcgcctacgttgtggcgtcaatgggcctcgcttttacgtcattggctgaagtctttctggggcttcggattcttcaggcttgtggtgcctcggcgtgccttgtttccacgtttgcaacagtacgtgacatttacgcaggtcgcgaggaaagtaacgtcatttacggcatactcggatccatgctggccatggtcccggcggtaggcccattgctcggagcgctcgtcgacatgtggcttgggtggcgggctatctttgcgtttctaggtttgggcatgatcgctgcatctgcagcagcgtggcgattctggccagaaacccgggtgcaacgagttacgggcttgcaatggtcgcagctgctactccccgttaagtgcctgaacttctggttgtacacgttgtgttacgccgctggaatgggtagcttcttcgtctttttctccattgcgcccggactaataatgggcaggcaaggtgtgtctcagcttggcttcagcctgctgtttgccacagtggcaattgccatggtgtttacggctcgttttatggggcgtgtgatacccaagtggggcagcccaagtgtcttgcgaatgggaatgggatgcctgatagctggagcagtattgcttgccatcaccgaaatatgggcttcgcagtccgtgttaggctttattgctccgatgtggctagtgggtattggtgtcgccacagcggtatctgtggcacccaatggcgctcttcaaggattcgaccatgttgctggaacggtcacggcagtttacttctgcttgggcggtgtactgctaggaagcatcggaacgttgatcatttcgctgttgccgcgcaacacggcttggccggttgtcgtgtactgtttgacccttgcaacagtcgtgctcggtctgtcttgtgtttcccgagcgaagggctctcgcggccagggggagcatgatgtggtcgcgctacaaagtgcggaaagtacgtcaaatcccaatcgttga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1759,Drugs,MEG_1759|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,644808165|WP_025368619.1|NG_047652|1|1|cmlA4|cmlA4|chloramphenicol_efflux_MFS_transporter_CmlA4 NG_047652:101-1360,6
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5607,Drugs,MEG_5607|Drugs|betalactams|Class_C_betalactamases|PDC,959904657|WP_058169941.1|NG_056103|1|1|blaPDC-225|blaPDC|class_C_beta-lactamase_PDC-225 NG_056103:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGTAATGGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCGAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGACATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCGCCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1370,Drugs,MEG_1370|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_43_NZ_CAVU010000015,0
,TTTTTGTTTGGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGAAAGGCCCTTTCGGGGGTACTCGAGTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTTTGGGATAAGCCTGGGAAACTGGGTCTAATACCGAATACACCCTGCTGGTCGCATGGCCTGGTAGGGGAAAGCTTTTGCGGTGTGGGATGGGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGTGACCGGCCACACTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCACAGACGAAGCGCAAGTGACGGTATGTGCAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGCAGACTAGAGTACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCTTGGGATCCGTGCCGTAGCTAACGCATTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGCACAGGACGCCGGCAGAGATGTCGGTTCCCTTGTGGCCTGTGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCTCATGTTGCCAGCACGTTATGGTGGGGACTCGTGAGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCGGTACAAAGGGCTGCGATGCCGTGAGGTGGAGCGAATCCTTTCAAAGCCGGTCTCAGTTCGGATCGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAAAGTCGGTAACACCCGAAGCCGGTGGCCTAACCCTTGTGGAGGGAGCCGTCGAAGGTGGGATCGGCGATTGGGACGAAGTCGTAACAAGGTAGCCGTACCGGAAGGTGCGGCTGGATCACCTCCTTTCT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,Aminoglycosides,MEG_9,Drugs,MEG_9|Drugs|Aminoglycosides|Aminoglycoside-resistant_16S_ribosomal_subunit_protein|A16S,gb|NC_008596.1|+|5027948-5029475|ARO:3003541|Mycolicibacterium smegmatis 16S rRNA mutation in the rrsB gene conferring resistance to streptomycin [Mycolicibacterium smegmatis MC2 155] ,2
,ATGGAAAAATACAACAATTGGAAACGAAAATTTTATGCAATATGGGCAGGGCAAGCAGTATCATTAATCACTAGTGCCATCCTGCAAATGGCGATTATTTTTTACCTTACAGAAAAAACAGGATCTGCGATGGTCTTGTCTATGGCTTCATTAGTAGGTTTTTTACCCTATGCGATTTTGGGACCTGCCATTGGTGTGCTAGTGGATCGTCATGATAGGAAGAAGATAATGATTGGTGCCGATTTAATTATCGCAGCAGCTGGTGCAGTGCTTGCTATTGTTGCATTCTGTATGGAGCTACCTGTCTGGATGATTATGATAGTATTGTTTATCCGTAGCATTGGAACAGCTTTTCATACCCCAGCACTCAATGCGGTTACACCACTTTTAGTACCAGAAGAACAGCTAACGAAATGCGCAGGCTATAGTCAGTCTTTGCAGTCTATAAGCTATATTGTTAGTCCGGCAGTTGCAGCACTCTTATACTCCGTTTGGGATTTAAATGCTATTATTGCCATCGACGTATTGGGTGCTGTGATTGCATCTATTACGGTAGCAATTGTACGTATACCTAAGCTGGGTAATCAAGTGCAAAGTTTAGAACCAAATTTCATAAGGGAGATGAAAGAAGGAGTTGTGGTTCTGAGACAAAACAAAGGATTGTTTGCCTTATTACTCTTAGGAACACTATATACTTTTGTTTATATGCCAATCAATGCACTATTTCCTTTAATAAGCATGGAACACTTTAATGGAACGCCTGTGCATATTTCTATTACGGAAATTTCCTTTGCATTTGGGATGCTAGCAGGAGGCTTATTATTAGGAAGATTAGGGGGCTTCGAAAAGCATGTATTACTAATAACAAGTTCATTTTTTATAATGGGGACCAGTTTAGCCGTTTCGGGAATACTTCCTCCAAATGGATTTGTAATATTCGTAGTTTGCTGTGCAATAATGGGGCTTTCGGTGCCATTTTATAGCGGTGTGCAAACAGCTCTTTTTCAGGAGAAAATTAAGCCTGAATATTTAGGACGTGTATTTTCTTTGATCGGAAGTATCATGTCACTTGCTATGCCAATTGGGTTAATTCTTTCTGGATTCTTTGCTGATAAAATCGGTGTAAATCATTGGTTTTTACTATCAGGTATTTTAATTATTGGCATTGCTATAGTTTGCCAAATGATAACTGAGGTTAGAAAATTAGATTTAAAATAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,MLS,MEG_3825,Drugs,MEG_3825|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFA,gi|909837468|gb|CP003357.2|1841917-1840700 gi|815827235|emb|LN812955.1|5946-7163 gi|698841295|emb|LK020698.1|7706-8923 gi|698841236|emb|LK020697.1|36073-34856 gi|556027507|gb|CP006844.1|1764728-1763511 gi|341932553|gb|CP002925.1|269318-268101 gi|321157379|emb|FR671415.1|21081-19864 gi|321157336|emb|FR671413.1|18233-17016 gi|298237097|gb|CP001993.1|2026415-2025198 gi|283440973|gb|CP001849.1|987304-988521,7
,ATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAACATTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAATATTCCTTACCATTTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2796,Drugs,MEG_2796|Drugs|MLS|23S_rRNA_methyltransferases|ERMB,(MLS)ErmB:M11180:714-1451:738,7
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACATCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTGATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6482,Drugs,MEG_6482|Drugs|betalactams|Class_A_betalactamases|SHV,gi|743569396|gb|CP006722.1|2875596-2876456 gi|77702545|gb|DQ219473.1|1-861,0
,atgcttaaacagagtatcaacacggtagtactactcctttttctgacattcagttctttgtttgcctgtgctcaaaaagtagcagaacctacaagaaatccgccagaatggactcagccttaccagcctttccggattgcaggtaatttatattacgtgggtaccagtgatctggccagttatctgattacaaccccaaaaggtcatattctgatcaatactggtctttcttcatctttatcatcgattaaagcgaatgtaaaaaccctgggcttcaaatttagcgatatcaaaatactactgaccactcaggctcattttgaccacatgggtgcaatggcagctatcaaaaaactgactggtgctaagtttatggtagatgaaaaggatgcgaaagttgcagcagatggaggaagatcagattatgccctgggtggtcatagaagtacttatgtaccggttaaggcagaccgtattttacatgataaggataagataaccttaggtgggatggagctcgttatgctacatcatcccggtcatacccaaggttcatgcagtttcctgtttaatgtcaaagatgaaagcagagtttatagcgtcctgatagccaatatgccaacaattgtcacagaaaaaaagttctccgaagtaacgacctatccaggcattgccaaagattatgcctatacgctgaatgcgatgaaaaagctgaaatttgatatgtggctttcctctcatgccagtcagtttggactgctgaccaaacacaagcctggtgatgcctataatcctgccgcatttattgatcagaagggttatgattcagcaatccgagatttagaagataaatttctcaggaaagaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5792,Drugs,MEG_5792|Drugs|betalactams|Class_B_betalactamases|PLN,754466891|WP_041884311.1|NG_055471|1|1|blaPLN-1|blaPLN|subclass_B3_metallo-beta-lactamase_PLN-1 NG_055471:101-970,0
,atgaatagttcgacaaagatcgcattggtaattacgttattcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccactttggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagtgcatttgcctttttagcgtttatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaccaatgcaaccggtgttattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7045,Drugs,MEG_7045|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,447011808|WP_001089064.1|NG_048173|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048173:101-1306,4
,GGGCCCGGACACCTTTTTGCTTTTAATTACGGAACTGATTTCATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTCTCCACATTTGCTGCCGCAAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGATCGGTTAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGCTGCACTTAGCCACCTATACGGCAGGCGGCCTACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCATTTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGCCCGTACACGCTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCCGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGCTCCACTGGTGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1848,Drugs,MEG_1848|Drugs|betalactams|Class_C_betalactamases|CMY,gb|AB587082|+|0-1188|ARO:3002069|CMY-59 [Escherichia coli] ,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataatggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctgtggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaacattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4634,Drugs,MEG_4634|Drugs|betalactams|Class_D_betalactamases|OXA,1391852898|WP_109545083.1|NG_057500|1|1|blaOXA-628|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-628 NG_057500:1-747,0
,atgaaaaccagacttgaacaagttttagaacgctatctcaacggacgcgaggtagttgtatggggtgttccgacacgccgtttgcttcgtgcattaaaaccttttaaatttcgtgttgacgatcgcgttgaccctcaatatcattatgttgttgctgtaaacgatgacgacttatccgactttttatccgatgaacagagcaagtcgtttcaatacgctaatgactatctgacgtttgacgatgagggaggcgaacttccgtttgaacgaatgtgcttcaatgtccccgttggcaggcaaacgtattttggagacggtgtcgtaggagcttgcaaaaacgggtatatcaagagcatcggccaatttacatcgattaacggcacggcagagatccatgtgaaccatcagttaaacatgacctttgtaagcgacgatattcaaaacttcttcaatgaagagagtatggctatattccatgaaaagctgcgaaaggacccgaaacacccttatgcttacagcaaagaacctatgaccataggtagcgatgtttatatcggcgcacatgcattcatcaatgcttccactgtgacaagcatcggtgacggtgctataatcggctcgggcgcagtggttctggaaaatgttcctccttttgctgtcgtcgttggtgtccctgcgagaatcaagcgttaccgcttctcaaaggagatgattgaaaccctgcttcgtgtcaaatggtgggactggagtatagaggaaattaatgaaaatgctgatgcgcttatatcacctgaactatttatgaagaagtacgggggtttatag,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_1102,Drugs,MEG_1102|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|APMA,504872863|WP_015059965.1|NG_047475|1|1|apmA|apmA|aminocyclitol_acetyltransferase_ApmA NG_047475:101-925,2
,atgtcacttaatgtaaaaccaagcagaatagccatcttgtttagctcttgtttagtttcaatatcatttttctcacaggccaatacaaagggcatcgatgatattaaaaaccttgaaacagatttcaatggtagaattggtgtctacgctttagacactggctcaggtaaatcatttacgtacaaagcaaatgaacgatttccattatgtagttctttcaaaggttttttagctgctgctgtattaaaacgctctcaagataatcaactcagtcttaatcagatcgtgaattacaatacaagaactttagagttccattcacccatcacaactaaatataaagataatggaatgtcattaggtgatatggctgctgccgctttacaatatagtgacaatggtgctactaatattattcttgaacgttatatcggtggtcctgagggtatgactaaattcatgcggtcgattggagatgaagattttagactcgatcgttgggagttagatctaaacacagctattccaggcgatgaacgtgacacatctacacctgcagcagtagccaagagcctgaaaaccattgctctgggtaacatacttagtgagcgtgaaaaggaaacatatcagacatggttaaagggtaacacaaccggtgcagcgcgtattcgtgctagcgtaccaagcgattgggtagttggcgataaaactggtagttgcggagcatacggtactgcaaatgattatgcggtagtctggccaaagaaccgggctcctcttataatttctgtatacactacaaaatacgaaaaagaagccaagcatgaggataaagtaatcgcagaagcttcaagaatcgcaattgataaccttaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3301,Drugs,MEG_3301|Drugs|betalactams|Class_A_betalactamases|IMI,1693892933|WP_140423310.1|NG_065426|1|1|blaIMI-19|blaIMI|carbapenem-hydrolyzing_class_A_beta-lactamase_IMI-19 NG_065426:1-879,0
